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**Background/Aims:** The overall 10-year survival rate for middle-age adults with differentiated thyroid cancer declines to 40% in the presence of distant metastasis. A 34 year old female patient, diagnosed with follicular thyroid cancer, having had completion thyroidectomy and multiple radioiodine therapies, and appearing to be disease-free for six years, presented with elevated thyroglobulin but negative diagnostic ^131^I whole body scan. **Methods:** ^18^F-FDG positron emission tomography showed probable locoregional nodal metastases. Empiric therapy with 5550 MBq ^131^I was given for ablation. **Results:** Post-radioiodine therapy whole body scan with single-photon emission computed tomography/computed tomography done two days after oral administration revealed multiple osseous metastases with no lesions in locoregional nodes. **Conclusion:** This case discusses the most common tools used in monitoring thyroid cancer recurrence and metastasis. Emphasis is given on the clinical utility of thyroglobulin, the advantage of optimal thyroid stimulating hormone level prior to diagnostic tests, the role of empiric ^131^I therapy, and the value of post-radioiodine therapy whole body scan with single-photon emission computed tomography/computed tomography.
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**Background/Aims:** The optimal activity of radioiodine (^131^I) in papillary and follicular thyroid cancer following thyroidectomy remains unknown in long term follow-up. Some, shorter follow-up studies suggest that activities 1.1 GBq and 3.7 GBq are considered equally effective. We evaluated the long term outcomes of primary ablation to extend current knowledge about the optimal ablative dose of I-131. **Methods:** In our cohort, 160 adult patients (129 females, 31 males; mean age 46±14 years, range 18-89 years) diagnosed with histologically confirmed papillary or follicular thyroid cancer, were randomized in prospective, phase III, open-label, single-center study, during 2000-2004, to receive either 1.1 GBq or 3.7 GBq of I-131 after thyroidectomy. At randomization, patients were stratified according to the histologically verified cervical lymph node status, and were prepared for ablation using thyroid hormone withdrawal. No uptake in the whole body scan with I-131 and thyroglobulin concentration \<1 ng/mL at 4-8 months after treatment was considered successful ablation. **Results:** Median follow-up time was 13.02 years (mean 11.03±4.80 years; range 0.33-17.13 years). Altogether 81 patients received 1.1GBq, ablation was successful in 45 (56%) after one administration of I-131 and 36 (44%) needed one or more administrations to replete the ablation. Of these, 4 (8.9%) and 5 (14%) patients were later relapsing respectively. Of the 79 patients treated with 3.7 GBq 45 (57%) had successful ablation after one administration and 34 (43%) needed several treatments. Of these, 2 (4.4%) and 9 (26.5%) patients were relapsing respectively. Of these 79 participants, three died from thyroid cancer during the median follow-up of 13 years. Activity groups did not differ in the proportion of patients relapsing (p=0.951). **Conclusion:** During follow-up of median 13 years 1.1 GBq is as effective as 3.7 GBq for ablation of the thyroid remnant.
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**Background/Aims:** The goal of this study, in addition to confirming that ionizing radiation in differentiated thyroid cancer (DTC) patients ablated with radioiodine causes stress oxidative, was to evaluate protective and mitigative effect of vitamin C on this phenomenon. **Methods:** 58 DTC patients for radioactive iodine therapy (RAIT) by 5550 Mbq Iodine-131 were divided into four groups. Group one (control group) were 16 patients who underwent RAIT, routinely. Groups 2, 3 and 4 received 1500 mg vitamin C daily 2 days after, 2 days before to 2 days after and 2 days before RAIT, respectively. Serum oxidative stress markers including malondialdehyde (MDA), glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD) were measured immediately before and 2 days after RAIT. **Results:** A significant increase in MDA after RAIT was observed in all groups (p\<0.05). The concentrations of MDA were significantly higher in the control group compared to the intervention groups (p\<0.05). A significant decrease in the control group (p=0.049) and increase in group 4 (p=0.026) were observed in GSH level after RAIT (p\<0.05). Mean variation of GSH was significant between control group with groups 3 (p=0.008) and 4 (p=0.003). The results indicate that activity of SOD remained unchanged in all groups (p\>0.05). A significant increase was observed in CAT activity after RAIT in all groups (p\<0.05), which was higher in control group than intervention groups. In groups 3 (p=0.043) and 4 (p=0.05), this increase in CAT activity was significantly lower than the control group. **Conclusion:** RAIT causes serum oxidative stress, which can be ameliorated by using vitamin C as an antioxidant. These results indicate that radioprotective effect of vitamin C is preferable to its mitigative effect.
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**Background/Aims:** The primary objective of the study was to investigate the prevalence of BRAFV600E and TERT promoter mutations in papillary thyroid cancer and secondary objective was their correlation with various clinicopathologic features in the Indian population. **Methods:** A retrospective study of 160 pathologically proven papillary thyroid cancer patients including 105 women and 55 men with a median age of 35 years (range 13--77 years) was conducted in the Department of Nuclear Medicine, AIIMS, New Delhi, India. The study period was from the year 2008 to 2016 with a mean follow-up of 32.7 months (12-101 months). Univariate and multivariate analysis was performed to determine the association of BRAFV600E and TERT promoter with clinicopathologic features. Prognostic factors affecting the event-free survival were analysed by Kaplan-Meier curves. **Results:** The prevalence of BRAFV600E mutation was in 33% (53/160) and TERT mutation in 17.5% (28/160) of patients. Both mutations (genetic duet) were co-existent in 19 (11.8%) of patients. No mutation (wild type) was detected in 98/160 (61.3%) PTC patients. Interestingly, no mutation was detected in follicular variant of PTC (0/28) compared to 40% in classic PTC. Prognosis: compared to wild type, BRAFV600E alone or TERT alone showed significant associated with extrathyroidal extension (p=0.030), radioiodine (RAI) refractory persistent disease (p=0.0393) until end of follow-up (p=0.017). Patients with co-existing mutations were significantly associated with poorer outcome. Kaplan-Meier graph depicts the association of wild-type versus various mutations with event-free-survival. **Conclusion:** Patients with co-existing BRAFV600E and TERT mutations showed the worst clinicopathologic outcomes. The detection of these mutations paves path for the early treatment of RAI refractory disease patients with alternate therapeutic options.
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**Background/Aims:** Total thyroidectomy followed by radioiodine therapy (RIT) and life long hormone replacement is the routine protocol of differentiated thyroid cancer management. During follow up usually we consider serum thyroglobulin (Tg) and whole body scan (WBS) with ^131^I. This study was designed to unravel the impact of ultrasonography in patients with recurrent thyroid cancer where WBS was negative and normal Tg level. **Methods:** We enrolled ten patients (age 36±13 years; 9 female) who were attended to Institute of Nuclear Medicine & Allied Sciences (INMAS), Dhaka for routine follow up. All patients were sent for further management after total thyroidectomy. Thyroid scan with ^99m^Tc and other relevant laboratory tests were performed initially. RIT was given according to our institutional protocol. During follow up at certain intervals WBS with 4 mCi ^131^I and Tg level were evaluated. Along with these, neck palpation and high resolution ultrasound were done routinely for specific features of metastasis (i.e loss of hilar fat, rounded shape & micro calcification). **Results:** All of them had differentiated papillary thyroid carcinoma. Two patients needed revision surgery for removing residual tissue. Lymphovascular invasion was present in 4 patients and substantially they needed radical neck dissection. Four patients needed nodal dissection for the 2^nd^ time. Six patients took 150mCi radioiodine, one patient 75mCi, one patient 50mCi, and remaining patient underwent operation abroad and had 30mCi. Six patients needed radioiodine ablation twice. Tg level at the time of recurrent disease was 6.5±3.85ng/ml (Normal range 6.45-20.27ng/ml) and all of them showed normal findings in WBS. **Conclusion:** During routine check up not only Tg & WBS, neck palpation and high resolution ultrasound played pivotal role for evaluating nodal metastasis where WBS and Tg level were unfavourable. This work may open new research window.
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**Background/Aims:** Risk stratification in well-differentiated thyroid cancer is based on various available prognostic scoring system which help in differentiated thyroid cancer management. Most of the prognostication data available in literature comprises of papillary thyroid cancer but very few have addressed this issue in patients with follicular thyroid cancer (FTC) alone. Moreover, there are several limitations in existing prognostic scoring systems. These systems only address survival rates and not recurrence, and as the number of deaths from thyroid cancer is small, this poses a restriction in the use of the current risk stratification systems. The aim of this study was to establish the accuracy of the various scoring systems in risk stratification disease specific survival of FTC patients in Pakistan. **Methods:** Retrospective review was undertaken of 76 patients with FTC treated at a Nuclear Medicine, Oncology & Radiotherapy Institute (NORI) Islamabad, between January 2006 to December 2016. Demographic, clinical, pathological and treatment outcomes were analysed. Prognostic scoring systems evaluated for the cohort included TNM, AGES, MACIS, AMES, NTCTCS, clinical scoring system, Ankara Scoring System and EORTC (European Organisation for Research and Treatment of Cancer). Statistical analysis was performed by plotting Kaplan--Meier survival curves and using the Cox proportional hazards model. **Results:** There were 17 male and 59 female patients with a mean age of 45 years. The mean follow-up duration was 56 months and there were 7 deaths (9.21%). The ten-year overall survival rate was \> 76%. Factors predictive of survival on univariate analysis were age, size of tumour, invasiveness, completeness of resection, metastasis, and risk scores using the TNM, Clinical Scoring and MACIS scoring systems (*p*\<0.05). On multivariate analysis, AGES and MACIS provided the best prognostic information. **Conclusion:** MACIS is the best prognostic scoring system currently available for FTC and it is superior to other scoring systems in term of guiding management. TNM, NTCTCS and clinical scoring also provided useful information in guiding the clinical management. The scoring systems require alterations to address the variations in regional clinical practice and to improve the prognostic power.

P007: The Role of Air Pollution in the Incidence and Mortality of Thyroid Cancer in 27 Countries of the European Union for the Years 1992, 2002, 2012
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**Background/Aims:** During past decades, an increasing incidence of TC has been reported, while its mortality is almost constant and comparatively low. It is currently unclear whether the observed increases are real or due to increased diagnosis, as there exist many analyses stating a real increase in the incidence and mortality of TC of all sizes and stages, with different distribution depending on gender, race, age and environmental conditions. Recent studies are examining risk factors such as diet and exercise, benign thyroid diseases as well as genetic factors. There are only few epidemiological studies examining the effects of exposure to chemical agents. Therefore, the study of environmental factors, potentially influencing the onset and prognosis of TC, such as air pollution is a research field of great interest. The aim of this study is to investigate the role of air pollution in the incidence and mortality from TC in 27 countries of the EU for the years 1992, 2002, 2012. **Methods:** This is an analytical, ecological, observational study. There were conducted a thorough literature review, data collection from online databases, statistical processing and analysis. This ecological study used age-adjusted incidence and mortality rates of thyroid cancer for the year 2012 with respect to 23 air pollutants as well as 179 socioeconomic confounding factors in the EU for the above years. **Results:** Data analysis revealed a positive correlation between male incidence of 2012 and male mortality of 1992 of TC and levels of benzo(k)2fluoranthene (BKK) (p=0,04, r^2^=0,21) and mercury (Hg) (p=0,04, r^2^=0,17) respectively. Socioeconomic factors examined as confounders, presenting a positive correlation between male incidence of 2012 and Gross-National-Income-per-capita (NIPC), purchasing-power-parity as well as between male mortality of 1992 and adjusted-net-NIPC, adjusted-net-NIPC, hospital-beds-per-1,000-people, Gross-Domestic-Product, Gross-NIPC and purchasing-power-parity. Multiple linear regression did not reveal any statistically significant correlation between the above epidemiological and confounding factors. **Conclusion:** A positive correlation between the incidence and mortality of TC and BKK & Hg levels was revealed. Although higher socioeconomic status was associated with increased incidence and mortality, no apparent confounding effect was detected in TC's correlation to air pollution.
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**Background/Aims:** To explore the patients' recurrence or metastasis status and prognosis of the coexistence of autoimmune thyroid disease (AITD) with differentiated thyroid carcinoma (DTC), explain the association between DTC and the abnormal thyroid autoimmunity. **Methods:** 132 patients with DTC who had undergone thyroidectomy with positive TgAb were divided into two groups as A1 (n=84) and A0 (n=48) according to whether the patient present with concurrent AITD or not. Evaluation of the patients' recurrence or metastasis status according to ^131^I whole body scan (^131^I-WBS), SPECT/CT and ultrasound examination. Compared TgAb levels, the incidence of recurrence or metastasis, and the median time for disappearance of TgAb between the two groups. **Results:** Of the 132 DTC patients with positive TgAb, 84 (63.3%) were concurrent with AITD. There was no significant difference between the two groups (t=-1.613, p=0.110) in TgAb levels. The incidence of recurrence or metastasis between group A1 and group A0 were 42.9% (36/84) and 22.9% (11/48) respectively, the difference was statistically significant (x^2^=5.297, p=0.021). The median time for disappearance of TgAb of the patients who had followed-up regularly in 6-27 months (n=85) were 12.75 months in group A1, and 20.74 months in group A0, the difference was statistically significant (p=0.040). **Conclusion:** The existence of elevated levels of TgAb in DTC patients may indicates the coexistence of AITD. DTC patients concurrent with AITD probably have a greater incidence of recurrence or metastasis, while the enhanced thyroid autoimmune reactions may also produce a protective effect on the prognosis of DTC patients.
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**Background/Aims:** To identify clinical conditions closely associated with thymic uptake on ^131^I post-therapeutic scan in patients with differentiated thyroid carcinoma (DTC). **Methods:** Post-therapeutic ^131^I whole body and SPECT or SPECT/CT scans of 599 consecutive patients were retrospectively reviewed. Radioiodine thymus gland uptake (RTU%), was observed in 16 (3.1%) patients (3 male). Although, without histological confirmation, all patients had a CT scan suggestive of residual thymus. A possible relation with age, sex, type and TNM stage of DTC, total administered ^131^I dose, number of therapies, type of TSH stimulation (withdrawal or rhTSH), TSH, Tg, TgAb levels was assessed. **Results:** Mean age of patients with thymic uptake was significantly lower (p\<0.001). LT4 withdrawal and repeated ^131^I therapies also proved to be significant indicators for RTU% (p=0.03). Logistic regression analysis revealed that only the repeat radioiodine therapies and young age were correlated with RTU% (p\<0.001). **Conclusion:** Especially in young patients with repeated ^131^I therapies, physiological radioiodine concentration by the thymus gland is a potential cause of false positive post-therapy ^131^I scans.

P010: Clinical and Image Parameters Associated with the Total Absorbed Dose Assessed by Iodine Scan-Based Dosimetry in Differentiated Thyroid Cancer Patients
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**Background/Aims:** To assess clinical and image parameters associated with the total absorbed dose assessed by iodine scan based dosimetry in differentiated thyroid cancer (DTC) patients. We performed I-131 whole body scan (WBS) based dosimetry in postoperative radio-active iodine (RAI) ablated DTC patients of Chonnam National University Hwasun Hospital (CNUHH). **Methods:** Ongoing research work with 38 thyroidectomized DTC patients till now. Study subjects had first RAI therapy after TSH stimulation with recombinant human thyrotropin (rhTSH). Patients with high serum anti-Tg antibody (TgAb, ≥ 100 U/mL), TSH stimulation with thyroid hormone withdrawal and extensive metastases were excluded. Three sequential WBSs on post ablation days 2 and 7 (2 scans on D2 and 1 on D7) and corresponding serum Thyroglobulin (Tg), TgAb and TSH were measured on therapy day (D0), D2 and D7. Residence times of remnant thyroid tissues were calculated using a dosimetric toolkit and total absorbed doses with OLINDA/EXM software. Patients were classified in Group 1 (total absorbed dose ≤145) and group 2 (\>145) for further analysis and comparison with D7Tg. **Results:** Thirty patients (M=10, F=20) were eligible for preliminary analysis; 15 in group 1 and 15 in group 2. Total absorbed doses in thyroid bed remnants calculated in this study fall into a wide range (36-1347 mSv/MBq) with a mean (± SD) of 242.33±28. Based on univariate analysis, D7Tg (4.27±9.81 vs. 33.81±65.81; p\<0.000) and thyroid count (1.78±0.74 vs. 5.59±2.45; p\<0.000) were significantly higher in group 2. On the other hand, gender, tumour (T) stage, lymph node (N) stage, primary lesion size, multiplicity or bilaterality of primary tumour, positive BRAF mutations were not significantly different in the two groups. **Conclusion:** Higher Tg level and neck activities on post-therapy I-131 scans were associated with the total absorbed dose. Survival analysis will be done in the patient groups.
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**Background/Aims:** The aims of the study were: 1) to investigate the relationship between the level of TgAb and its recurrence or metastasis in patients with differentiated thyroid carcinoma (DTC) after surgery and 131-iodine (^131^I) treatment; and 2) to evaluate the diagnostic value of TgAb in the post-operation of DTC and ^131^I treatment. **Methods:** A total of 253 post-surgical patients with DTC were divided into two groups, respectively the metastasis group and non-metastasis group, according to pathology, imaging diagnosis (including ^131^I-SPECT/CT tomography, CT, MRI, ultrasonography, etc.) and clinical follow-up. The level of TgAb in the stimulated serum of the abovementioned two groups were measured and analysed with independent t test. Out of all patients studied, 46 patients with positive level of TgAb and undertook repeated ^131^I treatments were selected and divided into cured or improved group (i.e. effective group) and no change or aggravated group (i.e. ineffective group). The level of TgAb in these two groups were continuously monitored and analysed with chi-square test. **Results:** Overall, 18.9% of all patients studied were identified as TgAb positive. The percentage of TgAb positive patients in the metastasis group and non-metastasis group were 11.7% and 21.6%, respectively. The level of TgAb in the metastasis group were 153.96±550.52 IU/mL, and that in the non-metastasis group were 190.01±515.67 IU/mL. There was no statistical significance in the difference between the level of TgAb in the metastasis group and non-metastasis group (t=-0.514, p=0.608). Continuous monitoring found that the level of TgAb in the effective group increased in 3 cases and decreased in 24 cases, while the level of TgAb in the ineffective group increased in 15 cases and decreased in 4 cases. The changes in the level of TgAb in these two groups was statistically significant (x^2^ =21.546, p\<0.001). **Conclusion:** TgAb positive is of little value in the diagnosis of the recurrence or metastasis of DTC. However, the continuous decrease of TgAb can indicate the decrease in the size or number of lesions, while the continuous increase may signal the increase in the size or number of lesions.
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**Background/Aims:** Papillary thyroid carcinoma is the most common histological subtype of thyroid carcinoma. Management primarily is surgical with post-operative radioiodine therapy to ablate thyroid tissue remnants. Although the management of uncomplicated papillary thyroid carcinoma is well established, treatment of patients affected with Moyamoya disease as a co-morbidity is limitedly described. There are concerns with regards to doing radioactive iodine radiation which might affect the diseased arteries in Moyamoya disease. We present a patient with a known case of Moyamoya disease who developed papillary thyroid carcinoma and was subjected to radioactive iodine therapy post-operatively. **Methods:** We report a case of a 36-year old male, previously diagnosed with Moyamoya disease, who noticed an enlarging anterior neck mass. Biopsy revealed papillary thyroid carcinoma and subsequent total thyroidectomy was performed. The patient underwent radioactive iodine therapy with a dose of 5.7 GBq (155.0 mCi). There were no complications encountered in relation with the patient's Moyamoya disease. Post-ablation scan was done showing functional thyroid tissue remnants in the lower anterior neck with suspicious distant tracer-avid focus. He was then maintained on levothyroxine 50 mcg daily and was advised short interval scintigraphic monitoring. **Results:** Surgery with post-operative radioiodine therapy is still the treatment of choice for the patient given his risk assessment. The Moyamoya disease co-morbidity of the patient was considered and did not resulted in radiation induced arteritis or any other complications during high dose post-operative radioiodine ablation therapy. **Conclusion:** Our patient with Moyamoya disease who developed papillary thyroid carcinoma reports no complications almost one year after he had undergone surgery and radioactive iodine therapy.
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**Background/Aims:** To evaluate the clinical characteristics and implications of midline uptake on post-ablation whole body scans (Rx-WBS) after initial ^131^I ablation. **Methods:** Differentiated thyroid cancer patients, underwent initial ^131^I ablation after total thyroidectomy, without metastasis on Rx-WBS or other imaging studies, followed up 6 months after remnant ablation, were enrolled in our study. Two groups were classified according to midline uptake above the thyroid bed on Rx-WBS: group 1 was negative (only thyroid remnants on the thyroid bed); group 2 was positive (midline uptake above thyroid bed). Patients with star artifact or any other ambiguous Rx-WBS findings and positive thyroglobulin antibody were excluded. The baseline characteristics and follow-up results after initial remnant ablation between two groups were analysed. Response-to-therapy system was based on 2015 ATA guidelines. **Results:** A total of 160 patients were studied, and female patients were more than male patients (140 vs. 20). 81 patients were in group 1 and 79 patients were in group 2. Based on univariate analysis, baseline characteristics, such as age, sex, stimulated thyroglobulin before ^131^I ablation, risk stage and recurrence risk stage were not significantly different. But the positive rate of thyroid scintigraphy (χ^2^=17.587, p=0.001) and thyroid radioiodine uptake rate (2.69±1.59 vs. 4.25±4.01, t=-4.208, p=0.001) were significantly higher in group 2. The success rate of ^131^I remnant ablation (χ^2^=1.011, p=0.315) and response-to-therapy (χ^2^=1.05, p=0.592) were not significantly different, too. **Conclusion:** The midline uptake on post-ablation whole body scans is related to enhance ability to accumulate ^131^I, but which is not related to success rate and response assessment of initial ^131^I ablation.
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**Background/Aims:** Medullary thyroid carcinoma (MTC) is a rare thyroid carcinoma developing from parafollicular C-cells secreting calcitonin and carcinoembryonic antigen (CEA). Imaging techniques in the diagnosis of MTC is still problematic. Seventy-five percent of MTCs reveal overexpression of somatostatin receptors (SSTR), so it is promising nuclear medicine imaging techniques. The aim of the study was to determine the usefulness of PET/CT imaging of somatostatine receptors with ^68^Ga-DOTATATE in patients with medullary thyroid carcinoma. **Methods:** This was a prospective study approved by the Ethical Committee of Medical University of Warsaw. 12 patients (6 males and 6 females, age 54.7 ± 16.1) with histologically proven MTC were enrolled in the study. The clinical indication for imaging was the preoperative staging in three of them and the suspicion of recurrence after surgery in the remaining group. All patients underwent somatostatin receptor imaging (SRI) with ^68^Ga-DOTATATE PET/CT (60 minutes post 120-160MBq injection). PET/CT findings were compared with histopathological examination or clinical follow-up. **Results:** All patients had rising calcitonin levels with the median calcitonin level of 202.7 pg/ml (N\<10 pg/ml). The CEA level was normal in 5 patients and elevated with median 10.4 ng/ml (N\<5.0) in the rest. ^68^Ga-DOTATATE PET/CT was positive in 11 patients, negative in one patient. All patients with primary tumours had positive examinations. The patients with the recurrence of the disease had a positive uptake in the lymph node. ^68^Ga-DOTATATE PET/CT was true positive in 9 patients, true negative in one patient and false positive in 2 patients. The sensitivity, specificity, positive and negative predictive values were 90%, 33.3%, 81% and 100% respectively. There was no correlation between the calcitonin and CEA level and the result of ^68^Ga-DOTATATE PET/CT. **Conclusion:** Results of our report indicate that ^68^Ga-DOTATATE PET/CT is a promising tool for the imaging of MTC.
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**Background/Aims:** Most of thyroid nodules are benign nodules that require no surgery. One of the treatment options for benign thyroid nodules is radioactive iodine (RAI). However, this treatment is more effective for hot/warm thyroid solid nodules. Cold thyroid solid nodules are characterized by the lack of iodine uptake compared to normal thyroid tissue. Oral retinoid acid (RA) is a synthetic derivatives of vitamin A. The effect of RA to the uptake of radioactive iodine is still controversial. The aim of this study was to evaluate the effect of RA in the ability of cold thyroid solid nodule to take up RAI. **Methods:** Subjects with solid thyroid nodule and less iodine uptake based on ultrasonography and thyroid scintigraphy were included. Subjects with liver dysfunction, smoking, and pregnant were excluded. Each subject underwent thyroid uptake scintigraphy twice (pre- and post- RA consumption) using 35 -- 37 MBq NaI-131. Subjects consumed RA with dose of 1 mg/kg BW for 2 weeks followed with 1.5 mg/kg BW for the next 4 weeks. This study was approved by Dr. Hasan Sadikin General Hospital Ethic Committee. **Results:** There were 12 subjects included in this study, 2 subjects were dropped off. A total of 12 cold thyroid solid nodules were evaluated from 10 subjects. The mean percentage of the nodules uptake value pre- and post-intervention were 1.11% and 0.62% respectively (p=0.004), while normal thyroid tissue uptake value pre- and post-intervention were 27.57% and 13.40% respectively (p=0.002). The percentage alteration of nodules and normal thyroid tissue uptake value were 42.4% and 51.5% lower respectively (p=0.354). **Conclusion:** This study showed that RA reduce the ability of cold thyroid solid nodule to take up RAI as well as normal thyroid tissue.
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**Background/Aims:** The value of post-ablation ^131^I whole body scintigraphy (PAS) is less described in staging and initial risk-stratification of children with thyroid cancer. The current study was designed to determine the diagnostic value of PAS during initial staging and risk-stratification in children with thyroid cancer. In addition, the relation between the pre-ablation stimulated Tg levels and PAS findings was examined. **Methods:** From August 2009 to December 2015, consecutive children with thyroid cancer undergoing remnant ablation was retrospectively recruited. A lung computed tomography was performed for each child within 2 weeks of the initial diagnosis of thyroid cancer for examination of metastatic lesions. PAS was obtained 5 days after administration of ablation activity of ^131^I. ROC curve analysis was employed to find a cutoff level of pre-ablation stimulated Tg as a predictor of distant metastases at the time of ablation. **Results:** Fifty-seven children were eligible for the analysis. Initial lung CT showed that pulmonary metastases in 15 (26%) children. Metastases were noticed on PAS in 20 (35%) children: 5 post-operative residual neck lymph node metastases, 4 post-operative residual neck lymph node and lung metastases, 3 mediastinal lymph node and lung metastases, 8 lung metastases. None of the children staged pN0 or M0 was found to have unexpected regional and distant metastasis. Neither staging nor initial risk-stratification was altered after completing PAS in study cohort. A significant difference in pre-ablation stimulated Tg levels was found in children with distant metastases compared with those without distant metastases, 5.7 vs. 603.5 ng/mL, respectively. A pre-ablation s-Tg level of 156 ng/mL was established as the optimal cutoff point to predict distant metastases. **Conclusion:** The role of PAS in improving staging or initial risk-stratification was minimal in children with thyroid cancer. A relationship was observed between pre-ablation stimulated Tg levels and PAS findings, indicating that pre-ablation stimulated Tg could potentially act as a predictor of distant metastases at the time of ablation in children with thyroid cancer.

P018: Distribution and Association of Preablation Stimulated Thyroglobulin and Clinical-Pathological Characteristics
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**Background/Aims:** The prognostic role of pre-ablation stimulated thyroglobulin (s-Tg) in thyroid cancer has attracted increasing attention. The current study was designed to investigate the distribution and association of post-operative pre-ablation s-Tg and clinical-pathological characteristics. **Methods:** From January 2013 to July 2015, consecutive thyroid cancer patients undergoing remnant ablation was retrospectively recruited. All patients have had to undergo total thyroidectomy and in all cases, no grossly visible thyroid remnants remained. Pre-ablation s-Tg and TgAb levels were measured during hypothyroidism just before the ablative ^131^I administration. Patients with positive TgAb (\>40 IU/mL) and distant metastases noticed on post-ablation whole body scintigraphy and other imaging modalities were excluded. **Results:** The study cohort consisted of 664 patients. The initial risk-stratifications according to the ATA 3-level risk category were low-, intermediate- and high-risk for 174 (26%), 436 (66%) and 54 (8%) patients, respectively. The mean time interval between surgery and pre-ablation s-Tg measurements was 3.2 months. The mean values of pre-ablation s-Tg were 1.55 ng/mL, 8.97 ng/mL, and 25.01 ng/mL (normal range: 0.04--244 ng/mL), respectively, for low-, intermediate- and high-risk patients (p\<0.05). Notably, only 1% of low-risk patients had pre-ablation s-Tg higher than 10 ng/mL, 42% of intermediate-risk patients and 13% of high risk patients had pre-ablation s-Tg \<1 ng/mL. None of the criteria characterising the population (age at diagnosis, sex) or the disease (TNM stage, tumour size, the presence of extra-thyroidal extension, the presence of aggressive histology, location and number of lymph node metastases) was statistically significant association with pre-ablation s-Tg levels. **Conclusion:** There is an overlap in pre-ablation s-Tg levels across different initial risk-stratification groups.
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**Background/Aims:** Thyroidectomy is a procedure with well-known potential risks and complications, amongst others, hypocalcemia following surgery. Patients routinely undergo post-operative testing to exclude hypocalcemia following thyroidectomy as patients may initially be asymptomatic. Once patients are treated in our thyroid cancer clinic, there is no further routine investigation of serum-calcium levels, except if the patient becomes symptomatic. There have been reports in literature to suggest that some patients may become hypocalcemic following the administration of radioactive iodine, whether transient or permanent. This prompted us to investigate the incidence of possible hypocalcemia in our patient population to identify asymptomatic patients requiring calcium supplementation timeously. This may indicate whether routine testing of serum-calcium should be performed in our institution. **Methods:** This is a prospective, ethics approved, study of patients referred to the Thyroid Cancer Clinic at Charlotte Maxeke Johannesburg Academic Hospital. The patients consented to be enrolled in the study. Serum calcium was measured and compared to the initial calcium levels following surgery. We aimed to enrol 50 patients for an audit of the incidence of patients that may have been hypocalcaemic or became hypocalcaemic. **Results:** 52 patients (5 males; 47 females) entered the study (mean age 49.7±13.7 years). Seven were found to be hypocalcaemic (s-Ca \<2.15mmol/l) \[Normal 2.15-2.50mmol/l\]. They had s-Ca levels ranging from 1.73 mmol/l to 2.11 mmol/l (mean 1.99 mmol/l). Six patients were already hypocalcaemic following surgery and 1 patient had a normal calcium of 2.29 mmol/l post-surgery. This patient received 5550MBq I-131 and now presented with a s-Ca of 1.75mmol/l and PTH = 1.2pmol/l \[normal 1.60 -- 6mmol/l\]. There were no obvious other causes that could account for the patient' current hypocalcaemia other than ^131^I therapy. **Conclusion:** Routine measuring of s-Ca may assist in detecting patients that are not on optimal calcium replacement or may have become hypocalcaemic following treatment with radioactive iodine.

P022: The Optimum Level of Serum Thyroid Stimulating Hormone Necessary for Complete Ablation in Patients with Low- to Intermediate-Risk Differentiated Thyroid Carcinoma
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**Background/Aims:** Elevated serum thyroid stimulating hormone (TSH) level is necessary to achieve uptake of radioactive iodine in remnant thyroid tissue during ablation. A cut-off value of 30 mIU/L is commonly use; a decision without a strong support from the literature. We aimed to determine the optimum TSH level necessary for complete ablation of well differentiated thyroid carcinoma using I-131 following initial thyroidectomy in patients with low- to intermediate risk thyroid carcinoma. **Methods:** A total of 108 patients (female=76, male=32; mean age=45 years) with low- to intermediate-risk differentiated thyroid cancer treated with 370GBq of I-131 were divided into three groups based on pre-ablation serum TSH levels (30 - \<60 (n=38); 60 - \<90 (n=24) and ≥90 (n=46)). They were followed-up for 12-24 months post treatment with stimulated serum thyroglobulin level, anti-thyroglobulin antibodies, clinical examination and diagnostic whole-body scan with radioactive iodine I-123. Treatment outcome was classified according to the four response-to-therapy categories recommended by the American Thyroid Association. Approval for the study was obtained from the institution's review board. **Results:** Sixty-two patients had papillary thyroid carcinoma while 46 had follicular carcinoma. Complete ablation was seen in 67.4% of patients with TSH level ≥90, in 70.8% of the 60 to \<90 group and 44.7% in the 30 to \<60 group (p=0.017). In a multivariate analysis done to determine the predictors of complete ablation, only pre-ablative TSH level was found to be an independent predictor of successful ablation, Odds Ratio=1.754 (95% CI 1.190-2.586, p=0.005). The effect of other factors such as age, gender, histological sub-type and pre-treatment thyroglobulin level did not reach statistical significance. **Conclusion:** In patients with low- to intermediate-risk differentiated thyroid carcinoma treated with 370 GBq of I-131 post-thyroidectomy, the highest rate of complete ablation is obtainable at TSH levels between 60 and 89 mIU/L.
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**Background/Aims:** Total thyroidectomy and radioiodine (I-131) ablation have been used for patients with differentiated thyroid cancer (DTC). Before radioiodine ablation theraphy, thyroid scintigraphy with ^99m^Tc-pertechnetate is performed to evaluate the remnant thyroid tissue existence and to investigate possible metastatic regions in the neck. **Methods:** Twenty-eight patients who received radioiodine ablation for DTC were examined retrospectively. Every patient had ^99m^Tc-pertechnetate scintigraphy 3-6 weeks after the surgery and postablative (RxWBS) ^131^I whole body scan 7-10 days after the radioiodine ablation therapy. Remnant tissue localisations and number of foci were compared. **Results:** Thirteen (46.4%) of 28 patients have exactly the same number of foci at the same localisations at both images. ^99m^Tc-pertechnetate scintigraphy showed no uptake of remnant thyroid tissue at 2/28 (7.1%) patients, while RxWBS exposed radioiodine avid remnant tissues. 7/28 (25%) patients had more number of remnant foci at ^99m^Tc-pertechnetate scintigraphy, and 6/28 (21.4%) patients had more at RxWBS. **Conclusion:** Eight patients had more number of foci at RxWBS than ^99m^Tc-pertechnetate scintigraphy due to different uptake mechanisms of these two agents. 7 (25%) patients had more number of foci at ^99m^Tc-pertechnetate scintigraphy due to star artifact. As a result, while evaluating the remnant thyroid tissue existence there was no prominent difference between these two scanning procedures. ^99m^Tc-pertechnetate scintigraphy is easy to perform and cost-effective; it is appropriate to evaluate the remnant thyroid tissue before radioiodine ablation of differentiated thyroid cancer. **Disclosure of interest:** Y Parlak conflict with Celal Bayar University.

P024: Rare Presentation of a Thyroid Cancer Patient with Radioiodine Uptake in Aspergilloma
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**Background/Aims:** Radioiodine (^131^I) ablation and post therapy whole body scan (PTWBS) are standard procedures for thyroid cancer management. Administration of ^131^I has advantages of having therapeutic effects and visualising residual/metastases in thyroid cancer patients. Unusual pathologies may be visualised as false positive scan findings. **Methods:** 54 year old male was treated for papillary carcinoma of the thyroid in 2014. Histology revealed capsular and vascular invasion, no positive lymph nodes. Initially, total thyroidectomy and post-surgical residual ablation dose of 1110mBq was given 6 weeks post-surgery. Pre-therapy serum thyroglobulin (sTg) was 56.1 ng/dl at TSH \>56miu/L. First PTWBS showed significant residual thyroid tissues. Hence second ablation dose of RAI 1110mBq was given after 6 months. The second PTWBS shows no functioning residual thyroid tissue or metastases and sTg has reduced to 0.2 ng/dl at TSH maximum stimulation. Findings were concluded as successful ablation. He is a diabetic with mild renal impairment due to renal stones. He is a farmer, non-smoker. **Results:** He has been on thyroxine since 2014, and recently presented with right side chest discomfort with intermittent blood-stained sputum. No fever or cough. Chest X ray showed well defined opacity in the right apical lung feild which was not seen in previous chest X-rays. It was suspected as lung metastases inspite of low serum Tg level (\<1ng/dl) and negative PTWBS. 3^rd^ RAI ablation dose and PTWBS was suggested. Bronchoscopy examination showed no abnormality. Mantoux test and sputum for acid fast bacillus were negative. 3^rd^ PTWBS showed focal intense radioiodine uptake in the right apical region where the large opacity was seen in the chest X ray. Rest of the scan showed physiological radioiodine uptake. A contrast enhanced CT scan showed a well circumscribed lesion typical of fungus ball which was diagnosed as an aspergiloma. Due to renal impairment and limited pulmonary function surgical resection was not done. Literature survey too showed aspergillosis can lead to radioiodine lung uptake mimicking pulmonary metastases. This is the first case we came across. He was put back on Thyroxine replacement and is being followed up. **Conclusion:** Pulmonary aspergilloma is a known cause of a false positive radioiodine uptake which mimic pulmonary metastases.
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**Background/Aims:** Radioactive iodine thyroid remnant ablation improves the quality of life in patients with differentiated thyroid carcinoma (DTC). Low dose (1110 mBq) ablation is cost effective and widely practiced on an outpatient basis reducing the radiation burden to the patient. Lack of in-ward facilities and inadequate radioiodine supply led us to practice low dose ablation. This study was done to assess the clinical effectiveness of low dose thyroid remnant ablation as on outpatient basis. **Methods:** Cross sectional retrospective study done using the thyroid cancer database at the Nuclear Medicine Unit, University of Peradeniya. All patients were explained the procedure and informed written consent was obtained for necessary multiple therapy administration. DTC patients who were treated with radioiodine and had post-therapy whole body scans from January 2006 -- October 2017 were selected for data analysis. Negative whole-body scan with serum thyroglobulin level of less than 2.0 ng/ml was considered as successful treatment. **Results:** A total of 838 DTC patients were treated and followed up during this period (116 males and 722 females) with a mean age of 42.7 years (range 15-81 y). Common histology type was follicular or follicular variant of papillary carcinoma. Successful ablation with 1110 mBq of Iodine was achieved in 74.9% of the patients (n=404/539) after single administration, in 98.7% (n=69/70) with two doses, in 93.75% (n=15/16) with three doses. Out of 10 patients 9 had to receive (90%) more than 3330mBq (three doses) to achieve successful ablation. Overall success rate was 77.9% (n=482/618) with several 1110 mBq of iodine administration on an outpatient basis. 21.7% of the patients had persistent residual thyroid tissues while 8.4% had nodal or bone metastases which required inward high dose treatment. **Conclusion:** Over 3/4^th^ of DTC patients were successfully treated with low dose radioactive iodine on an outpatient basis.

P027: Comparative Efficacy of Short- and Long-Term Administration of 13 Cis-retinoic Acid as Redifferentiation Drug in Refractory Thyroid Cancer
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**Background/Aims:** Differentiated thyroid cancer accounts for 95% of all thyroid cancers worldwide. Management is mostly by surgery, radioiodine and suppressive dose of levothyroxine. Metastasis occur in about 7-23% of these patients and among them 2/3^rd^ become refractory to radioiodine. To assess comparative efficacy of radioiodine positivity following 6 and 12 weeks administration of 13 Cis-retinoic acid (RA). **Methods:** Twenty-eight patients of refractory thyroid cancer with persistence of disease were administered RA at a dose of 1.5 mg/kg body weight. 15 patients were given for 12 weeks and 13 were given for 6 weeks of RA. Then, radioiodine scan of whole body was done following 4 weeks stoppage of levothyroxine or with recombinant human TSH. Patients who showed positive radioiodine scan was considered as redifferentiation and radioiodine therapy was continued at timed interval. **Results:** Out of 28 patients 13 were male and 15 were female. 23 were papillary carcinoma of thyroid (recurrence, pulmonary or cervical lymph node metastasis), 1 follicular carcinoma, 1 poorly differentiated thyroid cancer, and 3 were Hurthle cell variants. 4/28 (15%) of patients showed positivity following 6 weeks oral administration of RA. These patients were treated with 100-150 mCi of radioiodine depending on disease burden. Long term administration i.e 12 weeks of RA did not add to positivity on radioiodine scan. Following radioiodine therapy, there was decrease in serum thyroglobulin level and increase in radioiodine uptake and clinical improvement. **Conclusion:** Our findings suggest that 13 Cis-retinoic acid redifferentiation therapy for 6 weeks seems to be optimal duration of administration for inducing redifferentiation in refractory thyroid cancer rather than 12 weeks as it did not offer any additional value with respect to radioiodine positivity. This is an alternative therapeutic approach to otherwise untreatable thyroid cancers as RA has mild side effects like mucositis.

P028: Calcium Stimulation Test is a Reliable Test Instead of the Pentagastrin Test for the Diagnosis and Follow-Up of Medullary Thyroid Cancer
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**Background/Aims:** Calcitonin (CT) is an important tumour marker for the diagnosis and follow-up of medullary thyroid cancer (MTC). The aim of this study was to evaluate the reliability of calcium stimulation test (CST) for MTC diagnosis and follow-up as compared with pentagastrin test. **Methods:** A total of 256 patients (123 females and 133 males, mean age of 56±27 years, range 21-83 years) had both pentagastrin (0.5 µg/kg body weight) and calcium (2.5 mg/kg body weight calcium gluconate) stimulation tests. Among them, 28 patients with thyroid goiter had thyroidectomy after both CST and pentagastrin test. **Results:** Stimulated CT levels after administration of pentagastrin or calcium were significantly correlated in all groups. The cut-off values with best sensitivity and specificity to differentiate between MTC and C-cell hyperplasia (CCH) plus healthy individuals were above 727 pg/ml for men and above 395 pg/ml for women. The cut-off values for differentiation between MTC plus CCH and healthy individuals were above 590 pg/ml in men and above 160 pg/ml in women. **Conclusion:** CST seems to be a reliable, safe and effective test and may replace the pentagastrin test for the diagnosis and follow-up of MTC.
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**Background/Aims:** This prospective study was to investigate the value of ^11^C-acetate PET and ^18^F-FDG PET in the detection of differentiated thyroid cancer (DTC). **Methods:** Eight patients (5 female, 3 male; age range 61--82 years, mean 68 years; 3 papillary and 5 follicular carcinoma) with metastatic DTC underwent ^11^C-acetate PET and ^18^F-FDG PET. ^131^I-whole body scan (WBS) was performed 3--5 days after oral administration of the therapeutic dose. **Results:** A total of 29 lesions \[14 lung, 7 bone, 4 mediastinum, 3 lymph node (LN), 1 brain\] were diagnosed as metastases by histopathology and/or other imaging modalities (US, CT, MRI, bone scan and ^131^I-WBS). The lesion-related sensitivity of ^11^C-acetate PET, ^18^F-FDG PET and ^131^I-WBS was 31% (n=9), 86% (n=25) and 45% (n=13), respectively. ^18^F-FDG PET, ^11^C-acetate PET and post-therapeutic ^131^I-WBS revealed eleven (79%), three (21%) and seven (50%) lung metastases, respectively. Four (100%), one (25%) and one (25%) mediastinum metastases demonstrated by ^18^F-FDG PET, ^11^C-acetate PET and post-therapeutic ^131^I-WBS, respectively. ^18^F-FDG PET, ^11^C-acetate PET and post-therapeutic ^131^I-WBS showed five (71%), three (43%) and three (43%) bone metastases as well as three (100%), two (67%) and one (33%) lymph node metastases, respectively. ^18^F-FDG PET and ^11^C-acetate PET were positive in 11 (85%) and only 2 (15%) of the thirteen ^131^I-WBS positive lesions, respectively, and also in sixteen (100%) and seven (44%) of the sixteen ^131^I-WBS negative lesions, respectively. Comparison of ^18^F-FDG PET with ^11^C-acetate PET revealed concordant results in 12 lesions, and discordant results in 17 lesions (sixteen with positive ^18^F-FDG PET alone and one with positive ^11^C-acetate PET alone). **Conclusion:** ^18^F-FDG PET is much superior to ^11^C-acetate PET in terms of ability to detect metastases of DTC.

P030: The Influence on Low-Iodine Diet by Continuation of Levothyroxine with Recombinant Human Thyroid Stimulating Hormone Stimulated Thyroglobulin Levels at Radioactive Iodine Ablation
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**Background/Aims:** Radioactive iodine (RAI) ablation is a beneficial, adjuvant therapy for the management of differentiated thyroid cancer (DTC) after thyroidectomy. Radioactive iodine uptake is enhanced by stimulating TSH levels prior to ablation. One method of stimulating TSH is the use of recombinant human TSH (rhTSH), and rhTSH can continue medication of levothyroxine. But the influence on low-iodine diet (LID) due to continuation of medication of levothyroxine has not been known. This time, we investigated whether continuation of levothyroxine affects LID at RAI ablation by using urinary iodine concentration. **Methods:** We targeted 60 patients who needed RAI ablation with 1110 MBq after thyroidectomy of high-risk DTC. We divided the patients into two groups, A group (49 patients, ablation therapy using rhTSH only) and B group (11 patients, discontinued levothyroxine for the last 3 days including the day of the ablation therapy, in addition to the protocol of A group). They were taught of the protocol and meal of LID for 2 weeks by nuclear medicine specialists and nutritionists. Each urinary iodine concentration was measured and the success rate of LID was calculated. The success of LID was defined as a pre-ablation spot urinary iodine concentration of \<100 mcg/l and/or a urinary iodine to creatinine ratio of \<100 mcg/gCr. **Results:** Success rates of Group A and Group B were 76% (37/49) and 82% (9/11), which were nearly equal. **Conclusion:** When TSH stimulation with rhTSH was performed, it was presumed that continuation of medication of levothyroxine was considered to have no effect on LID and it was considered that withdrawal of levothyroxine was not necessary.

P031: Incident of Thyroglobulin Elevated and Negative Iodine Scan Syndrome on Differentiated Thyroid Carcinoma Patient with Radioiodine Ablation in 2016
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**Background/Aims:** In differentiated thyroid carcinoma (DTC) cases, elevated stimulated thyroglobulin level with negative whole body iodine scan (WBS), which known as thyroglobulin elevated and negative iodine scan (TENIS) syndrome, is a challenge both in therapy and diagnostic. This study aimed to determine the incidence of TENIS syndrome during 2016 in Dr. Hasan Sadikin General Hospital (RSHS), Bandung and the characteristics of patients with TENIS syndrome. **Methods:** TENIS syndrome cases was collected by tracking the medical records of DTC patients having ^131^I therapy in RSHS during 2016. Data on sex, age, DTC type, TSH levels, thyroglobulin levels, antithyroglobulin antibody levels prior to therapy, and post therapy WBS (rxWBS) results were analysed. Thyroglobulin level were divided into 3 groups (group A: 10-30 ng/mL, group B: \>30-50 ng/mL and Group C: \>50 ng/mL). **Results:** TENIS syndrome cases were observed in 37/372 (9.9%) DTC cases. TENIS syndrome was found in 9 (24.3%) male patients (all of them \>40 years old) and 28 (75.6%) female patients with 15 of them \>40 years old. There were 28 papillary thyroid carcinoma (PTC), 4 PTC follicular variant, 4 follicular thyroid carcinoma (FTC), and 1 FTC oncotic variant. Pre-^131^I thyroglobulin levels were in range of 13.1-3107ng/mL (group A: B: C = 12:3:22 cases,), TSH level in range 8.7-209.7 μIU/mL and antithyroglobulin antibody level in range 0-\>3000 IU/mL. 21/37 cases (56.7%) underwent SPECT/CT imaging. Non-iodine avid lymphadenopathy was found in 14 cases. **Conclusion:** TENIS syndrome is not an uncommon finding. Most patients were more than 40 years old with thyroglobulin levels \>50 ng/mL and PTC as the subtype of DTC.

P032: The Ability of BRAF Therapy to Convert an Iodine Negative to Iodine Positive Thyroid Cancer Patient
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**Background/Aims:** A 77 year old man presented with a cerebral metastasis from papillary carcinoma of the thyroid. Investigations revealed a left thyroid lobe primary with extensive locoregional lymph involvement and pulmonary metastases. He was treated with a total thyroidectomy, central and left lateral lymph node resection and a 5.8GBq dose of I-131. Unfortunately, the post treatment scan revealed uptake in the thyroid bed but no uptake in the pulmonary metastases. **Methods:** The tumour was found to be BRAF positive. The patient was commenced on 2 BRAF inhibitors - cobimetinib and vemurafenib, for treatment of his metastatic disease. It was also hoped that these agents may result in redifferentiation of his tumour. **Results:** After 3 months of BRAF inhibitor therapy, an I-123 scan confirmed uptake in right cervical lymph nodes and multiple pulmonary metastases, a further therapeutic dose of 5.8GBq of I-131 was then administered. Following this second treatment, the post therapy scan confirmed excellent uptake in right cervical lymph nodes and pulmonary metastases. This result mimics the findings reported previously when the MEK inhibitor, selumetinib, was shown to be able to reverse radioiodine refractory disease.\[[@ref1]\] **Conclusion:** This case illustrates the ability of BRAF inhibitor therapy to convert radioiodine refractory disease into iodine positive disease, enabling I-131 therapy to be administered more effectively in a patient with a BRAF positive tumour.

P033: Prognostic Value of First Thyroglobulin in Low- and Intermediate-Risk Patients with Differentiated Thyroid Cancer
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**Background/Aims:** To define prognostic value of the first Tg (fTg) measured after thyroidectomy and just before radioiodine therapy (RIT), in low/intermediate risk patients and to find optimal threshold of fTg for prediction of incomplete response. **Methods:** This is a retrospective study in 383 patients with low/intermediate risk DTC who were treated with surgery followed by risk based administration of 1110-5550MBq of I-131. Response to treatment was assessed 1 and 2 years after RIT. Odds ratio of different risk factors like age, sex, TNM stage, fTg and Anti-Tg Ab were compared between patients with and without incomplete response 1 and 2 years after treatment. Receiver operating curve (ROC) analysis was used for definition of optimal fTg cut off for prognostic purpose. **Results:** 273 patients (218 female:55 male) with DTC including 252 PTC and 21 FTC with mean age of 37.5±14.5 years had negative anti-Tg antibody. 86 patients (31.5%) received 1100 MBq of I-131, 70 patients (25.6%): 3700MBq and 117 patients (42.9%): 3700-5550MBq. Using ROC analysis, fTg≥33.5 ng/ml and fTg/TSH ratio of ≥0.36 had the optimal sensitivity and specificity for detection of incomplete response 1 and 2 years after treatment. Multivariate analysis showed that fTg was the most potent risk factor for prediction of treatment failure 1 and 2 years after RIT. **Conclusion:** fTg was the most important risk factor for prediction of treatment failure after RIT and should be included in decision algorithm regarding RIT or optimal iodine dose determination in low/intermediate risk patients with DTC.

P034: Can Dynamic Monitoring of Thyroglobulin Doubling Time Predict Disease Progression in Differentiated Thyroid Cancer?
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**Background/Aims:** Thyroglobulin-doubling time (TgDT) with suppressed serum thyrotropin levels and undetectable anti-Tg antibody is a very strong prognostic predictor in the patients with differentiated thyroid carcinoma (DTC). However, the value of dynamic monitoring of TgDT has not been extensively studied. The purpose of our study is to evaluate the value of dynamic TgDT for monitoring the progression in the patients of DTC. **Methods:** We retrospectively reviewed 22 DTC patients, who had at least 4 serum Tg measurements at a time when serum thyrotropin concentrations were \<0.1mIU/L and with undetectable anti-Tg antibody. Patients were differentiated as progression disease (PD) and stable disease (SD) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. TgDT was computed using Tg values measured during routine follow-up and was calculated by Excel based doubling time and progression calculator. Whole data (WDT), initial 4 data (IDT) and recent 4 data (RDT) of TgDT after total thyroidectomy were calculated and compared by chi-square test. Correlation between the date when dynamic RDT was less than one year and when cancer progressed were compared. **Results:** Among 22 patients, 11 patients were classified into PD and 11 were into SD. The increase rate of Tg between total thyroidectomy and recent data did not show significant difference between PD and SD patients (p=0.3). However, short WDT, IDT and RDT (less than one year) showed correlation with PD (p\<0.05). RDT showed the highest predictive value, with the sensitivity of 90.9%, the specificity of 100% and the accuracy of 95.5%. Among 11 PD patients, 10 patients showed RDT less than one year before progression of disease (median duration, 153 days; range, 88-252). **Conclusion:** Dynamic monitoring of RDT may be a strong PD predictor in patients with DTC.
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**Background/Aims:** To analyse the relations between BRAF^V600E^ mutation and some pathological parameters in Papillary Thyroid Carcinoma (PTC), and to investigate BRAF^V600E^ mutation in PTC coexisting with Hashimoto's thyroiditis or nodular goiter. **Methods:** To retrospectively analyse data of 179 cases of post-operation PTC patients. Clinical data were reviewed and evaluated using SPSS 21.0 statistical software package. **Results:** Among the 179 Chinese PTC patients, the presence of BRAF^V600E^ mutation was 61.5%. There is a correlation between BRAF^V600E^ mutation rate and age or numbers of lymph node metastasis (p\<0.05 respectively). The BRAF^V600E^ mutation rate is higher in PTC patients coexisting with nodular goiter (p=0.024, OR=2,349). **Conclusion:** The BRAF^V600E^ mutation rates have correlation with age, numbers of lymph node metastasis and whether coexisting with nodular goiter.
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**Background/Aims:** Congenital Hypothyroidism (CH) is a condition that causes intellectual disability that can be prevented by thyroid hormone intervention as early as possible. Data from Dr. Hasan Sadikin General Hospital and Dr. Cipto Mangunkusumo General Hospital during 2000 to 2005 found incidence was 1:3528 births. The functional morphological features of the thyroid gland of CH are varies, also affect the management of CH. The aim of this research is to describe the profile of functional morphology of thyroid gland from CH cases which perform thyroid scintigraphy (TS) at Dr. Hasan Sadikin General Hospital in 2014-2015. **Methods:** Retrospective descriptive based on CH medical records data 2014-2015. The functional morphological features of the thyroid gland are obtained from TS examination using ^99m^Tc-pertechnetate. The imaging results may be agenesis, hypoplasia, ectopic and dishormogenesis. **Results:** The number of TS studies on CH for the period 2014-2015 is 66 cases: 21 (31.8%) male and 45 (68.2%) women. Age at examination ≤1 month: 12 cases (18.2%), \>1 month: 54 cases (81.8%). Functional morphological features showed agenesis in 31 cases (46.9%), dyshormogenesis in 24 cases (36.4%), and hypoplasia in 11 cases (16.7%). Case of ectopic thyroid gland were not found. **Conclusion:** The most common functional morphological feature of the HK case at Dr. Hasan Sadikin General Hospital in 2014-2015 is agenesis. Ectopic thyroid gland case not found.
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**Background/Aims:** The primary usefulness of the radioiodine uptake measurement (RIU) is to differentiate Graves' hyperthyroidism from that caused by subacute or painless thyroiditis or factitious hyperthyroidism. ^99m^Tc pertechnetate scintigraphy is another option to measurement of thyroid function. The aim of this retrospective study was to assess the feasibility of ^99m^Tc-uptake ratio determination via gamma camera in comparison with established ^131^I RIU in diagnosis of benign thyroid diseases (BTD). **Methods:** Between 2012 and 2016, a total of 159 patients with BTD were screened, 78 of whom met the inclusion criteria a retrospective analysis was performed of 78 patients (age range 20-81 years, mean age 52 years, 58 women and 20 men) with BTD. All patient files were scanned for the necessary examinations within the scope of current guidelines (anamnesis, TSH, free T3 and free T4, neck ultrasound and planar ^99m^Tc-pertechnetate scintigraphy (TS)) and those with recent RIU test were included in the study group. Two and 24 hr RIU values recorded, and TS quantifications parameter were repeated after then accepting of study group. Thyroid--to-background ratio (TBR~max~, TBR~mean~), thyroid--to-salivary gland ratio (TSgR~max~, TSgR~mean~) were observed. **Results:** The 2 hour RDR was the best correlated with TBR~max~, TBR~mean~, TSgR~max~, TSgR~mean~ (r:0,86, r: 0.86, r: 0.88, and 0.88 respectively, p\<0.0001). 24 hr RIU values was correlated with TBR~max~ (r:0.67, p\<0.0001). 2 hour and 24 hour RIU was correlated (r: 0.64, p\<0.001). **Conclusion:** In the literature, the normal range of values is usually given as between 10% and 35% for a 24 hour uptake, and between 6% and 18% for 4 hour uptake. Alternatively, thyroid uptake can be determined, less accurately, using intravenously administered ^99m^Tc-pertechnetate and a gamma camera. The thyroid uptake of ^99m^Tc pertechnetate ranged from 0.15-2.14%. The effective dose generated by the test with ^131^I RIU is 41 rem/mCi. On scintigraphy with ^99m^Tc, this dose is 0.048 rem/mCi. Since radiation exposure to the patient is approximately a thousand times higher, if there is no other obstacle, TcO4^-^thyroid scintigraphy in hyperthyroid patients is sufficient for diagnosis and differential diagnosis.
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**Background/Aims:** To retrospectively analyse the clinical application value of multiple treatment of iodine-131 for hyperthyroidism with goiters in the past 14 years. **Methods:** From 2003 to 2016, 12658 cases of hyperthyroidism iodine treatment in our department were retrospectively analysed, and 6279 cases of 5217 patients were selected after the follow-up more than a year. **Results:** In 5217 patients, 3790 (72.6%) were female, whereas 1427 (27.4%) were male. Patients of single iodine dosage were 4343 (83.3%), and patients of multiple treatments were 874 (16.7%), whereas 3 times of treatments were 146 cases (2.8%), 4, 5 and 6 times were 32, 8 and 2 cases retrospectively. The dosages of 131 iodine (mCi) for first, second, third, fourth and fifth of treatment were 6.7±1.8, 6.8±2.3, 7.8±3.9, 10±6.8 and 10±7 retrospectively. In the single dosage, the minimum was 3 mCi, the maximum was 15mCi. In the multiple treatments: the single minimum is 2 mCi, the single maximum was 30 mCi, whereas the minimum cumulative dosage was 4 mCi (2 times), the maximum cumulative dosage was 102.5 mCi (5 times) retrospectively. **Conclusion:** In a small portion of hyperthyroidism with goiters of more than 2 years, multiple iodine treatments were necessary. The iodine dosage was needed more in 3rd, 4th and 5th than that of in the 1st and 2nd treatment. Due to the different personal sensitivity of iodine, the therapeutic effect of low iodine dosage as well as high iodine dosage has also been observed.
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**Background/Aims:** TIRADS is a risk stratification system for classifying thyroid lesions and was recently recognized in an American College of Radiology (ACR). TIRADS classification is now being used in daily routine categorization of sonographically visualized thyroid nodules, followed by thyroid scan done with ^99m^Tc. FNAC is done only when the TIRADs scores are 4 or greater than 4, as increasing scores indicate higher suspicion of malignancy. All nodules categorized as suspicious i.e TIRADS 4-5 need to be evaluated by thyroid scan categorized as hot, warm or cold. The aim of this study was to evaluate the diagnostic accuracy of the TIRADS score by correlating it with thyroid scan and fine needle aspiration cytology. **Methods:** Ultrasound of thyroid was carried out on GE logic with linear transducer of 7.5--12 MHz frequency. 210 patients referred for sonography of thyroid nodules were included in the study from 1^st^ January 2016 to 31^st^ July 2017. Thyroid scan was performed after ultrasound and before FNAC to avoid misleading increase post intervention and to assess the uptake of radiotracer in the sonographically detected nodule. Fine needle aspiration was carried out under ultrasound guidance and cytology was done of all nodules categorised as TIRADS 4 and above. **Results:** A total of 210 patients with 253 nodules of mean size 2.5 ± 1.5 cm were included. PPV for malignancy was 38%, 56%, 78%, and 91% for TIRADS 2, 3, 4a, 4b, 4c, and 5 categories, respectively. **Conclusion:** TIRADS (Thyroid Imaging Reporting and Data System) is a useful diagnostic classification in predicting malignancy and with the help of thyroid scan and FNAC unnecessary surgical procedures and associated risks can be everted.

P040: A Fixed I-131 Dose in Therapy of Patients with Autonomously Functioning Thyroid Nodules and Normal Thyroid Stimulating Hormone Level

Lacic\*

Miodrag

1

Department of Thyroid, Polyclinic Lacic, Zagreb, Croatia

**Background/Aims:** The purpose of this study was to evaluate the results of radioactive iodine-131 (^131^I) therapy in patients with autonomously functioning thyroid nodules (AFTN) and a normal thyroid stimulating hormone (TSH). Up to our knowledge, this is the first study which has scintigraphically evaluated the effect of ^131^I therapy in patients with AFTN and normal TSH level. **Methods:** In this study 58 cytological benign AFTN in 51 patients (45 female and 6 male) with normal TSH level have been treated with a fixed ^131^I doses (370 MBq). Clinical exam, ultrasonography with color Doppler (US), fine needle aspiration biopsy (FNAB), TSH, fT4, fT3, anti-TPO, anti-Tg and thyroid scan (scintigraphy) have been performed in all patients before and 6 months after ^131^I therapy. **Results:** The median age of the patients was 57 (range 37-83) years. AFTN were located more frequently in the right thyroid lobe (33 nodules) than in the left lobe (25 nodules). In 11 patients, a solitary AFTN has been found on ultrasonography and the other 40 patients had AFTNs in multinodular goiter. Seven patients had two AFTNs. On post-^131^I therapy thyroid scan in 41 AFTN, complete therapy effect has been observed, but in 17 AFTN a scintigraphycally partial effect has been noted. Statistical analysis showed a significant reduction in the thyroid (p=4.7515E-15) and AFTN (p=0.0018) volume after ^131^I therapy. TSH value significantly increased (p=0.0048) and FT4 value significantly decreased (p=0.0012) after ^131^I therapy. FT3 (p=0.3508), anti-TPO (p=0.8701) and anti-Tg (p=0.6805) values did not change significantly. **Conclusion:** In conclusion, we wish to stress that fixed ^131^I doses in therapy of patients with AFTN and normal TSH level is a simple, cheap and very effective modality. The effect of the ^131^I therapy on AFTN can be exactly evaluated with a post ^131^I therapy thyroid scan.
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**Background/Aims:** Thyrotoxicosis is a potential side effect of amiodarone treatment, an iodine-rich drug used to treat serious tachyarrhythmias refractory to other treatments. Amiodarone-induced thyrotoxicosis (AIT) is classified into two types each with a different therapeutic approach. Excessive hormone synthesis and release causes AIT I which is treated with carbimazole (thionamides). AIT II is a result of destructive thyroiditis and responds to prednisolone (glucocorticoids). Some patients may have mixed forms, and differentiating the two clinically is challenging. **Methods:** A 36 year old male with AIT was referred to Nuclear Medicine so that the type of AIT could be determined. He was an outpatient found to be thyrotoxic on routine pathology and a two year history of amiodarone treatment. The patient was referred for ^99m^Tc-sestamibi thyroid scintigraphy (^99m^Tc-STS) and colour flow Doppler sonography (CFDS). ^99m^Tc-STS was performed where planar images were acquired at 2, 10, 15 and 60 minutes post-injection. Thyroid-to-background ratios (TBRs) were calculated using the Pattison *et al*.\[[@ref2]\] method and displayed on a time activity curve. The observed result showed no significant uptake. **Results:** The early TBRs fell within the range determined to be suggestive of Type II, aside from the final ratio at 60 minutes which was indefinite. Overall the scintigraphic images and TBRs were interpreted to be in keeping with AIT II. The ultrasound performed on the same day found normal thyroid vascularity and appearance; suggesting AIT II. Scintigraphic and ultrasound imaging were congruent. This led to the patient being treated with Prednisolone 40mg daily for four weeks which resolved his thyroxicosis. **Conclusion:** ^99m^Tc-STS played a vital role in confirming the diagnosis of AIT II for this patient and guided his treatment. The justified use of prednisolone was important due to his medical co-morbidities of type II diabetes mellitus and obesity, both of which prednisolone may exacerbate.
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**Background/Aims:** The 2015 American Thyroid Association Guidelines stipulate that thyroid scintigraphy should be performed in a patient with biochemical hyperthyroidism as evidenced by a suppressed TSH. It is implicit that the subsequent management of a cold nodule demonstrated in such a patient should be in accordance with the guidelines. Our aim was to review the patterns of management of cold nodules in a cohort of hyperthyroid patients and factors that influenced the clinician's decision to proceed to radioactive iodine therapy (^131^I). **Methods:** Retrospective study of consecutive patients who presented to an Australian tertiary teaching hospital and were shown to have cold nodules on thyroid scintigraphy from 2/2015 to 8/2017 in relation to thyroid function test results, correlative ultrasound & fine needle aspiration findings as well as subsequent radioactive iodine therapy. **Results:** Of the 70 patients whose case records were reviewed, 101 cold nodules were demonstrated all of which had ultrasound correlates. The vast majority of these nodules (n=93, 92% of all cold nodules) were associated with multinodular goitres. Of the 47 patients (67% of all patients) who were hyperthyroid, 12 patients subsequently received ^131^I therapy, 8 of whom had not undergone any fine needle aspiration procedure prior to therapy. Of these 8 patients, all were referred direct by endocrinologists or under the direction of endocrinologists, all were above the age of 55 with 4 patients above 70, and 3 had toxic nodules. None of these 8 patients developed cancer within the study period. **Conclusion:** Age, endocrinologist assessment of risk profile and demonstration of toxic nodules appeared to influence the decision to proceed with ^131^I therapy without prior fine needle aspiration of concomitant cold nodules uncovered on thyroid scintigraphy.
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**Background/Aims:** The aim of the study was to analyse the outcome of ^131^I therapy for autonomous thyroid adenomas in long period of follow up. **Methods:** We had 68 patients with Plummer's disease (50 females, 18 males, mean age 54,7 yrs, range 21-79 yrs) for period 1997-2016. 92.6%(63/68) patients had a unifocal nodule, while 7.4% (5/68) patients had multifocal toxic autonomous nodules. Patients stopped antithyroid drugs for at least one month prior to the radioiodine treatment and than we administered a ^131^I activity of 740+/-200 MBq (range 550-1100 MBq), based of size and weight of "hot" nodules and the value of radioiodine uptake. Volumetry was done by ultrasound. The mean duration of follow up was 5,84 years. **Results:** 65/68 (95%) patients were administered a single dose, while 3/68 (5%) patients needed two doses. 55/68 (80.9%) patients who were treated with radioiodine were euthyroid with scintigraphic normalization. The percentage of euthyroidism did not significantly change in long term of 20 years observation. The recurrent hyperthyroidism was 2.9% (2/68) patients. The cumulative incidence of hypothyroidism was 16.2% (11/68) patients within 1-6.2 years. Hypothyroidism developed earlier in patients who were euthyroid before ^131^I therapy (3.5-7.7 months) than in the subclinically hyperthyroid patients, who became hypothyroid within 7.2-13.6 months (p=0.001). The development of hypothyroidism was higher in pts who showed extranodular uptake and after TSH suppression. The nodular volume was statistically higher in pts who had recurrent hyperthyroidism over hypothyroidism (p\<0.01) and euthyroidism (p\<0.02). No differences were observed in the results between unifocal and multifocal nodules. **Conclusion:** ^131^I therapy is a simple, safe and effective treatment of autonomous functioning thyroid adenoma with a low rate of recurrent hyperthyroidism (3%) and development of hypothyroidism (16%).
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**Background/Aims:** To demonstrate the importance of considering a potential parathyroid adenoma in avid nodules posterior to the thyroid are found on ^18^F-Flurodeoxyglucose (^18^F-FDG) positron emission tomography/computed tomography (PET/CT) scans. ^18^F-FDG PET/CT scans are predominantly utilised for oncology indications but it is essential to contemplate that there is a plethora of benign and inflammatory conditions which may exhibit ^18^F-FDG metabolism. **Methods:** A case report of a scan that contains an incidental finding of a potential parathyroid adenoma on a ^18^F-FDG PET/CT scan presented in poster format. **Results:** A case study of a ^18^F FDG PET scan in a 61 year old female with a suspicious malignant 15mm right lower lung nodule shows an incidental finding of an intensely avid 2.4 cm nodule posterior to the left thyroid gland. Given that the 15mm lung nodule is not ^18^F-FDG avid, the incidentaloma is reported as a likely parathyroid adenoma. The consequential biochemistry suggests the patient has primary hyperparathyroidism with elevated parathyroid hormone (PTH) level of 14.0 mmol/L and a serum calcium level of 3.04 mmol/L. The pathogenesis of primary hyperparathyroidism is most commonly due to the presence of a parathyroid adenoma therefore a parathyroid scan, ultrasound and fine needle aspiration were successively performed. **Conclusion:** The patient was subsequently diagnosed with a parathyroid adenoma posterior to the left thyroid gland and underwent a parathyroidectomy. The patient was also found to be suffering with osteopenia and was managed appropriately. The consideration of a parathyroid adenoma in this case considerably altered this patient's management. This case study is an excellent example of the sensitivity of ^18^F-FDG PET/CT scans and the importance of exploring all likely causes of unusual avidity.
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**Background/Aims:** Primary hyperparathyroidism (PHPT) is a disease whose natural history leads to symptomatic hypercalcaemia, renal calculi, premature osteoporosis, and increased risk of fracture. Operative management remains the only cure, and is indicated if a patient is osteoporotic. Our aims were to: 1) evaluate how often the (distal) radius findings changed the overall bone mineral density (BMD) assessment, and 2) evaluate whether considering other sites other than hip, spine or distal-third radius in dual-energy x-ray absorptiometry (DXA) scans increased the incidence of osteoporosis diagnosis. **Methods:** 2277 consecutive DXA scans at a tertiary hospital were retrospectively reviewed from the years 2012 to 2016 inclusive. The cohort for this study was identified by selecting patients who had a forearm DXA performed, and diagnosis of PHPT noted on their DXA request. Individuals had their T- and Z-scores at the hip, spine, distal third radius, ultra-distal (UD) radius and total radius tabulated. T- and Z-scores for the UD radius and total radius were obtained from a standardised reference population (combined NHANES/Lunar). **Results:** 65 instances of a patient who had a DXA scan for PHPT were identified, corresponding to 56 unique individuals. These individuals were predominantly female (42:14) and had a mean age of 62.8 years. Of the 56 individuals identified, 6 (10.7%) had a diagnosis of osteoporosis made on distal third radius when they otherwise had osteopenia based on hip and spine DXA only. Interestingly, an additional 5 patients (8.9%) would have a diagnosis of osteoporosis if the UD radius was included in addition to the three sites above. **Conclusion:** This study identified a significant cohort of patients who, if radial BMD sites are considered, would have a diagnosis of osteoporosis and an indication for parathyroidectomy. While the UD radius is not currently advocated as a location for diagnosis in osteoporosis, the findings of this study supports emerging literature advocating for inclusion of this data.
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**Background/Aims:** Evaluate the utility of portable gamma-camera (pGMC) at real time intraoperative imaging for assessing localization of parathyroid adenoma in patients with oncologic disease. **Methods:** This was a retrospective analysis of patients with parathyroid adenoma and oncologic underlying condition, such as breast cancer, renal, prostate, cervix, ovarian, and melanoma; who underwent radioguided surgery at Instituto Nacional de Cancerología (INCan, México). Planar scintigraphy was performed 15 minutes after intravenous injection of ^99m^Tc-MIBI, 60-120 minutes before intervention. pGMC was used to identify the adenoma during surgery, as well as to verify if it was removed completely. All surgical specimens were taken for intraoperative histopathological evaluation. **Results:** 20 patients were diagnosed with parathyroid adenoma (17 with usual location and 3 with ectopic location). Parathyroid adenoma was localized intraoperatively with a portable gamma-camera in all patients, reducing the time of surgery. After removing the adenoma, the activity it was verified in vivo and ex vivo. All surgical specimens were confirmed as parathyroid adenoma in the intraoperative and definitive histopathological evaluation. In all cases the radioactivity measured intraoperatively with pGMC, identified the affected gland, which coincided with the scintigraphy findings previous. pGMC showed sensitivity, specificity, diagnostic accuracy, PPV, and NPV values of 100%. No patient was identified disease multiglandular. All patients had normal levels of calcium postoperative serum with mean 9.5 mg/dl (CI 95%: 7.65-10.33 mg/dl), and PTH values with mean 47 pg/ml (CI 95%: 10-55 pg/ml). **Conclusion:** pGMC in intraoperative identification of parathyroid adenoma has contributed to the development of minimally invasive parathyroidectomy. Therefore, in our opinion, in addition to the realization of preoperative scintigraphy, radioguided surgery with pGMC should always be performed, thus reducing complications, hospital stay, surgical and recovery time, with the same therapeutic effectiveness as classical treatment.
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**Background/Aims:** Surgical resection of the abnormal parathyroid glands is the only curative treatment for primary hyperparathyroidism (PHPT). Radioguided parathyroidectomy with ^99m^Tc-sestamibi has been successfully used in patients with PHPT. This study was designed to evaluate the results of a series of patients with PHPT who underwent minimally invasive radioguided parathyroidectomy (MIRP) using very low dose (1 mCi) of ^99m^Tc-sestamibi (MIBI) without application of intraoperative parathyroid hormone (PTH) assay or frozen section analysis. **Methods:** Eighty-seven patients with PHPT were prospectively studied from November 2012 to January 2015. Following neck ultrasound and MIBI scan concordant for single gland disease, patients underwent MIRP using a handheld gamma probe. The technique involved injecting of 1 mCi MIBI in the operative room before the beginning of the intervention. All patients were followed up for a minimum of 6 months postoperatively. **Results:** MIRP was successfully performed in 86 out of 87 patients (98.85%). The gamma probe was particularly useful in detection of ectopic parathyroid adenomas in upper mediastinum. Mean operative time was 23.95±7.982 min and mean hospital stay was 1.44±0.604 days. No major surgical complications were recorded. **Conclusion:** The MIRP technique using very low dose (1 mCi) of ^99m^Tc-sestamibi without intraoperative PTH assay and frozen section analysis resulted in excellent cure rate for PHPT. This technique involves a radiation exposure to patients and surgical staffs 20 times lower than conventional MIRP using 20 mCi ^99m^Tc-sestamibi. Besides, patients with PHPT due to ectopic parathyroid adenoma may especially benefit from MIRP.
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**Background/Aims:** Parathyroid adenomas result in primary hyperparathyroidism and surgery is the mainstay of therapy. Localisation, however, can be challenging. Although ^99m^Tc-MIBI SPECT/CT is the gold standard for detection, recently 4DCT and ultrasound (US) are being utilized. This retrospective study compared SPECT/CT, 4DCT and US studies in detection of adenomas prior to surgery. Additionally, feasibility of intraoperative localisation with preop injection of Tc-MIBI was evaluated. **Methods:** Of 102 patients who underwent parathyroid imaging, 41 patients (31 female, 10 male) underwent surgery. Patients' age ranged 28-77 (mean 57.9 years) with PTH levels ranging 44-2400 pg/mL (mean 326). All patients underwent SPECT/CT with 20 mCi Tc99m-MIBI. Thirty-five patients had additional US imaging and 14 patients had 4DCT scans. Additionally, 15 patients had injection of 10mCi Tc99m-MIBI on the day of surgery. Pathological correlation was performed. **Results:** There were 37 adenomas, 3 normal tissues and 1 parathyroid carcinoma. Comparing SPECT/CT vs 4DCT resulted in sensitivity (0.84 vs 0.35, p=0.03), specificity (0.33 vs 1.0, p=0.002) and accuracy (0.80 vs 0.38, p=0.02). Comparing SPECT/CT vs US resulted in sensitivity (0.84 vs 0.42, p=0.03), specificity (0.33 vs 0.67, p=0.02) and accuracy (0.80 vs 0.46, p=0.02). Combination of SPECT/CT and 4DCT increased sensitivity to 0.91, specificity to 0.33 and accuracy to 0.72. Combining SPECT/CT with US resulted in sensitivity of 0.92, specificity of 0.78 and accuracy of 0.78. Intraoperative localisation improved in patients who received preop injections. **Conclusion:** SPECT/CT remains the best imaging modality for preoperative localisation of parathyroid adenomas with high sensitivity. Combining SPECT/CT with either 4DCT or US in challenging cases resulted in increased sensitivity and accuracy. We recommend utilizing SPECT/CT as the primary modality in detection of parathyroid adenomas, and for challenging cases addition of 4DCT or US. Intraoperative localisation and adjunctive imaging may improve surgical management of patients with hyperparathyroidism.
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**Background/Aims:** Diabetes is an increasing problem in the Australian population. Only 50% of people with diabetes are tested and diagnosed. Therefore, a significant portion of the population have undiagnosed diabetes. For a PET scan, patients routinely fast overnight. Before the test a blood glucose level is taken using a blood glucose monitor (BGM). The Australian standard for the diagnosis of diabetes is: fasting glucose (serum) \> 7 mmol/L, HbA1c \> 6.5% (48 mmol/L), random glucose \> 11.1 mmol/L and oral glucose tolerance test. In asymptomatic patients, the standard for diagnosis is an abnormal result on two different diagnostic tests. A BGM measurement that is greater than 6mmol/L, in a fasting patient not known to be diabetic, requires further assessment. This work assesses the incidence of previously undiagnosed diabetes, the accuracy of blood glucose monitors and the efficacy of this approach in a PET scan setting. **Methods:** In patients with a BGM of \>6mmol/L with no history of diabetes, blood was collected along with a patient history and a fasting blood glucose level and a HbA1c were performed. If the results indicated diabetes then a letter including the results was sent to the patient's doctor. **Results:** The BGM was found to overestimate a patient's BSL with a mean difference of 0.871 (paired t-test, p\<0.0001). Of 728 PET scan patients, 101 had known diabetes. Of the remainder, 103 had a BGM above 6 mmol/L. Of these, 43 patients had a fasting glucose blood test and a HbA1c; 3 were found to have diabetes and 11 had results indicating pre-diabetes. **Conclusion:** Patients that have a BGM over 6 mmol/L should be tested for diabetes and follow up and management should continue with the patient's doctor.

P054: 25-Hydroxyvitamin-D Serum Levels in Patients with Type 2 Diabetes Mellitus: Correlation with Disease Severity

Katsibri

M

1

Tsigalou

C

2

Lambropoulou

M

3

Pistola

A

1

Orestia

Z

1

Lianou

T

4

Darousi

S

1

Aristotelidou

V

4

Papanas

N

5

Zissimopoulos\*

Athanasios

1

Department of Nuclear Medicine, Democritus University of Thrace, Alexandroupolis, Greece

Laboratory of Biopathology-Immunology, Democritus University of Thrace, Alexandroupolis, Greece

Laboratory of Histology-Embryology, Democritus University of Thrace, Alexandroupolis, Greece

Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece

B'Pathological Clinic, Democritus University of Thrace, Alexandroupolis, Greece

**Background/Aims:** Diabetes Mellitus (DM) is a condition of increasing prevalence worldwide. In recent studies, there is an association with vitamin D deficiency and the risk of developing diabetes and diabetes complications. The aim of this study is to evaluate the 25-hydroxyvitamin-D (25-ΟΗ-D) serum levels in patients with type 2 diabetes mellitus in correlation with the disease severity. **Methods:** We studied 108 patients (66 male and 42 female) aged between 43 and 70 years old (median age 58±12 years) with type 2 diabetes mellitus, with or without diabetes complications. All were followed up at the University Hospital of Evros. The vitamin D levels were measured by radioimmunoassay (RIA) method with Diasorin kits at in-vitro laboratory of Nuclear Medicine Department of the University Hospital of Evros, Democritus University of Thrace. We also studied 40 healthy individuals (blood donors) as the control group. Statistical analysis was performed by the x^2^-test (student test) and statistical significance was considered for p\<0.005. **Results:** Diabetes mellitus patients had lower levels of (25-ΟΗ-D) than controls (p\<0.005). In 62 patients with severe complications of the disease the levels of (25-ΟΗ-D) were significantly low, at 0-20ng/mL (p\<0.005) (deficiency). In 28 patients with mild complications of the disease the levels of (25-ΟΗ-D) were 20-29ng/mL (insufficiency), and the rest 18 with no complications had sufficient levels of (25-ΟΗ-D) \>40 ng/mL (p\<0.005). **Conclusion:** Diabetes mellitus patients had lower levels of (25-ΟΗ-D) than controls. Patients with severe complications of the disease had significantly lower levels than the others. Vitamin D deficiency may be a risk factor for DM. Clinical trials with vitamin D supplementation are needed.
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**Background/Aims:** ^68^Ga-citrate is, like ^18^F-FDG, a PET tracer that images infection and inflammation. In this study, we compared these 2 tracers in patients with known or suspected tuberculosis (TB). **Methods:** Approval for the study was granted by the institutional ethics committee. Every participant had at least one pair of PET/CT scans (^68^Ga-citrate and ^18^F-FDG). The scans were acquired within two weeks of each other. All lesions detected by the tracers were counted and maximum standard uptake values (SUV~max~) were recorded. **Results:** 21 patients were prospectively recruited (age±mean was 37.95±10.25 years; Male=9, Female=12). A total of 54 PET/CT scans were acquired. One pair of scans was acquired in 15 patients while six patients had two pairs (five at baseline and two months after therapy, and one at baseline and at the end of therapy). 12 patients had microbiologic confirmation, six had clinical confirmed diagnosis and three had suspected TB. 15 of the patients were HIV-positive. ^68^Ga-citrate detected significantly less lesions (718 vs. 601, p\<0.001) and had lower mean SUV~max~ (2.27 vs. 5.56, p\<0.0001) compared to ^18^F-FDG. The extra lesions detected by ^18^F-FDG were mostly additional lymph nodes around the vasculature that did not change management. In one patient, TB of the pericardium detected by ^18^F-FDG was not detected by ^68^Ga-citrate. In another patient, ^68^Ga-citrate detected more intracranial abscesses than ^18^F-FDG. Inflammatory lesions were detected in three patients on ^18^F-FDG when ^68^Ga-citrate showed no uptake. ^68^Ga-citrate correctly diagnosed no residual vertebral TB when findings on ^18^F-FDG were equivocal. Both tracers detected good response in all five patients with confirmed TB that correlated with their good clinical outcome. **Conclusion:** Despite finding less lesions, ^68^Ga-citrate performed as well as ^18^F-FDG PET in the management of TB. ^68^Ga-citrate can be particularly useful in the detection of intracranial lesions.
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**Background/Aims:** ^18^F-FDG PET has proven added value in many malignant diseases, and its role in infectious diseases is increasing but for many indications it still has to be defined. Here, we evaluated the added value of ^18^F-FDG PET compared with conventional imaging in the management of patients with invasive fungal infections (IFIs). **Methods:** Patients with proven IFIs (by histology or cultures) who underwent a ^18^F-FDG-PET/CT were included. All patient dossiers were checked for infection parameters, clinical history, and imaging procedures. ^18^F-FDG-PET/CT findings were compared to the findings on other imaging modalities to determine if ^18^F-FDG--PET/CT could provide more information. The ^18^F-FDG-PET findings were also correlated to the infection markers. The local institution review board approved this retrospective study and waived the requirement for informed consent. **Results:** A total of 80 scans were acquired in 46 patients (mean age±SD = 43.75±23.68 years, M:F = 29:17). ^18^F-FDG-PET detected significantly more lesions (533 vs. 343, p\<0.001) compared to conventional imaging. In 19 patients, more lesions were detected. The majority (17) of these patients had extra-thoracic disease. In 6 patients, ^18^F-FDG-PET/CT noted disease activity where findings on other modalities were equivocal. In 4 patients, ^18^F-FDG-PET/CT excluded infection allowing immunosuppressive therapy to be undertaken. In 3 patients, follow-up ^18^F-FDG-PET/CT resulted in a change in antifungal therapy. In 3 patients, there was no evidence of metabolic uptake when lesions persisted on conventional imaging allowing antifungal therapy to be stopped. In total, ^18^F-FDG-PET/CT showed added value in 35 (83.3%%) patients, potentially influencing clinical decision making. No correlation was found between the infection parameters and ^18^F-FDG-PET/CT findings. **Conclusion:** ^18^F-FDG PET/CT has significant added value over conventional imaging in both the initial staging of IFIs and follow-up of disease, leading to changes in therapy decision making.

P057: Positron Emission Tomography/Computed Tomography in Evaluation of Extrapulmonary Tuberculosis and Treatment Monitoring in Multidrug-Resistant Tuberculosis
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**Background/Aims:** FDG PET/CT has the ability to quantify ^18^F-FDG uptake in infection and can localize the active tuberculosis (TB) with extension. This study observed the ability of FDG PET/CT in evaluation of extra-pulmonary tuberculosis (EPTB) and monitoring treatment response in multidrug resistance (MDR) TB. **Methods:** This prospective study was approved by the Medical Research Ethics Committee and conducted at National Institute of Nuclear Medicine and Allied Sciences, Dhaka, Bangladesh, under an IAEA CRP 15021. Twenty-five EPTB patients, among them thirteen were culture positive for MDR TB enrolled from November 2015 to November 2017. All patients underwent baseline whole-body 18F FDG PET-CT scan before starting anti-tubercular drugs. In MDR TB patients first and second follow up scans were performed after two and eight months of initiation of therapy. Standardised uptake values (SUV^max^) and size of the lesions were measured in follow up respectively and then compared. **Results:** All 25 patients (15 male, 10 female, age range 18-65 years, average age 26.5±12.3years) showed increased FDG uptake in extra-pulmonary lesions in baseline PET/CT scan. The mean SUV~max~ values of pleural, pulmonary lesions and lymph nodes in MDR TB patients were 4.56±5.35, 7.0±5.35 and 6.17±4.97 respectively with average size of involved lymph node 15.74±9.12mm. Follow-up scans showed reduced FDG uptake with decreased mean SUV~max~ values comparing to the baselignificant inine, which was not significant in first follow up but s second follow up. Follow-up scans also showed morphological change with significant reduction of size of lymph nodes at second follow up. **Conclusion:** ^18^F-FDG PET/CT plays a potential role in localising EPTB and treatment monitoring of both pulmonary and extra-pulmonary MDR TB. Reduction of SUV~max~ value and size of lesions after anti MDR TB treatment suggests response.

P058: A Prospective Comparison of Disease Burden, Pattern and Response Assessment between HIV-Positive and HIV-Negative Patients with Extrapulmonary Tuberculosis using
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**Background/Aims:** Extrapulmonary tuberculosis (EPTB) patients require swift and accurate stratification prior management, but the disease remains difficult to diagnose and treat. Imaging with ^18^F-FDG PET/CT may emarge as one of the significant steps in the managemnet of tuberculosis. We aim to evaluate the value of ^18^F-FDG PET/CT in the assessement of tuberculosis actvity, pattern and response to therapy in comparison with CT in HIV negative and positive patients with EPTB. **Methods:** Ehical approval was granted, and consented patients with EPTB undewent imaging with ^18^F-FDG PET/CT prior to therapy, after 2-months on anti-tuberculosis treatment and post-therapy. Findings were evaluated qualitatively and semi-qualitatively (SUV~max~) and compared to CT results. **Results:** Thirty-two patients with EPTB (mean age 38 years, range 18-58 years) underwent a total of 53 ^18^F-FDG PET/CTs. Twenty-two (68%) patients were retroviral disease positive, of whom 13 (59%) had absolute CD4 counts \<200 cells/uL. ^18^F-FDG PET/CT was positive in 31 of 32 baseline scans (96%). HIV positive patients (57%) demonstrated a more extensive extranodal burden compared to the HIV negative patients. PET was superior to CT in discriminating responders to non-responders. Furthermore, PET outperformed CT in 10 (31%) patients, with more extensive disease detected. **Conclusion:** ^18^F-FDG PET/CT is useful in the assessment of EPTB activity, pattern and response to therapy comparison with CT in HIV naive and positive patients with extrapulmanary tuberculosis.

P059: Iliopsoas Abscess-Hidden Pathology Revealed by Three-Phase Bone Scan
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**Background/Aims:** A 75 year old woman with a history of stage III C undifferentiated ovarian cancer presented with right hip pain. Previous plain films were normal. The patient did not have any musculoskeletal tenderness. A bone scan was requested to exclude bony metastases. **Methods:** The patient was injected with 725 MBq ^99m^Tc-HDP. Early images included anterior blood flow of the pelvis followed by anterior/posterior blood pool images of the lumbar spine and pelvis on a Symbia S system. Delayed images included anterior and posterior whole body, lateral skulls and oblique rib views with SPECT/CT of the pelvis acquired on a Phillips Brightview XCT. **Results:** Blood flow of the pelvis was normal. Blood pool images of the pelvis and lumbar spine showed a region of hyperaemia in the right iliac fossa. Delayed images showed a focus of mild increased activity in the distal left femur which was later confirmed on x-ray as enchondroma. Delayed images showed the right kidney and proximal ureter were obstructed. SPECT/CT images of the pelvis demonstrated an abnormal soft tissue density in the right retroperitoneum adjacent the right psoas muscle which correlated with the hyperaemia on early blood pool imaging. Appearances were consistent with retroperitoneal lymphadenopathy or haematoma with associated ureteric obstruction. No osteoblastic metastases were demonstrated. A subsequent diagnostic CT abdomen and pelvis confirmed a right iliopsoas abscess with associated inflammatory changes. Cytology performed on the abscess fluid was negative for malignant cells. **Conclusion:** Although SPECT/CT is often credited for improved bone scan sensitivity, this case clearly demonstrates that early imaging is still an integral component of whole body scintigraphy. The diagnosis of a soft tissue mass, in this case an iliopsoas abscess, was made possible by performing a full three phase bone scan.
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**Background/Aims:** Proteinuria is common for lupus nephritis and it can reflect the severity. The semiquantitative planar ^67^Ga image has been used as a surrogate to assess severity. However, bowel preparation is required. We therefore use SPECT/CT to obviate this problem. **Methods:** A retrospective review of 18 cases with lupus nephritis was conducted from May 2016 to June 2017. The study has been approved by the local Institutional Review Board and Ethics Committee. A waiver of consent has also been obtained. The urinalysis and ^67^Ga images from the subjects were recorded for analysis. The proteinuria was measured by test strip methods (0 to +4). The regions-of-interests of ^67^Ga SPECT/CT were placed on the liver, left kidney and spines. The kidney/liver (LK/L) and kidney/spine (LK/S) were calculated. Spearman's correlation coefficients (ρ) were calculated for the image measures and the test strip results. **Results:** Correlation analysis of the image measures with the test strip results showed that the ρ for LK/L and LK/S were 0.124 and 0.412, respectively. In order to realise the inter-subject variability of liver uptake, we also calculated the liver to spine ratio (L/S). The maximum and minimum of L/S were 2.696 and 0.774, respectively. The average of L/S was 1.622, with a standard deviation of 0.488. **Conclusion:** The LK/S better correlates with proteinuria, although the correlation is only moderate. The LK/L shows poor correlation with proteinuria, probably related to a high intersubject variability of liver uptake. Thus, liver is not a good reference organ for semiquantitative analysis. Further larger study number and correlation with pathologic finding are needed.

P061: Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging in the Evaluation of Diabetic Foot Infections
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**Background/Aims:** A new hybrid technology combining positron emission tomography (PET) with magnetic resonance imaging (MRI) has been increasingly used in cancer and brain imaging. We evaluated its utility in patients with diabetic foot infections. Infected wounds in the foot are common problem in patients with diabetes. Diagnosis of osteomyelitis in the setting of chronic foot infections is very challenging. **Methods:** We performed 17 PET/MRI scans in 14 patients with diabetic foot infections in order to determine involvement of the bones. Well delineated focal increased FDG uptake in the bone within the region of soft tissue infection suspected for the bone involvement was considered as osteomyelitis. Signal abnormalities on MRI imaging were graded and classified as normal (grade 0), edema (grade 1), and confluent T1 hypointense signal (grade 2). Grade 2 signal in bone was considered as indicative of osteomyelitis. In 14 cases surgery was performed and histopathological correlation was obtained. **Results:** In 13 cases, abnormal PET/MRI findings indicated bone involvement in diabetic patients with foot infections. Sites of osteomyelitis included phalanges (8), metatarsals (4), tarsal bones (2) and calcaneus (1). In 10 of these positive cases histopathology was available and confirmed osteomyelitis (sensitivity 100%). Also in 4 patients without PET/MRI findings for bone involvement pathology results were negative. There was discrepancy between PET and MRI findings in three patients with false negative results on MRI images (MRI sensitivity 70%). **Conclusion:** FDG PET/MRI proved to be highly accurate modality for diagnosis of osteomyelitis in diabetic patients with chronic foot infections. While PET appears to be more sensitive modality, simultaneous MRI acquisition and its superior tissue contrast resolution is essential to localize abnormal FDG uptake in the bones and achieve high specificity.
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**Background/Aims:** Study aims at demonstrating the potential use of ^18^F-FDG-PET/CT in evaluating the disease burden in Pott's spine, and to assess its complementary role with MRI spine. Finally, to explore its impact in planning duration of treatment, change in management and establishing therapeutic end point. **Methods:** 36 Pott's spine patients were recruited and subjected to standard ^18^F-FDG PET/CT imaging. At baseline, scan results were independently assessed and region specific comparison was done with MRI spine. In follow up, only ^18^F-FDG PET/CT was done and results were compared with its previous scan results. Based on the metabolic response in the follow up scans, subjects were categorised as progressive disease (PD), stable disease (SD), partial response (PR) or complete metabolic response (CMR). **Results:** Among 36 patients, median age was 47 (range, 18-75) years, and men representing 57% of the total study subjects. ^18^F-FDG PET/CT confirmed MRI findings in all the subjects, and also revealed additional findings in these subjects, such as extensive lymph-node involvement in 9 subjects, lung lesions in 10 subjects, bilateral psoas abscess in 3 subjects, a right sternoclavicular joint uptake and 12 subjects with extensive bone marrow activation. In the follow-up study, 15 subjects underwent a 2^nd^ scan, of which 3 had CMR, 10 had PR and 2 with PD. Third follow-up scan was done in 6 subjects, of which 2 had CMR, 2 had PR and 2 with PD. Progressive disease patients had MDR disease status. **Conclusion:** ^18^F-FDG PET/CT has an admirable role in delineation of actual disease burden in tuberculosis and a complementary association with MRI. Thus, it can be a one shop stop modality in assessing the disease burden at the start of the treatment, can play a pivitol role in individualizing management, monitoring disease status and help in guiding the physicians to reach the therapeutic end point.

IAEA, Coordinated Research Project E 15021.
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**Background/Aims:** Ethambutol labelled ^99m^Tc-pertechnetate (^99m^Tc-Ethambutol) will be specifically taken up by *Mycobacterium tuberculosis* (*M. tuberculosis*) and it can be used to detect tuberculosis. The aim of this study was to know the diagnostic ability of ^99m^ Tc-Ethambutol scintigraphy in identifying *M. tuberculosis* infection of pulmonary tuberculosis (pulmonary TB). **Methods:** A case control study was conducted on 43 Subjects suspected of pulmonary tuberculosis who came to Pulmunology Policlinic of Dr. Hasan Sadikin General Hospital consecutively. Subjects were divided into two groups (25 subjects of pulmonary TB as cases and 18 subjects of non-pulmonary TB as control group).^99m^Tc-Ethambutol scintigraphy was performed in all subjects and then qualitatively analysed by observing pathological uptakes by 1, 4 and 24 hours. **Results:** The data were analysed by 2x2 table. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of ^99m^Tc-Ethambutol scintigraphy were 92%, 72%, 82%, 87% and 84% respectively. False negative and false positive were observed due to ^99m^Tc-Ethambutol uptakes based on characteristic of tuberculosis lesions. **Conclusion:** ^99m^Tc-Ethambutol scintigraphy is a promising diagnostic modality which showed good performance in detecting of pulmonary tuberculosis lesions.
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**Background/Aims:** Mycobacterium avium complex (MAC) is a non-tuberculous mycobacterial infection more commorn in women, in those with underlying structural lung damage, the elderly and in immunocompromised patients. Treatment regimens are complex and often poorly tolerated. Multi-resistance is becoming an increasing problem limiting treatment options. This is a case of incidental treatment of MAC using ^131^I as adjuvant therapy for papillary thyroid carcinoma. **Methods:** 72 year old female with history of MAC infection presented with symptoms of weight loss, persistent cough and breathlessness. Past history: NIDDM; 40 pack year cigarette exposure. Patient was undergoing CT surveillance and was not on any treatment for MAC infection. Progression of nodules were noted therefore an FDG PET scan was ordered. PET scan revealed a "hot" thyroid nodule. Biopsy confirmed a thyroid malignancy. Total thyroidectomy pathology revealed a 15mm papillary carcinoma with involved margins and extrathyroidal extension. 2/8 central lymph nodes were involved. After counselling she was treated with 4.5 GBq of ^131^I following Thyrogen™ stimulation. **Results:** Post-Thyrogen TSH: 160 mU/L; thyroglobulin 0.4 ug/L. Post ^131^I therapy scan: remnant activity in the thyroid bed. ^131^I uptake in lungs correlated on SPECT/CT to the known granulomatous lung disease. Post-therapy monitoring at 3 months revealed significant clinical improvement with resolution of cough, weight gain and improved well-being. Thyroglobulin 0.1 ug/L. There was objective radiological improvement in the form of a contraction in the lung lesions and clearance of prior inflammatory changes. This clinical and radiological benefit has persisted over time. **Conclusion:** This patient presented with an incidental thyroid cancer detected by FDG PET. In our published data this occurs in approx 1% of FDG PET scans and approx. 40% of FDG-avid nodules are due to thyroid malignancy.\[[@ref3]\] ^131^I accumulation in granulomas has been described.\[[@ref4]\] The mechanism is not well understood. Ionizing radiation has bacteriocidal,\[[@ref5]\] and sterilisation effects and is used in a number of industries.\[[@ref6][@ref7]\] To our knowledge this is the first reported case of mycobacteriocidal effect of ^131^I administered for adjuvant treatment of thyroid cancer. This has potential implications for the growing problem of multi-resistant mycobacterial infection.
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**Background/Aims:** Russell body gastritis is a rare reactive mucosal infiltration of plasma cells filled with cytoplasmic Russell bodies, thought to be related to Helicobacter pylori infection. This case presentation illustrates its importance as a potential mimic of gastric lymphoma on ^18^F-FDG-PET CT imaging. **Methods:** Serial surveillance ^18^F-FDG-PET/CT imaging over an 18-month period from October 2014 to May 2016 was performed on a patient undergoing treatment for Stage IV follicular non-Hodgkin's lymphoma. The distribution and intensity of gastric FDG avidity was correlated with histopathological analysis of gastric biopsy specimens obtained during gastroscopy in April 2016. **Results:** Diffuse intense gastric FDG avidity, initially attributed to extra-nodal gastric involvement of follicular non-Hodgkin's lymphoma, was subsequently found to be caused by Russell body gastritis after analysis of histopathological specimens obtained during gastroscopy. Gastric FDG avidity completely resolved following completion of Helicobacter pylori eradication therapy. **Conclusion:** Russell body gastritis is an under-recognised mimic of gastric lymphoma on ^18^F-FDG-PET/CT imaging performed during lymphoma surveillance. It should be considered in cases of isolated diffuse gastric FDG avidity which is discordant with overall lymphoma treatment response.

P066: Clinical Value of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Rheumatologic Diseases
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**Background/Aims:** FDG PET/CT, integrating functional and anatomical images, has been used worldwide as a powerful imaging modality in oncology. FDG, being a glucose analogue, can also be taken up by inflammatory lesions due to increased glucose metabolism in activated inflammatory cells, such as activated macrophages and proliferating fibroblasts. In the last two decades, there is evolving evidence of the clinical value of FDG-PET/CT in the evaluation of rheumatologic diseases. Several authors have demonstrated the usefulness of FDG PET/CT imaging in the diagnosis and/or the assessment of the severity of inflammatory diseases, including rheumatoid arthritis, spondyloarthritis, polymyalgia rheumatica, adult-onset Still's disease, relapsing polychondritis, large vessel vasculitis, granulomatosis with polyangiitis, polymyosistis and dermatomyositis. In addition, FDG-PET/CT imaging appears to be useful in the therapy response assessment of some of these inflammatory conditions. FDG-PET/CT has also been shown to have a role in sarcoidosis, a multisystem granulomatous disease that can coexist or mimic rheumatologic diseases such as systemic lupus erythematosis, rheumatoid arthritis and ankylosing spondylitis. In this study, we retrospectively evaluate the clinical value of FDG PET/CT in rheumatologic diseases using our data from the Illawarra PET Centre. **Methods:** Retrospective study to determine the clinical value of FDG PET/CT in a cohort of rheumatologic patients who had scans at the Illawarra PET Centre over a three and a half year period. These PET/CT scans, reports and relevant clinical data will be reviewed by two experienced PET/CT specialists. **Results:** During the period from 11.02.2014 to 11.08.2017, there were 139 FDG PET/CT scans performed at the Illawarra PET Centre for the evaluation of rheumatologic disease or presentations. These will be reviewed and discussed. **Conclusion:** A conclusion will be drawn based on our research findings.
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**Background/Aims:** Voriconazole is an antifungal that can cause periostitis. We present the bone scan and FDG PET findings in such a case. **Methods:** A 20 year old male with treated B-cell acute lymphoblastic leukemia presented with severe generalised joint pain, deconditioning and weight loss. He was on voriconazole for presumed fungal infection for 7 months and periostitis was diagnosed. A bone scan and FDG PET scan were ordered for hypercalcemia. The whole body bone scan with 800 MBq ^99m^Tc MDP performed with SPECT/CT covered neck to pelvis. PET/CT with 285 MBq ^18^F FDG covered vertex to thighs. This case report was approved by the ethics committee of our hospital. **Results:** The bone scan showed diffuse arthropathy in upper and lower limbs and the axial skeleton. The CT showed osteophytes in the long bones adjacent to joints, vertebral interspaces, manubrium and scapulae which were radiotracer avid compatible with voriconazole induced periostitis. The PET showed marked FDG marrow avidity in the axial and appendicular skeleton compatible with leukemia recurrence which was confirmed on marrow biopsy. In addition, some of the MDP avid osteophytes were also FDG avid indicative of active inflammation. **Conclusion:** Voriconazole induced periostitis can result in florid bone scan abnormalities which resemble a paraneoplastic process. FDG PET will also demonstrate active bone inflammation and should be a diagnostic consideration in patients on voriconazole. Voriconazole causes debilitating diffuse periostitis possibly from fluoride toxicity that induced bone formation with bone scan appearance resembling paraneoplastic hypertrophic osteoarthropathy in the long bones. The distinguishing feature was the florid bony involvement that included the axial skeleton. The FDG PET showed leukemia recurrence. FDG avidity was demonstrated in sites of active periosteal reaction as it can detect active inflammation. This case highlights the importance of knowing the clinical history when interpreting scans.

P068: The Role of Flourodeoxyglucose Positron Emission Tomography/Computed Tomography in Determining the Foci of Infection Postvascular Grafts
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**Background/Aims:** A 87 year old female, with a recent history of thoracic endovascular aortic repair (TEVAR) for a penetrating aortic ulcer, presented with fevers and gram negative bacteraemia with no identifiable source. A ^18^F-Fluoro-deoxyglucose (FDG) PET/CT study was requested for investigation of the infective focus. **Methods:** A total body FDG PET/CT study was undertaken according to standard departmental protocol, with the patient scanned from skull vertex to toes following intravenous administration of 222MBq of ^18^F-FDG and an uptake period of 69 minutes. Images were acquired on the Philips Ingenuity TF 128 scanner. **Results:** Moderately intense FDG uptake was demonstrated along the length of the descending thoracic aortic graft, along with associated FDG uptake in the peri-aortic soft tissues, which was consistent with infection of the thoracic aortic graft. Additionally, mild FDG uptake was identified within small hilar and mediastinal lymph nodes, as well as within bilateral pleural effusions, which were considered reactive. The patient subsequently underwent appropriate antibiotic therapy resulting in resolution of the infection. **Conclusion:** Infection of prosthetic vascular grafts is a rare but potentially severe complication in reconstructive vascular surgery, although early diagnosis can substantially reduce morbidity and mortality.\[[@ref8]\] The sensitivity of FDG PET/CT in the detection of such infections is well established. This case highlights the value of FDG PET/CT in infectious disease identification and localisation, as well as its concurrent benefits such as non-requirement of ex-vivo blood handling and decreased patient radiation burden compared with traditional procedures for infection imaging.

P069: Tracking Zika Virus Disease Pathology with Flourodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging
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**Background/Aims:** Apart from the brain and testes, the primary organ sites of Zika virus (ZIKV)-induced pathology during the course of infection are still largely unknown. ^18^F-fluorodeoxyglucose (FDG)-PET/CT is clinically validated for tracking metabolic changes in tumours, and is increasingly explored for tracking inflammation and infection. With our recent success in using FDG as a PET imaging biomarker in dengue virus infection, we extended our study to include ZIKV. We hypothesized that FDG-PET/CT imaging of ZIKV-infected mice will facilitate non-invasive monitoring of metabolic changes during infection and reveal inflammation-mediated disease pathology in organs affected by ZIKV replication. **Methods:** All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Duke-NUS Medical School. We infected AG129 mice (deficient in IFNα/β and γ receptors) with ZIKV and performed serial FDG-PET/CT imaging over the one-week course of acute lethal infection. FDG uptake was confirmed by *ex vivo* biodistribution and digital autoradiography. Imaging data was validated against detailed gross and histopathological examination of the infected animals, and tissue viral load was measured. **Results:** Serial *in vivo* PET/CT imaging revealed markedly increased FDG uptake in the heart and brown fat, as well as slight increase in the brain, compared to pre-infection baseline levels. The increased uptake occurred as early as 1 day post-infection; brown fat uptake peaked at day 5, while heart uptake remained high until the last day of imaging at day 9 post-infection. Autoradiography and histopathological analysis of brain tissues revealed widespread inflammation throughout the brain, corroborating our FDG-PET/CT results. **Conclusion:** FDG-PET/CT imaging in our preclinical ZIKV infection model has the potential to identify sites of virus-induced inflammation-mediated disease pathology.
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: P071: Can You Replace Two-Dimensional Whole-Body Planar with a Three-Dimensional Whole-Body Single Photon Emission Computed Tomography/Computed Tomography? A Technical Guide for Implementing and Evaluating Three-Dimensional Imaging Protocols
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**Background/Aims:** Advances in gamma camera technology and software algorithms have allowed faster scans. SPECT/CT has facilitated the development of advanced quantitative reconstruction allowing SPECT to generate SUV equivalent information similar to PET with the clinical applications still to be determined. In this research we have investigated if 3 bed whole body SPECT/CT could replace the traditional 2D whole body planar for Gallium, Bone and ^123^I-mIBG patient studies. **Methods:** A retrospective review of gallium, bone and ^123^I-mIBG studies acquired over a 6 month period was undertaken to determine the incidence of clinically significant lower limb abnormalities on the 2D whole body planar scan. Only gallium and bone studies with an indication of Pyrexia of Unknown Origin (PUO) or an infective process such as bacteremia or endocarditis were included, excluding studies with known or suspected lower limb pathology. Workflow improvements and scan time efficiency including analysis of ideal acquisition parameters for a multi-bed SPECT/CT for Bone and Gallium scans were assessed based on image quality, patient compliance and impact on clinical workflow. **Results:** A total of 50 patients having a Gallium scan were reviewed with 36 having a bone scan with 2D planar whole body imaging. The patients had a mean age of 69 years (range: 16-92), 36 of 50 were imaged 48 hours post injection. 33 (66%) an indication of PUO, 5 MSSA bacteraemia, 5 osteomyelitis and 6 infective endocarditis. Of the 50 Gallium scans, 7 patients (14%) had abnormal uptake in the lower legs with 5 of 7 being degenerative, 1 with known gout and 1 a recent fracture. There were 24 of 50 patients that had 2 or more SPECT/CT studies acquired with the remaining 26 having a single SPECT/CT study. The total time taken to acquire a bone and gallium using the standard clinical protocol is 45 minutes and 70 minutes respectively, compared with 25 to 30 and 45 minutes using multi-bed SPECT/CT. **Conclusion:** Based on these results, the acquisition of 3 bed SPECT/CT could replace 2D planar whole body for bone and gallium studies. Improvements in workflow efficiency, time saving and image quality along with the known gains in sensitivity, specificity and accuracy of SPECT/CT would support replacing 2D with 3D multi-bed SPECT/CT. Generating reprojected 2D data from multi-bed SPECT/CT is currently being developed.
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**Background/Aims:** The administered dose used for renal scintigraphy with Glomerular Filtration Rate (GFR) measurement at our institution is 600 MBq ^99m^Tc-Diethylene-triamine-pentaacetate (DTPA) and 100 MBq is GFR measurement only. The dose is higher than used for MAG3 due to the lower first pass extraction and glomerular filtration of the tracer. The aim of this study was to review the dose required to accurately assess renal function using DTPA scintigraphy. **Methods:** A retrospective review of patients on ^177^Lu-DOTATATE (Lutate) therapy having renal DTPA GFR assessment at baseline, mid-cycle and follow-up was performed. The studies were acquired using a dynamic 2-phase protocol following oral hydration with 300-600mL of water and voiding prior to commencing imaging. Studies were analysed using a standard clinical protocol generating whole kidney time activity curves as well as differential perfusion and function. Data was collected on administered dose, height, weight, creatinine, eGFR, absolute and normalized DTPA GFR for each study. A visual assessment was done by 2 expert reviewers comparing the whole kidney curve noise characteristics using a 3 point score at each time point per patient to determine the impact of injected dose on image quality and accuracy of semi-quantitative analysis. This was correlated with DTPA GFR measurements, creatinine and eGFR to look at the significance of changes in kidney function. **Results:** A total of 10 patients, each having 3 renal studies performed were analysed, with 30 studies reviewed. All patients had normal renal function with a mean eGFR 84 ml/min (range 58-90 ml/min), creatinine 73 umol/L (range 70-95 umol/L), absolute DTPA GFR of 94ml/min (range 91-129 ml/min) and normalized DTPA GFR 84 ml/min/1.73 m^2^ (range 92-122 ml/min/1.73 m^2^). The administered dose range was 423-637MBq with an average of 535MBq. Expert review showed no correlation between the curve noise and administered dose and no impact on semi-quantitative analysis of kidney function. **Conclusion:** A change in administered dose to the patient did not affect the noise characteristics of the time activity curve or impact the semi quantitative calculation of kidney function. Therefore, a dose reduction of 25% could be implemented resulting in a lower dose to the patient and compliance with the 50^th^ percentile diagnostic reference level (DRL) recommended by ARPANSA.

P073: To Gate, Or Not to Gate? That Was the Question
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**Background/Aims:** It is well known that respiratory motion degrades image quality and can lead to reduced diagnostic accuracy in reporting avidity and metabolic activity of lower lung nodules on ^18^F-FDG PET scans. There are various imaging strategies utilised to minimise respiratory motion artefact. One such strategy is quiescent period respiratory gated PET imaging. **Results:** Patient administered 197MBq ^18^F-FDG following a 6 hour fast period. Uptake time 87 minutes. Imaging on Siemens Biograph mCT Flow with continuous-bed-motion and respiratory-gated PET, along with contemporaneous low dose CT. Gated PET scan and reconstruction parameters: 200 x 200 matrix, 8 FWHM, 21 subsets x 2 iterations, attenuation correction and scatter correction. Multiple ^18^F-FDG avid lung nodules visualised. Largest lung nodule with SUV~max~ 15.8 and dimensions 22 mm x 20 mm x 22 mm. Multiple hepatic foci suspicious for metastases found. **Conclusion:** The patient set up time is minimal. Respiratory gated PET is an efficient and effective imaging strategy to reduce motion artefact related to respiration. This inherently improves diagnostic accuracy in reporting metabolic activity and avidity of lung and upper abdominal disease on ^18^F-FDG PET scans.

P074: Dose Optimisation: What, Why, How, My Department's Experience
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**Background/Aims:** Dose optimisation is the confirmation that the lowest radiation dose is given to the patient following the ALARA principle, while being able to provide the appropriate diagnostic information. Injected doses for procedures don't change regularly. When assessing injected doses, you need to ask, can we do better? The first and easiest way is to compare your injected doses to the Diagnostic Reference Level (DRL's). DRL's give the mean, upper and lower dose values of the collection group. When comparing to the DRL's you then can decide to match or get closer. **Methods:** Technology changes, further education and increasing numbers of specific scans lead us to choose bone, lung V/Q, myocardial perfusion and gated blood pool scans (GBPS). We looked at the scan injected doses and determined criteria for dose and imaging protocol change. To measure change an average injected dose for each procedure was calculated for one month's patients in 2011 and the same month in 2017. **Results:** We were able to see decrease injected doses for bone scans by 8%, GBPS by 6%, and myocardial perfusion rest study by 9%. However, change was not seen in the injected doses for myocardial perfusion stress study and for 'Standard Adult' ^99m^Tc-MAA. **Conclusion:** The process is useful in applying change that saw decreases in bone scan and GBPS injected doses. Decrease in the lung V/Q scan ^99m^Tc-MAA dose and myocardial perfusion stress dose was the desired outcome. However, the doses are true representation and more suitable to patient habitus. The process also helped our protocol for V/Q lung imaging of pregnant patients. The future direction is to look at other studies for further dose reductions. Dose optimisation is not a daunting process and should be a priority for all departments.
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**Background/Aims:** The whole body absorbed radiation dose from an administered dose of 200 MBq ^67^Ga-citrate is approximately 15 mSv, significantly higher than the majority of nuclear medicine diagnostic procedures. This is due to the longer half-life being 78 hours and administered activity. The aim of this study was to evaluate a method to reduce the administered dose to optimise image quality and reduce radiation dose. **Methods:** An externally triggered gated ^67^Ga-citrate SPECT/CT study was acquired using an Esser-Modified Jaszczek PET phantom with 8, 12, 16 and 25 mm cylinders at contrast ratios of 29:1 and 14:1. Data was acquired using 128x128 matrix with 60 projections per detector (3 degree steps) at 20 seconds per projection on a Siemens SymbiaT16. The gated SPECT raw data was rebinned using in-house software to generate 10 ungated SPECT studies each of varied time per projection (2 sec, 4 sec, 6 sec up to 20 sec) to represent 10%, 20%, 30% up to 100% of the administered dose. Studies were reconstructed using iterative reconstruction with CT-based AC, Flash-3D resolution recovery and Gaussian at FWHM 8.5 to 10mm. Regions of interest were drawn over background and the hot cylinders for all reformatted images. Mean and SD for each region for each dataset was used to calculate the signal and contrast to noise ratios (SNR & CNR) and coefficient of variation (CoV) to assess image quality. **Results:** Results for phantom data with a contrast ratio of 14:1 were analysed equating to an injected activity used clinically equivalent to 200 MBq ^67^Ga-citrate. Preliminary results of the SNR and CoV for background plateau at 12 to 14 seconds per projection with values of 12.4 and 7.8% respectively, representing 60 to 70% of total activity. The CNR values for all cylindrical sizes showed similar trends with the highest CNR seen in the 25mm and 16mm cylinders as expected based on the resolution of a SPECT system. **Conclusion:** Preliminary results would suggest that a reduction of total activity by 25 to 30% does not impact on image contrast and quality, therefore giving an injected dose of 150MBq with a 14 second per projection SPECT acquisition will not compromise clinical interpretation. Further clinical validations are needed on clinical cases using a gated SPECT acquisition to validate and confirm these results.

P076: Does Oral Hydration Reduce Bladder Activity in
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**Background/Aims:** ^68^Ga-PSMA-11 (Prostate Specific Membrane Antigen) is a PET tracer used in the imaging of prostate cancer. It is primarily excreted through the urinary system and as such is highly accumulated in the bladder. This high physiologic activity in the bladder can result in severe photopenic artifacts masking potential abnormal pelvic nodal uptake. The aim of the study is to evaluate the impact of a pre-and post-hydration protocol on activity within the bladder. **Methods:** A retrospective evaluation of ^68^Ga-PSMA scans with and without oral hydration protocols were included. The oral hydration protocol included the patient being instructed to drink up to 1000mL of water over the uptake period. The volume of water consumed during this time was recorded. Vertex to mid-thigh PET/CT scans were acquired 60 to 90 minutes after injection using a Siemens Biograph mCT/x64, reconstructed using ToF, scatter correction and CT-based attenuation correction. A region was then drawn in the middle of the bladder to define the SUV~max~ and SUV~mean~. The patients were then divided into four groups: non-hydrated, hydrated 1000 mL, hydrated 500-950mL and hydrated 100-450 mL, to assess the impact of hydration volume on bladder activity. The average SUV~mean~ and SUV~max~ in the bladder for each group was calculated. **Results:** A total of 118 patients were included for analysis, with 33 having the non-hydration protocol and 85 having the hydration protocol. The overall average SUV~mean~ for non-hydrated, hydrated 1000mL, hydrated 500-950mL and hydrated 100-450 mL were 67, 24, 26 and 36 respectively. For the SUV~max~, the results were 81, 28, 31 and 36 respectively. As such, the highest SUV~mean~ and SUV~max~ in the bladder were seen in the non-hydrated group, whilst the lowest were seen in the group hydrated with 1000mL of water. **Conclusion:** Based on these results, hydrating patients with a minimum of 500mL water during the uptake period significantly decreases the SUV~max~ within the bladder. The intensity of bladder activity is less, reducing the impact of any photopenic artefacts that may preclude visualisation of clinically significant abnormal pelvic nodal uptake.

P077: The Evaluation of Lateral Scatter Ray of Gamma Camera
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**Background/Aims:** Generally, a collimator that installed in front of detector set a direction of gamma ray and remove a scatter ray. By the way, a lateral or oblique scatter ray is detected into crystal through collimator. At this study, we will evaluate a mount of count and a spectrums of lateral scatter ray. **Methods:** We used the Skylite (Philips) as a gamma camera, and a ^99m^Tc 1.11Gbq point source as a phantom. we located this point source at backside 50cm of detector. After acquiring 1min, we turned a detector 10 degree. Likly this, we acquired a count at every 10 degree from 0° to 360°, analysed a images and a spectrums. In case of patient study, we choose 3 phase bone scan patient who had a hand disease, because scatter ray from body would detected on crystal. After acquiring a blood flow and a blood pool scan, we analysed a image and a spectrums. Additional, we set a lead gown on his hand, let wear a gown on his body. And then we compared and evaluated 3 types of blood pool images (non-lead gown, lead gown on a hand and on body). **Results:** In case of phantom study, a count of phantom is same with a background count at backside (270°\~90°). By the way, a count of oblique side (0°\~50°, 220°\~270°) ray is 100\~600 cps, front side's count is over 4Mcps. In case of patient study, a count of blood pool scan at hand is 1510cps. But a count of hand with lead gown on hand, on body are 1554cps, 1299cps at each. **Conclusion:** Therefore, even though there is a collimator at detector, a lateral scatter ray detect at crystal and affect at image and spectrums. Especially if there is a high activity source at outside of detector when we examine a low activity organ like hand, foot, we have to shield and remove a outside activity for a good image.

P078: Comparison of Ischaemia Detectability due to the Difference in Myocardial Perfusion Tracer by the Same Patient using Semiconductor Single Photon Emission Computed Tomography
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**Background/Aims:** Many previous studies on ischaemia detectability due to differences in myocardial perfusion tracer in the myocardial perfusion SPECT have been reported. Furthermore, there is no difference between ^99m^Tc-sestaMIBI/tetrofosmin and ^201^TlCl in those reports. However, there is a report that the myocardial blood flow extraction fraction has a lower ^99m^Tc-sestaMIBI/tetrofosmin than ^201^TlCl. We compared the ability of the same patient to detect ischaemia with ^99m^Tc-sestaMIBI/tetrofosmin and ^201^TlCl with myocardial perfusion SPECT. **Methods:** Of the 3525 patients who underwent stress myocardial SPECT from 2014 to 2016, myocardial perfusion SPECT performed by the same patient with different tracers in the same stress method 20 cases (exercise stress: 13, adenosine stress: 7). Also, patients who received PCI and CABG during this period were excluded. Those were studied by the semiconductor SPECT (D-SPECT, Spectrum Dynamics Medical). The scanning method was taken with count scanning (1.2M counts). And then Ischaemia (% myocardium) calculated by Quantitative Perfusion SPECT software 2012ver. was compared. **Results:** The mean value of the ischaemia value of exercise stress is 2.00% for ^99m^Tc-sestaMIBI/tetrofosmin and 4.14% for ^201^TlCl. And then the mean value of the ischaemia value of adenosine stress is 3.29% for ^99m^Tc-sestaMIBI/tetrofosmin and 3.88% for ^201^TlCl. In both stress, the ischaemia value tended to be larger in ^201^TlCl than in ^99m^Tc-sestaMIBI/tetrofosmin. Exercise stress has a larger difference in the ischaemia value than adenosine stress. **Conclusion:** ^201^TlCl is sensitive to detect myocardial ischaemia than ^99m^Tc-sestaMIBI/tetrofosmin. **Disclosure of interest:** Y Suzuki conflict with Spectrum Dynamics.
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**Background/Aims:** ^11^C-PIB synthesis has been performed by a loop-methylation and HPLC purification in our lab. However, this method is time-consuming and requires complicated systems. Thus, we developed an on-cartridge method which simplified the synthetic procedure and reduced time greatly by removing HPLC purification step. We compared 6 different cartridges (C18, tC18, tC18 environmental, alumina, HLB, CM) and evaluated the ^11^C-PIB production yields and specific activities. **Methods:** The cartridges were prewashed with 5 mL EtOH and purged with nitrogen gas. Precursor (1 mg 6-OH-BTA-0, ABX, Germany) in 100 µL of cyclohexanone was loaded each cartridge.\[^11^C\]MeOTf was synthesized by using TRACERlab FXC Pro (GEMS, Sweden) and was transferred into the cartridge by blowing with helium gas for 3 min at room temperature. To remove byproducts and impurities, cartridges were washed out by 20 mL of 30% EtOH in 0.5 M NaH~2~PO~4~ solution (pH 4.5) and 10 mL of distilled water. And then, ^11^C-PIB was eluted by 5 mL of 30 % EtOH in 0.5 M NaH~2~PO~4~ into the collecting vial containing 10 mL saline. **Results:** Among the 6 cartridges, only tC18 environmental cartridge could remove impurities and byproducts from ^11^C-PIB completely and showed higher specific activity than traditional HPLC purification method. This method took only 8 \~ 9 min from methylation to formulation. For the tC18 environmental cartridge and conventional HPLC loop methods, the radiochemical yields (EOS) were 12.3±2.2% and 13.9±4.4%, respectively, and the specific activities were 420.6±20.4 GBq/µmol (n=3) and 78.7±39.7 GBq/µmol (n=41), respectively. **Conclusion:** We successfully developed a facile on-cartridge methylation method for ^11^C-PIB synthesis which enabled the procedure more simple and rapid, and showed higher specific activity than HPLC purification method.

P080: Studies on the Precision Improvement of the Heart-to-Mediastinum Ratio Measurement by using Single Photon Emission Computed Tomography/Computed Tomography Data Extracted for the Myocardium and Mediastinum
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**Background/Aims:** In myocardial sympathetic nerve scintigraphy, the heart-to-mediastinum ratio (HMR) is widely used as an indicator of myocardial ^123^I-MIBG uptake. It is difficult to accurately measure HMR because of overlapping of the activities from the myocardium and lungs, and mixing with scatter component. In this study, we obtained the virtual planar image (synthetic planar image: SP image) by using the SPECT images and attenuation map. We aimed to improve HMR measurement accuracy by extracting the clear myocardium and mediastinum fields. **Methods:** We defined the radioactivity concentration ratio of the myocardium, mediastinum, liver, and lungs as 15:1:10:8, and enclosed these concentrations of ^123^I-MIBG solutions into the respective areas of the torso phantom. The planar image was acquired using the low-medium energy general purpose collimator. SPECT acquisition was performed for 360 degrees rotation. Images were reconstructed 360 degrees data and 180 degrees data from each projection angle with scatter correction (SC). The lung fields were extracted on the CT images, the activities from the lung fields was removed from SPECT images, and the clear myocardium and mediastinum fields were extracted. We used the attenuation map for the SPECT images and acquired SP images with or without lungs by attenuating and forward projecting the count per pixel. We compared HMR values calculated from SP images with and without lungs and the errors in setting region of interest (ROI) for the myocardium among operators. **Results:** HMR calculated from the planar image was 2.1. The average value of HMR calculated from SP image with lungs was 2.38 (SC+), or 2.02 (SC-), and that calculated from SP image without lungs was 1.92 (SC+), or 1.61 (SC-). It was found that lungs from SP image reduced HMR by 20%. Thus, HMR was reduced by 20% when calculated with SP image from which lungs were removed. The results indicated that accurate ROI for the myocardium could be obtained by using SP image from which lungs were removed. **Conclusion:** Accurate ROI for the myocardium can be obtained by using SP images from which lungs were removed and it makes the precision improvement of HMR measurement.

P081: Health Effects of Occupational Radiation Exposure in Nuclear Medicine Technologists in Australia
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**Background/Aims:** Exposure to ionising radiation is known to produce biological effects. As such there are limits placed on occupational exposure. Historically these occupational dose limits have been set from extrapolating data from known responses of high dose radiation exposure. Occupational ionising radiation exposure to a nuclear medicine technologist (NMT) is generally considered low level chronic exposure. The aim of the research was to conduct a literature review investigating health effects relating to occupational radiation exposure in NMTs. **Methods:** A literature search was performed using Embase, Medline and CINHAL catalogues using the search terms: "occupational radiation health effects", "low dose threshold model", "long term low level exposure", "medical radiation exposure", "nuclear medicine or radiologic or molecular imaging or functional imaging" with "scientist or technologist or technician or staff or personnel". A systematic review of the literature was completed using PRISMA protocols.\[[@ref10]\] **Results:** Sixty journal articles were initially identified. Thirty of these were excluded for being duplicates. The remaining 30 records were screened for eligibility. Six studies were included in qualitative synthesis. Four articles reported on cytogenetic damage and potential to cause carcinogenesis. One article discussed cataracts, leukaemia and theorised shortened life span for individuals exposed to chronic low level radiation. One article proposed good health for chronic low level radiation workers through the radiation hormesis paradigm. **Conclusion:** Literature on low dose levels of radiation exposure in an occupational setting is sparse, especially in the NMT cohort. One limitation of previous research on the effects of low level exposure is the lack of data on participant lifestyle factors e.g. tobacco, diet and other possible occupational carcinogenic exposures.\[[@ref11]\] It is recommended that these factors be included in future research.

P082: Evaluation of Metal Artifact Reduction Software in Positron Emission Tomography Quantification for Artificial Knee Joint: Phantom Experiment
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**Background/Aims:** This study evaluated the effect of metal artifact reduction (MAR) software on positron emission tomography (PET) quantification on ^18^F-Na PET. **Methods:** We prepared a phantom using an artificial knee joint, (JOURNEY Smith & Nephew), and 20mm-diameter spheres in an acryl container. We filled ^18^F in spheres and the background for the radioactivity ratio was 4:1. PET/CT was conducted on a Discovery MI (GE Health care). The PET acquisition time was 90 seconds. The X-Ray tube voltage for CT was 120 kV, and tube current was 100mA to 400mA. To acquire reference values, the same acquisition parameters were used without knee joint. The reconstruction parameters for PET were 3D-OSEM (TOF+PSF, Subset 2, Iteration 17, Gaussian Filter 4mm) and Q.Clear (TOF, β =400) with/without MAR. We estimated the standardized uptake value max (SUV~max~). **Results:** MAR did not affect SUV~max~ without knee joint. The streaks in the images caused by artificial knee joint were decreased by MAR. SUV~max~ with knee joint using 3D-OSEM without MAR was 3.8% smaller than reference values and that with MAR was 12.5% smaller than reference values. SUV~max~ with knee joint using Q.Clear without MAR was 2.1% smaller than reference values and that with MAR was 11.9% smaller than reference values. **Conclusion:** CT images were improved, but SUV~max~ was underestimated when using MAR. The PET quantification had accuracy within 5 % from the reference, even with metal artifacts.

P083: Incidental Finding of a Suspected Chondrosarcoma on a Bone Scan for Arthropathy
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**Background/Aims:** Chondrosarcomas are malignant cartilaginous tumours typically arising in middle aged patients with predominance in men. The most common site is in the long bones, particularly the femur although it can be found in other skeletal sites. Patient presentation includes pain, pathological fracture and/or a palpable mass. **Methods:** A 73 year old gentleman presented to the Nuclear Medicine department for a bone scan to assess the extent of arthropathy. The patient had a history of generalised joint pain and tenderness treated with methotrexate. The patient had normal inflammatory markers and was anti-cyclic citrullinated peptide (anti-CCP) antibody positive. The patient was injected with 900 MBq of ^99m^Tc-methyl diphosphonate (^99m^Tc-MDP) intravenously. Whole-body and regional blood pools and delayed planar images with single photon emission computed tomography/computed tomography (SPECT/CT) were obtained. **Results:** Increased uptake in keeping with degenerative change was demonstrated the acromioclavicular joints and thoracic spine as well as the joints of the hands and feet. Patchy increased uptake within the right distal femoral shaft was seen on SPECT/CT to correlate with medullary serpiginous sclerosis/calcification. While bony infarcts can demonstrate low grade activity at the periphery when active and minority of endochondromas can show increased uptake on bone scans, the degree of uptake raised suspicion for a low grade chondrosarcoma. A subsequent x-ray confirmed a sclerotic lesion with appearance of chondroid matrix mineralisation extending over 20cm of the femoral shaft. On magnetic resonance imaging (MRI), a large lesion involving mid-diaphysis to distal metaphysis was observed, highly suspicious for a low grade chondrosarcoma. No pathological fracture seen. **Conclusion:** The routine whole body scan demonstrated an unexpected bone lesion suspicious of chondrosarcoma in a patient with generalised bone pain. This case highlights the value of nuclear medicine in diagnosing bony disease in a patient, in conjunction with x-ray and MRI.

P084: Development of Disinfection Validation Protocol for GMP in Radiopharmaceuticals Production Facility
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**Background/Aims:** The validation of Disinfection in GMP facility of Radiopharmaceuticals is to confirm whether disinfectants kill microorganisms in controlled clean area such as manufacturing room, sterility test room and Class A equipment. PIC/S and the government require the disinfection validation for GMP certification but there is no protocol or method for validation of disinfection at many PET drug facilities. So, we try to develop the widely used protocol of disinfection validation and simple method. **Methods:** The Cavicide (Metrex Co., USA) and the TX3267 (Texwipe Co., USA) were used for this validation as disinfectant. Each main ingredient of disinfectant is Ethyl Alcohol and Isopropyl Alcohol. We purchased growth promotion test suspensions (Excelsior Scientific Co., UK) and clinical strains (Microbiologics Co., USA) for Disinfection validation. All of the clean areas were divided into portions under the PIC/S regulations and the environmental monitoring was carried out with TSA (Tryptic Soy Agar, HARDY Diagnostics Co., USA) plate media. TSA plate media were incubated at 35°C for 3 days and we identified 45 microorganisms from the colony on TSA plate media after 3 days. Among 45 microorganisms, we decided to use the 14 representative genera for validation. 14 microorganisms were inoculated 3 plate media for positive control and for Disinfection validation. Each disinfectant was sprayed on the surface of the plate media except positive control. No inoculation plate medium was used for negative control. All media were incubated at 35°C for 3 days and checked the growth in every day. **Results:** 10 microorganisms formed colony and 4 microorganisms did not formed colony. Control group was showed positive and negative results. The media which was sprayed Isopropyl Alcohol did not form any colony and the media which was sprayed with Ethyl Alcohol formed colony from 7 media. **Conclusion:** The Disinfection validation for radiopharmaceuticals GMP system was validated with reliable results and our new protocol.

P085: Comparative Study of Glomerular Filtration Rate Measured by Single Photon Emission Computed Tomography/Computed Tomography with Low Energy High Resolution Collimator and Low Energy General Resolution Collimator
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**Background/Aims:** To evaluate the differences in measuring glomerular filtration rate (GFR) by renal dynamic imaging of SPECT/CT with low energy high resolution collimator and low energy general resolution collimator. **Methods:** The group A which used low energy high resolution (LEHR) collimator to measure gGFR (n1=605, and the group B which used low energy general resolution (LEGR) collimator to measure gGFR (n2=228). The dGFR of all cases were measured by double-phase plasma method. Both of the two groups were respectively divided into 4 subgroups according to the results of double-phase plasma method: 1. The severely reduced group (0-29.9); 2. The medium reduced group (30-59.9); 3. The mild reduced group (60-89.9); 4. The normal group (\>90) \[ml. min^-1^/1.73 m^2^/1. The results of double-phase plasma method (gGFR) were used as gold standard. To test the normal distribution of the data with the Kolmogorov Smilov (K-S) method. Paired T-test was used to compare the diagnostic efficacy difference between the gold standard and each groups. **Results:** The standard deviations of group A and B were 21.92 and 22.73 with no statistical significance (p=0.083). There was no statistical significance between 1,3,4 groups of A and B with p-values of 0.1, 0.899, 0.864. But the difference of group 3 between group A and B was statistically significant (p\<0.001). **Conclusion:** GFR messured by spect with LEHR and LEGP have the same efficiency in measuring GFR for group 1,3,4. The SPECT with LEGR collimator has the better efficiency in measuring the one with mild renal function loss. So, it is better to perform renal dynamic imaging measuring GFR with LEGP collimator.

P086: Diagnosability of Dynamic Myocardial Perfusion Single Photon Emission Computed Tomography of
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Tc-Sestamibi using CZT Semiconductor Single Photon Emission Computed Tomography-Conventional Myocardial Perfusion Single Photon Emission Computed Tomography versus Myocardial Flow Reserve
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**Background/Aims:** ^99m^Tc-sestamibi has poor myocardial ischaemia detection ability as compared with myocardial perfusion PET formulation due to low extraction fraction. However, in recent years, dynamic myocardial perfusion SPECT by CZT semiconductor SPECT became possible. We examined coronary artery lesion detection ability by myocardial blood flow reserve obtained from Dynamic myocardial perfusion SPECT by CZT semiconductor SPECT. **Methods:** Subjects were 12 patients underwent myocardial perfusion SPECT and coronary angiography. The standard doses for rest-first ^99m^Tc-sestamibi one day SPECT protocol used were 148MBq at rest and 592MBq at stress. Myocardial flow reserve was calculated by Stress Flow Index/Rest Flow Index and Corridor 4DM 2017 was used for analysis. First, Rest Dynamic SPECT was performed for 6 minutes, Rest Perfusion SPECT was performed for 4 to 8 minutes, adenosine stress was performed for 6 minutes, Stress Dynamic SPECT was performed 6 minutes from the start of stress 3 minutes, and lastly Stress Perfusion SPECT was performed for 2 minutes. Conventional myocardial perfusion SPECT was visually diagnosed by a cardiovascular physician. The coronary artery dominant region was defined as 9 segments of LAD, 4 segments of LCX and 4 segments of RCA. In coronary artery dominant region, a segment with Myocardial Flow Reserve of 2.0 or less was judged to be positive in 1 segment or more. In coronary angiography, stenosis of 50% or more was judged as positive. Diagnostic performance evaluation was evaluated by total of sensitivity, specificity and accuracy calculated for each coronary artery. **Results:** The diagnosability of visual assessment of conventional myocardial perfusion SPECT was 29.63% sensitivity, 100% specificity and 47.22% accuracy. The diagnosability of dynamic myocardial perfusion SPECT was 81.48% sensitivity, specificity 70%, accuracy 80.56%. **Conclusion:** Visual assessment of conventional myocardial perfusion SPECT cannot detect coronary artery lesions sensitively. However, myocardial perfusion reserve by dynamic myocardial perfusion SPECT dramatically improves the ability to detect coronary artery lesions. **Disclosure of interest:** Y Suzuki conflict with Spectrum Dynamics Medical.

P087: Application of Particle Analysis to the Evaluation of Shape of the Striatum Accumulation in
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I-Ioflupane Single Photon Emission Computed Tomography
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**Background/Aims:** ^123^I-Ioflupane single photon emission computed tomography (Ioflupane SPECT) is useful for the diagnosis of diseases such as Parkinson's disease. With Ioflupane SPECT, semi-quantitative analysis of the specific binding ratio (SBR) is widely performed. However, the evaluation of the accumulated shape of the striatum is performed visually, and a quantitative analysis has not been conducted. We therefore tried the application of the particle analysis to evaluate the shape of striatum accumulation. **Methods:** Ioflupane SPECT images with different accumulation shapes of the striatum were prepared by Monte Carlo simulation. Several different models of Ioflupane SPECT were created by a digital phantom. The ratio of striatum count to background count in models of Ioflupane SPECT were set at 8:1 or 4:1. In addition, we created projection data by calculating these model data with the Monte Carlo simulation code SIMIND (Lund University). Furthermore, image reconstruction of projection data was performed, and the shape of the striatum accumulation was evaluated by particle analysis software on the transverse image. **Results:** Particle analysis was carried out to calculate the aspect ratio and circularity of accumulation of the striatum. The aspect ratio showed a value smaller than the true value due to blurring of the SPECT image. On the other hand, the circularity became higher than the true value, and the evaluation was close to a perfect circle. In addition, as the ratio of striatum count to background count decreases, setting the threshold of binarization becomes important. **Conclusion:** Application of particle analysis to shape evaluation of striatum accumulation was studied in simulation images. Particle analysis could be applied to shape evaluation of striatum SPECT. It is necessary to verify the reproducibility of binarization as a future task. Application of particle analysis to shape evaluation of striatum accumulation was studied in simulation images. Particle analysis could be applied to shape evaluation of striatum SPECT. It is necessary to verify the reproducibility of binarization as a future task.
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F-Fluoroazomycin Arabinoside Positron Emission Tomography/Computed Tomography Image-Derived Blood standardised uptake values
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**Background/Aims:** ^18^F-Fluoroazomycin arabinoside (FAZA) PET can be used for imaging hypoxia of cervix tumours by comparing the amount of FAZA in tumour to blood or a reference tissue. The purpose of this study was to validate image-derived standardised uptake values (SUV) for blood and a reference tissue by comparing image-derived to blood-sample-derived SUV (accuracy), and also by investigating intra- and inter-operator variability (precision). **Methods:** Patients with cervix tumours were imaged with PET/CT 2 hours after FAZA injection (12 of planned 20 scans) as part of a research ethics board approved study. A venous blood sample was taken to calculate blood-sample-derived SUV. To measure image-derived SUV~mean~, fixed spherical volumes-of-interest were placed using the fused CT for guidance on PET regions of the left ventricular cavity (LV), aorta, and each gluteus maximus muscle. To evaluate accuracy, image-derived SUVs were correlated to the "gold standard" blood-sample-derived SUVs. In addition, mean percentage differences (%Diff) were calculated by comparing the image-derived to blood-sample-derived SUVs. Precision was evaluated by calculating coefficients of variation (CV) of SUVs for the intra-operator and four independent operators. **Results:** The data demonstrate that the LV is the most accurate of the image regions. R^2^ and %Diff for LV were 0.97, 0.98 and-1.1%,-0.1% for both intra-and inter-operators, respectively. The %CV was also lowest for LV; 1.5 and 2.2% for both intra-and inter-operators. Overall, the highest single %CV for all three regions was only 6.4% for aorta, while the gluteus maximus values fell in between LV and aorta, indicating good precision among the four operators. **Conclusion:** Validation of image-derived accuracy demonstrated that the LV SUV is equivalent to blood-sample-derived SUV. Precision evaluation showed there was little difference for all three regions among all operators based on %CV, thereby demonstrating operator-independent determination of image-derived blood SUVs.

P089: Optimization of Reconstruction Conditions for Tau Positron Emission Tomography imaging using
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**Background/Aims:** Tau imaging using positron emission tomography (PET) should facilitate the detection of tau pathology in Alzheimer's disease and tauopathies, as well as precise assessments of disease severity and therapeutic efficacy. Therefore, standardized reconstruction parameters are required for tau PET imaging. The present study aimed to establish optimal reconstruction conditions for ^18^F-THK5351 tau imaging using phantoms and clinical images. **Methods:** Hoffman and cylindrical phantoms contained 0.94MBq of ^18^F which was determined as described in a previous report.\[[@ref12]\] All images were acquired using a Discovery PET/CT 710 (GE Healthcare) within 20 minutes. Phantom images were reconstructed using three-dimensional ordered-subset expectation maximization (3D-OSEM) with time-of-flight (TOF; 16 subsets, 128 × 128 matrix, and 2 mm/pixel), a variable number of iterations (1-10) and a Gaussian filter with full width at half maximum ranging from 0-10 mm. The reconstructed images were evaluated using grey/white matter contrast (%contrast; \[%\]) for the Hoffman phantom and uniformity (standard deviation, SD) and image noise (coefficient of variation, CV; \[%\]) for the cylindrical phantom.\[[@ref13]\] The institutional review board approved the protocols for this study of three healthy participants (male, n=3; mean age, 56.3 \[range 30-82\] years). Optimal reconstruction conditions were determined by the consensus of a neurologist and a nuclear medicine technologist from phantom and clinical images. **Results:** The %contrast and SD reached convergence at more than 3 iterations and were 55.9% and 0.101 with 4 iterations and without the Gaussian filter, respectively. The CV was 15.1% with the Gaussian filter set at 5mm. We determined the Gaussian filter of 4mm by visual inspection in human images. **Conclusion:** The optimal reconstruction conditions in 3D-OSEM with TOF comprised 16 subsets, 4 iterations and a Gaussian filter of 4mm.

P090: The Optimal Acquisition Protocols for
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Ga-DOTANOC Positron Emission Tomography/Computed Tomography Imaging Based on Injected Dose and Acquisition Time
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**Background/Aims:** This study was to determine the optimal acquisition protocols based on patient body mass index (BMI) and the injected dose per kilogram for ^68^Ga-DOTANOC PET/CT imaging. **Methods:** This study was a retrospective analysis of 51 patients who were administrated with 39.55-110.11 MBq of ^68^Ga-DOTANOC for PET/CT imaging, the patients had an average weight of 62.39±10.88 kg, an average height of 1.64±0.09 m, and an average BMI of 23.18±3.45 kg/m^2^. The study population was classified into 4 groups based on BMI: less than 18.5 kg/m^2^ (underweight), 18.5-23.9 kg/m^2^ (normal weight), 24-27.9 kg/m^2^ (overweight), and 28 kg/m^2^ or greater (obese weight). The patients were also divided into 3 groups: less than 0.74 MBq/kg (low dose), 0.74-1.48 MBq/kg (moderate dose), more than 1.48 MBq/kg (high dose). Image quality was evaluated by coefficient of variance (CV) in the liver slice. This clinical study was performed with the approval of the ethical committee. **Results:** The CV significantly increased with increasing weight and BMI (r=0.647, 0.483, p\<0.01), and significantly decreased with increasing injected dose per kilogram (r=0.695, p\<0.01). The CV differed significantly among 4 BMI-based groups, except for normal weight group versus overweight group and overweight group versus obese group (p\<0.01), the ratio for overweight group and obese group to normal weight group was approximately 1.1 and 1.2, respectively. Meanwhile, The CV had a significant statistical difference among the 3 injected dose per kilogram groups (p\<0.01), the ratio of that for low dose group and high dose group to moderate dose group was approximately 1.2 and 0.8.**Conclusion:** It is feasible to achieve good quality PET images with low dose of less than 110 MBq and shorter acquisition time. The recommended injected dose per kilogram was approximately 1.0-1.5 MBq/kg, and the maximum injected dose was about 2.0 MBq/kg in underweight patients. In addition, the injected dose in underweight patients tend to be reduce to 0.8 times, and optimal acquisition time should be at least 1.2 times longer than in patients of normal weight both in overweight patients and who received low dose less than 1.0 MBq/kg.

Nuclear Medicine Innovation: P091: Nuclear Medicine: A One Stop Shop to Performing Positron Emission Tomography/Computed Tomography, Diagnostic Computed Tomography and Ultrasound-Guided Fine Needle Aspiration under General Anaesthetic for Squamous Cell Carcinoma of the Head and Neck

Dimitri\*

Mikayla

1

Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

**Background/Aims:** Limitations exist in obtaining adequate diagnostic imaging in cases where patients present with intellectual disabilities, largely due to motion artefacts. In patients who require multiple diagnostic procedures where numerous general anaesthetics are contraindicated, there is benefit in providing a multidisciplinary service, within nuclear medicine, to drastically improve patient care. **Methods:** After failing multiple Positron Emission Tomography/Computed Tomography (PET/CT) attempts, the patient was referred to the Royal Brisbane and Women's Hospital (RBWH). The patient also required a diagnostic Computed Tomography (CT) of the Head, Neck, Chest, Abdomen, and Pelvis with intravenous contrast and a Fine Needle Aspiration (FNA) biopsy of clinically suspicious submandibular nodes. To achieve succinct diagnostic testing, staff included anaesthetists, sonographer, radiologist, cytotechnologist, nuclear medicine scientists, radiographer and nurses. Patient weight was obtained for calculation of injection of ^18^F-Flurodeoxyglucose (^18^F-FDG) and the patient was left to rest for their uptake period. After one hour, the patient was anesthetized on the scanning bed for a dedicated PET/CT acquisition of the head and neck. Guided by PET/CT, FNA under Ultrasound guidance commenced, followed by cytotechnologist collection and analysis of the extracted sample, finishing with a torso PET/CT and Diagnostic CT with intravenous contrast. Ethics approval sought and confirmed for publication. **Results:** Initial head and neck dedicated PET/CT was able to identify ^18^F-FDG avid lymph nodes which guided ultrasound FNA. PET/CT identified pathological lymph nodal involvement that was normal by size criteria on diagnostic CT, representing disease functionality and progression, outlining the importance of PET/CT scanning on patient management. **Conclusion:** Through collaboration with several multidisciplinary teams, nuclear medicine was able to cater to the referrers and patients' needs, reducing risks associated with multiple general anaesthetics. An intricate case study such as experienced with this patient, highlights the innovative and expanding scope of practice exhibited by nuclear medicine at the RBWH.

P092: Impact of Mobile Phone Interference on the Performance of a Gamma Camera
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**Background/Aims:** Electromagnetic interference (EMI) due to a mobile phone device has been reported to produce a detrimental effect on the function of a gamma camera system. The outcomes from this proposal will provide justification and validation of set rules and regulations regarding their use within nuclear medicine departments due to possible degradation of camera function and resulting image quality. **Methods:** A 3G apple iPhone 6 was tested against a thyroid phantom in four operating modes, in three positions. Testing was carried out on a Siemens E-Cam gamma camera and a GE Discovery 670 SPECT/CT gamma camera. The protocols were standardised for operation on both systems with static images obtained for assessment. Assessment was made arithmetically by means of subtraction. Results of potential EMI were determined following comparison to a baseline image. **Results:** Initial assessment of static images acquired provided no abnormality between modes and positions. Following the application of arithmetic processes, the inferior right lobe presented with an increased ring of activity upon activation of mobile signals regardless of position when tested on the Siemens E-Cam gamma camera. When compared to the GE Discovery 670 SPECT/CT gamma camera, these results did not appear to be present. This was confirmed numerically as a statistical significant difference was noted in count differences between the Siemens E-Cam and GE Discovery (p=0.0004). **Conclusion:** The function of a gamma camera has the potential to be influenced by EMI produced by mobile phone devices. Further investigation is warranted employing SPECT acquisition to assess the potential amplification of errors. The additional SPECT investigation would also allow usage and evaluation of different systems in common use. While this result was only demonstrated on one gamma camera system, it is recommended that caution be exercised when using mobile phones (in all modes) in immediate proximity to a gamma camera during data acquisition.

P093: An Evaluation of Direct Quantification using xSPECT Quant in Everyday Clinical Practice

Duncan\*

Iain

1

Ingold

N

1

Garran Medical Imaging, Canberra, Garran, Australia

**Background/Aims:** To evaluate the clinical utility and practicality of direct quantification using xSPECT Quant in everyday clinical practice. **Methods:** After installation xSPECT quant in August 2016 we used direct quantification in every scan, both to standardise windowing and evaluate all lesions considered significant. Patient symptoms and available clinical data were entered into an android based database that populated a google spreadsheet. Correlative CT and MRI imaging was available in many cases. Specific cases were flagged for follow-up or more detailed review to evaluate the benefits of direct quantification in our practice. **Results:** Data was collected from 300 general/musculoskeletal (Tc-HDP), 60 oncology (Tc-HDP and Tc-PSMA), and 15 Cardiac amyloid (Tc-PYP) cases. xSPECT Quant has proven to be a reliable way of windowing xSPECT/CT and SPECT/CT scans, most particularly in serial evaluations. It has provided a more reliable and definitive way of serially assessing oncology cases and evaluating response to therapy. We have accumulated data regarding range of uptake values in specific pathologies, most particularly in symptomatic lesions. Specific cases are presented to illustrate the benefits of direct quantification. **Conclusion:** Direct and absolute quantification has become an invaluable tool in our practice. It is used in every xSPECT scan both to standardize the scan and to evaluate individual lesions. For oncology cases, it has become an integral/critical part of the evaluation. For musculoskeletal problems, it has become a guide to severity of uptake and has standardised our assessment. As criteria develop over time it may find more specific application in stress fracture grading, Paget's disease, sacroiliitis, and in assessing periprosthetic uptake. **Disclosure of interest:** I Duncan conflict with Collaboration Siemens Healthcare, N Ingold conflict with Collaboration Siemens Healthcare.
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**Background/Aims:** Diabetes mellitus (DM) is a common disease worldwide and metformin is the first line antidiabetic medication. It frequently encountered DM patients receiving metformin for ^18^F-FDG PET scans for various disorders. Effects of metformin on imaging quality, however is still not clarified. We retrospectively observed possible differences in tissue FDG uptake in patients, with and without metformin treatment. **Methods:** Thirty-three metformin treated patients who revealed characteristic diffused bowel uptake patterns were recruited. Twenty-five age, gender and BMI-matched non-diabetic patients with staged IA/B *drug*-*naive* lung cancer served as the controls. Imaging data were corrected with corresponding lung background (Bkg) and serum blood glucose (Bg) and analysed using PMOD software to calculate ^18^F-FDG mean standardised uptake value (SUV~mean~) of the brain (grey matter), liver, muscle tissues and lung (Bkg). Data were expressed as mean±SD (SEM). **Results:** The Bkg corrected meformin group revealed significantly increased SUV~mean~ of liver and muscle compared to the controls \[Liver: 3.51±1.04 (0.18) vs. 2.59±0.5 (0.1), p\<0.0001; Muscle: 1.11±0.35 (0.06) vs. 0.89±0.18 (0.04), p=0.004\] but significantly decreased in the grey matter \[5.66±1.53 (0.27) vs. 7.66±2.12 (0.42), p\<0.001\]. Corrections combined Bkg and Bg provided a similar result as blood glucose correction alone \[Liver: 3.56±0.91 (0.16) vs. 2.67±0.64 (0.13), p\<0.0001; Muscle: 1.13±0.35 (0.06) vs. 0.92±0.25 (0.05), p=0.014\]. The tissue-Bkg different ratios and Bkg corrected SUV~mean~ brought the same results as SUV~mean~. **Conclusion:** Metformin appears increased hepatic and muscular FDG uptake yet decreased brain grey matter uptake.

P095: Constrained List Mode Reconstruction of Activity and Attenuation Maps on the Positron Emission Tomography/Magnetic Resonance System from Emission Data
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**Background/Aims:** Photon attenuation correction is a necessary step on the PET system to have accurate images. Activity and attenuation maps on the TOF PET system can be determined from emission data up to a constant term. The aim of this study is to limit the number of unknown attenuation coefficients and incorporate some additional information on the emission-based method in order to improve the estimated activity and attenuation maps. **Methods:** The proposed method uses a maximum a posteriori framework to incorporate the histogram-based information on the attenuation map reconstruction. It includes a successive optimization approach in which activity and attenuation maps and the hyper parameters of attenuation map are updated alternately. A single scatter simulation technique was used for scatter correction and random coincidences were estimated using a delayed window method. **Results:** The performance of the algorithm is studied with some simulated phantoms using Monte Carlo simulation toolkit (GATE). The simulated geometry of system was based on GE 690 PET scanner at different time resolutions. A good agreement was found between the actual images and those produced by the proposed algorithm. Also, results for time resolutions of 544 ps that are commercially available (GE 690 PET/CT) show that the proposed method can be combined with segmentation-based attenuation extraction methods on the current commercial PET/MR systems. **Conclusion:** The proposed method indicates a robust and reliable alternative to other methods for attenuation map extraction on the PET/MR systems. The results showed that presented method suppress the cross-talk problem of emission-based activity and attenuation reconstruction. Moreover, it the potential to be used as a stand-alone or even combined with other methods for attenuation correction on the PET/MR systems.

P096: Basic Study on Removal of Extracardiac Uptake using Deep Learning
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**Background/Aims:** The extracardiac uptake by technetium radiopharmaceuticals in myocardial images has influence on image diagnosis. High uptake of liver and intestinal tract may show abnormal uptake when close to the myocardial, which also causes misdiagnosis. In the past study, there are mask processing by image processing and by normalization of count, but it was not perfect. Therefore, we devised a system for image recognition and removal at the pixel level of the cardiac accumulation using deep learning out of artificial intelligence. We conducted a basic study on the accuracy of image discrimination between cardiac and extracardiac uptake. **Methods:** We used deep learning for artificial intelligence learning methods. From the clinical axial image of 30 cases obtained using ^99m^Tc radiopharmaceuticals, we used the selective search for cutting out of 334 images assumed to be myocardial region and 1406 images other than the myocardial, for creating teaching data. We made these images learn two patterns other than the myocardial and the extaracardiac to the artificial intelligence system. When defining the myocardial region, the position in the image, the number of counts, etc. were determined. This time, our image recognition system used Adam. In the verification method, 35 cardiac regions and 49 other than the myocardial were excised from another patient group, and how the system identifies each image was verified. **Results:** The ratio of recognising that it is a cardiac image was able to be identified with accuracy of 92% as a result of 50 rounds of learning. It was also confirmed that the recognition of the extracardiac can be similarly identified with an accuracy close to 90%. **Conclusion:** We have learned the system with the system with 300 images (cardiac) and 1400 images (extracardiac) of 30 cases, and verified the accuracy. However, since both learning cardiac data and extracardiac data are in few cases, it is necessary to consider the case in which the myocardial and the extracardiac uptake are closely related, the extracardiac uptake is very large, and the defect of the myocardium is large. For that reason, it is necessary to increase the number of cases by verifying under various conditions. In the future, we believe that the effect of extracardiac can be alleviated by increasing the accuracy of the recognition technique for imaging myocardial images.

P097: Basic Study on New Ischaemic Defect Model Create for Myocardial Image Evaluation
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**Background/Aims:** In order to evaluate the image quality of myocardium, we evaluate lesions of simulated defects such as acrylic and plastic phantoms in myocardium. It was intended to create a defect, not a model assuming ischaemia. The ischaemic model up to now has been created in a pseudo manner by changing the thickness of the chunk of the defect. However, in actual ischaemia, defects and normal parts were mixed, and the true ischaemia model did not exist. Therefore, we examined whether a myocardial ischaemia model with normal and defect mixed can be created and used for image evaluation. **Methods:** We created a cylindrical myocardium model with a total length of about 200mm. There were created a total of 5 ischaemia models consisting of 4 models with a degree of ischaemia of 60% to 90% up to 10% and one model in which ischaemia continuously varies from 60 to 90%. The material of the ischaemia model was acrylic, and the entire phantom was made using acrylic material. Specific methods of creating ischaemia are: (1) Drill two different holes of 2 mm φ and 3 mm φ in acrylic to create an ischaemic model, (2) Create ischaemia with slit with adjusted depth and width. It was collected with ^99m^Tc and ^201^Tl. Acquisition protocol was 180 and 360 degree, in addition the matrix was 64 and 128. We used FBP for image reconstruction and 0.5 \[c/cm\] for BW filter. Evaluation was used by circumferential profile curve. **Results:** Regardless of the acquisition angle aria and type of radiopharmaceutical used, the slit of type (2) was more sensitive to the difference of ischaemia. Regarding the ischaemic type of the hole (1), regardless of the number of holes or the number of counts, the rate of count decrease remained about 50% of the maximum count, and there was no change. On the other hand, type of slits (2), there was a gradual increase in counts in the 90% to 60% ischaemia model. In fact, it was 52% 56% 61% 74% relative to the maximum count. **Conclusion:** We thought that the slit type (2) to be able to create more better ischaemia model by also considering slit number, depth width. In the hole type of (1), it is considered that the radiopharmaceutical did not pass through the hole, and it entered the same state as the defect due to the entry of air. We thought that the slit type (2) to be able to create a better ischaemia model by also considering slit number, depth width.

P098: The Role of Bone Seeking Radiopharmaceuticals in Overall Survival of Breast Cancer Patients with Multiple Bone Metastases
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**Background/Aims:** Bone is a common site of metastases in breast cancer. Bisphosphonates, denosumab, chemotherapy and hormonal therapy have proven efficacy. External beam radiation and surgery are used in complicated cases. Nuclear therapy is usually used to manage prostate cancer, it may be also useful in breast cancer cases. Nuclear therapy has proven efficacy reducing pain, but influence on survival remains unclear. The aim of this retrospective cohort study is to assess overall survival (OS) of breast cancer patients with bone metastases. **Methods:** 160 breast cancer patients with multiple progressive bone metastases treated with ^153^Sm-EDTMP (83%), ^188^Re-ZA (8%) or ^89^Sr-Cl2 (9%) were included in the study. Median age was 59 years (range 79-31). In 80% of cases, it was hormone-sensitive erb2 negative type; in 9% was hormone-sensitive erb2 positive type: in 5% was triple negative; and other cases was erb2 positive. 58% of patients at the last follow up visit had no extra-skeletal metastases. More than 20 lesions according to the bone scan at the start of the therapy were in 35% of cases; from 6 to 20 lesions in 28%; from 3 to 6 lesions in 13%, and total skeleton involvement observed in 24% of cases. Median time from diagnoses of bone involvement was 9.3 months (range from 0.04 to 125 months). In the majority of cases, nuclear therapy applied repeatedly was independent from pain syndrome. Median number of cycles were 3 (Range: 1-10), with median 4 month interval between the 1st two cycles (Range: 2-27). OS after the start of the treatment and after diagnosis if bone metastases was calculated and compared with contemporary data from the literature. **Results:** Median OS after the 1st cycle of nuclear therapy was significantly higher than after external beam therapy applied to painful bone sites: 33.6 and 23 months, respectively.\[[@ref14]\] Median OS after diagnosis of bone metastases in our cohort was 5.2 years. It is much higher than the OS in two great populational studies: 2.3,\[[@ref15]\] 2.2 and 2.5 years.\[[@ref16]\] **Conclusion:** Nuclear therapy in breast cancer patients is safe and potentially life-prolonging treatment option. There is need in further evidence based trials to assess influence of the therapy on the OS compared to external beam radiation or best standard of care.
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**Background/Aims:** A 52-year old male with a family history of prostate cancer and a rising prostate-specific antigen (PSA) level presented to the molecular imaging department in a high-risk prostate cancer bracket. His digital rectal examination was normal and his magnetic resonance imaging (MRI) concluded prostatitis. However, his biopsy resulted in a Gleason score of 4+4 (8) and 4+3 (7). Due to these results, pre-operative positron emission tomography (PET) was requested. This case study aims to show the benefits of using an imaging protocol combining both PET/MRI and PET/computed tomography (CT) for the diagnosis, staging and treatment planning of prostate cancer. **Methods:** 2-(3-{1-carboxy-5-\[(6-\[^18^F\]fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid (^18^F-DCFPyL) is a radiotracer that binds to prostate-specific membrane antigen (PSMA) receptors which are found on prostate cancer cells.\[[@ref17]\] The patient was injected with 222 megabecquerels (MBq) of ^18^F-DCFPyL and had an uptake time of 120 minutes. A 1-bed position PET/MRI was performed over the prostate followed by a vertex to thigh PET/CT. Ethics was approved through the Princess Alexandra Hospital local ethics committee on behalf of Metro South Health. **Results:** The PET images displayed a PSMA-avid focus in the right peripheral zone of the prostate with a Prostate Imaging-Reporting and Data System (PI-RADS) score of 4, suggesting it was highly suspicious of malignancy. As both modalities demonstrated a localised lesion with no metastases present, a prostatectomy was the recommended treatment pathway. Following surgery, the patient's PSA level declined and was in the normal range. **Conclusion:** The PET/MRI and PET/CT imaging protocol was able to provide information to accurately diagnose stage and treat this patient. The combination of using both hybrid modalities could become the new gold standard as it provided a thorough screening of a high-risk prostate cancer patient, where other tests failed.
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**Background/Aims:** A nuclear medicine lymphoscintigraphy study is performed in conjunction with breast surgery for patients with diagnosed breast malignancies. Currently the study involves coordination of three clinicians to be present which results in waiting times greater than the target of 45 minutes. The aim of this study was to identify procedural changes to reduce patient waiting time. **Methods:** A baseline audit (October 2016-January 2017) was conducted. Consultation with the associated professions involved in the procedure facilitated implementation of strategies to improve the process bottlenecks in February 2017. A follow-up audit (March-July 2017) was undertaken to monitor the impact. Patient demographics and waiting times were collated and analysed. **Results:** The baseline audit (50 patients) identified that 30% of patients were injected within the target 45 minutes for their procedure. Procedural changes implemented included the development of a new referral template; engagement with Women's Imaging for patients undergoing hookwire procedures; medical review of previous imaging and request forms the day prior to the procedure and confirmation of injection technique before patient arrival. Following implementation of these changes, the audit (56 patients) identified that 48% of patients were injected within the target 45 minutes. **Conclusion:** Procedural changes have reduced the waiting times for lymphoscintigraphy studies, however 52% of patients are still waiting longer than the target 45 minutes. Work is currently underway to expand the scope of the nuclear medicine scientists to perform the lymphoscintigraphy procedure and further reduce waiting times.

P101: Count Rate Dependence of Sensitivity for Quantitative Single Photon Emission Computed Tomography with the GE-670 and Q.Metrix
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**Background/Aims:** The GE670 SPECT/CT combined with the Q.Metrix\[[@ref18]\] toolkit provides a clinically applicable system for quantitative SPECT. By taking into account camera sensitivity, scan parameters and patient demographics, the counting statistics in the image can be mapped to activity concentration. One consideration in implementing this, is the count rate dependence of sensitivity. For ^99m^Tc, dead time effects manifest at count rates in the clinical range decreasing the sensitivity. This work aims to characterise the count-rate dependence of the sensitivity to apply Q.Metrix over a wider operating range. **Methods:** The sensitivity values required for Q.Metrix are measured using the planar sensitivity measurement described in the NEMA-NU1\[[@ref19]\] which correlates well with volume sensitivity values.\[[@ref20]\] The planar sensitivity was measured for activities ranging from 70MBq to 1500MBq. A cylindrical uniform source with volume 6.035L was filled with 1500MBq of ^99m^Tc and acquired over a period of approximately 30 hours. Each acquisition was then reconstructed with Q.Metrix using clinical parameters and analysed using the corresponding count-rate dependent planar sensitivity. A comparison of the reconstructed voxel activity concentration against the known activity concentration then allows for an assessment of the accuracy of Q.Metrix over a range of system count rates. **Results:** The measured planar sensitivities ranged from 90.1 cps/MBq at 70MBq to 68.4 cps/MBq at 1543MBq with no paralysable effects observed. Application of the count-rate dependent sensitivity to the Q.Metrix reconstruction of the uniform cylinder phantom for activity concentrations of 153.1 kBq/ml and 44.37 kBq/ml results in reconstructed voxel concentrations of 158.5 kBq/ml and 45.3 kBq/ml respectively which corresponds to approximately 3% overestimation for both cases. **Conclusion:** Consideration of the count rate dependent planar sensitivity is required when applying Q.Metrix in order to achieve reliable quantitation. Future work is to quantify the sensitivity of the system for a range of isotopes.

P102: Custom Apps: A New Generation of Relational Databases
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**Background/Aims:** To create a relational database with additional functionality to address workflow issues in a busy thyroid therapy clinic, and then assess the ease of implementation and benefits to clinicians and support staff. **Methods:** Several software products able to create a relational database (custom application or app) were considered with regards to functionality, cross platform compatibility, software design, cost and level of support. Development was in-house, rather than through an external developer. Secure electronic data capture needed to include all patient demographics, medical and treatment information, as well as referrer demographic data. Generation of customized clinic letters and improved communication between clinic staff, patients and referrers was also required. Following development and implementation, an electronic survey was performed to assess the ease of use, improvement in communication and documentation of patient interactions, as well as increased turn-around times of clinic letters and other a performance indicators.**Results:** The Thyroid Intervention Management System (TIMS) was developed on FileMaker Pro 15 over approximately 100 hours by a single physician, who had no previous programming experience. Implementation was completed over several weeks, on existing hardware and infrastructure, and all clinic staff were exclusively using TIMS within three months. Benefits included up to date patient information across the site being available to auto-populate consult notes, letters and request forms, as well as generate new bookings. Communication was improved using time-stamped logs, template emails, auto-saved documents and updated contact information. **Conclusion:** FileMaker Pro can be used to create custom apps that are intuitive for the user and can be modified or expanded as the need arises. In the clinical workspace, these custom apps can be used as a secure solution when managing large amounts of patient data, with benefits with regards to reduction in support resources required and turn-around times, and increased user satisfaction.

P103: Positron Emission Tomography/Magnetic Resonance Imaging: A Retrospective Analysis of Clinical Utilisation
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**Background/Aims:** PET/MRI remains an emerging imaging modality at present. The hybrid combination of PET + MRI became a reality for clinical use in humans in 2010.\[[@ref20]\] The Princess Alexandra Hospital (PAH) acquired the 1^st^ clinical based PET/MRI scanner \[Siemens Biograph mMR (3T)\] in Australia in September 2014. Subsequently the first clinical PET/MRI scan in the Southern Hemisphere was completed on December 2^nd^, 2014. Our aim is to review the use of PET/MRI in routine clinical practice including pathologies investigated, radiopharmaceuticals utilised and the primary scan indications. **Methods:** A retrospective review of all PET/MRI studies completed at the PAH between 2^nd^ December 2014 and 31^st^ of October 2017 was performed, utilising local records and picture archiving and communication system (PACS) databases. The need for patient consent was waived by the institution ethics review board. **Results:** A total of 1775 PET/MRI studies were recorded, among which clinical scans accounted for 64.28%. This was followed by dedicated diagnostic MRI imaging (20.90%) and finally research/audit scans (14.82%). The most common radiopharmaceutical utilised was ^18^F-Fluorodeoxyglucose (^18^F-FDG) accounting for 60.44%, ^68^Ga-Prostate Specific Membrane Antigen (^68^Ga-PSMA) accounted for 30.70% and ^68^Ga-DOTATATE (^68^Ga-DOTATATE) 5.93%. The most common pathology investigated utilising the PET/MRI was prostate cancer accounting for 25.21% of cases, followed by diagnostic MRI imaging for myeloma on the PET/MRI (12.60%) and PET/MRI for colorectal cancer (8.05%). **Conclusion:** The clinical utility of PET/MRI in routine clinical practice continues to evolve. Prostate cancer imaging is the key clinical pathology being imaged using PET/MRI and ^18^F-FDG remains the most utilised radiopharmaceutical in our study. Although the most common reason to perform a PET/MRI is shown to be for clinical use (64.28%), PAH continues to perform extensive clinical trials to unveil the expanded utility of PET/MRI in clinical practice, which is key should this modality make its way into routine clinical use.

P104: Study on Introduction of Positron Emission Tomography Nuclides into Glutamate Transporter Inhibitor
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**Background/Aims:** Positron emission tomography (PET) imaging is a useful method to analyse the biological functions of receptor and transporter in the CNS. The demonstration of the functional changes would also lead to an early diagnosis of various brain diseases. To develop useful imaging agents that bind to glutamine transporters, we have investigated tamoxifen derivatives and tetrahydrobenzopyran derivatives that are known to affect the functions of the Glt by exposing some of the compounds to \[^18^F\]F^-^or \[^11^C\]CH~3~I, \[^11^C\]methyl triflate be labeled. **Methods:** First, we performed an *in silico*-binding assay by generating various derivatives of tamoxifen and tetrahydrobenzopyran using our protein-ligand docking calculations. Next, we synthesized the precursors of the desired derivatives: The tamoxifen-derived derivatives were conjugated to those of the ketone using the McMurry coupling reaction. The derivatives of tetrahydrobenzopyran were synthesized from diketone components and cyano analogs. After purification of the reaction mixture by flash column chromatography and recrystallization, the label precursors were obtained, and were reacted with \[^18^F\]F^-^or \[^11^C\]CH~3~I, \[^11^C\]methyl triflate on an automated synthesis system. **Results:** In the present study, we synthesized the \[^11^C\] or \[^18^F\] labeled derivatives of tamoxifen and tetrahydrobenzopyran. At present, we are attempting to improve the yields and the resultant compounds in the labelling reaction. **Conclusion:** We performed an *in silico*-binding assay and synthesized the labeled derivatives of tamoxifen and tetrahydrobenzopyran, which are thus possible ligands of the Glt. The experiments with an *in vivo* small animal imaging device are also underway in our group.
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**Background/Aims:** Small-animal research, which is widely used in laboratories for biomedical research, drug development, gene expression and novel detector technology, is an emerging field in preclinical molecular imaging with positron emission tomography (PET). Small-animal PET has been used extensively in modern biomedical research. In this study we have developed a new small-animal PET scanner. **Methods:** Each detector block consists of a 24×24 LYSO: Ce array with 2×2×10 mm3 pixels coupled to a SiPM device and multiplexing Printed Circuit Board (PCB) placed in aluminum housing. We used SensL ARRAYC-30035-144P which is a 12×12 array of C-series SiPM pixels. The system compromises of 10 detection blocks connecting to a digital coincidence processing unit (DCPU). We implemented time-to-digital converter (TDC) in Xilinx's SPARTAN6 field programmable gate array (FPGA) by using a 64-tap delay line. After acquisition, the list mode data generates 3D sinogram with user configuration and then it will be ribinned to 2D sinogram. The iterative 2D OSEM is used for image reconstruction. The base design uses the single-slice re-binning (SSRB) and ordered subset expectation maximization (OSEM) image reconstruction methods. **Results:** The averaged energy resolution at 511 keV was about 16% for all heads with negligible differences. Spatial resolution of the system was measured as 1.8 mm at the center without resolution recovery. In addition, the sensitivity of the system was calculated as 1.2%. The reconstructed images of the rat NaF scan and image quality phantom revealed good imaging performance of the system resolving skeletal structure including acceptable resolutions for the vertebrae and the ribs. The transaxial slice of the reconstructed image of the Jaszczak phantom without resolution recovery shows that the sections containing 1.8 mm rods is visually clear with adequate resolving. **Conclusion:** The preliminary performance evaluation shows the system can be a reliable PET imager for preclinical molecular imaging.

P106: Design and Development of a Dedicated Single-Photon Emission Computed Tomography System for Cardiac Imaging
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**Background/Aims:** Cardiac SPECT imaging have a crucial role in assessing myocardium in patients with suspended coronary artery disease. We designed and developed a dedicated cardiac SPECT system called ProSPECT to cover patients with different sizes. Also, the scanner provides both supine and prone imaging. This dedicated cardiac imaging system introduces an optimized FOV to minimize inappropriate activity uptake of other organs. It should be noted that the system increases comfort patients specially patients with claustrophobia disorder because the head of patients comes out of the bore of gantry during scanning. The aim of this study is to report the design and performance characterization of ProSPECT based on NEMA-NU2 2007 standards for gamma cameras. **Methods:** The scanner have two perpendicular detectors that are including NaI (Tl) crystal followed by an 4x6 array of square PMTs (76x76 mm). The use of square PMT provides full coverage of the crystal and decreases the dead zone in the detector. A non-linear recursive filter that we successfully registered as US patent is applied in readout electronics of the detector. **Results:** The proposed scanner has introduced acceptable uniformity (2.5% integral uniformity and 1.3% differential uniformity) and linearity (0.8 mm absolute and 0.2 mm differential linearity) in UFOV. The intrinsic and extrinsic spatial resolutions with low-energy high-resolution (LEHR) collimator on the surface of the detector were 3.7 mm and 7.5 mm, respectively. The energy resolution of the camera was determined 9.3% and the sensitivity of the system was 180 cps/Mbq. **Conclusion:** The performance evaluation demonstrated the proposed scanner is appropriate for cardiac imaging. The system is currently under clinical tests.

P107: A Simple Quality Test Postservice Simulating Clinical Conditions on a GE Discovery 710 Positron Emission Tomography/Computed Tomography Camera
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**Background/Aims:** On a GE Discovery 710 PET/CT camera, the existing quality control routine performed post-service or after fault repair by GE Healthcare engineers does not test some elements of image quality and performance under simulated patient conditions. On one occasion, routine tests did not identify a fault which resulted in breakdown during patient scanning and a reportable radiation incident. We sought to develop a minimum impact additional quality control test in consultation with GE engineers to test the system under simulated patient conditions before returning the camera to service after fault repair or routine service. **Methods:** The existing well counter calibration phantom supplied with the PET/CT camera was used as a patient surrogate. It was positioned in the body position over two bed positions and filled with Gallium-68 eluate, which is readily available at our centre. A seven bed acquisition was acquired at one minute per bed in addition to CT attenuation correction scan. The images were processed as a normal patient scan and qualitatively examined for image quality, including stitching of bed positions, registration, and miscellaneous artefacts. Quantitative performance was also assessed through determination of mean standardised uptake values (SUV~mean~) on the attenuation-corrected images. The non-attenuation-corrected images were also examined for artefacts. **Results:** The quality test has been performed three times. Qualitative performance has been reproducible on a fully-functioning Discovery 710 PET/CT camera. Quantitatively, SUV~mean~ -values were identical between results (0.90). Additionally, the initial fault was successfully identified when the conditions under which the fault occurred were replicated. **Conclusion:** This test will be incorporated into the routine post-service and post-repair tests at our centre. The test will be performed collaboratively with engineers, nuclear medicine technologists and medical physicists.
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**Background/Aims:** To establish the utility of baseline ^18^F-Fluorocholine PET/CT and bone scintigraphy (BS) in the outcome prediction of patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with ^223^Ra. **Methods:** Prospective, multicenter and non-randomized study (ChoPET-Rad study). ^18^F-Fluorocholine PET/CT and BS were performed before the initiation of ^223^Ra (basal PET/CT and BS). Bone disease was classified attending the number of lesions in baseline BS and PET/CT. PET/CT was semiquantitatively evaluated to obtain the SUV~max~ in the 5 bone lesions with the highest metabolism and the average SUV~max~. Gleason score, baseline levels of prostate specific antigen (PSA), alkaline phosphatase (AP) and lactate dehydrogenase (LDH), time of evolution of prostate cancer, time of evolution of BM and ^223^Ra line were registered. Each patient was clinically and biochemically monitored. Progression free survival (PFS) and overall survival (OS) since the onset of ^223^Ra treatment were calculated. Therapeutic failure was considered when patient did not finish the ^223^Ra treatment. Relations between clinical and imaging variables with PFS and OS were evaluated by Pearson, Mann-Whitney tests and Kapplan-Meier analysis. Univariate and multivariate Cox regression analysis was performed. **Results:** Forty patients were enrolled. The mean±SD of PFS and OS were 4.6±2.3 and 11.2±8.1 months respectively. 33 patients progressed and 13 dead during the follow-up. The extension of the bone disease by PET/CT (p=0.011, χ^2^= 10.63), BS (p=0.044, χ^2^=8.04), SUV~max~ (p=0.012) and average SUV~max~ (p=0.014) were related to OS. No significant association was found for the PFS. ROC analysis revealed significant association of SUV~max~, average SUV~max~ and basal PSA with OS. Only therapeutic failure was associated with OS In the multivariate analysis (HR=3.6, p=0.04). **Conclusion:** ^18^F-Fluorocholine PET/CT had prognostic aim in the prediction of OS. None clinical or imaging variable was able to predict the PFS, probably due to the high rate of progressive disease.

P109: Assessment of the Impact of Time-of-Flight on Reduction of Metal Induced Artifact in Positron Emission Tomography/Computed Tomography Imaging: Phantom Study
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**Background/Aims:** CT-based AC of PET data causes some artifacts in PET images such as metal artifact which affects tracer uptake value and decreases quantitative accuracy. In this study, we evaluated the impact of TOF reconstruction on reduction of metal induced artifact in PET/CT imaging. **Methods:** NEMA IEC body phantom was adapted to hold a pacemaker generator in the removable lung insert. Phantom background and spheres were filled with 5.3kBq/ml and 10.6kBq/ml (2:1activity-ratio), respectively. All images reconstructed using two algorithms including, non-TOF and TOF. **Results:** In place of pacemaker generator and its surroundings, both underestimation and overestimation were observed. Error in ^18^F-FDG uptake value was calculated using comparison between measured activity (SUV~max~) and expected activity. In case of overestimation, percentages of overestimation were 93.8% and 32.7% for non-TOF and TOF reconstruction, respectively. Also, with integrating TOF to reconstruction, percentage of underestimation was changed from -15.5% to -6.9%. The hot spheres of phantom were also evaluated. In this case, spheres with 37, 28 and 17 mm in diameter, mostly affected by light streaks while 3 other spheres affected by dark streaks caused by metal artifact. In spheres influenced by light streaks, TOF led to reduction in SUV~max~. Relative differences of SUV~max~ between non-TOF and TOF images were -10.4%, -4.2% and -11.6% in 37, 28 and 17 mm sphere, respectively. In other spheres which mostly influenced by dark streaks, TOF led to increase in SUV~max~. Relative differences of SUV~max~ between non-TOF and TOF images were 1.4%, 5.7% and 1.7% in 22, 13 and 11 mm sphere, respectively. **Conclusion:** Pacemaker generator produced artifact which decreased accuracy of measured activity. Using the TOF technique, metal-induced artifact was reduced efficiently so that overestimation and underestimation of activity were obviously decreased. We can conclude that integrating TOF technique to reconstruction, have a potential to reduce the artifacts related to the presence of high density materials such as metallic implants.

P110: Quantitative Assessment of Ring Diameter, Energy Window and axial field of view on the Sensitivity of Xtrim SiPM Based Animal Positron Emission Tomography Scanner Using the NEMA NU-4 Standards
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**Background/Aims:** In this study, the sensitivity of Xtrim animal PET system by evaluating the influence of ring diameter, energy window and axial field of view (AFOV) using Monte Carlo method has been optimised. **Methods:** Xtrim SiPM based animal PET system has been recently designed and developed in our department. The sensitivity of system was evaluated for five different ring diameters, eight energy window lengths and four AFOVs. The minimum ring diameters are considered, which are 133, 152, 170, 188 and 206 mm for 8, 9, 10, 11 and 12 modules respectively. The energy windows include \[100-700\], \[250-700\], \[300-700\], \[300-650\], \[350-650\], \[375-650\], \[375-625\], \[400-600\] with a length of 600, 450, 400, 350, 300, 275, 250 and 200 keV respectively. The AFOVs evaluated are 50 mm, 52 mm (adding a pixel crystal column), 60 mm and 100 mm (adding a module column). The NEMA NU 4-2008 standards were used for evaluating sensitivity. The system was well defined in the GATE Monte Carlo code in details. **Results:** The sensitivity for 8, 9, 10, 11 and 12 modules was respectively 1.74, 1.28, 1.42, 1.11 and 1.21%. The sensitivity for 600, 450, 400, 350, 300, 275, 250 and 200 keV energy window length was respectively 2.50, 1.75, 1.59, 1.58, 1.42, 1.38, 1.37 and 1.33%; and sensitivity for 50, 52, 60 and 100 mm AFOV was respectively 1.42, 1.60, 2 and 3.72%. **Conclusion:** By reducing the ring diameter, sensitivity of the system increases but states with the number of paired modules are more sensitive because they can better detect the pair gamma photons resulting from the positron annihilation. As the energy window length increases, the sensitivity of the system increases Because more photons can pass through the window. Depending on the data, by doubling the energy window, the sensitivity of the system increases 1.7 times and the system resolution decreases. By increasing the AFOV, the sensitivity of the system increases more than the other cases without reducing the system resolution, so that by doubling the AFOV, sensitivity of the system increases more than 2.6 times.

P112: Salt Activation to Assess Neutron Flux as a Proxy for Radiation Damage in a Cyclotron Vault
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**Background/Aims:** We have modified the methods of Fujibuchi et. al. to provide a rapid assessment of relative thermal neutron flux to allow locating and shielding of electronics to avoid activation.\[[@ref21]\] The use of bonner spheres in future work will allow assessment of damage from more energetic neutrons. **Methods:** Stable 23Na (100%) =\> 24Na emitting 1.37 and 2.75 MeV gammas with a 14.9 h ½ life. Stable 35Cl (76%) =\> 36Cl emitting 251keV betas with a 3.01 E+5 yr ½ life. Stable 37Cl (24%) =\> 38Cl emitting 1.64 and 2.17 MeV gamma with a 37 min ½ life. 2 gram samples of salt were placed around a GE PETtrace cyclotron over single productions of 100 to 400 GBq ^18^F. Samples were placed inside various forms of shielding to assess the relative reduction in activation. Samples were decayed for \>4 hours to reduce 38Cl activity to \<0.2 % before being counted in a Perkin Elmer Wizard 2480 Auto Gamma Counter with an open window for 6 minutes. The count per minute (CPM) data was corrected to the end of bombardment, normalised by mass and total cyclotron beam current. The count data was used to assess the relative shielding of boronated plastics and concrete. **Results:** The activation from a single cyclotron run produced good count statistics 10-30 kCPM. The 24Na 2.75 MeV gamma required the samples to be separated for counting to avoid cross talk. The mass and decay corrected counts correlate with cyclotron use. Samples of boron impregnated plastic produces reduction of activation by a factor of 5 and concrete by a factor of 9. **Conclusion:** The method allows a rapid assessment of neutron activation which can be used as a proxy for radiation damage.

P113: Static and Moving Phantom Studies for Radiation Treatment Planning in a 4-Dimentional Positron Emission Tomography/Computed Tomography
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**Background/Aims:** Respiratory motion is known to have a potential risk of inadequate target coverage in the setting of radiotherapy. In this study, static and moving phantom experiments for radiation therapy planning were conducted to validate target volume delineation using 4-dimensional (4D) PET/CT. **Methods:** Six sphere phantoms of 10, 13, 17, 22, 28, and 37 mm in diameter were placed in a body phantom, and the phantoms were filled with FDG solution. A body phantom (background) was filled with 1028 Bq/ml of FDG, and spheres were filled with FDG activity to achieve source-to-background (S/B) ratios of 10, 15, and 20. The body phantom with sphere phantoms was placed on a moving device and scanned by 4D PET/CT. In static phantom experiments, an appropriate threshold value was determined. In moving phantom experiments, total translations were 10, 20, and 30 mm. Moving data during CT and PET scan were recorded to generate 10 breathing phases. The maximum size of 4D PET delineation was measured in both the axial and sagittal planes. The difference between the theoretical distance (sphere diameter+translation distance) and the delineated longitudinal distance on fused PET image was calculated. **Results:** An appropriate threshold value for the spheres of 17 mm or more determined by static experiments was 35% of the maximum FDG activity, independent of the S/B ratio. On each breathing phase image, sizes of PET delineation with 35% threshold value were in good agreement (\<2 mm) with the actual sphere diameter in both axial and sagittal planes. In terms of fused image of 10 breathing phases, sizes of PET delineation with 35% threshold value were in good agreement (\<3 mm). In the translation distance of 10 mm, the differences between the theoretical and the delineated longitudinal distance of fused PET delineation of 17, 22, 28, and 37 mm sphere in the sagittal plane were 8.4, 5.8, 2.0, and 1.2 mm, respectively. In the translation distance of 20 mm, the differences were 8.6, 6.0, 5.5, and 1.4 mm, respectively. In the translation distance of 30 mm, the differences were 5.5, 6.2, 5.7, and 4.9 mm, respectively. **Conclusion:** This preclinical study indicates 4D PET/CT images have the potential to provide an individualized internal target volume. The fused PET delineation can be used to counter gross tumour volume when tumours are larger than 30 mm and total translation within 20 mm.

P114: PET20.0: System Characterization of a Novel Total Body Positron Emission Tomography Scanner Based on Monolithic Detectors
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**Background/Aims:** Total body PET (TB-PET) is a very promising concept for new applications in the field of molecular imaging and biomedical research with the only drawback the high material costs for building the system. The aim of this study is to compare a novel PET system design with current state of the art PET/CT systems. **Methods:** The PET20.0 design is based on monolithic scintillator technology which should push the resolution to the lower limits for body PET. The system also has a compact bore (inner diameter of 65 cm) and limited axial FOV of 1m. Crystal thickness is set at 16 mm to optimize the spatial resolution, cost and DOI performance of the detectors. The full system performance is compared using NEMA and realistic phantoms mimicking real patients with GATE PET monte Carlo simulations. These system simulations are based on realistic detector models. **Results:** The total amount and cost of detectors for this Total Body PET design is about 3-4 x higher than in a current PET/CT. Scatter fraction is comparable to the current PET/CT scanner designs. System sensitivity for total body scans is 15-20 times higher for a long NEMA phantom and also for realistic FDG distributions. The spatial resolution improves to 2 mm at the system level. **Conclusion:** The much higher system sensitivity for imaging torso or total body is the major benefit of total body PET and can be exploited for faster imaging or lower dose. The use of monolithic technology can enable simultaneous improvements in TOF, DOI and the improved spatial resolution will have a major impact on the quality of PET imaging. **Disclosure of Interest:** S. Vandenberghe Conflict with: Molecubes.

P115: Impact of different Reconstruction Algorithms and Ordered Subset Expectation Maximization Reconstruction Parameters on Quantitative Results in SPECT/CT
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**Background/Aims:** To evaluate the effects of 3-dimensional ordered subset expectation maximization (3D-OSEM), 2-dimensional ordered subset expectation maximization (2D-OSEM), filtered-back projection (FBP), and the number of OSEM iterations and subsets on quantitative results in SPECT/CT. **Methods:** A Jaszczak cylindrical phantom and IEC body phantom were performed routine SPECT/CT using CT attenuation correction, scatter correction and 3D-OSEM reconstruct image. The system volume sensitivity (cpm/kBq) were acquired from the reconstructed image of Jaszczak phantom, the absolute activity concentration (kBq/ml) of the hot sphere from IEC phantom was calculated, which was compared with true activity concentration, then quantitative error was calculated. Changing the reconstruction algorithm (2D-OSEM, FBP) and OSEM reconstruction parameters (number of iterations and subsets) to reconstruct the IEC phantom, the difference of quantitative results from different reconstruction algorithms and OSEM iterations and subsets was compared. **Results:** When reconstructing images with 3D-OSEM, 2D-OSEM and FBP, the quantitative error of each sphere increased with the decrease of the spherical volume (*r*= -0.831, -0.831, -0.826, all *P*\<0.05). The quantitative error of different volume spheres among three reconstruction algorithms was statistically significant (*F*=8.850, *P*\<0.05), among them that 3D-OSEM was less than that of 2D-OSEM (*P*\<0.05), 2D-OSEM was less than that of FBP (*P*\<0.05). The quantitative error of different volume spheres decreased with the increase of number of iterations (*r*= -0.721, -0.681, -0.691, -0.711, -0.845, -0.893, all *p*\<0.05), and decreased with the increase of number of subsets (*r*= -0.670, -0.694, -0.717, -0.852, -0.956, -0.998, all *p*\<0.05). **Conclusion:** The quantitative accuracy of 3D-OSEM reconstruction based on CT attenuation correction and scattering correction is significantly better than 2D-OSEM and FBP. Choosing the appropriate OSEM reconstruction parameters is helpful to improve the quantification accuracy in SPECT/CT.

**Disclosure of Interest:** K. Huang conflict with: Financial Support, Y. Feng-conflict with: Technical support.

P116: Validation of a Noninvasive Analysis Method for CBF Positron Emission Tomography
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**Background/Aims:** Quantitative brain PET with ^15^O-H~2~O can provide kinetic parameters, K1 (CBF) and k2, but requires invasive blood sampling for arterial input function (AIF). To obviate the need for blood sampling, researchers have proposed non-invasive methods, which fall into two approaches: 1) image-derived AIF; and 2) compartmental model-based analysis using tissue time activity curves (TACs). Among the tissue-curves methods proposed so far, the blind estimation method by Di Bella (PMB, 1999) is superior in terms of less assumptions and simultaneous estimation of kinetic parameters in multiple regions. The aim of this study was to investigate applicability of the Di Bella's method to ^15^O-H~2~O PET. **Methods:** List-mode PET data were acquired after bolus injection of ^15^O-H~2~O (370 MBq) during 4 minutes for patients with cerebrovascular steno-occlusive disease (n=10), and were reconstructed into dynamic images (5-sec x 48-frames). AIFs measured for each patient were used with the conventional method, that is K1-k2 fitting. Tissue TACs were calculated for 30 regions of interest (ROIs). By applying the modified Di Bella's method, we estimated the kinetic parameters, K1 and k2, simultaneously for the 30 ROIs without using AIF. In this method scaling of K1 is undetermined; R1, relative K1, was calculated with reference to white-matter region in each patient. These results were compared with the results from the conventional methods. **Results:** Both with R1 and k2, analysis for each patient showed a strong correlation between the conventional method and the present method. Differences in R1 estimates between the methods were lower than 5% (average over the ROIs) for all the patients. For k2, however, discrepancy of the methods was greater, such as that differences in k2 between the methods were larger than 10% for three patients with up to 34%. **Conclusion:** The present non-invasive method provides R1 and thus relative CBF with reasonable accuracy. When whole-brain distribution volume of water (Vd = K1/k2) is assumed, absolute CBF (K1) can be calculated from R1 and k2 estimates. However, estimation of absolute k2 has substantial errors for some patients, and absolute CBF determination is difficult without the arterial blood sampling.

P117: Impact of Detector Geometry on Image Quality for Awake Animal Single-Photon Emission Computed Tomography
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**Background/Aims:** Conventional Single-Photon Emission Computed Tomography (SPECT) requires the animal be anaesthetised to prevent motion artefacts in reconstructed images. We are developing a purpose-built SPECT system for awake animal imaging using an adaptive detector geometry and integrated motion tracking. In this work, we investigate the ideal detector geometry for awake mouse imaging, in terms of noise, resolution and contrast recovery in the reconstructed motion corrected images. **Methods:** The simulated system consists of stationary detectors with parallel hole collimation beneath the animal, with pinhole collimated detectors in front and beside the housing. To maximise the tomographic information, an additional mobile (6-degrees-of-freedom) detector with pinhole collimation continuously follows the moving animal, performing an arc-like motion, so that the area of interest (e.g. brain) remains focused within the field of view. A rigid digital mouse phantom, comprised of regions of different contrast, uniform activity and lesions of varying diameter, was used to make measurements of application-specific system performance, as a function of the selected detector geometry. Both the mouse and detectors were simulated using Monte Carlo GEANT4 GATE. Simulated phantom motion was based on measured mouse trajectories. The data were corrected for motion and reconstructed using a modified version of the MLEM algorithm. The reconstructed images for different acquisition geometries were assessed using basic image quality metrics. **Results:** We demonstrate the variation in contrast, resolution and noise over the different geometries considered. Additionally, the trade-off between resolution and noise is explored and the flexibility to optimise requirements for specific scenarios and imaging requirements are demonstrated. **Conclusion:** We have demonstrated, by simulation, that the proposed SPECT system geometry permits awake animal imaging of a rigid structure such as the head. While this investigation concentrates on the flexibility of the proposed design, in future, we plan to quantify the optimal operating geometry for specific imaging tasks.

P118: Variation in Background Activity Affects SUV-based Volumetric Measures in Differently Reconstructed Fluorodeoxyglucose-Positron Emission Tomography Images: A Phantom Study
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**Background/Aims:** Volumetric PET imaging parameters such as Metabolic Tumour Volume (MTV) and Total Lesion Glycolysis (TLG) have been suggested in quantifying tumour burden for various neoplasms. To understand the effect of variation in background activity on SUV-based volumetric parameters, we determined image quantification in differently reconstructed PET/CT images. **Methods:** Measurements were performed on a GE D-690 PET/CT scanner. A custom-built NEMA-like phantom including six fillable cylinders (25 mm height and diameter of 10 to 37 mm) and the background activity level of 2.6 kBq/ml and 5.3 kBq/ml were applied. Images were reconstructed employing four different reconstruction algorithms: HD (OSEM with no PSF or TOF), PSF only, TOF only, and TOFPSF, with Gaussian filters of 3 and 6.4 mm in FWHM. SUV~max~ and SUV~peak~ were obtained and used as cut-off thresholding; the MTV and TLG were measured. The volume recovery coefficients (VRCs), the relative percent error (ΔMTV), and Dice similarity coefficient were assessed with respect to true values. **Results:** SUV~max~ and SUV~peak~ decreased and MTV increased as function of increasing the background dose. The most differences occur in smaller volumes with 3-mm filter; Non-TOF and Non-PSF reconstruction methods were more sensitive to increasing the background dose in the smaller and larger volumes, respectively. TLG value for each target volume is not significantly changed by increasing background dose. In a range of target volumes, differences between the mean ΔMTV in the high and low background dose varied from-11.8% to 7.2% using SUV~max~ and from 2.1% to 7.6% using SUV~peak~ inter reconstruction methods. **Conclusion:** The effect of the background activity variation on SUVs and SUV-based volumetric quantification were small; however, some reconstruction methods are more sensitive to background dose.

P120: Fusion of Whole Body Scintigrams and Optical Images as Tool for Precise Detection of Thyroid Rest after Radioiodine Therapy in Patients with Differentiated Thyroid Carcinoma
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**Background/Aims:** After radioiodine therapy of DTC sometimes is practically impossible to perform precise topographic localization of regions where is located the tissue which accumulate ^131^I on WB scintigram (WBS). **Methods:** In order to solve this problem, we have developed Vision-Fusion system for web camera (WC) image acquisition simultaneously with WBS acquisition on gamma camera (GC). We used GC ecam (Siemens, Germany) in WB acquisition modality with matrix 256x1024 pixels and bed movement of 6cm/min. For optical image acquisition, we have used WC C905 (Logitech, USA) with resolution 1600x1200 pixels, connected to head of GC. Vision-Fusion software for image acquisition and fusion was developed using NI LabVIEW programming environment (National Instruments, USA). WC is in continuous acquisition mode during patient bed movement, with frame rate of 6 frames per minute. This bed movement produces displacement step of 1cm, which is equal to displacement step of 15pixels in acquisition matrix. Software extracts on each frame the central region of interest (ROI) with the height of 15 pixels. All extracted ROIs are placed next to each other forming the optical WB image. We used two markers (small plastic vials with 1 MBq of ^99m^Tc) visible on both images for estimate relation between length and number of pixels in both axes of matrices. Those relations we used for rescaling of WBS to fit it to WB optical image. **Results:** We tested our system in 10 patients with DTC 72 hours after application 3.70GBq of ^131^I. We found that our system ensures a precise identification of anatomical position of tissue which accumulate ^131^I. **Conclusion:** Based on our first results during clinical testing of our system, we can conclude that our system can improve diagnostic ability of WBS in patients with DTC after radioiodine therapy.

P121: Effects of Magnetic Resonance Contrast Agent on Positron Emission Tomography Quantitation in Liver Positron Emission Tomography/Magnetic Resonance Imaging RI Study
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**Background/Aims:** A hybrid PET/MRI facilitates the accurate registration of metabolic and molecular imaging of the cancer with correlation to anatomical findings. The use of MR contrast agent plays an important role in PET-MRI imaging for tumour diagnosis. The purpose of this study is to evaluate the influence of MR contrast agent on PET imaging using clinical liver PET/MRI cases. **Methods:** In this study, patients (n=10) with ^18^F-FDG liver PET-MRI (Biograph mMR 3.0T, Siemens) studies were collected. PET data is acquired with before and after contrast enhancement (Gd-based MR contrast agent) for 3 minutes, respectively. PET reconstruction was performed by an enhanced 2-point dixon attenuation correction method with 3D OSEM (iteration: 3, subset: 21). PET images in normal lesion and tumour of liver applied by Pre and Post MR enhancement were assessed by SUV~max~ and SUV~mean~. **Results:** No significant difference was observed between SUV of pre- and post-PET images in normal lesions of liver. The SUV of post-PET images in tumour lesions were slightly increased by MR contrast agent (SUV~max~ 5.2%, SUV~mean~ 4.1%). However, there was no significant relation between the SUV and MR contrast agent (p\<0.01). **Conclusion:** The using of MR contrast agent on liver PET/MRI had only a small effect on the SUV of FDG uptake and did not change the interpretation for patients. This approach appears to be practical and valid for other kinds of tumour.

P122: Impact of Time-of-flight for a Mismatched Respiration Phase on Positron Emission Tomography/Computed Tomography Acquisition
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**Background/Aims:** We evaluated the impact of time-of-flight (TOF) for an error of attenuation correction due to respiratory motion on PET/CT acquisition in phantom and clinical studies. **Methods:** We used a Biograph mCT with a system time resolution of 555 ps. In phantom study, we used a heart-liver phantom filled with ^18^F-FDG. PET scans were acquired in the matched and mismatched position with CT scans. The mismatched positions defined as displacement from the matched position to the caudocranial (CdCr) and the craniocaudal (CrCd) direction of 15, 30, and 50 mm. In clinical study, 21 patients with respiratory motion were divided into two groups by liver displacement in the CdCr (n=13) and the CrCd (n=8) directions. PET images were reconstructed using the iterative reconstruction (IR) with and without TOF (IR and IR + TOF). The impact of TOF was quantitatively evaluated regarding mean standardised uptake value (SUV~mean~) of the matched and mismatched liver on the PET images. **Results:** In phantom study, the difference of SUV~mean~ with the IR + TOF was slightly reduced compared with the IR. The SUV~mean~ of artifact cases was lower at the CdCr direction and higher at the CrCd direction than that of matched liver. The difference between both of SUV~mean~ was grown with increasing the motion magnitude. In clinical study, the artifact with the IR + TOF was reduced apparently at the CdCr direction. However, at the CrCd direction, the SUV~mean~ of the artifact with the IR + TOF was higher in anterior area and lower in posterior area than that of normal liver. **Conclusion:** The TOF was useful to reduce the artifact in the incorrect attenuation correction. However, the TOF might be no marked improvement for the artifact due to liver displacement in the CrCd direction.

P123: Dose Calibrator Modelling with GEANT4
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**Background/Aims:** Dose calibrators are used for dispensing of accurate levels of radiotracer to be injected into patients undergoing quantitative diagnostic molecular imaging procedures. As a result of some uncertainty in the dose calibrator gain settings for ^68^G, the question of the relative contribution of high-energy positron emissions and electron capture induced K-shell x-ray emission arises. A GEANT4 simulation of the dose calibrator response was performed to compare the manufacturer tabulated gain settings across a range of isotopes with the modelled response and to determine the contribution to the response from various mechanisms. **Methods:** A Capintec CRC25-PET series dose calibrator was modelled calorimetrically. Based on the documented,\[[@ref22]\] and inferred construction of the dose calibrator, a GEANT4 geometry was established. GEANT4 physics processes were defined and a set of simulations were performed with a range mono-energetic photon/electron energies and common radiotracer isotopes. **Results:** From the modelled results, the dose calibrator is found to receive a negligible contribution from K-shell x-rays and high energy positrons. For the positron emitters with higher end-point positron kinetic energy, there is a small contribution from the positron induced bremsstrahlung. A comparison of the emission photon energy per decay with the manufacturer recommended gain settings showed good agreement. From the modelled photon/electron response and documented beta spectra,\[[@ref23]\] the positron/electron induced bremsstrahlung response can be calculated easily for a wide range of beta emitters. **Conclusion:** A GEANT4 model of a Molecular Imaging Dose calibrator yields good agreement with the manufacturer gain settings for a range of isotopes. The combination of syringe material, plexiglass insert and aluminium chamber wall ensures that the contributions to the chamber sensitivity from K-shell x-rays and high energy beta emission is negligible. Using the results of the modified NIST ^18^F standard,\[[@ref23]\] excellent agreement is obtained for the ^68^Ga/^18^F ratio of the dose calibrator gain settings when compared to the calculated ^68^Ga/^18^F ratio for the energy deposition per decay. A GEANT4 dose calibrator model can be used for inferring dose calibrator gain settings for novel isotopes or non-standard source geometries.

P124: The Measurement of Standard Uptake Value Stability for Philips Gemini/Ingenuity Positron Emission Tomography/Computed Tomography Cameras
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**Background/Aims:** The Department of Molecular Imaging and Therapy, Austin Health operates a Philips Gemini PET/CT-64 and two Philips Ingenuity PET/CT-128 scanners. A weekly QC programme is in place to measure the stability of a range of performance parameters, one of which is the Standard Uptake Value (SUV). The SUV is a semi-quantitative measure used in PET as an indicator of regional tissue metabolism and is determined from the image derived regional tissue activity concentration, the patient injected activity and patient weight. These three parameters are in turn determined by the accuracy and stability respectively of the camera sensitivity, the dose calibrator and the weight-scales. A weekly measurement of a series of uniform phantoms provides a measure of the stability of the PET camera sensitivity and dose calibrator. **Methods:** The weekly QC regime includes measurements of three uniform phantoms of ^68^Ge, ^18^F and ^68^Ga respectively. The ^68^Ge (half-life 270 days) phantom consists of a cylinder (20 cm diameter, 20 cm length) filled uniformly with an epoxy gel of ^68^Ge. The ^18^F & ^68^Ga phantoms consist of cylinders (20 cm diameter, 30 cm length) filled uniformly with water. All phantoms have a low dose CT acquired for attenuation correction purposes and emission scans of duration 20 minutes, 15 minutes and 15 minutes respectively and encompassing 180 mm and 360 mm, 360 mm respectively. Following acquisition and standard clinical reconstruction in SUV units, the data sets are analysed with PMOD with a cylindrical Volume of Interest (18 cm diameter, 13 cm length) from which the mean SUV is derived. **Results:** The results of a 12 month series of weekly measurements for the Gemini PET/CT and Ingenuity PET/CT-1 &-2 respectively are given below: (1) ^68^Ge: 0.949 ± 0.009, 0.977 ± 0.006, 0.959 ± 0.004. (2) ^18^F: 0.979 ± 0.021, 1.034 ± 0.026, 1.019 ± 0.017. (3) ^68^Ga: 0.901 ± 0.026, 0.955 ± 0.018, 0.942 ± 0.031. **Conclusion:** The stability of the PET camera sensitivity indicated by the ^68^Ge SUV measurements ranges from 0.4-0.9%, whilst the combined stability of the PET camera sensitivity and the doe calibrator indicated by the ^18^F and ^68^Ga SUV measurements ranges from 2-3%. The Philips Gemini and Ingenuity PET/CT cameras exhibit excellent sensitivity of \<1% variability. The inferred variability in SUV due to dose calibrator stability is of order 1-2%.

P126: Comparing Performance of Gaussian Filter and Butterworth filter: A Phantom Study
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**Background/Aims:** This study was conducted to compare the performance of Gaussian and Butterworth filter. **Methods:** A digital phantom having image size 128 x 128 was created. It consists of 8 objects (three squares, one circle, three solitary rectangular bars, and one triangle made up of 6 rectangular bars) of different sizes. Gaussian noise (variance: 0.003 to 0.15 incremented at the rate 0.003) were added to the phantom image, thus creating 50 noisy images. Gaussian filters and Butterworth filter having sizes 3, 5, 7, 9 and 11-pixel size were implemented in spatial domain and applied to noisy images. All experiments were conducted using Matlab R2013b installed on Windows operating system. The output image quality was assessed both subjectively and objectively. The peak signal to noise ratio (PSNR) was used as an objective assessment criterion to evaluate the performance of the Gaussian and Butterworth filter. **Results:** The amount of noise removed from the image increased with increase in the size of the filter from 3-pixels to 11-pixel width. The excessive amount of noise when added to the image destroyed the structures present in the image, in this case, even the 11-pixel size filters could not clean the noise and restored the structures. Moreover, they blurred the edges present in the image. The filter size having 7-pixel width produced the image without excessive distortion of the structure present in the image. Butterworth filter was found to be superior in comparison to Gaussian filter as introduced less blurring at the edges. At 7-pixel width PSNR value of Butterworth filter was greater than that of Gaussian filter. **Conclusion:** Butterworth filter perform better than Gaussian filter based on both visual and objective assessment criterion (for filter size having 7-pixel width, PSNR for Butterworth filter = 15.6, and PSNR for Gaussian filter = 14.8).
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**Background/Aims:** ^18^F-fluorodeoxyglucose positron-emission tomography (FDG-PET) reconstruction algorithms can have substantial influence on quantitative image data used, e.g., for therapy planning or monitoring in oncology. Reconstruction protocols in PET/CT procedure contain two modifiable parameters: Smooth/Sharp and Speed. We analysed all the possible combinations of these two parameters and the values defined internally for Relaxation, Iteration and Kernal Width parameters in these combinations. The purpose of this study was to evaluate the activity concentrations of different reconstructed FDG-PET images and to determine the influence of varying activity concentration in distribution, signal background rate (SBR) and quantification (standardised uptake value \[SUV\]. **Methods:** A nonuniform "body phantom" was prepared with 6 lesions (distance; 10mm to 35mm) and filled with 207MBq ^18^F-FDG-water. The phantom was scanned by positioning in the center of the PET/CT (Philips, TruFlight Select, 16 slices) gantry. PET images acquired with the nonuniform phantom simulating a ''body'' were reconstructed by using nine different reconstruction combinations. For all combinations, data analyses were carried out using SPSS 11.0. Reconstruction algorithms, sphere diameters, SBR of the reconstructed PET data were used to analyse the association between these factors. **Results:** When quantitative images were studied, small differences between reconstruction algorithms were found. The most effective combination with better count statistics and the highest magnitude SUV~max~ have 3 iterations (33 subsets) and kernel width of 18.7 cm. **Conclusion:** Especially patients with head and neck malignancies, we suggest that the reconstruction protocol, combination of 3 iterations and kernel width of 18.7 cm, should be used.

P128: A Comparative Assessment of Standard Uptake Value with Positron-Emission Tomography/Computed Tomography by the Variation among Computed Tomography Devices in Positron-Emission Tomography Scans
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**Background/Aims:** PET scanning is being used increasingly for cancer diagnosis and determining therapeutic effects. Organizations including the European Association of Nuclear Medicine (EANM) recommend a scan using the same device to make an accurate comparison of the Standard Uptake Value (SUV) in a follow-up, thereby increasing the interest in the use of the same type of PET/CT. On the other hand, as hospital conditions make it impossible to perform a PET scan in many cases, more effort is being made to identify factors for accurate SUV comparisons and to draw up a plan to secure inter-device compatibility. **Methods:** From this perspective, three different types of PET/CT devices were used to estimate the SUV and determine if they were compatible with one another. Discovery 690, Discovery 690Elite, and Discovery 710 were used to estimate the SUV for an ACR phantom, NEMA IEC Body phantom, SNM Chest phantom, and 68Ge-cylinder phantom to determine the variations in SUV among the devices. **Results:** SUV~mean~ and SUV~max~ were estimated using each device: the inter-device variation ranged from 0.19% to 3.61% in SUV~mean~ and from 0.03% to 4.11% in SUV~max~ for each phantom. The variation in the SUV among the three PET/CT devices in this experiment was less than 5%, which is the permissible range of the inter-device variation in the SUV, as recommended by the manufacturers. Therefore, it is possible that different CT types will result in insignificant variations in SUV. **Conclusion:** Because hospitals in practice have difficulty in purchasing several devices of the same type, the use of different types of PET/CT devices with a SUV within the permissible range would result not only in higher efficiency, including appointment rescheduling, but also in greater accuracy of a quantitative assessment in a follow-up, where use of the same device is recommended.

P130: Initial Design of Animal Positron-Emission Tomography Scanner Based on a Monolithic Scintillator and Silicon Photomultiplier
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**Background/Aims:** In nuclear preclinical imaging systems, our striving is to obtain lowest intrinsic spatial resolution and highest sensitivity without increasing cost and complexity. Common systems based upon photomultiplier tube PMT and pixelated crystals although show fine performance, escalating cost and decreasing sensitivity. Our study shows by replacing pixelated with optimized monolithic scintillators, spatial resolution and sensitivity can make better and cost decrease. We do not use complex depth of interaction (DOI) algorithm and it make our design more fast and reliable. For optimisation we simulate physical characteristics of the scanner. **Methods:** We used GEANT4 Monte Carlo simulation library to simulate the optical photon processes. The simulation was performed for an Animal PET with 10 detector module which are equipped to LYSO monolithic scintillator crystals with entrance area 50.2×50.2 mm^2^ and thicknesses 8 mm (The optimised thickness) coupled to a silicon photomultiplier (SiPM). For validation and comparison, we simulated Xtrim Animal PET equipped 10 pixelated crystals with 2\*2 mm^2^ pixel size and thickness of 10 mm. **Results:** Our simulation indicated 1.1 mm and 1.5 full width at half maximum (FWHM) of spatial resolution without any resolution recovery and DOI correction which were in a relatively good agreement with the experimental results obtained from Xtrim. Furthermore, simulation of animal PET with a centric point source showed that resolution improve for Animal PET with monolithic crystal and SiPM module. As result of removing dead area between segments in pixelated crystal in monolithic crystal the sensitivity improved more than 18 percent. **Conclusion:** The GEANT4 simulation established to estimate and compare the intrinsic spatial resolution and sensitivity of different animal PET system. Furthermore, using monolithic crystal decrease cost. This simulation can be used to provide an optimal design of animal PET based on monolithic detector without DOI correction and using time consuming algorithm.

P131: Comparison of the SiPM and PMT Influence on Resolution and Sensitivity of Gamma Camera Detector, with Anger and Correlated Signal Enhancement Positioning Method by Using Monte Carlo Simulation
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**Background/Aims:** In imaging systems, intrinsic spatial resolution and sensitivity depend on identifying the position of interaction and the number of detected photons. These factors are affected by propagation of the scintillation photons in the scintillator, positioning algorithm and physical characteristic of the detector. This study was intended to use Monte Carlo simulation to estimate and compare intrinsic spatial resolution and sensitivity of Gamma Camera detector, between two detector configurations: one coupled to 24 PMTs and another one equipped to silicon photo multiplier SiPM. **Methods:** We used GEANT4 Monte Carlo simulation library to simulate the optical photon processes. The simulation was performed for an SPECT with a detector equipped to NaI (Tl) scintillator crystals with 40\*25 cm^2^ area and thicknesses 9.5 mm coupled to 40, 12×12 SiPM with 50.2\*50.2 mm^2^ entrance area. The simulation results compared with a commercial case named RoboSPECT with same physical features but coupled to an array of 6\*4 of square PMTs with 76\*76 mm^2^ area. Anger and Correlated Signal Enhancement (CSE) were used as positioning algorithm. **Results:** Our simulation predict 3.8 mm and 1.9 mm for spatial resolution in Anger and CSE for NaI (TI) detector coupled to SiPM. These results show an improvement relative to the experimental case with PMTs (Anger and CSE, 6 and 3.8 mm). Simulation of a centric point source showed that the best resolution and sensitivity obtained by CSE algorithm, showed better performance in edge and centric positioning (resolution with 15cm offset from the center of the crystal by CSE method was calculated 42% lower than Anger). As a result of decreasing dead space by using SiPM, the sensitivity improved 21%. **Conclusion:** The GEANT4 simulation established to estimate the intrinsic spatial resolution and sensitivity of SPECT detector with Anger and CSE positioning algorithm and also different photo detector (PMT & SiPM).

P132: Reduction of Contrast Agent Induced Artifact in Dual Modality Positron Emission Tomography/Computed Tomography Imaging Using TOF Technique
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**Background/Aims:** Attenuation correction of PET images using CT causes some artifacts, including respiratory-artifact, metal-artifact and contrast agent artifact. In this study, the impact of TOF reconstruction on reduction of contrast agent artifact in PET/CT imaging was evaluated. **Methods:** The influence of TOF on contrast agent artifact was assessed using a phantom contained 5.3KBq/ml background activity and 9 cylinders with 2.5 cm in diameter and 10 cm in height. 3 cylinders were filled only with contrast-agent and 6 cylinders were filled with combination of contrast-agent and activity (two different activity ratio including 1:1 and 2:1 with 10, 15, 30 ml/L concentration of Meglumine compound). The images were reconstructed using 2 reconstruction algorithms, including non-TOF with 3iteration, 18subset and 6.4mm filter (routine protocol), and TOF with 2iteration, 18subset and 6.4mm filter. Recovery coefficient and SUV~max~ were used for quantitative analysis. **Results:** In 3 cylinders in which any activity was not actually exist, image reconstruction using non-TOF algorithm led to produce false positive activity. Integrating TOF technique to reconstruction reduced the virtual activity. The relative differences of SUV~max~ between TOF and non-TOF images were-18.2%, -18.6% and -29.5% in 20, 30 and 40 ml/L concentration of Meglumine compound, respectively. In hot cylinders with 1:1 activity ratio, recovery coefficients changed from 1.01 to 0.99, 1.05 to 1.00 and 1.08 to 1.01 in 10, 15 and 20 ml/L concentration of Meglumine compound, respectively. In 3 other hot cylinders the relative differences of SUV~max~ were 2.9%,-3.22% and-5.0% in 10, 15 and 20 ml/L concentration of Meglumine compound, respectively. **Conclusion:** TOF can effectively improve contrast-agent artifact and increase quantitative analysis accuracy. In addition, the corrective effect of TOF increases with increase in contrast-agent concentration. We can conclude that the TOF technique has a potential to reduce contrast-agent artifact and can be used as a method for the artifact correction.

P133: Three-Dimensional-Printing Standardization Across Computer-Aided Design and Manufacturing and Digital Imaging and Communications in Medicine: Proof of Concept using Positron Emission Tomography/Computed Tomography Datasets
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**Background/Aims:** Stereolithography (STL) is a technology in computer-aided design and manufacturing (CAD/CAM) for three-dimensional (3D) printing. STL is designed for manufacturing industry; it cannot capture patient information. Digital Imaging and Communications in Medicine (DICOM) standards are adopted in healthcare industry to transfer images via picture archiving and communication systems. Recent surge of patient-tailored 3D printing posed demand to integrate both standards, hence the draft "DICOM Encapsulation of STL Models for 3D Manufacturing" by DICOM Standards Committee, but no commercial solution was available yet. This research's objective is to test a new integration method. **Methods:** A prototype DICOM-STL-Archive was designed to be connectable with DICOM server to query and retrieve medical images and DICOM Modality Worklist including patient demographics, accession numbers, study dates and times. Retrieved datasets were post-processed to create 3D computer models using marching cube algorithm. Models were stored as STL formats with filenames incorporating related accession numbers etc. Demographics were stored in STL file headers modified with special DICOM remarks. STL file locations and headers were stored within Archive's database structure. Medical 3D models could be printed directly via the Archive and then subject to physician's evaluation for accuracy. **Results:** The developed DICOM-STL-Archive could connect to a DICOM server and retrieve image datasets, which were converted to STL data files and could be automatically modified into the Archive's database. STL data files could then be queried and retrieved to a computer client, verified by physician side-by-side against original PET/CT images on medical workstation before exported to a 3D-printer. The printed models were compared to original DICOM datasets to fall within an accuracy of ± 0.5 mm. This prototype was successfully tested on seven sets of complex imaging datasets obtained from hybrid positron emission tomography and computed tomography (PET/CT). **Conclusion:** The prototype DICOM-STL-Archive proved the concept on integration of STL and DICOM standards by a novel method of between-system connection, which is different from the recently proposed method of "DICOM encapsulation of STL models" by the DICOM Standards Committee.\[[@ref24]\]
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**Background/Aims:** International measurement traceability underpins the accurate measurement of radiopharmaceuticals, which contributes to improved patient outcomes, consistency of clinical trial data, obtaining quantitative data from imaging and radiopharmaceutical trade. The International Reference System (SIR) was established in 1976 at the International Bureau of Weights and Measures (BIPM) to compare radionuclide standards submitted by national metrology laboratories and to evaluate their equivalence. Due to its location in France, the SIR is inaccessible to many countries for short-lived radionuclides, and a Transfer Instrument (SIRTI) was developed by the BIPM in 2013 to compare such standards. Australia had its first opportunity to host the SIRTI and participate in this comparison during November 2017. **Methods:** ANSTO Radionuclide Metrology (RM) applied the 4π (LS)β-γ coincidence extrapolation technique to standardise solutions of ^99m^Tc, ^18^F and ^64^Cu independently of any calibrated equipment. This was the first time that ^99m^Tc-and ^64^Cu was measured by a primary method in Australia. The ^18^F primary standard developed in 2001 was updated to make this standard eligible for the SIRTI comparison. The standards were transferred to the Australian Secondary Standard Ionisation Chamber (SSIC) by the development of calibration factors for the SIR standard geometry of 3.6 mL in a glass ampoule. The SIRTI consists of a well-characterised NaI (Tl) well detector, stability check source and data acquisition system. Sources were standardised in the calibrated SSIC before being measured in the SIRTI by BIPM personnel. **Results:** ANSTO's data will be analysed and the results compared to those of other participants in the SIR and the degrees of equivalence evaluated. The results will be presented at the conference. **Conclusion:** ANSTO RM is renewing their secondary standards for ^99m^Tc, ^18^F and ^64^Cu for geometries relevant to nuclear medicine. Dissemination of these standards will support the calibration of PET scanners, which are generally designed to be calibrated using ^18^F; quantitative imaging for SPECT and PET; and ^64^Cu SARTATE clinical studies performed by Clarity Pharmaceuticals.

^99m^Tc was supplied by ANSTO Health CQ, ^18^F was supplied by PETTECH, ^64^Cu was provided by Clarity Pharmaceuticals and SAHMRI.

P135: Accuracy of I-131 Activity Quantification in Preclinical Single-Photon Emission Computed Tomography Imaging: A Phantom Study
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**Background/Aims:** Accurate quantification of radionuclide activity in mouse tissues is crucial to study the absorbed dose dependence of healthy-tissue toxicity due to radionuclide therapy. This study aimed to evaluate, by means of a phantom experiment, the accuracy of activity quantification of ^131^I studies using VECTor+/CT (MILabs, The Netherlands), a small-animal PET/SPECT/CT. The influence of following parameters was studied: approach for delineation of regions of interest (ROI), attenuation correction, scatter correction and number of OSEM updates used for SPECT reconstruction. **Methods:** SPECT/CT quantitative imaging was performed on a mouse-sized phantom filled with ^131^I-NaI solution. The phantom consists of multiple cylindrical objects with different diameters (1-6 mm). A high-energy general-purpose mouse collimator was used for SPECT acquisitions. ROIs of different dimensions were drawn in the center of each hot rod and activities were quantified. Reference activities were calculated from the activity concentration of the ^131^I solution determined with a radionuclide calibrator. Activity recovery coefficients were calculated for all settings tested. **Results:** Due to partial volume effects, the quantitative accuracy is strongly dependent on the rod diameter and the ROI size used for quantification. Most accurate results are obtained with small fractional ROIs, for which the recovery coefficients are around 100% for 3-6-mm hot rods and below 70% for smaller (1-2 mm) rods. Using a sufficiently high (\>50) number of OSEM updates is crucial for improving the accuracy and visibility of small hot objects. Instead, the impact of scatter correction is moderate (usually \<10%) and, while photon attenuation is also not negligible (13% higher with attenuation correction), its quantitative effect may be compensated by an appropriate calibration factor. **Conclusion:** All parameters tested have a significant effect on SPECT quantification. The optimization of ROI segmentation strategies and SPECT reconstruction settings are key for accurate ^131^I activity quantification with small-animal SPECT.
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**Background/Aims:** Radionuclide dose calibrators are equipped with pre-set calibration numbers for a range of radionuclides. The calibration numbers are based on measurements of radionuclides in specific source geometries or derived from dose calibrator response data. The source geometries measured in clinical settings vary widely, so the impact of geometry on dose calibrator response must be well understood and quantified in order to ensure measurement accuracy. The aim of this study is to quantify the geometry dependence of medical radionuclides including ^18^F, ^131^I and ^68^Ga. **Methods:** Quantities of ^18^F-FDG, ^131^I and ^68^Ga solutions were compared against the Australian standard for radioactivity to establish accurate and traceable activity concentration measurements. The ^18^F-FDG and ^68^Ga were dispensed into commonly used vials and syringes in a range of different volumes. The ^131^I was dispensed into therapy capsules and contained in glass and plastic vials. The sources were carefully weighed to determine the quantity of activity in each. They were compared against the Australian standard and measured in commercial dose calibrators which had been calibrated against the standard. **Results:** Dose calibrator measurements of ^18^F-FDG in syringes were within 2% of the standard, however vial measurements showed discrepancies of up to 5%. Ga-68 in vials was regularly over 4% discrepant from the standard, and up to 9% for syringe geometries. The difference between measurements of ^131^I in solution and in a capsule was in the order of 1.5%. Capsules contained in glass or plastic vials showed a negligible difference in activity when measured using an appropriate dose calibrator. **Conclusion:** Accurate measurement of radioactivity contributes to effective and safe patient treatment and is an important aspect of regulatory compliance. The impact of source geometry on activity measurements must be taken into account to ensure the correctness of measurements and prevent incidences of maladministration due to dose inaccuracy.

P139: Residual Dose Rates after Radiactive Iodine-131 Treatment in the Day of Hospital Discharge
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**Background/Aims:** Turkish Atomic Energy Authority has its own regulations for the patients who were undergone radioactive treatments. Our aim is to investigate the discharge dose rates of patients who were administered 3700 MBq I-131 treatment for thyroid cancer. **Methods:** A total of 91 patients (64 female, 27 male) who were totally thyroidectomised with a diagnosis of well differentiated thyroid cancer, previously and administered 3700 MBq I-131, hospitalized for two days between 2011 and 2013 included to the study. Their dose rates on the time of discharge were evaluated, statistically. **Results:** Discharge dose rate mean value was 1.75±0.89 mR/h (17.5 μSv/h±8.9) and the mean restriction period for recommendations up to Turkish Regulations about travel times, close contact, for public radioprotection were 13.44±4.02 days. Dose rate of eight patients were equal to legislation limits (3 mR/h). On the day of discharge three patients have dose rates above the limits. Mean residual activity measured at one meter distance at the discharge calculated by the formula (A. Iγ/d2) measured and was 307.1±156.14 MBq. Their calculated dose rates were 4 (40 μSv/h), 4 (40 μSv/h), and 5 (50 μSv/h) mR/h from one meter. Those patients who had high dose rates were not have been discharged until their dose rate decreased. In our group of patients (80/91) of patients had lower dose rates than the limits after forty eight hours hospitalisation and only 1/91 patients had one more night hospitalisation, where two patients had eight hours postpone of discharge. **Conclusion:** Medical radiation exposures are applied to patients when benefits of treatment overcome the damages. Radiation dose that is received by people during exposure after treatment with radionuclides, countermeasures must be taken.
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**Background/Aims:** Having a control of the radiation to which the patient is subjected and the time it remains in the body is of great importance, since clinical procedures suggest methods in which the patient is continuously irradiated. However, if an asymmetric control of the radiation absorbed by the body is not maintained, it is possible that both the patient and the doctor in charge suffer a cellular deterioration due to the radiation to which they are subjected. **Methods:** Control estimates are made on the amount of radiation that per patient must be subjected to fast neutron rays that are produced by reactors, cyclotrons (d + Be) and linear accelerators and according to the Bergonie law and tribondeau It will determine that both cells are affected, both for the patient and for the operator of the machine. For the study, two radiation machines, one for fast neutrons and one for gamma radiation, were simulated in GEANT4; the geometric schemes and the intensities of the energies will allow us to determine how much the patient and the doctor radiate, this to take measures in the radiological safety control. **Results:** Under the modifications and geometric concentrations of magnetic fields or neutron detonators in the clinical instruments responsible for generating the radiation, it is possible to increase the efficiency of the instrument by collimating the radiation, decreasing the effective section of impact and decreasing the amount of radiation to which both the patient as the doctor in charge of handling the radioactive instrument are subject. **Conclusion:** It is possible to reduce the intensities of the radiation to which both the patient and the doctor are subject, this is achieved by proposing improvements in the instrument, geometric changes and changes in the structure of the instrument's collimator, which allows us to reduce the intensity of the radiation. the treatment time and the levels of non-cancerous dead cells. The radiological safety controls can be controlled if the physics involved in them is well known. Within the field of physics and using simulation tools, we can analyse the advantages and failures of a radiation instrument in this case at high energies, which allows security measures to be taken and measures to increase equipment efficiency.
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**Background/Aims:** Currently research for the treatment of cancer cell elimination are aimed at developing efficient techniques and little harmful to control carcinogenic diseases; one of the techniques is based on the interaction of an initially stable nucleus with neutrons at energies of the order of 0.025 eV, such interactions are those generated by the capture of bromine atoms with neutrons. **Methods:** To evaluate the efficiency and the limits in which the technique of detection and elimination of cancer cells are efficient and not harmful, based on the interactions between neutrons and nuclear structures, a simulation was performed in GEANT4 where it is possible to show the amounts of radiation in which a patient depending on his physical texture and his chemical background can be radiated, and as part of this radiation affects the cancer cells in stages where they are in development and in the case where it is limited where metastasis occurs. **Results:** Estimates of the limits of the amount of radiation submitted by the patient as a function of time were obtained. In order to evaluate the limits in which the technique is efficient, modifications were made in the simulation which allows controlling the number of incident neutrons and the reactions generated with the nucleus, for this case, variations of nuclei were made, which, when interacting with the neutron generates radiation, led us to estimate a suitable nuclear structure for the treatment of elimination of cancer cells. **Conclusion:** The simulation allows us to precede causes that arise after the patient is radiated, and how the radiation to which the patient is subjected can be controlled, with the aim that this does not cause a minimal effect on non-cancerous cells. The control of radiation indices harmful to the patient are key factors in the treatment, under an estimate of the physical structure of the time it is possible to establish radiation controls to which the patient can be subjected.

P142: A Quantitative Assessment of Biokinetic Models for Patients Undergone Nuclear Examinations: Verified with Multi-compartments Water Phantom
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**Background/Aims:** The aims of study were to evaluate multiple biokinetic models using MATLAB program, to estimate internal dosage and to predict the time-dependent quantity of radiolabelled complexes in crucial organs. **Methods:** Five biokinetic models were separately defined by five groups of simultaneous differential equations to obtain the time-dependent radioactive concentration changes inside the water phantom. The five groups of derived time-dependent concentrations for the boxes were estimated either by a MATLAB program or by scanning via a gamma camera facility. A dimensionless agreement (AT) index was recommended to evaluate the comparison in each case. **Results:** The water phantom was assembled by seven acrylic boxes in four different sizes, and the boxes were linked to different combinations of hoses to signify the multiple biokinetic models from the biomedical perspective. The boxes that were connected by hoses were then regarded as a closed water loop with only one infusion and drain. 129.1 ± 24.2 MBq of ^99m^Tc-labelled methylene diphosphonate (MDP) solution was fully infused into the water boxes before gamma scanning, then the water was replaced with de-ionized water to simulate the biological removal rate among the boxes. The water was driven by an automatic infusion pump at 6.7 c. c./min. and the biological half-life of the four different sized boxes was 4.8, 10.7, 18.8, and 45.5 min. **Conclusion:** The derived biokinetic model represented the metabolic mechanism in the human body and helped to solidify the internal circulatory system into reality with numerical verification.
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**Background/Aims:** Metastasis of breast cancer to the brain presents a pressing therapeutic challenge. Vascular cell adhesion molecule 1 (VCAM-1) is upregulated on brain endothelial cells during the early stages of metastasis and provides a target for the detection and treatment of early brain metastases. We have developed a Monte Carlo model representing brain vasculature to evaluate the efficacy of a variety of potential therapeutic nuclides; alpha-emitters: ^149^Tb, ^211^At, ^212^Pb, ^213^Bi and ^225^Ac; beta and Auger electron-emitters: ^90^Y, ^161^Tb and ^177^Lu, ^67^Ga, ^89^Zr, ^111^In and ^124^I for targeted radionuclide therapy (TRT). **Methods:** Histologic sections of mouse brain parenchyma were used to inform a cylindrical vessel geometry using the GEANT4 general purpose Monte Carlo (MC) toolkit. The micron-scale dose distributions from all radioactive decay products were modelled in GEANT4, as well as eV-scale interactions through the G4DNA models.\[[@ref25]\] These interactions were then superimposed on an atomic-scale DNA model\[[@ref26]\] to estimate strand break yields for representative beta-and alpha-emitters, ^177^Lu and ^212^Pb. Relative biological effectiveness (RBE) values were determined by only evaluating DNA damage due to physical interactions. Some of the alpha emitters have decay chains with multiple daughter nuclei; we investigate the change in dose profiles and biological effectiveness as a function of time. **Results:** ^177^Lu produced 2.69±0.08 DSB per GbpGy, without significant variation from the lumen of the vessel to a radius of 100 µm. The DSB yield of ^212^Pb included two local maxima produced by the 6.1 MeV and 8.8 MeV a-emissions from decay products, ^212^Bi and ^212^Po, with yields of 7.64 ± 0.12 and 9.15 ± 0.24 per GbpGy, respectively. Given its higher DSB yield ^212^Pb may be more effective for short range targeting of early micrometastatic lesions than ^177^Lu. **Conclusion:** MC simulation of a model of early brain metastases elucidates the potential efficacy of radionuclides for TRT. ^212^Pb, which has the attributes of a theranostic radionuclide since it can be used for SPECT imaging, showed a favourable dose profile and RBE.
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**Background/Aims:** Dosimetry guided approaches to ^177^Lu-DOTATATE radionuclide therapy seek to maximise the absorbed dose to tumours while minimising toxicity to normal tissues.\[[@ref27][@ref28]\] However, multi-measurement protocols (MMP) are inconvenient for patients and consume staff resources. This study aims to estimate the accuracy of renal and tumour lesional dosimetry derived from a single uptake measurement compared to a MMP using quantitative SPECT. **Methods:** Dosimetry data from 33 patients (33 kidneys, 32 measurable lesions \> 2cm diameter) with metastatic Neuroendocrine tumour (NET) undergoing ^177^Lu-DOTATATE therapy within a state-wide radionuclide therapy service was analysed retrospectively. An institutional Human Research Ethics Committee approval (HREC/17/QRBW/386) for low-risk research was obtained. Renal and tumour lesional uptake measurements at single time-points (4, 21, 44, and 117 hours) were linearly correlated with cumulative activity calculated from a MMP using quantitative SPECT.\[[@ref29]\] The derived linear relationship was used to estimate the absorbed dose from single uptake measurements and the deviation from the MMP was calculated. **Results:** Single uptake measurements demonstrated excellent correlation with cumulative activity calculated using the MMP. For renal uptake, squared correlation coefficients were 0.84 (p \<0.001) for 4 hours, 0.90 (p \<0.001) for 21 hours, 0.96 (p \<0.001) for 44 hours, and 0.97 (p \<0.001) for 117 hours post administration (p. a.). Lesional uptake measurements had squared correlation coefficients of 0.98 (p \<0.001) for 4 hours, 0.98 (p \<0.001) for 21 hours, 0.99 (p \<0.001) for 44 hours, and 1.00 (p \<0.001) for 117 hours p. a. Deviation between dose estimates using single uptake measurements and the MMP reduced as measurement time increased. Renal doses had mean (± 2σ) deviations of 2.1±31% for 4 hours, 1.1±23% for 21 hours, 0.3±14% for 44 hours, and 0.5±13% for 117 hours p. a. Similarly, tumour lesional absorbed doses had mean (± 2σ) deviations of 11±62% for 4 hours, 9.1±53% for 21 hours, 7.1±40% for 44 hours, and 1.9±14% for 117 hours p. a. **Conclusion:** Renal and tumour lesion absorbed dose estimates based on a single uptake measurement \>21 hours provides a safe and clinically acceptable approximation of renal and lesion doses compared with a multi-measurement protocol.
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**Background/Aims:** Radiation dose to the kidneys in ^177^Lu-DOTATATE PRRT (Lutate) is considered to be the main potential side-effect from treatment. Prospective assessment of kidney dose can be made with SPECT, however, this requires an intensive imaging regime over a number of days. For this reason, a retrospective investigation of the reproducibility of kidney uptake using quantitative SPECT was performed. The aim of the study was to compare the estimated radiation dose to kidneys for each cycle, to test whether full imaging over multiple days for the initial cycle can be used to estimate kidney dose for subsequent cycles. **Methods:** Seventeen patients treated with Lutate for metastatic neuroendocrine tumours had full imaging for each of their treatment cycles on a Siemens Intevo SPECT/CT gamma camera. One course of treatment consisted of 3 or 4 cycles approximately 8 weeks apart spanning 6 months. SPECT/CT scans of the abdomen were acquired at 3 time points (4, 24 and 96-120 hours) after administration of \~7.8 GBq of Lutate. Nine patients received three cycles in total and eight patients had four cycles. Volumes of interest (VOIs) were defined on a CT scan co-registered with the SPECT images and repeated over all time points, to give the radioactivity in the kidney. Whole organ dosimetry was estimated using OLINDA/EXM using an exponential clearance model. This gives an estimate of radiation absorbed dose to kidney (Gy/GBq) for each treatment cycle. The mean of the 3 or 4 cycles and variation can then be determined. **Results:** The mean amount of Lutate administered per cycle for all 17 subjects was 7.76±0.36 GBq. From this, the average kidney dose was 0.23 Gy/GBq (range: 0.06 -- 0.42) and average variation between cycles for all subjects expressed as a percentage was (12.5±7.8)% (median:11.4%, range:1.8%--29.4%). **Conclusion:** Estimated radiation dose to the kidneys for Lutate PRRT shows good reproducibility (typically \<20% variation) within an individual across all cycles within one course of treatment (up to 4 cycles). The errors introduced by assuming that the dosimetry estimate per unit GBq administered from the initial cycle could be used for subsequent cycles within a course are unlikely to contribute significantly to the overall estimate of radiation burden and are likely to be safe.
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**Background/Aims:** Positron emission tomography/Computed tomography (PET/CT) has been proposed as noninvasive imaging methods to assess the disease extent in patients. This study aims to assess the effective radiation dose of ^11^C-Choline, and ^18^F-FDG in PET/CT patients. **Methods:** The study has been approved Human Research Ethics Committees, Chulabhorn Research Institute. Twenty-four patients with cholangiocarcinoma (CCa) or hepatocellular carcinoma (HCC), aged 39-74 years (mean±SD, 55.67±14.80), were included and underwent ^11^C-Choline and ^18^F-FDG whole body PET/CT scans at National Cyclotron and PET Centre, Chulabhorn Hospital. Radiation absorbed dose to target organs and effective whole-body dose were calculated by using the biokinetic model from ICRP 106 publication for ^18^F-FDG and the US FDA publication for ^11^C-Choline. The patient dose from CT scan was calculated from dose-length product (DLP) multiplied by region-specific normalized effective dose per DLP (E~DLP~). **Results:** Mean administered activities of ^18^F-FDG and ^11^C-Choline were 358.27 MBq and 439.38 MBq respectively. The average whole-body effective dose from ^18^F-FDG PET scan was 6.81±1.09 mSv (4.44 to 8.60 mSv) and 12.95±3.33 mSv (6.22 to 18.55 mSv) from CT scan, resulting in a mean total patient dose of 19.76 mSv. For ^11^C-Choline, an effective whole-body dose was 1.90±0.40 mSv (0.89 to 2.87 mSv) from PET scan and 14.20±3.14 mSv (9.06 to 19.26 mSv) from CT scan, with a mean total patient dose of 16.01 mSv. To discuss, ^11^C-Choline accumulates mainly in the liver, lungs and stomach. Meanwhile, the accumulation of ^18^F-FDG is mainly in urinary bladder, lungs and liver. ^11^C-Choline PET scan gives the liver dose of 330 ± 65 µSv and dose from ^18^F-FDG to urinary bladder is 1.81±0.33 mSv. There is no statistical difference of effective dose between ^18^F-FDG and ^11^C-Choline CT scans. However, the effective dose of ^11^C-Choline PET scan is 3.6 times lower than ^18^F-FDG PET scan (p\<0.05). **Conclusion:** In this study, the average effective dose for patients undergoing whole-body ^18^F-FDG PET was 3.6 times higher than ^11^C-Choline PET. Whilst, the total effective dose from ^11^C-choline and ^18^F-FDG PET/CT were 16.10 mSv and 19.76 mSv, respectively. Moreover, the effective dose from CT scan was more than 2.9 and 8.5 times greater than ^18^F-FDG and ^11^C-Choline PET scans, respectively.
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**Background/Aims:** In the present study, we evaluate the distribution of Auger electron emitting therapeutic constructs ^111^In-DTPA-hEGF and ^111^In-Trastuzumab in a 3-D spheroid model using the microautoradiography (MAR) method and use this information together with radiobiological parameters derived from clonogenic assay experiments to predict tumour control probability (TCP) by Monte Carlo (MC) modelling. **Methods:** A closed packed algorithm, which accounts for the variations in cell and nucleus radii as well as random packing behaviour of cells, was used to generate a monolayer of cells for three different cell lines, namely MDA-MB-468, SQ20B and 231-H2N. The PENELOPE MC code\[[@ref30]\] was used to model electron transport. Theoretical survival fractions were estimated using internalization data and simulated energy deposition, and the results were then compared with clonogenic assay experiments of cells treated with ^111^In-DTPA-hEGF and ^111^In-Trastuzumab for 1 and 24 hours. Radiobiological parameters deduced from the comparison were used in predicting the TCP for the 3-D spheroid model, which was similarly generated using the closed packed algorithm, based on spatial distribution of radioactivity determined from the MAR method. **Results:** Theoretical survival fractions were in good agreement with experiments when an increased relative biological effectiveness (RBE) was applied to self-dose deposited by sources located in nucleus. Only MDA-MB-468 spheroid treated with ^111^In-DTPA-hEGF could potentially achieve TCP=0.5 after several days and thus be controlled, due to higher radiosensitivity and nuclear uptake of therapeutic constructs as well as more uniform radioactivity distribution. **Conclusion:** It is imperative when evaluating the distribution of radionuclides in models emulating micro-metastatic disease to include biological endpoints. The spatial distribution of radioactivity is a clear indicator of biological effect and TCP as was demonstrated by this study.
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**Background/Aims:** Internal radiation dosimetry is considered necessary for managing risk during the delivery of therapy with Lu-177 octreotate (Lutate). Voxel-level analysis has been proposed, in which region of interest (ROI) definition is deferred until after a dose distribution image has been created. This approach has been compared, using a simulated biodistribution study, against a conventional method where regions are defined prior to cumulated activity estimation. **Methods:** The ICRP male voxel phantom was modified by the addition of 2 roughly elliptical tumours to the liver. Radiopharmaceutical kinetics of Lutate were approximated using a linear compartment model with sources representing blood, extra-cellular fluid, kidney retention and reservoirs in liver, spleen and tumours. The GATE Monte Carlo package was used to create a reference dose distribution for the phantom. Tomographic imaging was simulated at 7 time points between 1 and 168 hours using GATE, then reconstructed using an OSEM algorithm incorporating corrections for scatter, attenuation and collimator-dependent resolution. Cumulated activity was estimated from the reconstructed images by a piecewise calculation of area under the time/activity curve, both for individual voxels and for ROIs derived from the original phantom. The absorbed dose distribution for each method was estimated from the cumulated activities using GATE, then compared against the reference dose distribution using the ratio of mean ROI doses and dose volume histograms. **Results:** Mean ROI cumulated activity and absorbed dose were essentially identical for both methods. The errors relative to reference values were small for the kidneys, spleen and large tumour (\<20%) but significant for the liver (240%) and small tumour (30%). Dose volume histograms were highly discordant in every case. **Conclusion:** Voxel-level analysis can be used to estimate mean absorbed dose in ROIs but does not provide accurate information about the distribution of dose within those regions.

P149: Current Nuclear Cardiology Practices and Radiation Exposure in Brazil: A Cross-Sectional Survey

Vitor Braga Rodrigues\*

Carlos

1

Fernandes

F A

1

Mesquita

C T

1

University Hospital Antônio Pedro, Niterói, Brazil

**Background/Aims:** Nuclear medicine is widely used in Latin America, particularly in Brazil. Myocardial Perfusion lmaging (MPI) represents more than 55% of tests performed in the Nuclear Medicine Services (NMS) in Brazil, in over 240,000 tests in the public health system and more than 800,000 in private practice per year. Due to the exponential growth in recent years, important concepts about radioprotection must be taken. Worldwide there are great efforts to reduce the radiation used in patients. The International Atomic Energy Agency (IAEA) promoted the research "INCAPS", which adopts 8 "best practices" to evaluate the exposures to ionizing radiation during the MPI. The objective is to evaluate the adherence of the "best practices" and correlate with the NMS features.\[[@ref31]\] **Methods:** Cross-sectional study in NMS performing MPl. **Results:** In a total of 63 NMS, we observed that 100% of them do not use thallium-201 as the preferred protocol. About the use of ^99m^Tc, 57% inject activities above the threshold recommended. "Stress-only" is practiced by 6% and 19% uses camera-based dose-reduction strategies. Only 52% answered that always adjust the doses by weight and 35% manage miscalculated doses in 1-day protocol. We noted that is more frequent find better Quality Indexes in academic hospitals (p=0.046), NMS with a complete multidisciplinary team (p=0.030) and NMS that performs more MPI per month (p=0.043). **Conclusion:** According to the parameters adopted by INCAPS, a considerable number of NMS in Brazil do not follow the "best practices"; only 20% of NMs adopted at least six of them and we find some features in common between them. There are opportunities to improve the quality of MPl in Brazil without increasing costs. This comprehensive view of the nuclear medicine practices in cardiology may be used to plan strategies for policy-making in healthcare.
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**Background/Aims:** To present the methodology and institutional experience of performing fully 3D quantitative renal dosimetry on patients receiving Lutate therapy. **Methods:** Patients undergoing Lutate treatment for neuroendocrine tumours underwent SPECT/CT of the abdomen at time points 4, 24 and 96-120 hrs after injection. SPECT data were quantified using in-house software written in IDL, incorporating compensation for dead time, transmission-derived scatter and attenuation correction, and a camera-specific sensitivity factor. Co-registered data were segmented using the x-ray CT (Dosisoft, Cachan, FRA) and total radioactivity in each kidney recorded for every time point and expressed as a fraction of injected radioactivity. The time-activity curve data were fitted in OLINDA-EXM with an exponential fitting function for the appropriate adult phantom model (male/female) to estimate the absorbed dose to kidneys for each cycle. **Results:** To date, a total of 80 studies from 18 patients have been analysed, where one study corresponds to all time points of imaging from a given cycle of treatment. Absorbed dose has been reported in the clinic and used to maintain treatment safety adhering to current kidney dose constraints (23 Gy). The average dose per cycle was 2.60±1.01 Gy/cycle. Known limitations include errors in quantification, co-registration and segmentation, as well as errors in curve fitting and use of a standard model. A processing time of approximately 1.5 hrs was associated with assessment of one cycle of treatment when this process was performed by a trained medical physicist. Our data provide us with an opportunity to investigate the feasibility of choosing a single, optimal time point to image for dosimetry estimates. **Conclusion:** Fully quantitative 3D imaging and renal dosimetry is feasible in the clinical environment when scanning facilities and physics resources are available, however, it does place a great burden on facilities, staff and, of course, the patients.
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**Background/Aims:** Copper-67 (^67^Cu) is a promising therapeutic agent with theranostic capabilities based on pairing with the diagnostic agent ^64^Cu. In view of performing patient specific dose estimates for ^67^Cu-SARTATE, the aim of this work was to establish the feasibility and accuracy of ^67^Cu quantitative SPECT. **Methods:** Experimental work was performed on the Siemens Intevo SPECT/CT using medium energy collimators and imaging the 185 keV photon peak with a 20% energy window width. The system scatter function and scatter fraction were modelled as well as system sensitivity and dead time. Narrow-beam attenuation correction maps were derived using interpolation of NIST values modelled on a bi-linear relationship between HU and material density. Quantitative validation was performed over a period of 7 days with decaying phantom activity (1.6--0.4 GBq) using the IEC NEMA body phantom with a sphere-to-background ratio of 8:1. **Results:** Based on nine separate acquisitions acquired over a 7 day period, the average difference between true and measured total activity in the phantom and measured background concentration was -2.1% and -1.7%, respectively. The 37mm diameter sphere suffered from 20% count losses due to partial volume effects when using a threshold grown VOI to derive average hot-sphere concentration suggesting the need for resolution recovery. **Conclusion:** Quantitative SPECT and dosimetry of ^67^Cu acquisition data is feasible and returns accurate measures in large warm areas. Small hot lesions can expect to under-estimate dose due to partial volume effects.

**Disclosure of Interest:** K. Willowson Conflict with: work financially supported by Clarity Pharmaceuticals, M. Harris Conflict with: employee of Clarity Pharmaceuticals (holder of ^67^Cu-SARTATE), C. Jeffery Conflict with: employee of Clarity Pharmaceuticals (holder of ^67^Cu-SARTATE), C. Biggin Conflict with: employee of Clarity Pharmaceuticals (holder of ^67^Cu-SARTATE), A. Hedt Conflict with: employee of Clarity Pharmaceuticals (holder of ^67^Cu-SARTATE), D. Bailey Conflict with: consultant to Clarity Pharmaceuticals.
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**Background/Aims:** Preparation and application of radiopharmaceuticals are activities that are associated with the exposure of workers to ionizing radiation. Mobile device KARl100, on the transport of radiopharmaceuticals ^18^F-FDG for PET, and RAD-INJECT, for its application, offer the possibility to reduce the doses of radiation exposure to staff and the optimisation of radiation protection in the workplace. The aim of the communication is to compare the results of personal dosimetry before and after the installation of mentioned equipment. **Methods:** To compare was used the value of the collective dose for the years 2015 and 2016 for staff of Institutional Pharmacy Department (preparation of radiopharmaceuticals), and Nuclear Medicine Department (application of radiopharmaceuticals). The collective dose here means the sum of doses of all staff a given section in half-year. The collective dose Hp (10) determines the personal dose equivalent at a given point beneath the surface of the body at a depth of 10mm, taken as the value for the whole body dose; the collective dose H~T~ is the equivalent dose on hand. **Results:** From dosimetry measurements of Institutional Pharmacy Department is evident doses reduction on finger dosimeter by more than 40% after the installation of the device KARl100. The results of the measurement of whole body dosimetry are balanced both before and after the installation of the device KARl100. The Nuclear Medicine Department initially had values decrease on the finger dosimeter and a slight rise in the whole body dosimetry, but both doses decreased by about 50% after training. **Conclusion:** By comparing the data from 2015 and 2016, the values of collective doses for staff of the Institutional Pharmacy Department on finger dosimeter, and from whole body dosimetry have remained at the same level, despite their slight increase in assumption. For staff of the Nuclear Medicine Department, there is a reduction in the values of collective doses to the finger and whole body dosimetry.

P153: Perception and Awareness Regarding Radiation amongst Medical Professionals in a Tertiary Care Centre Setting in Uttarakhand in India
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**Background/Aims:** Every healthcare worker will be utilising/dealing with medical radiation directly or indirectly. There are various myths and perceptions associated with radiation and information is unstructured usually through hearsay.\[[@ref32][@ref33]\] We aimed to assess perception and awareness of radiation amongst medical workers not working in radiation areas. We then provided systematic information and assessed changes. **Methods:** In various levels of medical professionals in a tertiary care medical centre, pre-test evaluation of all participants was done by getting a simple questionnaire with total of 15 questions based on perception (4) and knowledge (11) of radiation. Intervention in the form of a short interactive workshop was conducted followed by post-test evaluation. The pre-and post-test were compared and results assessed baseline and changes. **Results:** Total of 235 medical professionals at the level of interns (52), junior (92), senior residents (33) and faculty (58) participated in the study of which 100 were females. Overall, we observed assertive responses in pre-test and post-test of of 78.8% and 86.3% respectively. Overall improvement in perception and knowledge of 7.4% was seen. Maximum (9.1%) and minimum (4.8%) improvement was noted amongst faculty and interns respectively. No difference in preference for working in and around radiation areas was observed after intervention. **Conclusion:** Fear of cancer and infertility due to radiation were the most common negative perceptions. Improvement in positive perception and knowledge after imparting systematic knowledge to students in this sub-group of medical professionals in Uttarakhand, India.
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**Background/Aims:** Positron Emission Tomography (PET) is potentially a higher radiation exposure workplace. When the opportunity arose to design our PET Suite our priority was to minimise radiation exposure to the technologists to 1 µSv per patient. Shielding, equipment and patient flow were all necessary considerations in reaching this target. A retrospective analysis of the last decade was performed to determine if the 1 µSv/patient goal was met. **Methods:** The PET Suite was appropriately shielded in hot patient areas and staff areas were allocated away from these zones. Custom designed dispensing and injecting devices were built. Patient positioning shields were utilised to minimise staff exposure. Technologist exposure was recorded using electronic personal dosimeters (EPD), a cumulative dose equivalent (Hp (10)) was recorded daily for the rostered PET technologists. The number of technologists and patients were also recorded. Inpatient numbers and the delivered dose vial activity were assessed. **Results:** The number of ^18^F-Fluorodeoxyglucose studies has increased on average 10% annually since 2006. The rostered technologist numbers have remained at two per day. The exposure rate to technologists was consistently 1 µSv/patient, with newly trained staff receiving a higher dose initially. Twenty-four technologists have rotated through the PET Suite and all have reduced their daily exposure per patient with experience. Inpatient numbers have increased with varying degrees of illness, occasionally requiring general anaesthesia. Delivered activity in the vial has increased and is now one delivery per day, a source of increased exposure due to the large activity. **Conclusion:** Despite increasing our patient numbers each year on average by 10% and staff levels remaining unchanged, our doses have remained consistent with the original goal of 1 µSv/patient. Increases in inpatients as well as the delivered dose vial are areas of potential increased exposure. Department adaptations of equipment, shielding and patient flow have impacted positively on exposure rate.
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**Background/Aims:** Paraguay, as a state member, has received the support of the IAEA and, on an institutional level, through the Nuclear Medicine Service of the Department of Biomedical Engineering and Images of the Institute of Research in Health Sciences-National University of Asunción (IICS-UNA) has the only available nuclear medicine service in the public health sector found at the IICS-UNA, uses SPECT (single photon emission tomography) technology and it will provide the coupling of a CT scanner and thus will offers hybrid SPECT/CT technology for diagnosis by images, mainly benefiting patients of the public sector of the whole country.\[[@ref34]\] **Methods:** IAEA expert mission and technical meetings with the different areas of the institution speciality: radiopharmacy, imaging, equipment, construction, management and directory for the shielding calculation and writing report based on calculations and considerations of design, considering, radiation scattered in the patient's body and equipment leakage.\[[@ref35][@ref36]\] **Results:** The data of the report were used in shielding implemented in the institution. Expert recommendations suggest that the use of own isodose curve values and variables such as studies type and frequency, activity and radioisotope type. **Conclusion:** The shield designed and implemented is suitable for coupling the CT, and once installed will be verified.\[[@ref35][@ref36]\]
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**Background/Aims:** In compliance with the key aspects of the statutory and regulatory requirements enacted by the Australian Federal and Victoria State government in protecting workers against ionising radiation hazards, the employees exposed to radiation in the Department of Molecular Imaging and Therapy (MIT) were regularly monitored. This study assessed and compared the occupational radiation exposures to all monitored staff members in the department. **Methods:** A total of 5150 dose records of the personal radiation monitors worn by the monitored workers were registered in the period from 2011 to 2017. The dose records of short-term staff were excluded from the analysis. Annual and monthly effective doses were calculated in individuals and compared among different professional groups. Extremity monitoring was also provided for the workers involved with high radiation activity procedures. All equivalent dose records of finger TLDs were included for analysis. **Results:** There were no cases of effective doses exceeding the annual limit of 20 mSv or equivalent doses to hands exceeding the annual limit of 500 mSv during the period. The average monthly dose of all the records with non-zero values was 0.20±0.18 mSv in MIT. The radiopharmacy group received the highest exposure with the monthly effective dose of 0.30±0.22 mSv and hand equivalent dose of 14.63±12.15 mSv. Nurses and Molecular Imaging Technologist were the largest exposed groups with significant individual differences in radiation exposure. Imaging Technologist in NM and PET received the monthly doses of 0.22±0.17 mSv, comparing with 0.03±0.02 mSv in Bone Mineral Density Unit. Nurses only working in MIT received higher monthly dose of 0.09±0.05 mSv, comparing with those rotated in both the Departments of Radiology and MIT (0.04±0.03 mSv). **Conclusion:** Radiation exposure control and continuous occupational dose reduction have been achieved in the investigated department. The waiting time in identifying the exceptionally high effective doses was minimised by employing new monitoring technique. Therefore, the assessment and audit of radiation events for recommending correction actions of related work practice could be implemented in more timely fashion.
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**Background/Aims:** with alpha-emitters is rapidly evolving. Th-227 is a promising candidate. It decays (T½=18.7d) through Ra-223 (T½=11.43d) to stable Pb-207 in 7 steps (5 alpha, 2 beta) with short half-lives (ms to minutes). Total energy is 34 MeV. X-ray/gamma lines (\~1% of energy) at 50-400 keV allow external detection. Dose coefficients for (Th-227/Ra-223) are high: (7.8E-6/6.9E-6)Sv/Bq for inhalation and (8.9E-9/1.0E-7)Sv/Bq for ingestion (ICRP119). Effective dose of 1mSv may be received by a single inhalation of \<130 Bq. Radiation authorities request documentation for staff compliance with dose limits (20 mSv/y). **Methods:** Our low-background whole-body-counter (WBC) is underground in a construction built from selected low-activity materials, shielded with 15 cm steel and lined with Pb and Cd. Four detectors (6\*4" NaI-cylinders) are placed above and below the bed. We measure ½h in a 20-445 keV window. Sensitivity (cps/Bq) and background uncertainty determine minimal detectable activity (MDA) limits (Currie 1968). Sensitivity was calibrated with a known Th-227 sample under realistic conditions. Background (TB) was either person-based (paired measurements) or modeled as the sum of empty-chamber value (CB) and a spill-down value estimated as individual K-40 counts times a BMI dependent factor (BMIF) determined by linear regression including 18 persons with no history of radionuclide-work (BMI 20-44). Four persons handling Th-227 have subsequently been measured 33 times in total. **Results:** Calibration factor for uniformly distributed pure Th-227 was 80 Bq/cps in a 77kg phantom. CB=17.1±0.1 cps. BMIF=(0.0733BMI+1.82, r^2^=0.76). Average (n=18) BMIF=3.69, average K-40 value =1.93 cps, average TB= 24 cps. No Th-227 was detected in the 4 (33) persons, mean/std (-10±25) Bq. **Conclusion:** Our detection limits with WBC are sufficient to document compliance with dose limits if measuring shortly (week) after handling. Knowledge of true background is essential. The model can be refined including body-size dependent shielding effects on CB, measured with K-40 free water phantoms.
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**Background/Aims:** Radiation waste disposal is a common problem experienced by Nuclear Medicine departments worldwide, particularly in those using radionuclides with longer half-lives such as ^131^I and ^32^P. Monitoring of waste for disposal after storage results in unnecessary exposure to the technologist from items not yet decayed sufficiently. Though there are tracking systems available commercially, we have developed a simple in-house method for accurate storage and disposal, limiting unnecessary exposure to staff at effectively zero cost to the department. **Methods:** A Microsoft excel worksheet has been developed to track movement of radioactive waste in and out of the department. This worksheet has the ability to categorise waste via staff input, in terms of radiation level at time of entry and waste type, provide clear locations within our storage room and identify the required storage time and estimated date of disposal for when radiation levels are approximately background. This is accomplished through radiation decay algorithms, Microsoft excel formulas and features, simple data entry requirements of staff and colour-coded output values. **Results:** Through the implementation of this process, the ability to track and manage radiation waste has improved. Identification of waste ready for monitoring and likely disposal has been simplified and the burden of unnecessary waste storage has been reduced. As a result, we have also experienced lower exposure time and dose to staff due to the reduced need to handle and monitor waste that is not ready for disposal. Waste disposal can also be documented more effectively and is retrievable at any instance. **Conclusion:** Through more efficient procedures for radioactive waste management, departments can more accurately track radiation waste in and out of the department as well as reduce staff exposure levels to radiation in the process of waste disposal.

P159: The Analysis of Radioactive Concentration in Drainage when Using Radioiodine
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**Background/Aims:** With regard to the use of radioiodine in domestic medical institution, the case of exceeding the allowance of Nuclear Safety Act about radioactive concentration in drainage was found. Through understanding the cause of exceeding case and analysing radioactive concentration in drainage, evaluating the relationship of the public waters in surroundings and usefulness. **Methods:** From November 1, 2014 to April 30th, 2015, the research is aiming at domestic twenty hospitals for six months. By Using a HPGe gamma-ray spectrometer (Canberra DSA-1000) and GENIE-2000 Analysis software for comparative analysis, measuring a radioactive concentration of radioiodine in drainage. **Results:** Consequently, we confirm the excess of radioactive concentration of radioiodine in seven medical institutions. Conducting a survey of twenty hospitals and average radioactive concentration of radioiodine in drainage appears 42,100 Bq/m^3^. The features of domestic hospitals where show a high radioactive concentration are a number of medical treatment patient when using radioactive iodine and the absence of private rest room. During I-131 whole body scan, the pre-treatment procedure of urinating is considered emission of residual Iodine. **Conclusion:** In public waters, the cause of exceeding detection of radioactive concentration in drainage suppose a diagnostic radioactive iodine. We confirm the importance of enhanced education, providing safety control instructions and installing private restrooms for patients who were injected a low capacity radioiodine. Also, constructing institutional and legal management system is considered about the emission management standard in drainage.

P160: Learning from Incidents -- Australian Radiation Incident Register
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**Background/Aims:** The Australian Radiation Incident Register (ARIR) is a national database to which Commonwealth, state and territory regulators across Australia submit details of radiation incidents.\[[@ref37]\] Regulators acquire de-identified information about incidents from licence holders within the relevant jurisdictions. **Methods:** The ARIR forms part of a national radiation-reporting framework, which aims to ensure that radiation incidents are not only managed on a local level, but lessons learned can be shared across institutions and national jurisdictions. The ARIR is a powerful tool, which enables the identification and analysis of radiation incidents and hazards as well as the effectiveness of controls across Australia. **Results:** The most recent report, which includes all incidents that occurred in 2016, incorporates a feature section focusing on nuclear medicine practices. The ARIR annual report and this presentation provides highlights of the learnings of licence holders, and the outcomes of the analysis of the findings. This information provides a method to learn from mistakes rather than repeat them and to help focus resources on important issues and hazards. This presentation will also highlight some recent enhancements made to ARIR, including a web-based reporting system. **Conclusion:** Practitioners in the nuclear medicine community can have a significant impact on the ARIR through the reporting of incidents, identifying causes and suggesting solutions that could be adopted in other practices across the country. The strength of a register such as ARIR relies on the data submitted and hence clinical facilities can play an important role in reporting through their local jurisdictions. This data and subsequent analysis will aid in increasing the safety culture within nuclear medicine facilities.

P161: Development of a Ceiling-mounted Radionuclide Therapy Patient Monitor with Predictive Exposure Rate Capability
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**Background/Aims:** Patients receiving large doses of radionuclides for therapy often require admission to a specialized ward where they can be isolated from staff and the public until their external radiation exposure rates have decreased to acceptable levels. Our newly developed ceiling-mounted radiation monitor has an innovative detector design which continuously monitors exposure rates and is integrated into the hospital IT network to allow monitoring from any PC that can access the detector, either internally or externally. **Methods:** Based on a solid state sensor and a small GM detector, the device is contained in a uniquely designed casing to distinguish it from other ceiling-mounted devices such as fire alarms, smoke detectors, sprinklers and CCTV cameras. It is activated by Power Over Ethernet (POE). It has an ethernet interface for connection to the hospital LAN. The system is located approximately 1.8 meter above the patient bed but the detector is calibrated for this and gives the estimated "exposure at 1 meter". Multiple detectors in different rooms can be supported on one PC. The software performs real-time curve fitting (assumed mono-exponential) and extrapolation to estimate when the radiation exposure from the patient will be lower than the local regulatory limit. **Results:** Samples were collected at 1 minute intervals starting approximately 10 minutes after administration until discharge. We have studied clearance patterns in 13 subjects. Soon after administration the exposure rate from patients who have received a 4GBq capsule of I-131 can exceed 250 micro-Sv/hr which is 10 times greater than the local limit for discharge back into the public. In patients who had radioiodine ablation with thyroglobulin pre-treatment and normal renal function the effective clearance half-time measured was 10.5±1.1 hours. However, one patient with impaired renal function had an effective t-half of \>40 hours. Upon discharge, at approx. 40 hours after administration, the majority of radioiodine patients have exposure rates of between 2--20 micro-Sv/hr @ 1 m (local limit is 25 micro-Sv/hr). Many could be discharged earlier than is done with our current practices. **Conclusion:** This device helps to optimally manage patients admitted for radionuclide therapy. It can be used for any radionuclide that emits photons where minimising exposure to the public must be ensured.

**Disclosure of Interest:** C. Munoz-Ferrada Conflict with: Gammasonics Institute for Medical Research Pty Ltd.

P162: An E-Learning System for Medical Staff about Ionizing Radiation and Radioactive Materials. A Nuclear Physicians' Approach in Japan
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**Background/Aims:** Systematic learning about ionizing radiation and radioactive materials is not easy for medical staff. After a nuclear accident at the Fukushima Daiichi Nuclear Power Station on March 11, 2011, many patients in Japan declined radiological examinations despite doctors' recommendation. It is important for nuclear physicians to encourage medical staff to have knowledge to correct prejudiced public understandings on ionizing radiation and human health, especially at low radiation doses. **Methods:** We had been taking more than 30 classes for medical staffs from 2011 to 2016. Based on questions and answers in these classes, our e-learning system was created, and 127 physicians had taken this e-learning. We also provided self-check tests after e-learning. **Results:** Following five contents for e-learning system were chosen; 1: Radiation around us; 2: Devices for measuring radiation; 3: Effects on humans; 4: Internal exposure; 5: Radiation emergency medicine. The results of the self-check test showed that estimation of internal radiation doses was the most difficult to understand. **Conclusion:** E-learning system was created for medical staffs which can correct the misunderstanding about the effect of ionizing radiation on human health.
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**Background/Aims:** The synthesis of ^11^C-PET radiotracers produces radioactive waste gases, which require careful management to ensure minimisation of release and compliance with regulatory requirements. The Austin Health Department of Molecular Imaging and Therapy produces multiple ^11^C radiotracers for clinical trials (eg ^11^C-PIB, ^11^C-PK11195), hence work was undertaken to monitor production and release of radioactive ^11^C gas from our cyclotron facility. **Methods:** A management plan for ^11^C gas release was implemented, requiring the installation and modification of a range of equipment. Further radiation monitoring systems were installed throughout the facility ventilation system with special attention made to release points. Synthesis module waste systems were modified to address challenges in gas handling, while hotcell ventilation design was revised to accommodate an Air Compression System (ACS) to allow delay and decay capabilities. **Results:** Release of ^11^C gas was reduced to levels as low as 9MBq per production, corresponding to a 24 hour disposal concentration of 32 Bq/m^3^ and a release of 0.008% of total activity. Internal exposure from inhalation at the release point on the facility roof was estimated to be less than 2.6 nSv per production. **Conclusion:** Release concentrations have been effectively reduced to safe levels, and detailed information on dosimetry and disposal of ^11^C to air has been obtained. These results highlight the importance of monitoring and management of ^11^C gas byproduct of production of ^11^C radiotracers.

P164: A Flexible Magnetic Resonance Imaging-Compatible Mobile Personal Radiation Shield and Radiopharmaceutical Delivery device for Single Photon Emission Computed Tomography, Positron Emission Tomography and Radionuclide Therapy
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**Background/Aims:** The development of PET/MRI necessitated a high degree of technological innovation. However, most radiation survey devices and personal shielding systems are incompatible with operation in the MRI suite & thus further technological innovation is required. This prompted us to develop a system for administering PET radiopharmaceuticals in this environment while adhering to the ALARA principle of maximally protecting staff. **Methods:** The device, called "Syriporter+", consists of a 300-mm wide vertical lead barrier with 15 mm Pb shielding designed to achieve \>10-fold reduction in exposure rates for PET radionuclides. It currently has a 35mm thick Pb-glass window (15 mm Pb equivalent) but this will be replaced by a touch screen PC and camera in future versions. The lead barrier contains an up/down drive motor to adjust for different individuals' heights. The system supports both syringe (in syringe shield) and infusion pump administration of radiopharmaceuticals with saline flush. The radiopharmaceutical is typically loaded from a shielded container in the facility's radiopharmacy and wheeled to the patient bedside for injection. Importantly, after the delivery of the radiopharmaceutical to the patient the operator remains protected behind the radiation shielding unlike other automated delivery systems. Measurements for a range of different radionuclides (Co-57, Lu-177, Ga-68 and Cs-137) with different photon energies and emissions in the form of point sources or liquid in a flask have been made to evaluate the transmission rate when using the barrier. **Results:** Indicative transmission rate reductions measured through the Pb-glass viewing window were: (i) Co-57 (122 keV)-\>100x, (ii) Lu-177 (113, 208 keV) -- 19.1x, (iii) Ga-68 (511 keV) -- 13.3x, and (iv) Cs-137 (663 keV) -- 18.2x. Variations in available source geometries might account for some apparent inconsistencies between the measurements. **Conclusion:** The Syriporter+ is suitable for all applications involved in administering radiopharmaceuticals for general nuclear medicine or PET, for PET/CT or PET/MRI, and for radionuclide therapies. Future versions will support interfacing to the hospital information system to minimise errors. It has the advantage of protecting the operator during and subsequent to automated or manual delivery of the radiopharmaceutical.

**Disclosure of Interest:** C. Munoz-Ferrada Conflict with Gammasonics Medical Research Institute,

P165: A Study on the Strategies to Lower Technologist Occupational Exposure According to the Performance form in Positron Emission Tomography Scan Procedure
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**Background/Aims:** For nuclear medicine technologists, it is difficult to avoid or be separate from radiation sources compared to workers who are using radiation generating devices. When technologists are familiar with work practices, their work in nuclear medicine is recognized as an optimized method. The aims of this study are to measure radiation exposure of technologists' working in PET and to evaluate the occupational radiation dose after the implementation of strategies to lower exposure. **Methods:** We divided into four working types: QC for PET, injection, scan and etc. in PET scan procedure. In QC for PET, we compared the differences in radiation exposure when controlling the table next to the ^68^Ge cylinder phantom and controlling the table in console room remotely. In injection, we compared the radiation exposure when guiding a patient in the waiting room before the injection and after injection. In the scan procedure of PET, we compared the differences in radiation exposure between moving the table using the control button located next to the patient and moving the table using the control button located a farther distance away. The Personal Electronic Dosemeter (PED), TracercoTM was used for measuring exposed radiation doses. **Results:** The average doses of exposed radiation were 0.27±0.04 µSv when controlling the table directly and 0.13±0.14 µSv when controlling the table remotely while performing QC. The average doses of exposed radiation were 0.97±0.36 µSv when guiding the patient after injection and 0.62±0.17 µSv when guiding patient before injection. The average doses of exposed radiation were 1.33±0.54 µSv when using the control button located next to the patient and 0.94±0.50 µSv when using the control button located in far distance while acquiring image. As a result, there were statistically significant differences (p\<0.05). **Conclusion:** From this study, we found how much radiation technologists are exposed to on average at each step of the PET procedure while working in a PET center and how we can reduce the occupational radiation dose after the implementation of strategies to lower exposure. If an effort is made to seek other methods to reduce technologist occupational radiation, we can minimize and optimize the amount of exposed radiation in departments of nuclear medicine.

P166: An Australian Local Diagnostic Reference Levels for Paediatric fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
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**Background/Aims:** The radiation dose associated with PET/CT is of particular concern in paediatric patients. If local diagnostic reference levels (DRLs) exceed the national DRL, there may be a need for optimisation of the PET/CT protocol. The aim of this study was to establish the local DRL for paediatric patients undergoing PET/CT examinations at one Australian centre. **Methods:** A survey was sent to retrospectively assess 12 months of ^18^F-FDG PET/CT data in order to establish the local DRL based on the 50^th^ percentile for the infant/baby (0-4 years) and child (5-14 years) age categories. Collected data included administered radioactivity (MBq), CT dose index volume (CTDI~vol~) and the CT dose length product (DLP). Total effective dose (ED) was also calculated. **Results:** The 50^th^ percentiles for administered total activity (MBq) and activity normalised to body weight (MBq/kg) in the infant/baby category (n=21) were 81.36 MBq and 5.61 MBq/kg, respectively. For the children category (n=92) these were found to be 145 MBq and 3.85 MBq/kg, respectively. The 50^th^ percentiles for CTDI~vol~ and DLP for the infant/baby category were 0.81 mGy and 71 mGy.cm, respectively. The total PET/CT ED for infant/baby and child groups were 8.79 mSv and 6.96 mSv, respectively. The ED from administered radioactivity was higher than CT dose. The MBq/kg administered radioactivity for the infant/baby group was higher than child age group due to independent minimum administered activity (60 MBq) required for diagnostic image quality. **Conclusion:** A local DRLs for paediatric ^18^F-FDG PET/CT imaging has been determined. This is an important first step in establishing an Australian national DRL for paediatric PET/CT examinations.

**Disclosure of Interest:** T Kitsos Conflict with: The University of Sydney, Faculty of Health Sciences, K Willowson Conflict with: The University of Sydney, Faculty of Health Sciences.
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**Background/Aims:** The advantage of Re-188 for radionuclide therapy including its inexpensive and availability from the W-188/Re-188 generator is been proven in nuclear medicine. Our efforts in PARS Isotope Co. towards the development of therapeutic radionuclides was focused on production of W-188/Re-188 generator which can be used in hospitals and nuclear medicine centers as a radioisotope supplier for production of therapeutic radiopharmaceuticals. **Methods:** This new W-188/Re-188 generator with the name of PARSRhen is a system where W-188 as tungstic acid adsorbs on a column of alumina. After W-188 loading the manufactured generators are slowly washed (1mL/min) with 0.9% NaCl solution (100-150 mL) and completely air dried before dispatch. PARSRhen uses high specific activity W-188 and modified alumina sorbent. Suitable formulation for W-188 was obtained and sufficient shielding for decreasing operator exposure were designed and manufactured. The quality control test such as radionuclide and radiochemical tests were done on the eluted Re-188 from the generator. **Results:** Re-188 elution yields in PARSRhen were generally 75% to 80% of the available Re-188. W-188 breakthrough values were typically in the range of 10^-6^. Chemical, Radiochemical, radionuclide and sterility tests which are regular in the world were evaluated according to pharmaceutical standards. Eluted Re-188 from PARSRhen was labeled with different agents and tested on animals and patients. All the results were based on standards and satisfying. **Conclusion:** At the moment, a portable W-188/Re-188 generator with usability in nuclear medicine centers is designed and introduced all over the world to develop using of Re-188 radiopharmaceuticals for needy patients.

P168: Potential of Prelabelling Method for On-Site Preparation of Radiometal-Labeled Antibody

Andriana\*

Putri

1

Hanaoka

H

2

Yamaguchi

A

2

Tsushima

Y

1

Department of Diagnostic Radiology and Nuclear Medicine, Gunma University, Maebashi, Japan

Department of Bioimaging Information Analysis, Gunma University, Maebashi, Japan

**Background/Aims:** Imaging with a radiolabelled antibody would be a promising strategy to select patients suitable for the respective antibody treatment. Nevertheless, widespread application of this approach is limited due to the complexity related to conventional radiolabelling technique, including requirement for time, cost, and germ-free condition during chelate-antibody conjugate preparation. Pre-labelling technique, which the radiometal complex is formed first and then conjugated to the antibody, has the potential to become useful method since this technique save labour for advance preparation of chelate-antibody conjugate. Pre-labelling technique would be more efficient and applicable for general use in clinical field, if highly-reactive and easily separable radiometal complex is available. Our aim was to develop a new bifunctional chelating agent and establish a purification method suitable for pre-labelling technique. **Methods:** DO3A-PEG~4~-COOH was obtained by solid phase synthesis. DO3A-PEG~4~-COOH or DOTA was labeled with ^111^In in acetate buffer or HEPES buffer. Radiochemical yield was analysed by cellulose acetate electrophoresis. To establish a method to separate antibody from unconjugated radiometal complex, purification study was performed using a mixture of ^111^In-DO3A-PEG~4~-COOH and ^125^I-labeled antibody. The mixture was applied to a size-exclusion cartridge, then the tracers were eluted with phosphate buffered saline, and the fractions were collected into tubes. Radioactivity of each tube was measured by γ-counter. **Results:** When the standard radiolabelling condition of ^111^In-DOTA was applied, radiochemical yield of ^111^In-DO3A-PEG~4~-COOH was approximately 91%. By using HEPES buffer instead of acetate buffer, ^111^In-DO3A-PEG~4~-COOH was obtained with radiochemical yield of more than 95%. The separation with size-exclusion cartridge yielded ^125^I-labeled antibody in high purity (containing less than 5% of ^111^In-DO3A-PEG~4~-COOH or ^111^In-DOTA) and recovery yield of approximately 50%. **Conclusion:** DO3A-PEG~4~-COOH enabled ^111^In-labelling with high radiochemical yield. The resulting radiometal complex was easily separable from antibody by using a size-exclusion cartridge. These results suggest that DO3A-PEG~4~-COOH would be a promising chelate for pre-labelling technique.

P169: Do we Really Need an Onsite Cyclotron? The RNS Hospital Experience
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**Background/Aims:** Currently there are over 1200 cyclotrons being used in nuclear medicine worldwide for the production of radioisotopes. Radioisotopes produced in cyclotron decay by either positron emission or electron capture. Although there is no (or plan for) cyclotron at RNSH, there is a growing list of positron emitting and cyclotron-produced radiopharmaceuticals being used for routine and research applications. Here we report on the RNSH experience. **Methods:** The number of patients being treated and/or diagnosed with cyclotron-produced and positron-emitting radiopharmaceuticals was obtained using GE RIS/PACS for the most recent year (2016). These were then separated into in-house-generator produced and cyclotron-produced radiopharmaceuticals. The percentage of total scans for each radiopharmaceutical was determined. ^99m^Tc-based radiopharmaceuticals were excluded for the comparison. **Results:** The results showed that the cyclotron-produced ^18^F-FDG was the most common (72%) followed by the in-house-generator produced ^68^Ga-DOTATATE (13%) and ^68^Ga-PSMA (12%). A list of these and their applications are summarised below. There are other cyclotron-produced radiopharmaceuticals at development stage and will be entering into mainstream use in the foreseeable future.

\[^18^F\]-FDG (deoxyglucose) ^†^: Cancer, brain, cardiac, inflammation

\[^18^F\]-FET (tyrosine) ^§^: Cancer -- DNA synthesis

\[^18^F\]-FLT (thymidine)^†^: Cancer -- "Ki67 analogue"

\[^18^F\]-FMISO^§^: Hypoxia

\[^18^F\]-NaF^†^: Bone scan, atherosclerosis

\[^18^F\]-Florbetaben^†^ (soon): Cerebral amyloid (Dementia)

\[^18^F\]-PBR111 (TSPO) ^§^ (soon): Cerebral microglial activation

\[^68^Ga\]-DOTATATE^§^: Somatostatin receptor imaging (NETs, meningioma)

\[^68^Ga\]-PSMA^§^: Prostate cancer

\[^68^Ga\]-Citrate^§^: Infection

\[^68^Ga\]-Galligas (GaCl~2~) ^§^: Lung ventilation

\[^68^Ga\]-MAA^§^: Organ (lung) perfusion

\[^124^I\]-Minicells (EnGeneIC) ^§^: Chemotherapy/drug delivery vehicle

\[^89^Zr\]-Nanoparticles^§^: PET/MRI imaging/drug delivery

\[^90^Y\]-SIR-Spheres^†^: Post-SIRT dosimetry

^†^Imported ^§^Radiolabelled in-house.

**Conclusion:** Although cyclotron-produced radiopharmaceuticals are currently in demand, an on-site cyclotron is not essential in order to carry-out most, if not all, of the PET/CT scans. This is on the provision that there are commercial cyclotrons available within distance allowed by the radionuclide's half-life. The generator-produced PET radionuclides (eg ^68^Ga) can be used on-demand.
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**Background/Aims:** The ALCEO solid target system has been developed by Comecer for cyclotron production of ^64^Cu and ^89^Zr. The aim of this work was to expand on the utility of the ALCEO system for the production of ^68^Ga and ^45^Ti radioisotopes. Production and labelling results for all four isotopes will be presented. **Methods:** Enriched ^64^Ni was electroplated onto a target shuttle and irradiated with 14.4 MeV protons to produce ^64^Cu, which was then separated from the irradiated ^64^Ni using AG® 1-X8 resin (Biorad). Natural yttrium was irradiated with 14.4 MeV protons to produce ^89^Zr, while natural scandium was irradiated with 12.1 MeV protons to produce ^45^Ti. Both radioisotopes were separated from their irradiated starting materials using ZR resin (TRISKEM). ^68^Zn was electroplated onto a target shuttle and irradiated with 12.1 MeV protons to produce ^68^Ga. The ^68^Ga was separated from the irradiated ^68^Zn using LN resin (TRISKEM), then labelled to PSMA-11 and DOTATATE using Eckert & Ziegler's Modular-Lab eazy synthesis module. **Results:** ^64^Cu was routinely produced with a yield of 131±40 MBq/µAh (n = 20) and was successfully utilised for the process validation of \[^64^Cu\]Cu-SARTATE (n = 3) conducted at SAHMRI. ^89^Zr was produced with a yield of 22.4±1.5 MBq/µAh (n=2), while ^45^Ti was produced with a saturation yield of 312 MBq/µA (n=1). ^89^Zr was labelled to DFO-trastuzumab with radiolabelling yield \>80% and radiochemical purity \>90% (n=2). ^68^Ga was produced with a saturation yield of 1330±590 MBq/µA (n=2), and was labelled to PSMA-11 (radiolabelling yield=79%) and DOTATATE (radiolabelling yield=76%), with radiochemical purity of 99% and 91% respectively. **Conclusion:** The Comecer ALCEO solid target system has been successfully used to produce ^64^Cu, ^89^Zr, ^68^Ga and ^45^Ti. Future work includes optimisation of the separation processes, and production of ^44^Sc.

**Disclosure of Interest:** M Malinconico Conflict with: Comecer spa; F Boschi Conflict with: Comecer spa, G Guidi Conflict with: Comecer spa.

P171: Initial Standardisation of Next Generation Theranostics: Preparation for Clinical Trials with Cu-64 SARTATE
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**Background/Aims:** In preparation for clinical studies with Cu-64 SARTATE in children with neuroblastoma, Clarity Pharmaceuticals and ANSTO Radionuclide Metrology have collaborated to develop an initial Cu-64 standard for clinical manufacturing sites and clinical research sites. This initial standard will be updated late in 2017 when ANSTO performs a Cu-64 primary standardisation and compares this standard with the International Reference System using the SIRTI transfer instrument (BIPM). By harmonising the dose calibrators dial settings between sites, more confidence is gained in the dosimetry estimates from PET images collected at clinical sites. This is especially relevant for next generation theranostic radiopharmaceuticals such as Cu-64 SARTATE and Cu-67 SARTATE, where personalised dosimetry can be used to optimise therapeutic efficacy while maintaining patient safety. Cu-64 SARTATE is a positron-emitting radiopharmaceutical that has important advantages over current PET agents. Clarity's therapeutic product is Cu-67 SARTATE, a beta emitter, which has the potential to be used to treat a range of cancers including neuroendocrine tumours, meningioma, and neuroblastoma in paediatric patients. **Methods:** ANSTO developed an initial calibration factor for their Secondary Standard Ionisation Chamber (SSIC) through interpolation of its response curve. A Cu-64 solution provided by Clarity's contract manufacturer was then standardised using this calibration factor. ANSTO established preliminary dial settings for Cu-64 on their dose calibrators from the same standardised solution. Additional Cu-64 was sub-dispensed into vials, standardised by measurement in the SSIC, then sent to clinical and manufacturing sites involved in Clarity's Phase 1 study for establishing dial settings. **Results:** All clinical and manufacturing sites were able to establish dial settings for Cu-64 that were within ±1.1% of the value measured from ANSTO. **Conclusion:** By establishing measurement equivalency between clinical manufacturing and research sites at the outset of the trial, more consistent and meaningful data can be obtained.

**Disclosure of Interest:** C Biggin Conflict with: Clarity Pharmaceuticals, C Jeffery Conflict with: Clarity Pharmaceuticals, A Hedt Conflict with: Clarity Pharmaceuticals.

P172: An Improved, Highly Reproducible Formulation of (Tc-99m) TRODAT-1 for Routine Clinical Use
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**Background/Aims:** The tropane derivative, TRODAT-1 when labelled with \[Tc99m\] has been shown to bind dopamine transporter (DAT) with high affinity and selectivity. In this study, we have modified and standardized the procedure for TRODAT-1 cold kit formulation. We investigated if the labelling procedure could be improved by using a heating-block and to be more efficient and consistent than using autoclaving or boiling water-bath methods as described previously. **Methods:** Briefly, 1mg of TRODAT-1 was dissolved in 100µl of ethanolic-HCl. To this solution 440µg SnCl~2~, 160mg sodium glucoheptonate, 19mg EDTA were added and mixed. The bulk solution containing TRODAT-1 was aseptically dispensed in 1mL aliquots and stored at-80°C. TRODAT-1 was radiolabelled by adding 1.4GBq of \[Tc-99m\]pertechneate in 3ml saline and heated for 30min at 100^o^C using a heating-block enclosed with a lid. The radiochemical purity (RCP) was analysed using iTLC-SG paper with saline as the solvent and HPLC was performed using 0.1% TFA/H~2~O & ACN. As proof of concept, biodistribution of \[Tc-99m\]TRODAT-1 was studied in a rabbit model. Animals were injected with 30MBq of \[Tc-99m\]TRODAT-1 and images were acquired at 60min post-injection with a SPECT/CT (Siemens Symbia) camera. **Results:** Previous studies have used autoclaving method or a boiling water bath for radiolabelling TRODAT-1 with \[Tc-99m\]. These methods had the limitation of water evaporating during boiling, uncontrollable temperatures, variable yield and possibility of contamination. To ensure consistent temperature and eliminate the possibility of contamination we used heating-block. RCP of \[Tc-99m\]TRODAT-1 (R*f*=0.0) by iTLC was \>99% and reproducible. The retention time by HPLC for labelled product was16min and for free \[Tc99m\] was 2.5 minutes with radiolabelling yield of \>99%. Animal biodistribution studies showed brain hippocampus uptake of 0.32±0.08 %ID/g at 60min post-injection. As expected, kidney uptake was high as the agent is excreted renally. **Conclusion:** This study describes a simple formulation and method of preparation for \[Tc-99m\]TRODAT-1, which is reproducible with high yield and purity (RCP \>99%). The pre-clinical results in rabbits indicated specific binding to dopamine receptors and therefore has the potential for use in DAT imaging in patients.
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**Background/Aims:** The aim of this paper is to present the novel concept of labelling the technetium-kit-like radiopharmaceuticals using microfluidic chip systems. **Methods:** We designed and tested the labelling of the technetium compounds on microfluidic chip systems using the following commercially available kit lyophilisates: Technescan HDP (Mallinckrodt Medical B. V, Holland), Technescan MAG3 (Mallinckrodt Medical B. V, Holland), CARDIOSPECT (MEDI-RADIOPHARMA Ltd., Hungary), SENTISCINT (MEDI-RADIOPHARMA Ltd., Hungary), Tektrotyd (POLATOM, Poland), VASCULOCIS a TECEOS (CIS bio International, France). The labelling was performed with ^99m^Tc-eluate from Drytec ^99^Mo/^99m^Tc generator (GE Healthcare Limited, Great Britain) on non-commercial chips "One in--One out" PMMA GSlite (Department of Radiopharmaceuticals, Nuclear Physics Institute of the CAS) with canal dimensions width-neck-depth: 0.5-0.1-0.05 mm and total canal length of 15 cm equipped with turbulent mixers. Activity used in these studies varied from 1 to 5 GBq and the eluate was applied on the chip with various flow-rate. The transchelatation lyophilysates were labelled using a heating magnetic stirrer (set on 90 °C). Radiochemical purity was determined according to SPC using radiochromatographic scanner Scan 2 (EMPOS & BQM, Czech Republic). **Results:** Radiochemical purity of studied substances was always ≥ 95%. Labelling of every studied substance took in general 50% less time than when compared to kit-like preparation of radiopharmaceuticals with a high radiochemical yield and the whole process was remotely controlled. **Conclusion:** The presented method of labelling of technetium-kit-like pharmaceuticals using microfluidic chip systems is a more rapid, reliable and high radiochemical purity providing alternative for daily radiopharmaceutical practice. Moreover, this modern approach allows for simple scaling of the precursor's amount and decreases significantly personnel's radiation burden.
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**Background/Aims:** Vascular adhesion protein-1 (VAP-1) is an endothelial glycoprotein present on the endothelial surface of tissues affected by infection/inflammation that recruit lymphocytes from blood. VAP-P1 is a VAP-1 selective peptide (sequence GGGGKGGGG) which, according to previous studies, conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and labelled with ^68^Ga, could be used as imaging agent capable to differentiate between normal bone healing and bone infection. The aim of this paper is to study the potential of 1,4,7-triazacyclononane-triacetic acid (NOTA)-conjugated, ^68^Ga and ^64^Cu labelled VAP-P1 peptide for possible clinical applications. **Methods:** Synthesised peptide VAP-P1 was conjugated with NOTA-SCN, purified using semi-prep HPLC and lyophilized. The conjugate was then labelled with ^68^Ga or ^64^Cu. *In vitro* plasma protein binding and stability in human serum in time (0, 30, 60 and 120 min) were determined using transfected Chinese Hamster Ovary cells (CHO) that express human VAP-1 and HT-29 (negative control). Each experiment was performed in octaplicate, and the data were reported as percentage of total added activity. **Results:** The peptide was conjugated with NOTA chelator and labelled with ^68^Ga and ^64^Cu with radiochemical purity ≥ 95 %. Radiolabelled analogue \[^64^Cu\]NOTA-VAP-P1 presented here was rapidly internalized into CHO cells versus negative control HT-29. The internalization of the surface bound peptide was time-dependent. It sharply increased during the first 30 min reaching internalization levels of 80--90%. **Conclusion:** *In vitro* studies showed that NOTA-VAP-P1 labelled with ^68^Ga or ^64^Cu may provide a faster and a simpler method of diagnostics of inflammation/infection compared to the method of labelled leucocytes. The concept deserves to be tested *in vivo*.
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**Background/Aims:** ^86^Y has applications in preclinical and clinical studies as a molecular imaging partner to ^90^Y-labelled particle, peptide and antibody therapy. We have implemented ^86^Y production via the ^86^Sr (p, n)^86^Y reaction, using a 13MeV proton beam and purified with an automated disposable-cassette based module which was manufactured in-house. In this study, we aimed to introduce an efficient way of preparing the ^86^SrO target that allows longer irradiations and higher currents, as well as simplifying purification procedures. **Methods:** 30mg of ^86^SrO was ground into a fine powder, and then left in a desiccator overnight. The powder was then pressed into a cylindrical cavity in a Niobium disk using a bench vice and held under pressure for 5 minutes. The target was then kept in a desiccator overnight for irradiation the following day. The irradiated target was then dissolved and purified by an in-house developed automated module, which uses a selective DGA Normal resin column (N, N, N',N'-tetra-n-octyldiglycolamide, 50-100µm particle size) to purify the ^86^Y. The purified ^86^Y was then eluted from the column with ultrapure water. **Results:** Proton irradiation of the ^86^SrO target material at 10µA for 2 hours yielded approximately 800 MBq at EOB, with no significant target material losses observed. Typically, 75-80% of the activity is recovered in the elution volume. Gamma spectrum analysis using an HPGe detector has shown that the final purified solution contains 0.45% ^87^Y and 0.1% ^88^Y when normalised against ^86^Y. **Conclusion:** Optimization of target preparation methodology has shown significant improvements in target stability at higher beam currents compared to the widely used method of ^86^SrCO~3~ as the target material.^1^ Use of an in-house developed automated module has also minimized radiation safety concerns by eliminating manual handling procedures as well as improving accuracy and reproducibility of productions. The final purified ^86^Y solution is obtained in a small volume appropriate for subsequent radiolabelling.
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**Background/Aims:** Primary hepatocellular carcinoma (HCC) is the most common form of primary hepatic carcinoma, particularly in Asia and sub-Sahara Africa. The therapeutic modalities such as chemotherapy, radiotherapy, and trans-hepatic arterial embolization (TAE) gave unsatisfactory results. Alternative methods of therapy using Lipiodol as a carrier for chemotherapeutic agents or radioisotopes are currently under investigation. Synthesis of ^131^I-labelled Lipidol is a challenge in order to make under strict recommendation of regulatory authority along with maintaining the worker safety. Time is required to fully automate the process to synthesise the required quantity and quality of radiotracer. **Methods:** In this study, we describe the fully automated labelling of ^131^I with lipiodol, using Sumitomo's CFN MPS-100 automated synthesis module with minor modification in software and module intake of reagents. Synthesis was performed at around 100^o^C having mixture of iodized-lipiodol (LIPIODOL Ultra Fluid supplied by Guerbet, France) and carrier-free ^131^I. The reaction was catalyst by phase transfer catalyst such as Crown ether (PTC) or Pivalic acid melt down method. At different concentration of PTC or acid, the radiolabelling yield were studied. After variable time of incubating, the mixer was transfer to product vial by passing through 0.22µm sterile filter. All quality control tests were performed for being used as clinical product. **Results:** The overall radiochemical yield in the range of 85-95% with the labelling purity is more than 98%. The reproducibility of this automated synthesis module is very high. **Conclusion:** we have developed a protocol for reliable, repeatable fully automated chemistry protocol for clinical grade ^131^I-Lipiodol.
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**Background/Aims:** Peptide receptor radionuclide therapy (PRRT) has emerged to be a significant asset to nuclear medicine involving generator-based gallium-68 (^68^Ga) that became opportunely available to hospital radiopharmacies. The supply of ^68^Ga-DOTA-Tyr^3^-octreotate tremendously facilitates patients undergoing ^177^Lu-DOTA-Tyr^3^-octreotate-PRRT, which is used successfully in South Africa.\[[@ref39]\] Lacking a commercially-available radiochemical synthesiser, higher attention was given to a flexible, cost-efficient ^68^Ga-DOTA-Tyr^3^-octreotate radiolabelling solution including a "safe-and-simple" handling protocol suitable for a hospital radiopharmacy. We describe an optimized ^68^Ga-DOTA-Tyr^3^-octreotate preparation using in-house-manufactured, freeze-dried, multi-dose prepared kits and demonstrate the significance towards human application. **Methods:** A 0.9-2.0 ml ^68^Ga-GaCl~3~ fraction was yielded from a newly-manufactured ^68^Ge/^68^Ga-generator; 25 consecutive manual ^68^Ga-DOTA-Tyr^3^-octreotate (13.3±1.3 µM) productions were compared with 10 kit-based radiosyntheses (14.2±0.4 µM; p=0.101). Kits were manufactured containing DOTA-Tyr^3^-octreotate in sodium acetate buffer to warrant pH of 3.5-4 during radiolabelling. Radiolabelling was carried out as detailed.\[[@ref39]\] Ethical approval for tracer injections was given. **Results:** DOTA-Tyr^3^-octreotate was obtained with radiochemical purities of 98.8--100%, from freeze-dried formulations after reconstitution with 30% less ^68^Ga-GaCl~3~ (*P*=0.003) than required for manual radiolabelling (≥95.6%). All kit-based productions were significantly better than the average manual production (labelling efficiency of 86±5% vs. 48±26%; p\<0.001) and led to reduction of production time (26±5 minutes; p\<0.001), ^68^Ga-colloids (7.5±3.6%; p=0.014), free ^68^Ga (H~2~O)~6~ (6.3±2.2%; p\<0.001) and C~18~-cartridge-bond radioactivity (3.0±1.9%; p=0.019). Consequently, 1.7-fold higher radiochemical yield (678±174; p\<0.001), 2.0-fold increased specific activity (26±10 MBq/nmol; p\<0.001) and 1.4-fold more radioactivity for tracer administration (499±89 MBq; p=0.037) was accomplished. From one DOTA-Tyr^3^-octreotate kit, two patient doses (2.2±0.8 MBq/kg; 17±6 nmol DOTA-Tyr^3^-octreotate, p=0.026; N=14) were obtained and safely administered. **Conclusion:** Significant improvements accompanied our kit-based ^68^Ga-DOTA-Tyr^3^-octreotate radiolabelling approach with reduced radiation exposure to operating personnel.
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**Background/Aims:** PET/CT using ^18^F-sodium fluoride is a sensitive imaging technique for diagnosis of bone metastases but their efficient treatment remains a clinical challenge. Zoledronate (ZOL), a bisphosphonate with superior affinity to hypoxyapatite, was recently conjugated with bifunctional chelators such as 1,4,7-triazacyclononane,1-glutaric-acid-4,7-acetic-acid (NODAGA), allowing for ^68^Ga-labelling\[[@ref40][@ref41]\] to monitor endoradiotherapeutic efficiency. We demonstrate a single-vial solution for quantitative ^68^Ga-NODAGA-ZOL radiolabelling. The procedure was modified to accommodate the more-acidic ^68^Ga-eluate of a SnO~2~-based ^68^Ga/^68^Ge-generator. Additionally, the safety of the tracer administration was tested in a small patient population. **Methods:** A ^68^Ga/^68^Ge-generator was fractionally eluted yielding 85% (697±27 MBq) or 93% (862±50 MBq) of the elutable ^68^Ga-activity in 1.2 or 2.0 ml, respectively. The radioactivity was buffered with 2.5 M sodium acetate to yield a pH of 4.0-4.5 before mixing it into a vial containing 74 nmol NODAGA-ZOL. After 10 min incubation at 95˚C, the mixture was sterile-filtered into buffered saline to yield tracer formulation (pH 6.7) for human administration. Quality control measures included radiochemical and radionuclidic purities, pH and sterility. Given ethical consent, ^68^Ga-NODAGA-ZOL was administered intravenously to ten patients followed by whole-body PET/CT imaging at 60 minutes.\[[@ref40]\] **Results:** Quantitative ^68^Ga-NODAGA-ZOL radiolabelling (%LE=94.2-97.0; ^68^Ga-colloids \<7.0%, RCP \>98.5%; n=6) was achieved using 30 µM precursor, but not with NODAGA-ZOL concentrations \<20 µM (%RCP 73.5±3.7; n=3). The radiochemical yield of 480±59 MBq was sufficient to dispense two doses/radiosynthesis. The 5.5-10.5 ml intravenous ^68^Ga-NODAGA-ZOL bolus injection (2.5±0.8 MBq/kg containing 31±8 nmol NODAGA-ZOL; specific activity 7.3±0.9 GBq/µmol; n=10) did not cause any adverse effects in humans. PET images were of high quality with no unexpected tracer distribution. **Conclusion:** The herein produced ^68^Ga-NODAGA-ZOL is a safe-to-administer radiopharmaceutical which can be further evaluated towards its value as a PET/CT imaging agent, monitoring outcome of personalised endoradiotherapies of bone metastases, such as particle-emitting radiopharmaceutical therapy.
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**Background/Aims:** The translocator protein (TSPO) is a receptor complex located in mitochondria in human.\[[@ref42][@ref43]\] TSPO is a bio-marker for inflammation associated with numerous diseases including cancer, multiple sclerosis, Parkinson's and Alzheimer's diseases, stroke, Huntington's disease and HIV encephalitis.\[[@ref44][@ref45]\] Consequently there is significant interest in radiolabelled TSPO ligands as new radiotracers. This includes \[^18^F\]PBR111 which shows potential for imaging neuroinflammation\[[@ref46][@ref47]\] but suffers from significant de-fluorination in vivo. This leads to non-ideal bone uptake and non-ideal specific and non-specific binding in vivo, which ultimately leads to lower quality PET images. To address these problems, a deuterated 2nd generation radiotracer has been synthesised and its metabolic stability compared to regular \[^18^F\]PBR111. **Methods:** Radiolabelling precursors and non-radioactive standards were synthesised following an adaptation of our previous method.\[[@ref46]\] The deuterated side chain synthon was synthesised via a three step reaction sequence of LiAlD~4~ reduction, bromination and protection. Radio-synthesis were performed on a Synthra RNplus synthesis module following an adaption of a previous method.\[[@ref46]\] In vitro microsomal assays were performed with either rat or human liver microsomes, and subsequent radio-metabolite analysis was performed using radio-HPLC. SPE analysis of radio-metabolites were performed using Waters Oasis HLB cartridges. **Results:** The rate of in vitro metabolism (using rat and human microsomes) of \[^18^F\]PBR111-d4 is reduced compared to non-deuterated \[^18^F\]PBR111. In vivo PET imaging in rats showed a 42% reduction of the median \[^18^F\]PBR111-d4 uptake in bone (vertebrae) compared to non-deuterated \[^18^F\]PBR111. Conversely, in the adrenal glands (where TSPO is expression is high) a 30% increase of the median \[^18^F\]PBR111-d4 uptake was observed. **Conclusion:** A deuterated radiotracer-\[^18^F\]PBR111-d4-was developed and evaluated in vivo in rats, demonstrating that it is more resistant to metabolic breakdown compared to non-deuterated \[^18^F\]PBR111. Careful choice of the site of deuteration resulted in a decreased rate of de-fluorination and a notable increase in the median uptake in regions with high TSPO expression. Work to evaluate \[^18^F\]PBR111-d4 in animal models of excitotoxin-induced neuroinflammation is currently underway and will be reported on in future publications.
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**Background/Aims:** A strategy to implement professional standards and a workplace training and assessment program for the practice of Radiopharmaceutical Science in Australia. **Methods:** For new graduates entering the radiopharmaceutical sciences, our strategy included the implementation of a postgraduate degree in basic radiopharmaceutical science, and a mentored, workplace training and assessment program resulting in professional certification. For the existing workforce, a process of professional certification has been established to ensure standards are understood and practiced. **Results:** A Clinical Training Guide encompassing essential knowledge and skills, arranged into competencies was developed by a panel of expert RPSS to ensure safe clinical practice in radiopharmaceutical science. Experienced RPS seeking certification, submit an application, with supporting evidence against these competencies, which is assessed by a panel of peers. Applicants demonstrating proficiency in standards of practice, were eligible for admission to the Register of RPS Specialists, administered by ACPSEM. In parallel, and in collaboration with the Australian Council for Education Research, the RPS Training, Education and Assessment Program (TEAP), was developed for trainees, incorporating contemporary theory and practice in education, training and assessment. TEAP design incorporates practical assessment as a driver of the learning process using progressive assessment. Each competency area has clear outcomes against which the submitted assessment task is evaluated, to ensure consistency, quality and validity of assessment. **Conclusion:** Strategies were developed to support the education and training requirements for a growing radiopharmaceutical workforce through progressive learning, training and practical assessment directly in the workplace.
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**Background/Aims:** ^11^C-choline has been extensively used clinically for imaging prostate cancer.\[[@ref48]\] ^11^C-Choline is prepared by ^11^C-methylation of \[^11^C\]methyl iodide and 2-dimethylaminoethanol (DMAE). It is important to determine accurately the quantity of DMAE in the final product. The most common method for the determination of the substance of ^11^C-choline or DMAE was by co-injection of carrier-choline or DMAE method, and by two separate analysis LC system and gas chromatography.\[[@ref49][@ref50][@ref51]\] The quality control procedures for ^11^C-labeled radiopharmaceuticals is acquired rapid assessment due to short half-life radionuclide (about 20 minutes). Thus, we developed a rapid and simultaneous measurement method for the molar radioactivity, radiochemical purity, and chemical impurity of the ^11^C-choline injection using the radio-HPLC coupled with the corona-charged aerosol detector (CAD). **Methods:** The molar radioactivity, radiochemical purity, and chemical impurity (DMAE) of the ^11^C-choline injection was measured using the radio-HPLC-CAD with the post-column method. We also validated the measurement of choline and DMAE using this HPLC, and evaluated these parameters of the accuracy, precision, specificity, quantitation of limit, and linearity. **Results:** The molar radioactivity, radiochemical purity, and chemical impurity were over 130 GBq/μmol (over 0.1 μg/mL) at end of synthesis (EOS), over 95% at EOS, and less than 0.5 μg/mL of DMAE, respectively. In the validation, the percentages of recovery of choline and DMAE were within 100±5%. The RSD of choline and DMAE were less than 10%. Resolution between obtained choline and DMAE peak was over 1.5. The limit of quantitation of choline and DMAE was 0.1 and 0.5 μg/mL, respectively. The coefficient of correlation (R^2^) of choline (0.1-50 μg/mL) and DMAE (0.5-50 μg/mL) found to be \>0.9999. **Conclusion:** We developed and optimized the simultaneous measurement method for the molar radioactivity, radiochemical purity, and chemical impurity of the ^11^C-choline injection using the radio-HPLC-CAD with the post-column method.
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**Background/Aims:** ^99m^Tc-(Ca)-phytate colloid continues to persist as the routine radiopharmaceutical for hepatosctintigraphy because of its particle size. The commercially available pharmaceutical phytic acid is reconstituted with ^99m^Tc-pertechnetate to yield ^99m^Tc-phytate, and in the presence of calcium ions it forms ^99m^Tc-(Ca)-phytate colloid. More recently the radiopharmaceutical chemistry of Gallium-68 has been investigated to prepare potential PET scanning agents. The aim of this study was to prepare a ^68^Ga-mixed metal-phytate colloid with suitability for liver imaging. **Methods:** The radiocolloid was prepared by mixing an aqueous solution of phytic acid, ^68^Ga^3+^ ions, a dispersant, Mg^2+^ and Ca^2+^ ions, and then heating the contents at 100°C for 5 minutes. After cooling the vial to 5°C, the solution was basified to pH 5 and stored in the cold. The best formulation was characterised for radiochemical purity, radioactive particle size, and the biodistribution in normal rats. Ethics approval was obtained in advance of the study. **Results:** The resulting product contained 92±3% of ^68^Ga-colloidal particles and 8±3% of soluble ^68^Ga-Mg-Ca-phytate. Radioactive particle size distribution of the formulation was 6±4% \<20 nm, 90±6% 20 to 200 nm, and 4% were \>200 nm in diameter. The biodistribution of the ^68^Ga-colloid in rats resulted in 93% uptake by the liver plus spleen, 1% lungs, 1% total blood, and 6% in the carcass after 20 minutes. This optimal formulation remained stable at 5°C for 1½ hours in vitro, and it resulted in the same biodistribution as the formulation prepared at t = 0 hours. **Conclusion:** ^68^Ga-Mg-Ca-phytate colloid was successfully synthesised and characterised by different methods. The preclinical data so far indicate that is has excellent potential as a liver imaging agent.
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**Background/Aims:** \[^18^F\]FSPG has been proved to be a promising tracer for imaging xC^-^transporter (xCT^-^) and clinically applied in various oncological studies.\[[@ref52][@ref53][@ref54]\] In order to fulfil the clinical need of several studies in Taiwan, we have modified TracerLab F~xFDG~ module to automatically synthesize \[^18^F\]FSPG with GMP compliance and studied its whole-body biodistribution in mice using microPET before human studies are undertaken. **Methods:** Based on reported radiosynthesis method,\[[@ref54]\] the \[^18^F\]FSPG was automatically produced with a modified TracerLab F~xFDG~ module and its complete QC tests were carried out for qulaity confirmation. For animal study, male ICR mice (30-40 g) were injected with a bolus of about 300 μCi of \[^18^F\]FSPG. By using small-animal Argus PET/CT scanner, dynamic sinograms were produced and VOIs were defined on co-registrated PET/CT images. **Results:** The radiochemical yield of \[^18^F\]FSPG synthesized by this method was \~8% (EOS, n\>3) in a synthesis time of \~80 min from EOB. Both the chemical and radiochemical purity of \[^18^F\]FSPG were \>95% with a specific activity of 377±162 mCi/µmol. Whole-body microPET imaging in normal mice showed that the radioactivity in kidneys, pancreas and bladder increased with time suggesting \[^18^F\]FSPG was eliminated via the renal systems. **Conclusion:** With the modified Fx~FDG~ module, \[^18^F\]FSPG could be reliably produced for preclinical and clinical studies. After preclinical imaging validation studies, clinical study of \[^18^F\]FSPH for cancer patients is ongoing now at NTUH.
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**Background/Aims:** ^64^Cu-SARTATE is a promising radiopharmaceutical for PET imaging of neuroendocrine tumours, paediatric neuroblastoma, and meningioma. ^64^Cu-SARTATE is an analogue of octreotate, incorporating a chelator (MeCOSar) that has superior radiolabelling characteristics specifically for copper radioisotopes. Copper-64, with its longer half-life (12.7hr) relative to other PET radioisotopes, offers the ability to centrally manufacture radiopharmaceuticals and distribute drug product to multiple locations. The advantages of centralised manufacture are that manufacturing resources are controlled within one facility, leading to efficiencies in the costs of production and staff resources; and the clinical sites receive a ready-to-use drug product. This project aimed to establish centralised manufacture of ^64^Cu-SARTATE at MITRU-SAHMRI, for distribution within 24 hours of manufacture to interstate hospitals undertaking clinical trials on behalf of Clarity Pharmaceuticals. **Methods:** Clarity Pharmaceuticals developed the manufacturing and QC processes required for ^64^Cu-SARTATE. MITRU are an ideal site for centralised manufacture of ^64^Cu-SARTATE, having a TGA licenced facility that can supply radiopharmaceuticals Australia-wide; and who have a well-developed Cu-64 production program. Technology transfer and site validation (including full manufacture and full QC) were undertaken to establish that ^64^Cu-SARTATE could be produced to meet Clarity Pharmaceuticals final drug product specifications. Final drug product was supplied to multiple interstate hospitals. **Results:** Process validation (n=3) was successfully completed, with all drug product specifications met. The model for centralised manufacture and distribution to clinical sites for injection within 24 hours has been proven to be feasible. **Conclusion:** Centralised manufacture of ^64^Cu-SARTATE was established and validated at MITRU-SAHMRI, for supply of GMP-like, ready-to-use drug product to multiple sites. This centralised manufacture model will also be utilised to supply ^64^Cu-SARTATE within the United States. The model has advantages for clinical sites that wish to perform PET imaging with octreotate analogues, but who do not have access to a dedicated radiopharmaceutical production facility.

**Disclosure of Interest:** C Jeffery Conflict with: Clarity Pharmaceuticals; C Biggin Conflict with: Clarity Pharmaceuticals; M Harris Conflict with: Clarity Pharmaceuticals.
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**Background/Aims:** Synthesis of ^131^I-RGDyC-PAMAM and research if it can target to tumour cells and the effect of radiation inhibition *in vitro* and *in vivo* of the animal. **Methods:** The nano probe ^131^I-RGDyC-PAMAM was prepared. Observed the inhibitory effect of ^131^I-RGDyC-PAMAM on cells. Injecting ^131^I-RGDyC-PAMAM into a tumour-burdened mouse and imaging by SPECT at different timing after injection of drugs; After injection, analysis the distribution of different organs of radioactive drugs at different timing. Analyse the inhibit tumour growth *in vivo* and do weight analysis. **Results:** The nano probe ^131^I-RGDyC-PAMAM was prepared succesfully. ^131^I-labelled RGDyC-PAMAM rate at about 86%, ^131^I-RGDyC-PAMAM have good stability in different solution. Cell uptake and elution experiment: compare to free ^131^ I, ^131^I-RGDyC-PAMAM nano probe can combine with A549 cell specifically, and its stability is good. The cell inhibition and apoptosis in vitro experimental results show that the ^131^I-RGDyC-PAMAM has certain inhibitory effect on the A549 cells. Under the condition of high dose, ^131^I-RGDyC-PAMAM has certain effect on promoting apoptosis and destruction of A549. The zoological experimental shows: ^131^I-RGDyC-PAMAM in tumour local has a longer retention time. The biological study *in vivo* distribution shows in A549 tumour nude mice, the perturbation values of tumour is significantly higher than the normal organs. The treatment experiment shows, ^131^I-RGDyC-PAMAM treatment group was obviously inhibited tumour compared with the control group and with significant difference (p\<0.05). **Conclusion:** Can successfully get ^131^I-RGDyC-PAMAM. Subsequent cell *in vitro* experimental results showed that ^131^I-RGDyC-PAMAM on A549 cell has certain inhibitory effect of growth, promoting apoptosis destruction. ^131^I-RGDyC-PAMAM can be better gathered in a tumour-burdened mice tumour site. In subsequent tumour-burdened anti-tumour effect in mice showed ^131^I-RGDyC-PAMAM inhibit the growth of A549 tumour.

P186: Peptide Targeted Liposomes for the Treatment of Inflammatory Arthritis
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**Background/Aims:** Delivering drugs to inflamed joints remains a major therapeutic challenge which may be overcome by incorporating synovium targeting peptides in liposomes. The aims of this study were to determine the therapeutic efficacy of long circulating polyethylene glycol (PEG) liposomes coupled to targeting peptides (RGD or HAP-1) containing prednisolone or a therapeutic peptide. Liposomes were labelled with ^99m^TC to determine the bio-distribution and uptake in inflamed joints. **Methods:** Glutathione (GSH) loaded liposomes were prepared and labelled with ^99m^Tc-HMPAO-GSH for biodistribution studies. Targeting peptides (HAP-1 or RGD) were conjugated to the surface of liposomes to localise to the synovia. Prednisolone or peptide encapsulated liposomes were synthesised, sized and used to treat adjuvant induced arthritic joints in rats. Arthritis was induced with an injection of heat killed *Mycobacterium tuberculosis* suspended in 100μl of squalene, at the base of the tail of the individual rat. Rats were deemed to be arthritic when there was redness or swelling in the same joint(s), over two consecutive days. One day after the first sign of arthritis was noted, the therapeutic liposomes were administered by IVI on two consecutive days each injection containing 0.5 mg peptide or prednisolone/0.5 mL/250g rat/day. The parameters for measurements were determined by: affected joint numbers, overall joint swelling, weight loss and histological assessment of joints. **Results:** Imaging studies showed that ^99m^Tc-HMPAO liposomes accumulate in the joints of normal and arthritic rats. With this proof of evidence, therapeutic studies were commenced in a rat model with liposomes containing drugs. Prednisolone containing liposomes slowed the progression of arthritis, however arthritis flared once treatment ceased. Rats treated with HAP-1 targeted liposomes loaded with prednisolone slowed down the progression of arthritis while on treatment and led to the alleviation of arthritis over a 2 week period. By contrast rats administered therapeutic peptide liposomes conjugated with HAP-1 were fully treated of their arthritis and this was sustained until the experiment finished 2 weeks after the last treatment. **Conclusion:** ^99m^Tc-labelled liposomes can be engineered to target and carry a variety of drugs to inflamed synovium.
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**Background/Aims:** Recently, Tang et al reported the syntheses and PET studies using tumour model mice of ^11^C-labeled *S*-methyl-L-cysteine (LMCY) and its D-isomer (DMCY).\[[@ref55][@ref56]\] They concluded DMCY has more potential for tumour imaging than the L-isomer. Unnatural amino acids often have different transporter selectivity and metabolic pathways from natural ones. These properties result in unique characters as PET tracers therefore their radiolabelling is an attractive target for tracer development. In this context, we decided ^11^C-labelling of α-methyl analog of *S*-methyl-L-cysteine as a novel PET tracer because methyl group incorporation yields high metabolic stability for deamination and causes varied transporter recognition.\[[@ref57]\] Here we describe whole body distribution of ^11^C-labeled *S*-methyl-(*S*)-α-methylcystein (SMMCY) and comparison with LMCY in tumour-bearing mice. **Methods:** SMMCY and LMCY were synthesized by the methylation using \[^11^C\]methyl iodide and Hunig base at room temperature for 3 min. Tumour-bearing mice were prepared by subcutaneously inoculating small cell lung cancer SY cells. These mice were intravenously injected with each tracer and biodistribution at 1, 20, and 60 min was evaluated and 60-min PET imaging was conducted. Tracer uptake was semi-quantified as % injected dose (ID)/g tissue. All animal experiments described here have approval under local and ethical rules. **Results:** The ^11^C-labelling of (*S*)-α-methylcystein and L-cysteine gave SMMCY and LMCY respectively without significant amount of ^11^C-labeled byproducts. The biodistribution studies showed that distribution of SMMCY and LMCY was different and high accumulation was observed in the pancreas (66%ID/g) for SMMCY and the liver (21%ID/g) and pancreas (27%ID/g) for LMCY at 20 min. Tumour uptakes of SMMCY and LMCY increased time-dependently until 60 min and SMMCY uptake in tumour (11%ID/g) was higher than LMCY (7%ID/g) at 60 min. These results were confirmed by dynamic PET studies. **Conclusion:** SMMCY is a promising PET tracer for tumour imaging.

P188: New Theranostic Probe for Molecular Imaging and Radionuclide Therapy of Medullary Thyroid Cancer and other Cholecystokinin-2 Receptor Expressing Tumours
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**Background/Aims:** Thyroidectomy is the primary treatment of medullary thyroid carcinoma (MTC), whereas the use of vandetanib and cabozantinib is restricted to patients with advanced or progressive MTC. An urgent need of alternative imaging and treatment options exists for patients with persistent disease or recurrence. We present a new theranostic probe targeting the cholecystokinin-2 receptor (CCK2R) overexpressed in \>90% of MTC allowing for high sensitivity imaging and radionuclide therapy. **Methods:** Different minigastrin derivatives (MGS1-5) were synthesised and conjugated with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Radiolabelling was optimized for ^111^In, ^177^Lu and ^68^Ga in order to achieve quantitative yield and radiochemical purity \>91%. A thorough preclinical evaluation allowed the selection of one most promising peptide analogue. All animal studies were approved by the National authorities. A kit formulation was developed to allow a standardized preparation of the radiopharmaceutical in the clinical setting. **Results:** The peptide derivative DOTA-MGS5 showed the highest receptor affinity as determined using A431 cells transfected with human CCK2R and 28-68% cell uptake after 2 hour incubation when radiolabelled with different radiometals. HPLC analysis of the blood of BALB/c mice injected with ^111^In-DOTA-MGS5 revealed that \>69% of the radiopeptide remained intact up to 1 hour post injection (p. i.). An impressively high tumour uptake was found in xenografted BALC/c nude mice (^111^In: 23.5±1.2% 4 h p. i.; ^177^Lu: 24.5±3.1% 4 h p. i.; ^68^Ga: 23.2±4.7% 1 h p. i.), as well as high tumour-to-kidney ratios (^111^In: 6.1; ^177^Lu: 6.5; ^68^Ga: 4.1) and elevated target-to-background ratios in Nano-SPECT/CT. **Conclusion:** A new highly specific peptide analogue targeting CCK2R was developed for peptide receptor imaging and therapy. A first proof of concept of high sensitivity PET imaging in patients with advanced MTC is envisaged to pursue the clinical translation. This new theranostic concept promises to improve the patient follow-up and prognosis of patients with CCK2R expressing tumours.

P189: Development of H2-ATSM Labelling with Copper-64 on Modular-Lab PharmTracer
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**Background/Aims:** The Molecular Imaging and Therapy Research Unit (MITRU) at SAHMRI has successfully completed the development of copper-64 production process for the manufacture of \[^64^Cu\]Cu-SARTATE, a novel radiopharmaceutical agent of Clarity Pharmaceuticals Ltd. as part of a phase 1 clinical trial. Recently, there has been a renewed interest in the development of radiolabelled copper with diacetyl-bis (*N*^4^-methylthiosemicarbazone) (H~2~-ATSM) for hypoxia imaging.\[^64^Cu\]Cu-ATSM has a relatively low molecular weight, is highly lipophilic, and therefore has high membrane permeability -- all of which are desirable properties for rapid diffusion into cells. With a half-life of 12.7 hours, copper-64 is an ideal radioisotope for hypoxia imaging. Another advantage of such long lived radioisotope is the ability for the radiopharmaceutical agent to be manufactured in-house and delivered to multiple scanning facilities. The aim of this project is to expand on the synthetic utility of \[^64^Cu\]CuCl~2~, by labelling onto H~2~-ATSM on the Modular-Lab PharmTracer. **Methods:** The manufacture of \[^64^Cu\]CuCl~2~ begins with the plating of enriched nickel-64 onto an Pt beaker in an aluminium shuttle. The target was irradiated, the crude product was taken up in 6 M HCl solution, and then purified using an ion exchange resin (BioRad AG 1-X8). The purified product, \[^64^Cu\]CuCl~2~ was then reconstitute to the desired HCl concentration (0.05 M) and used for the manufacture of \[^64^Cu\]Cu-ATSM using Eckert & Ziegler's Modular-Lab PharmTracer synthesiser. **Results:** Initial results from the radiolabelling of \[^64^Cu\]CuCl~2~ onto H~2~-ATSM showed promising results, with a radiolabelling yield of 73% (n=6). RCP yields of \>99% across all samples were achieved with starting activity ranging between 110MBq to 1490MBq. **Conclusion:** The radiosynthesis of \[^64^Cu\]Cu-ATSM has been successfully demonstrated on the Modular-Lab PharmTracer. Future work will focus on the optimisation of the radiolabelling yield and radiosynthesis at higher starting activities.
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**Background/Aims:** The introduction of radiopharmaceuticals that contain urea based pharmacophores targeting PSMA has had widespread impact on prostate cancer research. We present the site validation, data trends and efficiencies of production of ^68^GaPSMA-11 and ^18^FPSMA-1007, for use in clinical research. **Methods:** ^68^GaPSMA-11 is manufactured (Scintomics GRP Synthesiser) using kits (ABX SC-01), PSMA-11 (GMP, ABX 9919.0000.010) and ^68^Ge/^68^Ga generators (iThemba 50 mCi, IGG100 50 mCi and/or 65 mCi). ^18^F-PSMA-1007 is manufactured (GE Tracerlab MX) using kits (ABX PEPS-0095-R/H including precursor) with F-18 generated on-site. Quality control testing of each batch aligns with monograph guidelines for related radiopharmaceuticals. Each batch is reviewed by the Quality Assurance Manager prior to release for use in clinical research programs. **Results:** ^68^Ga-PSMA-11 has been produced at Q-TRaCE for more than 3.5 years and a summary of data trending (\>800 batches) will be presented. Data analysis supports a reliable and robust process that yields high-quality, sterile injectables suitable for use in human trials. Process optimisation enabled the implementation of multiple generator inputs to increase the product activity, which translates to greater patient throughput per batch and/or improved transport logistics. Additional analytical testing (quantitative) was also adopted for the reaction buffer (HEPES), which is classified as an impurity if detected in the product formulation. This resulted in a V~max~ restriction applied to each batch to comply with monograph guidelines and ensure patient safety. The more recent implementation of ^18^F-PSMA-1007 offered efficiencies through use of a longer lived radioisotope and higher starting activities. Product yields are typically \>20% and further work to increase product activity is planned. **Conclusion:** Validation work undertaken at Q-TRaCE has resulted in the availability of ^68^Ga-PSMA-HBED-CC and ^18^F-PSMA-1007 for use in clinical research programs focused on improved diagnosis and management for prostate cancer patients. In particular, the availability of a cyclotron based PSMA radiopharmaceutical increases access to PET imaging, and potentially widens the patient recruitment catchment in research trials due to the logistics of supplying a longer lived radiopharmaceutical in a statewide network.
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**Background/Aims:** As the limitations of 2-deoxy-2-^18^F-fluoro-D-glucose (^18^F-FDG) imaging, e. g., high uptake of FDG in brain and in non-malignant, inflammatory cellular elements, amino acid metabolism positron emission tomography (PET) imaging is one important supplement for the clinical FDG application. In the present study, a novel N-^18^F-fluorodeoxyglycosyl amino acid (^18^F-FDGly-NHPhe), was synthesised. We also evaluated its characteristics as a potential tumour metabolism imaging agent. **Methods:** The (^18^F-FDGly-NHPhe) was prepared from directly condensation of ^18^F-FDG with L-4-aminophenylalanine in acidic condition, and purified with semi-preparative-high performance liquid chromatography (HPLC). The *in vitro* stability wds conducted in PBS (pH 6.5-9.18) at room temperature (RT) and in fetal bovine serum at 37 °C. The preliminary cellular uptake studies were tested in Hep-2 cell with comparison to that of ^18^F-FDG. To give an indication of the transport pathways, a competitive inhibition experiments was performed. The bio-distribution studies, PET imaging and metabolism studies were performed and compared with ^18^F-FDG on ICR mice. **Results:** The radiochemical yield of ^18^F-FDGly-NHPhe was 20.20±3.21% (n=10), with high stability in PBS at pH 6.5-9.18 and fetal bovine serum. The preliminary cellular study showed that the tracer could be transported via both glucose and amino acid transporters. The competitive inhibition experiment showed that ^18^F-FDGly-NH-Phe was primarily transported by Na^+^-dependent various systems including L, A, ASC systems, and not incorporated into proteins. The bio-distribution in normal ICR mice showed faster blood radioactivity clearance, lower brain and heart uptake rates than ^18^F-FDG. PET imaging of ^18^F-FDGly-NHPhe with excellent tumour visualization and high tumour to background ratios was achieved, while no accumulation of inflammatory lesions compared to ^18^F-FDG. Metabolism studies indicated the high *in vivo* stability in plasma and urine and the acid sensitive decomposition in tumour acid microenvironment. **Conclusion:** All the above results indicated that ^18^F-FDGly-NHPhe as a novel tumour-specific PET tracer mediated with two transporter systems shows the capability of differentiating tumour from inflammation, and has the potential of further routine clinical applications.
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**Background/Aims:** ^68^Ga-PSMA has been rapidly accepted as a major advance in imaging prostate cancer patients. The classic radiolabelling method for ^68^Ga-PSMA-11 requires a long preparation time, high level of expertise and relatively expensive infrastructure. This limits the clinical and commercial utility. A simple GMP kit based formulation has been developed by ANMI (Belgium). Stability studies have shown this kit to be stable for 18 months following manufacture. We present our experience in 103 patients at 2 separate Theranostic Australia sites with this novel kit based PSMA imaging solution. **Methods:** IRE ^68^Ge/^68^Ga generator eluted; mixed with buffer in PSMA-11 vial. Mixed at room temp. 5 min. Radiochemical purity (RCP) of ^68^Ga-PSMA-11 determined by ra-dio-TLC (stationary phase: iTLC-SG paper; stationary phase: NH4OAc 1M/MeOH 1:1 (v/v); Rf of free and colloidal ^68^Ga: 0-0.2; Rf of ^68^Ga-PSMA-11 = 0.8-1). Following QC, if RCP determined to be \>95% agent administered into patients. Imaging performed on GE PET camera 30-45 minutes after administration. Delayed imaging of up to 120 minutes performed in selected patients. Dose between 120-180 MBq. Image quality assessed by 2 experienced imaging specialists with local experience in reporting over 500 ^68^Ga-PSMA scans (HBED, I&T). **Results:** From August to November 2017, 43 kits and 103 patient doses prepared. Average RCP of 98%. RCP \< 90% reported on 4 occasions (due to incomplete transfer of buffer to reacting vial). Otherwise, incident-free, rapid, with minimal radiation exposure. Total production and QC time approx. 20 min, yielding 850-900 MBq product from new IRE ^68^Ge/^68^Ga generator. Patients experienced no adverse effects from tracer administration. All studies of diagnostic quality with typical PSMA biodistribution. Image quality determined to be at least equivalent to other ^68^Ga-PSMA agents. **Conclusion:** Our experience with PSMA-11 GMP sterile cold kit production in 103 patients confirms an easy, rapid and cost-effective solution for prostate carcinoma imaging. It displays excellent imaging characteristics and safety data appears equivalent to current agents. Given the robustness, simplicity and high yield of the kit, the technology is readily accepted by a range of personnel. The minimal set up costs and high yields makes this a potential viable option in regional/outer metropolitan areas as well as in high volume practices.

**Disclosure of Interest:** N. Lenzo Conflict with: Australian Distributor.

P195: Factors Impacting Synthesis Efficiency of Routine 2-Deoxy-2-\[18F\]fluoroglucose Production at Sir Charles Gairdner Hospital Over 2017
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**Background/Aims:** Sir Charles Gairdner Hospital in Perth houses the only cyclotron in WA for PET radiopharmaceutical production. As the sole local provider of ^18^F-FDG (2-Deoxy-2-\[18F\]fluoroglucose) for patients in the state, our site is motivated to seek greater efficiencies to continue to service ever-growing clinical demands. An overview of ^18^F-FDG production data was undertaken to identify which combination of practices may yield greater efficiency. **Methods:** For this study synthesis efficiency was taken as the ratio of EOS (end of synthesis) to EOB (end of bombardment) expressed as a percentage. The EOB was the activity of ^18^F measured in the lines from the cyclotron to the synthesis unit whilst the EOS was the activity of ^18^F-FDG to arrive in the dispensing unit directly after synthesis was completed. These values were not adjusted for decay. RAPID houses an IBA Cyclone 18/18 cyclotron installed in 2003 (upgraded in 2012), with both sources being proton beams. Available targets were IBA Conical 12, Conical 8, XXL and LV. There were three varieties of synthesis units in use-a GE Fastlab2, an IBA Synthera and two GE MX units of differing ages. A retrospective analysis of data from all successful routine production runs was analysed to determine which of the following factors lead to a favourable synthesis efficiency: ion source, target, target fill volume, bombardment time, synthesis unit, synthesis kit (Citrate single vs Citrate Duo on GE Fastlab2) and time since last service. Further determinants are ongoing. **Results:** The greatest determinant upon synthesis efficiency was the synthesis unit used. The GE Fastlab2 gave consistently higher synthesis efficiencies than the other units available. When using the GE Fastlab2, the duo kits showed a minor improvement over the single use. None of the other factors showed any significant effect. **Conclusion:** Our group will favour Fastlab2 duo kits for production of ^18^F-FDG in 2018.
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**Background/Aims:** Cell-based therapies are potentially transformative treatments. To support development of cell-based therapies, cell labelling agents that enable longitudinal in vivo tracking of administered cells are required. We report the first use of a radiolabelled peptide that adheres to extracellular membranes for cell tracking using SPECT imaging. **Methods:** A radiolabelled "cytotopic" peptide (CTP), ^111^In-DTPA-CTP, was prepared. This consists of (i) myristoyl groups for insertion into the phospholipid bilayer, (ii) positively-charged lysine residues for electrostatic association with negatively-charged phospholipid groups and (iii) a diethylenetriamine pentaacetate derivative that coordinates gamma-emitting ^111^In^3+^. In vitro cell uptake, retention and viability was assessed in 5T33 murine myeloma cells, and compared with that of clinically-used ^111^In-(oxine)~3~. In vivo SPECT/CT imaging of (i) ^111^In-DTPA-CTP-labelled 5T33 cells, (ii) cell-free ^111^In-DTPA-CTP, and (iii) ^111^In-(oxine)~3~-labelled 5T33 cells was undertaken (with institutional ethics approval) in a mouse model for which the biodistribution of these cells is well characterised (initial lung localisation). **Results:** In vitro, ^111^In-DTPA-CTP binds to 5T33 murine myeloma cells, but 77% of radioactivity is released after 2 h incubation (compared to release of 24% of radioactivity in the case of ^111^In-(oxine)~3~-labelled cells). Cells labelled with ^111^In-DTPA-CTP demonstrate higher viability than cells labelled with ^111^In-(oxine)~3~. In vivo SPECT/CT imaging demonstrates that although initial lung migration of ^111^In-DTPA-CTP-labelled 5T33 cells is observed, 5T33 cells release ^111^In-DTPA-CTP, resulting in high liver ^111^In accumulation 2 h post-injection. This contrasts the behaviour of ^111^In-(oxine)~3~-labelled cells, which demonstrate high lung retention 2 hours post-injection. **Conclusion:** ^111^In-DTPA-CTP enables qualitative SPECT tracking of myeloma cells' migration to lungs immediately after intravenous administration. Although ^111^In-DTPA-CTP dissociates from cell membranes rapidly and thus falls short of cell adhesion stability requirements for quantitative long-term cell tracking, this proof-of-principle study demonstrates the simplicity and feasibility of using synthetic cell membrane binding/penetrating peptides for radiolabelling cells.
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**Background/Aims:** ^131^I-sodium iodide (Na^131^I) is widely used for internal radiation therapy of patients with thyroid cancer. Na^131^I, however, has several limitations due to relative long range of β^-^particles resulting in a relapse eventually. ^211^At, an α particle emitter, is known as one of the promising nuclides for radiotherapy and behaves as a halogen similarly to iodine. While a crude product of Na^211^At dissolved in water often contains oxides of ^211^At. Aims of this study are to prepare Na^211^At aqueous solution in high radiochemical purity and to evaluate its biological properties in rats. **Methods:** ^211^At is produced by a ^209^Bi (α,2n)^211^At nuclear reaction and dissolved in water after dry distillation of ^211^At in a target material. To the ^211^At solution (5-20MBq/mL) ascorbic acid was added in a concentration of 1% under a weak basic condition (pH8-9), and the solution was stirred for 30min. The resulted solution was analysed by thin layer chromatography (G60; ACN/water/TFA=67/33/0.5). The solution was intraveously injected to rats (1MBq/rat). The rats were imaged by a SPECT camera at 30min, 3hr, 6hr and 24hr after the injection. The rats were sacrificed at the 24hr time point and organs (thyroids, lungs and others) were counted by a gamma counter. The protocol was approved by the Animal Care and Use Committee of the Osaka University Graduate School of Medicine. **Results:** The ^211^At aqueous solution treated with 1% ascorbic acid afforded Na^211^At in a high radiochemical purity (\>95%), although the radiochemical purity of the crude solution was low. The planer images and the biodistribution study revealed that the ^211^At aqueous solution treated with 1% ascorbic acid provided 3-5 times larger uptake in thyroids than the crude solution did. **Conclusion:** Ascorbiic acid can be used for the preparation of Na^211^At aqueous solution in the high radiochemical purity.

This work was supported by JSPS KAKENHI Grant number T16K102770.

P198: Towards the Development of Novel Fluorine-18 Agents as Alternatives to Ceretec for Neuroimaging
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**Background/Aims:** ^99m^Tc-HMPAO (Ceretec) is a SPECT imaging agent which is a small molecule technetium complex and is both neutral and lipophilic\[[@ref58]\] (logP of 1.9) enabling blood brain barrier permeability. We are interested in the development of novel fluorine-18 labelled compounds that have comparable properties to Ceretec, since these may be useful as PET neuroimaging agents. Synthesis of metal-fluorine complexes are of particular interest since recent studies have demonstrated the formation of stable metal-^18^F bonds.\[[@ref59][@ref60]\] The metal-^18^F complexes previously reported are hydrophilic and therefore the focus of this work is to develop lipophilic metal-fluoride moieties which can be incorporated into new radiopharmaceuticals for potential applications in neuroimaging. **Methods:** A series of substituted thiosemicarbazone gallium nitrate complexes have been synthesised.\[[@ref61][@ref62]\] We have investigated the exchange of the nitrate with ^19^F-fluoride and have characterised these fluoride complexes with NMR and X-ray crystallography. Lipophilicity of these fluoride complexes was assessed by measuring the octanol/water partition coefficient. The thiosemicarbazone gallium nitrate complexes have been reacted with ^18^F-fluoride and imaging studies of ^18^F-diphenylthiosemicarbazone gallium fluoride in mice were performed using preclinical PET/CT. **Results:** We have synthesised Ga-^18^F complexes of thiosemicarbazones from the corresponding nitrate derivatives. The resultant complexes are lipophilic and the measured logP of ^19^F-diphenylthiosemicarbazone gallium fluoride is 1. PET imaging studies in mice showed rapid uptake of the ^18^F-diphenylthiosemicarbazone gallium fluoride complex in the brain with an injected dose per gram of around 2 to 3%. **Conclusion:** We have synthesised the first lipophilic metal-fluorine-18 complexes, and these thiosemicarbazone gallium fluoride complexes are neutral. Lipophilicities of these compounds are comparable to Ceretec and imaging studies have demonstrated uptake in the brain, highlighting the potential of using ^18^F-thiosemicarbazone gallium fluoride compounds as radiopharmaceuticals for neuroimaging with PET.
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**Background/Aims:** Cu-67 (t~1/2~ = 2.6 days) decays via beta/gamma emission to stable Zn-67. The energy of the beta emissions (E~max~ = 561.7kev) is highly suitable as a therapeutic radionuclide, while the gamma emission (185keV) introduces the option for quantitative SPECT imaging of patients treated with Cu-67. We developed an improved process for producing high quality Cu-67 using an electron linear accelerator (e-LINAC) instead of a high energy proton accelerator. The beta/gamma emitting radionuclide Cu-67 was created using the (g, p) reaction on isotopically enriched Zn-68 (nominally 40g, 98% enrichment). **Methods:** The high energy photons were produced by Bremsstrahlung conversion of electrons from a 45 MeV e-LINAC. A specially designed water cooled converter, end station and target were built and utilized for the transmutation. An additional system was designed and constructed for remote removal of the activated target. Following transmutation, the Cu-67 was separated from the isotopically enriched Zn-68 target using a two-step process: physical separation using low pressure evaporation/sublimation (\<0.001 mbar, 600^o^C) and purification using anion exchange column chromatography (BIORAD ™ AG 1X8, 200 mesh). The specific activity and radionuclidic purity of the final product was determined using an ICP-MS and an HPGe detector. Cu-67 produced from the process was used to radiolabel SARTATE (Clarity Pharmaceuticals) with radiochemical purity \>95%, yield 75±10%. SARTATE utilizes the sarcophagine chelator, MECOSAR conjugated to octreotate, and has the potential to treat a range of diseases including neuroendocrine tumours, meningioma in adults and neuroblastoma in paediatrics. **Results:** Production yields are \>50 microCi (1.85MBq) g^-1.^kW^-1.^hr^-1^ with a Cu-67 specific activity routinely \>200 Ci (7.4TBq)/mg. **Conclusion:** High specific activity and high purity Cu-67 is being produced routinely, shipping to customers in USA and Australia on demand, and at lower cost than proton accelerator-produced isotope. Cu-67 has been used to successfully produce Cu-67 SARTATE for development for first-in-human clinical trials.

**Disclosure of Interest:** M Harris: Conflict with Clarity Pharmaceutical Ltd, C Jeffery: Conflict with Clarity Pharmaceutical Ltd, C Biggin: Conflict with Clarity Pharmaceutical Ltd.
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**Background/Aims:** The Molecular Science Cyclotron Facility (MSCF) of Liverpool Hospital recently commenced in-house manufacture of ^18^F-Fluorodeoxyglucose (FDG). A component of the method validation was a study aimed at optimising the HPLC conditions used during the QC and identifying peaks in the ECD (electrochemical detector) chromatogram not associated with the product. **Methods:** FDG was produced from \[^18^F\]F^-^ (GE PETtrace 880 cyclotron, 16.5 MeV protons, Huayi H~2~^18^O) by automated synthesis (GE FASTlab-2). Formulated product was sterilised by filtration, sampled for QC, and dispensed into multidose vials for distribution. HPLC analysis of the chemical and radiochemical purity was conducted using a Shimadzu Prominance HPLC on a Carbopac PA 10 (Dionex, 150 x 3.0mm, 6mm) column running 50mM NaOH as the mobile phase at 0.5mL/min. Chemical and radiochemical detection was achieved by EC (Antec Leyden Decade Elite) and scintillation (1' NaI, Flow-RAM LabLogic) detectors in series. Standards and other reference compounds were purchased from ABX, Sigma Aldrich and CarboSynth. Mannose triflate, citrate buffer, ethanol and acetonitrile were obtained from a used FASTlab cassette. All injections were 2 mL. Standards were 50 μg/mL, solvents 1000 μg/mL. **Results:** The results of the study revealed 50 mM NaOH gave a retention time of 11.7 min for FDG and a resolution of 2.6 for FDM/FDG. Glucose, 1,6-anhydroglucose and ethanol are identifiable in the FDG chromatogram. The glucose derivatives form by base-catalysed decomposition of unreacted mannose triflate and FTAG. Acetonitrile, kryptofix, water, citrate buffer, sodium triflate, sodium acetate, chlorodeoxyglucose, and isosaccharinic acid-1,4-lactone were injected and did not correspond to peaks in the FDG chromatogram. **Conclusion:** Using 50 mM NaOH as the mobile phase gave excellent FDG/FDM resolution and a run time of \<25 minutes. Ethanol, glucose and 1,6-anhydroglucose were identified components of FDG. Other compounds in the FDG chromatogram remain unidentified; however, they form during the base-catalysed hydrolysis of labelled intermediate/unreacted mannose triflate.
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**Background/Aims:** Zirconium-89 (^89^Zr) holds great promise as a radionuclide in novel radiotracers for immuno-positron emitting tomography (PET) imaging. This is due to the prolonged half-life of ^89^Zr (3.3 days), which allows sufficient time for a ^89^Zr-antibody agent to localise at target site of interest. However, there is a limited number of Zr (IV) chelators reported that could be ideally used for immuno-PET imaging. The only clinically proven ^89^Zr ligand is desferrioxamine B (DFOB). Despite successes with ^89^Zr-DFOB based PET radiopharmaceuticals, sub-optimal *in vivo* stability for clinical applications has been observed with skeletal uptake of liberated ^89^Zr. To this end, the aim of the project describes four chelators designed and synthesised to possess improve Zr^4+^ complex stability compared to DFOB. Each chelator retains the hydroxamate binding group as found in DFOB, however these chelators are structurally different to DFOB. **Methods:** The library consist of linear and macrocyclic hexadentate ligands and linear and macrocyclic octadentate ligands. All chelators were synthesised from the same starting monomeric subunit (7-(2-amino-*N*-hydroxyacetamido)heptanoic acid). The synthesis of the monomeric subunit follow adapted synthetic procedures as previously reported.^1^ Each chelator were synthesised using the monomeric subunit and following standard HATU peptide coupling protocols. The stability of the chelators were assessed by incubating each ^89^Zr-chelator with EDTA, serum and 1 mM ferric chloride in PBS buffer. **Results:** The synthesis of linear hexadentate chelator was achieved in 5% yield over 8 steps. The synthesis of linear octadentate chelator was achieved in 11% yield over 9 steps. Both chelators were confirmed by HPLC, MS and NMR. Preliminary results by radio-TLC have indicated both linear hexadentate and octadentate chelator had comparable ^89^Zr-complex stability profile to the gold standard DFOB. **Conclusion:** We have confirmed the feasibility of the proposed synthetic strategy. Current efforts are focused on macrocyclisation of both linear chelators and completion of radiochemical characterisation.
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**Background/Aims:** Currently, there are several accepted methods of radiochemical purity testing for ^99m^Tc-Sestamibi (Methoxyisobutyl Isonitrile). They commonly involve thin layer chromatography (TLC) using various stationary and mobile phases or solid phase extraction. The latter is more expensive, yet fast and convenient option utilised at Austin Health. Radiochemical purity is tested by separation of radioactive impurities such as free \[^99m^Tc\]-TcO~4~^-^, \[^99m^Tc\]-TcO~2~ from ^99m^Tc-Sestamibi. Sep-Pak alumina N cartridges are the stationary phase, and 100% (v/v) ethanol is used as the mobile phase. There is no available information validating the reuse of these Sep-pak cartridges and its expiry for ^99m^Tc-Sestamibi quality testing. **Methods:** A number of experiments were conducted to analyse the effectiveness of the cartridge in accurate separation of the impurities and ^99m^Technetium-Sestamibi at different time points of the cartridges lifetime. Additionally, \[^99m^Tc\]-TcO~4~^-^was added to some cartridges to evaluate its influence on radiochemical purity and whether 0.9% sodium chloride wash could help reduce any effects it may produce. TLC method of analysis involving Silica Gel strips and acetone were also used to compare against the cartridge method. **Results:** Cartridges up to three months old (which had at least once weekly use) compared to fresh cartridges showed a \~2% decrease in calculated radiochemical purity. Despite these differences, the results passed the radiochemical purity limit (\>90% ^99m^Tc-Sestamibi). **Conclusion:** Although there is a decrease in observed radiochemical purity, it does not pose harm to product quality and patient safety. There is the potential of yielding false negative results which are then retested with a new Sep-pak for confirmation. Recycling of cartridges is a viable method to reduce costs yet, still maintain integrity in product quality of ^99m^Tc-Sestamibi.
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**Background/Aims:** Recently the cyclotron production of alpha/beta emitting radionuclides has been attracting an increasing attention because of the progress in the field of Theranostics. In order to address this demand, Sumitomo Heavy Industries, Ltd. has developed a "Multi-Purpose" cyclotron named CYPRIS MP-30 that accelerates proton, deuteron and alpha particle beams for the production of a wide variety of radionuclides. In this work, some features of the CYPRIS MP-30 cyclotron system are presented. **Methods:** The cyclotron was designed for proton/deuteron beam formation with continuously variable energy by adjusting the stripper foil. The alpha particle beam is extracted through an electrostatic deflector at fixed energy. Irradiation energy of alpha particles is optimized using an energy degrader. The beam is transported to a vertical irradiation system that accommodates target materials in different forms and shapes. An automatic target transport system provides safe handling of the target after irradiation and a dissolution station located on the irradiation room allows the transfer of irradiated targets to the hot cell as a solution. **Results:** The system achieved the expected beam performance for proton (15-30 MeV; 100 uA), deuteron (8-15 MeV; 50 uA), and alpha particles (32 MeV; 30 uA). The production of several radionuclides, such as Zn-62, Tc-99m, Ge-68, Lu-177, and At-211 was also accomplished. **Conclusion:** A versatile cyclotron with a vertical irradiation system, target transport system, target dissolution system, as CYPRIS MP-30, was newly developed. The performance tests proved the system to be flexible and able to safely and efficiently produce alpha and beta emitting radionuclides. Development to increase the production yield of At-211 is currently undergoing. The CYPRIS MP-30 Cyclotron System will undoubtedly contribute to the development of new radionuclides for the targeted alpha therapy.

P204: High Tumour Accumulation and Rapid Background Clearance for Radio-theranostics by Using Liposomes Encapsulating Radionuclide-ligand Complexes
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**Background/Aims:** Radiolabelled liposomes are promising for tumour imaging and radionuclide therapy because of their capacity to accumulate in the tumours. However, conventional liposomes also accumulate non-specifically in the normal tissues, especially in the liver, hindering their clinical application. In this study, we devised a new strategy, i. e., to quickly expel radionuclides from the liver after accumulation through rapid urinary excretion, by combination of liposomes and unique radionuclide-ligand complexes. **Methods:** Liposomes encapsulating ^111^In-ethylenedicysteine (EC), ^111^In-NTA or ^111^In-DTPA were prepared using active loading methods. They were intravenously injected to sarcoma-180-bearing or FaDu-bearing mice and time-dependent biodistribution were evaluated. This study was approved by the Institutional Animal Care and Use Committee and carried out according to its regulation. **Results:** Striking time-dependent contrasts were observed in the biodistribution of novel ^111^In-EC-liposomes and conventional ^111^In-NTA-or ^111^In-DTPA-liposomes. While ^111^In-EC-liposomes were once taken up by the liver, radioactivity was subsequently cleared from the liver while maintaining good retention in the tumour. Urinary excretion of ^111^In was rapid, and the original complex structure of ^111^In-EC was kept intact in the urine. By contrast, large amount of ^111^In remained in the liver for a long time with ^111^In-NTA-liposomes and ^111^In-DTPA-liposomes. Subsequent HPLC analysis demonstrated that liposomes mostly remained intact in the tumour whereas they were well degraded in the liver. Liposomes that were broken in the liver should released encapsulated radionuclide-ligand complexes. ^111^In-EC had a unique character, in which it was able to escape from the liver and consequently be excreted in urine. The original complex structure of ^111^In-EC was found to keep intact in the urine.^111^In-EC liposomes successfully achieved both sufficient tumour accumulation and rapid BG clearance. *In vivo* SPECT/CT imaging also depicted it well. **Conclusion:** ^111^In-EC-liposomes achieved sufficient tumour accumulation and rapid background clearance, consequently radionuclides accumulated almost only in the tumour. Our concept is applicable to diagnostic and therapeutic radionuclides, such as ^111^In, ^90^Y, and ^177^Lu. These findings should become driving force targeting radionuclide therapy and radio-theranostics.

**Disclosure of Interest:** H Fujii Conflict with: Nihon Medi-Physics Co. Ltd.
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**Background/Aims:** To explore the effect of ^131^I therapy on ovarian function in female patients with differentiated thyroid carcinoma (DTC) of childbearing age. **Methods:** 71 women of childbearing age were chosed who were postoperative patients with thyroid cancer that were treated with ^131^I. Compared the changes of menstrual cycle before and after treatment. Compared the differences of FSH, LH, E~2~, AMH with normal level after therapy. **Results:** There were 3 patients had menstrual irregularities before therapy, and 34 women after therapy. The average age of patients who had menstrual irregularities were significantly higher than that had no menstrual irregularities (37.41±5.389 vs. 34.14±6.417 years, p=0.023). There was no significantly difference in the dose of the last treatment (3.7GBq and γ5.55GBq) and the median cumulative dose of ^131^I (7.4GBq vs. 3.7GBq) between women who experienced menstrual irregularities and did not after therapy. Patients with higher serum levels of FSH were more likely to have oligomenorrhea (p=0.004). In a period of 5 to 20 weeks after treatment, the serum levels of AMH were significantly lower than that before treatment (p\<0.05). **Conclusion:** ^131^I therapy of DTC may lead to a transient failure in ovarian function in women of childbearing age, and the damaging can be repaired by itself. There were not a significant relationship between the risk of ovarian dysfunction after ^131^I therapy of DTC and the cumulative dose, or dose of latest treatment, if the dose of ^131^I was 3.7 \~ 9.25GBq in a single therapy. Compared with FSH, LH and E~2~, AMH can be used to evaluate the ovarian function more accurately and early.
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**Background/Aims:** D-allose is a C-3 epimer of D-glucose with 80% of the sweetness of sucrose. D-allose is one of many rare sugars that exist in very small quantities in nature. This sugar has potential biological activities such as anti-inflammatory, anti-oxidative, and anti-proliferative activities against tumour cell growth. Because of growing interest in the biological properties of D-allose, two ^18^F-labeled analogues, 3-deoxy-3-\[^18^F\] fluoro-D-allose (3-\[^18^F\] FDA) and 6-deoxy-6-\[^18^F\] fluoro-D-allose (6-\[^18^F\] FDA), were synthesized as probes for bio-functional analysis. **Methods:** 1,2,4,6-tetra-*O*-acetyl-3-*O*-trifluoromethanesulfonyl-β-D-arabinose and 1,2,3,4-tetra-*O*-acetyl-6-*O*-trifluoromethanesulfonyl-β-D-arabinose were used as precursors for radiolabelling of 3-and 6-\[^18^F\] FDA, respectively. Automated radiosynthesis was performed by nucleophilic ^18^F-fluorination of each corresponding precursor with Kryptofix/K~2~CO~3~-activated \[^18^F\] fluoride ion, followed by acidic hydrolysis of the acetyl protecting groups. The reaction mixture was diluted with water and purified by passing through a series of solid-phase extraction cartridges. Preliminary biodistribution studies of 3-and 6-\[^18^F\] FDA in male ddY mice were performed. The Institutional Animal Care and Use Committee approved the animal studies. **Results:** The total synthesis times of both 3-and 6-\[^18^F\] FDA were within 45 minutes from the end of bombardment. The decay-corrected radiochemical yields based on \[^18^F\] fluoride at the end of synthesis of 3-and 6-\[^18^F\] FDA were 35% and 33%, respectively, with \>98% radiochemical purity. Biodistribution studies showed high blood levels of radioactivity of both tracers. The brain uptake of 3-\[^18^F\] FDA peaked at 30 min after injection and gradually decreased thereafter. In contrast, 6-\[^18^F\] FDA did not show any significant uptake into the brain. No significant uptake in the bone was found, indicating the absence of de-fluorination in mice. **Conclusion:** 3-and 6-\[^18^F\] FDA were successfully synthesized with an automated synthesizer. 3-\[^18^F\] FDA, but not 6-\[^18^F\] FDA, showed significant uptake into the brain.
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**Background/Aims:** 4-\[^18^F\] FDEX is a new radioligand for positron emission tomography (PET) imaging of muscarinic acetylcholine receptors (mAChR) particularly M1 subtype. This radioligand is promising diagnostic agent for cognitive dysfunction in schizophrenia. Our department has developed and optimised the HPLC quality control method to evaluate the in-house radiosynthesis of 4-\[^18^F\] FDEX for human clinical trial. **Methods:** Phenomenex Luna 5µm C18 75 x 4.6mm column with 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) at a flow rate of 0.5 mL/min with a gradient from 5% (B) to 90% (B) in 16 minutes. Shimadzu HPLC system with FlowRam radioactive detector was used for UV absorbance and radioactive detection. LabSolution software from Shimadzu was used for analysis. FDEX, flurobenzaldehyde (precursor 1) and nordexetimide (precursor 2) reference were prepared to determine the separation efficacy of our HPLC method. Serial dilution of each was also performed to determine the minimum detectable concentration and establishing standard a curve for specific activity calculation. **Results:** Baseline separation was achieved with retention times of flurobenzaldehyde, FDEX and nordexetimide were approximately 7, 11 and 14 minutes respectively. Standard curve of FDEX yielded a r^2^ value of 1 with a minimum detectable limit of 1 µg/mL. **Conclusion:** We have developed a robust HPLC method to evaluate the in-house production of 4-\[^18^F\] FDEX for human trial.
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**Background/Aim:** Recent studies have demonstrated the high sensitivity of positron emission tomography (PET) imaging with ^68^Ga-labeled octreotide derivatives for the detection and staging of neuroendocrine tumours. A somatostatin receptor ligand that is easily radiolabelled with ^18^F-fluoride could improve the availability of PET imaging of neuroendocrine tumours. However, their laborious, multistep radiosynthesis represents a major obstacle to their clinical translation. Thus, we investigated a one-step, one-pot approach for preparing the radiolabelled analogue, Al^18^F-NOTA-PEG~6~-TATE, and examined its utility in a murine model. **Methods:** NOTA-TATE was radiofluorinated via an Al^18^F intermediate based on two reaction solutions, sodium acetate buffer (pH 4) and acetonitrile, to synthesize Al^18^F-NOTA-PEG~6~-TATE. After the tracer was purified using a C18 column, its specific cell binding and retention properties were analysed in U87MG cells. The tumour targeting efficacy and *in vivo* profile of Al^18^F-NOTA-PEG~6~-TATE were evaluated in a subcutaneous U87MG glioblastoma xenograft model through biodistribution and micro PET analyses. **Results:** Al^18^F-NOTA-PEG~6~-TATE was successfully prepared within 60 minutes, with a decay-corrected yield of 70-100% using the sodium acetate buffer and 64-74% using acetonitrile. Al^18^F-NOTA-PEG~6~-TATE is highly hydrophilic and stable in plasma with rapid, cellular uptake and efflux. High tumour uptake was also observed along with rapid urinary system clearance. However, high uptake of Al^18^F-NOTA-PEG~6~-TATE was also observed in the bone and could not be blocked with an excess of unlabelled precursor, which is suggestive of *in vivo* defluorination of the probe. **Conclusion:** Al^18^F-NOTA-PEG~6~-TATE may represent a potential PET tracer candidate for monitoring neuroendocrine neoplasm. Its favourable *in vivo* performance and easy production warrant further optimisation of this probe as well as a radiofluorination strategy to accelerate the clinical translation of ^18^F-labeled somatostatin analogues.
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**Background/Aims:** This study is planned to see the hypothyroid effects on renal function using GFR value as a marker of renal function., and camera based GFR assessment. **Methods:** Total of 58 patients were involved in this study. Out of 58 patients, 53 patients were had thyroid carcinoma, in whom hypothyroidism was due to discontinuation of thyroxine (51 patients) or injection of rTSH (2 patients). The remaining 5 hypothyroid patients were post-radioactive iodine for hyperthyroidism. Renal function tests (urea/creatinine) and serum electrolytes followed by ^99m^Tc-DTPA renal scan for GFR assessment (GATES' method) were carried out in all subjects twice during the study-one study during hypothyroid state (TSH \> 30mIu/ml), and the other during euthyroid state (TSH between 0.4 to 4 iU/ml). In addition, renal function was assessed with creatinine clearance in those subjects who showed raised creatinine values in either of study (hypothyroid or euthyroid state). **Results:** The results of student's t-test showed significant difference in renal functions. In case of creatinine, the paired t-test revealed a mean of 1.014±0.428, with standard error of 0.669, for creatinine clearance the mean was 80.11±14.12 with standard error of 1.94, for urea the mean was 28±12.13 with standard error of 1.607 and for GFR of individual kidneys is 38.056±8.56 with standard error of 1.3717. **Conclusion:** Hypothryoidism, irrespective of the cause, impairs renal function to a significant level and hence needs to be prevented and corrected as early as possible.
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**Background/Aims:** The aim of this study was to find out predictive factors of postoperative ^99m^Tc-DTPA scan for predicting rejection of renal transplantation within 3 months. **Methods:** Total of 45 patients who underwent early postoperative renal scan within 8 days after transplantation were enrolled retrospectively. Rejection group was determined by renal biopsy which was done within 3 months after transplantation. Normal group was determined either by renal biopsy which was done within 3 months or by level of serum creatinine which was maintained as normal (\<1.5 mg/dL) during the 1 year of follow-up. Variables from renal scan were GFR, Hilson perfusion index, time to peak and peak to 1/2 peak. Other clinical variables of age, sex, height and weight at the timing of renal scan were also analysed. P\<0.05 was considered as significant. **Results:** GFR and scaled GFR were significantly different between groups. Less than 44.48 ml/min of GFR at postoperative renal scan could predict rejection within 3 months (sensitivity 88.9%, specificity 64.7%, AUC 0.724, p=0.0067). Less than 39.05 of scaled GFR can predict it (sensitivity 77.8%, specificity 81.2%. AUC 0.76, p=0.0045). There is no significant difference between AUCs. However, other factors were not different between groups. **Conclusion:** Lower GFR or scaled GFR of baseline renal scan could predict rejection within 3 months.

P212: Impact of Method used for Tumour Bed Closure (Standard Sutures versus Tissue Adhesive) on the Functional Renal Volume Preservation Following Nephron Sparing Surgery: Assessment by Quantitative SPECT of
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**Background/Aims:** NSS is now considered as the preferable treatment for most patients with organ-confined renal cancer. Such approach provides excellent cancer control comparable to that obtained after radical nephrectomy with the advantage of renal function preservation. The aim of our study was to compare the degree of functional renal tissue preservation after lesion removal between patients where the tumour bed was closed with absorbable sutures rather than closed with biologic Glue for the same purpose. **Methods:** Sixty-nine adults (30 women and 39 men), mean age 60.33 years (range 29-85 years) with enhancing solid renal mass who underwent NSS at our institution were included in the study. Patients were divided into 2 groups, group 1 (43 patients): tumour bed was closed with absorbable sutures, group 2 (26 patients): tumour bed was closed with biologic glue. Baseline patient characteristics were similar for both groups. QDMSA before and 3--6 months after surgery was used for evaluation differences in renal function volume preservation of each kidney. Statistical calculations of the functional volume were done with SPSS v. 20. Ethic approval was granted from Bnai Zion Helsinki committee. **Results:** Comparison of QDMSA before and after surgery demonstrated a decrease in the functional renal volume of 11.67±15.83% in group 1 and a decrease of 3.99±15.85% in group 2 (p=0.49). QDMSA in the non-operated contralateral kidney shown a decrease of 1.61±10.87% in group 1 and 4.65±3.66% in group 2. **Conclusion:** The utilization of biologic glue rather than sutures in NSS allows a better volume preservation of a functional kidney tissue after lesion removal.

P214: Description of GFR and Diuretic Renogram in Obstructive Uropathy Cases in Nuclear Medicine and Molecular Imaging Department RSUP Hasan Sadikin 2012--2016
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**Background/Aims:** It is well known that obstructive uropathy (OU) can cause acute renal failure and chronic renal failure (CRF). Beside renal function, obstruction degree should be known for OU treatment. Therefore, it is necessary to perform GFR and diuretic renography on OU cases. The aim of this study was to describe the GFR and diuretic renogram results of OU cases in RSUP Hasan Sadikin Bandung in 2012-2016. **Methods:** This study was a descriptive retrospective analysis. Data was taken from medical records of adult OU cases undergoing diuretic renography and GFR examinations which were performed simultaneously about 30 minutes using the ^99m^Tc-DTPA and gamma camera. Gates method was used to quantify GFR value. Based on GFR value, cases were divided into 15-30 ml/minute and \>30 ml/minute groups. While based on obstruction degree (response to furosemide), cases were divided into responsive (declining of the excretion slope), partial (slightly declining of excretion slope) and unresponsive (continuously rising curve) groups. **Results:** There were 53 OU cases \[38 (72%) male; 15 (28%) female\], with age ranging between 18-77 years old. Bilateral OU was observed in 17/53 cases. Cases of GFR 15-30 ml/min was observed in 36/81 (45%) and GFR \> 30 ml/min in 45/81 (55.5%). Responsive, partial, and unresponsive to frusemide were observed in 3/81 (3.7%), 66/81 (81.48%) and 12/81 (14.80%) respectively. All responsive cases had renal GFR value of \> 30 ml/min. In partial group, 29/66 (43.9%) cases had GFR value of 15-30 ml/min, the remaining 37/66 (56.1%) cases had GFR value of \> 30 ml/min. While in unresponsive group, 7/12 (58.3%) cases had GFR of 15-30 ml/min and the remaining 5/12 (41.7%) cases had GFR of \> 30 ml/min. **Conclusion:** Similar number was observed between OU cases with GFR value of the affected kidney \>30 ml/min and 15-30 ml/min. Most cases showed excretion phases that slightly declining with frusemide intervention. The appearance of diuretic renogram (F+15) of the kidney with OU apparently related to the value of GFR.

P215: Glomerular Filtration Rate in Cases of Chronic Renal Disease and Its Role in Determining the Need of Renal Transplantation
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Dr. Hasan Sadikin General Hospital, Bandung, Indonesia

**Background/Aims:** Kidney transplant can be performed in RSUP Dr. Hasan Sadikin. Glomerular filtration rate (GFR) study is not only important for determining the stage of chronic renal disease (CKD), but also for the need of kidney transplant. Kidney transplantation is required when GFR \< 15 ml\\min (CKD stage 5) and recommended in adulthood. The aim of this study was to know the profile GFR value in cases of CKD and the number of CKD cases that require renal transplant. **Methods:** Descriptive retrospective research based on medical records of CKD patients undergoing GFR in 2012-2016. ^99m^Tc-DTPA dynamic imaging was performed for 7 minutes using a gamma camera. The GFR value was determined based on the calculation of Gates. Data were analysed based on CKD groupings according to GFR: stage 1: \>90ml/min, stage 2: 60-89ml/min, stage 3: 30-59ml/min, stage 4:15-29 ml/min, and stage 5: \<15 ml/min. **Results:** There were 3062 GFR studies from 2012-2016 (2116 men and 946 women). Average age of patients was 50 years old. The number of patients in stage 1, 2, 3, 4 and 5 were 190 (6%), 248 (8%), 667 (23%), 658 (21%), and 1299 (42%) respectively. The number of patients that was referred for kidney transplants based on CKD staging and age (18-65 years) was 1061 (34.6%). **Conclusion:** Most CKD patients in this study had GFR value \<15 ml/min (CKD stage 5). In the period of 2012-2016 there were 34.6% patients eligible for kidney transplant based on GFR result and age.
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**Background/Aims:** In February 2017, an eleven year old boy with autism was referred for radioiodine therapy post total thyroidectomy for papillary thyroid carcinoma. Routine treatment requires the child to swallow a capsule containing radioiodine and remain isolated (usually 48 to 72 hours) until the level of radioactivity satisfies discharge guidelines. The Women's and Children's Hospital in Adelaide has a purpose built, child-friendly therapy room. From the first consultation, it was clear that the complex needs of this patient would make isolation a challenge. The child co-slept with his mother, was not responsible for his own personal hygiene including aspects of toileting and exhibited social and behavioural issues due in part to autism. His parents demonstrated apprehension to progress his independence and were concerned that he would not be able to comply with restrictions. **Methods:** Options for successful management during treatment were considered and explored including extended general anaesthesia, restraint, medication, behavioural therapy and treatment at home. Each option held its own risks and challenges. During this time, diagnostic imaging demonstrated metastatic spread and the need to fast track treatment. Treating the patient as soon as possible without sedation was pursued with regular, frequent contact between the child's parents, clinical psychologist, play therapist and nuclear medicine personnel for counselling and behaviour modification; familiarisation of the child with the staff and procedures including trial visits, capsule swallowing and admission; and identifying the child's tolerances and preferences. **Results:** Following extensive collaboration with a multidisciplinary team and the patient's family, the patient was successfully treated with radioiodine therapy in October 2017. Radiation exposure to the family, staff and general public was lower than expected. **Conclusion:** Utilising the expertise of a diverse group of professionals, a complex paediatric patient was successfully isolated and treated with radioiodine therapy, despite overwhelming obstacles.
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**Background/Aims:** Germline succinate dehydrogenase (SDHX) mutation carriers, especially SDHB, are at increased malignancy risk and require life-long surveillance. Current guidelines recommend biennial whole body MRI\[[@ref65][@ref66]\] but several series have documented superior lesion sensitivity with GaTate PET/CT.\[[@ref67][@ref68][@ref69]\] We assessed the incremental value of GaTate PET/CT compared to MRI or CT in such patients. **Methods:** Twenty consecutive patients (median 46 years, 10 males) were retrospectively reviewed. Detection of number of lesions on restaging/surveillance GaTate PET/CT were compared to MRI/CT, and management changes were assessed. Proof of lesions were based on histopathology or clinical/imaging follow-up. **Results:** Fourteen patients had SDHB, 4 SDHD, 1 SDHC and 1 SDHA mutation, median age at diagnosis 30 years. Two had no known lesions, 2 organ of Zukerkandl primary, 2 pheochromocytoma, 14 with PGL (3 abdominal, 2 pelvic and 9 head and neck). Fourteen patients had prior surgery ± radiotherapy. Nine were imaged for surveillance without known disease, 9 with known disease, and 2 for raised catecholamines. Median time from PET/CT to MRI/CT was 1.5 months (MRI contraindicated/not performed in 2 patients). GaTate PET/CT correctly identified more lesions in 10 of 18 patients (56%), and correctly clarified negative disease in 1 of 3 patients with equivocal MRI/CT (no follow-up is yet available for the 2 other cases). No false-positive avid lesions identified. Change of management resulted in 8/20 patients (40%): 3 identified with limited disease had localised treatment, 1 changed to observation due to extra disease detected, and 4 with metastatic disease had peptide receptor radionuclide therapy. **Conclusion:** Incremental diagnostic information from GaTate PET/CT compared to conventional anatomical imaging was frequently observed with consequent management impact in SDHX-PPGL. We suggest incorporation of this modality and alternating GaTate with MRI on an annual or biennial basis to minimise life-time radiation exposure while ensuring more accurate long-term follow-up of such patients.

P218: Normal Brain Metabolism on Fluoro-D-Glucose Positron Emission Tomography--Magnetic Resonance Imaging during Childhood and Adolescence
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**Background/Aims:** To investigate the normal patterns of brain metabolism determined by FDG PET/MRI during childhood and adolescence. **Methods:** A retrospective analysis was performed on all paediatric patients who underwent FDG PET/MRI at The Royal Children's Hospital, Melbourne, Australia between March 2016 and August 2017. Exclusion criteria were proven or suspected neurological disease, central nervous system metastases, previous chemotherapy/radiotherapy, general anaesthesia/sedation and medications suspected to affect cerebral metabolism. SUV~mean~ and SUV~max~ were calculated for 12 brain gray matter regions on the left and right sides. Subgroup analysis of childhood (≤10 years old) and adolescence (≥ 11 years old) was also performed. **Results:** From 492 FDG PET/MRI scans, a total of 28 patients (11 children and 17 adolescents) met the inclusion criteria and were deemed representative of normal brain metabolism. Both SUV~mean~ and SUV~max~ increased with age in all brain regions. The highest rates of increasing SUV~mean~ were demonstrated in the thalamus, basal ganglia, frontal lobes, insula and occipital lobes. Higher SUV~mean~ was demonstrated in the right frontal lobe, right lateral temporal lobe, right temporal pole, right cingulate/paracingulate, right thalamus, left occipital lobe, left basal ganglia, left insula and left cerebellum compared to the contralateral side. This left/right asymmetry in SUV~mean~ was present in both childhood and adolescence in the majority of regions. The highest rates of increasing SUV~max~ with age were demonstrated in the occipital lobes, frontal lobes, thalamus and central region. There was no left/right asymmetry in SUV~max~ in the majority of regions. **Conclusion:** This FDG PET/MRI study demonstrates that normal brain metabolism measured by SUV~mean~ and SUV~max~ increases with age in all brain regions, proceeding at different rates between distinct anatomical sites. Our results suggest there is mild asymmetry in SUV~mean~ but mostly symmetric SUV~max~ during normal development.

P219: Correlation of Clinical Outcome with Stimulated Cholescintigraphy Results in Patients with Suspected Chronic Acalculous Cholecystitis Using a Standardised Ensure Plus Fatty Meal Protocol
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**Background/Aims:** To correlate clinical outcome with stimulated cholescintigraphy results in patients with suspected chronic acalculous cholecystitis using a standardised Ensure Plus fatty meal protocol. **Methods:** A retrospective study was performed on patients referred to our institution for evaluation of suspected chronic acalculous cholecystitis between March 2013 and November 2016. All patients with gallbladder visualisation 60 minutes after administration of Tc-99m DISIDA underwent fatty meal stimulation using 240 mL of Ensure Plus. A gallbladder ejection fraction (GBEF) of \< 33% was considered abnormal. Clinical outcome was determined using a gallbladder symptom questionnaire. Follow-up was performed a minimum of 3 months after scanning or 3 months after surgery in patients treated with cholecystectomy. **Results:** A total 101 patients consented to participate in the study. Median follow-up time was 27 months (range 9 -- 48 months). Of the 101 patients, 29 (29%) had an abnormal GBEF, 70 (69%) had a normal GBEF and 2 (2%) had no gallbladder visualisation on initial imaging. Of the 29 patients with an abnormal GBEF, 19 (66%) underwent cholecystectomy and 10 (34%) received conservative management. Overall improvement in symptoms occurred in 18/19 (95%) patients with abnormal GBEF who underwent a cholecystectomy and in 5/10 (50%) patients with abnormal GBEF who were managed conservatively (p=0.01). Of the 2 patients with no evidence of gallbladder visualisation, both underwent cholecystectomy with subsequent overall improvement in symptoms. **Conclusion:** Stimulated cholescintigraphy using the Ensure Plus fatty meal protocol is a useful technique to predict good surgical outcome in patients with suspected chronic acalculous cholecystitis.

P220: Investigating Suitable Voxel Size for Patients of Varying Body Mass Index to Enhance Image Quality of Positron Emission Tomography and Computed Tomography Images
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**Background/Aims:** PET emission reconstructions are routinely performed at 4mm for clinical whole body studies. At Austin Health, an additional 2mm reconstruction is generated for patients with head & neck cancer, a Body Mass Index (BMI) \<23, or on request by the Consultant. The reconstruction server does not allow for two concurrent reconstructions, therefore reconstructing a 2mm image for each patient increases the computational burden on the server causing a backlog and inefficient workflow. The aim of this study was to compare the contrast resolution and image quality of the 4mm and 2mm whole body PET reconstructions for patients in different BMI categories and to determine which is best suited for each category. **Methods:** BMI categories were set to \<25, 25.1--30 and \>30. Ten oncology patients were selected for each of these categories. The PET emission data was reconstructed for all patients as a standard 4mm reconstruction and additionally as 2mm reconstruction with varying relaxation parameters. The reconstructions for each patient were visually analysed by two senior Consultants, who were blinded by the BMI of the patient, and a decision was made to which reconstruction was best suited. **Results:** Analysis of image datasets revealed that image contrast was enhanced whilst not compromising image quality when reconstructed as a 2mm voxel for all patients. The 2mm reconstruction with a relaxation parameter of 5 was the preferred reconstruction for patients with a BMI \>25, where a relaxation parameter of 3 was preferred for a BMI \<25. **Conclusion:** Enhanced contrast resolution can be achieved when reconstructing image data to a 2mm voxel with an appropriate relaxation parameter for all patients, regardless of their BMI. Hence, lesion detectability may also be increased as a result of enhanced contrast resolution. Performing one preferential reconstruction per patient reduces computational burden on the reconstruction server and optimises workflow.

P221: Lung Conundrum: A Case Study
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**Background/Aims:** A 15 year old male presented to the Lady Cilento Children's Hospital with known Ebstein's anomaly, complicated surgical history, acute pleuritic chest pain and elevated D-dimer. This poster aims to highlight a rare congenital condition and the modified Ventilation/Perfusion (V/Q) lung scan performed to exclude pulmonary embolism after an inconclusive Computed Tomography Pulmonary Angiogram (CTPA) and Computed Tomography Coronary Angiogram (CTCA) due to atypical cardiovascular anatomy. **Methods:** A protocol was determined using knowledge of the patient's anatomy; the patient's weight was obtained and procedure explained. Ventilation was performed using ^99m^Tc-Diethylenetriaminepentaacic Acid (DTPA) via cadema and Single Positron Emission Computed Tomography (SPECT) and statics were acquired. A half dose ^99m^Tc-Macro Aggregated Albumin (MAA) injection was given via left arm cannula and the first perfusion SPECT and statics were acquired. A second half dose ^99m^Tc-MAA injection was given via left foot cannula and the perfusion SPECT and statics were repeated. Quantitative analysis was performed to determine differential blood flow. Ethics approval and patient consent were obtained to publish a case study poster. **Results:** Ventilation images showed a defect aligning with known right lower lobe atelectasis, bilateral pleural effusions and an enlarged cardiac silhouette. Images following injection into the left arm showed no left lung perfusion. Images flowing injection into the left foot showed perfusion to the left lung, with minimal increase in the right lung. There were no segmental perfusion defects in either lung. Quantitative analysis demonstrated preferential perfusion of the right lung from blood returning via the superior vena cava, and relatively symmetric perfusion to both lungs from blood returning via the inferior vena cava. **Conclusion:** Performing modified V/Q scans to exclude pulmonary embolism in patients with atypical cardiovascular anatomy could significantly reduce duplication of inconclusive exams, anxiety, cost to patients and the healthcare system and radiation exposure while maintaining image quality.

P222: Assessment of Background Parenchymal Uptake on Molecular Breast Imaging in an Australian Population with Mammographically Dense Breast Tissue
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**Background/Aims:** Molecular Breast Imaging (MBI) is a novel technique employing dual Cadmium Zinc Telluride (CZT) direct conversion detectors, providing high resolution functional imaging of the breast. MBI was developed in response to the requirement for an effective supplemental screening technique in women with mammographically dense breast tissue who are at increased risk of developing breast cancer. Mammography has reduced sensitivity in dense breasts. MBI has shown to be highly sensitive and specific for the detection of breast cancer independent of breast density. Varying levels of Background Parenchymal Uptake (BPU) have been depicted on MBI studies overseas.\[[@ref70][@ref71][@ref72][@ref73][@ref74]\] BPU is assessed as one of four categories: Photopenic, Minimal to Mild, Mild to Moderate or Marked. Mild to Moderate and Marked BPU has been associated with an increased incidence of breast cancer, suggesting it could serve as a functional imaging biomarker. The aim of this study is to assess levels of BPU on MBI in an Australian dense breast population and potentially use this data to identify a subgroup with a higher risk of developing breast cancer. **Methods:** MBI was performed for supplemental screening in the standard projections of Craniocaudal and Mediolateral Oblique after intravenous injection of 240-280MBq of ^99m^Tc-Sestamibi. BPU was assessed by two readers using a visual analogue 4-point scale. **Results:** Preliminary results show that MBI depicts Minimal to Mild BPU in the majority of cases. Correlation between the two readers was high suggesting good inter-observer reproducibility. **Conclusion:** In an Australian dense breast population, Molecular Breast Imaging demonstrated Minimal to Mild Background Parenchymal Uptake in most patients, placing this group at reduced risk of developing breast cancer compared to those with higher levels of BPU. We anticipate that BPU on MBI may serve as a risk stratification tool to identify women at increased risk, enabling closer monitoring in this group to aid early detection.

**Disclosure of Interest:** R. Harrup Conflict with: Owner of MBI system.

P223: Selective Mitogen Activated Protein Kinase Pathway Inhibition in Radioiodine Refractory Differentiated Thyroid Cancer: A Single Center Experience
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Department of Cancer Imaging, University of Melbourne, Melbourne, Australia
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**Background/Aims:** Some patients with advanced differentiated thyroid cancer (DTC) lack iodine avidity and are therefore unsuitable for radioactive iodine (RAI), the most effective treatment of DTC. Limited experience in the literature suggests selective mitogen activated protein kinase (MAPK) pathway inhibitors can restore expression of the sodium--iodide symporter, hence rendering patients amenable to RAI treatment.\[[@ref75][@ref76]\] **Methods:** Patients at Peter MacCallum Cancer Center who were treated with a MAPK kinase inhibitor for redifferentiation of metastatic DTC were reviewed retrospectively. Selection criteria mandated mutation testing, imaging and biochemical progression despite treatment with RAI within the past twelve months or metastatic disease that had never been RAI-avid. The patients with NRAS mutation were treated with the MEK-inhibitor Trametinib (2mg daily), and BRAF-V600E mutation with combined Trametinib (2mg daily)/and BRAF-inhibitor Dabrafenib (150mg twice-daily) for four weeks. Concurrently the patients underwent withdrawal of thyroid hormone replacement except one patient whom received recombinant human thyroid stimulating hormone, due to underlying comorbidities. Restoration of RAI uptake and administered activity of RAI was based on two time-point ^124^I PET/CT imaging. Imaging and biochemical response were assessed at three months post RAI. **Results:** From 2015 to 2017, four patients (age range 46 to 70, three female) received redifferentiation therapy. Three patients had NRAS mutations (two with Follicular TC (FTC) and a poorly differentiated (PDTC) component, one with PDTC), and one patient had BRAF V600E mutation papillary TC (PTC). Two of four patients demonstrated satisfactory restoration of RAI uptake and proceeded to RAI (150-250mCi). One patient with NRAS mutation demonstrated partial imaging response (RECIST 1.1) with 60% reduction in thyroglobulin at three months which was durable at two-year follow-up. The patient with BRAF mutation showed stable imaging and 38% reduction in thyroglobulin at three months. Two patients developed grade 3 acneiform rash without satisfactory restoration of RAI avidity, and were subsequently managed with ongoing tyrosine kinase inhibitors. **Conclusion:** MAPK pathway inhibition is a promising strategy to re-differentiate RAI refractory DTC in a sub-set of patients, including FTC.

P224: The Optimal Imaging Time for Imaging Cardiac Amyloidosis - Single-Photon Emission Computed Tomography-Computed Tomography Analysis
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**Background/Aims:** ^99m^Tc-diphosphonate Imaging for cardiac amyloidosis is generally performed at 1 or 3 hours post injection but the optimal imaging time remains unclear. SPECT images at 1 and 3 hours have been acquired in a group of clinical patients and analysed for comparison to clarify this issue. **Methods:** Sixty-five patients were referred for detection of suspected/possible cardiac amyloidosis. Depending on referral urgency the patients were scanned with ^99m^Tc-DPD (technetium-3,3-diphosphono-1,2-propanodicarboxylic acid) (56/65) after SAS approval or with ^99m^Tc-PYP (technetium-pyrophosphate) (9/65) if the referrer requested (as requested by the referrer). As part of our imaging protocol chest SPECT/CT (Siemens Symbia T6) was acquired at 1 hour and for comparison a SPECT at 3 hours. A IDL (RSI Systems) program was developed to segment the patients CT scans to provide bone, lung, liver heart and fat volumes of interest. Uptake within these regions were compared to a reference region on the aortic arch for the 1 and 3 hour SPECT images which were corrected for attenuation and scatter. **Results:** Myocardial uptake greater than blood pool was identified on 1 and 3 hour SPECT for 28/65 patients which is typical of transthyretin related (TTR) cardiac amyloidosis. Tissue samples were available for 25/28 myocardial positive patients and all demonstrated cardiac amyloid deposition (4 TTR, 20 TTR subtypes, 1 amyloid light chains). Uptake was generally stable in cardiac (29/65) and liver (32/65) however increases (Cardiac 17/65, Liver 13/65) and decreases (Cardiac 19/65, Liver 19/65) between time points of more than 5% were demonstrated. Accumulation of tracer in lung (50/65), bone (55/65) and fat (46/65) was identified. **Conclusion:** Changes in uptake indicate that early and delayed imaging focused on the heart and liver will both be required. Bone, lung and fat uptake is less variable and only delayed imaging of these areas will be necessary. Imaging protocol can be adjusted given these findings.
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: P001: Cerebral Glucose Metabolic Alteration by Forniceal Deep Brain Stimulation in Severe Alzheimer's Disease: A Case Report
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**Background/Aims:** The lack of effective therapeutic approaches against Alzheimer's Disease (AD) makes it one of the leading ten death causes worldwide. While FDA-approved medications including cholinesterase inhibitors have limitations in altering the disease course of AD dementia, deep brain stimulation (DBS) has recently shown promising treatment effect as an alternative treatment for AD. Previous forniceal DBS (f-DBS) studies focused on mild to moderate AD dementia, showing this surgical technique could benefit the patients as demonstrated by neuropsychological scaling as well as by ^18^F-fluorodeoxyglucose positron emission tomography ^18^F-FDG PET. However, whether f-DBS could also benefit severe AD patients has not yet been validated. **Methods:** We performed an f-DBS exploration on one severe AD patient and conducted followed-ups with both neuropsychological tests and ^18^F-FDG PET scans. **Results:** Only ADL score decreased (from 65 points) to 47 points, indicating the quality of the patient's daily living improved distinctly. Meanwhile, MMSE, MoCA-B, CDR and GDS remained unchanged, suggesting that no distinct improvement of the patient's cognitive function was observed. Follow-up ^18^F-FDG PET scan demonstrated increased glucose metabolism in the classical AD-related brain regions. **Conclusion:** The recovery of ADL scores occurred along with the recovery of hypometabolism in multiple cerebral cortical regions responsible for different cognitive functions.
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**Background/Aims:** The Centiloid scale was developed to allow the expression of Aβ burden in the brain as assessed by different PET tracers in a single universal scale. We have previously validated the PET-only quantification method CapAIBL (milxcloud.csiro.au) for Centiloid quantification using the Centiloid Level-1 ^11^C-PiB data. In this study, we extended the use of CapAIBL for the Centiloid transformation of F-18 tracers, namely ^18^F-NAV4694 (NAV) and ^18^F-florbetaben (FBB). **Methods:** The 34 young controls (YC) and 45 Alzheimer's disease (AD) patients PiB PET calibration scans from the Centiloid level-1 study were used to calibrate CapAIBL against the prescribed Centiloid SPM pipeline. Additionally, 991 PiB PET scans and their matching MRI from the AIBL study were used to refine the regression against the SPM pipeline. Ten YC and 47 elderly participant that underwent PiB, NAV and MRI, and another 10 YC and 24 elderly participants, that underwent PiB, FBB and MRI from Centiloid Level-2 studies, were quantified using CapAIBL and SPM. For both SPM and CapAIBL, NAV and FBB SUVR were then converted into a PiB-like SUVR using linear regression. The resulting SUVR were converted into Centiloids using the equation obtained with the Centiloid Level-1 PiB images. A linear regression between standard SPM-Centiloids and CapAIBL-generated Centiloids allowed the final transformation of CapAIBL-generated Centiloids into Centiloids. **Results:** The correlation between SPM and CapAIBL PiB-like NAV SUVR was very high (R2=0.99, sum of square of the residuals (SSr)=0.11). The same results were found for the corresponding PiB SUVR. The correlation between SPM and CapAIBL PiB-like FBB was also very high (R2=0.99, SSr=0.13), and so it was for the corresponding PiB SUVR (R2=0.99, SSr=0.06). The difference between SPM and CapAIBL derived Centiloids was not significant for either tracer. **Conclusion:** Robust and reliable Centiloid estimates can be obtained for PiB, NAV and FBB using the PET-only CapAIBL method. SPM and CapAIBL showed good agreement for both F-18 tracers (R2=0.99) and had low SSr. The PET-only CapAIBL validation using other F-18 tracers (^18^F-flutemetamol and ^18^F-florbetapir) is currently underway.

P003: MilxCloud: A Web-Based Platform for Positron Emission Tomography and Magnetic Resonance Quantification
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**Background/Aims:** Visual reading of PET and MR images is part of the standard of care for supporting the diagnosis of neurodegenerative diseases. Visual reading can however be subjective, and with MR images, is typically limited to the identification of gross changes in the mesial temporal lobe and ventricles in AD, or the in the frontal lobe for FTD. When reading Aβ PET images, separating negative from positive subjects can also be challenging, especially when different tracers are used. We introduce MilxCloud, a publicly available cloud computing platform for PET (CapAIBL: Computational Analysis of PET from AIBL) and MR quantification (CurAIBL: Computational qUantification of mRi from AIBL). These tools facilitate visual inspection with quantitative values, z-score maps, and normative graphs in relation to a reference population. **Methods:** CapAIBL is a PET-only method tool that allows quantification of FDG and all Aβ PET tracers without the need of a corresponding MRI. Results are presented in terms of SUVr and Centiloid. CurAIBL implements a pipeline that segments and parcellates brain MR images. Cortical GM and hippocampal volumes are reported on a graph with confidence intervals for an aged-matched normal population. Computed z-score maps of cortical thickness are displayed over a normalised template. Both tools provide key quantitative values, graphs and mesh rendering on a pdf report which is emailed to the user at the end of the procedure. **Results:** CapAIBL showed great accuracy, with errors less than 5% compared to MR-based quantification. CurAIBL was evaluated on the AIBL database, and showed similar results to that of FreeSurfer. **Conclusion:** CurAIBL provides an efficient clinical inspection and quantitative tool for MR imaging and complements PET assessments (such as FDG or Aβ PET) with CapAIBL, offering a comprehensive neuroimaging tool for the assessment of Alzheimer's disease and other neurodegenerative conditions. Both tools are available at milxcloud.csiro.au.
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**Background/Aims:** In vivo tau imaging with PET is a promising new modality that offers a unique insight into Alzheimer's disease (AD) pathology. ^18^F-AV1451 is a tau tracer currently being evaluated in both AIBL and ADNI. While MR-based quantification remains the gold standard, there is great interest in PET-only quantification techniques. We evaluate 3 PET-only methods and compare them to MR-based quantification in both AIBL and ADNI. **Methods:** ^18^F-AV1451 and MR images from AIBL (N=94) and ADNI (N=87) were used. The pons was used for SUVR normalisation. Global SUVR was defined as the mean of the 3 ROIs from the MeTeR scale (Mesial-temporal (Me), Temporoparietal (Te) and Rest of neocortex (R)). Global SUVR was measured using MR images and 3 PET-only methods: spatial normalisation to a mean PET atlas; adaptive PET atlas based on the linear combination of a negative and positive atlases (based on the 75^th^ percentile of the global SUVR); PCA-based adaptive atlas. The ADNI dataset was used to build the atlases/PCA models and test them (in a leave one out fashion), while the AIBL dataset was used as an independent test dataset. **Results:** The 3 approaches produced comparable results in both cohorts, with an average quantification error close to 2% (was 2.9% in PiB). Therefore, the simpler mean atlas approach appears to be sufficient, although the PCA approach might be closer to MR quantification in the Me. Looking at the PCA decomposition, it is interesting to note that hippocampus uptake is mostly driven by spill over from the choroid plexus (CP). The CP is prominently represented in the mean image, and in the 3rd mode (5% of the variability). Uptake in the CP is therefore fairly consistent across the population, and variations in its uptake are independent from tracer retention in the Me. While not significant, there was a trend association between increasing CP uptake and increasing age in both AIBL (p=0.10) and ADNI (p=0.25) cohorts. **Conclusion:** Results show that all quantification performed using PET-only normalization approaches did equally well, with an average quantification error around 2% in both cohorts. Partial volume correction might however be required to account for spill over.

P005: The Impact of APOE ε4 Carriage and Gender on the Age of Onset of Amyloid Deposition
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**Background/Aims:** Knowledge of the onset and the rate of neocortical Aβ-amyloid deposition is paramount to elucidating disease mechanisms and optimising the timing of therapeutics. Reports have suggested that APOE ε4 carriage may alter the metabolism, onset, or accumulation of neocortical Aβ-amyloid and that this may be further modulated by gender. This study evaluates the impact of APOE ε4 carriage, gender and their interaction on neocortical Aβ-amyloid deposition and its age of onset. **Methods:** Cox proportional hazards models of survival and Kaplan-Meier plots were employed to determine the age at which 317 AIBL participants reached abnormal levels on Aβ deposition (SUVR≥1.4). Further analyses elucidated the effects that gender and APOE ε4 carriage had on the age of onset. **Results:** Findings indicate the natural history of neocortical Aβ-amyloid deposition was similar between APOE e4 carriers and non-carriers, however a shift was observed showing higher Aβ-amyloid levels 15 years earlier in APOE e4 carriers. In APOE e4 carriers, the threshold of Aβ-amyloid abnormality was reached at age 62 in comparison to non-carriers at age 77. No differences were observed in the natural history of Aβ-amyloid deposition for gender, either in its own right or in interaction with APOE e4. **Conclusion:** Understanding genetic and potential sex-based differences in the pathogenesis of Alzheimer's disease, are essential for informing clinical trials to provide the best chance of success in delaying and preventing this debilitating disease.

P006: Tau, Aβ-Amyloid, and Cognitive Function Following Service-Related Traumatic Brain Injury in Vietnam War Veterans
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**Background/Aims:** Often labelled the "signature wound" of modern day warfare, Traumatic Brain Injury (TBI) has been diagnosed in over 355,000 US military service personnel since 2000. Epidemiological research indicates that veterans with TBI are 2-4 times more likely to develop dementia than controls; however, mechanisms contributing to this relationship are poorly understood. The aim of this study was to investigate if Vietnam war veterans without mild cognitive impairment or dementia, but with TBI show evidence of Alzheimer's disease (AD) pathological markers, as assessed by Aβ-amyloid, tau and glucose metabolism using PET, alongside neuropsychological testing. **Methods:** Fifty-five male participants-29 veterans with TBI (aged 68.1±2.25 years) and 24 veteran controls (aged 69.6±5.29 years)-underwent neuropsychological assessment, FDG, tau (^18^F-AV1451) and Aβ-amyloid PET (^18^F-Florbetaben) scans. Standardized Uptake Value Ratios (SUVR) for all PET tracers were calculated using the cerebellar cortex as reference region. Analyses were adjusted for scores on the Geriatric Depression Scale and Clinician-Administered PTSD Scale. **Results:** The TBI group performed significantly worse than controls on a number of measures across cognitive domains: WMS Logical Memory I & II (10.24±3.78 vs. 14.33±3.91, p\<0.001; 8.48±3.90 vs. 11.63±4.89, p=0.01), MoCA (25.59±2.24 vs. 28.12±1.85, p\<0.001) and MMSE (27.76±1.70 vs. 28.67±0.96, p=0.02). However, the TBI cohort did not differ significantly from controls in ^18^F-AV1451 (1.17±0.09 vs. 1.15±0.08, p=0.29), ^18^F-Florbetaben (1.34±0.20 vs. 1.27±0.20, p=0.23), nor FDG tracer retention (1.08±0.09 vs. 1.08±0.07, p=0.95). **Conclusion:** These preliminary findings suggest that whilst TBI is associated with later-life cognitive deficits, these deficits are not associated with AD pathology. Further study is needed to confirm our observations and to determine if direct brain injury can be detected to explain these later life deficits.

P007: Pathological Correlates of
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F-THK5351 Positron Emission Tomography in Tauopathies
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**Background/Aims:** Human blocking studies using selegiline have shown that ^18^F-THK5351 PET signal contribute the binding to monoamine oxidase B (MAO-B). The aim of study was to validate ^18^F-THK5351 PET signal in autopsy-confirmed cases of tauopathies such as Alzheimer's disease (AD) and progressive supranuclear palsy (PSP). **Methods:** We performed postmortem examination of brain samples from autopsy-confirmed an AD case and two PSP cases who underwent ^18^F-THK5351 PET before death. Case 1 was clinically diagnosed as AD. Case 2 and 3 were clinically diagnosed as Richardson syndrome (PSP-RS) and progressive non-fluent aphasia (PNFA), respectively. *In vitro* autoradiography of ^3^H-THK5351 was performed using frozen brain sections. We quantitatively measured tau pathology, amyloid-β, MAO-B, and GFAP in autopsy brain tissues and examined the correlation between ^18^F-THK5351 retention and each substrate. This study was approved by the Ethics Committee of the Tohoku University Hospital. **Results:** ^18^F-THK5351 PET showed prominent tracer retention in the inferior temporal lobe as well as hippocampus in AD, while significant ^18^F-THK5351 retention was observed in the globus pallidus and midbrain in case 2 (PSP-RS). In case 3 (PNFA), additional ^18^F-THK5351 retention was observed in the temporal cortex. In *in vitro* autoradiography, the specific THK5351 binding was detected in the area of antemortem ^18^F-THK5351 retention, and the binding was substantially reduced by MAO-B inhibitor lazabemide. THK5351 binding to PHF-tau was also detectable in the brain samples from AD case, while the binding was completely displaced in the brain samples from PSP cases. Regional ^18^F-THK5351 SUVR in ante-mortem PET image was significantly correlated with the density of reactive astrocytes as well as tau pathology at postmortem examination. **Conclusion:** ^18^F-THK5351 PET signals reflect MAO-B expressing reactive astrocytes associated with tau accumulation in tauopathies.

**Disclosure of Interest:** S Furumoto Conflict with: GE Healthcare and CLINO Ltd; Y Kudo Conflict with: GE Healthcare and CLINO Ltd; N Okamura Conflict with: GE Healthcare and CLINO Ltd.

P008: Global Tau Burden Correlates with Basal Forebrain Atrophy in Healthy Aging Subjects

Hearn

N

1

Doré

Vincent

2

3

Fripp

J

2

Grothe

M

4

5

6

Teipel

S

4

6

7

Williams

S

3

Masters

C L

8

Rowe

C C

3

9

Coulson

E

1

Villemagne

V L

3

9

University of Queensland, Brisbane, Australia

The Australian Health Research Centre, CSIRO, Brisbane, Australia

Austin Health, Melbourne,

The Florey institute of Neuroscience and Mental Health, Brisbane, Australia

The University of Melbourne, Melbourne, Australia

German Center for Neurodegeneration Diseases (DZNE), Rostock, Germany

University Medicine Rostock, Rostock, Germany

University of Rostock, Rostock, Germany

Department of Psychosomatic Medicine, University Medicine Rostock, Rostock, Germany

**Background/Aims:** Alzheimer's Disease (AD) is characterised by the presence of certain pathological hallmarks: extracellular Aβ-amyloid (Aβ) plaques, intracellular neurofibrillary tangles (NFT) of tau, and associated neurodegeneration of the cortex, hippocampus and basal forebrain. In this study, we investigated if the presence of high tau global retention in cognitively normal elderly controls (NC) was associated with early signs of neurodegeneration. **Methods:** Fifty-four cognitively normal subjects from the AIBL cohort underwent a MRI and two PET scans. Aβ-amyloid imaging was undertaken through ^18^F-flutemetamol or ^18^F-florbetapir and tau imaging was acquired with ^18^F-THK5351 or ^18^F-AV1451. PET scans were normalized using CapAIBL. For each tau tracer, a threshold was obtained as the 75^th^ percentile of the normal controls, resulting in a ^18^F-THK5351 SUVR~Pons~ threshold of 0.926 and a ^18^F-AV1451 SUVR~Pons~ threshold of 1.33. The basal forebrain volumes were estimated on the MRI using SPM and were corrected for intra-cranial volume and age. **Results:** From the population of 54 NC, 17 (32%) had a high global tau (tau+). There were no significant differences in age, sex or education between tau+ and tau-subjects. Tau+ NC subjects had a significantly smaller posterior basal forebrain volume (mean volumes: tau-0.0887cm3, tau+ 0.0838cm3, p\<0.05). **Conclusion:** These findings are consistent with previous imaging studies in MCI and AD populations showing associations between basal forebrain, Aβ-amyloid and tau markers, and with post-mortem histological data and suggest that before cognitive impairment is evident, neurodegenerative changes in the basal forebrain associated with tau accumulation have already occurred.

P010: Validation of mGluR5 as a Imaging Biomarker for Alzheimer's Disease
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**Background/Aims:** Glutamate is the major excitatory neurotransmitter in central nervous system and it regulates learning and memory. Previous studies demonstrated that Aβ oligomers (Aβo) directly impose deleterious effects on glutamatergic neurotransmission, particularly on the metabotropic glutamate receptor type 5 (mGluR5). Dysregulation of mGluR5 by Aβo synaptic toxicity is known to be related with the early symptom of cognitive dysfunction in Alzheimer's disease (AD). The purpose of this research is to validate the potential of mGluR5 as a biomarker for AD by means of positron emission tomography. **Methods:** Four male 5xFAD transgenic mice as a rodent model of Alzheimer's disease and same number of wild type mice as age-matched controls. The mice were anesthetized with 2.5% isoflurane in oxygen and ^18^F-FPEB was intravenously administered. Simultaneously PET scan was performed for 90 minutes in list mode. Volumes of interests (VOIs) are hippocampus, striatum, and cerebellum. **Results:** Brain PET imaging revealed that radioactivity in the mGluR5 rich regions such as hippocampus and striatum showed 18-21% lower uptakes in the 5xFAD group compared with control group. Also, non-displaceable binding values based on the cerebellum for 5xFAD were 22-25% lower than those for control group. **Conclusion:** mGluR5 levels in 5xFAD mice were down regulated in the limbic system. From this perspective, mGluR5 is considered as an effective imaging biomarker for AD.

P011: Assessment of Severity of Alzheimer's Disease by Application of Easy Z-Score Imaging Systems in Brain Single-Photon Emission Computed Tomography Study-Initial Experience in Bangladesh
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**Background/Aims:** Decreased regional cerebral blood flow (rCBF) in posterior cingulate gyri, precunei and parietal lobe on brain perfusion SPECT images had long been a qualitative identifier of Alzheimer disease (AD). Aim of this study was to apply easy Z-score imaging system (e-ZIS) on brain SPECT images for quantitative evaluation of perfusion deficit severity in patients with clinically suspected AD and find out association of Z-score with clinical mini mental state examination (MMSE) scoring. **Methods:** Patients were divided into two groups on the basis of MMSE score (group A= 20 or higher, group B = less than 20). All patients were underwent brain SPECT study from February to July 2017 with dual head SPECT camera with IV Tc-99m ethyl cysteinate dimer (ECD). For the quantification of perfusion deficit, e-ZIS version 3 \\was used. **Results:** Brain SPECT was performed on 20 patients (six female) with clinically suspected AD with mean age of 60.6±9 years (range 45-77) and mean duration since clinical onset of 10.7±5.3 months (range 6-24). Mean MMSE and mean severity scores were 23.2±0.63 and 0.99±0.40 in group A (n=10) while 17.7±0.95 and 2.82±0.45 in group B (n=10), respectively. Categorically on the basis of e ZIS scoring, five patients were normal (Z score 0-1), six had slightly decreased perfusion (Z score 1-2), six had moderate disease (Z score 2-3) and three had significantly decreased perfusion (Z score \>3). There was strong negative correlation between MMSE and e ZIS score (r = 0.96, paired sample t = 21.10, p=0.000, 95%CI 16.7-20.4). **Conclusion:** Quantification of perfusion deficit with a ZIS score correlated well with clinical MMSE scoring in this study group. This was the first time application of e ZIS in brain perfusion SPECT imaging in Bangladesh.

P012: Posterior Cortical Atrophy Variant of Alzheimer's Disease Presenting As Homonymous Hemianopia: An Unusual Presentation of a Rare Disease Variant Diagnosed by Hexamethylpropyleneamine Oxime Cerebral Perfusion Single-Photon Emission Computed Tomography Imaging
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**Background/Aims:** An 81 year old female complained of impaired vision and was found to have a right homonymous hemianopia (HH) by an ophthalmologist. There were no hallucinations or reported cognitive function concerns, although on closer examination she had great difficulty completing clock face drawing and scored 13/30 on Montreal Cognitive Assessment. Brain CT, MRI and MRA showed no cause for right HH. She was referred for a HMPAO (hexamethylpropyleneamine oxime) cerebral perfusion scan to investigate the possibility of a neurodegenerative or neuroinfective process. **Methods:** Cerebral perfusion SPECT images were acquired one hour post administration of 1Gbq ^99m^Tc-HMPAO over 24 minutes on a GE Discovery 670 camera with fan beam collimators. Images were iteratively reconstructed with Chang attenuation correction and statistical analysis was performed using Neurostat. **Results:** Large, moderately severe perfusion defects were demonstrated in the associative parietal cortices extending into the temporo-occipital cortices bilaterally, with involvement of the primary visual cortices bilaterally (worse on the left), and the precuneus/posterior cingulate cortices bilaterally. The scan findings were consistent with the posterior cortical atrophy (PCA) variant of Alzheimer's disease (AD), with involvement of the left primary visual cortex in keeping with right HH. Neuropsychological assessment subsequently demonstrated significant impairment in multiple domains, worse in visual processing, suggestive of PCA variant of AD, in keeping with the HMPAO scan findings. Aricept was commenced with good effect as part of the AD management plan. **Conclusion:** PCA is a rare, progressive neurodegenerative disorder in which the predominant symptoms are higher visual cognitive dysfunction.\[[@ref77]\] HH has been rarely described in this syndrome^1^ and this case is especially unusual because this patient presented with a visual field defect rather than cognitive impairment. The HMPAO scan was especially helpful in making the diagnosis of PCA variant of AD and led to early appropriate management with beneficial treatment.

P013: Cerebrovascular Pathology in Alzheimer's Disease: Findings From the Australian Imaging, Biomarkers and Lifestyle study of Aging
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**Background/Aims:** Cerebrovascular disease often coexists with Alzheimer's disease (AD), likely having a synergistic effect on cognitive decline.\[[@ref78]\] However, it remains unclear how cerebrovascular pathology contributes to dementia. This study investigates the relationship of Aβ-amyloid deposition and cerebrovascular pathology in the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort. **Methods:** 311 AIBL participants (aged 60-89, F/M: 151/160) with both PET and MR imaging were involved in the study and included 50 AD patients, 56 patients with mild cognitive impairment (MCI) and 205 healthy controls (HC). Neocortical Aβ-amyloid deposition was quantified from PiB-PET images using CapAIBL,\[[@ref79]\] where SUVR ≥ 1.4 indicated the presence of Aβ-amyloid pathology. Cerebrovascular pathology was assessed on 3D FLAIR images in terms of brain infarction screened by a neurologist and WMH that were automatically segmented using HIST.\[[@ref80]\] Periventricular and deep WMH were classified based on the distance from and confluence with ventricles. The presence of cerebrovascular pathology was defined as subjects with a brain infarct and/or WMH over 0.71% of the total intracranial volume, which was estimated from non-demented AIBL participants aged over 70 as the threshold of the top tertile.\[[@ref81]\] **Results:** No significant correlation was observed between Aβ-amyloid load and WMH in either HC, MCI or AD group. The same findings were obtained for periventricular and deep WMH. Moreover, logistic regression analysis, controlling for age, sex, education, APOE ε4 and clinical diagnosis, showed that the presence of Aβ-amyloid pathology was not significantly associated with the WMH burden or brain infarction. Similarly, there was no statistically significant association observed between the neocortical SUVR and the presence of cerebrovascular pathology, after correction for the mentioned factors. **Conclusion:** Our study provided cross-sectional evidence suggesting an independence of the association between amyloid deposition and cerebrovascular pathology. To confirm these findings, future longitudinal studies are needed.
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F-FEONM as a Novel Tau Protein Imaging Agent in the Streptozotocin-Induced Alzheimer's Disease-Like Model
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**Background/Aims:** Tau protein is a microtubule-associated protein which abundant in the neurons. The abnormal aggregation of tau protein could be found in some neurodegenerative disorders, such as Alzheimer's disease (AD). Under pathological situations, tau protein is hyperphosphorylation and aggregated in the neurons, which resulted in paired helical filaments and neurofibrillary tangles. Tau protein aggregation is a progressively process, no obvious clinical symptom in the early onset of neurodegenerative diseases, is difficult to diagnosis. The positron emission tomography (PET) provided functional images and important evidence for early detection of tauopathies and diagnosis. ^18^F-FEONM, a novel PET radioligand basing on ^18^F-FDDNP structural modification, expected to noninvasively detect abnormal aggregation of tau protein in brain. In this study, we validated the feasible and sensitivity of ^18^F-FEONM as a tau protein imaging agent in the streptozotocin intracerebralventricular (STZ-icv)-induced AD-like rat model. **Methods:** The ^18^F-FEONM was synthesised and analysed the purification of product by HPLC. The 8-week-old rats were grouped into sham and STZ-icv groups. The STZ-icv rat received STZ (3 mg/kg in citrate buffer) injection in the lateral ventricles. The radial arm maze (RAM) test and ^18^F-FEONM/small animal-PET were performed to evaluate the learning memory and the phosphorylated tau protein. The images were analysis and presented by standardized uptake values (SUVs). All animal experimental studies have approval from Institutional Animal Care and Use Committee (IACUC), National Defense Medical Center. **Results:** At 4 weeks after the STZ-icv, the STZ-icv rat showed the impairment of memory in RAM test. The time-activity curve of ^18^F-FEONM in normal and STZ-icv rat were analysed from dynamic imaging. The SUVs of ^18^F-FEONM in STZ-icv rat were higher than those of sham rat. **Conclusion:** The results of this study will assistance to estimate the validity and sensitivity of ^18^F-FEONM as a tau protein imaging agent. These results will be important for future clinical applications.
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**Background/Aims:** Fibrillary tau aggregates in tauopathies including Alzheimer's disease (AD) and allied neurodegenerative disorders have been visualized *in-vivo* by positron emission tomography (PET), while mechanistic links between PET-detectable tau deposits and neurotoxicity remain elusive. Here, we took advantage of transgenic mouse models of tauopathies to evaluate associations between PET and postmortem measures of tau probe binding and their relation to neuronal loss. **Methods:** PET with a tau probe, ^11^C-PBB3, and volumetric magnetic resonance imaging (MRI) were performed for rTg4510 and non-transgenic mice. Binding of ^11^C-PBB3 and its blockade by another tau binding compound, AV-1451 (also known as T807), in homogenized brains of tauopathy patients (AD and progressive supranuclear palsy (PSP)) and rTg4510 and PS19 mice were quantified, and PBB3-positive and phosphorylated tau lesions in sectioned brains of these mice were assessed. **Results:** *In-vivo* ^11^C-PBB3 binding to the rTg4510 forebrain was increased relative to controls, and was correlated with local atrophy. *In-vitro* ^11^C-PBB3 binding in the forebrain was also well correlated with *in-vivo* radioligand binding and regional atrophy in the same individual rTg4510 mice. By contrast, *in-vitro* ^11^C-PBB3 binding was elevated in the brainstem but not hippocampus of PS19 mice, despite a pronounced loss of neurons in the hippocampus rather than brainstem. Finally, PBB3 and AV-1451 showed similar binding properties between mouse models and tauopathy patients. **Conclusion:** The present findings support the distinct utilities of ^11^C-PBB3-PET along with MRI of rTg4510 and PS19 mice for quantitatively pursuing mechanisms connecting PET-detectable and PET-undetectable tau aggregations to neuronal death, which recapitulate two different modes of tau-provoked neurotoxicity.

P016: Cannabinoid Receptor 1 is Associated with the Pathogenesis of Alzheimer's Disease-A Longitudinal
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**Background/Aims:** The role of type 1 cannabinoid receptor 1 (CB~1~R) in the pathogenesis of Alzheimer's disease (AD) is unclear, hampering the elucidation of disease mechanism.\[[@ref82][@ref83][@ref84][@ref85]\] We aimed to evaluate the brain profile of CB~1~Rs in an aging APP/PS1-21 mouse model of AD using longitudinal PET with ^18^F-FMPEP-*d*~2~, a CB~1~R inverse agonist. **Methods:** ^18^F-FMPEP-*d*~2~ binding ratios were measured with 30-min static PET/CT scans 90 min after injection using thalamus as a reference region. Male APP/PS1-21 (n=8) and wild-type (WT) control (n=8) mice were imaged at 6, 9, 12 and 15 months of age. Additional APP/PS1-21 (n=29) and WT (n=26) mice were employed for *ex vivo* ^18^F-FMPEP-*d*~2~ brain autoradiography studies. Western blot and immunohistochemistry analyses were performed to evaluate the tracer binding, pretreatment with rimonabant to verify the binding specificity, and thin-layer chromatography to evaluate tracer metabolism in plasma and brain. All animal experiments were approved by the Regional State Administrative Agency for Southern Finland with guidelines of the International Council of Laboratory Animal Science. **Results:** APP/PS1-21 mice had lower (p\<0.05) ^18^F-FMPEP-*d*~2~ binding ratios in the parietotemporal cortex and hippocampus than age-matched WT mice. Western blot demonstrated no differences between APP/PS1-21 and WT mice in the CB~1~R abundance, whereas lower (p\<0.05) receptor expression was observed in 9-month-old male mice compared to female mice. One radioactive metabolite was found in the brain, and the amount of unchanged ^18^F-FMPEP-*d*~2~ in the brain was 84% 240 minutes after the injection. **Conclusion:** The results provide the first demonstration that ^18^F-FMPEP-*d*~2~ PET imaging can be used in APP/PS1-21 mice to monitor impairments in CB~1~R availability, but not receptor density. This radioligand is a promising PET imaging tool for AD research in terms of CB~1~R function, which may further facilitate ongoing development of novel therapeutic approaches based on endocannabinoid regulation.

P017: Noninvasive Metabolic Analysis in Rat Brains Using L-\[3-11C\]lactate with Positron Emission Tomography
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**Background/Aims:** While recent researches suggest a possibility of lactate to be utilized as an energy source and a signaling molecule in living brains, it lacks clear evidence based on *in vivo* data. We thus aimed to synthesize L-\[3-^11^C\]lactate in one-pot enzymatic synthetic procedure, evaluate chemical forms in the blood after intravenous administration, and perform *in vivo* positron emission tomography (PET) scans with normal and fasted rats followed by pharmacokinetic analysis. **Methods:** The study protocol was approved by animal welfare committee of our institute. Racemic \[3-^11^C\]alanine was obtained by ^11^C-methylation of the corresponding precursor and a deprotection step, which was followed by the reaction with an enzyme mixture to provide L-\[3-^11^C\]lactate via \[3-^11^C\]pyruvate. The chiral purity was measured by an HPLC method using a Shodex ORpak CRX-853 column. Radioactive chemical forms in the arterial blood of SD rats 10 min after bolus *iv* injection of L-\[3-^11^C\]lactate were evaluated by an HPLC method using a Cosmosil HILIC column. PET scans were performed in normal and fasted SD rats administrated with L-\[3-^11^C\]lactate followed by 1-tissue-2-compartment model analysis. **Results:** L-\[3-^11^C\]lactate was synthesized with 13.4% radiochemical yield, \>95% radiochemical purity, and \>99% enantiomeric excess within 50 min. The blood radioactivity reached its peak immediately after L-\[3-^11^C\]lactate injection, rapidly decreased to the bottom level within 90 sec, and slowly cleared thereafter. The blood radioactivity existed mainly as \[^11^C\]glucose (78.9%) and slightly as L-\[3-^11^C\]lactate (12.1%). Insulin pretreatment partly inhibited the glyconeogenesis conversion leading to 55.4% as \[^11^C\]glucose and 38.9% as L-\[3-^11^C\]lactate. The fasted rats showed a higher rate constant for radioactivity transfer from blood to brain than normal rats. **Conclusion:** We successfully synthesized L-\[3-^11^C\]lactate in one-pot enzymatic synthetic procedure and revealed a rapid metabolic conversion to \[^11^C\]glucose in the blood. The pharmacokinetic PET analysis indicated a possibility of active lactate usage in the brains *in vivo*.

P018: Validation of Computer-aided Diagnosis of Diffuse Lewy Body Disease Using Cerebral Blood Flow Studies
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**Background/Aims:** Diffuse Lewy body disease (DLB) is a complex neurodegenerative disorder whose diagnosis may be assisted by cerebral perfusion single-photon emission computed tomography/computed tomography (SPECT/CT). However, the low specificity of cerebral perfusion SPECT/CT and overlapping features of neurodegenerative disorders can impair image interpretation and diagnosis.\[[@ref86]\] NEUROSTAT™, a computer-aided diagnostic system, may improve this interpretation. We aim to examine the usefulness of NEUROSTAT™ for the investigation of DLB by clinicians with varying years of experience and in patients of different age ranges. **Methods:** Cerebral perfusion SPECT/CT data of 58 patients with suspected DLB was retrospectively retrieved from two sites and classified into possible or probable DLB by two experienced clinicians. Four clinicians of varying years of experience individually interpreted the SPECT/CT data twice for each patient. Firstly, the data was visually interpreted with no additional software used. The data was re-interpreted after at least a one-month break with the addition of NEUROSTAT™. For each patient and interpretation, the clinicians selected a diagnosis of not DLB, possible DLB or probable DLB. The clinicians' diagnoses from the initial and NEUROSTAT™ interpretations were compared for each patient. The influence of NEUROSTAT™ was analysed on the basis of the clinicians' experience (in years) and the age-ranges of the patients (e. g. 50--59, 60--69, 70--79 years old). This study received ethical approval from the SA Health Human Research Ethics Committee and the University of South Australia Human Research Ethics Committee. **Results:** NEUROSTAT™ may be a useful asset when investigating suspected DLB on cerebral perfusion SPECT/CT imaging. The additional value of NEUROSTAT™ was deemed greater in clinicians of lesser experience. **Conclusion:** A combination of visual interpretation and NEUROSTAT™ has demonstrated value in improving the specificity of cerebral perfusion SPECT/CT studies, and is useful in the diagnosis of DLB.
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**Background/Aims:** The cingulate island sign (CIS) that reflects sparing of the posterior cingulate cortex (PCC) relative to the precuneus plus cuneus on FDG-PET and brain perfusion SPECT, has been proposed as a feature of dementia with Lewy bodies (DLB). As the CIS is influenced by concomitant Alzheimer's disease (AD)-type neurofibrillary tangle (NFT) pathology, we postulated that the CIS gradually disappears as DLB progresses. **Methods:** To determine temporal changes in the CIS, 24 patients with mild DLB and 7 with prodromal DLB underwent ^123^I-IMP--SPECT and MMSE twice at an interval of two years. The CIS was evaluated as a ratio that was derived by dividing IMP accumulation in the PCC with that in the precuneus plus cuneus. **Results:** We found that the CIS changed over time and that the relationship between CIS ratios and MMSE scores was inverted U-shaped. We have fitted the relationship with quadratic function and the peak was in the vicinity of an MMSE score of 22 and it gradually diminished as the MMSE score decreased. Moreover, a lower CIS ratio in mild DLB was associated with a worse prognosis for cognitive decline, presumably due to concomitant AD-type NFT pathology. **Conclusion:** Our findings of the temporal change of CIS would provide a foundation for the appropriate usage of CIS as a biomarker.
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**Background/Aims:** We evaluated the difference in the status of dopamine transporters (DATs) depending on Parkinsonism, cerebellar, and autonomic features using ^18^F-FP-CIT positron emission tomography (PET) in multiple system atrophy with cerebellar ataxia (MSA-C). We also assessed whether the DAT PET could be useful in the management of MSA-C. Forty-nine patients who were clinically diagnosed as possible to probable MSA-C were included. **Methods:** Forty-nine patients who were clinically diagnosed as possible to probable MSA-C were included. ^18^F-FP-CIT PET images were classified into normal and abnormal scans by visual and quantification analysis. The differences in patient characteristics, clinical symptoms and drug response between the normal and abnormal scan groups of ^18^F-FP-CIT PET were evaluated. **Results:** Based on the ^18^F-FP-CIT PET results, patients were classified into normal (n=25) and abnormal (n=24) scan groups. There were statistically significant differences in rigidity, bradykinesia, postural instability, asymmetry, and specific uptake ratio (SUR) between the two groups but no significant differences in tremor and cerebellar/autonomic symptoms. Dopaminergic medications were administered to 22 patients. All seven patients with normal scans showed no change, while 10 of the 15 patients with abnormal scans showed clinical improvement. There was a trend of a negative correlation between levodopa equivalent dose and SUR, but it was not statistically significant. **Conclusion:** DAT imaging, such as ^18^F-FP-CIT PET, may be useful in predicting the response to dopaminergic medication regardless of cerebellar/autonomic symptoms in MSA-C. In addition to being used for the diagnosis of the disease, it may be used as a treatment decision index.
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F-FE-PE2I Positron Emission Tomography versus DaTSCAN™ Single-Photon Emission Computed Tomography: A Clinical Comparison
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**Background/Aims:** The highly selective Dopamine Transporter (DAT) tracer ^18^F-FE-PE2I\[[@ref87]\] is under evaluation within the PEARL-PD-study (Eudra CT: 2015--003045-26). One aim is to compare the diagnostic performance of DAT-imaging with ^18^F-FE-PE2I PET to conventional ^123^I-FP-CIT SPECT (DaTSCAN™, GE Healthcare). A *head-to-head* comparison of striatal DAT-activity with ^18^F-FE-PE2I and DaTSCAN™ is done in healthy controls (HC) and *de novo* Parkinson´s Disease patients (PD). Initial results from the first clinical study comparing these ligands are presented. **Methods:** A baseline DaTSCAN™, a dynamic ^18^F-FE-PE2I PET (separated by 5-21 days) and a 3T-MRI were acquired in 27 HC (mean age 69 years) and 8 patients (mean age 68 years) with newly onset PD according to United Kingdom´s Parkinson´s Disease Brain Bank criteria. MRI-based segmented volumes of interest (FreeSurfer v 6.0.0), manually delineated substantia nigra (SN), and thresholding of PET-data were used for \[^18^F\]FE-PE2I binding potential quantification. The commercially available software DaTQuant™ was used for DaTSCAN™ semi-quantitative image analysis (reference values derived from our HC cohort). **Results:** DAT-measurements correlated satisfactory between ^18^F-FE-PE2I and DaTSCAN™ (ICC\>0.8, p\<0.001). However, in HC the caudate/putamen-ratio was inverted between methods and striatal DAT-binding correlation with age was slightly higher for ^18^F-FE-PE2I (R=-0.523, p=0.005) than DaTSCAN™ (R=-0.396, p=0.041). Four patients had normal DAT-uptake (mean of left and right side) in striatal compartments with both methods and in the SN with ^18^F-FE-PE2I; remaining patients had significantly reduced DAT-uptake in the caudate and putamen with both methods (p \<0.001) and also in the SN with ^18^F-FE-PE2I (p\<0.001). **Conclusion:** A good agreement of striatal DAT-binding with ^18^F-FE-PE2I PET and DaTSCAN™ suggests comparable basic diagnostic performance. The possibility of DAT-quantification in the SN with ^18^F-FE-PE2I PET, which might add important diagnostic information, is an advantage. Ongoing analysis in a larger group of patients will further elucidate these findings.

P022: Effect of Copper Treatment on Striatal D2 Receptor Expression in a Mouse Model of the Copper-Deficient Parkinson's Disease Brain: A
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C-Raclopride Positron Emission Tomography Study
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**Background/Aims:** Studies in patients with Parkinson's disease suggest that selective dopaminergic neuron vulnerability is associated with a regional copper deficiency. Furthermore, copper delivery to the brain is beneficial in different animal models of Parkinson's disease. In this study, we investigated the dopaminergic system in genetically-modified mice exhibiting a copper-deficiency in the CNS and how it is affected following copper treatment utilising PET imaging using ^11^C-Raclopride, a radiolabelled selective antagonist on D2 dopamine receptors. **Methods:** Thirty two Slc31a1tm21Djt/J Ctr1+/-mice were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (45mg/kg MPTP) to induce substantia nigra dopamine cell loss. Randomly selected animals were treated with daily oral administration of 3mg/kg of copper(II)-bis(thiosemicarbazonato) (Cu-GTSM) (or vehicle) for 21 days and allowed 7 days acclimatisation following interstate transportation. A group of eight non-MPTP-treated were used as control. Animals were imaged on an Inveon PET/CT system following administration of ^11^C-Raclopride. Following scan, animals were sacrificed and dissected for further *in vitro* analysis. Use of animal for this experiment was approved by Sydney University Animal Ethics Committee. **Results:** *In vitro* experiments showed reduction in striatal levels of dopamine (60.5% reduction, p=0.01) and the primary dopamine metabolite (DOPAC, 50.8 reduction, p=0.006) following MPTP lesion. In Cu-GTSM treated MPTP lesioned mice, striatal levels of dopamine and DOPAC were not significantly different to unlesioned vehicle-treated controls, suggestive of a mild neuroprotective effect. PET showed no significant difference between any of the groups in the binding potential of ^11^C-Raclopride to the D2 receptor in the striatum. **Conclusion:** Our data suggests copper delivery to the CNS may attenuate MPTP-induced dopamine loss in the striatum in this mouse model, however, this effect appears to be independent of the binding potential of D2 dopamine receptors. Further investigation of, for example, other dopamine receptor subtypes or dopaminergic markers of nigrostriatal integrity is required to understand the mechanism underlying these observed changes.
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**Background/Aims:** Dopamine transporter (DAT) imaging using \[I-123\]ioflupane (FP-CIT) SPECT is widely used for clinical assessment of the nigrostriatal function in patients with parkinsonian syndromes (PS). For evaluation of functional reduction, semi-quantitative values of specific binding ratio (SBR) are usually obtained using various methods. To calculate the SBR appropriately with a simple and easy way, a new count-based striatal extraction method was developed. **Methods:** A total of 200 patients (mean age 72 ± 10 years) who were suspected of PS or dementia with Lewy body (DLB) were included in this study. The patients were divided into 3 groups of PS (n=100), DLB (n=11) and non-PS (n=89) after the DAT-SPECT and clinical follow-up. The patients underwent FP-CIT SPECT/CT 3-4 hours after the 167MBq tracer injection. The image data were reconstructed into three images, with attenuation and scatter correction (ACSC), only with CT attenuation correction (CTSC) and without any correction (NAC). The SBR values for each patient were obtained using the Tossici-Bolt's method and our new method. The new method extracted striatal voxels and counts using the average volume of the striata, and calculated the SBR with reference counts in the occipital cortex. **Results:** There were no differences in the mean age and gender in the 3 groups. The mean SBR values for the 3 groups and the two methods were significantly different each other. The coefficients of variation (CV) of the SBR were significantly smaller in the new method compared with the Tossici-Bolt's method (p\<0.0001, F-test) except for the CTAC reconstruction images. There were no differences in the SBR results between two operators if they used the new method. **Conclusion:** Our new method for SBR calculation in the FP-CIT SPECT showed less CV with high reproducibility, which would be useful in clinical setting.
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**Background/Aims:** A cause of Parkinson's disease (PD) is well known as dysfunction of nigrostriatal pathway. ^18^F-FP-CIT PET is a useful tool for evaluation of Parkinson's disease (PD), based on the mechanism of dopamine transporter (DAT). T2 FFP (T2-fast field echo) MRI has demonstrated nonspecific findings of substantia nigra (SN) in parkinsonism such as hypointensity of SN and 'smudging sign' (the ambiguity between the SN and the red nucleus, RN). We tried a sequential imaging with ^18^F-FP-CIT PET/MRI and T2 FFE MRI (T2\*-weighted MRI) to diagnose PD. **Methods:** Five patients (4 male, ages 52, 61, 67, 70 respectively, and one female, age 81) with hand tremor or gait disturbance underwent ^18^F-FP-CIT PET/MRI (tandem type). PET/MRI images were acquired at 3 hours after 185 MBq ^18^F-FP-CIT administration. T2 FFE MRI (field strength: 3T) images were obtained before the PET imaging. ^18^F-FP-CIT uptake of striatum and signal intensity of SN were visually assessed by a nuclear medicine physician. **Results:** We performed sequential imaging of ^18^F-FP-CIT PET/MRI and T2 FFE MRI successfully without any difficulties. Three patients demonstrated hypometabolic state of DAT in the striatum by ^18^F-FP-CIT PET/MRI. T2 FFE MRI also showed the hypointensity or smudging sign of the SN in these patients. Two patients demonstrated that there was no abnormal metabolism of DAT in the striatum nor abnormal findings in the SN. **Conclusion:** A combined model of ^18^F-FP-CIT PET/MRI and adjunctive T2 FFE MRI imaging is feasible to evaluate parkinsonism. It can be a useful modality without position change of the patient, especially in the field of brain study. It needs more data and experiences to establish the usefulness of ^18^F-FP-CIT PET/MRI and adjunctive T2 FFE MRI in PD.
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**Background/Aims:** ^123^I-MIBG cardiac scintigraphy could be helpful in differentiating Parkinson's disease (PD) from other neurodegenerative parkinsonism. The purpose of the present study is to validate the feasibility of ^131^I-MIBG scintigraphy in differential diagnosis of Parkinson syndrome. **Methods:** We prospectively recruited 9 patients with PD, 12 patients with Parkinson plus syndrome (PPS), including 9 patients with multiple-system atrophy (MSA) and 4 patients with progressive supranuclear palsy (PSP), and 6 controls who had no neurodegenerative disorder. After a 60-min resting period, patients and controls received an intravenous injection of 111MBq ^131^I-MIBG. A 5-min planar image of the chest was obtained in an anterior view at different time points (15min, 30min, 1h, 2h, 4h, 1D, and 2D post-injection). Regions of interest (ROI) were manually drawn over the heart contour (H), the upper mediastinum (M), and the left lung (L) for each planar image. Average counts per pixel in the ROIs were used to calculate heart-to-mediastinum (H/M), heart-to-left lung (H/L) ratio, and washout rate. Total counts per image (TC) at different imaging time points were also recorded. The discriminative index (DI) was defined as the difference between cardiac and lung uptake. **Results:** There was no significant difference in either gender, H-Y stage or disease duration between groups. Patients in PD group were significantly older than those in PPS group. TC decreased gradually, but remained above 200K within 4-hour post-injection. DI at 4h post-injection is significantly higher than those at other time points (P\<0.05). The H/M ratios and WR in PD patients were significantly lower than those in PPS patients, or controls at all imaging time points (P\<0.05). The threshold values of H/M at 4h post-injection that distinguished PD patients and PPS patients were 2.02 (sensitivity, 83.3%; specificity, 100%; accuracy, 85.7%). The threshold values of WR at 4h post-injection that distinguished PD patients and PPS patients were 35% (sensitivity, 91.7%; specificity, 88.9%; accuracy, 90.4%). **Conclusion:** ^131^I-MIBG scintigraphy is a feasible and economical method to depict cardiac sympathetic activity and the diagnostic performance is comparable to that of ^123^I-MIBG.
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**Background/Aims:** Bottom of the sulcus dysplasia (BOSD) is a common cause of apparently lesion negative epilepsy after initial MRI. There is often an 'easy to miss' small area of increased signal in the base of a sulcus and sometimes a transmantle tail on MRI. Despite the features that define the existence of a dysplasia, even in expert centres 20% of these are not identified on initial assessment of the MRI study. In these patients with an initially negative MRI assessment, ^18^F-FDG PET has a potential role in identifying subtle abnormality on structural imaging. The aim of this study is to explore the role of ^18^F-FDG PET and MRI in identifying BOSD in patients with focal epilepsy. **Methods:** We identified 20 patients with pathologically proven BOSD from the Austin Hospital Comprehensive Epilepsy Surgery program. All had MRI positive findings on a high-quality MRI, although 5 were not identified on initial assessment. **Results:** In three cases the MRI abnormality was detected only after finding a focal abnormality on the ^18^F-FDG PET study and re-examination of this area on the structural MRI study. In all cases that had a ^18^F-FDG PET study there was focal or regional abnormality associated with the BOSD. Good seizure free outcome from highly focal surgical resection was achieved in most cases. **Conclusion:** Bottom-of-sulcus dysplasia is a distinctive malformation of cortical development that can be diagnosed based on imaging characteristics. ^18^F-FDG PET has an important role in suggesting the presence of these lesions as they are typically hypometabolic in a focal cortical area. Reliable identification of this type of malformation of cortical development is clinically important because the lesion is highly epileptogenic and the prognosis for seizure control is excellent after focal resection. Focal ^18^F-FDG PET hypometabolism should suggest an intense review of the MRI for these lesions.

P027: Metabotropic Glutamate Receptor Subtype 1 Positron Emission Tomography Imaging in Medial Temporal Lobe Epilepsy Patients with Hippocampal Sclerosis
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**Background/Aims:** Metabotropic glutamate receptor subtype 1 (mGluR1) is a crucial target in the development of new medications to treat central nervous system disorders including epilepsy. Though some previous basic research suggested that the mGluR1/5 contributed to the formation of the epileptogenesis, their behaviour was still unknown in the epilepsy patients. We have recently developed newly radiotracer, which was specific to the mGluR type1, N-\[4-\[6-(isopropylamino)pyrimidin-4-yl\]-1,3-thiazol-2-yl\]-4-^11^C-methoxy-N-methylbenzamide (^11^C-ITMM), which made mGluR1 in vivo imaging possible using positron emission tomography (PET). We report the initial mGluR1 PET images of medial temporal lobe epilepsy (mTLE) patients with hippocampal sclerosis (HS). **Methods:** Four mTLE patients with HS were included in this study. They completed three different PET studies preoperatively: ^18^F-FDG, ^11^C-flumazenil (FMZ) and ^11^C-ITMM. Regions of interest (ROIs) were drawn manually on each MRI. Template ROIS included hippocampus, amygdala, parahippocampal gyrus, lateral temporal cortex, and frontal cortex. Template ROIs were applied to each subject's PET image and mean voxel values were extracted for each ROI. Values of ipsilateralside were compared to the contralateral side. **Results:** ^11^C-ITMM PET images showed that mGluR1 binding decreased in both sclerotic hippocampus and amygdala (78% of contralateral binding, 82%), but they unchanged in the lateral temporal and frontal cortex. ^11^C-FMZ PET images revealed binding to the central benzodiazepine receptors decreased at hippocampus and amygdala (61%, 71 %), similar to the ^11^C-ITMM PET study. ^18^F-FDG PET showed glucose metabolism decreased in amygdala, hippocampus, parahippocampal gyrus and lateral temporal cortex (78%, 90%, 85% and 90%). **Conclusion:** Binding to the mGluR1 decreased at sclerotic hippocampus and amygdala, similar to the ^11^C-FMZ PET study. These data suggested mGluR1 receptor decreased at epileptic foci because of the neuronal loss. ^11^C-ITMM PET has potential to diagnose and visualize epileptic focus. Furthermore, ^11^C-ITMM PET might be useful clinical imaging tool to clarify the mGluR1 contribution to the epilepsy.

P028: Adenosine A1R Positron Emission Tomography Imaging in Mesial Temporal Lobe Epilepsy Patients
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**Background/Aims:** The positron emission tomography (PET) radioligand for adenosine A1 receptor (A1R) \[1-methyl-^11^C\] 8-dicyclopropylmethyl-1-methyl-3-propylxanthine (MPDX) has recently been developed for human brain imaging. In the present study, we evaluated the alteration of the A1R in patients with mesial temporal lobe epilepsy (mTLE) *in vivo*. **Methods:** Fourteen patients with mTLE were included in this study. Three PET examinations were sequentially performed to measure A1R binding with ^11^C-MPDX, glucose metabolism with ^18^F-fluorodeoxyglucose (FDG), and central benzodiazepine receptor binding with ^11^C-flumazenil (FMZ), decreases of ^11^C-FMZ uptake indicate neuronal loss. **Results:** ^11^C-MPDX did not depict any lesion with significantly decreased nondisplaceable binding potential (*BP*^ND^) in comparison to healthy controls in ROI analysis. Instead, it showed a significant increase of *BP*^ND^ in the frontal and lateral temporal cortex (p\<0.01) in ROI analysis. In ^18^F-FDG PET, the standardized uptake values (SUV) were decreased in the mesial temporal lobe to controls (p\< 0.01). In ^11^C-FMZ PET, the SUV was also decreased in medial temporal lobe in ROI analysis (p\<0.01). The area with significantly increased ^11^C-MPDX binding did not overlap with the areas of neuronal loss showing decreased ^11^C-FMZ binding, and did not overlap with reduced^18^F-FDG uptake areas. **Conclusion:** We obtained the first ^11^C-MPDX PET images reflecting the A1R *BP*^ND^ in mTLE patients. ^11^C-MPDX depicted increased A1R *BP*^ND^ in the areas surrounding the injured brain, whereas ^18^F-FDG demonstrated reduction areas throughout the brain. The results suggested that A1R might continuously confer neuroprotective or neuromodulatory effects in mTLE patients.

P030: Automated Injector for Ictal Single-Photon Emission Computed Tomography in Epilepsy
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**Background/Aims:** To present the main features of the first remotely controlled automated injector system for ictal SPECT (epiJET, LemerPax, Nantes, France) used in patients with refractory epilepsy. We report the results of injection time (Ti) and seizure focus (SF) localisation with ictal SPECT using epiJET. **Methods:** Ti and SF localisation using epiJET in 35 patients were compared with Ti (t-test) and SF localisation (X^2^) of the retrospective database of the historic pool of 126 patients injected manually during 2011-2015. Injection dose error and radiation dosimetry were analysed. **Results:** EpiJET injects the full volume of the perfusion radiotracer (3-8 ml) in 3,5 s on average (2-6 s) and all injections were performed without any problem. Ti with epiJET, using the remote control system and doing the injection from the control-EEG room was 13±7,1 s. Manual Ti was 17±11,7 s on average (p\<0,001). Otherwise, when the manual injection took place with the operator waiting the seizure from the control room (same conditions used in epiJET), the Ti in these group of 54 patients was 24±12 s (P\<0,001). When the manual injection took place with the operator waiting the seizure inside the patient room (bedside and worse conditions compared with epiJET), the average Ti in these 72 patients were 13±9,7 s (P=0,04). Ictal SPECT with epiJET localized SF in 27/33 (81%) patients and with manual injection in 89/117 (76%) of patients (p\>0.05). EpiJET calculate the volume to inject in real-time accounting of the ^99m^Tc decaying, so injection dose error decreased from \<12% with manual injection to \<5% with epiJET. EpiJET reduce the risk of radiation contamination and decreases radiation dosimetry of nurses. The closed cartridge avoid any manipulation of radioactive tracer in the epilepsy unit. Radiation exposure is also very low, so with the syringe filled with 3700 MBq of ^99m^Tc, the radiation exposure at 50 cm was 0.07 µSv/h. **Conclusion:** EpiJET, the first commercially available dedicated automated injector for ictal SPECT simplify the methodology for injecting radioactive doses during seizure, making ictal SPECT more accessible. First results using epiJET are promising in reducing injection time and improving SPECT accuracy.

P031: A Comparison of the Different Attenuation Correction Methods for Calculating Semiquantitative Parameters of TRODAT-1 SPECT
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**Background/Aims:** Chang's method has long been used as an attenuation correction (AC) method for brain SPECT. Nonetheless, AC by CT is robust and presumes to be the reference standard. The aim of this study is to compare the semiquantitative TRODAT-1 binding ratio derived from these two AC methods. **Methods:** Twenty-two ^99m^Tc-TRODAT-1 brain SPECT/CT were reviewed. The study has been approved by the local Institutional Review Board and Ethics Committee. A waiver of consent has also been obtained. Regions-of-interest (ROI) were placed on the caudate nuclei, putamina, and occipital cortices. The binding ratio was calculated in average counts: (ROI of caudate nucleus or putamen-occipital cortex)/occipital cortex. Difference between two AC methods was analysed by paired T-test. Pearson's correlation was used to study the correlation between these 2 methods and the Bland-Altman plot was used to study the bias. erived from these two AC methods. **Results:** The binding ratio in all 4 (bilateral caudate nuclei and bilateral putamina) striatal regions showed significant difference between two AC methods (p\<0.01). The biases between two AC methods in the 4 striatal regions were around 0.1, with higher value using Chang's method. The Pearson's correlation coefficient constantly showed excellent correlation across all 4 regions between these two AC methods (r\>0.9). **Conclusion:** Chang's AC method slightly overestimates the binding ratio with statistical significance. Suggesting that the normal reference values for these two AC methods can not be used interchangeably. Nevertheless, the correlation between two AC methods is excellent. Suggesting that Chang's method still can reliably be used to estimate striatal TRODAT-1 binding ratio.

P032: A New Noninvasive Graphical Method for Quantification of Cerebral Blood Flow with \[123I\] N-isopropyl-p-iodoamphetamine
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**Background/Aims:** \[^123^I\] N-isopropyl-p-iodoamphetamine (^123^I-IMP) is an ideal perfusion tracer for single photon emission computed tomography (SPECT), which shows good linearity between cerebral blood flow (CBF) and accumulation. However, quantification of CBF using ^123^I-IMP without arterial blood sampling was challenging and previous methods needed regression formulae to calculate CBF. **Methods:** We have developed a new non-invasive quantification method for CBF using ^123^I-IMP and dynamic planner images. Our method does not need any regression formulae and it can measure CBF value by itself. **Results:** CBF obtained by our method showed significant correlation with established autoradiograph (ARG) method. **Conclusion:** Our method was proved to be easy to execute and reliable.

**Disclosure of Interest:** M Kameyama Conflict with: Nihon Medi-Physics, K Watanabe Conflict with: Nihon Medi-Physics.

P033: Cerebral Blood Flow and Oxygen Metabolism in Chronic Cerebral Hypoperfusion Model of Rat
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**Background/Aims:** Cerebral perfusion and oxygen metabolism has not yet been clarified in the cerebral hypoperfusion rat model by occlusion of bilateral common carotid arteries (BCAO). We aimed to evaluate cerebral perfusion and oxygen metabolism in BCAO rat model. **Methods:** O-15 PET images were acquired in the BCAO and the sham rats in the acute phase (1 week after the surgery) or in the chronic phase (6 weeks after the surgery) by using small-animal PET system based on O-15 gas steady-state inhalation method mice under isoflurane anesthesia with repeated arterial blood sampling described in our previous study.\[[@ref88]\] **Results:** As a result of PET study, in the BCAO, significantly lower CBF and significantly higher OEF than in the Sham in the acute phase, and significantly lower CMRO2 and significantly higher CBV than in the Sham in the chronic phase were observed. **Conclusion:** Cerebral perfusion and oxygen metabolism in the cerebral hypoperfusion rat model in the acute and the chronic phases under anesthesia were clarified by O-15 PET based on steady-state method.

P034: Scintigraphic Pattern of
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**Background/Aims:** Diagnosis of non-infectious autoimmune mediated limbic encephalitis (LE) is largely based on clinical criteria including detection of specific anti-neuronal autoantibodies. MR imaging is frequently employed. However, few case reports in published literature are available where PET/CT imaging is utilized to depict a characteristic scintigraphic configuration of brain ^18^F-FDG uptake. PET/CT imaging is primarily done to exclude concurrent malignancy. This case report aims to describe the representative scintigraphic pattern of ^18^F-FDG uptake in the brain in a patient with LE. **Methods:** An 18 year old female with history of epilepsy and clinical query of LE was referred to Nuclear Medicine Department, Al-Jahra Hospital Kuwait for ^18^F-FDG imaging as part of work up to exclude concurrent malignancy. Her serum autoantibodies result was pending at the time of imaging. She had MR Brain done prior to nuclear imaging. Her BMI was 24.56kg/m^2^. She underwent PET/CT imaging vertex to mid-thigh acquisition with 8.3mCi (307.1MBq) F-18 FDG, 60 minutes post injection. A dedicated Brain protocol was also acquired at 120 minutes post injection. **Results:** Symmetrical hypermetabolism was seen in the mesio-temporal region (SUV~max~: Right 9.9; Left 11.4). Further hypermetabolism of the basal ganglia was also noted with patchy distribution in the right basal ganglia. No significant active focal hypermetabolic abnormality was observed elsewhere to suggest any tracer avid malignant process. MR Brain was unremarkable. **Conclusion:** Scintigraphic pattern of ^18^F-FDG brain uptake in this patient with LE appear to be concordant with the representative pattern observed in published literature.

P035: PET Study on Traumatic Olfactory Loss Patients
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**Background/Aims:** Head trauma is one of major causes of olfactory dysfunction. It is well known that traumatic brain injury induces severe olfactory loss, which does not respond well to conventional treatment compared to post infectious or sinonasal olfactory disorders. Pathological study showed that around brain region microglia accumulate as a neuroinflammation process for tissue recovery. Since the agent, PK11195 binds to benzodiazepine receptors on microglia, assessment of ^11^C-PK11195 binding by Positron Emission study is useful for observation of brain tissue restoration. It was reported ^11^C-PK11195 binding is enhanced for many years, meaning brain restoration continues for long time. Therefore, we analysed whole brains of the patients with posttraumatic olfactory loss twice with 6-month interval. **Methods:** Five patients with traumatic olfactory loss were recruited. It was confirmed that they had neither sinonasal disease nor neurodegenerative disease. Their olfactory functions including odor detection and recognition were assessed by T&T olfactometry. PET experiments were conducted twice with 6-month interval using PET scanner. At ^11^C-PK11195 injection we started dynamic PET scan for 60 minutes. **Results:** In 1 case who did not show improvement in olfactory recognition, high activity in bilateral thalamic area was depicted. Remaining cases, however, showed low activity or no change in the thalamus. **Conclusion:** Thalamic nuclei is the gateway to the cerebral cortex. It interconnects between the orbitofrontal cortex and olfactory cortex. High activity in ^11^C-PK11195 indicates that neuroinflammation involving microglia takes place in the thalamus. Our results show inflammation in the thalamus correlates brain restoration under improvement of olfactory recognition.

P036: Brain Over Body-conscious Regulation of Cold Perception
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**Background/Aims:** Autonomous mechanisms of thermoregulation are only weakly affected by top-down modulation, allowing only transient tolerance for extreme cold. There is however, anecdotal evidence of a unique set of individuals known for extreme cold tolerance. Here we present a case study of a 57-year old Dutch national, Wim Hof, the so-called "Iceman", with the ability to withstand frequent prolonged periods of extreme cold exposure based on the practice of a self-developed technique involving a combination of forced breathing, cold exposure and meditation (referred to as WHM). The relative contributions of the brain and the periphery that endow the Iceman with these capabilities is unknown. To investigate this, we conducted multi-modal imaging assessments of the brain and the periphery using a combination of fMRI and PET/CT imaging. **Methods:** Thermoregulatory defense was evoked by subjecting the Iceman (and a cohort of typical controls) to a fMRI paradigm designed to generate periods of mild hypothermia interspersed by periods of return to basal core body temperature. fMRI was acquired in two separate sessions: in a typical (passive) state and following the practice of WHM. In addition, the Iceman also underwent a whole body PET/CT imaging session using the tracers C11-hydroxyephedrine (HED) and 18F-fluorodeoxyglucose (FDG) during both thermoneutral and prolonged mild cold conditions. **Results:** fMRI analyses indicated that the WHM activates primary control centers for descending pain/cold stimuli modulation in the periaqueductal gray (PAG), possibly initiating a stress-induced analgesic response. In addition, the WHM also engages higher-order cortical areas (left anterior and right middle insula) that are uniquely associated with self-reflection, and which facilitate both internal focus and sustained attention in the presence of averse (e.g. cold) external stimuli. However, the activation of brown adipose tissue (BAT) was unremarkable. **Conclusion:** Our results provide compelling evidence for the primacy of the brain (CNS) rather than the body (peripheral mechanisms) in mediating the Iceman's responses to cold exposure. They also suggest the compelling possibility that the WHM might allow practitioners to develop higher level of control over key components of the autonomous system.

P037: Postural Orthostatic Tachycardia Syndrome Associated to Myalgic Encephalomyelitis and Chronic Fatigue Syndrome: Brain Perfusion Findings
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**Background/Aims:** Postural orthostatic tachycardia syndrome (POTS) is a form of dysautonomia associated with abnormal increase in heart rate, blood pressure, lightheadedness, dizziness and fainting caused by postural changes from lying to standing/sitting. The severity of symptoms deteriorates patient quality of life. Possible factors involved in POTS include impaired vascular innervation, high plasma norepinephrine concentrations, immune mediated factors, α-receptor sensitivity, β-receptor hypersensitivity and baroreceptor dysfunction. In our experience, some severe myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS) patients also have POTS. Our aim is to describe brain perfusion abnormalities in ME/CFS patients with POTS. **Methods:** We report on ^99m^Tc-HMPAO brain perfusion SPECT findings in six ME/CFS and POTS patients diagnosed according to the Canadian Consensus Criteria by one of the investigators (BH). HMPAO-SPECT studies obtained in Canada were reprocessed in Chile to obtain an age-matched normal database comparison by means of Segami OASIS -- Neurogam software. Results are expressed in standard deviations from the normal mean and visually analysed. **Results:** All ME/CFS patients show significant unilateral temporal hypoperfusion and associated marked hypoperfusion of the cingulate gyrus. In POTS, there is hypoperfusion (a) particularly severe in Brodmann's 38 (b) in the medial aspect of the cerebellum in 5/6 patients (bilateral in 4) and (c) hypoperfusion of the frontoparietal operculum (overlying the insular cortex) in 5/6 patients. In all ME/CFS patients, multifocal non-organized cortical hypoperfusion can be found in the frontal, parietal and occipital lobes. **Conclusion:** We suspect that our abnormal perfusion findings in the temporal lobe(s), operculum and/or cerebellum in ME/CFS patients can be the cause of POTS or the consequence of dysautonomic episodes of these symptomatic POTS patients. Further evaluation of brain perfusion in pure POTS patients is needed.

P038: Acetazolamide Stress Brain Perfusion Single-Photon Emission Computed Tomography First Time in Bangladesh: A Case Report
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**Background/Aims:** Nuclear neuroimaging techniques have been used in Bangladesh for last 20 years within limited scopes of occasional planar and SPECT imaging. In 2017, with IAEA's support for neuroimaging skill development, Bangladesh has started performing brain perfusion SPECT/CT and PET/CT on regular basis. This is a report of a brain Perfusion SPECT with cerebral vasodilator challenge which to our best knowledge is the first one in Bangladesh. **Methods:** Our patient was a 30 years old female with five month history of right sided hemiplegia, left middle cerebral artery territory (MCA) infarct and a totally occluded left common carotid artery. She, with an aim to evaluate cerebrovascular reserve before a revascularization bypass surgery, underwent brain perfusion SPECT with vasodilator challenge at National Institute of Nuclear Medicine and Allied Sciences (NINMAS), Dhaka. A one day split dose baseline-stress sequence was followed that used a dual head gamma camera and Tc-99m ECD. For vasodilator challenge, 1250 mg of acetazolamide (ACZ) was administered orally. Easy Z-score imaging system (eZIS) v3 was applied for image analysis. **Results:** Baseline images revealed a big photon deficient area in left fronto temporal region with reduced perfusion in ipsilateral basal ganglia, thalamus and frontal lobe; indicating infarct in left MCA territory. Normal perfusion was maintained in right hemisphere. Post ACZ images showed diminution of the perfusion deficit area in comparison to the baseline images. An inference of moderate peri-infarct ischaemia or perfusion reserve in left MCA territory was made. The patient was kept under medical management. Improvement of neurological deficits was seen after four months. **Conclusion:** This was the first brain perfusion SPECT with ACZ as well as the first experience of using eZIS for evaluation of cerebrovascular reserve in Bangladesh which was clinically influential because the course of management was changed resulting in a satisfactory outcome.

P039: Usefulness of Radioiodinated 2-\[4-(2-iodophenyl)piperidino\]cyclopentanol (OI5V) for Early Diagnosing Neurodegenerative Disorder Caused by Stress
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**Background/Aims:** Sigma-1 receptor (σ-1R) is associated with adjustment of the nerve transmission of the central nervous system and learning memory, cognitive function. Furthermore, sigma-1 receptor plays an important role of remission of the stress. We had already reported that ^123^I-OI5V, vesamicol analogue with 5-membered ring structure, showed characteristics of sigma-1 receptor radioligand with high affinity and selectivity. In this study, we investigated change of the regional brain distribution of the stress model mice made by the forced immobilization test, and evaluated the potential usefulness of radioiodinated OI5V as a sigma-1 receptor mapping agent for early diagnosing neurodegenerative disorder caused by stress. **Methods:** ^125^I-OI5V was prepared from o-tributylstannyl-cyclopentanevesamicol (OT5V) by iododestannylation reaction under no-carrier-added conditions. ^125^I-OI5V was injected intravenously into the stress model mice and normal mice. The mice were sacrificed at 30 minutes post-injection and interest regional brain region were collected, weighed and counted to investigate the regional brain distribution. **Results:** ^125^I-OI5V was obtained with radiochemical purity of greater than 99%, and the radiochemical yield was 79%. The uptake of ^125^I-OI5V in cerebral cortex, striatum, cerebellum and rest brain in the normal mice and the stress model mice showed 16.53±4.28, 14.55±3.86, 18.33±4.68, 14.87±4.78, and 10.43±1.25, 9.17±0.91, 13.82±0.89, 9.34±1.10, respectively. The uptake of ^125^I-OI5V in cerebral cortex and striatum, reduced significantly in comparison with normal mice. **Conclusion:** These results showed that sigma-1 receptor of the central nervous system are decreased by chronic stress. Radioiodinated OI5V as a sigma-1 receptor mapping agent may be useful for early diagnosing neurodegenerative disorder caused by stress.

P040: Decomposition of the Functional Magnetic Resonance Imaging BOLD Signal Into Neural and Vascular Components Using Simultaneous Functional Magnetic Resonance Imaging and Functional
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**Background/Aims:** Functional magnetic resonance imaging (fMRI) uses the blood-oxygen level dependent (BOLD) response to generate high spatial (\~1-3mm) and moderate temporal (\~1-2seconds) resolution images of brain function. The oxygenated blood that produces the BOLD contrast originates in the tissue and drains through venous vasculature. In this work, we used continuous infusion 18-F Flurodeoxyglucose positron emission tomography (FDG-fPET) simultaneously acquired with fMRI, to identify and map the vascular component of the BOLD-fMRI signal. **Methods:** The institutional ethics committee approved this study. Ten volunteers were scanned (3T Biograph mMR Siemens, Erlangen) during a continuous-infusion of FDG (100MBqs, 36 mL/hr) with 90-minutes of PET list-mode data collection. BOLD-fMRI was simultaneously acquired. An embedded on/off design (32/16-seconds), flickering checkerboard (8 Hz) task was performed for 10 minutes (10-minute rest periods before and after). List-mode data was reconstructed into 1-minute bins, corrected for motion\[[@ref90]\] and photon attenuation,\[[@ref91]\] and spatially normalised to MNI space. Both the fMRI and fPET data was smoothed (5mm). Two independent component analyses\[[@ref92]\] (ICA) were performed on the fMRI and fPET data. Per-subject Z-score maps were generated using dual regression.\[[@ref93]\] A joint ICA\[[@ref94]\] was performed on the fMRI and fPET Z-score maps. **Results:** Separate analyses of the fMRI and fPET time series produced activation maps of the visual cortex. Two distinct components were obtained in the joint analysis. The first joint component showed positive correlation of visual cortex activity between fMRI and fPET. The second component contained a predominantly positive fMRI signal, with similar but smaller spatial extent to the separate analysis, which was negatively associated with the fPET signal in the venous vasculature. **Conclusion:** The simultaneous fPET and fMRI imaging strategy provided high temporal resolution functional and metabolic imaging, and enabled the deconstruction of the BOLD-fMRI signal into neural tissue and vascular components.

P041: Case report: Early Detection of Shunt Fracture on Cerebrospinal Fluid Shunt Study with Incidental Dominant Thyroid Nodule
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**Background/Aims:** Ventriculoperitoneal shunts are used to treat hydrocephalus. To investigate for shunt malfunction, radionuclide shunt study complements other imaging tests. Other organs are also imaged by the recycled radiopharmaceutical. **Methods:** A 40 year old male with a VP shunt for congenital hydrocephalus presented with a one week's history of increasing headaches, nausea and vomiting. Shunt blockage was suspected but not confirmed on head CT and plain X rays. A radionuclide CSF Shunt Study was thus ordered. The study was performed with 60MBq of filtered ^99m^Tc-pertechnetate. Serial planar images of the head, neck and abdomen were then acquired followed by SPECT/CT. This case report was approved by the ethics committee of our hospital. **Results:** The initial images showed prompt flow of radiotracer down the distal limb of the shunt into the abdominal cavity, suggesting shunt patency. However focal tracer accumulation was noted near the angle of the mandible. This was external to the tubing on the SPECT/CT indicative of shunt fracture. Another right sided prominent focus in the neck was localised to the right lobe of thyroid on SPECT/CT. The rest of the thyroid was suppressed. **Conclusion:** CSF shunt study allows early diagnosis of shunt fracture undetected by other imaging. Pathology in other organs which are pertechnetate-avid such as a dominant thyroid nodule maybe incidentally identified. CSF shunt study is for evaluating shunt patency. Although patent, the VP shunt in this case was fractured. This was confirmed on SPECT/CT. The fracture was not detected in structural imaging that relied on demonstration of catheter discontinuity and distal fragment migration. The recycled radiopharmaceutical also allowed an incidental detection of a dominant hypermetabolic thyroid nodule.
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**Background/Aims:** Spontaneous intracranial hypotension (SIH) is a rare condition of low cerebrospinal fluid (CSF) volume caused by leakage through a dural defect along the neuroaxis. There is a lack of clinical guideline or established management algorithm. This study aims to evaluate the value of radionuclide cisternography in SIH. **Methods:** This study retrospectively reviewed consecutive referrals for clinically suspected or diagnosed SIH. The samples were recruited from a 1600-bed regional hospital over 16 years between June 2001 and May 2017. Radionuclide cisternography was performed using a standardized protocol: 18.5 MBq ^111^In-diethylenetriaminepentaacetic acid administered intrathecally followed by serial imaging up to 48 hours. Single-photon computed emission tomography and low-dose computed tomography was performed for anatomical localization of abnormal tracer activity. Positive finding for CSF leak was defined as accumulation of radiotracer in the extra-arachnoid space. Presence of indirect findings of CSF leakage included early visualization of urinary activity within 4 hours and non-visualization of activity over brain convexities by 24 hours. **Results:** There were a total of eight subjects (6 male, 2 female: aged 26 to 64 years) suspected to have SIH. Five (63%) subjects had positive findings for CSF leakage on radionuclide cisternography. Three (60%) had CSF leakage localised at thoracic spinal level, two (40%) at cervical spinal level, and all 5 studies were positive for both indirect findings of CSF leakage. Of the 5 cases with positive findings on radionuclide cisternography, two had history of severe subdural haematoma associated with decrease in conscious level requiring operative drainage. Of the 3 cases with negative findings on radionuclide cisternography, one developed subdural haematoma but spontaneously improved. One (20%) subject with leakage demonstrated at cervical level received targeted epidural blood patch with subsequent resolution of symptoms. **Conclusion:** Radionuclide cisternography may be a useful investigation in detecting and localising CSF leakage in patients suffering from SIH for it potentially guides local treatment of any dural defect. Positive findings on radionuclide cisternography may be associated with more severe symptomatology or complications of SIH and would warrant further investigations to confirm this observation.

P043: Ventriculopleural Shunt Dysfunction Due to a Loculated Pleural Collection Demonstrated on Single-Photon Emission Computed Tomography/Computed Tomography Imaging
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**Background/Aims:** A 35-year-old female presented with increasing drowsiness and lethargy on a background of childhood meningitis and hydrocephalus managed with a ventriculopleural shunt. Her cerebral Computed Tomography (CT) and chest X-ray were unchanged from previous imaging and did not identify significant pathology. Due to clinical suspicion of cerebral spinal fluid (CSF) shunt dysfunction, she was referred for a CSF shunt study. **Methods:** Dynamic and planar imaging was performed following the intrathecal administration of 38MBq of double filtered ^99m^Tc-diethylene-triamine-pentaacetate (^99m^Tc-DTPA) to assess for ventriculopleural shunt dysfunction. Delayed planar scintigraphy demonstrated an irregular pyramidal-shaped accumulation of tracer at the left chest. Single Photon Emission Computed Tomography (SPECT) with CT was performed. Ethics is not required as this is a retrospective case report. **Results:** Tracer accumulation was demonstrated within a loculated pleural collection at the costodiaphragmatic recess of the left lung at the distal tip of the catheter. Ventriculopleural shunt dysfunction was confirmed by the absence of tracer dispersion elsewhere throughout the pleural cavity. **Conclusion:** Ventriculopleural shunts are rarely used as a long-term measure for CSF diversion.\[[@ref89]\] Ventriculoperitoneal shunts are preferred due to fewer and less severe complications.\[[@ref90]\] The use of ventriculopleural shunts are generally used as a temporary measure when a ventriculoperitoneal shunt has failed, or in the presence of peritoneal adhesions or peritonitis.\[[@ref89][@ref91]\] Shunt dysfunction is relatively common, with up to 50% failing within 2 years and 70% within 10 years after placement.\[[@ref92][@ref93]\] The most common locations for shunt obstruction are at the ventricular catheter tip and shunt valve. One possible complication, as seen in this patient, is the formation of pseudocysts around the distal catheter tip due to adhesions caused by chronic pleural irritation.\[[@ref94]\] The addition of SPECT/CT to conventional imaging aided in characterising the shunt dysfunction and nature of the pathology; and altered the patient's management.

P044: Imaging Characteristics of Radionuclide Cisternography in Spontaneous Intracranial Hypotension Syndrome
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**Background/Aims:** To investigate the imaging characteristics and clinical significance of radionuclide cisternography (RNC) in patients with spontaneous intracranial hypotension syndrome (SIHS). **Methods:** 19 patients with SIHS underwent lumbar puncture and ^99m^Tc-DTPA was injected into the spinal subarachnoid space. Multitemporal RNC was performed. SPECT/CT tomography was added to the abnormal distribution. Comprehensive analysis of RNC image features. **Results:** 12 cases (12/19) of direct cerebrospinal fluid (CSF) leakage were detected on the basis of radioactive abnormal concentration in epidural. The detection rate was 63.2%, including 8 cases of CSF leakage in cervical and thoracic segment joint, 1 case in lumbar spine, 2 cases of CSF rhinorrhea. Indirect CSF leakage in 5 cases. No direct CSF leakage was found in these cases. But found that radionuclide quickly disappeared in the subarachnoid space (\<4 hours), and/or premature appearance (\< 2.5 hours) in the bladder, or radioactivity is difficult to rise to the base pool to the brain, and intracranial radioactivity is less than normal. CSF circulation was normal in 2 cases. Comparing the MRI findings of 17 patients, there was no significant difference between MRI and RNC in the diagnosis of low intracranial pressure (χ^2^ = 3.01, *P*\> 0.05), but RNC was superior to MRI in detecting CSF leakage (χ^2^ = 12.5, *P* \<0.005). In this study, except for one case of high-flow CSF leakage who was cured by invasive epidural blood plaster, the remaining 18 patients were cured by conservative treatment. **Conclusion:** RNC can assist the diagnosis of SIHS by direct or indirect signs and is superior to MRI in detection of CSF leakage. It can also reflect the amount of CSF leakage and facilitate individualized treatment, which has important value in diagnosis and treatment of SIHS.

P045: Differential Diagnosis of Neurodegenerative Dementias Using Metabolic Phenotypes on F-18 Fludeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging
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**Background/Aims:** Positron emission tomography (PET) imaging with F-18 fluorodeoxyglucose (FDG) can be used as a hallmark of neurodegenerative dementia. Characteristic patterns of regional glucose metabolism have been used to classify the dementia subtypes, namely Alzheimer's dementia (AD), frontotemporal dementia (FTD), diffuse Lewy body (DLBD), vascular dementia (VD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), etc. PET/MRI benefits neurologic clinical care and research by providing spatially and temporally matched anatomic and metabolic imaging. We undertook this study to assess the utility of FDG-PET/MRI in the differential diagnosis of dementia subtypes. **Methods:** Fourty patients diagnosed with dementia had FDG-PET/MRI performed. Imaging-based diagnosis of dementia type was established by visual assessment of individual scans by PET physician blinded to the clinical diagnosis. Concordance of visual analysis of FDG-PET/MRI scans with clinical diagnosis of the dementia type was evaluated. **Results:** This concordance was 90% for various subtype diagnosis of dementia by the metabolic pattern of FDG PET from PET/MRI with clinical diagnosis. MRI provided accurate anatomic information. Simultaneous PET/MRI provides efficient acquisition of multiple temporally matched datasets, and opportunities for motion correction and improved anatomic assignment of PET data. **Conclusion:** ^18^F-FDG PET/MRI performed after the initial work-up of dementias is useful for supporting the clinical diagnosis of dementia subtype.
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**Background/Aims:** To estimate the place of the scintigraphy imaging in French-speaking black African cardiological practice. **Methods:** Cross-sectional study conducted from February 1st till May 30th, 2017 including 97 cardiologists practicing in French-speaking black African countries. The accessibility and the frequency of prescription of the examinations of nuclear cardiology as well as the interest carried in these examinations by the cardiologists were analysed. **Results:** A department of nuclear medicine existed in their country, city and hospital of exercise respectively in 56.3%, 49.5% and 14.4% of cases. A great majority of the cardiologists had never prescribed a myocardial perfusion scintigraphy (70.1%), or pulmonary perfusion scintigraphy (81.4%) and a multigated acquisition (MUGA) scan (94.8%). Only 5.2% of the cardiologists asserted prescribing often the myocardial perfusion scintigraphy and pulmonary scintigraphy and rarely the MUGA scan. The low frequency of prescription was connected with the rarity of nuclear medicine departments in 82.6%, and with the weak diagnostic contribution in 8.2 % of the cases. The most sensitive examination for the diagnosis of the ischaemia or the myocardial infarction was coronarography according to 66% of them and myocardial scintigraphy according to 26.8%. In the evaluation of left ventricle function, 64.9% considered that echocardiography is the most satisfactory with 35.1% for MUGA scan. To eliminate a pulmonary embolism in front of a normal thoracic radiography, only 14.4% would ask for a pulmonary perfusion scintigraphy. **Conclusion:** The place of the scintigraphy imaging is unsatisfactory in French-speaking black African cardiological practice and a raising awareness of the cardiologists on the diagnostic interest and forecasts of the nuclear cardiology is imperative so that it occupies its special place.

P047: Differences in Perfusion and Regional Functional Abnormalities Identified by Rest Gated Myocardial Perfusion Scintigraphy in Dilated Cardiomyopathy Patients with Ischaemic and Non-Ischaemic Aetiology Based on Coronary Angiography Results
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**Background/Aims:** Dilated cardiomyopathy (DCM) is a common problem and it is very important to differentiate its ischaemic cause from non-ischaemic for management and prognostic purposes. This study was conducted to evaluate rest gated myocardial perfusion scintigraphy (GMPS) in patients with ischaemic and non-ischaemic DCM, and to compare mean summed perfusion score (SPS), mean summed thickening score (STS) and mean extent of perfusion abnormality (EPA) between them. **Methods:** This descriptive case series study was conducted at the nuclear cardiology department of Punjab Institute of Nuclear Medicine (PINUM), Faisalabad over a period of six months from 01-01-2013 to 30-06-2013. Resting GMPS were performed in 102 patients with known DCM (aged 17 to 70 years, mean age 49.12 ± 11.8 years, M: F = 86:16) by injecting 20 mCi of ^99m^Tc-MIBI. Patients were subdivided into ischaemic (n=74) and non-ischaemic group (n=28) by using the coronary angiography results. SPS, STS EPA were calculated by using twenty segment model. Results of GMPS were compared between ischaemic DCM and non-ischaemic DCM by using independent samples t-test. P-value of \<0.05 was taken as statistically significant. **Results:** SPS and EPA are significantly higher in ischaemic than non-ischaemic subgroups (26.46±10.80 vs. 7.86±5.13 p\<0.001; and 7.16±1.97 vs 4.32±1.70, p\<0.001 respectively). STS was significantly higher in non-ischaemic group than ischaemic group of DCM patients (33.21±7.13 vs. 23.99±7.81). **Conclusion:** Our study shows that there are statistically significant differences in the values of summed perfusion score, summed thickening score and extent of perfusion abnormalities between ischaemic and non-ischaemic DCM groups, calculated by using rest gated myocardial perfusion scintigraphy. Combined evaluation of the perfusion and wall thickening on rest gated myocardial perfusion scintigraphy is useful to identify ischaemic and non-ischaemic aetiology of DCM.

**Disclosure of Interest:** M B Imran Conflict with: Punjab Institute of Nuclear Medicine; M Iqbal Conflict with: Punjab Institute of Nuclear Medicine; O B Qadeer Conflict with: Punjab Institute of Nuclear Medicine.

P049: Three Renin-Angiotensin-Aldosterone System -Related Gene Polymorphisms are Linked to Abnormal Myocardial Perfusion: Correlations Based on Myocardial Gated Single Photon Emission Computed Tomography Imaging
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**Background/Aims:** Renin-angiotensin-aldosterone system (RAAS)-associated gene polymorphisms have been implicated in the development of coronary artery diease.\[[@ref95]\] However, little evidence is available regarding the direct correlations of these polymorphisms with myocardial perfusion.\[[@ref96]\] We evaluated the associations between three polymorphisms and myocardial perfusion, using gated single photon emission computed tomography (SPECT). **Methods:** The study sample consisted of 810 patients who were referred to our departments between December 2015 and February 2017, for a clinically indicated myocardial perfusion imaging. Summed stress score (SSS), summed rest score (SRS), suumed difference score (SDS), transient ischaemic dilation (TID), and lung/heart ratio (LHR) were recorded. Three RAAS-associated gene polymorphisms were investigated: angiotensin-converting enzyme (*ACE*) insertion/deletion (I/D), angiotensinogen (*AGT*) T174M, and angiotensin II type 1 receptor (*AT1R*) A1166C. **Results:** The heterozygotes or homozygotes on *ACE* D allele were 7.54 times more likely to have SSS ≥3 (p\<0.001), and the homozygotes of *ACE* D had significantly higher values on TID (p=0.005) and LHR (p=0.006). The *AGT* (T174M) heterozygotes were 5.19 times more likely to have abnormal SSS (p=0.023), and had higher values on TID (p=0.012). Moreover, the *AT1R* heterozygotes had greater odds for having abnormal SSS (p=0.029), and had significantly higher values on LHR (p=0.010). Finally, the patients carried *AT1R* homozygosity of C allele had significantly higher values on TID (p=0.050). **Conclusion:** According to our results, *ACE* D allele had the strongest association with abnormal myocardial perfusion.

P050: Can Nuclear Medicine Detect a Broken Heart?
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**Background/Aims:** A 72 year old female presented for a Myocardial Perfusion study (MPS). She initially presented to the hospital with chest pain and associated rise in troponin levels. The patient had a recurrent history of Takotsubo Cardiomyopathy, the last episode occurring 18 months prior. Takotsubo Cardiomyopathy is also referred to as stress induced cardiomyopathy or broken heart syndrome. It is typically temporary and can be brought on by a stressful incident occurring. Its symptoms are similar to that of a heart attack, however no blockages are present. The chambers within the heart itself can enlarge or change shape which ultimately affects its ability to contract effectively. **Methods:** The patient underwent a MPS within our department. This involved administering 39mg of Dipyridamole to the patient to 'stress' the heart. Once an optimum heart rate was achieved they were injected with 382MBq of ^99m^Technetium-Sestamibi (^99m^Tc-MIBI). The patient then underwent a Single-Photon Emission Computed Tomography (SPECT) study in conjunction with a low energy Computed Tomography scan (CT). There was then a delay of three hours, after which the patient returned to us and was then re-administered with 950MBq of ^99m^Tc-MIBI, and subsequently had another SPECT scan. **Results:** The MPS showed an area of fixed, reduced activity within the anterior and anterolateral wall. There was no evidence of reversible myocardial ischaemia elsewhere. The gated image showed a left ventricle which was within a normal size range, but with reduced movement; this can be further reflected with an ejection fraction of 39%. **Conclusion:** In regards to the MPS, reduced systolic function and ejection fraction was seen within the left ventricle, as well as the fixed defects mentioned previously. With this in mind, and after the patient underwent subsequent Magnetic Resonance Imaging showing similar findings, it was deemed that the patient was suffering from another episode of Takotsubo Cardiomyopathy.

P051: 25-Hydroxyvitamin-D Deficiency in Patients of Northern Greece with Coronary Artery Disease. Correlation with Single Photon Emission Computed Tomography Myocardial Scintigraphy
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**Background/Aims:** Recent have reported that low serum vitamin D levels are associated with a variety of diseases, including cardiovascular disease and in particular ischaemic heart disease. The evaluation of 25-hydroxyvitamin-D serum levels in patients with CAD, as a prognostic factor of the disease severity, in correlation with SPECT myocardial scintigraphy. **Methods:** We studied 108 patients (63 male and 45 female) aged between 37 and 68 years old (median 52±6 years) with CAD. All patients came from the Cardiology Clinic of the University Hospital of Evros. Blood samples were taken for (25-OH-D) determination and after this in everyone SPECT myocardial scintigraphy with ^99m^Tc-MIBI was performed. The vitamin D status was measured by radioimmunoassay method with kits Diasorin at Nuclear Medicine Dept. **Results:** 57 patients with myocardial infarction had low values of vitamin D deficiency (p\<0.005). In this group, there is statistical significance in the relationship between very low values of vitamin D and patients with extensive myocardial infarction (p\<0.005). Therefore, the very low levels are associated with impending patient death. These patients might need more intensive monitoring. 39 patients with reversible myocardial ischaemia had low values of vitamin D 20-40 ng/mL (p\<0.005). Therefore, the very low levels associated with the progression of the disease. 12 patients with normal myocardial scintigraphy had normal vitamin D values \>40ng/mL (p\<0.005). **Conclusion:** In conclusion, low vitamin (25-OH-D) levels may underlie established cardiovascular risk factors. The very low levels associated with the severity of (CAD) disease and the impending death of patients. The determination of vitamin D levels in patients with CAD is essential to monitor patients in the treatment and outcome of disease.

P052: The Prognostic Value of Diastolic and Systolic Mechanical Left Ventricular Dyssynchrony among Patients with Coronary Heart Disease
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**Background/Aims:** Systolic left ventricular dyssynchrony measured by gated single photon emission computed tomography (GSPECT) myocardial perfusion imaging (MPI) is associated with worse outcomes. Novel analytical algorithms now allow for evaluation of diastolic left ventricular dyssynchrony. Our aim was to examine if diastolic dyssynchrony has independent and incremental prognostic value in patients with coronary artery disease (CAD). **Methods:** We included patients who presented to Duke University for GSPECT MPI between 2003 and 2009. Patients had at least one major epicardial CAD. Dyssynchrony variables were computed using Emory Toolbox software and compared to a control population without CAD. We performed unadjusted Cox proportional hazard modelling for diastolic dyssynchrony variables with all-cause mortality and cardiovascular mortality as outcomes. Adjusted modelling included clinical baseline characteristics, electrical dyssynchrony (QRS duration, left bundle branch block), left ventricular ejection fraction and diastolic as well as systolic dyssynchrony parameters. **Results:** Total of 1310 patients were included in the analysis. Of them 69.7% were male and 73% Caucasian, with a median age of 64 years. About 8% of patients had significant mechanical dyssynchrony. After mean follow-up of 6.7 years, 543 deaths occurred. At 5 years, the mortality estimate was 21.2% among patients with low degree of diastolic left ventricular mechanical dyssynchrony (LVMD) and 41.7% among those with a high degree of LVMD (p\<0.001). The addition of diastolic dyssynchrony to the model of clinical variables, electrical dyssynchrony and systolic LVMD had incremental predictive value (global Chi-square of 211.9 vs. 222.8, p=0.004) for cardiovascular mortality. **Conclusion:** Systolic and diastolic LVMD, measured by GSPECT MPI is prevalent amongst patients with CAD. Both systolic and diastolic dyssynchrony have a strong association with poor clinical outcomes. However, diastolic dyssynchrony appears to have incremental predictive benefit on top of clinical, electrical dyssynchrony and cardiac functional assessment.

P053: The Importance of Appropriate Reporting and follow-up of Incidental Findings on Computed Tomography Attenuation Correction Images in Myocardial Perfusion Scintigraphy: A Case Report
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**Background/Aims:** Prior reviews of incidental findings on computed tomography attenuation correction (CTAC) images in myocardial perfusion scintigraphy (MPS) have reported cases of newly diagnosed lung cancer.\[[@ref97][@ref98][@ref99][@ref100][@ref101]\] Patients undergo MPS for evaluation of coronary artery disease which shares many risk factors with lung cancer and therefore represent a high-risk group. The routine review of CTAC images is controversial however and has been advised against.\[[@ref100][@ref102]\] **Methods:** This case was identified as part a retrospective audit of incidental CTAC findings in MPS. Electronic and paper-based medical records and databases were used to obtain all relevant information. Ethical approval was granted by the local Human Research Ethics Committee. **Results:** We present the case of a 74-year-old man who underwent MPS as part of a pre-operative assessment prior to abdominal aortic aneurysm repair. A suspicious 10-millimetre subpleural opacity within the right lower lobe was incidentally noted on CTAC images and described in the MPS report, with further investigation with diagnostic CT directly advised. Unfortunately, appropriate further evaluation of the incidental finding was not carried out based on the MPS report. Diagnostic CT 14 months following MPS showed that the lesion had more than doubled in size to 23 mm with associated hilar lymphadenopathy. Biopsy revealed lung squamous cell carcinoma and diffuse hepatic metastases were identified on staging. Urgent chemotherapy was commenced but the patient died within two months. **Conclusion:** This case highlights the importance of routine review of CTAC images in MPS. The crucial role of effective communication between nuclear medicine and treating physician following identification of any suspicious incidental finding is clear. Further, referring physicians must follow-up and appropriately investigate potentially significant incidental findings promptly. Failure at any step can result in adverse patient outcomes.

P054: Diagnostic Performance of Vasodilator Stress Myocardial Single Photon Emission Computed Tomography According to Radiotracers using Cadmium-Zinc-Telluride Camera System as Assessed by Fractional Flow Reserve
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**Background/Aims:** Although stress myocardial perfusion imaging (MPI) using a cadmium-zinc-telluride (CZT) camera is reported to have good diagnostic accuracy, few studies have shown the diagnostic value according to the type of radiotracer in the detection of functionally significant stenosis among the intermediate coronary narrowing as assessed by fractional flow reserve (FFR) measurements. **Methods:** We retrospectively evaluated 234 consecutive patients who underwent both ATP stress MPI and CAG with FFR measurements within 3 months' interval. FFR measurements were performed in 323 coronary vessels (184 201Tl, 139 99mTc-radiotracers) considered to have intermediate lesions excluding infarct-related vessels. Severe coronary artery stenosis of \>90% diameter narrowing or mild stenosis of \<40% narrowing was not evaluated with FFR measurements. An FFR≤0.80 was defined as significant stenosis. **Results:** FFR value was similar in coronary vessels when 201Tl or 99mTc-radiotracers was applied for MPI (0.79±0.10 vs 0.79±0.10; p=ns). To detect individual coronary stenosis with 201Tl, the respective sensitivities, specificities, accuracies were 90%, 32%, 72% for LAD, and 60%, 76%, 70% for non-LAD. In contrast, with 99mTc-radiotracers, the respective sensitivities, specificities, accuracies were 60%, 47%, 57% for LAD, and 48%, 85%, 73% for non-LAD. **Conclusion:** These results suggested that the CZT camera system may be superior when using 201Tl to 99mTc-radiotracers in the detection of functionally significant coronary stenosis, at the expense of specificity for myocardial ischaemia.

P055: Diagnostic Usefulness of the Integrated Risk Scores Combined with Myocardial Single Photon Emission Computed Tomography for Patients with Suspected Coronary Artery Disease
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**Background/Aims:** Recently, the integrated risk scores (IRS) based on coronary risk factors and symptoms are reported to identify high-risk CAD patients. We sought to better diagnose CAD patients by combining IRS with stress myocardial SPECT using cadmium-zinc-telluride camera. **Methods:** We retrospectively studied 527 patients with suspected CAD who underwent stress myocardial SPECT and coronary angiography within 3 months' interval. Each SPECT image was analysed using the 17-segment model. An SDS ≥2 was defined as myocardial ischaemia. A diameter stenosis ≥90% and/or fractional flow reserve ≤0.80 was considered as hemodynamically significant stenosis. IRS for each patient was assigned depending age, gender, hypertension, diabetes mellitus, family history, current smoking habits, and chest symptoms (either 0 or 1, except for age). In addition, IRS of lower than 2SD was categorized as the low-risk group. **Results:** Of 527 patients, IRS average was 8.8±1.4, and the area under curve was 0.71. Significant stenosis was observed in 319 patients. On SPECT, sensitivity, specificity, and accuracy were 88%, 49%, and 72% in detecting significant CAD while 88% sensitivity, 48% specificity and 74% accuracy were similar in 492 patients in the intermediate to high-risk group. In 35 patients in the low-risk group, only 3 of 18 patients with positive SPECT had significant CAD (75% sensitivity, 52% specificity and 54% accuracy), whereas 1 of 17 patients with negative SPECT also had CAD (p=0.603). **Conclusion:** IRS helps better identify false positive findings of myocardial SPECT by categorising the low-risk group.

P056: Effect of Different Acquisition Arcs on the Appearance of each Left Ventricular Wall in Myocardial Perfusion Single Photon Emission Computed Tomography
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**Background/Aims:** Conventional single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is performed in the supine position range RAO45°−LPO45°, but the effect of other acquisition arcs on imaging quality are not well described. In this study, we compared radioactivity activity over left ventricle walls as measured by different acquisition arcs to identify optima for specific applications. **Methods:** In total,125 low-risk coronary heart disease patients underwent ^99m^Tc-MIBI stress MPI, of which 52 received 360° acquisition with reconstruction using different 180° projections and the remaining 73 received conventional 180° (LPO45°−RAO45°) and left-side 180°(POST180°−ANT0°) acquisition consecutively. Statistically compare the radioactive activity and defect score of each left ventricular wall from different acquisition arcs. Voluntary informed consent was obtained from all study population. The work described in this abstract has appropriate approval under local ethical rules. **Results:** Myocardial slices reconstructed from POST180°−ANT0° yielded highest radioactivity uptake from inferior, lateral, and septal walls, LPO45°−RAO45° from the anterior wall, and LPO35°−RAO55° from the apical region. Compared to conventional 180° acquisition, the segments with decreased defect scores were observed in 27.67% (101/365) using left-side 180° acquisition. The proportion was significantly higher for males (p=0.035) and patients with high BMI (p=0.036). Segments with decreased defect score were mainly in inferior, septal, and lateral walls, and a greater proportion of males than females exhibited in inferior wall (p=0.004). **Conclusion:** The different arc of data acquisition could significantly affect the appearance of each wall of the left ventricle, POST180°−ANT0° acquisition arc represents a useful and significantly enhanced imaging quality of inferior walls especially in males.
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P057: Diagnostic Accuracy of Right Ventricular Visualization in Resting Thallium Myocardial Perfusion Scan in Identifying Right Ventricular Hypertrophy among Patients with Coronary Artery Disease
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**Background/Aims:** Accurate evaluation of right ventricular function and structure is challenging because of its complex geometry. Cardiac magnetic resonance imaging is said to be precise for quantitation of ventricular volumes and morphology. However, due to cost and availability, 2-D echocardiography is most commonly used. Visualization of right ventricle in thallium myocardial perfusion scan (MPS) is usually seen in patients with right ventricular pressure and/or volume overload. This study aims to establish the accuracy of visual assessment of right ventricular uptake on myocardial perfusion scan in identifying right ventricular hypertrophy compared with 2-D echocardiography and to establish the association of right ventricular uptake with right ventricular dysfunction seen in echocardiography. This could aid in the interpretation of future cardiac scintigraphy in identifying patients at a higher risk as compared to those without right ventricular uptake on MPS. **Methods:** Chart review of a total of 227 adult patients with angiographically proven coronary artery disease, who underwent resting thallium MPS and had echocardiography results within three months for the past five years was performed. Hypertrophy was indicated by right ventricular wall thickness of \>0.5cm and systolic function by right ventricular fractional area change (normal value of \>35%) in echocardiography. Presence of right ventricular uptake on MPS was analysed visually by two experienced observers blinded to the findings of echocardiography. **Results:** Right ventricular visualization on MPS has a sensitivity of 95.7% and specificity of 65.4% in identifying right ventricular hypertrophy, with overall accuracy of 80.6%. An association between right ventricular uptake on MPS and right ventricular dysfunction measured by echocardiography was demonstrated (Cramer's V=0.5911, p\<0.0001). Patients with right ventricular uptake also showed lower left ventricular ejection fraction (p\<0.001). **Conclusion:** Right ventricular visualization on resting thallium-201 MPS had high sensitivity (95.7%) but limited specificity (65.4%) in identifying right ventricular hypertrophy, with overall accuracy of 80.6%. There was an association between right ventricular uptake on MPS and right ventricular dysfunction measured by echocardiography.

P058: Utilization of Myocardial Perfusion Imaging, other Diagnostic Tests and Percutaneous Coronary Intervention for Coronary Artery Disease in Taiwan
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**Background/Aims:** Myocardial perfusion imaging (MPI) has been found to be useful for diagnosis, risk stratification and potentially for decision-making of invasive coronary procedures for coronary artery disease (CAD). The purpose of this study was to investigate the utilization of MPI, other diagnostic tests and treatment with percutaneous coronary intervention (PCI) for CAD in Taiwan. **Methods:** Taiwan's National Health Insurance (NHI) system is a single-payer social insurance program organized by the government under the jurisdiction of the National Health Insurance Administration (NHIA), Ministry of Health and Welfare. NHI system was funded was established in 1995 and now covers more than 99% of the population. In this study, we investigated the total numbers of MPI, treadmill exercise test (TET), stress echocardiography (SE), invasive coronary angiography (CAG) and PCI in 2016 from the data provided by NHIA. Cardiac MRI and CT were not reimbursed by NHI for CAD, therefore these two tests were not included in this study. **Results:** In 2016, the total numbers were 151254 for MPI, 190227 for TET, 1750 for SE, 91137 for CAG and 49806 for PCI, respectively. The utilization rate of MPI was 643 per 100000 of the population, which was only inferior to USA in the world. The TET to MPI ratio was only 1.26, however, MPI to SE ratio was as high as 86.43. The MPI to CAG ratio was 1.66 for Taiwan, but only 0.39 for Japan in 2016 and 0.24 for Germany in 2012. The MPI to PCI ratio was 3.04 for Taiwan but only 0.55 for Germany in 2012. **Conclusion:** Taiwan has a high MPI utilization rate for the work-up of CAD. MPI now is playing an important role of gatekeeper for invasive coronary procedures. This experience is useful and valuable for other countries on the promotion of appropriate use of MPI for CAD.

P059: Usefulness of Posterior Leads Derived from the 18-Lead Electrocardiogram in the Diagnosis of Posterior Myocardial Infarction
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**Background/Aims:** Although abnormal Q-waves in the posterior leads (V7-9) suggest prior posterior myocardial infarction (MI), clinical features of MI patients with Q-waves limited only to V7-9 leads has not been fully elucidated. The synthesized 18-lead ECG (Nihon Kohden), which has been developed recently, estimates V7-9 leads waveforms from the standard 12-lead ECG, without placing ECG leads on the back. We sought to evaluate the usefulness of posterior leads derived from the 18-lead ECG in the diagnosis of posterior MI. **Methods:** Myocardial SPECT was retrospectively analysed in prior non-anterior MI patients (n=218). The extent and severity score in the inferior or lateral area were analysed using a 17-segment model. The relation between these SPECT score parameters and Q-waves in the V7-9 leads was analysed using an 18-lead ECG. Patients with prior anterior MI, history of coronary artery bypass grafting, right or left bundle branch block, right or left ventricular hypertrophy, Wolff-Parkinson-White syndrome, a cardiac device implantation such as pacemaker or cardiac resynchronization therapy, were excluded. **Results:** Among 218 patients, Q-waves were solely limited to V7-9 leads in 15 patients (7%). No Q-wave in the inferior leads or high R-wave in the V1 lead was observed in these patients. Extent score in the lateral area was greater in 15 patients with Q-waves in V7-9 leads (2.2±1.9 vs 1.1±1.5; p=0.005) than in 203 patients without such findings, while extent score in the inferior area was similar (1.2±1.4 vs 2.0±1.7; p=NS). Severity score in the lateral area was also greater in patients with Q-waves in V7-9 leads (6.5±7.7 vs 2.2±3.8; p=0.05) than in those without, while extent score in the inferior area was similar (2.1±2.2 vs 3.0±4.0; p=NS). Among 15 patients with Q-waves limited to V7-9 leads, coronary angiography showed LCX lesion in 12 patients while distal RCA lesion in 3 patients. **Conclusion:** Even if a standard 12-lead ECG is masked to detect abnormal findings, the 18-lead ECG analysis reveals Q-waves in V7-9 leads, which is regarded as a simple indicator for posterior MI.
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**Background/Aims:** Stress myocardial perfusion imaging (MPI) using single-photon emission computed tomography (SPECT) is useful for risk stratification of seriously cardiac events. Now several software packages to analyse including the quantitative perfusion SPECT (QPS),\[[@ref103]\] cardioREPO,\[[@ref104]\] and Heart Risk View are available, which contain unique algorithm for automatic epi/endocardial extraction of each software. However, the automatic extraction sometimes does not work well in clinical cases with abnormal SPECT findings, in which we need to modify the segmentation manually. The modification affects uptake scores such as summed stress score (SSS) to estimate the prognosis of cardiac events. The purpose of this study is to investigate the difference of each automatic extraction and the influence of the manual modification. **Methods:** We reviewed 59 patients who underwent stress MPI using Tl-201, with SSS between 5 and 13 under the regular protocol in our institute. Their data were reprocessed with automatic extraction using QPS, adding manual modifications by less-experienced technologist and experienced technologist. Whereas automatic extraction was also performed using cardioREPO and Heart Risk View software. In parallel, an expert radiologist gave visual scoring without any quantitative results from software. Then we compared each SSS and summed rest score (SRS) between those automatic extractions, modifications, and visual scoring by correlation analysis. **Results:** SSS with the manual modification by the experienced technologist had the highest correlation to visual scoring SSS (R=0.76). SSS with automatic extraction (R=0.55) was lower than SSS with the manual modification even by the less-experienced technologist (R=0.68). Of automatic extractions, cardioREPO had the highest correlation, however was inferior to the manual modification by the experienced technologist. Regarding SRS, there was the same tendency as SSS. **Conclusion:** Manual modification is recommended to provide appropriate cardiac SPECT images to a clinician.

P062: Myocardial Perfusion Images in Patients with Three Vessel Coronary Artery Disease: Comparison with Visual and Software Program Assessment
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**Background/Aims:** Evaluation of ischaemia has been increasing its value in diagnosis and prognosis especially for patients with severe coronary artery disease such as multi vessel disease. It is difficult to exactly detect lesions in patients with balanced ischaemia in myocardial perfusion images(MPI). Recently software program using Artificial Neural Network (ANN) based on many characteristics from Japanese data base has been provided to assist interpretation of MPI. We compared visual assessment with two versions of software program assessments, old version based on European data base and new one based on Japanese data base, in MPI of patients with three vessel disease. **Methods:** Ten patients with three vessel disease diagnosed by coronary angiography were enrolled in this study. All of them underwent MPI. Stress and rest SPECT studies were performed. In visual assessment, two expert physicians in nuclear medicine detected myocardial abnormality. SPECT data were also analysed by software programs. **Results:** The age of the patients ranged from 50 to 70 years old. All patients had at least 90% stenosis in 2 vessels and ischaemic lesion. Four cases showed total occlusion vessels and myocardial damage. In this study, 80% of the patients had ischaemic lesion in apical and inferior wall and 60% of them in septal and lateral wall. In visual assessment, lesions were interpreted more severe than in software programs. In new version program, ischaemic area was clearer than old one. In cases of small heart, new version program could detect apex lesions well. About apex or anterior lesions, some cases showed different results of segmentation in visual assessment and software program assessment. **Conclusion:** There will be possibility of software program to support interpretation in MPI of patients with three vessel diseases. It needs to pay attention to variation of coronary artery distribution and sensitivity of software program.

P063: A New Insight into Myocardial Washout Rate of iodine-123-β-Methyl Iodophenyl-Pentadecanoic Acid: As a Crucial Index for Diagnosing Triglyceride Deposit Cardiomyovasculopathy
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**Background/Aims:** Triglyceride deposit cardiomyovasculopathy (TGCV) is a novel clinical entity found in Japanese patients waiting for heart transplant. TGCV is characterized by the accumulation of triglyceride into the myocardium and coronary artery. Diagnosing TGCV is often difficult because the patients are generally treated as coronary artery disease, heart failure or cardiomyopathy. In addition, plasma triglyceride level is not directly associated with TGCV. Remarkably reduced washout rate (WOR) of iodine-123-β-methyl iodophenyl-pentadecanoic acid (BMIPP) is useful for the diagnosis and it is one of the major diagnostic criteria for TGCV. However, executing additional delayed image is burdensome in some institutes, and WOR is sometimes substituted by reduced accumulation BMIPP in the early image. Therefore, we evaluated the usefulness of early BMIPP indices by comparing to the WOR of BMIPP in diagnosing TGCV. **Methods:** We executed early and delayed cardiac BMIPP imaging in 129 patients with cardiac disease to calculate WOR, and they were applied to diagnostic criteria for TGCV. In addition, early BMIPP indices, the heart to mediastinum ratio (H/M) of BMIPP and the relative accumulation of BMIPP to Tl (BM/Tl) were also calculated. **Results:** Among 129 patients, 59 received the definitive diagnosis of TGCV. The diagnostic values of the BMIPP indices were evaluated by ROC analysis. Area under the curve of H/M and BM/Tl were 0.53 and 0.75, respectively. The optimal diagnostic cut-off values of the H/M and BM/Tl were 2.50 (sensitivity = 52.5%, specificity = 56.3%) and 0.934 (sensitivity = 66.5%, specificity = 83.2%), respectively. **Conclusion:** For diagnosis of TGCV, early BMIPP indices cannot replace the WOR although BM/Tl uptake ratio might be useful in some extent. In any case, BMIPP scintigraphy has to be performed for patients with idiopathic coronary artery disease, heart failure and cardiomyopathy.

P064: Comparison of Diagnostic Accuracy of Myocardial Perfusion Imaging Between Visual Assessment and Artificial Neural Networks Based Diagnostic System in Both Cadmium-Zinc-Telluride Camera and Standard Anger Camera
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**Background/Aims:** Although an artificial neural network (ANN)-based diagnostic system is reported to have good diagnostic accuracy in the myocardial perfusion imaging using the Anger cameras,\[[@ref105]\] the applicability of the ANN-based diagnostic system for cadmium-zinc-telluride (CZT) camera remain to be elucidated. **Methods:** The study group comprised of 84 consecutive patients who underwent a 1 day ^99m^Tc-sestamibi stress/rest myocardial perfusion imaging (370 MBq for stress, 740 MBq for rest) and performed data acquisition with both a conventional Anger camera and CZT camera (Discovery NM530c). Myocardial perfusion was assessed by each coronary territory using a 17-segment model visually, and summed scores were analysed. The perfusion abnormality at stress SPECT derived by the ANN-based diagnostic system was determined using cardioREPO®. **Results:** Among 252 coronary territories visually evaluated, 102 territories showed normal findings, 54 fixed defects (FD), 95 reversible defects (RD), and 1 reverse redistributions (RR) in a standard Anger camera. By contrast, 91 territories showed normal findings, 61 FD, 67 RD and 33 RR in a CZT camera. On the Anger camera, the ANN-based analysis showed less area under the ROC curves (AUC) than summed stress score (SSS) (LAD: 0.57 vs. 0.76, p\<0.05, RCA: 0.75 vs. 0.87, p=NS, LCx: 0.65 vs. 0.84, p\<0.05). On the other hand, on the CZT camera, the ANN-based analysis showed equivalent AUC compared with SSS (LAD: 0.75 vs. 0.71, RCA: 0.81 vs. 0.78, LCx: 0.78 vs. 0.76, respectively; all p=NS). **Conclusion:** These results indicate that ANN-based diagnostic analysis may be useful as the auxiliary diagnostic tool even in CZT camera system.

P065: Stress-Induced Left Ventricular Diastolic Dysfunction Assessed by Quantitative Gated Myocardial Perfusion Single Photon Emission Computed Tomography as a Determinant of Coronary Artery Disease Severity
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**Background/Aims:** The aim of this study was to evaluate the utility of stress-induced left ventricular (LV) diastolic dysfunction assessed by ^99m^Tc-tetrofosmin gated single photon emission computed tomography (SPECT) in determining the presence and extent of coronary artery disease (CAD). **Methods:** Two hundred and one patients (135 men; mean age 70y) who underwent a one-day adenosine stress-rest ^99m^Tc-tetrofosmin myocardial perfusion imaging with subsequent coronary anatomy evaluation by invasive or computed coronary angiography were included. The summed difference score (SDS) was calculated for each patient. Peak filling rate (PFR), 1/3 mean filling rate (MFR/3) and time to PFR (TTPFR) after stress and at rest were derived from standard 16-frame gated SPECT images, and the percent stress-to-rest difference of these parameters were determined to describe stress-induced diastolic dysfunction. **Results:** In the overall population, the mean SDS was 5±4, while mean PFR at rest and after stress were 2.1±0.6 end-diastolic volumes (EDV)/s and 2.0±0.7 EDV/s, respectively. The mean rest and stress MFR/3 were 1.2±0.4 EDV/s and 1.1±0.4 EDV/s respectively, while the mean TTPFR was 248±121ms at rest and 261±115ms after stress. There is a significant correlation (p\<0.05) between the presence and extent of CAD and both myocardial SDS and more altered diastolic function parameters. Furthermore, there was trend of increasing extent of CAD and worsening stress-induced LV diastolic dysfunction described as decreasing percent stress-to-rest difference in PFR and MFR/3 and increasing TTPF. The independent diastolic function determinants of the presence and extent of CAD in this study are the percent stress-to-rest TTPF difference (p=0.006) and the stress TTPF value (p=0.006). Other significant determinants noted are myocardial SDS (p=0.002), resting ejection fraction (p=0.001), indexed resting end-systolic volume (p=0.007) and indexed end-diastolic volume at stress (p=0.009). **Conclusion:** This study shows that stress-induced LV diastolic dysfunction assessed by gated SPECT aids in the detection of the presence and extent of CAD.

P066: Does Aspirin Modify Gastric Wall Sestamibi uptake in Patients Taking a Proton Pump Inhibitor?
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**Background/Aims:** Gastric wall sestamibi uptake is a source of artefacts on myocardial perfusion imaging (MPI) and has been associated with proton-pump inhibitor (PPI) therapy. PPI treatment predictably increases serum gastrin, a hormone known to induce expression of the COX-2 isoenzyme and prostaglandin synthesis in the gastric mucosa. Prostaglandin effects including mucosal hyperplasia and increased blood flow are plausible mechanisms for increased sestamibi uptake. Thus, it was hypothesised that concurrent use of aspirin, an irreversible inhibitor of COX-2, might reduce the effect of PPIs on gastric wall sestamibi uptake. **Methods:** We reviewed medical records and images of 319 consecutive patients undergoing MPI Between July 1 and September 30, 2015, for clinically significant gastric wall sestamibi uptake (greater than myocardium), PPI use, and aspirin use. We estimated the relative risk (RR) for significant gastric wall uptake associated with PPI use stratified according to aspirin use. (Approved by TPCH HREC.) **Results:** Significant gastric wall sestamibi uptake was seen in 55/135 (41%) of patients taking a PPI versus 32/184 (17%) not taking a PPI for a RR of 2.3. The RR due to PPI use stratified by aspirin use was:

![](WJNM-17-49-g001.jpg)

**Conclusion:** There was evidence of an association between PPI use and clinically significant gastric wall sestamibi uptake (RR 2.3). The effect of PPIs was stronger in the absence of concurrent aspirin use (RR 3.8) but weak or non-existent in the subgroup taking aspirin. Therefore, aspirin may inhibit the increased gastric uptake on MPI studies due to PPI therapy in keeping with mediation by the gastrin-COX-2-prostaglandin pathway. Our study raises the possibility that short-term use of aspirin or a selective COX-2 inhibitor may improve image quality in patients taking a PPI.

P067: Performance Evaluation of a Myocardial Perfusion Analysis Software with the Artificial Neural Network in Stress Myocardial Perfusion Scintigraphy
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**Background/Aims:** Myocardial perfusion analysis software has been widely used for the detection of ischaemic heart disease and evaluation of prognostic. in myocardial nuclear medicine. A newly released myocardial perfusion analysis software, cardioREPO (cREPO: FUJIFILM RI Pharma, Tokyo, Japan; with EXINI Diagnostics, Lund, Sweden), has an artificial neural network. Recently, its usefulness of ischaemia evaluation in myocardial perfusion single photon emission computed tomography (SPECT) has been reported. However, the diagnosis accuracy of cREPO in each coronary artery branch areas has not yet reported. The purpose of this study was to evaluate for the diagnostics concordance rate of cREPO and the quantitative perfusion SPECT (QPS) using the 17-segment detect score in myocardial perfusion SPECT in each coronary artery branch areas. **Methods:** (1) The retrospective survey of a125 participants who had undergone ^99m^Tc-methoxy-isobutyl-isonitrile (^99m^Tc-MIBI) scintigraphy were conducted. The image data of ^99m^Tc-MIBI stress myocardial perfusion SPECT were analysed with cREPO and QPS, and summed defect scores in each coronary artery branch areas (summed DS) were calculated. (2) The receiver operating characteristic (ROC) analysis were performed for cREPO and QPS based on the diagnosis data from cardiac catheterization. **Results:** The summed DS of cREPO and QPS were significantly concordant in each branch areas (RCA: r~s~=0.07, LAD: r~s~=0.66, LCx: r~s~=0.57). There were no significant differences between area under the curve values of cREPO and that of QPS (p\>0.05). **Conclusion:** It was suggested that cREPO is useful to evaluate ischaemia in each coronary branch areas as well as QPS.

**Disclosure of Interest:** H Miyauchi Conflict with: FUJIFILM RI Pharma; T Iimori Conflict with: FUJIFILM RI Pharma; K Sawada Conflict with: FUJIFILM RI Pharma; Y Kuwabara Conflict with: FUJIFILM RI Pharma; Y Kobayashi Conflict with: FUJIFILM RI Pharma, Tokyo, Japan.

P068: Relationships between Electrical and Mechanical Dyssynchrony in Patients with Right Bundle Branch Block
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**Background/Aims:** Right bundle branch block (RBBB) can cause electrical dyssynchrony but it´s association to mechanical dyssynchrony is not as thoroughly understood. In this study, we characterized electrical and mechanical dyssynchrony and analysed their relationships in RBBB patients as well as in healthy controls. **Methods:** We analysed data of 994 patients who underwent myocardial perfusion imaging (MPI) SPECT. Thirty patients fulfilled criteria for RBBB (Surawicz et al. 2009) and twenty-four for controls. 12-lead-ECGs recorded along with MPIs were transformed to vector electrocardiography (VECG) for characterizing electrical activation. Left ventricular (LV) mechanical dyssynchrony was analysed by using MPI phase analysis method. MPI parameters representing mechanical dyssynchrony were phase analysis bandwidth (phaseBW), standard deviation and Entropy%. **Results:** 43% of RBBB patients had LV-mechanical dyssynchrony. ECG/VECG parameters that were significantly different between RBBB patients with and without mechanical dyssynchrony were QRS/T angle (105° vs. 59°, p=0.018) and QRS-angle in sagittal plane (QRSsag;-56° vs. 26°, p=0.049). In multivariate analysis, independent predictors for mechanical dyssynchrony were QRS duration (QRSd) and QRSsag. Together these two parameters explained 40% of the variation in phaseBW. The optimal cut-off value for predicting mechanical dyssynchrony was 144 ms for QRSd with the sensitivity of 67% and the specificity of 80%. For QRSsag the cut-off value was 49° with the sensitivity of 73% and the specificity of 77%. **Conclusion:** Almost half of the RBBB patients have LV mechanical dyssynchrony analysed with MPI phase analysis. RBBB patients with mechanical dyssynchrony had wider QRS/T angle and more negative QRSsag compared to controls and RBBB patients with more synchronous LV contraction. This finding may have clinical value when evaluating patients for cardiac resynchronizing therapy.

**Disclosure of Interest:** S Sillanmäki Conflict with: Educational support from GE Healthcare.
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**Background/Aims:** Amyloidosis is a heterogeneous group of diseases characterized by localised or systemic deposition of insoluble extracellular fibrillary proteins into organs and tissues. Several types of amyloid can infiltrate the heart which can result in restrictive cardiomyopathy, heart failure and even cardiac arrhythmias. Scintigraphy is a non-invasive method that has been shown to facilitate early diagnosis of cardiac amyloidosis, hereditary or wild type (wt) ATTR. Since wt ATTR, formerly designated as senile systemic amyloidosis (SSA), is normally found in elderly males matching the ages found in prostate cancer patients referred to bone scan, we wanted to investigate the incidence of cardiac uptake in patients examined with ^99m^Tc-HDP and frequency of contemporary atrial fibrillation, hypertension and heart failure. **Methods:** A total of 1000 patients during 2012-2016 referred to skeletal scintigraphy with ^99m^Tc-HDP were consecutive included in this retrospective study. Data were obtained from referral and journals for both men and women in accordance with the approved ethical application. Data of diagnosed hypertension, heart failure or atrial fibrillation were collected. For tables and statistics, Excel 10 was used. p-values \<0.05 was considered statistically significant. All patients received intravenous injection 550MBq of ^99m^Tc-HPD. 3 hours after the injection, the entire body was scanned with anterior and posterior planar imaging. All scans were visually graded by an experienced radiologist with nuclear medicine according to Perugini *et al*.\[[@ref106]\] **Results:** Cardiac uptake were seen in 1.6% of the patients, predominant in elderly men. In a subgroup of men over 80 years of age 8.9% had cardiac uptake. The presence of atrial fibrillation and heart failure was statistically significantly higher in both men and women with cardiac uptake, p \<0.001, even after age correction. No significant association with hypertension was seen. **Conclusion:** Cardiac uptake of ^99m^Tc-HDP in clinical routine is associated with a higher frequency of atrial fibrillation and heart failure compared to age matched controls. Thus,^99m^Tc-HDP can be proposed as a potential biomarker for ATTR.
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**Background/Aims:** Efforts continue in decreasing radiation to patients from radiographic investigations. The ^99m^Tc-sestamibi stress scan, if performed as a 2 part study requires two separate radiotracer injections and a prolonged period in the laboratory. The stress only protocol, followed by a resting study if abnormal or equivocal, is an established alternative and has advantages in substantially reducing radiation burden, test time, cost and improving patient throughput. Some centres however prefer the two-part protocol in all patients for both clinical and logistic reasons. The aim of this study was to determine if certain pretest clinical characteristics correlated with absence of ischaemia on ^99m^Tc-sestamibi stress scan, so that selected patients could be pre-emptively allocated to stress-only protocol thereby minimising disruption to department scheduling. **Methods:** We conducted a retrospective review of 158 consecutive patients who undertook ^99m^Tc-sestamibi stress scans in our department. Patient and clinical characteristics of age, sex, coronary risk factor (CRF) status, prior myocardial infarction, prior ischaemic heart disease, left ventricular dysfunction, type of stress undertaken and admission status were correlated to the patient's myocardial perfusion scan result. **Results:** Of 158 patients, 42 (27%) had a positive and 116 (73%) a negative ^99m^Tc-sestamibi scan for ischaemia. Negative scans correlated with fewer CRFs (2.1:2.7 p\<0.01), a non-diabetic state (p\<0.05), normal left ventricular function (p\< 0.001) and patients were more likely to be female (p\<0.05). There was no significant correlation with age, history of myocardial infarction or ischaemic heart disease, absence or specific CRFs excluding diabetes, need for pharmacologic stress and inpatient status. **Conclusion:** Certain clinical and patient characteristics correlate significantly with absence of myocardial ischaemia, and could be used pre-emptively to individually prescribe stress only ^99m^Tc-sestamibi stress protocols to low risk patients, specifically to spare them an unnecessary radiation and temporal burden.

P072: Normal Values of Cardiac Mechanical Synchrony Parameters in Korean Population using Gated Myocardial Perfusion Single-Photon Emission Computed Tomography
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**Background/Aims:** The aim of this study was to evaluate the normal values of cardiac mechanical synchrony parameters in Korean population using one day low dose rest/high dose stress with adenosine gated myocardial perfusion SPECT. **Methods:** A total of 78 healthy controls consisted with 36 men and 42 women were retrospectively enrolled in the study. The healthy control was defined as people with low pretest likelihood of coronary artery disease, no abnormal finding in gated myocardial perfusion SPECT using one day low dose rest/high dose stress with adenosine, and QRS interval less than 120ms in electrocardiogram. For quantification of cardiac mechanical synchrony parameters, phase standard deviation (PSD), and phase histogram bandwidth (PHB) were measured on both rest and stress phases. Comparison of the normal values was performed by t-test. This study was approved from institutional review board. **Results:** PSD were 14.4 ± 2.5˚ (rest) and 15.2 ± 3.4˚ (stress) in male and 10.2 ± 1.9˚ (rest) and 11.3 ± 2.1˚ (stress) in female, PHB were 40.3 ± 4.5˚ (rest) and 47.2 ± 5.3˚ (stress) in male and 35.9 ± 4.8˚ (rest) and 40.6 ± 6.1˚ (stress) in female. Significant difference was noted in PSD between men and women both stress and rest and in PHB of the men between stress and rest. **Conclusion:** The normal values of cardiac mechanical synchrony parameters in Korean population showed significant difference in PSD between men and women on both stress and rest and in PHB of the men between stress and rest. Thus, centers using GMPS should have its normal database for men and women and stress and rest, respectively.

P073: Validation of Left Ventricular Ejection Fraction with the IQ•Single-Photon Emission Computed Tomography System in Small-Heart Patients
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**Background/Aims:** The IQ•SPECT system, which is equipped with multifocal collimators (SMARTZOOM) and uses ordered-subset conjugate gradient minimization as the reconstruction algorithm, reduces the acquisition time of myocardial perfusion imaging compared with conventional SPECT systems equipped with low-energy high-resolution collimators. We compared the IQ•SPECT system with a conventional SPECT system for estimating left ventricular ejection fraction (LVEF) in patients with a small heart (end-systolic volume \< 20 mL). **Methods:** The study consisted of 98 consecutive patients who underwent a 1 day stress-rest myocardial perfusion imaging study with a ^99m^Tc-labeled agent for preoperative risk assessment. Data were reconstructed using filtered back projection for conventional SPECT and ordered-subset conjugate gradient minimization for IQ•SPECT. End-systolic volume, end-diastolic volume, and LVEF were calculated using quantitative gated SPECT (QGS) and cardio REPO software. We compared the LVEF from gated myocardial perfusion SPECT to that from echocardiographic measurements. **Results:** End-diastolic volume, end-systolic volume, and LVEF as obtained from conventional SPECT, IQ•SPECT, and echocardiography showed a good to excellent correlation regardless of whether they were calculated using QGS or using cardio REPO. Although LVEF calculated using QGS significantly differed between conventional SPECT and IQ•SPECT (65.4%±13.8% vs. 68.4%±15.2%, p=0.0002), LVEF calculated using cardio REPO did not (69.5%±10.6% vs. 69.5%±11.0%). Likewise, although LVEF calculated using QGS significantly differed between conventional SPECT and IQ•SPECT (75±9.6 vs. 79.5±8.3, p=0.0005), LVEF calculated using cardio REPO did not (72.3%±9% vs. 74.3%±8.3%). **Conclusion:** In small-heart patients, the difference in LVEF between IQ•SPECT and conventional SPECT was less when calculated using cardio REPO than when calculated using QGS.
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**Background/Aims:** 'Low carbohydrate' diets are recommended to suppress cardiac glucose uptake and enhance image interpretation of ^18^F-FDG PET scans when diagnosing cardiac sarcoidosis. A review was undertaken to identify low carbohydrate dietary prescriptions within the cardiac sarcoidosis literature. **Methods:** A critical review of human studies in any language was undertaken using MEDLINE and PubMed databases until April 2017. Search terms included: Fluorodeoxyglucose F18; Myocardium OR Cardiac; diet OR carb\* OR fat; sarcoidosis. **Results:** Four studies were identified, all rated as NHMRC quality level III-3 to IV. One study described dietary preparation quantitatively (\<5g carbohydrate/meal) and qualitatively ("egg, tofu, grilled chicken with stir-fried vegetables").\[[@ref107]\] One study described preparation qualitatively, listing permitted (e.g. non-processed poultry, fish, meat, eggs) and prohibited foods (e.g. sugar, pasta, bread, starchy vegetables, fruit, milk, candy, sauces, alcohol).\[[@ref108]\] Intervention groups followed the same dietary preparation for differing lengths of time, with no comparison to high carbohydrate preparations. Two studies provided minimal dietary details; one described a "carbohydrate-restricted, fat-and protein-allowed diet for at least 12 hours"\[[@ref109]\] and another described a "fat meal: cheese, egg, etc, no carbohydrates before a 12 hour fast".\[[@ref110]\] In the four studies, dietary preparation protocols included: diet and fasting for 6, 12 or 18 hours and low carbohydrate diet for 1 meal, 12 hours, 24 hours or 72 hours. While prohibited foods were confirmed as high carbohydrate, no studies described carbohydrate as a proportion of energy. **Conclusion:** Despite published studies recommending low carbohydrate diets prior to ^18^F-FDG PET scans for diagnosing cardiac sarcoidosis, preparation advice and protocols greatly varied. Stronger study designs to determine a quantitative definition of a low carbohydrate diet are required to translate into clinical dietetic prescription and practice.
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F-Fludeoxyglucose Uptake by Untreated Fresh Autologous Pericardial Valve at Pulmonary Position: Positron Emission Tomography/Computed Tomography Valuation at Mid Term
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**Background/Aims:** Pericardium is most commonly used material for creating a cardiac valve. Commercially available bioprosthetic valve utilises treated xenogenic tissue. Autologous pericardial tissue is also in use for this purpose albeit treatment with gluteraldhyde. When untreated, it has the advantage of having living cells while creating the cardiac valve. However, there is no information if the property of living tissue at operation continues in years to follow when untreated pericardium is used as material for construction of cardiac valve. **Methods:** Pericardium was used to construct a competent pulmonary valve in patients of tetralogy of fallot requiring enlargement of pulmonary annulus. Between 2006 and 2012, 78 patients required reconstruction of pulmonary valve. Of these, 19 patients with more than 3 years of follow-up who consented for the study were included. The study was cleared by the ethics committee. All the patients underwent ^18^FDG PET scan following overnight fasting. Uptake of FDG by pericardial valve leaflet, native aortic and pulmonary valve leaflet is calculated. Uptake for LV and RV myocardium is also calculated. RV function is assessed by right ventricle fractional area shortening (RVFAC) in 2 D echocardiography. RVFAC of \<35% is considered RV dysfunction. **Results:** Median age was 14 years (9-37 years) and 16 were male. Follow-up is for median 4 years (3 -- 9). FDG uptake is observed in pericardial valve leaflet. Uptake show significant strong correlation with the native aortic leaflet (p=0.0001, AUC= 0.861) and native pulmonary leaflet in some cases (p=0.0001, AUC=0.844). RVFAC correlated with ratio of RV and LV FDG uptake (p=0.049). **Conclusion:** At midterm follow-up, pericardium to create pulmonary valve, has confirmed uptake of glucose. This was similar to the native aortic valve uptake. Uptake of glucose confirms living tissue, though its characterisation is not possible in the scope of study.

P077: Assessment of Left Ventricular Remodelling and Angiogenesis in Ischaemic-Reperfused Rat Hearts Protected by Dodecafluoropentane Oxygen-Carrier
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**Background/Aims:** We have previously demonstrated that NVX108, an oxygenated nano-emulsion of dodecafluoropentane (DDFP), can limit acute myocardial infarct (MI). It was unclear whether excess oxygen generation by DDFP delivery might have a negative impact on infarct repair. This study used SPECT to determine the effects of NVX108 on postinfarct left ventricular (LV) remodelling and angiogenesis in an ischaemic-reperfused (I/R) rat heart model. **Methods:** I/R rat hearts prepared by ligation of the left coronary artery (LCA) for 45-min followed by reperfusion were treated by intravenous injection of NVX108 (0.6 mL/kg) (n=8) or saline as control (n=6) 15-min after LCA-ligation. High-resolution SPECT studies were performed over 16 weeks. ^99m^Tc-sestamibi (MIBI) was used to assess myocardial perfusion and LV dilation. ^99m^Tc-3P~4~-(Arg-Gly-Asp)~2~ (^99m^Tc-3P~4~-RGD~2~, RGD) was used to assess α~v~β~3~ integrin expression associated with angiogenesis. After the final imaging session, the rats were sacrificed for postmortem analyses of myocardial RGD uptake and histopathological changes. **Results:** MIBI images showed LV defects in all hearts. The defects in the control hearts enlarged significantly from 1 week to 16 weeks (31.8±3.5% of LV vs. 39.7±4.8%, p\<0.05), whereas those in the NVX108-treated hearts did not (25.7±2.1% vs. 27.7±3.6%, p\>0.05). LV cavity size on MIBI tomography indicated that the LV dilated by a factor of 1.29±0.06 over 16 weeks in the controls and 1.05±0.04 in the NVX108-treated hearts (p\<0.05). Angiogenesis in the infarcted myocardium was most active at 1-week and still detectable at 16-week; there was no difference in the RGD activity (%ID/g) between the controls and NVX108-protected hearts (0.14±0.01 vs. 0.13 ±0.01%, p\>0.05). Autoradiography confirmed increased RGD uptake in the LV ischaemic areas-at-risk. **Conclusion:** Significant attenuation of post-infarct LV remodelling, as assessed by MIBI imaging, was achieved with administration of NVX108 as an oxygen carrier after an I/R incident. It appears that NVX108 limits adverse LV enlargement, while not showing inhibition of post-MI angiogenesis.
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Tc-Haxamethylpropyleneamine Oxime-Labelled Leukocytes -Labeled Leukocyte Single-Photon Emission Computed Tomography-Computed Tomography and Echocardiographic Results in Infective Endocarditis
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**Background/Aims:** Infective endocarditis (IE) is one of the most common life-threatening infection syndromes, with remaining high mortality. Establishing diagnosis is a clinical challenge. Single photon emission tomography (SPECT) and computed tomography (CT) with ^99m^Tc-haxamethylpropyleneamine oxime-labelled leukocytes (^99m^Tc-HMPAO) has recently been introduced as a novel diagnostic tool in patients with suspected IE. The aim of this study was to evaluate ^99m^Tc-HMPAO SPECT/CT and to compare with echocardiographic study. **Methods:** The study group included 40 consecutive adults with suspected IE, based on standard medical diagnostic process. Patients underwent transthoracic and transoesophageal echocardiography (TTE and TEE) for assessment of lesions typical for IE. Subsequently all patients had ^99m^Tc HMPAO SPECT/CT. Scans were evaluated for presence and location of increased radioactivity foci, which correspond to the accumulation of the radiolabelled leukocytes in inflammatory lesions. The patients were followed up for 6 months, which included outpatient visits and TTE. **Results:** For IE diagnosis, ^99m^Tc-HMPAO SPECT/CT was characterised by 93% sensitivity, 88% sensitivity, 96% negative predictive value,81% positive predictive value. There is statistically significant correlation between TEE and scintigraphic results. Extracardiac foci of increased radioactivity were observed in 47.5% of patients, with most common location in digestive system. **Conclusion:** In patients with suspected IE, ^99m^Tc-HMPAO SPECT/CT provides information about localisation and range of infection. ^99m^Tc-HMPAO SPECT/CT and echocardiography are complementary modalities in diagnosing IE, ^99m^Tc-HMPAO SPECT/CT can distinguish patients with IE and other systemic infections.
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**Background/Aims:** Cardiac amyloidosis is an infiltrative condition increasingly recognised as an important cause of diastolic heart failure and arrhythmias. The two main subtypes of this condition include Immunoglobin light-chain amyloidosis (AL) and Transthyretin-related amyloidosis (ATTR) characterised by extracellular deposition of misfolded proteins, thus forming deposits in the heart resulting in myocardial dysfunction. Differentiating AL from ATTR type is imperative for patient's prognosis and management. This case series aims to demonstrate how nuclear medicine can be used as a diagnostic tool in the diagnoses of ATTR in patients not suitable/considered for cardiac biopsy. **Methods:** Literature review was undertaken to demonstrate the validity of using ^99m^Technetium pyrophosphate (^99m^Tc-PYP) in the diagnosis of ATTR amyloid. In our case series, ^99m^Tc-PYP was administered to patients who were suspected of having ATTR amyloid and scanned 1 hour post injection. Semiquantitative and quantitative analysis was calculated through both visual scores and heart to contralateral ratio as per the protocol by Bokhari et al, Circ Imaging 2013. Definitive diagnosis was correlated on clinical findings, ECG, echocardiography, cardiac MRI when available and other relevant findings (eg. serum electrophoresis/fat pad biopsy). **Results:** Five subjects over a 12 month period were referred for cardiac amyloid scanning with ^99m^Tc-PYP. Three out of the five patients had a negative study for ATTR cardiac amyloid. The two out of five that were positive for ATTR cardiac amyloid demonstrated a visual score of 3 and Heart: Contralateral ratio of \>1.5% alongside highly suggestive clinical history/ECG/Echo +/-CMR findings. **Conclusion:** Nuclear medicine ^99m^Tc-PYP scintigraphy is a simple and widely available tool in the diagnoses of ATTR cardiac amyloidosis. ^99m^Tc-PYP may be considered as an alternative method to differentiate ATTR from AL cardiac amyloidosis in patients not considered for cardiac biopsy.

Gastrointestinal/Hepatobiliary

: P081: Unraveling a Decade-Long Case of Chronic Obscure Gastrointestinal Bleeding with
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**Background/Aims:** Representing 5% of approximately all cases of gastrointestinal bleeds, obscure gastrointestinal bleeding (OGIB) is defined as chronic occult or overt bleeding from the gastrointestinal tract that remains unexplained by standard upper and lower endoscopic and radiological gastrointestinal investigations. Causes of OGIB can range from vascular, neoplastic, inflammatory, and extraluminal etiologies. Endoscopic evaluation remains the cornerstone of the diagnosis and management of OGIB. However, for patients who are bleeding profusely or are hemodynamically unstable, this may pose a challenge. Arteriography or nuclear scintigraphy may therefore be considered in these situations. This case report details the case of a patient with a 10-year history of chronic OGIB that was eventually resolved with the aid of ^99m^Tc-red blood cell (RBC) scintigraphy. **Methods:** A 65-year-old male with a 10-year history of OGIB presented at the emergency department (ED) due to acute episodes of mixed hematochezia and melena. Multiple and varied previous work-ups for bleeding episodes over the years were unsuccessful in determining the etiology. He was referred to our department for RBC scintigraphy. **Results:** Scintigraphic examination done at the time of initial presentation was inconclusive. A month later, patient sought follow-up due to recurrence of OGIB. Repeat RBC scintigraphy demonstrated evidence of bleeding in the jejunal segments, which on oral enteroscopy revealed an ulcerated mass in the mid-distal jejunum. Resection and histopathologic examination of the mass confirmed a diagnosis of a gastrointestinal stromal tumour (GIST). **Conclusion:** RBC scintigraphy is a quick, simple, and non-invasive procedure that requires no specific patient preparation, making it useful in situations where endoscopy may not be immediately feasible or tolerated by the patient. It is a sensitive test that also enables continuous monitoring of the entire GI tract for up to 24 hours, thus increasing the likelihood of detection over other techniques that are limited to a single time point.

P082: Correlation between Preoperative Gastric Emptying Scintigraphy and Clinical Outcome after Bariatric Surgery
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**Background/Aims:** As morbid obesity continues to rise, more patients are turning to bariatric surgery for weight-loss. These surgeries, however, may potentially result in long-term motility disorders. This retrospective study assessed the value of gastric emptying scintigraphy prior to surgery with patient's post-surgical clinical outcome. **Methods:** Pre-operative gastric emptying studies for 101 patients (96 females, 5 males, mean age 44.7 years) were analysed. Five patients who underwent gastric scintigraphy after surgery and 1 patient with a non-diagnostic pre-op study were excluded. The results of pre-operative gastric scintigraphy were reviewed on 95 patients. Patients underwent either laparoscopic sleeve gastrectomy (77) or Roux-En-Y gastric bypass (24). The average post-operative clinical follow-up was 3 months after surgery. **Results:** Of the 95 patients who were analysed, 71 had normal and 24 had abnormal pre-op gastric emptying scintigraphy. Of the 71 patients with normal pre-op results, 46 (64.8%) were asymptomatic and 25 (35.2%) were symptomatic after surgery. Of the 24 patients with delayed pre-op results, 13 (54.2%) were asymptomatic and 11 (45.8%) were symptomatic post-op. There was no significant difference between pre-op gastric emptying results and post-surgical adverse clinical outcomes (p=ns). 76 patients underwent sleeve gastrectomy. Of the 62 patients with normal pre-op gastric emptying results, 41 (66.1%) were asymptomatic, and 21 (33.9%) were symptomatic after surgery. Of the 14 patients with delayed pre-op results, 8 (57.1%) were asymptomatic and 6 (42.9%) were symptomatic post op. Nineteen patients underwent Roux-en-Y gastric bypass. Of the 9 patients with normal pre-op gastric emptying, 5 (55.6%) were asymptomatic, and 4 (44.4%) were symptomatic after surgery. Of the 10 patients with delayed pre-op results, 5 (50%) were asymptomatic, and 5 (50%) were symptomatic post op. There was no significant correlation between pre-op gastric emptying study results, surgery type, and post-surgical clinical outcome (p=ns). **Conclusion:** Pre-operative gastric emptying study was not a strong predictor of clinical outcome in bariatric surgery. There was no significant association between pre-op gastric emptying and surgery type. We recommend a larger sample size representing each surgery type and longer range of follow-up to predict patient's outcome.

P083: 25-hydroxyvitamin-D Serum Levels in Patients with Idiopathic Inflammatory Bowel Disease. Correlation with Disease Severity
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**Background/Aims:** Idiopathic bowel disease includes immune system diseases of unknown origin. The pathogenesis involves a complex between genetic, environmental, and immunologic factors. In the present study, we examine the vitamin D serum values of patients with IBD and its relation with the severity of the disease. **Methods:** 125 patients (78 men and 47 women), aged from 28 to 68 (average 54 +/-6), were examined in a 3 years period. 87 had IBD in several stages-48 with ulcerative colitis (25 men, 23 women) group A, 39 with Crohn's disease (23 men, 16 women) group B and 38 (30 men, 8 women), with general gastrointestinal diseases group C. Patients originated from clinics of University Hospital of Evros. The evaluation of vitamin D levels was made at the University Nuclear Medicine Department by using the radioimmunoassay method with kits Dia-Sorin Italy. Statistical analysis was performed by the x^2^-test (student test) and statistical significance was considered for p\<0.05. **Results:** 82% of group A patients had low values of vitamin D (deficiency), 12% showed insufficiency and 6% had sufficiency serum vitamin D levels (p \<0.05). In group B 83% had deficiency, 15% had insufficiency and 2% had sufficiency vitamin D levels (p \<0.05). It should be noted that in both groups A and B patients with severe diseases had a very low 25-hydroxyvitamin-D levels (p \<0.05). In group C patients had lower rates compared to those of groups A and B, where 57% showed a deficiency, 32% showed insufficiency and 11% showed sufficiency (p \<0.05). **Conclusion:** The evaluation of serum vitamin D in patients with IBD is useful in patients monitoring. The very low values of 25-hydroxyvitamin-D are associated with disease severity. Further studies are required for any possible improvement of patient status after vitamin D substitution.

P084: Evaluation of Sonographically Suggested Cases of Hepatic Hemangioma by
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**Background/Aims:** Hemangioma is the most common benign hepatic tumour and second most common neoplasm of the liver, following intrahepatic metastases. They are most common in people in their third to fifth decade of life. Women, especially with a history of multiparity, are affected more often than men. The female-to-male ratio is 4:1 to 6:1. The course of hemangioma is usually uncomplicated, differentiation from other lesions, such as metastases, is essential to avoid unnecessary or risky examination and treatment. Ultrasonogram is sensitive but not specific for evaluating hepatic hemangioma. Using CT, there is some evidence that metastatic lesions and hepatoma may have an appearance similar to that of hemangioma. **Methods:** An observational descriptive cross-sectional study, made on 110 sonographically suggested hepatic hemangioma cases in National Institute of Nuclear Medicine and Allied Sciences (NINMAS) were studied. Hepatic hemangioma with tumour size \<2cm and pregnant women were excluded from this study. **Results:** In this study, it was revealed that among 110 sonographically suggested hepatic hemangioma cases, 66 cases were true positive for hepatic hemangioma done by ^99m^Tc-RBC scintigraphy. There was a significant difference between 2 different age in RBC scan positive cases of hepatic hemangioma (p\<0.001). Among the patients with \<50 years, total 52 (69%) patients were true positive for hepatic hemangioma whereas among the patients with ≥50 years, total 14 (40%) patients were true positive for hepatic hemangioma. There was significant association between \<50 years and hepatic hemangioma (p\<0.001). **Conclusion:** Hepatic hemangioma is the most common benign tumour with a clinical diagnosis of a significant importance. Diagnosis of hepatic hemangioma is sometimes difficult by means of ultrasound. ^99m^Tc-RBC scintigraphy is very sensitive and specific imaging modality for this kind of lesion.

P085: Solitary Ischaemic Necrosis of the Liver: Role and Imaging Characteristics of
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**Background/Aims:** The liver has a unique dual blood supply-75% portal venous, 25% hepatic arterial-which makes ischaemic liver necrosis a rare finding. When observed, pre-existing conditions resulting in impaired blood flow should be excluded. We present a case illustrating the supportive role of multimodal imaging in diagnosis. **Methods:** Only a limited number of cases regarding solitary ischaemic liver necrosis have been published. Existing case reports were reviewed, supplemented by literature, regarding the pathophysiology of ischaemic liver disease. **Results:** A 52-year-old woman was transferred to Ghent university hospital after newly diagnosed infarction of liver segments 5 and 6, with concurrent occlusion of the celiac trunk and superior mesenteric artery. She suffered from chronic abdominal pain, inadequately responsive to drug treatment and resulting in total weight loss of 20 kilograms. Relevant history included heavy smoking, gastritis treated with proton-pump inhibitors and cholecystitis treated with antibiotics. Abdominal palpation showed no rebound tenderness. Laboratory results showed severely impaired liver function tests, marked inflammation and thrombocytosis. The urgent nature of this case initiated multiple investigations. Normal coronarography and repeat ECG made atherosclerotic and arrhythmogenic etiology highly unlikely. Autoimmune and infectious serology were normal. MRI scan confirmed stable liver necrosis. ^18^F-FDG PET/CT excluded large-vessel vasculitis and underlying neoplasm as thromboembolic origin, yet revealed low-grade cholecystitis, confirmed by cholecystectomy. Liver biopsy confirmed ischaemia and necrosis. After elaborate genetic testing, essential thrombocytosis was presumed the most likely diagnosis. Right hepatectomy was planned and prophylactic heparin was continued. Unfortunately, prior to surgery new thrombosis resulted in extensive acute mesenteric ischaemia and the patient's death. **Conclusion:** Solitary ischaemic liver necrosis is rare and rapid diagnosis of the underlying problem is mandatory. This case illustrates the supportive role of whole body ^18^F-FDG PET/CT in the diagnostic approach of life-threatening ischaemic liver necrosis excluding underlying pathology such as vasculitis and malignancy-related hypercoagulability.

P086: Evaluation of the Effect of Percutaneous Transhepatic Portal Embolization Using
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**Background/Aims:** ^99m^Tc-galactosyl human serum albumin (^99m^Tc-GSA) measures the total amount of asialoglycoprotein receptor within a subject's liver. The purpose of this study was to evaluate the effect of percutaneous transhepatic portal embolization (PTPE) to induce compensatory hypertrophy of the remnant lobe using ^99m^Tc-GSA SPECT/CT for assessment of hepatic function. **Methods:** This study was approved by our institutional ethics review board. ^99m^Tc-GSA SPECT/CT was performed before and 2 weeks after PTPE of the right portal vein in 9 patients. The liver uptake ratio (LUR) which reflects the amount of asialoglycoprotein receptor and liver volume (LV) using ^99m^Tc-GSA SPECT/CT data were calculated separately in the right and left lobes, as well as in the whole liver. Correlations between the LUR and LV values and the result of conventional test of the hepatic functional reserve, i. e., the indocyanine green retention rate at 15 minutes after administration (ICG15) were analysed. **Results:** The proportion of the non-embolized lobe (left lobe) LV to the total LV slightly increased after PTPE (p=0.085) and the proportion of the right lobe LV to the total LV slightly decreased after PTPE (p=0.085). After PTPE, the proportion of the right LUR to the total LUR significantly decreased (p\<0.04) and the proportion of the left LUR to the total LUR significantly increased (p\<0.04). The total LUR correlated particularly well with ICG15 (p\<0.001). **Conclusion:** ^99m^Tc-GSA SPECT/CT showed that PTPE induces a shift in hepatic function from the embolised part to the non-embolised part of the liver.
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: P087: The Bone Scan Pattern of Two Concomitant Rare Diseases in a Paediatric Patient
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**Background/Aims:** Sturge-Weber syndrome is a rare, sporadic neurocutaneous syndrome, characterized by leptomeningeal angiomatosis and an ipsilateral facial cutaneous vascular malformation. Ewing's sarcoma is a rare malignant tumour of the foot, very rarely occurring in the talus bone. **Methods:** The patient is a 15--year-old girl, with a background of Sturge-Weber syndrome who presented with Ewing's sarcoma of the left talus bone. Whole body bone scan showed tumoural involvement of the left talus bone extending to the left lower tibia, left ankle soft tissue involvement, and right humeral head metastasis. High diffuse radiotracer uptake of right skull half was also noted, which was confirmed as leptomeningeal angiomatosis on brain MRI. **Results:** Weber syndrome, in which angiosarcoma and malignant peripheral nerve sheet tumour have been demonstrated to be coinciding.\[[@ref111][@ref112]\] Existence of added risk of malignancies in patients with Sturge-Weber syndrome warrants further investigations and researches. **Conclusion:** It is a report of a case with concomitant two rare diseases.

P088: Enhanced Diagnostic Performance of Three Phase Bone Single-Photon Emission Computed Tomography for Osteomyelitis by Addition of Blood Pool Single-Photon Emission Computed Tomography
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**Background/Aims:** Bone scan is a highly sensitive modality for detection of osteomyelitis, however it has lower specificity. The purpose of this study was to investigate if addition of blood pool SPECT/CT could enhance the diagnostic performance of osteomyelitis (OM), compared to the conventional method using three phase bone scan (TPBS) with bone SPECT/CT. **Methods:** Twenty-one patients with suspected OM were enrolled, retrospectively, including patients who had history of old bone fracture (n=6), previous soft tissue inflammation (n=3), rheumatoid arthritis (n=2), diabetic foot (n=2), and no other relevant history of inflammation (n=8). TPBS, blood pool SPECT/CT and bone SPECT/CT were performed sequentially after a single injection of ^99m^Tc-MDP. The results were confirmed by surgery or clinical follow-up over 6 months. **Results:** OM was diagnosed in 11 of 21 patients (52.4%)-9 patients surgically, and 2 patients clinically. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 81.8%, 50%, 64.3% 71.4%, and 66.7% for TPBS; 90.9%, 80%, 83.3% 88.9%, and 85.7% for combined TPBS and bone SPECT/CT (conventional method); and 90.9%, 90%, 90.9%, 90%, and 90.5% for combined conventional method and blood pool SPECT/CT. In eight patients without any relevant history of inflammation, both TPBS alone and blood pool SPECT/CT alone showed high sensitivity (100%, respectively), while the specificity was higher in blood pool SPECT/CT alone (100%), compared to TPBS alone (specificity 50%). **Conclusion:** Addition of blood pool SPECT/CT could enhance the diagnostic accuracy and specificity of osteomyelitis, compared to conventional imaging methods using TPBS or combined TPBS and bone SPECT/CT, providing accurate anatomic information for the location of increased blood pool activity on CT images.

P089: Bone Single-Photon Emission Computed Tomography in Diagnostics of Vertebral Diseases
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**Background/Aims:** Whole body scintigraphy (WBS) is the diagnostic method most commonly used in nuclear medicine. There is an increased interest in the literature for the use of tomography in the diagnosis of vertebropathies. Retrospective analysis comparing the advantages of SPECT/CT over WBS in the diagnosis of vertebropathies. **Methods:** Using the gamma camera Phillips Bright View, 20% of the 2127 WBS performed 73% (1565) of the orthopaedic indication in 2015. SPECT/CT was added in 6% of cases. In detail, were analysed 87 patients 39M and 48F (64.1±12.5). From 2 to 18 vertebrae were evaluated in all patients by two independent observers. **Results:** In assessing the most serious pathology, the agreement between WBS and SPECT/CT was 35.2%. The most common disagreement 12x (54.5%) was between facet joint arthrosis (FJA) and spondylosteophytes (SPO). FJA was diagnosed in 9 patients with SPECT/CT, as compared with 18 unclear findings on WBS. The diagnosis of SPO was identical in 6 and specified in 23 cases. SPECT/CT revealed 18.6% more pathologic findings than WBS (increased sensitivity). Of 645 vertebrates, SPO were present on CT in 50.1% (323 cases). Their incidence was increased with the age of patients. Of these, there were only 28.2% scintigraphically active and the incidence only minimally correlated with age. **Conclusion:** SPECT/CT contributes to a marked increase in the sensitivity and specificity of skeleton scintigraphy in the diagnosis of pathological spine changes. A positive finding on the spine SPECT/CT shows the activity of the pathological process and the higher clinical severity of FJA and SPO, which cannot be detected by CT itself. Its wider use has the benefit of indicating and evaluating targeted vertebropathic treatment.

P090: Axillary Lymph Node Assessment on 18F Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Rheumatoid Arthritis Patients Treated with Biologic Therapies
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**Background/Aims:** Lymphadenopathy is a common extra-articular manifestation in rheumatoid arthritis (RA). We employed positron emission tomography (PET) with ^18^F-fluorodeoxyglucose (FDG) administration for assessing lymph node (LN) inflammation in RA patients treated with biologic therapies. We aimed to evaluate the correlation between the FDG uptake parameters of axillary LN and those of the arm joints as well as the disease activity before and after biologic treatment. **Methods:** Sixty-seven patients with RA were assessed. ^18^F-FDG PET and clinical evaluations were performed at baseline and 6 months after the treatment. Quantitative parameters including maximum standardized uptake value (SUV~max~), metabolic active volume (MAV), and total lesion glycolysis (TLG) were used for the FDG uptake. Clinical evaluations include the serum markers and the disease activity scores (DAS28 and DAS28-CRP). The D represents the differences of each parameter before and after treatment. **Results:** Significant correlations were observed between the FDG uptake parameters (DSUV~max~ and DTLG) of the axillary LN and those of the arm (elbow + wrist) joints (*r*=0.524, p\<0.001; *r*=0.424, p\<0.001, respectively). There were also positive correlations between the DSUV, DMAV, and DTLG of the axillary LN and the DDAS28 (*r*=0.412, p=0.001; *r*=0.315, p=0.009; *r*=0.370, p=0.002), DDAS28-CRP (*r*=0.455, p\<0.001; *r*=0.370, p=0.002; *r*=0.438, p\<0.001), respectively. **Conclusion:** The FDG uptake of the axillary LN may reflect the inflammatory activity of the elbow and wrist joints and correlate with the therapeutic response to the biologic treatment of RA.

P091: Positron Emission Tomography/Magnetic Resonance Imaging Fusion Demonstrates Hamstring Peritendonitis in Untreated Patients with Polymyalgia Rheumatica
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**Background/Aims:** To characterise ^18^F-fluorodeoxyglucose (^18^F-FDG) uptake on whole body positron emission tomography/computed tomography (PET/CT) in polymyalgia rheumatica (PMR), and identify its precise anatomic correlate using magnetic resonance imaging (MRI). **Methods:** Patients with newly diagnosed PMR according to the 2012 EULAR/ACR classification criteria were prospectively recruited. Participants with giant cell arteritis were excluded. A whole body ^18^F-FDG PET/CT scan was performed in all untreated patients. Qualitative and semi-quantitative (standardised uptake value maximum \[SUV~max~\]) scoring of abnormal ^18^F-FDG uptake was undertaken. MRI of the pelvis, knee and, wrist and hand was performed in three representative patients with anatomical correlation of FDG avid sites carried out using Medview fusion software. **Results:** Twenty-two patients with PMR were recruited. Mean age was 68.3±6.3 years and 13/22 were male. On whole body PET/CT, ^18^F-FDG uptake adjacent to the ischial tuberosities was observed in twenty-one participants (95.4%), and recorded the highest mean SUV~max~ value (3.6±1.7). A high frequency of posteromedial knee (61.9%) and, wrist and/or hand involvement (66.7%) was also appreciated. MRI pelvis revealed high T2 signal surrounding the proximal hamstring tendon origins of both semimembranosus and the conjoint tendon of semitendinosus and biceps femoris. At the knee, peritendonitis at the distal insertion of semimembranosus was observed. PET/MRI fusion at the pelvis and knee confirmed semimembranosus peritendonitis as the anatomical correlate of ^18^F-FDG uptake adjacent to the ischial tuberosities and of posteromedial knee structures. **Conclusion:** Hamstring peritendonitis is a common and distinctive manifestation of PMR on whole body PET/CT.

P093: Comparison of Diagnostic Capability About Different types of Bone Metastases between Positron Emission Tomography/Computed Tomography and Whole Body Bone Scan
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**Background/Aims:** The purpose of this study is to analyse the value of ^18^F-FDG PET/CT and ^99m^Tc-MDP whole-body bone scan to diagnose different types of bone metastases. **Methods:** Twenty-six patients with bone metastases underwent ^18^F-FDG PET/CT and whole-body bone scan were enrolled in this study. The diagnostic ability between ^18^F-FDG PET/CT and ^99m^Tc-MDP SPECT whole-body bone scan for bone metastases were analysed. The diagnostic sensitivities for different types of metastatic tumours of bone were compared between PET/CT and whole-body bone scan. **Results:** Among 135 lesions which were detected by PET/CT and whole-body bone scan, 121 lesions were clinically confirmed to be metastases and 14 lesions were benign. The statistical difference of diagnostic efficiencies between PET/CT and whole-body bone scan is significant (p\<0.05). The sensitivities for the diagnosis of osteolytic, osteoblastic, mixed and normal bone structure metastatic tumours diagnosed by PET/CT and whole-body bone scan were 95% (35/40) and 90% (36/40), 100% (25/25) and 72% (18/25), respectively. **Conclusion:** The diagnostic value of PET/CT for bone metastases is obviously better than that of whole body bone scan. For different types of bone metastases, the diagnostic capability is different between PET/CT and whole body bone scan. It is necessary to be rational selection of PET/CT and whole body bone scan in staging of primary neoplasms.

P094: Lumbar Spine and Hip Bone Mineral Densities of Healthy Filipino Adults Aged 20--39 Years
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**Background/Aims:** Bone Mineral Density (BMD) measurements are utilised in the diagnosis of osteoporosis and low bone mass, and are indicators of bone health. The Philippines has a rapidly aging population and it is anticipated that osteoporosis will be a major health issue in the future. Peak bone mass is achieved by age 18 to 25 and a current assessment of the BMDs of young Filipino adults may be beneficial to clinicians as a baseline reference for the possible trend of bone health. This study aims to present lumbar spine and hip BMD measurements of Filipinos aged 20 to 39 years old. **Methods:** Subjects included 105 healthy young adults who underwent Dual Energy X-ray Absorptiometry (DXA) from 2011 to 2016 at St. Luke's Medical Center. BMD measurements of lumbar spine and femoral necks were obtained using the GE Lunar DXA machine. Mean and standard deviations (SD) of measurements were determined. **Results:** Mean age of patients is 31.5 years. Fifty-seven percent of subjects belong to the 30-39 year age group. Results of BMD measurements were grouped according to sex and decade. Mean BMDs of females aged 20-29 are as follows: spine 1.092g/m^2^ (SD 0.143), left femoral neck (LFN) 0.853g/m^2^ (SD 0.085), and right femoral neck (RFN) 0.856g/m^2^ (SD 0.086). For females aged 30-39: spine 1.124g/m^2^ (SD 0.112), LFN 0.848g/m^2^ (SD 0.108), and RFN 0.854g/m^2^ (SD 0.113). For males aged 20-29: spine 1.159g/m2 (SD 0.195), LFN 0.976g/m^2^ (SD 0.195), and RFN 0.977g/m^2^ (SD 0.183). Lastly, for males aged 30-39 are: spine 1.129g/m^2^ (SD 0.115), LFN 0.869g/m^2^ (SD 0.159), and RFN 0.891g/m^2^ (SD 0.186). Of the 105 patients, 95 had BMDs within normal while 10 were below the expected range. **Conclusion:** Majority of subjects have BMDs that are within normal based on World Health Organization (WHO) and International Society for Clinical Densitometry (ISCD) standards.

P095: Relationship between Normal Thyroid Hormone Profile and Bone Mineral Density Among Healthy Euthyroid Subjects
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**Background/Aims:** Thyroid illness such as hyperthyroidism affect the bone mineral density and prone such patients to osteoporotic fractures. The normal range of thyroid profile with upper and lower limits could affect the bone mineral density with estimation of fracture risks. Such individuals may adopt measures for their bone health such as bone strengthening exercises, calcium and vitamin D supplements. **Methods:** The study was approved by the ethical committee of the Institution. Euthyroid subjects with normal thyroid hormone profile were enrolled in the study, having no systemic illnesses. Each subject underwent DXA scan of Lumbar Spine (L1-L4) & Hip regions. Bone mineral density values (BMD) were calculated and risk estimation of fractures were estimated on the basis of T-score with WHO classification. Pearson correlation (r-value) with statistical significance (p\<0.05) between serum thyroid hormone profile estimated by radioimmunoassay (TSH-Normal 0.3-5 mIU/L) & DXA derived BMD values were calculated. **Results:** A total of 93 subjects of both sexes, at or above 50 years of age were enrolled in the study. Total Lumbar Spine, individual vertebrae & Femoral neck BMD values with TSH showed positive correlation (r=0.22, p=0.0341), L1 (r=0.19, p=0.0681), L2 (r=0.23, p=0.0266), L3 (r=0.18, p=0.0843), L4 (r=0.22, p=0.0341) & Femoral neck (r=0.25, p=0.0157). **Conclusion:** Normal thyroid hormone profile does not affect the bone metabolism. However, TSH values in lower limit of normal range can affect the bone mineral density and appropriate bone strengthening measures are necessary to prevent osteopenia and osteoporosis.

P096: Atypical Femoral Fracture: An Incidental Finding. The Role of Bone Mineral Density Scans & Three Phase Bone Scintigraphy
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**Background/Aims:** Atypical femoral fracture (AFF) is rare and can be complete or incomplete, often bilateral and initially involves the lateral femoral cortex.\[[@ref113]\] There appears to be increased risk of AFF in patients on anti-resorptive therapy.\[[@ref114]\] We describe an incidental finding of AFF in a 63 year old male patient. His bone mineral density was being monitored due to prolonged glucocorticoid therapy for rheumatoid arthritis. In June 2013, he was diagnosed with osteoporosis and underwent anti-resorptive therapy. **Methods:** In July 2017, the patient had Dual Energy X-Ray Aborptiometry (DXA) scans of the lumbar spine and proximal femur, and a Single Energy Femur Scan (SEFS), on the Hologic Horizon DXA system. A nuclear medicine bone scan (BS) was performed 9 days later on the Symbia T16 SPECT/CT gamma camera. Following 723MBq intravenous injection of ^99m^Tc-MDP dynamic imaging commenced over the proximal femora. Blood pool static images were acquired over the distal femora, then delayed static images over the lumbar spine, femora and knees. SPECT/CT was performed over both the femurs. **Results:** The SEFS demonstrated slight focal thickening on the left lateral femoral cortex. In the BS, early imaging showed normal perfusion in the thighs, with small focus of mildly increased early blood pool activity in the right mid-to-distal thigh. Delayed imaging showed local increase in tracer uptake in the proximal left and mid-right femurs localising to the lateral cortex. The scan findings were consistent with bilateral healing lateral cortical femoral fractures. **Conclusion:** Our case illustrates the complementary use of DXA and BS in obtaining a definite diagnosis of AFF. The increased sensitivity and specificity of the BS confirmed bilateral incomplete AFF in our patient. It potentially has a role in AFF screening for patients on long-term anti-resorptive therapies, especially symptomatic patients with subtle abnormalities in the SEFS.
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: P097: Is Low-dose Radioiodine Ablation Sufficient for Low to Intermediate Risk Differentiated Thyroid Cancer Patients? (Endocrinology)
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**Background/Aims:** This study aimed to evaluate the effectiveness of low-dose RAI ablation in low to intermediate risk patients and target the factors associated with unsuccessful ablation. **Methods:** This is a single-center, retrospective study approved by Institutional Review Board of the Peking Union Medical College Hospital. Low to intermediate risk DTC patients underwent RAI ablation within 6 months after thyroidectomy from July 2010 to December 2016 were selected. Successful ablation was determined as proposed by the ATA guidelines. Factors as age, sex, tumour size, capsule invasion, pathological type, numbers and regions of metastatic lymph nodes, TNM stage, BRAF gene, TSH stimulation methods were analysed. T-test and logistic regression were used for statistical analysis. **Results:** A total of 737 patients (Male 213, Female 524) were enrolled. The mean age was 39 years. There were 35 low-risk and 702 intermediate-risk patients. 581 patients (26 low-risk, 512 intermediate-risk) have responses evaluated by October 2017. In the low-risk group, 96.2%(25) showed excellent responses (ER), 3.8%(1) indeterminate responses (IR). In the intermediate-risk group, 82.0%(420) ER, 1.8%(9) biochemical incomplete response(BIR), 3.3%(17) structural incomplete response (SIR) and 12.9%(66) IR. 43 patients (intermediate risk 40, low risk 3) were given a subsequent dose. Among them 55.8%(24) ER, 14.0%(6) BIR, 16.3%(7) SIR, and 14.0%(6) IR. Much residual thyroid tissues and many metastatic lymph nodes were significant factor related to unsuccessful ablation. **Conclusion:** Low-dose RAI ablation is sufficient for low-risk and majority of intermediate-risk patients. For patients with much residual thyroid and/or many metastatic lymph nodes, regular follow-up is essential and additional low-dose ablation may be needed. Smaller subgrouping may be required for further optimal dosing in future studies.

P098: Copper Sulfide-loaded Microspheres for Breast Cancer Theranostics (Nuclear Medicine Innovation)
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**Background/Aims:** Compared to conventional cancer treatment, combination therapy based on well-designed nanoscale platforms may offer an opportunity for eradication of tumours and reduce recurrence and metastasis. **Methods:** In this study, we prepared the multifunctional microspheres loading ^131^I-labelled hollow copper sulfide nanoparticles and paclitaxel (^131^I-HCuSNPs-MS-PTX) for imaging and therapeutics of orthopic W256/B breast tumour in rats. **Results:** ^18^F-fluordeoxyglucose (^18^F-FDG) positron emission tomography/computed tomography (PET/CT) imaging detected that the expansion of the tumour volume was delayed (p\<0.05) following intra-tumoural (i. t.) injection with ^131^I-HCuSNPs-MS-PTX plus near-infrared (NIR) irradiation. The immunohistochemical analysis further confirmed the anti-tumour effect. The single photon emission computed tomography (SPECT)/photoacoustic imaging mediated by ^131^I-HCuSNPs-MS-PTX demonstrated that microspheres were mainly distributed in the tumours with a relatively low distribution in other organs. **Conclusion:** Our results revealed that ^131^I-HCuSNPs-MS-PTX offered combined photothermal, chemo-and radio-therapies, eliminating tumours at a relatively low dose, as well as SPECT/CT and photoacoustic imaging to monitor distribution of the injected agents non-invasively. The copper sulfide-loaded microspheres, ^131^I-HCuSNPs-MS-PTX, can serve as a versatile theranostic agent in breast cancer orthotopic model.

P099: Positron Emission Tomography Response Assessment in Patients with Radioactive Iodine-Refractory Thyroid Cancer after Apatinib Treatment, a Novel Tyrosine Kinase Inhibitor of Phase II Study (Endocrinology)
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**Background/Aims:** Till now, there have been few specific markers for radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) after tyrosine kinase inhibitor (TKI) therapy. This work aimed at using PET/CT technique to early identify the response and predict the prognosis of RAIR-DTC treated with apatinib, a novel TKI targeting VEGFR-2. **Methods:** Twenty patients with RAIR-DTC were sequentially enrolled to receive oral apatinib (750 or 500 mg qd). ^18^F-fluorodeoxyglucose (^18^FDG) and ^68^Ga-NOTA-PRGD2 PET/CT were conducted, and standardised uptake value (SUV), metabolic tumour volume (MTV) and total lesion glycolysis (TLG) were evaluated by two nuclear medicine physicians. Tumour response were evaluated by RECIST 1.1 criteria every two cycles. **Results:** 16/20 (80%) patients achieved partial response (PR) and 4/20 (20%) had stable disease (SD) after apatinib therapy. Six progression-free survival (PFS) events occurred, and the median PFS had not been reached. Strong correlations were achieved between the best change in sum of diameter of target lesions (ΔCT%) and ^18^FDG PET/CT index at 1-cycle treatment (ΔMTV% \[p=0.0019\], ΔTLG% \[p=0.0021\] and ΔSUV~max~% \[p=0.0443\]). Significant difference in PFS was observed between patients with a ΔMTV% \<-45% and ≥-45% (9.3 \[95%CI,7.0-11.6\] months vs. not reached; p=0.0019), as well as between patients with a ΔTLG% \<-80% and ≥-80% (9.5 \[95%CI,6.8-12.2\] months vs. not reached; p=0.0065). Totally, 10/11 patients presented decrease in SUV~max~ in ^68^Ga-NOTA-PRGD2 PET/CT after 2 cycles of apatinib therapy, showing PR of the best response, while the one presenting increase in SUV~max~ only had SD of the best response. When a cut-off value of target/background ratio at-20% was used, two PFS curves showed significant difference (p=0.0016). **Conclusion:** Early assessment by ^18^FDG and ^68^Ga-NOTA-PRGD2 PET/CT were effective in prediction and evaluation of RAIR-DTC treated with apatinib.

P100: Higher Amyloid Deposition in the Striatum in VEOAD: A Preliminary Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance Imaging study (Neuroscience)
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**Background/Aims:** It is assumed that the abnormal amyloid-β deposition is an initiating event in Alzheimer's disease (AD). We evaluated the Pittsburgh compound-B-PET images of very early onset AD (VEOAD), sporadic late onset AD (LOAD) and cognitively normal elder controls (NC) to find whether a different amyloid deposit pattern existed among groups. **Methods:** ^11^C-PIB PET/CT or PET/MRI images of 5 VEOAD patients (M: F=1:4, age range: 36-43 years, 39.0±3.4), 10 LOAD patients (M: F=4:6, age range: 62-75 years, 67.2±4.0) and 10 NC subjects (M: F=6:4, age range: 60-72 years, 66.4±3.2) with definite clinical diagnosis and complete neuropsychological tests were reviewed. All subjects received ^11^C-PIB injection intravenously (4.44-5.55MBq/kg) 40 minutes prior to data acquisition, including 3 VEOAD at a PET/CT (Biograph 64, Siemens, Germany) and 22 subjects at a PET/MRI scanner (Biograph mMR, Siemens, Germany). Regions of interest were drawn over cortex, the striatum and cerebellar gray matter (CGM) in CT or MRI and their PIB-PET images manually. The CGM was chosen as the reference region for standardised uptake value ratio (SUVR) measurement. One way ANOVA analysis was used to assess the differences of ages, MMSE scores and SUVRs of cortical and striatum among 3 groups. **Results:** VEOAD patients were younger than LOAD and NC subjects (F=70.02, p\<0.05). Both the two AD groups' MMSE scores were significantly worse than NC (F=43.77, p\<0.05). No significant difference in cortical ^11^C-PIB retention were observed between VEOAD and LOAD patients, but were great higher than that of NC (F=50.61, p\<0.01). Significant higher SUVR of striatum was observed in VEOAD than LOAD and NC. In addition, the SUVR of striatum in LOAD was also higher than NC (F=28.93, p\< 0.01). **Conclusion:** Extensive higher striatal amyloid deposition as PIB-PET detected in VEOAD, along with diffused cortical deposition, which might be associated with their early-onset symptoms.

P101: Positron Emission Tomography Using a Gastrin Releasing Peptide Receptor Antagonist
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Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients (Molecular Imaging)
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**Background/Aims:** This study was designed to study the safety, biodistribution, radiation dosimetry of a gastrin releasing peptide receptor (GRPR) antagonist positron emission tomography (PET) tracer, ^68^Ga-RM26, to assess its clinical diagnostic value in prostate cancer patients, and to perform a direct comparison between GRPR antagonist ^68^Ga-RM26 and agonist ^68^Ga-BBN. **Methods:** This study was approved by the Institutional Review Board of Peking Union Medical College Hospital. Five healthy volunteers were enrolled to validate the safety of ^68^Ga-RM26 and calculate dosimetry. A total of 28 patients with prostate cancer were recruited with written informed consent. All the cancer patients underwent PET/CT scans at 15-30 min after intravenous injection of 1.85 MBq (0.05 mCi) per kilogram body weight of ^68^Ga-RM26. Among them, 22 patients accepted ^68^Ga-BBN PET/CT for comparison within 1 week. GRPR immunohistochemical staining of tumour samples was performed. **Results:** The administration of ^68^Ga-M26 was well tolerated by all subjects with no adverse symptoms being noticed or reported during the whole procedure and 2 weeks follow up. The total effective dose equivalent (EDE) and effective dose (ED) were 0.0912±0.0140 and 0.0657±0.0124 mSv/MBq, respectively. In the 17 patients with newly diagnosed prostate cancer, ^68^Ga-RM26 PET/CT showed positive prostate-confined findings in 15 tumours with maximum standard uptake value (SUV~max~) of 6.49±2.37. Compared with ^68^Ga-RM26 PET/CT, GRPR agonist ^68^Ga-BBN PET/CT detected less primary lesions and lymph node metastases as well as lower tracer accumulation. There was a significant positive correlation between SUV derived from ^68^Ga-RM26 PET and the expression level of GRPR (p \<0.001). **Conclusion:** This study indicates the safety and significant efficiency of GRPR antagonist ^68^Ga-RM26. ^68^Ga-RM26 PET/CT would have remarkable value in detecting both primary prostate cancer and metastasis. ^68^Ga-RM26 is also expected to be better than GRPR agonist as an imaging marker to evaluate GRPR expression in prostate cancer.
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**Background/Aims:** Surgical intervention in the form of parathyroidectomy is generally only considered in severe secondary hyperparathyroidism (SHPT). However, correct location of the parathyroid glands before parathyroidectomy is a challenge. The first purpose of this study is to compare the diagnostic value of early and delayed phase ^99m^Tc-sestamibi SPECT/CT in the detection of parathyroid tissue. The second purpose is to compare the findings of parathyroid scintigraphy with serum concentration of parathyroid hormone, and plasma calcium with positive parathyroid scan in secondary hyperparathyroidism patients. **Methods:** Forty-two patients with SHPT on hemodialysis were evaluated preoperatively with dual phase ^99m^Tc-sestamibi SPECT/CT parathyroid scintigraphy to locate parathyroid tissue prior to parathyroidectomy. The concentration of parathyroid hormone, plasma calcium in serum of these patients was monitored. The scintigraphic findings were graded from 1 to 5 according to the uptake degree of the avid lesion subjectively. The accuracy of ^99m^Tc-sestamibi early and delayed phase SPECT/CT scintigraphy were determined and compared. The correlation of PTH and plasma calcium with positive parathyroid scan were analysed. **Results:** The sensitivity, specificity, and accuracy of early and delayed phase per lesion was 72.8%, 79%, and 74.4%; 76%, 74.4%, and 75.6%. The sensitivity, specificity, and accuracy of dual phase was 80.8%, 74.4%, and 79.1%. Early phase ^99m^Tc-sestamibi SPECT/CT was able to detect 2.16 parathyroid glands (PTGs), while delayed phase ^99m^Tc-sestamibi SPECT/CT was able to detect 2.26 PTGs per study. The average value of PTH and plasma were 550.24±125.14 pg/ml (Grade 4), 787.84±194.78 pg/ml (Grade 5), and 2.24±0.07 mmol/L (Grade 4), 2.67±0.32 mmol/L (Grade 5). The average value of PTH and plasma were significantly higher in patients with higher grade of scintigraphic findings. Pearson Correlation Coefficient showed moderate relationship of PTH and plasma calcium (r=0.621, p\<0.001). **Conclusion:** Our study indicates that dual phase ^99m^Tc-MIBI SPECT/CT should be performed preoperatively in order to detect all PTGs without increase of radiation dose. Scintigraphy of parathyroid glands and the value of PTH, calcium in serum should be incorporated into the test algorithm for SHPT patients on hemodialysis.

P103: Dopamine Transporter Imaging and Metabolic Network Expression in Patients with Idiopathic REM Sleep Behaviour Disorder and Parkinson's Disease (Neuroscience)
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**Background/Aims:** Idiopathic rapid-eye-movement sleep behaviour disorder (IRBD) is regarded as the prodromal stage of Parkinson's disease (PD) characterised by nigrostriatal dopamine loss and a unique metabolic brain network (PDRP). This study aimed to investigate the abnormalities in striatal dopamine transporter (DAT) distribution and PDRP activity as well as the correlations between the two measures in the same IRBD patients with comparison to PD using a dual tracer imaging design. **Methods:** Age-matched 37 IRBD patients, 86 PD and 15 control subjects performed concurrent PET scans with ^11^C-N-2-carbomethoxy-3-(4-fluorophenyl)-tropane (CFT) to quantify striatal DAT binding and ^18^F-fluorodeoxyglucose (FDG) to quantify PDRP expression. **Results:** IRBD patients were divided into two subgroups: with normal (RBD-N) or abnormal (RBD-AB) DAT binding. Relative to the controls, significantly decreased DAT binding was present in all patient groups except for IRBD-N. By contrast, significant increase in PDRP expression was present in all patient groups. There're trends of decrease in DAT binding in the striatum and increase in PDRP expression from IRBD-N to advanced PD. Significant but weak correlations were observed between PDRP expression and DAT binding in all three parts of the striatum in PD. Stronger correlations were observed in the putamen in IRBD-AB. No significant correlation was found in IRBD-N. **Conclusion:** IRBD patients presented an intermediate state in striatal DAT distribution and PDRP activity between PD and normal controls. The modest correlations between dopaminergic dysfunction and abnormal PDRP expression in both IRBD and PD suggest differences in network activity can't be explained solely by nigrostriatal dopaminergic denervation.

P104: Functional Dyspepsia: Impaired Intra-Gastric Distribution or Impaired Gastric Emptying: An Attempted Evaluation by Nuclear Scintigraphy (Gastrointestinal)
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**Background/Aim:** Functional Dyspepsia (FD) is a heterogeneous disorder and is a diagnosis of exclusion. By definition, presence of symptoms originating in the gastro-duodenal region in the absence of any identifiable cause-should explain the condition. Some patients have delayed gastric emptying, but overall, there seems to be little relation between rate of emptying and symptoms. This study is an attempt to find the cause of symptoms of FD. **Methods:** We examined 18 patients, having symptoms of bloating and epigastric discomfort and 8 volunteers. All of them were served ^99m^Tc-DTPA mixed food. Then, they were asked to stand upright in front of gamma camera, and imaged for 1 minute over the area of upper abdomen, every 10 minutes, for a total of 90 minutes. Then, the images were divided into upper 1/3 (proximal) and lower 2/3 (distal) gastric portions and the time-activity curves (TAC) were obtained for upper 1/3rd, lower 2/3rd and total stomach region. **Results:** TAC of total stomach region between patients and volunteers was not significantly different in its information but TAC of distal stomach region (lower 2/3rd) was. In the volunteers, food remained predominantly in the proximal half and then moved towards the distal half. However, in the patient sub-group, food moved quickly from the fundus to the antrum and showed stasis of food for longer duration (in antrum). **Conclusion:** Our study indicates that the primary cause of FD is the intra-gastric maldistribution of food (stasis in the distal stomach and antrum) rather than the abnormal gastric emptying.

P105: Uncommon bone Metastasis from Thyroid Cancer (Endocrinology)
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**Background/Aims:** Metastasis thyroid carcinomas mainly include cervical lymph nodes, lung and bone. Vertebrae, femur, skull, pelvis and clavicle were the most common sites of metastases. Bone metastasis in the phalanx is rare site. **Methods:** We will discuss a rare case from the patient with phalanx metastasis from thyroid cancer with clinical course, imaging, pathological findings, and treatment. **Results:** In December 2016, a 40 years old female was referred to have second ^131^I therapy for follicular variant papillary thyroid cancer. She previously underwent total thyroidectomy followed by ^131^I ablation on September 2012 and also craniotomy for brain metastasis on November 2016. She complained of tenderness and swelling in her 4^th^ phalanx. She was given 150 mCi of ^131^I therapy. On post-therapy, the whole body scan revealed pathological uptake on left 4^th^ phalanx, parietal, ribs, pelvic and femur. X-Ray on her left hand showed lytic lesion on 4^th^ phalanx, which was amputated. The histopathological result showed metastasis from follicular variant of papillary thyroid cancer. **Conclusion:** Even though metastatic spread to phalanx are rare, any pathological uptake in that area should be carefully evaluated.

P106: Prevalence of Vertebral Fracture in Low Bone Mass Detected by Vertebral Fracture Assessment (Musculoskeletal)
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**Background/Aims:** Vertebral fracture assessment (VFA) is the useful technique to assess vertebral fracture. Detection of unnoticed vertebral fracture in low bone mass leads to changing of diagnosis and treatment decision. This study aims to determine the prevalence of unnoticed vertebral fracture in low bone mass patients by using VFA. **Methods:** Sixty-Five low bone mass patients (5 males, 60 females, mean age 64 years, range 44-81 years) diagnosed by BMD, T-scores between-1.0 and-2.5, and underwent VFA study using Hologic Discovery A (S/N 82938) at Division of Nuclear Medicine, Maharaj Nakorn Chiang Mai Hospital between January 2015 and June 2017 were enrolled. The patients had never been diagnosed vertebral fracture or had history of fragility fracture. VFA was done in supine position from T4 to L4. Vertebral fractures were defined by the two experienced radiologists in a consensus reading using combination of Genant semi-quantitative (SQ) approach and quantitative morphometry. Prevalence of vertebral fracture was calculated in percentage and an inter-observer agreement was determined using Kappa score. **Results:** Ninety-three percent of T4-L4 vertebrae and 98% of T7--L4 vertebrae were adequately visualized. Vertebral fractures were detected in 14 of 65 patients (21.5%, 1 male and 13 females). The inter-observer agreement between two experienced radiologists was excellent (Kappa score = 0.92). **Conclusion:** The additional VFA at the time of BMD study should be the standard investigation in low bone mass patients. VFA detected unnoticed vertebral fractures in 21.5% of low bone mass patients, which changes the diagnosis and treatment decision in this group of patients.

P107: Is 18F Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography a Potent Tool to Restage and Prognosticate Patients with Cervical Carcinoma? A Future Argument (Oncology)
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**Background/Aim:** To analyse the efficacy of integrated ^18^F-DG PET/CT in treated cervical carcinoma patients. **Methods:** A retrospective analysis of histopathologically confirmed patients with carcinoma cervix (n=193; age-range 32-82 years; mean-age 51.4 years) was done. All patients were treated either in combination or alone with surgery, radiotherapy or chemotherapy and referred for FDG PET/CT on the basis of clinical and imaging suspicion of residual or recurrent disease and for post-therapy monitoring. Histopathological examination and clinical or imaging follow-up (minimum18 months) were taken as gold standard. **Result:** Of the total 193 patients, PET/CT detected abnormal FDG uptake in 113 patients. Uptake at primary site was detected in 56/193 (29.01%) patients and only metastatic sites in 64/193 (33.1%) patients. Out of 56 patients with primary lesions, 28 had additional regional lymph nodes and 25 had additional distant lesions. In PET/CT, 11 patients were also suspected for metachronous primaries and confirmed on histopathology (lung-4, pharynx-2 breast-2, lymphoma-2 and rectum-1). We found that for residual/recurrence detection, FDG PET/CT has the sensitivity, specificity, PPV, NPV and accuracy 89.38%, 65%, 78.29%, 81.25% and 80% respectively. On ROC curve analysis, lesions with SUV~max~\>4.4 in PET/CT had sensitivity and specificity 78.8% and 83.7% respectively for being pathological. In the survival analysis, positive FDG PET/CT patients has significantly high risk of patient death \[hazard ratio =5.95 (p \<0.0001; 95%CI 3.43-10.3) and patients with SUV~max~ \>4.4 was significantly associated with higher patient death \[HR=6.45 (p\<0.0001; 95%CI 3.77-10.99)\]. **Conclusion:** We concluded that ^18^F-FDG PET/CT is accurate for detection of suspected residual/recurrent disease in cervical cancer patients and it also provides the valuable information for survival so patient management can be improved.

P108: Fixed dose of Radioactive Iodine in the Therapy of Hyperthyroidism-what is Outcome and Factors Affecting it: Experience at Our Institute (Endocrinology)

H Nohario\*

S

1

Laghari

N A

1

Iqbal

S S

1

Nuclear Institute of Medicine and Radiotherapy, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan

**Background/Aim:** Radioactive iodine therapy (RAI) for hyperthyroidism is safe and definitive, although post-treatment hypothyroidism and the need for life-long thyroxine are to be expected. Fixed dose radioactive iodine is increasing popular, but the responses may vary and the optimal dose of radioactive iodine for hyperthyroidism is still debated. The aim of this study is to evaluate the outcome of radioactive iodine therapy in patients with hyperthyroidism, using a standard dose and explore the outcome and the factors influencing it. **Methods:** A prospective study was conducted in hyperthyroid patients, who are referred to nuclear medicine department for the RAI therapies. We studied 207 patients with hyperthyroidism treated between June 2010 and June 2015 with a standard dose of 550MBq ^131^I. Patients were classified as Graves' disease, toxic multinodular goiter or intermediate aetiology. Anti-thyroid drugs were routinely stopped at least one week before radioiodine therapy. **Results:** Graves' disease was the most common cause of hyperthyroidism. One year after RAI treatment, 185 patients were hypothyroid, 13 patients were euthyroid, and 6 had required a further dose of ^131^I. Patients with Graves' disease were more likely to become hypothyroid than dose with toxic multi nodular goiter (97% vs. 87%) and less likely to become euthyroid (4% vs. 15%). Patients with a small goiter were more likely to be successfully treated by a single dose than those with large goiter (99% vs. 76%). Anti-thyroid treatment was taken by most of the patients. Patients with prior anti-thyroid treatment for many years were associated with increased failure rate compared to those who had anti-thyroid treatment for fewer periods (20% vs. 3%). High free T4 level at initial presentation was associated with an increased failure rate. **Conclusion:** A single fixed dose of radioactive iodine is a simple, safe, and highly effective in treating hyperthyroidism. The aetiology, goiter size, high basal free thyroxine concentration, prior anti-thyroid treatment for long periods all are associated with higher chance of failure and have significant effect on outcome. Higher radioiodine doses may be considered to improve the cure rate.
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**Background/Aim:** Purpose of this study is to evaluate sensitivity, specificity, accuracy, positive predictive value, negative predictive value of parathyroid scan (single isotope double-phase technique, dual isotope subtraction technique, SPECT/CT scan, combined 2 techniques of double-phase technique and dual isotope subtraction technique, and combined 3 techniques of double-phase technique, dual isotope subtraction technique, SPECT/CT scan) in patients with hyperparathyroidism, histologic analysis as the reference of standard. Sensitivity, specificity, and accuracy of dual isotope subtraction technique combined SPECT/CT scan, and combined 3 techniques were compared. **Methods:** Sixty-three consecutive patients had parathyroid scan before surgery for hyperparathyroidism. Analysis consisted of single isotope double-phase technique, dual isotope subtraction technique, SPECT/CT scan, and combined 3 techniques were retrospective review. Each review was scored from 1(definitely negative) to 4 (definitely positive) for location and certainty of focus by 2 readers. Pathological report was as the standard. Sensitivity, specificity, accuracy, positive predictive value, negative predictive values were determined for each method. **Results:** Of the 156 parathyroid lesions, 8 lesions were parathyroid adenoma, 148 lesions were parathyroid hyperplasia. Reading combined 3 techniques had the most sensitivity (65.97%) and accurate (70.51%); however, it was not significantly more sensitivity and accurate than reading by combined 2 techniques of double-phase technique and dual isotope subtraction technique (*p* \>0.05). Reading all images was significantly less sensitivity in the detection of lesions with weight less than 600 mg. **Conclusion:** The combined 3 techniques has the most sensitivity and accurate; however, reviewing dual isotope subtraction technique combined SPECT/CT scan, and combined 3 techniques has not significant difference in sensitivity, specificity and accuracy.
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**Background/Aim:** Stress radionuclide myocardial perfusion imaging is one of the initial evaluation methods of coronary artery disease. Nuclear medicine physicians usually use qualitative analysis method to interpret result. However, quantitative analysis has better reproducibility of measurements and equal diagnostic accuracy of visual observers. In this study, we used quantitative method of 4D-MSPECT software to evaluate ability to predict coronary artery stenosis. **Methods:** 122 patients who suspected coronary artery disease were done myocardial perfusion scan and followed by cardiac catheterisation. Perfusion severity scores of 3 coronary arteries and left ventricular ejection fraction (LVEF) values from 4D-MPECT software were analyzed with to predict significant coronary artery stenosis and factor association. **Results:** Higher perfusion severity score of 3 coronary arteries had more significant coronary artery stenosis. Significant coronary artery stenosis had higher mean difference of severity scores of myocardial perfusion, wall motion, wall thickening and LVEF than controls in all 3 coronary arteries (p\<0.05) except in wall motion severity score of left circumflex artery (p=0.479). **Conclusion:** Severity scores of stress radionuclide myocardial perfusion imaging and LVEF from 4D-MSPECT software can predict significant coronary artery stenosis of all 3 main coronary arteries and higher perfusion severity score had higher change for significant coronary artery stenosis.
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**Background:** FDG PET/CT is a well-established cancer imaging tool for diagnosis, staging and response assessment. It is also well known that, post chemotherapy or radiotherapy, metabolic response precedes morphologic response which is based on size criteria. However, earliest time needed for the maximum metabolic response post radiosurgery has never been assessed. Present study evaluates the metabolic regression velocity post SBRT with serial FDG PET/CT scans in patients with oligo solitary lung or mediastinal metastases. **Methods:** 5 patients with oligometastatic lung tumours (primaries: colorectal cancer-2, breast-2 and head and neck cancer-1) were planned for SBRT by deep inspiratory breath hold technique using active breath controller & risk fractionated protocol. Doses delivered were in the range of 110-116 Gy BED. All patients underwent diagnostic pre-and post-treatment PET/CT scans. Post-SBRT PET/CT scans were timed serially at 48 hours, 7 days, 30 days and 60 days post-treatment. PET/CT scans were reviewed in order to determine the pre-and post-treatment maximum standardized uptake value (SUV~max~) of the lesion, including "complete resolution" of FDG-avidity. Corresponding morphologic variations of the target lesions were studied on the CT images. **Results:** All the 5 patients showed serial regression in metabolic activity, with maximum regression in metabolic activity occurring at 1week post SBRT. The observed metabolic regression was between 40-54% (median 50%) at 48 hours and 67-82% (median 80%) at 1 week post-SBRT. During the evaluation period, there was no significant change in size of the lesion. After 1 week of SBRT, there was no further decrease in metabolic activity, most probably due to initiation of inflammation. **Conclusion:** In cases of recurrent solitary lung or mediastinal metastases, the metabolic response precedes morphologic response, with maximum response seen at 1 week post-SBRT. This is the first study reported in literature which looked in the metabolic regression velocity.
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Iqbal\*

Muhammad

1

Imran

M B

1

Afzal

M S

1

Akhtar

M S

1

Department of Nuclear Medicine, Pinum Cancer Hospital, Faisalabad, Pakistan

**Background/Aims:** Myocardial perfusion Scintigraphy (MPS) is a sensitive non-invasive imaging modality to assess myocardium for perfusion defects in known or suspected cases of coronary artery diseases (CAD). Its sensitivity may get compromised in certain patients like in patients with small hearts. The aim of this study was to assess small hearts for perfusion defects and compare results with general population. **Methods:** A total of 1000 MPS (combined set of Rest+Stress) images acquired by dual head SPECT/CT Hawkeye gamma camera were retrospectively analysed and categorized into two groups as general population i.e. ESV\>15ml and subjects with small hearts i.e. ESV≤15ml. Each group was further categorised as normal, reversible perfusion defect and fixed perfusion defects. Cases of dilated cardiomyopathy/post-nitrate rest studies were excluded from the study. **Results:** Out of total 1000 patients, 350 (35%) met criteria for small hearts and 580 (58%) for general population while 70 (7%) patients were excluded from the study. Irrespective of the risk factors, in the category of patient with small hearts, 310 patients (88.6%) showed normal perfusion and 40 patients (11.4%) showed reversible ischaemic defects while no patient showed fixed perfusion defect. In category of general population 240 patients (41%) showed normal perfusion, 180 patients (31%) showed reversible ischaemic defects and 160 patients (28%) showed fixed perfusion defects. **Conclusion:** Number of perfusion defects differs to a significant level in both categories. Low percentage of perfusion defects in small hearts may be because scintillation detectors are not able to pick small perfusion defects in small hearts due to inherent low spatial resolution. Secondly total phase analysis (combined full cycle systole/diastole images) of MPS images is usually done, which may hinder diagnosis of small perfusion defects in patient with small hearts. We think this problem may resolve with the use of solid state detectors with high spatial resolution and may also be overcome by single diastolic phase analysis of MPS images.

P113: Concordance among Single-Photon Emission Computed Tomography/Computed Tomography, Perioperative Neoprobe Sentinel Localisation and Patent Blue Dye Technique for Mapping Hidden Sentinel Nodes in Early Stage Breast Cancer Patients (Oncology)
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**Background/Aim:** Compare the detection efficacy of SPECT/CT vs. Patent Blue Dye (PBD) technique for sentinel Lymph Node (SLN) detection in breast cancer patients. **Methods:** Prospectively, 1024 early stage (tumours \<3cm) breast cancer patients with impalpable lymph nodes who underwent SLN mapping using radioisotope and PBD techniques between April, 2015 and March 2017 were studied. Cases who underwent SPECT/CT due to non-visualisation of SLN/equivocal findings on PS (n=134) followed by perioperative detection of hot node counts were included. Blue stained nodes were surgically removed and subjected to frozen section histopathological analysis. The histopathology results of SLNs detected by both techniques were compared for diagnostic value assessments. **Results:** Total 134 females underwent SPECT/CT and PBD injection for SLN on PS. Median age is 47 years. 49 (36.6%) T1, 85 (63.4%) T2. 131/134 (97.8%) had positive SLN detected by isotope and/or PBD technique. Six cases having no detectable radioactivity in the axilla had SLN identified only by PBD staining (blue-only) while none of the cases was only identified by isotopic detection, illustrating failure rates of 6.7% (9/134) and 2.2% (3/134) respectively. 26/134 had negative SPECT/CT lymphoscintigraphy but later neoprobe detected hot nodes in 20 cases. Therefore, the contribution of PBD to metastatic nodes identification was relevant for only 4.5%(6/134) patients. On subsequent axillary nodal dissection of three false negative cases on both isotope and PBD technique, all had nodal metastatic disease. The positive predictive value (PPV) of SLNs detected by isotope and PBD techniques were found to be 30.4% and 29% respectively. **Conclusion:** Role of PBD to reduce the false-negative rate of SLN mapping is limited to the rare cases in which no radioactivity is detectable in the axilla by SPECT/CT and/or Neoprobe detection (\<5%). When a radioisotope mapping has localized SLN, the use of PBD should be limited.
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**Background/Aims:** The selection of efficient shielding materials for radiation protection is important to protect medical staff in the field of nuclear medicine. Metallic materials having a high atomic number and high density shield γ-rays. In clinical settings, easily available aprons are made by lead but they are too thin to shield γ-rays. The aim of this study was to investigate shielding effects of a commercially available tungsten apron using a γ camera. **Methods:** Attachable tungsten shields (TSs) in a commercial tungsten apron (Chiyoda Technol Corp.) are set on the surface-ray source (GPA-09A, Toshiba). A lead apron (HAGOROMO 0.35 mmPb, Maeda) is used to cover the upper half of the surface source as an additional protector. ^99m^Tc and ^131^I are used as sources. A gamma camera (Symbia T6, Siemens) with low-energy/high-resolution and high-energy general-purpose collimators is used for ^99m^Tc and ^131^I imaging, respectively. Circular regions of interest (ROIs) are set in the shielded and non-shielded areas. The mean count density per pixel of each ROI was analysed. **Results:** Mean counts of ^99m^Tc were 201±12 in non-shielded area, 28±6 in the area shielded with 1 TS, 3±1 in that shielded with 2 TSs, 2±1 in that shielded with 3 TSs, and 1±1 in that shielded with 4 TSs. Additionally, the corresponding mean counts of ^131^I were 71±8, 53±7, 46±6, and 38±6, respectively. The linear attenuation coefficient (μ~L~) of the tungsten shield is calculated from the rate of attenuation. Mean μ~L~ values were 1.3±0.1 for ^99m^Tc and 0.1±0.006 for ^131^I. **Conclusion:** We demonstrated efficient shielding effects of the tungsten apron using a γ camera. The tungsten apron is promising shielding materials to protect medical staff in the field of nuclear medicine.

P115: Utility of Delayed-phase

11

C Methionine Positron Emission Tomography in the Evaluation of Focal Brain Tumours (Oncology)

Takanami\*

K

1

Takase

K

1

Department of Diagnostic Radiology, Tohoku University Hospital, Sendai, Japan

**Background/Aims:** ^11^C-methionine (MET) PET is used for the evaluation of brain tumours. The purpose of this study is to determine whether additional delayed-phase scan at MET PET study can improve the diagnostic accuracy in high-grade malignant brain tumours. **Methods:** This retrospective study included 21 patients who underwent MET PET and subsequently underwent brain tumour resection. At the PET studies, early-and delayed-images were scanned at 20-30 and 30-40 minutes after the administration of MET, respectively. MET uptake (SUV~max~) in the focal brain tumours and background (contralateral site) and the lesion-to-background SUV~max~ ratio (SUVratio) on the early-and delayed-images were obtained. Retention index of MET uptake (delayed-SUVratio/early-SUVratio) were calculated. High-grade malignant tumours were defined based on the pathological findings (grade 3 or 4 on WHO classification). Mann-Whitney test was used for comparing the results between the high-grade tumours and the others. p-value \<0.05 was set as a statistically significance. Receiver-operating characteristic (ROC) analysis was performed. **Results:** The 21 lesions consisted of 13 high-grade malignant tumours and 8 low-grade-/non-malignant tumours. Median of the early-SUV~max~, delayed-SUV~max~, early-SUVratio, delayed-SUVratio, and retention index were 4.17, 4.07, 2.63, 2.31, and 0.90 for the high-grade malignant tumours, and 2.58, 2.51, 1.72, 1.77, and 1.03 for the low-grade-/non-malignant tumours, respectively. There was a significant difference in each factor between the two groups (p\<0.05), especially in the retention index (p\<0.01). Area under the curve by ROC analysis was 0.78 for early-SUV~max~, 0.78 for delayed-SUV~max~, 0.84 for early-SUVratio, 0.78 for delayed-SUVratio, 0.87 for retention index. Sensitivity and specificity for detecting high-grade malignant tumours was 92.3% and 87.5% using a cutoff retention index of \<1, respectively. **Conclusion:** Additional delayed-phase MET PET may improve the diagnostic accuracy in high-grade malignant brain tumours.

P116: Usefulness of 18F Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Health Screening: Comparative Study with Korea Central Cancer Registry (Oncology)
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**Background/Aims:** The usefulness of PET/CT in patients is well known. In addition, studies on the usefulness of PETCT for healthy examinees have been conducted to some extent. Therefore, we investigated the usefulness of PET/CT for healthy examinees through cancer patients enrolled in Korea Central Cancer Registry (KCCR). **Methods:** The subjects were 236 registered at KCCR within one year after PET/CT examination was performed between 2010 and 2014 at the Total Healthcare Center of Kangbuk Samsung Hospital. The investigators were grouped by age and analyzed by which method the cancer was diagnosed. **Results:** Among 236 cancer patients, 88 were negative for PET/CT, but negative for other tests. On the other hand, there were 43 patients who were not diagnosed as having PETCT but were diagnosed as cancer by another test. **Conclusion:** It is expected that PET/CT can play a role in health checkups such as cancer diagnosis. Since PET/CT, which has recently reduced radiation exposure, has become available, it has become more likely to be used for health promotion. In the future, if only high price problems are solved, more use may be possible.

P117: Clinical Significance of Measurement of Serum Anti-thyroglobulin Antibodies in the follow up of Differentiated Thyroid Carcinoma (Endocrinology)
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**Background/Aim:** Despite the excellent prognosis, recurrence rate of differentiated thyroid carcinoma (DTC) is 20-40%. That's why long-term follow-up with sensitive tests is needed. Serum thyroglobulin (Tg) has an established role as a tumor marker of relapse. Tg measurement is important for follow-up after surgery in patients with DTC and for detection of persistent or recurrent thyroid cancer but in the presence of anti-Tg autoantibody (TgAb) a negative Tg result is most likely false-negative. So, recent guidelines recommend assessing TgAb, with simultaneously measurement of serum Tg, every 6-12 months after surgery. Complete elimination of follicular cells by total thyroidectomy followed by remnant ablation should lead to cessation of antigenic stimuli and a progressive decline in TgAb concentration, resulting in complete TgAb disappearance but persistence of TgAb after treatment, or increasing TgAb concentration indicates persistent or recurrent DTC. **Methods:** Retrospective study was done on 258 patients and the criteria of the study were collection of data of patients with DTC who have undergone total thyroidectomy along with I-131 ablation. Serial assessment of Tg and TgAb level was done in those patients. Conclusion and results were extracted after comparison of ATG level with available imaging modalities i. e. WBS, ultrasound, CXR, bone scintigraphy, CT and MRI. and response to therapy. **Results:** 221 patients (75.8%) out of total 290 patients was female while rest of 70 (75.8%) were males. 193 (66.5%) out of the total patients had papillary carcinoma, while the rest of 98 (33.5%) had follicular carcinoma. Total patients with increased TgAb of \>20 were 67 (23.1%), of which 19 (28.3%) patients had increased Tg and increased TgAb, while 49 (73.1%) patients with normal Tg and increased TgAb. Out of these 49 (73.1%) patients, 14 (28.58%) patients had ablated thyroid tissue, 16 (32.66%) patients had residual thyroid tissue, and 19 (38.76%) patients had residual thyroid tissue with metastasis. **Conclusion:** TgAb is also a tumour marker, rising when tumour is present and falling when it has been destroyed. There is a statistically significant correlation between the complete disappearance of thyroid tissue and the presence of thyroid antibodies, supporting the concept that continued antibody production depends on the persistence of autoantigen, so serial measurement of TgAb levels in the follow-up of patients with differentiated thyroid cancer is as important as the measurement of Tg level.
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**Background/Aims:** Thyrotoxicosis resulting hyperfunctioning metastatic thyroid cancer is extremely rare. It presents a therapeutic challenge, as both the metastatic cancer and thyrotoxicosis need to be treated. **Methods:** We report a 54 year old female patient diagnosed as papillary thyroid carcinoma with multiple bones and lungs metastases. She had symptoms of thyrotoxicosis during her thyroid hormone withdrawal as a preparation of second radioiodine (RAI) therapy. Clinical examination revealed tachycardia, tremors, and weight loss. Pre-treatment with high doses of anti-thyroid drugs and beta blocker were given and continued during the RAI therapy to avoid complications due to release of excessive thyroid hormones by the hyperfunctioning metastatic lesions. **Results:** The patient was treated with 150 mCi ^131^I without any significant side effects. After the ^131^I therapy, her thyrotoxicosis subsequently decreased, then anti-thyroid drug was discontinued. When patient became hypothyroid, she received L-T4 100 mcg daily to suppress her Thyroid Stimulating Hormone levels. At six months follow-up, there was significant reduction of Thyroglobulin and uptake of radioiodine scan in her multiple metastatic lesions which was appropriate with her clinical symptoms and other imaging modality results. **Conclusion:** Good response of this patient may due to high affinity of RAI to hyperfunctioning metastatic thyroid cancer. RAI treatment with anti-thyroid drug is the treatment of choice for hyperfunctioning metastatic thyroid cancer.

P119: Iodine Concentration Calculated by Dual-energy Computed Tomography as a Functional Parameter to Evaluate Thyroid Metabolism in Patients with Hyperthyroidism (Endocrinology)
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**Background/Aims:** Thyroid function in patients with Graves' disease is usually evaluated by thyroid scintigraphy with radioactive iodine. Recently, dual-energy CT (DECT) with two different energy X-rays can calculate iodine concentrations and can be applied for iodine measurements in thyroid glands. This study aimed to assess the potential use of DECT for the functional assessment of the thyroid gland. **Methods:** Thirteen patients with Grave's disease treated at our hospital from May to September 2015 were included in this retrospective study. Before treatments, all subjects had undergone both iodine scintigraphy \[3 and 24 hours after oral administration of ^123^I (20 µCi)\] and non-enhanced DECT. The region of interests (ROIs) were placed in both lobes of the thyroid glands, and CT values (HU: Hounsfield unit) and iodine concentrations (mg/mL) calculated from DECT images were measured. The correlation between CT values and iodine concentrations from DECT in the thyroid gland was evaluated and then the iodine concentrations were compared with radioactive iodine uptake ratios by thyroid scintigraphy. **Results:** Mean (±SD) ^123^I uptake increased from 46.3±22.2% (range 11.1--80.1) at 3 hours, to 66.5±15.2% (range 40--86.1) at 24 hours (p\<0.01). CT values ranged from 34.5 to 98.7 HU (mean 67.8±18.6), while the iodine concentrations calculated with DECT ranged from 0.0 to 1.3 mg/mL (mean 0.5±0.4). A moderate positive correlation between CT values and the calculated iodine concentrations in the thyroid gland was seen (R=0.429, p\<0.05). A significant negative correlation between ^123^I uptake at 3h and iodine concentration by DECT were seen (R= −0.680, p\<0.05), although no correlation was observed between ^123^I uptake at 3 h and CT values (p=0.087). No correlation was observed between ^123^I uptake at 24h and CT values (p=0.153) or that between ^123^I uptake at 24h and iodine concentration by DECT (p=0.073). **Conclusion:** The negative correlation of ^123^I uptake at 3h with iodine concentration evaluated by DECT was better than that observed with simple CT value. DECT may have a potential role in the evaluation of iodine turnover in hyperthyroid patients.
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**Background/Aim:** The present study is planned to see the hypothyroid effects on renal function using GFR value as a marker of renal function. To study the effect of hypothyroidism on renal function using camera based GFR assessment method. **Methods:** Total number of 58 patients were included in the study. Out of 58 patients, 53 patients were thyroid carcinoma in whom hypothyroidism was due to discontinuation of thyroxine (51 patients) or injection of recombinant TSH (2 patients). Remaining 5 hypothyroid patients were post-radioactive iodine treatment for hyperthyroidism. Renal function tests (urea/creatinine) and serum electrolytes followed by ^99m^Tc-DTPA renal scan for GFR assessment (GATES' method) were carried out in all subjects twice during the study-one study during hypothyroid state (TSH \> 30mIu/ml) and other during euthyroid state (TSH between 0.4 to 4 IU/ml). In addition, renal function was assessed with creatinine clearance in those subjects who showed raised creatinine values in either of study (hypothyroid or euthyroid state). **Results:** The results of Student's *t-test* showed significant difference in renal function (urea, creatinine, creatinine clearance, GFR values) in euthyroid state and hypothyroid state (p \<0.05). In the case of creatinine, the paired t-test reveal the mean 1.014±0.428, with standard error of 0.669 within 95% confidence interval, for creatinine clearance 80.11±14.12 with standard error of 1.94 within 95% confidence interval, for urea the mean 28±12.13 with standard error of 1.607 within 95% confidence intervals and for GFR for individual kidney is 38.056±8.56 with standard error of 1.3717 within 95% confidence interval. **Conclusion:** Hypothyroidism, irrespective of the cause, impairs renal function to a significant level and hence needs to be prevented and corrected as early as possible.
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**Background/Aim:** Pineal gland calcification is often dismissed as a clinically insignificant phenomenon on CT examination of the head. However, previous research has identified multiple possible associations including malignancy, migraines, and intracerebral hemorrhage. Yet, no association between pineal calcification and function has been identified, namely pineal hormone levels are not affected by the presence of calcification. While numerous studies have examined pineal function using secreted hormones as a proxy for function, no prior studies have looked at FDG avidity as a measure of pineal function. We hypothesise that FDG avidity will decrease with the presence and amount of calcification. **Methods:** In this study, we examine how the presence and degree of pineal calcification affects pineal FDG avidity as determined by obtaining an SUV~max~ from a region of interest circumscribing the pineal gland. We will examine 500 PET/CT examinations that include the pineal gland. The presence or absence of pineal calcification will be determined. For those glands that are calcified, both the volume of calcification as well as the density of calcification as measured by Hounsfield Units (HU) will be determined. **Results:** The *student's t-test* will be used to examine for statistically significant differences in FDG avidity between calcified and non-calcified pineal glands. Similarly, statistical analysis will be performed to determine if and how FDG avidity changes as the volume and density of pineal calcification increases. **Conclusion:** In this study, we aim to determine how pineal function, as measured by FDG uptake, is affected by the presence of calcification.

P123:
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Tc-PSMA I+S Single-Photon Emission Computed Tomography/Computed Tomography Imaging in the Diagnosis of Prostate Cancer in Myanmar (Oncology)
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**Background/Aim:** Prostate cancer is fourth most common malignancy worldwide, and third in Myanmar. Currently, serum PSA is the tumour marker of choice with highest positive predictive value in prostate carcinoma. Regarding staging of the disease, ultrasonography, CT, MRI and ^99m^Tc-MDP SPECT/CT bone scintigraphy are choices of investigations currently practicing. Because of the evidence-based, promising success of ^68^Ga-PSMA PET/CT imaging in the diagnosis of prostate cancer worldwide, we have to run ^99m^Tc-PSMA I+S imaging in Myanmar with the available facilities (SPECT/CT). **Methods:** Ten patients with castrate resistant metastatic prostate cancer were imaged with 20mCi of ^99m^Tc-PSMA SPECT/CT during three months period, from October 2017 to January 2018. We compared scan results with serum PSA level and ^68^Ga-PSMA PET/CT imaging abroad. **Results:** No abnormal radiotracer uptake is seen at normal serum PSA level and multiple skeletal and soft tissue uptakes are seen with raised serum PSA level. Though ^68^Ga-PSMA PET/CT imaging has good quality image, it is comparable to ^99m^Tc-PSMA SPECT/CT. It could provide prognosis of the disease and lead to treatment modality. **Conclusion:** This pilot study is the stepping stone of theranostics in Myanmar. Myanmar is one of the developing countries and people could not afford costly high-tech imaging techniques for diagnosis. ^99m^Tc-PSMA imaging for prostate cancer diagnosis is non-invasive, cost-effective, and provides an additional boon to our health-care system. This project will benefit both public and private sector hospitals and more importantly for the people of Myanmar.

P124: Early Outcome of Fixed Dose Radioiodine Therapy in Hyperthyroid Patients (Endocrinology)
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**Background/Aims:** Early outcome of fixed radioiodine therapy is significantly reduced morbidity in hyperthyroid patients. **Methods:** 31 patients (M: F 9:22, age 19-60 years, mean 40 years) with hyperthyroidism treated in the year of 2016 with the dose of 8mCi to 15mCi. Patients were classified as Graves' disease, toxic multinodular goiter, diffuse toxic goiter. Antithyroid drugs were stopped at least 3 days before radioiodine therapy. **Results:** Three months after radioiodine therapy, 3 (9.6%) patients were hypothyroid, 11 (35.48%) patients were euthyroid and remaining 17 (54.92%) patients were hyperthyroid. Patients having Graves' disease were developed more euthyroid (50%) than those who had toxic nodular goiter (18.18%) and diffuse toxic goitre (37.5%). **Conclusion:** Early outcome in hyperthyroid patients was significantly affected by aetiology, severity of hyperthyroidism as well as goitre volume.

P125: Tumour Marker Guided Positron Emission Tomography in Breast Cancer Recurrence (Oncology)
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**Background/Aim:** Early diagnosis and accurate restaging of recurrent breast cancer is important to the selection of the most appropriate therapeutic strategy, mainly by identifying patients with limited disease who could benefit from curative treatment. **Methods:** Integrated positron emission tomography/computed tomography (PET/CT), which combines anatomic and metabolic imaging information, has been shown to further improve diagnostic accuracy and clinical management of patients through accurate localisation of functional data on high-resolution anatomic CT imaging. **Results:** Although the utilisation of new therapeutic protocols aimed at reducing the recurrence risk is defined, the diagnostic approach for early detection remains to be clarifies. **Conclusion:** We aim to provide an overview of recently published reports on the use of tumour markers in breast cancer patients as a guide for ^18^F-Fluorodeoxyglucose PET/CT.

P126: Brain Perfusion Single Photon Emission Computed Tomography in Patients with Attention-deficit/Hyperactivity Disorder using
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Tc-ECD: A Report of Three Cases and Review of the Literature (Neuroscience)
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**Background/Aim:** Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent developmental disorder in children. The main symptom of the disorder is inattention, hyperactivity, and impulsivity, and is among the most prevalent of childhood disorders. Only a limited number of studies have investigated cerebral metabolism or perfusion in these patients. Therefore, such indices are not fully understood yet. **Methods:** In this study, three cases of ADHD underwent brain perfusion SPECT to evaluate cerebral perfusion. **Results:** All three patients showed abnormal cerebral perfusion on brain SPECT but normal MRI. Patient 1 was a 5 year old girl with ADHD. The SPECT showed moderate frontal hypoperfusion and bilateral inferior temporal hypoperfusion. The second patient was a 14 years old girl with ADHD. The SPECT showed generalized diffuse cortical hypoperfusion, more prominently on the superior pre-frontal cortex and also moderate hypo perfusion of cerebellar hemispheres. Patient 3 was a 7 year old girl with ADHD. The SPECT showed mild hypoperfusion of the right parietal-temporal region and sub-cortical structures. **Conclusion:** The study showed the frontal lobe is a key structure in ADHD that another area of the brain may contribute to the disease with various severity.
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Re-Lipoidol TARE in Inoperable Primary Liver Tumours-Institutional Experience from a Quarternary Care Centre in South India (Radionuclide Therapy)
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**Background/Aim:** Hepatocellular carcinoma has increasing incidence in developing countries. Chemoembolisation, radiofrequency ablation and transarterial radioembolisation (TARE) are few non-surgical modalities in non-resectable liver tumours. ^188^Rhenium-Lipioidol TARE is a new therapeutic alternative to Yttrium-SIRsphere in inoperable liver tumours. The aim is to assess feasibility and evaluate outcomes of ^188^Re-Lipioidol TARE in unresectable primary liver tumours. **Methods:** 35 patients of inoperable primary liver tumours underwent ^188^Re-Lipioidol TARE during a period of 18 months. Pre-therapy triple phase CT angiogram done and tumour volume calculated using CT-based software. Pre-therapy lung shunt calculated in 5 patients. Administered doses of ^188^Re-Lipioidol varied from 1 mCi/ml up to 3 mCi/ml. TARE was done by an interventional radiologist after super-selective cannulation of feeding artery through a femoral approach. Post-therapy imaging was done after 24 hours in all patients. Response evaluation was based on contrast CT or MRI after 6 weeks, performance score, AFP levels and time to progress. **Results:** 14.3% showed good response, 28.57% stable disease, 11.4% partial response. Progressive disease was seen in 22.8%, time to progress varied from 4 to 10 months. Longest response duration was 14 months. No significant pulmonary toxicity was observed. **Conclusion:** ^188^Re-Lipioidol TARE is cost-effective, well-tolerated, effective palliative therapeutic modality in inoperable primary liver tumours.
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Fatima\*

Shazia

1

Butt

S T

1

Saeed

M A

1

Ahmed

N

1

Mir

K B

1

Hussain

F

2

Miller

R N

3

Nuclear Medicine, Oncology and Radiotherapy Institute, Islamabad, Pakistan

Nuclear Medicine Centre, Armed Forces Institute of Pathology, Rawalpindi, Pakistan

Nuclear Medicine Section, International Atomic Energy Agency, Vienna, Austria

**Background/Aim:** The diagnosis and localisation of post-operative spinal infection remains a challenge for physicians, as change in morphological feature after surgery renders MRI interpretation challenging. ^99m^Tc-Ubiqucidin has shown promising role in musculoskeletal infections, however, its role in diagnosing post-operative spinal infections has not been fully explored. The purpose of this study was to evaluate the diagnostic value of ^99m^Tc-labelled Ubiquicidin SPECT/CT scan and magnetic resonance imaging (MRI) in diagnosing post-operative spinal infection. **Methods:** From December 2013 to November 2017 patients with a clinical suspicion of infection in patients having prior spinal surgery, were included if ^99m^Tc-Ubiquicidin SPECT/CT and MRI of the spine were performed within a 2-week time span. Imaging results were compared to histopathology, culture and final clinical diagnosis and follow-up data were collected. **Results:** Thirty-eight patients were included, of whom 23 patients were diagnosed with active infection. MRI showed an overall sensitivity of 66.67% and specificity of 85%. Diagnostic accuracy was 76.32%. ^99m^Tc-SPECT/CT showed a sensitivity of 72.22 % and specificity of 90%. While diagnostic accuracy was 81.58%. Inter-observer agreement was better with SPECT/CT compared with MRI as well. **Conclusion:** As compared to MRI, ^99m^Tc-Ubiquicidin SPECT/CT has superior diagnostic value for detecting post-operative spinal infections.

P129: GI Bleeding Scintigraphy (Gastrointestinal)
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**Background/Aim:** Gastro-intestinal (GI) bleeding scintigraphy is a useful non-invasive diagnostic procedure, used in acute cases of GI bleeding in order to localize the site of the bleeding, stratify the risk in patients with GI bleeding and try to assist in planning for other procedures or surgeries. Although it is more used in lower GI bleedings, GI bleeding scintigraphy can detect both upper and lower causes of GI bleeding and plays a complementary role to endoscopy and angiography. **Methods:** ^99m^Tc-Sulfur colloid and ^99m^Tc-RBC are the two radiotracers used for this study, with the latter being used more nowadays for its characteristic of remaining in the intravascular space for up to 24 hours. **Results:** GI bleeding scintigraphy has many advantages over the other diagnostic procedures, like: being non-invasive, having high sensitivity with low radiation dose, not requiring specific preparation and having the ability of scanning for long time which enables the detection of intermittent and slow bleedings. False positive cases can be seen when radiotracer accumulation is seen in the extra-vascular space; and such issues can be solved by acquiring extra images or by using SPECT/CT. **Conclusion:** Gastrointestinal bleeding scintigraphy is an important and very useful tool for diagnosis, localization and risk stratification of acute GI bleeding cases; with many advantages over the other diagnostic procedures. More studies are needed to answer the queries regarding the use of SPECT and SPECT/CT in the GI bleeding scintigraphy.
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**Background:** Optimising diagnostic imaging may be challenging in obese patients. The quality of conventional bone scintigraphy can be poor in the morbidly obese due to a combination of factors including high background soft tissue activity. In comparison, Sodium Fluoride (^18^F-NaF PET/CT) has a better target to background ratio attributed to rapid single-pass extraction and fast clearance from the soft tissues. The aim of the present study is to assess the diagnostic efficacy of ^18^F-NaF PET/CT in the evaluation of bone metastases in morbidly obese cancer patients. **Methods:** Two hundred and twelve morbidly obese patients (BMI 45±5.1 Kg/m^2^ and mean age, 57 years; range 32-81 years) with BMI \> 40 kg/m^2^ referred for sodium fluoride (NaF) PET/CT for osseous staging of malignancy were retrospectively analyzed. All patients underwent PET/CT scan by injecting 2.2 MBq/kg (0.06 mCi/kg) of ^18^F-NaF. **Results:** ^18^F-NaF PET/CT was definitely benign in 145, possibly benign in 3; equivocal in 4; possibly malignant in 13 and definitely malignant in 47 patients. The sensitivity, specificity, PPV, NPV and accuracy of ^18^F-NaF PET/CT were 93.1%, 96.1%, 90%, 97.3% and 95.2% respectively (95% CI). **Conclusions:** The results of the present study indicate that ^18^F-NaF PET/CT retains its high diagnostic accuracy in morbidly obese patients and by inference can be a preferred functional modality in these patients.

P131: Evaluating the Assessment of Vertebral Fractures with Bone Mineral Density in the Diagnosis of Osteoporosis; Reporting Initial Findings (Muscoloskeletal)
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**Background/Aim:** The Dual Energy X-ray Absorptiometry (DXA) is a gold standard for the assessment of the bone mineral density and is also the only validated technology that uses the BMD input for the WHO fracture risk assessment algorithm, FRAX. Identification of previously unrecognized vertebral fractures with VFA, have the tendency to change diagnostic classification, fracture risk assessment and decisions regarding treatment with alteration of management of the patient with reduction of morbidities. The rational of this cross-sectional study was to look into the problems and report the advantage of VFA with BMD (as reported by others) in our current settings and offer an algorithm for the assessment of osteoporosis. Reported here are the initial findings of the study. **Methods:** Acquisitions for the BMD and VFA was done and reported with standard Hologic reference database for Caucasian males/females. After the routine BMD, VFA was performed after positioning the patient in the right lateral position. Following the acquisitions, machine software will be used to generate the BMD as well the VFA report and a comprehensive report stating the bone mineral condition as well as vertebral fracture assessment is made and reported. This study uses descriptive statistics only. Quantitative data includes age, expressed as mean ± standard deviation (SD). Frequencies and percentages are being calculated for qualitative data such as gender and findings of osteopenia or osteoporosis (Yes/No). The subgroup comparisons are based on students t-test with a P value of 0.0 5 as cut-off. **Results:** In process; to be concluded when presented. **Conclusion:** In process; to be concluded when presented.
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**Background/Aims:** To identify availability of inflammatory and microcalcified molecular probe in detecting atherosclerotic plaques. Moreover, to study whether the combination of both molecular probe imaging could assess the vulnerability of atherosclerotic plaques. **Methods:** The ApoE^-/-^mice were selected to establish atherosclerotic plaques model through feeding with high fat and high cholesterol (HFC) diet, while the C57BL/6J mice feeding with chow diet were selected as control. Mice body weight, the weight of abdominal adipose, serum lipids and serum inflamed and calcific cytokines were investigated, when the mice have been fed for 12 weeks, 20 weeks and 33 weeks. After that, imaging related experiments were performed, included BSGI imaging, micro-SPECT/CT imaging and micro-PET imaging. After imaging aorta vascular of these mice were used for histopathological analysis. Fianally, the correlation between imaging results and histopathological analysis were conducted, to further match and confirm imaging results. **Results:** The ApoE^-/-^mice were with higher body weight than the C57 BL/6J mice both at 12 weeks and at 33 weeks. The weight of abdominal adipose of ApoE^-/-^mice at 12 weeks, 20 weeks and 33 weeks were lighter than those of C57BL/6J mice. The levels of serum lipids (TC, TG and LDL) in ApoE^-/-^mice were significantly higher than in C57BL/6J mice at different weeks. Inversely, the levels of serum HDL of ApoE^-/-^mice was lower than C57BL/6J mice. Compared with C57BL/6J mice, the levels of TNF-α, IL-1β, CRP and Runx-2 in ApoE^-/-^mice were higher, but only some with statistically difference. Based on micro-SPECT/CT and BSGI imaging, the results showed that the radioactivity signal of aortic plaque in ApoE^-/-^mice was gradually increased with HFC feeding, while the aorta in C57BL/6J mouse fed normal feed displayed no radioactive concentration. In addition, we isolated aorta to perform microcalcified ^18^F-NaF PET in vitro imaging. In addition, the results showed that ^18^F-NaF micro-PET gradually increased in ApoE^-/-^mice with feeding time moving forward, significantly higher than that of C57BL/6J mice. The aortic plaque showed C57BL/6J mice displayed no radioactive concentration in aorta. **Conclusion:** This study demonstrated inflammatory and microcalcified molecular probe imaging could dynamically monitor AS plaques.

P133: Dynamic Evaluation of Glucose Metabolism in Rats with Acute Myocardial Infarction, Using Positron Emission Tomography/Computed Tomography Imaging with 18F Fluorodeoxyglucose (Cardiology)
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**Background/Aims:** Micro PET/CT imaging of ^18^F-fluorodeoxyglucose (^18^F-FDG) was performed on acute myocardial infarction (AMI) models of rats, at different time points and different dietary state (fasted/non-fasted), to evaluate the metabolic changes of myocardium and brain after AMI. **Methods:** SD rats (n=12) were anesthetized with isoflurane. The ligation of left anterior descending (LAD) coronary artery was performed. MicroPET/CT imaging of ^18^F-FDG was acquired at different time points (pre-operation, day 1, day 3, day 7, week 4 and week 8 after operation) and different dietary states (fasted/non-fasted). Region of interests (ROIs) was drawn in myocardium (MI center, peri-infarction area and remote area), brain and liver. Standardised uptake values (SUVs) (SUV~mean~ and SUV~max~) were calculated. After the PET/CT imaging at week 8, rats were executed. Ex-vivo histopathological analysis was performed. All animal studies were performed under a protocol approved by the Beijing Administration Office of Laboratory Animal (BAOLA). **Results:** In non-fasted state, MI center showed the lowest radioactive uptake, while remote area showed the highest uptake. SUVs in MI center were gradually reduced from day 1 to week 8, indicated the severity of MI was gradually increased with time. In the meantime, SUVs in peri-infarction and remote area didn't change significantly. In fasted state, since day 7 after surgery, the peri-infarction area exhibited highest uptake. SUVs in peri-infarction area were significantly higher than that in MI center (F=17.037?p=0.001\<0.05). In fasted state, SUVs in brain was significantly higher than that in non-fasted state (p=0.001\<0.05). HE staining and Masson staining studies confirmed that, there was myocardial infarction and myocardial fibrosis formation in MI area. **Conclusion:** ^18^F-FDG PET/CT imging could be used to evaluate the myocardial viability (in non-fasted state) and the inflammatory reaction (in fasted state) in AMI models of rats. Brain glucose metabolism of rats in fasted state is significantly higher than non-fasted state, which has clinic meanings for the further study.

P134: Association Between Glycemic Control and Presence of Myocardial Ischaemia among Filipino Patients with Type 2 Diabetes Mellitus Using Stress Myocardial Perfusion Scintigraphy (Cardiology)
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**Background/Aims:** Coronary Artery Disease (CAD) is the leading cause of mortality among type 2 diabetic patients. Several studies evaluated glycemic control and MPS results with good correlation. In the Philippines, data concerning this matter is non-existent, hence this study. **Methods:** This study was approved by PHC IERB. Retrospective cohort study of selected Filipino type 2 diabetic patients without previous cardiac events who underwent stress or pharmacologic stress MPS (Tl-201 or Tc99m Sestamibi) over an 18-month period at the Philippine Heart Center. Patients were group into adequate glycemic control (HBA1c \<7.0%) and inadequate glycemic control (HBA1c \>7.0%). Association of myocardial ischaemia and risk of having significant CAD were computed using Pearson linear correlation analysis and logistic regression analysis based on summed stress score (SSS). **Results:** A total of 206 diabetic subjects-114 (HBA1c \<7.0%) and 92 (HBA1c \>7.0%), were included in the study. Male subjects dominate the population at 75%. Ischaemia on ECG were prominent among the 2nd group (p=0.018). LVEF values were significantly lower in the latter group (p*=*\<0.001). The distribution in the degree of myocardial ischaemia was significantly higher in the inadequate glycemic control group; with values of 46.7% (43/92) for insignificant, 16.3% (15/92) for mildly abnormal and 37% (34/92) for moderate to severely abnormal (p=\<0.001). It also had direct moderate association to abnormal MPS results (r=0.3279; p*=*\<0.0001) and relative risk for having significant CAD of 4.27 (95%CI 2.32-7.85, p=\<0.001) than their counterpart. Factoring the duration of inadequate glycemic control to \>10 years, showed increased in relative risk to 7.26 (95% CI 2.1-25). **Conclusion:** The study shows that Filipino patients with Type 2 diabetes with inadequate glycemic control have varying degrees of abnormal myocardial ischaemia, direct moderate association to abnormal MPS results, and increase relative risk for having significant CAD as seen on stress MPS.
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**Background/Aims:** Cardiac resynchronization therapy (CRT) is currently recommended in patients with wide QRS complex (≥120 ms), heart failure symptoms, and depressed left ventricular (LV) function (ejection fraction ≤ 35%) despite optimal medical therapy. CRT can improve symptoms, LV function, heart failure hospitalizations, and overall mortality. However, it is observed that a substantial group of patients who received CRT according to these selection criteria do not respond favourably to CRT. **Methods:** We selected 18 CHF patients already booked for CRT under Institute's selection criteria. All patients underwent presurgery detailed clinical assessment followed by baseline ^99m^Tc myocardial perfusion SPECT. CRT was done irrespective of results of myocardial perfusion scan. A follow up myocardial perfusion scan and clinical assessment was done after 6 months. Criteria for labelling improved clinical response was defined. **Results:** Phase analysis was carried out in 18 CHF patients having CRT. Based on pre-defined criteria; response was assessed at 6 month intervals. 66% were classified as responders and 34% were non-responders. It was also seen that SD (68.3±20.2 vs. 32.2±15, p\<0.001) and HBW (178±70 vs. 112±55, p\<0.001) were significantly higher in responders as compared to non-responders. The optimal cutoff values of SD (54°) and PHB (142°) for predicting CRT response were derived by receiver operating characteristic curve analysis. With these optimal cutoff values, phase analysis showed sensitivity/specificity values of 68% and 70%, respectively, in predicting clinical response to CRT. Regional mechanical activation was quantified. A 17-segment model is used to quantify the phase polar map, the mean phase of regions were compared. 78% patients had concordant lead placement while 22% patients had discordant lead placement. At 6 month follow-up, patients with a concordant LV lead position showed significant improvement in LVEF and reduction in LVESV (p\<0.05), whereas with a discordant LV lead position showed no significant improvement. **Conclusion:** Phase analysis by gated myocardial perfusion SPECT is an evolving technique for measuring LV mechanical dyssynchrony. SD and HBW parameters measured by phase analysis were shown to predict response to CRT. It was found useful in identifying site of latest mechanical activation.

P136: Reducing the Small-heart Effect in Paediatric Gated Myocardial Perfusion Single-photon Emission Computed Tomography (Cardiology)
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**Background/Aims:** We compared two reconstruction algorisms and two cardiac functional evaluation software programs in terms of their accuracy for estimating ejection fraction (EF) of small hearts (SH). **Methods:** The study group consisted of 66 paediatric patients. Data were reconstructed using a filtered back projection (FBP) method without the resolution correction (RC) and an iterative method based on an ordered subset expectation maximization (OSEM) algorithm with the RC. EF was evaluated using two software programs of quantitative gated single-photon emission computed tomography (SPECT) (QGS) and cardioREPO. We compared the EF of gated myocardial perfusion SPECT to echocardiographic measurement (Echo). **Results:** Forty-eight of 66 patients had an end-systolic volume \<20 mL which was used as the criterion for being included in the SH group, and the SH effect led to an overestimation of EF. While significant differences were observed between Echo (66.9±5%) and QGS-FBP without RC (76.9±8.4%, p\<0.0001), QGS-OSEM with RC (76.6±8.6%, p\<0.0001), and cardioREPO-FBP without RC (72.1±10%, p=0.0011), no significant difference was observed between Echo and cardioREPO-OSEM with RC (67.4±6.1%) in SH group. **Conclusion:** In paediatric gated myocardial perfusion SPECT, the SH effect can be significantly reduced when an OSEM algorithm is used with RC in combination with the specific cardioREPO algorithm.

P137: The Utility of Cross-calibration for Heart-to-mediastinum Ratio Using Planar Image Created from IQ-Single Photon Emission Computed Tomography System (Cardiology)
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**Background/Aims:** Myocardial sympathetic nervous scintigraphy with ^123^I-labeled meta-iodobenzylguanidine (MIBG) uses a planar image to measure heart-to-mediastinum ratio (HMR). However, planar images are not available from IQ-SPECT with SMARTZOOM collimator (SZC) due to its multi-focal collimation. Since we created the planar-equivalent (IQ-planar) images from the IQ-SPECT transverse image, the aim of this study was to demonstrate the utility of the new method for calculating HMR. **Methods:** The planar image with low-medium energy general-purpose collimator (LMEGP) and IQ-SPECT image with SZC were acquired with the four calibration phantoms filled with ^123^I-MIBG solution. The IQ-SPECT image reconstruction used ordered subset conjugate gradient minimizer method, and transverse images with attenuation and scatter corrections (ACSC) and without ACSC (NC) were obtained. Multi-planar reconstruction and ray-summation processing were applied to create the IQ-planar images with NC and ACSC. Linear regression between the measured HMR from the planar image and the mathematically calculated HMR was used to calibrate HMR to standardised values. We used the smartMIBG software for semiautomatic region setting. Both planar and IQ-SPECT images were obtained in 19 patients to compare the relationship between the HMR values before and after cross-calibration. **Results:** Scatterplots and linear regression lines between planar and IQ-planar HMRs before and after cross-calibration showed systematic differences both NC and ACSC conditions. The planar and IQ-planar HMR values with NC and ACSC were 2.65±0.68, 3.84±1.24 and 3.97±1.47 before cross-calibration, 2.90±0.78, 3.16±0.81 and 2.98±0.97 after cross-calibration, respectively. The IQ-planar HMR with NC and ACSC was significantly higher compared with that of the conventional planar image (p\<0.001). However, the IQ-planar HMR with NC and ACSC after cross-calibration was similar to standardised HMR calculated by planar image. **Conclusion:** The IQ-planar HMR using the new method could be used with the conventional planar HMR.

P138: Serial Change of Rat's Cardiac Function along with Growing (Cardiology)
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**Background/Aims:** There are few studies that evaluate normal rat's myocardial perfusion and ventricular function in the process of growing using *in-vivo* imaging. The purpose of the study was to evaluate cardiac perfusion and function serially in the growing rats by SPECT/CT for small animals and Quantitative Gated SPECT (QGS; Cedars-Sinai) software using ^99m^Tc-sestamibi. For cardiac volume measurement, phantom study was also performed. **Methods:** Using cardiac phantom with 179.8μL of inner cavity, we measured ventricular volume with SPECT/CT and QGS software. We performed gated SPECT/CT in 6 rats every week from 8 to 28 weeks after their birth. Left ventricular functional parameters were calculated by QGS software. **Results:** The ventricular phantom volume was calculated as 168μL by QGS software. The weight of the rats increased week by week from 8 to 16 weeks, and the increase rate became low from 16 to 28 weeks. The heart rates did not change significantly over time. The left ventricular end-diastolic volume (EDV) and stroke volume (SV) increased over time in a linear fashion. The ejection fraction (EF) showed some fluctuation but no tendency of change over time with an average of 49.5±9.21%. EDV, ESV and SV showed the strong positive correlation with weight. The EF showed weak correlation with the weight, but showed rather constant value in over 400g in weight. There is no correlation between each functional parameters and heart rate. **Conclusion:** We analysed the rat cardiac functional parameters in every week from 8 to 28 weeks after their birth using ^99m^Tc-sestamibi gated SPECT/CT with QGS software. EDV, ESV, SV showed high positive correlation with the weight, but EF showed rather constant value over time.
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**Background/Aims:** Good exercise capacity has a high negative predictive value (NPV) in patients with known or suspected coronary artery disease (CAD) similar to a normal gated myocardial perfusion imaging (GMPI). However, previous studies have suggested that diabetic patients undergoing single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) are at greater risk for cardiac events than non-diabetic patients with both normal and abnormal MPIs. Aim of this study was to evaluate NPV of functional capacity during treadmill exercise in diabetics with normal GMPI in Pakistani population. **Methods:** This was a prospective study which included 338 diabetics with normal exercise GMPI at Karachi Institute of Heart Diseases from June 2014 till June 2016. On the basis of metabolic equivalents (METS) achieved during exercise, these patients were divided into Group A: ≥7 METS (140 patients) and Group B: \<7METS (198 patients). These patients were followed up on telephone (for 18 ±3 months) for fatal or non-fatal myocardial infarction (FMI and NFMI respectively). Regarding risk factors in Group A and B, like obesity (50 vs. 54%), hypertension (61 vs. 60%), smoking (14 vs. 15%), dyslipidemia (32 vs. 42%) and family history (32 vs. 30%), no significant difference was found. **Results:** The mean age predicted HR (MAPHR) achieved in group was significantly higher than Group B (86% vs. 83%). No significant difference was found between LV functional parameters (like ejection fraction, end diastolic and systolic volumes) of two groups. During follow up period, the overall all cardiac events reported in Group A was 03 (all NFMI and no FMI) while in Group B 16 events (15 NFMI and 01 FMI) were reported. Annualized event rate for overall events, NFMI and FMI in two groups were 1.43 vs. 5.39%, 1.43 vs. 5.05 and 0% vs. 0.3% respectively. **Conclusion:** We conclude that NPV of a normal GMPI is higher in diabetic patients with a functional capacity ≥7 METS than their counterparts who could achieve \<7 METS on treadmill.
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**Background/Aims:** To find out clinical outcomes in diabetics with normal stress myocardial perfusion scans (MPS) having glycosylated hemoglobin (HBA1C) \> 7.3 or ≤ 7.3. **Methods:** This prospective study was conducted at nuclear cardiology department of Karachi Institute of Heart Diseases (KIHD), Karachi, Pakistan. Total 251 diabetics who had a normal stress MPS were included. On the basis of their HBA1C, these patients were categorized into Group A (HBA1C \>7.3) and Group B (HBA1C ≤ 7.3). This cut-off was taken from our previously published study performed upon early cohort. These patients were followed for 05 years for fatal and non-fatal myocardial infarction (FMI and NFMI). Follow-up was not available in 29 patients, who were excluded and leaving a cohort of 222. **Results:** Group A included 57 while Group B had 165 diabetics with a mean age of 59 vs. 57 years and male to female ratio of 42:58% vs. 40:60% respectively (non-significant). Mean body mass index (BMI) in Group A and B was 28.318 vs. 27.532 kg/m^2^ (non-significant). Mean HBA1C and fasting blood glucose in Group A were significantly higher than Group B (8.363 vs. 6.630 and 135 mg% vs. 120 mg% respectively). No significant difference was seen in prevalence of hypertension, dyslipidemia, family history of coronary artery disease (CAD) and smoking between two cohorts. Persantin (Dipyridamole) stress was used in 58% vs. 56% in Group A and B respectively (non-significant) while no significant difference was seen in effort tolerance (Metabolic Equivalent Task; METS) of participants of both groups during dynamic exercise. In both groups stress MPS was normal with normal left ventricular function parameters (non-significant). During 05 years follow-up, significantly higher NFMI was seen in Group A as compared to Group B \[11 (19.301%) vs. 04 (2.420%), significant p value\] only in last 03 years. FMI was non-significant in both groups \[02 (3.510%) vs. 01 (0.606%), non-significant p value\]. **Conclusion:** Higher non-fatal MIs were observed in diabetics with impaired glucose control (HBA1C \>7.3) and normal MPS. Event rate was significantly higher after 2^nd^ years of follow-up in these patients.
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**Background/Aims:** The C-C chemokine receptor type 2 (CCR2), which is consist of seven transmembrane protein, has been known to be a contributor to left ventricular remodeling after myocardial infarction. Imaging of the CCR2 expression may be a useful strategy for monitoring risk factors in developing heart disease. The purpose of the present study was to exploit the selective CCR2-binding peptide by incorporating a tricarbonyl ^99m^Tc complex for assessing the CCR2 expression caused by myocardial infarction (MI). **Methods:** The *N*-terminal of selective CCR2-binding peptide (QRLASYRRI) was conjugated with the (*N*-picoly)(*N*-hydroxycarbonylmethyl)glycine residue as the precursor. \[Re\]1 and \[^99m^Tc\]1 were synthesized by incorporating (NEt~4~)~2~\[Re(CO)~3~Br~3~\] and \[^99m^Tc(CO)~3~(H~2~O)~3~\]^+^ into the precursor, respectively. In vivo SPECT imaging and ex vivo autoradiography of \[^99m^Tc\]1 were performed in a mouse model of MI (4 days after surgery). Furthermore \[^99m^Tc\]1 was measured log D and in vitro stability. **Results:** \[^99m^Tc\]1 was prepared with 50% of radiochemical yields and more than 98% of radiochemical purity. The chemical identity of \[^99m^Tc\]1 (R*~t~* = 25.2 min) was confirmed by comparing HPLC retention time of \[Re\]1 (R*~t~* = 25.7 min). In vivo SPECT heart imaging and ex vivo myocardial distribution of \[^99m^Tc\]1 were shown the selective accumulation in the infarcted region. The characterization of immunofluorescence analysis revealed that nuclear signals correspond to the innate immune event with the elevated expression of CCR2. **Conclusion:** SPECT molecular imaging probe (\[^99m^Tc\]1) was successfully prepared from the selective CCR2-binding nonapeptide (1) with good yield. The results of in vivo studies suggest that CCR2 targeted peptide have potential to act as a promising SPECT imaging probe for the evaluation of CCR2 expression in heart disease and also provides the foundation for further in vivo biological studies.

P142: Simplified Quantitative Cardiac Perfusion PET Imaging using N-13 Ammonia: Compare with Compartment Model Analysis to Facilitate Clinical Use (Cardiology)
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**Background/Aims:** Myocardial blood flow (MBF) and myocardial flow reserve (MFR) enhance the diagnosis of coronary artery disease. We aimed to compare the quantitative results obtained from simple retention model and two-compartment model on the same cohort. **Methods:** Sixteen healthy volunteers and twenty-three patients with coronary artery disease received N-13 ammonia PET myocardial perfusion scan. Each dynamic PET image dataset was used for two-compartment model analysis, and was rebinned into two static images for simple retention model analysis. Global and regional MBF and MFR of the two models were compared. **Results:** Global and regional MBF and MFR of these two models were highly correlated for all subjects, and simple retention model had mean MFR higher than two compartment model. Bland-Altman plots of global MBF and MFR revealed small bias between simple retention model and compartment model (ΔMBF=-0.01 ml/min/g, ΔMFR=0.23). **Conclusion:** Simple retention model and two-compartment model for ^13^N-ammonia demonstrate good correlation in MBF and MFR. The difference of MFR between the two models needs to be considered in clinical practice.

P143: The Comparison between Prognostic Significance of Different Indices Achieved by Myocardial Perfusion Imaging and Fragmented QRS in Electrocardiogram (Cardiology)

Ayati\*

Nargess

1

Khosravi

S

1

Zakavi

R

1

Dabbagh

V R

1

Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran

**Background/Aims:** Fragmented QRS has been recently introduced as a sensitive electrocardiographic marker for myocardial scar detection. It has also emerged as a prognostic index in cardiovascular diseases. Considering the low cost and accessibility of ECG, this marker can play a pivotal role in predicting cardiac hard events and patient management. This study was aimed to compare the prognostic significance of fQRS and myocardial perfusion scan indices in predicting clinical outcome. **Methods:** Total numbers of 476 patients who had undergone myocardial perfusion imaging (PMI) and had been investigated for fQRS & Q wave markers in their ECGs were included in this study. After a mean time-interval of 64 months (Mean±SD=64±7.1), cardiac hard events (PCI, CABG, MI and cardiac death) as well as all cause mortality rate were evaluated retrospectively in this group of patients. The patients' follow up were done by direct contact with patients and relatives, medical recording units of related hospitals or through State civil registration office if needed. **Results:** Successful follow up was done in 414 cases (87%). 354 patients (85.5%) were alive at the time of follow up and the all cause mortality rate was14.4%. 50% of mortality was consisted of cardiac related death. Cardiac hard events had been occurred in 86/367 (23.4%) of population which was significantly more frequent in patients with both fQRS and Q wave in baseline ECG (p\<0.001). However, fQRS itself did not show any correlation with increasing risk of cardiac events (p=0.36). Myocardial scar in MPI (SRS\>2) was significantly correlated with adverse cardiac outcome (p\<0.001). The correlation of other MPI indices (except TID) with risk of cardiac events was also statistically significant. **Conclusion:** This study revealed that myocardial scar in MPI (SRS\>2) is an independent factor in predicting cardiac hard events. Also, MPI quantitative indices have prognostic value in predicting cardiovascular outcome. fQRS is not an independent factor in predicting cardiovascular events and it is of prognostic value only in simultaneous presence with Q wave.
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**Background/Aims:** In various pathological conditions, most notably in various cancers, strikingly enhanced midkine (MK) over-expression has been noted. We have presented the role of MK in thyroid cancer.\[[@ref119][@ref120][@ref121]\] This study aimed to investigate the value of dynamic changes of MK to monitor post-surgical patients with papillary thyroid cancer (PTC) who were managed with ^131^I therapies. **Methods:** Patients with papillary thyroid cancer (PTC) in pathology were recruited, while those with MK influencing co-morbidities and with positive thyroglobulin antibodies were excluded. Concentrations of MK were measured by enzyme-linked immunosorbent assay. MK concentration at initial ^131^I ablation therapy (MK1) as well as 10-12 months thereafter (MK2) was evaluated, and the dynamic changes of thyroglobulin (Tg) were compared (Tg1 and Tg2) too. This study received our Institutional Ethics Approval. **Results:** There were 241 PTC patients (36 males, 205 females) enrolled, 55 cases had metastases (8 males, 47 females) during follow-up. Disease-free survival curves were drawn by Kaplan-Meier method. For Tg, significantly higher cumulative rate of disease-free status was found if Tg could decrease to \<1.0 ng/ml under TSH stimulation, and the log-rank statistical value was 272.5. For MK, the same pattern was displayed with a log-rank statistical value of 112.7. Cox regression showed if Tg2 decreased (compared with Tg1), but not to \<1.0ng/ml with TSH stimulation, the risk of metastases was 12.6 times more than if it could decrease to the optimal level. If Tg2 increased, the risk is 19.5 times higher. As for MK, if MK2 level decreased (compared with MK1), but not to a normal level, the risk of metastases is 3x. If MK2 level increased, it would be 5x more likely to have metastases. **Conclusion:** Our results indicated that MK could potentially be used as a disease monitoring biomarker for PTC, although inferior to Tg.
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**Background/Aims:** The aim of this study was to assess the usefulness of integrin imaging with ^99m^Tc-3PRGD2 SPECT/CT for detecting recurrent disease in patients with differentiated thyroid cancer (DTC), negative radioiodine whole-body scan (WBS) and high serum thyroglobulin (Tg). **Methods:** Thirty patients who underwent total thyroidectomy followed by radioactive iodine ablation and had negative radioiodine WBS but elevated Tg levels were included. In an attempt to establish the presence of thyroid bed recurrence or regional/distant metastatic disease, ^99m^Tc-3PRGD2 SPECT/CT was performed 1 week after the negative diagnostic dose ^131^I WBS. Diagnostic performance indicators, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), for ^99m^Tc-3PRGD2 SPECT/CT was calculated. This study was approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University, and all participating patients provided an informed written consent. **Results:** The total number of patients included in this study was 30, with 4 being male and 26 being female. In all patients, the final diagnostic radioiodine scan was negative along with an elevated Tg level. In 26 (86.7 %) of 30 patients, ^99m^Tc-3PRGD2 SPECT/CT showed positive uptake. The sensitivity, specificity, PPV, and NPV of SPECT/CT to detect recurrent disease at follow-up were 96%, 60%, 92.31%, and 75%, respectively. Though the Tumour-to-Background (T/B) ratio was significantly higher in patients with Tg \>30 ng/mL than in patients with Tg ranging between 10 and 30 ng/mL, we did not detect any lineal correlations between serum Tg levels and the T/B ratio in these patients (r=0.076, P=0.541). **Conclusion:** Although the specificity was not high, ^99m^Tc-3PRGD2 SPECT/CT showed high sensitivity and PPV for the detection of recurrence in DTC patients with negative radioiodine WBS but elevated Tg levels. In addition, our results suggested that the probability of obtaining a positive SPECT/CT result was positively correlated with the serum level of Tg.
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**Background/Aims:** We aim to determine the difference in construction, function and metabolic pathway in papillary thyroid cancer (PTC) and the relationship between radioactive iodide refractory (RAIR) and gut microbiota. **Methods:** A total of 63 faecal samples from PTC patients were collected from January to June 2017, including 7 RAIR-PTC samples. This experiment study has prior Ethics Approval from institutional authority. The 16S rRNA sequencing were processed. α-Diversity was measured. To evaluate the discriminatory ability of the random forest model, operating characteristic curves (receiving operational curve, ROC) were constructed and area under curve (AUC) was calculated. The metagenomes of gut microbiome were imputed from 16S rRNA sequences with PICRUSt and the predicted functional composition profiles were collapsed into 3 level of KEGG database pathways. **Results:** The Shannon index is significantly higher in 63 PTC samples (p=0.0498). In the RAIR-PTC group, the α-Diversity showed difference compared with the normal PTC (p\<0.05). There are 9 bacteria (Ruminococcus gnavus group, Lactobacillus unclassified, Enterobacteriaceae, Anaerotruncus, Tyzzerella 4. Parabacteroides, norank-f-Ruminococcaceae, Bacteroides, norank-f-Lachnospiraceae) showing significant differences in abundance (p\<0.05), they were used to do Random Forest analysis, the AUC of ROC is 0.726. Fusicatenibacte, Faecalibacterium and Lachnospiraceae-ND3007-group showed lower abundance in RAIR-PTC (p\<0.05). The HTG level, therapeutic times and accumulated dose of administrated ^131^I showed positively correlation with Faecalibacterium (p\<0.05). The PPAR signal pathway was negatively with Prevotella 9. Faecalibacterium was negatively correlated with membrane and intracellular structural molecules and isoquinoline alkaloid biosynthesis (p\<0.05). **Conclusion:** The diversity of gut microbiome is lower in PTC, especially in RAIR-PTC. The comprehensive 9 significantly different expressed bacteria may be used to determine the PTC. Prevotella 9 may affect the metabolic of thyroid. Faecalibacterium may be related to the RAIR of PTC, or its expression may be affected by multiple ^131^I treatments.
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**Background/Aims:** Radioiodine therapy (RIT) for DTC patient, has improved their survival and disease-free lifetime period. For low risk DTC patients, none or low dose of ^131^I (30 mCi) and for high risk patients, high dose ^131^I is recommended (150 mCi or more). However, there is not a prompt recommendation for optimal dose of RIT ablation in intermediate risk patients. This study aimed to compare the treatment efficacy of low versus high dose RIT in intermediate risk DTC patients. **Methods:** This study was carried out on 117 DTC patients who had intermediate risk disease according to ATA 2015 criteria. These patients were randomized (according to computerized random number generator) to receive 30 mCi or 150 mCi of ^131^I for remnant ablation. They were followed up for at least 1 year and the treatment response was evaluated based on the laboratory data, ultrasonography and the diagnostic whole body iodine scan (if performed), according to the new response assessment criteria based on the last published version of ATA. **Results:** Among 117 patients who were categorized randomly to two groups, 105 patients were followed up for at least 6 months and 90 patients for at least 1 year. Group 1 (receiving 30mCi) consisted of 67 patients and group 2 had 50 patients. No statistical difference was noted between the age, sex, first serum TSH, first serum thyroglobulin and anti-thyroglobulin levels in the two groups. The 1 year therapeutic response was as follows: 67.6% excellent response, 23.5% acceptable response and 8.8% biochemical incomplete response in the 1^st^ (30mCi) group, these values were 51.7%, 40% and 8.3% for the 2^nd^ (150 mCi) group. These results did not show statistically significant difference (p-value=0.31). **Conclusion:** The success rate of remnant ablation is equal with high (150 mCi) versus low (30 mCi) dose of RAI. So, remnant ablation in intermediate risk DTC patients can be done with 30 mCi of ^131^I with the same therapeutic response as 150 mCi of ^131^I.
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**Background/Aims:** Autoimmune pancreatitis (AIP) is a type of special chronic pancreatitis mediated by an autoimmune inflammatory reaction. AIP is rare, but received attention recently. An accurate image diagnosis can avoid unnecessary surgery in clinical practice. AIP is a systemic disease which may involve extra-pancreatic organs. So, the aim of this study was to investigate the FDG uptake of extra-pancreatic lesions to improve the recognition accuracy of this disease. **Methods:** This study is a retrospective analysis based on FDG PET/CT image, which obtained the permission of the ethics committee of Changhai hospital. We reviewed 41 AIP patients (37 males and 4 females) of the department of Gastroenterology of Changhai hospital, who underwent a whole body FDG PET/CT scan from August 2010 to April 2017. **Results:** The mean age was 61 years (range 41-83 years). The pancreas showed high FDG uptake in 37 cases (90.24%, SUV~max~=5.2201±1.6674), one patient with mild FDG metabolic in pancreas (SUV~max~=2.581), and other three patients with none abnormal FDG uptake in pancreas. FDG uptake in extra-pancreatic lesions (EPLs) were observed in all 41 patients: hilar and mediastinal lymph nodes with increased FDG uptake (n=30); neck lymph nodes with increased FDG uptake (n=16); hepatic portal and pancreatic peripheral lymph nodes with high FDG uptake (n=9); prostate with high FDG metabolic (n=20); colon with increased FDG uptake (n=10); stomach with high FDG uptake (n=9); nasopharyngeal region (n=8); salivary gland (n=8); intra-hepatic bile duct and common bile duct (n=6); gallbladder (n=4); lung (n=5); kidney (n=6); blood vessels (n=5). **Conclusion:** Autoimmune pancreatitis (AIP) is a unique form of systemic disease. Recognition of the diagnostic features in the images of various involved organs will assist in the diagnosis of autoimmune pancreatitis. FDG PET/CT can exhibit the inflammation of pancreatic lesions, and also reflect the characteristics of extra-pancreatic organs. Imaging plays an important role in the diagnosis of AIP.
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**Background/Aims:** Fever of unknown origin (FUO), unexplained fever (UF) and fever non-responsive to therapy (FNT) without a documented focus of infection pose a clinical challenge and a practical compelling diagnostic ordeal. The aim of this study was to assess the utility of ^18^F-FDG PET/CT imaging in these scenarios by evaluating its impact on the patient's management. **Methods:** 23 consecutive (16 male: 7 female) patients referred to the Nuclear Medicine Department, Al-Jahra Hospital Kuwait from June 2014 to April 2017, with clinical queries of FUO, UF and FNT were included in the study. Mean age of the patients was 50.9 years (range 6-81). The weight-based tracer dosage was administered according to 0.08-0.1mCi/kg body-weight (3.0-3.7Mbq/kg body-weight). Mean-dosage of ^18^F-FDG administered was 7.07mCi (261.6MBq). The mean blood sugar level was 6.7mmol/l (120.6mg/dl). Three patients were bed-ridden. Mean BMI was 26.4kg/m^2^ (range 16.3-41.9). Impact on management was defined as significant if the PET/CT imaging was able to either localize a focus of infection or was able to provide supplemental information to explain the patient's symptom of fever. **Results:** In 17/23 (73.1%) patients there was significant impact on patient's management. In 6/23 (26.1%) no significant impact was ascertained. In 12/17 (71%) patients a potential focus of infection was localised while in 5/17 (29%) supplemental information was provided to explain for patient's fever. The specific localized potential infection sites were highly variable and unique, however, lungs being the most common. **Conclusion:** ^18^F-FDG PET/CT imaging has a significant impact on management of febrile patients. Further prospective studies with more patient numbers would endorse these outcomes.
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**Background/Aims:** Dengue virus (DENV) is an enveloped virus transmitted by mosquitoes, with 50-100 million people annually infected globally. Clinical manifestations range from mild fever to life-threatening complications for which there is no cure. Development of antiviral therapy against acute DENV is a challenge due to poor correlation between known serum biomarkers (such as viraemia) and pathology in target tissues. In previous studies, pro-inflammatory cytokine levels in tissues, but not in serum, strongly correlated with disease severity. Hence, we hypothesise that ^18^F-FDG PET can be repurposed as an inflammation imaging biomarker for tracking DENV infection and treatment efficacy of novel therapeutic compounds. **Methods:** All animal studies were conducted with approval from the Institutional Animal Care and Use Committee of Duke-NUS. AG129 mice, lacking IFNα/β and γ receptors, were infected with DENV and then serially imaged *in vivo* by FDG PET/CT over the course of infection. In parallel, *ex vivo* assessments were performed, including FDG tissue biodistribution, profiling of pro-inflammatory cytokines, and measuring serum and tissue viral load. The prognostic value of FDG-PET/CT in response to antiviral treatment was assessed by comparison to DENV-infected mice treated with the α-glucosidase inhibitor celgosivir. **Results:** Serial imaging and biodistribution studies revealed progressive focal FDG uptake in the intestines that strongly correlated with tissue-specific viral load and inflammatory cytokine (IL-6 and TNF-α) expression levels. In contrast, celgosivir treatment resulted in decreased uptake of FDG in the intestines, which was accompanied with lower cytokine expression levels. **Conclusion:** DENV disease progression can be non-invasively tracked by assessing FDG accumulation in inflamed tissues. Moreover, FDG robustly differentiates treatment-naive from drug-treated groups. Taken together, the diagnostic and prognostic value of FDG-PET/CT for identifying key inflammatory foci and response to therapy early in the course of disease will have important implications for assessing treatment response during therapeutic intervention trials.

P151: Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Assessment of Large and Craniofacial Vessel Involvement in Patients with Clinically Suspected Giant Cell Arteritis: Interim Data of a Prospective Trial (Infection/Inflammation)

Hsiao\*

Edward

1

Sammel

A

2

Nguyen

K

2

Bailey

E

1

Laurent

R

2

Schembri

G

1

Department of Nuclear Medicine and PET, Australia

Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia

**Background/Aims:** Giant cell arteritis (GCA) is a medium to large vessel vasculitis (GCA). It can be challenging to diagnose clinically. Temporal artery biopsy may miss affected arterial segments. FDG Positron emission tomography (PET/CT) scan has been used to detect large vessel arteritis. The superficial temporal, occipital, internal maxillary and vertebral arteries have not been prospectively evaluated due to limited spatial resolution on older generation scanners. We aim to prospectively evaluate the efficacy of current generation FDG PET/CT scan in detecting large vessel and craniofacial artery vasculitis in patients with suspected GCA. **Methods:** Ethics approval obtained (clinical trials. gov ID: NCT02771483). All patients recruited met ≥ 2 ACR criteria for GCA. Each patient underwent dedicated FDG PET/CT in addition to full clinical assessment. All underwent temporal artery biopsy (within 72 hours of commencing corticosteroid) except for one patient who had documented aortitis on CT. FDG PET/CT was performed following injection of 100MBq activity on a Siemens biograph mCT. Each study was reviewed by an experienced nuclear imaging specialist blinded to clinical information. **Results:** The mean age was 68 years (range 54-90 years). 68% had increased uptake in at least one of the evaluated vessels. 44% had increased uptake in carotid arteries, whilst 32% had increased uptake in vertebral arteries. Increased uptake in superficial temporal, internal maxillary and occipital arteries were reported in 27%, 29% and 15% of the patients, respectively. Among the 12 (29%) patients with increased uptake in internal maxillary arteries, 50% had positive biopsy. Conversely, the patients with no uptake in maxillary arteries had only 7 % chance of positive biopsy. **Conclusion:** FDG PET/CT is a promising adjunctive diagnostic tool in assessing the presence of large vessel and craniofacial vasculitis for patients with suspected GCA. Uptake in maxillary artery in the cohort is highly correlated with positive biopsy results.

P153: Fluorodeoxyglucose-Positron Emission Tomography/Magnetic Resonance Imaging in Recurrent or Residual Malignancy: Inter-Observer Agreement and Comparison to Positron Emission Tomography/Computed Tomography (Oncology)
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**Background/Aims:** Inter-observer error can potentially contribute to apparent differences in diagnosis performance between PET/MRI and PET/CT. This study compares the inter-observer agreement of FDG-PET/MRI to the diagnostic concordance between PET/MRI and PET/CT in patients with suspected or recurrent malignancy. **Methods:** The study adopted a single-centre prospective cross-over design in which 105 patients with suspected residual of recurrent melanoma, lymphoma or cancer of the head and neck or colon referred for FDG-PET also underwent PET/MR performed on the same day using the same administration of radiotracer. Dual-trained specialists in radiology and nuclear medicine independently rated PET/MRI studies as either: a) no tumour, b) indeterminate, c) local disease or d) disseminated disease. Consensus PET/MRI ratings were compared to the corresponding PET/CT findings independently rated using the same categories. Inter-observer agreement for PET/MRI and inter-modality agreement were expressed as weighted kappa values. **Results:** Inter-observer agreement for PET/MRI was high (kappa=0.922, 95%CI 0.871--0.974) and comparable to the inter-modality agreement (kappa=0.880, 95%CI 0.812--0.944). 6 of 10 cases rated discordantly on PET/MRI also showed discordance between PET/MRI and PET/CT. In comparison to PET/CT, PET/MRI upstaged 9 patients (8.6%) and downstaged 5 patients (4.8%). Inter-modality agreement was significantly lower for head and neck cancer (kappa=0.638, 95%CI 0.449--0.827). **Conclusion:** FDG-PET/MRI shows high-concordance with PET/CT in recurrent or residual malignancy. Discrepancy rates between modalities are of comparable magnitude to the inter-observer variability for PET/MRI. The reduced inter-modality agreement for head and neck cancer warrants further investigation.

P154: Preclinical Evaluation and In-Man Study of Al18F-PSMA for Prostate Cancer Imaging (Molecular Imaging)
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**Background/Aims:** Prostate cancer (PCa) is a common malignant tumour among men. PSMA is specifically over-expressed in prostate cancer cells. Tracers targeted PSMA had been established for the diagnosis of prostate cancer. ^18^F is a cyclotron-isotope with higher resolution, longer half-life and high yield, which has attracted our eyes. Here, we developed a novel Al^18^F labeled a PSMA targeted tracer Al^18^F-PSMA, the preclinical evaluation and in-man study were performed to evaluate its potential as an imaging agent for PCa imaging. **Methods:** NOTA-PSMA was designed, synthesized and labeled with Al^18^F. The stability and partitional coefficient value were determined. in vitro and in vivo studies on 22Rv1 (PSMA+) and PC-3 (PSMA-) were conducted. For blocking studies PSMA inhibitor, ZJ-43, was used. Prostate cancer sections from human were used for histological and autoradiographic analysis. In-man PET/CT imaging was performed on healthy volunteers and patient with prostate cancer. **Results:** NOTA-PSMA was synthesised and radiolabelled with Al^18^F to obtain Al^18^F-PSMA with high radiochemical purity and specific activity. Al^18^F-PSMA was hydrophilic and stable. The uptake in 22Rv1 cells was up to 1.32 IA%/10^6^ cells comparing with 0.61 IA%/10^6^ cells in PC-3 cells (p\< 0.05) at 1 hour. Biodistribution results exhibited that Al^18^F-PSMA showed high uptake in 22Rv1 tumour (7.87 ±2.37 ID%/g) and rapidly excreted by the kidney-urinary system. The micro-PET imaging demonstrated higher uptake in LNCaP tumour (1.70±0.21 milicounts/sec) than in kidney (1.44±0.26 milicounts/sec). Also, the uptake of Al^18^F-PSMA in 22Rv1 cells and tumours can be substantially blocked by co-administration of excess ZJ-43. Autoradiography of Al^18^F-PSMA showed the same high radioactive accumulation area with immunohistochemical staining of PSMA. PET/CT imaging on healthy volunteers showed clearly uptake in bladder, kidney, lacrimal glands, salivary glands and parotid glands. On patients with prostate cancer, original and metastatic lesions were clearly visualized. **Conclusion:** Al^18^F-PSMA was prepared in high radiochemical purity and high specific activity. Preclinical studies showed Al^18^F-PSMA was PSMA specific with high affinity. In-man PET/CT imaging showed Al^18^F-PSMA is with great potential for prostate cancer imaging, it is worthy transforming to clinic.
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**Background/Aims:** Cytoreductive surgery is widely used for the treatment of peritoneal dissemination in clinical practice; however, it is difficult to detect and remove tumours that are located deeply in the peritoneal cavity and easily changing the position during an operation. We have found that a PET probe ^64^Cu-PCTA-anti-EGFR antibody cetuximab (^64^Cu-cetuximab) highly accumulates in intraperitoneal tumours by intraperitoneal administration. Also, we have developed the world's first open-type PET system, called "OpenPET", which has open space for conducting surgery while monitoring objects at high resolution in real time. In this study, we examined a feasibility of an OpenPET-guided surgery with ^64^Cu-cetuximab to detect and remove tumours deeply located in the peritoneal cavity. **Methods:** Mice bearing HCT116-RFP tumours transplanted with Matrigel at deep sites in the peritoneal cavity were used. ^64^Cu-cetuximab (7.4 MBq/mouse) was administered intraperitoneally and at 24 h later, the OpenPET-guided surgery was performed with a small prototype of OpenPET, having a spatial resolution of about 2 mm. All animal experiments were approved by the institutional ethics committee. **Results:** During OpenPET-guided surgery, tumours were clearly detected behind other organs in the peritoneal cavity. The measurement time required to accumulate sufficient data to identify tumours was approximately 10-30 seconds. Tumours (≥3 mm in diameter) located deep inside the peritoneal cavity could be resected by surgery with OpenPET real-time imaging. OpenPET was useful in confirming the presence or absence of residual tumours during an operation. **Conclusion:** We demonstrated that the OpenPET-guided surgery with ^64^Cu-cetuximab would be promising to detect and remove intraperitoneal tumours deeply located in the peritoneal cavity. This method could provide a novel strategy for cytoreductive surgery of peritoneal dissemination.

**Disclosure of interest:** H Matsumoto Conflict with: An employee of Nihon Medi-Physics Co. Ltd.

P156: Immuno-Positron Emission Tomography Imaging of CD38 Expression in Murine Models of Lymphoma Using
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**Background/Aims:** CD38 is considered as a potential biomarker of multiple myeloma (MM) and has showed a strong link with chronic lymphocytic leukaemia since it has a high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immune-PET imaging with 89Zr-labeled daratumumab was used for differentiation of CD38 expression in murine models of lymphoma to provide a potential non-invasive method for monitoring CD38 in the clinic. **Methods:** Daratumumab was radiolabelled with ^89^Zr (t1/2 = 78.4 h) via the conjugation with desferrioxamine (Df). After Western blot was used to screen CD38 expression in five lymphoma cell lines, flow cytometry and cellular binding assays were performed to test the binding ability of labelled or conjugated daratumumab with CD38 in vitro. PET imaging and biodistribution studies were performed to evaluate CD38 expression after injection of ^89^Zr-Df-daratumumab. ^89^Zr-Df-IgG was also evaluated for the non-specific control group in Ramos models. Finally, CD38 expression in tumour tissues was verified by histological analyses. **Results:** Ramos cell line was found to express the highest level of CD38 while HBL-1 cell line has the lowest expression, screened by WB. Df conjugated or ^89^Zr labelled daratumumab displayed similar high binding affinity in Ramos cells. PET imaging of ^89^Zr-Df-daratumumab showed high tumour uptake from 9.6±5.2 to 26.6±8.0%ID/g for Ramos post-injection, and only from 2.4±0.8 to 6.6±2.9%ID/g for HBL-1 (n=4). ^89^Zr radiolabelled non-specific IgG also demonstrated low tumour uptake from 2.2±0.8 to 4.3±0.8%ID/g for Ramos. Ex vivo biodistribution studies showed similar trends with imaging results. Immunofluorescent staining of tumour tissues verified higher CD38 expression of Ramos than that of HBL-1. **Conclusion:** We investigated the role of ^89^Zr-Df-daratumumab for evaluating the CD38 expression in lymphoma models noninvasively, therefore provide a highly potential imaging agent of CD38 positive haematological diseases such as MM in the clinic in the future.
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**Background/Aims:** Vascular endothelial growth factor receptor (VEGFR) is highly expressed in human thyroid gland. In mice, normal capillaries of thyroid is known to regress after anti-VEGF therapy and grow back within 2 weeks of cessation of treatment.\[[@ref122]\] However, the effect of anti-VEGF agent bevacizumab (BEV) on normal organ blood flow has been rarely reported.\[[@ref123]\] The purpose of this study was to evaluate a change in thyroid gland blood flow after chemotherapy with BEV in humans using ^15^O-H~2~O PET. **Methods:** Four patients with advanced adenocarcinoma of lung underwent a 10 minute dynamic ^15^O-H~2~O PET scan before and 1-2 days after administration of carboplatin (CBDCA)+paclitaxel+BEV or CBDCA+pemetrexed+ BEV. One patient among four received post-treatment PET three times: at 1, 18 and 39 days after the beginning of chemotherapy. Using nonlinear regression, ^15^O-H~2~O thyroid gland time activity curves were fitted to the single-tissue compartment model using image derived input functions, which were determined using volumes of interest over ascending aorta. **Results:** The mean (SD) blood flow of thyroid gland were 1.1 (0.55) to 0.60(0.12) ml/min/cm^3^ at baseline and 1-2 day after the treatment, respectively. Statistically no significant changes were observed before/after the treatment. In the patient who received posttreatment PET three times, thyroid gland blood flow was decreased by 60% 1 day after the treatment, and recovered to 80% of the baseline blood flow at 18 days and 39 days. **Conclusion:** Blood flow of normal thyroid gland was not decreased significantly after the chemotherapy with BEV. The one case in which thyroid blood flow recovered suggests the reversibility of thyroid gland blood flow after administration of BEV.

P158: Discordant Interpretation of Serial BMD Measurements by DXA Using Vendor's and Institutional Least Significant Changes: Serious Impact on Decision Making (Musculoskeletal)
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**Background/Aims:** Meaningful change in bone mineral density (BMD) should be equal or higher than institutional least significant change (LSC). But some facilities use vendor's LSC which is discouraged by ISCD. Aim of this study was to find impact of scan interpretation upon interval BMD changes using vendor's and institutional LSCs. **Methods:** This prospective study was conducted at Joint Commission International (JCI) accredited facility of Pakistan from April--June 2017 using Hologic Discovery-A scanner. As per ISCD recommendations, precision error and LSC of two technologists were measured. Serial BMD changes like deterioration or improvement interpreted based on vendor's and institutional LSCs were compared. **Results:** Serial BMD changes in 102 patients were included, having a mean age, male: female ratio and mean BMI of 63 years, 94%:06% and 29.274 Kg/m^2^ respectively. Mean menopausal age was 47 years and mean duration between 2 DXA studies was 3 years. BMD changes over hip were found significant in 55% and 53% cases against vendor's and institutional LSCs respectively (non-significant discordance in 02%). BMD changes using vendor's and institutional LSCs were found significant over L1-4 (62%vs.46%; discordance: 14%) and distal forearm (77% vs. 35%; discordance: 41%) respectively. Interpretations based on vendor's LSCs revealed significantly over-estimated deterioration over forearm and improvement over L1-4 BMD values. **Conclusion:** We conclude that vendor's provided LSC for interpretation of serial DXA is misleading and has significant negative impact upon patients' management. Every DXA facility must use its own LSC as per ISCD guidelines. Furthermore, ISCD must consider publishing cut-off values for LSC for distal forearm measurement.

P159: Elevated Circulating MIC-1/GDF15 Level is a Diagnostic and Prognostic Biomarker for Osteosarcoma Patients (Oncology)
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**Background/Aims:** Osteosarcoma is the most frequent primary bone tumour that affects children and adolescents. However, diagnostic and prognostic biomarkers for osteosarcoma remain lacking. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) has been characterized as a candidate biomarker for many cancer types recently. However, the role of circulating MIC-1 in screening patients with osteosarcoma has not been well-established. **Methods:** In this study, we evaluated circulating MIC-1 level in osteosarcoma patients to explore its diagnostic and prognostic value for this particular malignancy. Circulating MIC-1 level was measured by ELISA in 100 osteosarcoma patients, 100 benign bone tumours patients and 100 healthy controls, followed by analysis of the correlation with clinic pathological characteristics. Receiver operating curves (ROC), Kaplan-Meier curves, and log-rank analyses as well as Cox proportional hazard models were used to evaluate diagnostic and prognostic significance. **Results:** Circulating MIC-1 level was significantly increased in osteosarcoma patients. Osteosarcoma patients with larger tumours, later-tumour stages, low tumour grades, and distant metastases had much higher MIC-1. Multivariate logistic regression analysis confirms that high circulating MIC-1 level was an independent risk factor for distant metastases. ROC/AUC analysis indicatesMIC-1 is a potential biomarker for screening MIC-1 patients from controls. Osteosarcoma patients with higher MIC-1 had relatively lower survival, and multivariate analyses for overall survival revealed that high circulating MIC-1 level was an independent prognostic factor for osteosarcoma. **Conclusion:** Our study suggest that elevated circulating MIC-1 level might be a novel diagnostic and prognostic biomarker for osteosarcoma patients.
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**Background/Aims:** The correct diagnosis of Parkinson disease (PD) is important, with regard to prognosis and therapeutic strategy. However, at initial assessment differential diagnosis between PD and atypical Parkinsonism (APism) remains relatively inadequate. Clinical diagnosis may be changed after a few years of follow-up. Here we investigated whether difference in striatal subregional dopamine transporter loss, in the time of initial diagnosis, can predict the reassessed diagnosis of patients with Parkinsonism after minimum 3 years of follow-up. **Methods:** Ninety-four patients with Parkinsonism who underwent ^18^F-FP-CIT PET in the initial diagnosis and who with at least 3 years follow-up periods (median 55.5 month) were retrospectively enrolled. After the follow-up, 49 patients were reassessed as PD, including 5 patients who were initially diagnosed as APism and 45 patients were reassessed as APism, with 21 PD patients initially. After PET normalization, in-house templates of 10 striatal subregions (bilateral anterior caudate (AC), posterior caudate (PC), anterior putamen, posterior putamen (PP), and ventral putamen) and 1 occipital were used to calculate the nondisplaceable binding potential (BP~ND~) for each subregion. Group comparisons, and receiver operating characteristic (ROC) analysis was conducted. **Results:** The BP~ND~s of all subregion in the APism patients were significantly lower than those in the PD (P \< 0.05). From the ROC analysis BP~ND~ of PC had the greatest area under curve (AUC) of 0.760, reflecting fair predictive value. Subgroup analysis, according to the diagnosis at initial assessment, was done respectively. In the initial PD group, BP~ND~ of PC (p=0.02) and PP (p=0.02) was significantly lower in the APism. From the ROC analysis BP~ND~ of PC had AUC of 0.680. In the initial APism group, BP~ND~ of PC (p\<0.01) was significantly lower in the PD. ROC analysis revealed BP~ND~ of PC to be excellent marker to discriminate reassessed PD from APism (AUC=0.983). **Conclusion:** Based on the reassessed diagnosis after minimum 3 years of follow-up, APism patients showed more prominent dopamine transporter loss in the striatum globally compared to PD group, with BP~ND~ of PC showing fair predictive value. From the subgroup analysis, ^18^F-FP-CIT PET showed excellent performance discriminating reassessed PD and APism at time of initial assessment, who show atypical features.

P161: Diagnostic Performance to Predict Conversion of Mild Cognitive Impairment to Alzheimer's Dementia Using Imaging Biomarkers of Structural Magnetic Resonance Imaging, Fluorodeoxyglucose Positron Emission Tomography and PiB Positron Emission Tomography (Neuroscience)
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**Background/Aims:** The aim of this study was to compare the diagnostic performances of structural MRI (sMRI), FDG-PET, and PiB-PET for predicting conversion of mild cognitive impairment (MCI) to Alzheimer's dementia (AD) by using the dataset of Japanese Alzheimer Disease Neuroimaging Initiative (J-ADNI). **Methods:** We used the J-ADNI data registered in National Bioscience Database Center Human Database. Subjects were 50 patients with MCI (mean age 71.7±5.11 years) who underwent FDG-PET, sMRI and PiB-PET at baseline. The PiB images were visually rated as positive or negative (equivocal is treated as positive). FDG-PET images were evaluated by visual classification,\[[@ref127]\] and by a semi-quantitative measurement, PET score.\[[@ref128]\] The Hippocampus volume + Entorhinal cortex volume/total gray matter volume (HEV/TGV) was calculated from sMRI data using FreeSurfer. The performances of each combination of imaging biomarkers were calculated by logistic analyses. This study was approved by Ethics Committee of National Center for Geriatrics and Gerontology, Japan. **Results:** Twenty-five out of 50 patients developed AD during three-year follow-up. In predicting conversion of MCI to AD, the visual read of PiB-PET showed the highest sensitivity (sensitivity 88%; specificity 52%; accuracy 70%). PET score demonstrated a higher specificity (sensitivity 52%; specificity 84%; accuracy 68%), while the expert reading of FDG-PET showed the higher sensitivity (sensitivity 80%; specificity 68%; accuracy 74%), which was similar to the performance of HEV/TGV (sensitivity 84%; specificity 64%; accuracy 74%). The combination of visual read of PiB-PET and FDG-PET showed superior performance (sensitivity 83%; specificity 81%; accuracy 82%) to the combination of PiB-PET and HEV/TGV (sensitivity 83%; specificity 69%; accuracy 74%), and to any other combinations. **Conclusion:** The results suggest that the combination of visual reads of FDG-PET and PiB PET is a better predictor of AD conversion from MCI than any other imaging biomarkers. Each imaging biomarker may reflect different pathophysiologies of MCI.
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**Background/Aims:** Extending their previous two-biomarker approach, Jack and colleagues (Neurology, 2016) have proposed a new classification scheme based on: "A" (Aβ-amyloid), "T" (tau), and "N" (neuronal injury). We investigated the impact of the ATN classification on disease progression and cognitive trajectories. **Methods:** 624 NC participants and 142 MCI participants who underwent evaluation for A status (either ^11^C-PiB, ^18^F-florbetapir, ^18^F-flutemetamol, or ^18^F-NAV4694 PET Imaging), T status (143 by either ^18^F-AV1451, ^18^F-THK5351 or ^18^F-THK5317 PET Imaging and 54 CSF pTau) and N status (3D-MRI) were considered. Membership to each ATN group and the impact of ATN classification on disease progression were evaluated. **Results:** 40.5% of NC, 14.3% of MCI and 14.3% of AD were ATN negative; whereas 3.0% of NC, 33.3% of MCI and 42.9% of AD were ATN positive. A linear mixed effect model of Verbal Episodic Memory in NC, identified that participants who were positive for A & N (B=-0.81; p=0.02) had a significantly worse performance at baseline compared to ATN negative, this was exacerbated in participants who were ATN positive (B=-2.45; p=0.005). The only group to have a significantly different decline from the ATN negative group were the ATN positive group (B=-0.52; p=0.00005). No other significant differences were found. Being positive for all three categories (A, T & N) is associated with the worst prognosis in terms of risk of progression towards AD. Approximately 7% of NC who are positive for one or less categories progress to MCI or AD whereas \~12% who are positive for two categories and 30% who are positive on all three categories progress. In MCI, it appears that being positive for A is associated with progression to AD with a higher percentage of progression in those who are also N positive or positive for all 3 categories. **Conclusion:** Increasing biomarker abnormality is associated with worse cognitive trajectories. The implementation of the ATN classification could help refine prognosis and identify those at-risk individuals more likely to progress for their inclusion in therapeutic trials.
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**Background/Aims:** Some first-generation tau tracers have been shown to either present "off-target" binding or lack of selectivity for tau. We evaluated the ability of ^18^F-MK6240, a second-generation selective tau tracer, to detect and measure global and regional tau burden in the brain. **Methods:** Eight probable Alzheimer's disease (AD), 3 mild cognitive impairment (MCI), 5 non-AD dementia (nADd), and 6 healthy elderly controls (HC), underwent Aβ-amyloid imaging with ^18^F-NAV4694 and 120-min dynamic tau imaging with ^18^F-MK6240. Global and regional ^18^F-MK6240 binding was assessed using Distribution Volume Ratios (DVR) and standardised uptake value ratios (SUVR) at 70-90 and 90-120 min post injection, calculated using the cerebellar cortex as reference region. **Results:** One AD participant had both low Aβ and tau tracer retention. Six of the 7 remaining Aβ+AD patients showed high ^18^F-MK6240 binding, greater in the temporoparietal and posterior-cingulate than in frontal cortex. Tracer retention in HC and nADd was very low. No "off-target" binding in choroid plexus or basal ganglia was observed. Significantly higher DVR~CbCtx~ was observed in Aβ+AD compared to HC in mesial temporal (Me, 1.26±0.28vs.0.80±0.05, *p=0.02*), temporoparietal (Te) 1.54±0.58vs.0.88±0.05, *p=0.02*), and rest of neocortex (R) (1.30±0.45vs.0.78±0.04, *p=0.02*). Similar differences were observed with SUVR~CbCtx~ at 70-90 min: Me (2.02±1.00vs.0.87±0.08, *p=0.04*), Te (2.56±1.86vs.0.96±0.07, *p=0.03*), and R (2.01±1.44vs.0.88±0.11, *p=0.04*), and at 90-120 time windows: Me (1.91±0.93vs.0.85±0.16, *p=0.04*), Te (2.60±1.84vs.0.93±0.10, *p=0.04*), and R (2.10±1.45vs.0.82±0.09, *p=0.04*) time windows. There was high agreement between regional DVR~CbCtx~ and SUVR~CbCtx~ at 70-90 min (r=0.93, *p\<0.0001*; r=0.94, *p\<0.0001*; and r=0.93, *p\<0.0001*, for Me, Te and R, respectively) and at 90-120 min (r=0.88, *p\<0.0001*; r=0.90, p*\<0.0001*; and r=0.89, p*\<0.0001*, for Me, Te and R, respectively. Identical interpretation resulted from visual inspection of 70-90 and 90-120 min images. **Conclusion:** ^18^F-MK6240 PET discriminates well between AD and HC, and should facilitate integration of tau imaging into clinical practice and therapeutic trials.

P164: Refining the Natural History of Global and Regional Aβ-Amyloid Deposition in Sporadic Alzheimer's Disease (Neuroscience)
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**Background/Aims:** We used longitudinal Aβ imaging data from the AIBL and ADNI studies to calculate the rates of global and regional Aβ-amyloid deposition. **Methods:** Four hundred and eighty-five participants from AIBL and ADNI (321 HC; 135 MCI; 29 AD) with 3 or more Aβ imaging assessments were included in the study. While AIBL participants underwent Aβ imaging with PiB and NAV4694 (n=220, median follow-up of 4.8 --range 2.5-10.6-- years), or flutemetamol (n=94, median follow-up of 3.2 --range 3.0-3.8-- years), ADNI participants underwent Aβ imaging with florbetapir (n=171, median follow-up of 4.1 --range 2.9-5.7 -- years). Aβ deposition was derived from the slope of the linear regression plots, and rates of accumulation were calculated from the time it took to go from the median levels of Aβ-HC to the median levels of Aβ+ AD, and they were expressed as both SUVR and Centiloids (CL). **Results:** Of 485 initial participants, 417 (86%) (270 HC; 118 MCI; 29 AD) showed positive rates of Aβ accumulation over 3 or more assessments. Irrespective of the Aβ tracer used, Aβ deposition spans more than two decades, averaging 31.6±5.7 (mean±SEM) years to go from the median levels observed in Aβ-HC (1.04 SUVR/3.8 CL) to the median levels observed in mild Aβ+ AD (2.06 SUVR/98.4 CL) confirming our previous estimates of 31.2 yrs. This translates in rates of Aβ accumulation of 0.032 SUVR/yr (2.99 CL/yr). The regional assessment showed faster Aβ accumulation in the posterior cingulate/precuneus and frontal areas, and slowest in the hippocampus. **Conclusion:** Our new assessment with a longer follow-up confirmed our previous findings that Aβ-amyloid deposition is a slow and protracted process, extending for more than two decades. Centiloids can be used to combine longitudinal Aβ imaging data obtained with different Aβ tracers.

P165: Iodine-123-metaiodobenzylguanidine Single Photon Emission Computed Tomography Scoring can be an Imaging Biomarker in Patients with Dementia Using IQ-Single Photon Emission Computed Tomography System (Neuroscience)
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**Background/Aims:** The heart-to-mediastinum ratio (HMR) of iodine-123-metaiodobenzylguanidine (MIBG) has been used to determine the uptake of the heart to evaluate sympathetic nerve activity. However, quantitative SPECT scoring is still uncommon because of the inferior attenuation artifact is often found in MIBG SPECT image. Therefore, we performed SPECT/CT-attenuation correction using IQ-SPECT/CT in a short-term acquisition protocol. We investigated the relationship between quantitative SPECT/CT scoring and HMR using IQ-SPECT and conventional collimator to test the hypothesis that MIBG scoring could be an imaging biomarker in dementia. **Methods:** The subjects include 247 patients who underwent MIBG imaging. IQ-SPECT was used for diagnosis, including Parkinson's disease and dementia with LBD. The early-and delayed-phase cardiac images were obtained. HMR was calculated by the ratio of mean counts between heart and mediastinum areas of interest drawn on a planar image by means of automated software analysis. SPECT images were obtained by IQ-SPECT system with SMARZOOM collimator using CT-attenuation correction. The disorders were assessed by QPS (Cedars-Sinai Medical Center, Los Angeles, CA) quantitatively, using the standard 17-segment and 5-point scoring system. A neurologist expert determined the final clinical diagnosis by using international clinical diagnostic criteria. **Results:** IQ-SPECT completed the acquisition of SPECT imaging in about 5 minutes (n=22). In part, conventional SPECT took 16 minutes (n=225). Interior decreased uptake was significantly improved by CT-attenuation correction using IQ-SPECT/CT. The quantitative QPS scoring showed significantly close relationships with MHR values (p\<0.0001). The quantitative QPS scoring showed significantly close relationships with MHR values (p\<0.0001). IQ-SPECT in a short time acquisition protocol was applied to the patients with dementia. SPECT scoring with IQ-SPECT identified LBD subjects (49±4 vs 4±3, p\<0.0001). HMR in LBD was significantly decreased than that of non-LBD (1.4±0.2 vs 3.2±0.6, p\<0.0001). Conventional collimator showed a close relationship between SPECT scoring and HMR (p\<0.0001). **Conclusion:** SPECT scoring with IQ-SPECT/CT using short acquisition protocol might be feasible. Quantitative SPECT scoring could be an imaging biomarker for evaluating severity of MIBG defect to identify cardiac neuronal damage.

P166: Diagnostic Accuracy of Fluorodeoxyglucose-Positron Emission Tomography/Magnetic Resonance for Dementia-Estimation of the Impact of Commercial Atlas-Based Magnetic Resonance Attenuation Correction (Neuroscience)
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**Background/Aims:** One of the best targets of PET/MR is the evaluation of dementia. However, incomplete MR-attenuation correction (MRAC) on commercial PET/MR cause the error of PET images, which may lead to decrease the accuracy of the evaluation. The purpose of this study was to estimate the impact of commercial MRAC on FDG-PET evaluation of Alzheimer's disease (AD). **Methods:** We obtained AD, mild cognitive impairment (MCI) and normal control subjects (n=203) were obtained from the Alzheimer's Disease Neuroinitiative database (ADNI). To clarify the statement of prediction of AD, PET probability score was calculated by using PALZ (Pmod) which software is widely used for FDG-PET/CT dementia study. Separately, we recruited 14 patients (median age 66 years, range 56 to 80) who underwent both PET/CT and PET/MR (GE SIGNA) examination. Two FDG/PET data was generated based on MRAC (Atlas-based method) and CTAC from the identical PET raw data on PET/MR. After the spatial normalization and smoothing for these PET images which procedure is the same as PALZ protocol, we calculated the error-map of PET where PET based on MRAC was divided by that on CTAC in each patient. We multiplied each 14 error map and each 203 ADNI data to which the same normalization and smoothing was performed as above. Totally, we could get 203\*14=2842 dataset. We performed PALZ evaluation to these simulated PET dataset. The diagnostic accuracy of the discrimination of AD and of predicting progression to AD was estimated in each 14 error map. **Results:** The accuracy, sensitivity and specificity for the discrimination of AD-patients from the normal control was not impaired by MRAC (Original vs. Error; 83.2%, 83.3% and 83.1% vs. 81.3% \[range 77.6-83.2%\], 82.6% \[range 79.2-85.4%,\] and 80.3% \[range 71.2-86.4%\]). The accuracy, sensitivity and specificity for predicting progression from MCI to AD during 2-year follow-up was not impaired either by MRAC either (Original vs. Error; 57.0%, 60.6% and 65.1% vs. 56.9% \[range 54.2-59.8%\], 61.5% \[range 54.5-72.7%\] and 64.5% \[range 54.0-73.0%\]). **Conclusion:** It was estimated that clinical PET/MR system using atlas-based MRAC could discriminate AD-patients from the normal control and predict the progression from MCI to AD based on the same manner with the same database for FDG-PET/CT. FDG-PET on clinical PET/MR system has enough accuracy to diagnose AD.

P167: Cardiac Sarcoidosis: Pitfalls of Cardiac Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging Scans, and How Cardiac Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging will Help (Cardiology)
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**Background/Aims:** Both cardiac ^18^F-FDG PET/CT and cardiac MRI scans can have false positive results in the diagnosis of cardiac sarcoidosis. This study is to retrospectively compare diagnostic value and pitfalls of cardiac ^18^F-FDG PET/CT and MRI scans in patients with suspected cardiac sarcoidosis. **Methods:** Twenty patients with clinically suspected cardiac sarcoidosis between October 2013 and October 2017 were included in this retrospective study following ethics committee approval. All patients underwent cardiac ^18^F-FDG PET/CT and MRI scans and reported as per criteria on Heart Rhythm Society (HRS) Expert Consensus Statement, and all patients received specific cardiac infiltration protocol (12 hours fast, high fat low carbohydrate diet for 24 hours to suppress myocardial FDG uptake) prior to ^18^F-FDG PET/CT scans. Findings of the original written reports were compared for concordant and discordant findings. **Results:** One of the patients had a simultaneous ^18^F-FDG PET/MRI scan. Of the nineteen patients, eight (42%) had concordant FDG PET/CT and MRI results (five were negative, three were positive for cardiac sarcoidosis), eight patients (42%) had discordant ^18^F-FDG PET/CT and MRI findings, and three patients (16%) had indeterminate FDG PET/CT findings due to presumed inadequate myocardial 18f-FDG suppression. Four out of the eight patients with discordant PET/CT and MRI findings had positive PET/CT results, all of which the MRI provided clarification. The remaining four patients in this group had ether a positive or equivocal MRI results that the ^18^F-FDG PET/CT results were helpful to clarify. Cardiac MRI was able to provide further information on all three patients with indeterminate ^18^F-FDG PET/CT results. The combination of cardiac ^18^F-FDG PET/CT and MRI was helpful in achieving a uniform diagnosis in 58% of patients. **Conclusion:** The combined interpretation of cardiac ^18^F-FDG PET/CT and MRI scans is useful in the assessment of suspected cardiac sarcoidosis, and highlights the importance of co-reporting and/or simultaneous acquisition of these two scans in achieving a uniform diagnosis.
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**Background/Aims:** We created a normal database of CT attenuation correction (CTAC_NDB) of ^123^I-IMP brain perfusion SPECT including 33 healthy volunteers. The aim of this study is to compare CTAC and Chang's AC for the statistical analysis of brain perfusion SPECT at three institutions and to assess the clinical utility of CTAC_NDB in Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB) and mild cognitive impairment (MCI). **Methods:** Different SPECT and CT systems in each institution were used. We identified 30 patients with AD, DLB and MCI who demonstrated the typical reduction patterns of each type of disorders according to a conventional analysis method. They were reanalysed by CTAC_NDB. We evaluated how the AD/DLB pattern changed, both visually and semi-quantitatively. This study approved by the ethics review committee of Fujita Health University. **Results:** Through the visual interpretation, the findings in the vicinity of the cranium, such as in the temporo-parietal, frontal, and visual cortices, became increasingly clear. However, there was no obvious change in the medial surface of the brain, such as the posterior cingulate gyrus and precuneus. These findings were confirmed by semi-quantitative analysis. We also found similar changes in the reduction pattern in the three institutions. **Conclusion:** CTAC_NDB in ^123^I-IMP brain perfusion SPECT might be applicable in AD, DLB and MCI for use in any other institutions.
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P169: Preclinical Monitoring of Therapeutic Response of Dual Targeted Hyaluronic Acid Nanodrug with Positron Emission Tomography/Computed Tomography (Nuclear Medicine Innovation)

Ma\*

Mengshi

1

Chen

M

1

Gao

S

1

Zhu

L

2

Ma

Q

1

China Japan Union Hospital, Jilin University, Changchun, China

Xiamen University, Xiamen, China

**Background/Aims:** Early detection treatment effect is very helpful for *in vivo* evaluation of drug potential and clinical doctors to adjust the therapeutic regimen in time. **Methods:** In this study, a dual targeted nanodrug, hyaluronic acid nanoparticles (HANPs) encapsulated with paclitaxel (PTX), were investigated. Preclinically, PTX-loaded HANPs (HANP/PTX) showed dose-dependent cytotoxicity to cancer cells (HT29, A549, MDA-MB-231, HepG2 and MDA-MB-435s) and significantly lower cytotoxicity against normal fibroblasts (NIH-3T3) than free PTX. In vivo, we administered PBS, free paclitaxel, paclitaxel protein-bound particles (Abraxane) and HANPs/PTX through vena caudalis to each group of athymic nude mice with MDA-MB-435s tumours. To monitor therapeutic responses, we performed positron emission tomography (PET) imaging, in sessions that lasted 90 mins, starting with injection via the tail vein catheters with ^18^F-RGD, followed by ^18^F-FDG 40 mins later. The ^18^F-FDG tumour time--activity curve was isolated from the 90-min dual-tracer tumour time--activity curve by subtracting the fitted^18^F-RGD tumour time--activity curve. All experiments and animal care procedures were approved by the Institutional Animal Care and Use Committee of Jilin University. Animal studies were carried out under a protocol approved by the National Institutes of Health Clinical Center Animal Care and Use Committee (CC/ACUC, Protocol \# NIBIB 13-03). **Results:** As expected, the control group, treated with saline and free PTX, exhibited a rapid increase in tumour size as a function of time. No significant increase in tumour size was found for the group treated with HANPs/PTX or Abraxane. On HANPs/PTX treatment, the tumour uptake of ^18^F-FDG and ^18^F-RDG is less than the untreated tumours' in a day-3 to day-0 ratio (0.86:1.18). **Conclusion:** Overall, HANP/PTX with well water-solubility and a decrease of toxic side effects showed promising potential as a dual targeted drug carrier for cancer therapy. ^18^F-FDG can monitor the glucose metabolism of tumour, while ^18^F-RGD is used for monitoring the angiogenesis molecular changing after treatment. ^18^F-FDG and ^18^F-RGD PET can be used for early detection treatment effect to monitoring therapeutic responses. Our research can provide the basis for the clinical transformation of medicine.

P171: Prediction of Clinical Outcome in Advanced Gastric Cancer by Tumour Metabolic Response Assessment with PERCIST: A Prospective Study (Oncology)
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**Background/Aims:** The role of early tumour response evaluation has been less evaluated in therapeutics of advanced gastric cancer (AGC). Tumour shrinkage is widely accepted as a therapeutic marker in response evaluation criteria in solid tumours 1.1 (RECIST). However, a change of tumour size after chemotherapy appears slowly. ^18^F-FDG PET/CT shows glucose metabolic activity of solid tumours, and can represent early change after chemotherapy. Recently, PET Response Criteria in Solid Tumours 1.0 (PERCIST) has been suggested as a standardized metabolic response evaluation guideline for solid tumours. We prospectively evaluated response evaluation with PERCIST and RECIST in AGC to predict clinical outcome. **Methods:** We analysed fifty-five patients with AGC who were enrolled in a prospective study. Each patient was assessed with ^18^F-FDG PET/CT before and after 2 cycles of standard palliative chemotherapy treatment. Response to the treatment was assessed as metabolic objective response rate in PERCIST (mORR~PERCIST~; complete metabolic response and partial metabolic response) and disease control rate in RECIST (DCR~RECIST~; complete response, partial response, and stable disease). Overall survival (OS) and progression-free survival (PFS) were assessed. **Results:** The mORR~PERCIST~ and the DCR~RECIST~ were 71% and 82%, respectively. The mORR~PERCIST~ had significantly longer OS (median 20 months vs. 6.3 months, p\<0.0001) and PFS (median 6.6 months vs. 2.8 months, p\<0.0001) compared to the non-mORR~PERCIST~. The mORR~PERCIST~ independently predicted OS (hazard ratio \[HR\], 0.1; p=0.001) and PFS (HR, 0.2; p=0.014) in the multiple cox-regression analysis with the established clinicohistopathologic factors of age, sex, histology, HER2, ECOG performance status, gastrectomy history, and peritoneal metastasis, and DCR~RECIST~. In the subgroup of DCR~RECIST~, the median OS of mORR~PERCIST~ (median 19.2 months) and non-mORR~PERCIST~ (median 10.2 months) was significantly different to each other (P = 0.0270). Additionally, there was a trend of difference of median PFS between mORR~PERCIST~ (median 7.6 months) and non-mORR~PERCIST~ (median 4.3 months) (p=0.065). **Conclusion:** This study prospectively demonstrated that metabolic response evaluation with PERCIST helps to predict clinical outcomes of patients with AGC.

P172: Highly sensitive thyroglobulin Immunoradiometric Assay for Thyrotropin-Releasing Hormone-Stimulated thyroglobulin detection in differentiated thyroid carcinoma (Endocrinology)
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**Background/Aims:** In patients with differentiated thyroid carcinoma (DTC), stimulated serum thyroglobulin (Tg) level is regarded as an important tumour marker during follow-up after thyroidectomy and radioiodine ablation. However, stimulation of serum Tg level to increase sensitivity of Tg detection causes inconvenience and financial cost. Recently developed immunometric assay allows highly sensitive assessment of serum Tg level less than 0.1 ng/mL. In this study, we retrospectively evaluated diagnostic ability of highly sensitive Tg immunoradiometric assay (IRMA) for stimulated Tg detection. **Methods:** Eighty-three paired sera of basal and TSH-stimulated, which were Tg-antibody negative (\<60 U/mL) were analysed. Two Tg IRMA assay kits, Dynotest Tg-plus (Tg-P) with a functional sensitivity 0.2 ng/mL and RIAKEY Tg IRMA (Tg-R) with a functional sensitivity 0.06 ng/mL were used. Prediction of stimulated Tg level of 2 ng/mL by basal Tg levels using two Tg IRMAs were analysed. **Results:** Basal Tg-P and Tg-R with cut-off of a functional sensitivity of 0.2 ng/mL and 0.06 ng/mL predicted stimulated Tg detection of 2ng/mL with a sensitivity of 60 and 80%, specificity of 86 and 78%, positive predictive value (PPV) of 57% and 53%, and negative predictive value (NPV) of 87% and 92%. Of 62 sera with basal Tg-P \<0.2 ng/mL, basal Tg-R had significant predictive power as area under the curve of the receiver-operating-curve (AUC-ROC) of 0.747 (p = 0.0159). **Conclusion:** A highly sensitive Tg IRMA may reduce TSH-stimulation for Tg detection during DTC follow-up based on its higher NPV.

P174: Feasibility of Prognosis Assessment for Cancer of Unknown Primary Using Texture Analysis of 18F Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (Oncology)
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**Background/Aims:** Cancer of unknown primary (CUP) is difficult to provide meaningful survival statistics since the primary lesion is not specified. ^18^F-fluorodeoxyglucose positron emission tomography-computed tomography (^18^F-FDG PET/CT) has been thought as a powerful tool for the diagnosis and staging in oncology. Recently, the intratumoural heterogeneity of ^18^F-FDG uptake has been suggested to have a relationship with treatment failure and survival time in various malignant tumours. Hence, we investigated the correlation between texture features in ^18^F-FDG PET/CT and the prognosis of CUP patients. **Methods:** This study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the local Clinical Institutional Review Board. A cohort of 23 CUP patients had undergone whole-body ^18^F-FDG PET/CT scan at the time of diagnosis. The median follow-up was 22.5 months. Volume of interest (VOI) was determined for the largest lymph node among all metastatic lymph nodes using the PET/CT images. Six first-order (including SUV~max~, SUV~mean~, and TLG), four second-order (derived from grey-level co-occurrence matrix (GLCM)) were calculated using a commercial texture analysis software. Receiver operating characteristic (ROC) curves and the area under the curve used to determine overall survival were calculated to determine cut-off values of several parameters. Overall survivals among different prognostic categories were calculated by Kaplan--Meier method. **Results:** TLG and four second-order (GLCM~homogeneity,\ entropy,\ dissimilarity,\ contrast~) were significantly correlated with overall survival. Patients were further stratified into two prognostic groups based on the cut-off values derived from ROC curves and the area under the curve. Based on the results of Kaplan-Meier analysis, TLG, GLCM~homogeneity,\ entropy,\ dissimilarity,\ contrast~, and metastasis (M) status were significantly affected overall survival. **Conclusion:** In patients with CUP, the texture analysis of ^18^F-FDG uptake in the largest metastatic lymph node showed a significant correlation with tumour aggressiveness, suggesting the usefulness for the assessment of the prognosis and the risk stratification.

P175: Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting Malignant Change in Benign Chondroid Tumours (Oncology)

Purandare\*

Nilendu

1

Shah

S

1

Agrawal

A

1

Puranik

A

1

Puri

A

2

Gulia

A

2

Nayak

P

2

Rekhi

B

3

Rangarajan

V

1

Department of Nuclear Medicine, Tata Memorial Hospital, Mumbai, Maharashtra, India

Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India

**Background/Aims:** Benign cartilaginous tumours can undergo malignant transformation. Conventional imaging modalities are routinely used to evaluate patients who present with clinical suspicion of malignant change. FDG PET/CT has been used as an adjunct to conventional imaging in this scenario. The aim of our study was to evaluate utility of FDG PET/CT for predicting sarcomatous transformation in benign chondroid neoplasms. **Methods:** Study included patients with a clinico-radiological diagnosis of a benign chondroid tumour who were referred for a FDG PET/CT study to evaluate clinical suspicion of malignant change. Study was approved by institutional review board. SUV~max~ of the suspected lesion was calculated and compared with final histopathology obtained after surgical resection or a biopsy. ROC curve analysis was performed to obtain a SUV~max~ cut-off value to differentiate benign lesion from those undergoing malignant transformation. In patients who were treated conservatively and also those where histopathology was not available, stability of the lesion on clinical follow up was considered to be an indicator of benignancy. **Results:** 58 patients (M: F-39:19) who underwent whole body FDG PET were included. Clinical and imaging data of 54 patients was available for analysis. Radiological features of osteochondromas were seen in 41 features and enchondromas in 13 patients at the time of initial evaluation. 37 patients had a solitary lesion and 17 patients had multiple lesions. 33 patients showed malignant change after surgical excision, majority (24) showing grade II chondrosarcoma. In 21 patients, diagnosis of a benign chondroid tumour was confirmed (9-surgical excision, 8-biopsy and 4-stability on clinical follow-up). Median SUV~max~ of malignant lesions was significantly higher compared to the benign lesions (4.0 vs. 2.1) (p=0.00). A SUV~max~ cut-off of 3.05 could differentiate benign lesion from those with malignant transformation with a sensitivity of 90.3% and specificity of 87%.(AUC-0.92). Dedifferentiated sarcomas show a significantly higher uptake than rest of the sarcoma types (Average SUV~max~ 20.4 vs 5.7). **Conclusion:** FDG PET/CT can detect malignant change in benign chondroid neoplasms by showing higher metabolic activity in the area of sarcomatous transformation. FDG PET/CT can identify focus of dedifferentiation which has prognostic and therapeutic implications.
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**Background/Aims:** To facilitate hypoxia imaging in a clinical setting, we developed 1-(2,2-dihydroxymethyl-3-\[^18^F\]-fluoropropyl)-2-nitroimidazole (^18^F-DiFA) as a new imaging tracer that targets tumour hypoxia. The objective of this study was to evaluate the radiation dosage, biodistribution and human safety after injection of a single dose of ^18^F-DiFA in healthy subjects. **Methods:** The study was approved by our institutional review board (\#015-0372) and written informed consent was obtained from each subject. Eight healthy male adults participated in this study. Subjects were injected with ^18^F-DiFA intravenously and remained at the hospital until completion of safety assessments 20-24 hours after dosing. All subjects visited the hospital 1 week after dosing for follow-up. A 60-minute dynamic scan was performed, followed by sequential whole-body PET/CT scans at 1, 2, 4, 6, and 20-24 hours post-injection. To evaluate renal clearance of ^18^F-DiFA, urine was collected until 20-24 hr post-injection. Absorbed dose estimates for all target organs were determined using MIRD schema with OLINDA/EXM software. **Results:** No significant changes in vital signs or the results of laboratory studies were observed. Whole body scans showed that ^18^F-DiFA was rapidly excreted from all the organs via the hepatobiliary and urinary system. The whole body mean effective dose from ^18^F-DiFA was 14.4±0.7 µSv/MBq. Among the organs, the urinary bladder received the largest mean absorbed dose (94.7±13.6 µSv/MBq). The mean absorbed doses of the other organs were almost equal to or less than those from other hypoxia tracers. Excretion of radioactivity via the urinary system was very rapid and completed after 24 hours with the renal excretion rate reaching 86.4±7.1% of the administered dose. **Conclusion:** ^18^F-DiFA is well tolerated and its radiation dose is comparable to those of other hypoxia tracers. ^18^F-DiFA is very rapidly cleared via the urinary system. These data support phase II clinical trials of ^18^F-DiFA for hypoxia imaging.
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**Background/Aims:** The management of prostate cancer has undergone advances since the introduction of ^68^Ga-PSMA PET scans. The use of ^68^Ga-PSMA PET scans in the setting of biochemical recurrence is increasingly well-recognized. However, the use of ^68^Ga-PSMA PET scans for initial staging of prostate cancer is less established. There is little data on the use of ^68^Ga-PSMA PET as an initial staging modality. This retrospective study aims to analyse the role and impact of ^68^Ga-PSMA PET when used in initial staging for prostate cancer in comparison to current conventional imaging modalities. **Methods:** One hundred and thirty-one patients with histological diagnosis of prostate cancer who had ^68^Ga-PSMA PET prior to definitive treatment in South Australia between March 2016 and March 2017 were included in this study. Data was collected on review of medical records. Stage pre-^68^Ga-PSMA PET and post-^68^Ga-PSMA PET were recorded. For the purposes of this study, stage was classified as A-localised disease, B-presence of regional lymphadenopathy, C-oligometastatic disease (up to 3 metastasis) and D-widespread metastasis. Management plans were recorded. This study was approved by the Human Research Ethics Committee at the Royal Adelaide Hospital (HREC/17/RAH/121). **Results:** This study showed that the use of ^68^Ga-PSMA PET resulted in a significant change of stage in 37 (28%) patients with an upstage in 17 (13%) patients and a downstage in 20 (15%) patients. Patients with stage C disease were most likely to be downstaged (9%) and patients with stage A disease were most likely to be upstaged (9%). ^68^Ga-PSMA PET further excluded oligometastatic disease in 11 (8%) of patients who had suspicious oligometastatic disease based on a single conventional imaging modality. This impacted on management in at least 24 (18%) of patients. **Conclusion:** This study showed that the use of ^68^Ga-PSMA PET scans in initial staging has a significant impact in staging and management when compared to current recommended imaging modalities.

P178: Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings in Melanoma Patients Exhibiting Treatment-Related Inflammatory Events During Immunotherapy (Oncology)
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**Background/Aims:** Immune targeted therapy is now a standard of care for patients with advanced melanoma. ^18^F-Fluorodeoxyglucose PET/CT has become a pivotal tool in the assessment of treatment response. However, treatment-related inflammatory events can produce PET appearances which if mistaken for true disease progression, could potentially lead to inappropriate early treatment cessation. This study aims to characterise the nature and frequency of treatment-related inflammatory events seen on PET/CT in melanoma patients receiving immunotherapy, and evaluate their relationship to treatment response. **Methods:** A retrospective review of PET/CT images of 174 patients treated with pembrolizumab, nivolumab, or combination therapy of nivolumab with ipilimumab was performed. The institutional ethics review board had waived the need for patient consent. All patients had biopsy proven metastatic melanoma and underwent baseline imaging prior to commencement of therapy. Treatment-related inflammatory events were identified as having at least two of the following: a) new or progressive sites of FDG uptake in the presence of response elsewhere, b) symmetrical pulmonary hilar and mediastinal uptake pattern, c) subsequent regression on therapy cessation. Imaging findings were correlated with subsequent clinical course. Best overall response was determined using immune response criteria. **Results:** A total of 56 patients were identified with serial images, including a pre-and interim/post-treatment imaging. 10 (17%) patients had evidence of treatment-related inflammatory events seen as symmetrical bilateral mediastinal FDG avid lymphadenopathy in 7. The remaining cases comprised thyroiditis, pneumonitis and exacerbation of inflammatory diverticular disease respectively. The presence of an immunological adverse effect on PET was associated with a 1.9 (95%CI 1.2 to 3.0) fold increased likelihood of achieving complete response as the best overall response (p= 0.04). **Conclusion:** Treatment-related inflammatory events are commonly seen on FDG PET/CT examinations in melanoma patients receiving immunotherapy but are associated with a significantly greater likelihood of achieving complete response to treatment.

P179: Fluoro-Phenylalanine Positron Emission Tomography/Computed Tomography in Brain Tumours: Early Detection of Tumour Recurrence and Differentiating Recurrence from Radiation Induced Cerebral Necrosis (Oncology)
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**Background/Aims:** 4-borono-2-^18^F-fluoro-phenylalanine (^18^F-FBPA) is a new amino acid tracer that has shown low physiological uptake in normal organs and low accumulation in inflammatory tissue suggesting its efficacy to specifically detect cancer cells. The present study aimed to evaluate the diagnostic ability of ^18^F-FBPA PET/CT to detect brain cancer recurrence and differentiate it from radiation necrosis, which remains a significant diagnostic challenge. **Methods:** ^18^F-FBPA PET/CT scan was performed on 12 patients of glioblastoma (9), malignant meningioma (1), hemangiopericytoma (1), and metastatic brain tumour (1) who had been previously treated with radiotherapy. A diagnosis of recurrent tumour (n=6) or radiation necrosis (n=6) was made on the basis of MRI and clinical course. ^18^F-FBPA (3.7MBq/kg) was administered intravenously after fasting for four hours. Whole-body PET/CT scan, using Eminence SOPHIA SET-3000 BCT/X (Shimadzu, Kyoto, Japan), was obtained 60 minutes after injection. Scan data were analysed using PMOD image analysis software (PMOD Technologies). Spherical volumes of interests (VOI) were set by encompassing the lesion with reference to an MRI. PET parameters were measured, which included mean and maximum standardized uptake values (SUV~mean~, SUV~max~), metabolic tumour volume (MTV) using blood SUV~mean~ as a threshold, and total lesion (TL) FBPA uptake (MTV x SUV~mean~). **Results:** All studied PET parameters showed significantly higher values for tumour recurrence than for radiation necrosis. Mean SUV~mean~ in tumour recurrence was 2.95±0.84 (mean±SD) vs. 1.18±0.24 in radiation necrosis (p=0.0028); mean SUV~max~ in recurrence was 4.63±1.23 vs 1.93±0.441 in necrosis (p=0.002); mean MTV in recurrence was 44.92±28.93 vs. 10.66±8.46 in necrosis (p=0.032); and mean TL FBPA uptake in recurrence was 121.01±50.48 vs. 12.36±9.70 in necrosis (p=0.0029). **Conclusion:** ^18^F-FBPA PET/CT scan can aid in the differentiation between tumour recurrence and radiation necrosis in patients with primary or metastatic brain tumours who have been treated with radiotherapy.

P180: Preclinical Study of Alpha-radioimmunotherapy Against HER+ Liver Metastasis of Gastric Cancer (Oncology)
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**Background/Aims:** Gastric cancer (GC) is one of the main causes of cancer-related death. Almost 1/3 of GC patients has distant metastasis at the time of diagnosis. Liver metastasis (LM) is one of the common metastatic pattern of GC, which is classified as stage 4. Unfortunately, the therapeutic efficacy of current standard treatments for LMGC are still limited and the five years survival is less than 10%. It has been reported that about 70% of LMGC are HER2-positive (HER2+), so HER2 can be an attractive therapeutic target. Alpha-radioimmunotherapy (alpha-RIT) is getting higher attention with the advantage of the combination of cancer specific targeting of antibodies and high cell killing effect of alpha-particle. Astatine-211 (^211^At) is one of the promising alpha-emitter, which has appropriate half-life (7.2 hours) and 100% emit alpha-particle during its decay. The aim of this study is to evaluate the therapeutic efficacy of alpha-RIT against HER2+ LMGC using ^211^At-labelled anti-HER2 antibody, trastuzumab (^211^At-trastuzumab). **Methods:** A LMGC mouse model was established by transplanting luciferase-labelled NCl-N87, HER+ human GC cell, to mice from splenic vein. ^211^At was labelled to trastuzumab by tin-halogen exchange. Biodistribution study was performed to evaluate the tumour accumulation of ^211^At-trastuzumab. Experimental therapy was performed by injecting ^211^At-trastuzumab (1 MBq) to LMGC mice from tail vein. The tumours were monitored by luminescence imaging and body weight and the number of white blood cells were monitored to check the toxicity. **Results:** Tumour accumulation of ^211^At-trastuzumab were increased along with the time and reached about 12% at 24 hours post injection. ^211^At-trastuzumab effectively eradicated the LMGC in our mouse model while the tumour in the control group were aggressively grown. **Conclusion:** Alpha-RIT using ^211^At-trastuzumab could be a novel therapeutic option for HER2+ LMGC.

**Disclosure of interest:** S Hasegawa Conflict with: Grant from Astellas Foundation for Research on Metabolic Disorders.
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**Background/Aims:** To fulfill a potential demand for earlier diagnosis of Alzheimer's disease, we are developing a brain dedicated PET system "helmet-neck PET", in which radiation detectors are arranged hemispherically to increase the system sensitivity. In this paper, we evaluated imaging performance of the first prototype. **Methods:** Our invention is based on a fact that the hemisphere detector arrangement can obtain 1.5 times higher sensitivity than a conventional cylindrical detector arrangement without increasing the number of detectors when they have the same height and radius. In addition, a small portion of extension of detector arrangement toward the back of the neck improves uniformity of the sensitivity.\[[@ref130]\] The developed prototype has 54 4-layer depth-of-interaction detectors each of which consists of 16x16x4 array of 2.8mmx2.8mmx7.5mm Zr-doped GSO scintillators and a 64-ch position sensitivity photomultiplier tube. The foot print of the gantry is smaller than 1/5 of commercial whole body PET systems. **Results:** Spatial resolution was 2-3mm. The sensitivity was 5-10%, which is about 2-3 times higher than that of commercial whole body PET systems, while the number of detectors used was only 1/4-1/5 of typical commercial whole body PET systems. A FDG-PET study with a healthy volunteer, which had been approved by our Institutional Review Board, supported excellent imaging performance of the system. **Conclusion:** We confirmed promising imaging performance of the helmet-neck PET prototype.
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**Background/Aims:** The purpose of this study was to determine the *in-vivo* pharmacokinetics and patient specific dosimetry for patients undergoing ^188^Re-HDD Lipiodol Transarterial Radioembolization(TARE) based on quantitative post treatment images. **Methods:** Imaging protocol was set as a whole body scan (anterior, posterior) along with SPECT/CT of liver at 3, 24 and 48 hours. The biodistribution, pharmacokinetics and normalized doses per injected activity were estimated for the following regions of interest: tumour, liver, lungs, stomach, kidneys and spleen (were performed using QDOSE, a software for dosimetry calculations in radionuclide therapies from ABX-CRO, Germany). **Results:** The average effective half-life in tumour was found to be \~12.52.0 hours (range 9.8-16 hours). Average normalized doses per injected activity in tumour, liver and lungs were found as 23.540.8 mGy/MBq (range 2.32-162 mGy/MBq), 2.121.78 mGy/MBq (range 0.48-7.8 mGy/MBq) and 0.270.13 mGy/MBq (range 0.11-0.54) respectively. Dose received by tumour is 5-10 times the dose received by the liver. **Conclusion:** The large interpatient variation of these normalized doses strongly indicate the significance of performing patient-specific dose calculations. It was found that the radiation burden received by the adjacent non-target regions were within acceptable limits, normal liver received maximum of \~13 Gy (acceptable limit \<30 Gy) and lungs received a maximum of 0.9 Gy (acceptable limit \<12 Gy) according to Zanzonico *et al*. 2004 protocol. Imaging at 3 hours and 24 hours were sufficient for the accurate dosimetry.

P183: An Australian Local Diagnostic Reference Levels for Paediatric FDG Positron Emission Tomography-Computed Tomography (Physics)
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**Background/Aims:** The radiation dose associated with PET/CT is of particular concern in paediatric patients. If local diagnostic reference levels (DRLs) exceed the national DRL, there may be a need for optimisation of the PET/CT protocol. The aim of this study was to establish the local DRL for paediatric patients undergoing PET/CT examinations at one Australian centre. **Methods:** A survey was sent to retrospectively assess 12 months of ^18^F-FDG PET/CT data in order to establish the local DRL based on the 50^th^ percentile for the infant/baby (0-4 years) and child (5-14 years) age categories. Collected data included administered radioactivity (MBq), CT dose index volume (CTDI~vol~) and the CT dose length product (DLP). Total effective dose (ED) was also calculated. **Results:** The 50^th^ percentiles for administered total activity (MBq) and activity normalised to body weight (MBq/kg) in the infant/baby category (n=21) were 81.36 MBq and 5.61 MBq/kg, respectively. For the children category (n=92) these were found to be 145 MBq and 3.85 MBq/kg, respectively. The 50^th^ percentiles for CTDI~vol~ and DLP for the infant/baby category were 0.81 mGy and 71 mGy. cm, respectively. The total PET/CT ED for infant/baby and child groups were 8.79 mSv and 6.96 mSv, respectively. The ED from administered radioactivity was higher than CT dose. The MBq/kg administered radioactivity for the infant/baby group was higher than child age group due to independent minimum administered activity (60 MBq) required for diagnostic image quality. **Conclusion:** A local DRLs for paediatric ^18^F-FDG PET/CT imaging has been determined. This is an important first step in establishing an Australian national DRL for paediatric PET/CT examinations.
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**Background/Aims:** There is a challenging trade-off between resolution and sensitivity in design of pixelated brain-dedicated PET scanners. In this study, we evaluate different crystal configurations using Monte Carlo simulation to address such a challenge in order to find an optimal configuration. **Methods:** Firstly, we validated Gate Monte Carlo toolkit using experimental results obtained by our manufactured Xtrim small animal PET scanner. Secondly, our newly developed cylindrical PET scanner with ring diameter of 38cm was simulated. Crystal pixel size from 2×2 to 4×4 mm^2^ and crystal thickness from 10 to 40 mm were evaluated. BGO, LYSO and GSO as scintillator materials were compared as well. To drive system sensitivity and spatial resolution, a F-18 point source was positioned in the center and also in 10 cm offset from center to investigate photons penetration behaviour. We calculated spatial resolution in addition to system sensitivity using FWHM and FWTM of reconstructed source image. The weighted-sum objective function was used to find optimum configuration by devoting 0.4 portion to sensitivity and 0.15 to each of FWHM and FWTM for point sources in two positions. **Results:** According to the obtained results system sensitivity increases from 4.1% to 16.2 % by increase of crystal thickness from 10 mm to 40 mm. Also for the same crystal thickness, we observed 1.2, 2.1, 2.1 and 3.9 mm increase in FWHM and FWTM for center and the off-center source positions respectively when pixel size varies from 2×2 to 4×4 mm^2^. Scintillation material evaluation indicated better spatial resolution for LYSO although BGO provide higher system sensitivity. Finally, we found 2×2×20 mm^3^ LYSO crystal as optimal configuration for our developed brain-dedicated PET scanner. **Conclusion:** Our study indicated that crystal configuration is of effective impacts on scanner performance thereby Monte Carlo simulation provides a helpful tool to achieve optimum PET design.
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**Background/Aims:** A MAG3 (mercaptoacetyltriglycine) renogram is a commonly performed nuclear medicine study that visually and functionally evaluates renal blood supply and glomerular filtration. After injection of ^99m^Tc-MAG3, multiple images are taken over 30 minutes. Both qualitative and quantitative data is produced to compare asymmetrical and overall renal function. The radiotracer imparts ionising radiation to the patient. By limiting the dose of radiotracer used, the amount of radiation could be lowered, however this often comes at the trade-off of a lower quality study. Our aim is to determine how far the radiotracer ^99m^Tc-MAG3 dose can be reduced while maintaining a diagnostic quality study in both adult and paediatric cohorts. **Methods:** Approved by the Gold Coast University Hospital Human Research Ethics Committee. Nine adults (age 19-66) and six paediatric patients (age 0-9) with a routine clinical renogram at Gold Coast University Hospital between April to July 2017 were retrospectively and selectively chosen to allow an even distribution of weight. Poisson resampling of acquired counts was applied to simulate MAG3 renogram scans at varying radiotracer doses (100%, 75%, 50% and 25%). These 60 reconstructed studies were deidentified and randomised to order, then reviewed by a blinded final year radiology registrar and nuclear medicine consultant and categorised as either excellent, satisfactory or suboptimal. **Results:** Five cases (33%) showed a drop in readability at lower radiotracer levels, and only one of these (6%) reduced quality from satisfactory to non-diagnostic. There was no statistically significant difference in readability variation between adult and paediatric patients, however paediatric patients were more likely (50% vs 11% in adults) to have a non-diagnostic study. **Conclusion:** Renogram ^99m^Tc-MAG3 dose can be significantly reduced while maintaining a diagnostic-quality study in both adult and paediatric populations.

P186: Performance evaluation of Quantitative SPECT Using NEMA NU-2 Positron Emission Tomography Measurements (Physics)
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**Background/Aims:** As quantitative imaging is necessary for radionuclide treatment planning and dosimetry, both SPECT and PET performances need to be evaluated using quantitative measurements. In this study, both SPECT and PET systems were tested using NEMA NU-2-2012 performance measurements. **Methods:** ^99m^Tc and ^177^Lu were used for SPECT, and ^18^F was measured on PET using methodology of NEMA NU-2 (2012). The methods were modified to model count rates and scatter fraction for SPECT without random coincidence estimations. The spatial resolution was measured at 1, 10 cm from the centre of FOV and 3/8 of FOV. The sensitivity was measured with a line sources surrounded by aluminium sleeves to compute attenuation-free sensitivity of the system at the centre of the FOV and 10cm offset. The image quality was tested with NEMA IEC body phantom. **Results:** The spatial resolution for radial/tangential directions at 1 cm were: 5.3/4.3 mm, 12.6/14.1 mm and 21.6/23.4 mm for ^18^F, ^99m^Tc and ^177^Lu, respectively. The event rates for ^99m^Tc showed a linear increase with activity. The sensitivities at 0/10cm off-axis were: 9.63×10^3^/9.59×10^3^ cps/MBq, 119.4/116.7 cps/MBq, and 47.6/47.5 cps/MBq for ^18^F, ^99m^Tc and ^177^Lu, respectively. The scatter fractions for ^18^F, ^99m^Tc and ^177^Lu were, in order, 0.32, 0.25 and 0.36. The background variability was 1.52%, 2.73% and 6.51% for ^18^F, ^99m^Tc and ^177^Lu, respectively. The hot sphere contrast was 69.8%, 78.5% and 64.7% for ^18^F, ^99m^Tc and ^177^Lu, respectively. True concentration ratio of ^99m^Tc and ^177^Lu on SPECT were 7.2:1 and 5.8:1, where SUV~max~ in hot spheres and background SUVs (= 1.0) were 6.9/0.98 and 5.5/1.04 for ^99m^Tc and ^177^Lu, respectively on the quantitative SPECT images. **Conclusion:** We propose NEMA NU2 measurement methodology can be applied for SPECT performance evaluation as well as that of PET. This study demonstrates a unified measurement methodology for the major imaging devices in the field of nuclear medicine.
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**Background/Aims:** Decreased renal function would be expected to alter iodine-131 metaiodobenzylguanidine (^131^I-MIBG) pharmacokinetics by glomerular filtration rate (GFR). Although less than 30mL/min/1.73m^2^ of estimated GFR (eGFR) are regarded as an absolute contraindication in the therapy, the influence of eGFR on whole body absorbed dose (WBAD) has not been cleared yet. The aim of this study was to assess the relationship of renal function and WBAD in ^131^I-MIBG therapy for malignant pheochromocytoma/paraganglioma. **Methods:** This study included 21 patients with malignant pheochromocytoma/paraganglioma (13 male, mean age 50±13 years, mean body weight 66±12 kg), who underwent ^131^I-MIBG therapy with a fixed dose of 7.4GBq between December 2013 and August 2017 (exception for patients with abdominal mass or diffuse bone metastases). The following equation was used to calculate the eGFR: eGFR (mL/min/1.73m^2^) = A × 194 × serum creatinine (mg/100mL)-1.094 × age(yr)-0.287, where A=1 for men and 0.739 for women. Time-activity data were fitted using a bi-exponential model of the OLINDA/EXM software (ver1.1). The WBAD was calculated using the medical internal radiation dose (MIRD) method: WBAD = Ã~WB~ × S~(WB←WB)~, where Ã is the cumulated activity and S~(WB←WB)~ is the dose per unit cumulated activity. S~(WB←WB)~ values were corrected for the weight. **Results:** Sufficient data was obtained to assess WBAD in ^131^I-MIBG therapy. The average of WBAD and eGFR was 0.65±0.17 Gy and 71±16 mL/min/1.73m^2^, respectively. The decrease of eGFR significantly correlated with the increase of WBAD by linear regression analysis (p=0.0005, R^2^=0.46). **Conclusion:** The linearity between eGFR and WBAD was confirmed in ^131^I-MIBG therapy for patients with malignant pheochromocytoma/paraganglioma. Lower eGFR has an unfavourable influence on the WBAD, thus ^131^I-MIBG therapies should be performed with caution according to eGFR level.
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**Background/Aims:** ^18^F-Fluorodeoxyglucose (^18^F-FDG) PET/CT imaging has become an important component of the management paradigm in oncology. However, the significant imparted radiation exposure is a matter of growing concern especially in younger populations who have better odds of survival. The aim of this study was to estimate the effective dose received by patients having whole body ^18^F-FDG PET/CT scanning as per recent dose reducing guidelines at a tertiary care hospital. **Methods:** This prospective study covered 63 patients with different cancers who were referred for PET/CT study for various indications. Patients were prepared as per departmental protocol and ^18^F-FDG was injected at 3 MBq/Kg and a low dose, non-enhanced CT protocol (LDNECT) was used. Diagnostic CT studies of specific regions were subsequently performed if required. Effective dose imparted by ^18^F-FDG (internal exposure) was calculated by using multiplying injected dose in MBq with coefficient 1.9×10-2 mSv/MBq according to ICRP publication 106. Effective dose imparted by CT was calculated by multiplying DLP (mGy. cm) with ICRP conversion coefficient "k" 0.015 \[mSv/(mG. cm)\]. **Results:** Mean age of patients was 49±18 years with a male to female ratio of 35:28 (56%:44%). Median dose of ^18^F-FDG given was 194 MBq (range: 139-293). Median CTDIvol was 3.25 (2.4-6.2) and median DLP was 334.95 (246.70-576.70). Estimated median effective dose imparted by 18FDG was 3.69 mSv (range: 2.85-5.57). Similarly, the estimated median effective dose by low dose (non-diagnostic) CT examination was 4.93 mSv (range: 2.14-10.49). Median total effective dose by whole body ^18^FDG PET plus low dose non-diagnostic CT study was 8.85 mSv (range: 5.56-13.00). **Conclusion:** We conclude that the median effective dose from a whole body ^18^F-FDG-PET/CT in our patients was significantly low. We suggest adhering to recently published dose reducing strategies, use of ToF scanner with CT dose reducing option to achieve the lower if not the lowest effective dose. This would certainly reduce the risk of second primary malignancy in younger patients with higher odds of cure from first primary cancer.
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**Background/Aims:** Polynomial regression is one of the most frequently utilised curves in regression analysis. It is an efficient and robust curve fitting method for nonlinear data. While artificial neural network (ANN) is a mathematical model that imitates the fundamental mechanism of the biological activity of nerve cells. It is capable for a rapid evaluation of medical imaging data at higher accuracy. This study aimed to compare the R-squared (*R^2^*) correlation coefficient and mean squared error (MSE) between polynomial regression and ANN in simulating the fluorodeoxyglucose (FDG) concentration of the kidneys in dynamic positron emission tomography/computed tomography (PET/CT) examinations. **Methods:** Four subjects were intravenously injected with the mean FDG activity of 302.29 ± 18.75 MBq prior to dynamic PET/CT scanning. The average values of the concentration of FDG within the abdominal aorta (input) and kidneys (output) were quantified and recorded for all scanning frames. The data analysis was conducted using MATLAB R2015a software and the *R^2^* and MSE values of both polynomial regression and ANN models were calculated. The study was acknowledged by the Research Ethical Committee Universiti Teknologi MARA (UiTM): 600-IRMI (5/1/6). **Results:** A total of 384 dynamic PET data were generated and entered into the polynomial regression and ANN models. The mean value of *R^2^* for the 15^th^ degree polynomial regression model was 0.85 with the MSE of 0.015 x 10^9^, while for ANN the *R^2^* and MSE values were 0.85 and 0.012 respectively. **Conclusion:** The findings of this study demonstrate that ANN produces more accurate prediction values as compared to the polynomial regression model. Therefore, ANN model is an excellent estimation tool that can be employed to simulate the distribution of FDG concentration in the kidneys using a large number of dynamic PET data.
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**Background/Aims:** Positron Emission Tomography/Computed Tomography (PET/CT) with ^18^F-FDG is an essential modality for cancer imaging and provides accurate lesion detection and improved image quality than PET and CT alone. For oncology patient management, repeated PET/CT scans are necessary eg. pre-therapy for determination of staging, post-therapy for monitoring the response, and follow-up for recurrence. These repeated PET/CT scan increases radiation exposure particularly to paediatric patients. The key intention is to be optimising the paediatric CT scan procedure in order to reduce radiation dose in PET/CT hybrid imaging. **Methods:** A group of 40 patients (each \<25 kg) were acquired on GE Discovery STE PET/CT scanner that comprises a combined PET system with a fully diagnostic 16 slice CT scanner. Dose reduction in PET/CT involves trade-off between image quality and effective dose. For major reductions in radiation doses from PET/CT scan, the following CT parameters were studied (kVp, mAs, pitch, slice thickness and noise index). All patients were scanned in the same position using a similar technique except for the changes made for CT dose optimisation. For effective dose, the volume CT dose index (CTDI~vol~) and dose length product (DLP) were recorded from reports generated by the scanner and anatomy-specific conversion factors. The studies were randomised and blinded for an experienced PET and CT reader who graded the imaging quality of anatomic structures. **Results:** The mean effective dose was reduced by 53% from 8.8mSv to 4.1mSv (p\<0.05). All studies were considered diagnostically adequate. **Conclusion:** Considerable radiation dose reduction can be achieved by modifying the acquisition parameters for CT without affecting image quality.
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**Background/Aims:** Radioactive I131 (RAI) therapy is a standard method to ablate the remnant thyroidal tissue after total thyroidectomy and its metastases in differentiated thyroid carcinomas, however, ^131^I also accumulates in non-thyroidal tissue, which may cause adverse effects and limit the ^131^I dose required for treatment. We hypothesised that montelukast, a known agent with anti-inflammatory and anti-oxidant properties, would ameliorate the radiation-induced histopathological characteristics such as pneumonitis and fibrosis in rat lungs after RAI. **Methods:** 50 female Wistar albino rats were randomly separated into 5 groups of 10. Group 1 was the control group; Group 2 was administered RAI only; Group 3 was administered RAI and montelukast, Group 4 was administered RAI after total thyroidectomy and Group 5 was administered RAI and montelukast after total thyroidectomy. All rats were sacrificed after 12 weeks and the lungs were evaluated in histological examination to determine the degree of inflammation and fibrosis and for immunohistochemical (IHC) staining for tissue expression of IL-1, IL-6 and TNF-alpha. **Results:** The RAI-administered groups were significantly different from the control group but the montelukast and RAI administered groups. Groups medicated with montelukast were not significantly different from the control group. All histopathological and IHC parameters were significantly less in the groups administered with montelukast compared to the groups not administered with montelukast. **Conclusion:** The results of this study demonstrated the radioprotective effect of montelukast in the pulmonary system through histopathological and IHC examination.
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**Background/Aims:** \[^18^F\]-MK6240 is a second-generation tau imaging tracer. We have developed and optimised the production of \[^18^F\]-MK6240 using the ORA Neptis Perform Radiosynthesiser. **Methods:** The first method developed for manufacturing \[^18^F\]-MK6240 involved radiolabelling the precursor with \[^18^F\] (3 min 100°C, 8min 140°C), followed by deprotection with 1 N Hydrochloric acid (HCl; 0.9 mL, 4min at 90°C). The crude reaction was neutralised with Sodium Hydroxide (NaOH; 1 mL 1N) and diluted with Mobile phase before preparative HPLC purification (GEMINI 5µm C18 HPLC Column, 110Å LC 250x 10 mm; 40% Acetonitrile: 60% 10mM Sodium Phosphate, 4 mL/min). The collected product was formulated for i. v. injection using a C18 Sep Pak cartridge and sterile filtration. A second, optimised method utilised 3N HCl for Boc group deprotection and Sep Pak pre-purification of the crude reaction prior HPLC purification. The radiochemical and chemical purity of the \[^18^F\]-MK6240 dose was analysed using a Kinetex 5μm EVO C18 100Å column, 100mm x 4.6mm eluted with a gradient of 0.01M disodium phosphate and Acetonitrile (1.5mL/min). **Results:** Labelling of the MK6240 precursor using 1N HCl gave 5-8% radiochemical yield with a total synthesis time of 70min. Specific activity was \>500 GBq/µmol. While this method resulted in low radiochemical yields, the production was reliable and consistent for starting activities of 37--55 GBq. Increasing the HCl concentration to 3N significantly increased the efficiency of the Boc deprotection and resulted in radiochemical yields between 12%\>18%. **Conclusion:** The initial method developed for the production of \[^18^F\]-MK6240 for patient studies at Austin Health using the ORA Neptis module has been optimised to improve poor Boc deprotection and issues with injecting the crude reaction onto the HPLC column. The changes made have resulted in a significant increase in the radiochemical yield.
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**Background/Aims:** The useful life of a ^68^Ge/^68^Ga generator is considered to be 1 year by the manufacturer, after which the elution yield of the generator drops below a feasible quantity for clinical administration or delivery to smaller satellites. To circumvent this issue, an automated dual ^68^Ge/^68^Ga generator pre-purification system has been developed -- allowing generators to be utilized for a prolonged period and increasing the elution yields by two-fold depending on the age of each generator. **Methods:** Two ^68^Ge/^68^Ga generators of different core were manually eluted onto a strong cation exchange cartridge (SCX). The ^68^Ga ions were liberated from the SCX cartridge using a solution of 5M sodium chloride (NaCl) and 5M NaCl spiked with concentrated hydrochloric acid (HCl) in an attempt to increase elution yields. Sodium acetate (0.25M) was used to buffer the reaction pH to within a suitable range for peptide labelling. The process was then automated to yield a total synthesis time of under 20 minutes including generator elution using an iPHASE technologies MultiSyn radiosynthesiser. **Results:** A dual ^68^Ge/^68^Ga generator system incorporating the same or different types of core was automated to give quantitative ^68^Ga absorption yields onto the SCX cartridge. The use of a 5M NaCl elution medium provided a ^68^Ga elution yield of 80-90%, with 10-20% remaining bound to the SCX cartridge. To overcome this problem, the NaCl solution was spiked with concentrated HCl. This allowed all the ^68^Ga to be quantitatively eluted from the SCX cartridge. **Conclusion:** A dual ^68^Ge/^68^Ga generator pre-purification system was developed to allow different types of generator cores utilizing varying acid concentrations to be combined for the one synthesis without detrimentally affecting the reaction pH. The merit of this system is in the flexibility it provides toward extending the lifetime of generators, significantly reducing generator impurities or simply obtaining a larger ^68^Ga elution yields.

P194: Synthesis of Small Novel Imaging Agents for Apoptosis by Using SPECT/Computed Tomography (Radiopharmaceutical Science)
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**Background/Aims:** Apoptosis plays a key role in the pathogenesis or aetiology of disease. Because most anticancer and therapeutic drugs induce apoptosis to kill the cancer cells, molecular imaging of apoptosis can be very useful in the early detection of disease, staging of tumour, and the efficacy of ongoing chemotherapy or radiation treatment. In the present study two SPECT based imaging probes ^125^I-iodophenyl malonic acid 1 and ^99m^Tc-methyl-pentyl-malonic acid 2 have been synthesised to detect apoptosis *in vivo*. **Methods:** Precursor 1 and 2 have been synthesised and radiolabelled by using optimised radiolabelling procedures via chloramine-T oxidizing agent and ^99m^Tc-tricarbonyl complex respectively. All radiotracers were characterized by using Radio-HPLC and Radio-TLC system and *in vitro* stability was determined in mouse serum under various conditions. For *in vivo* biodistribution study and SPECT/CT imaging 1 and 2 have been intravenously injected to healthy ICR male mice and apoptosis has been detected in the testes of the mouse. **Results:** Radiolabelled compound 1 has been synthesised in high radiochemical yield (75%, n=3) and high radiochemical purity (\>99%), while precursor 2 obtained in 84% (n=3) radiochemical yield and \>99% radiochemical purity. Radiotracers showed excellent *in vitro* stability up 12 h in mouse serum under physiological conditions. Precursor 1 showed high blood uptake during biodistribution study, while 2 demonstrated more favourable pharmacokinetic and fast blood clearance via kidneys. **Conclusion:** Radiolabelled compound 1 showed high testes accumulation because apoptosis an ongoing process in the testes of an adult male mouse, similar results were obtained in SPECT/CT imaging study. However, its high blood accumulation hampered its use as apoptosis imaging agent. Structural modifications are in progress to achieve more favourable pharmacokinetics. Radiolabelled 2 showed better biodistribution profile hence its study on apoptotic mouse model and *in vitro* cell study to confirm specificity towards apoptotic cells is in progress.
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**Background/Aims:** Neuropeptide Y (NPY) has been implicated in a wide variety of physiological processes including feeding, learning and memory, emotion, cardiovascular homeostasis, hormone secretion, and circadian rhythms. NPY mediates these processes via interaction with a family of G-protein coupled receptors (NPY Y~1~, Y~2~, Y~4~ and Y~5~). NPY Y~l~ receptor is the most widely studied among NPY receptors and is involved with many of these processes of NPY. BMS193885 was developed as a potent, selective NPY Y~1~ receptor antagonist (Ki = 3.3 nM).\[[@ref133]\] To image the function of NPY Y~1~ receptor using PET, we developed ^11^C-labeled BMS193885 (\[^11^C\]BMS) and its *O*-desmethyl derivative (\[^11^C\]DMBMS) as a PET tracer. **Methods:** \[^11^C\]BMS was synthesized from \[^11^C\]methyl iodide using DMBMS.\[^11^C\]DMBMS was synthesized from \[^11^C\]phosgene using the aniline and amine derivatives. Biodistribution studies were conducted in mice. Animal studies were approved by the Animal Ethics Committee of the National Institutes for Quantum and Radiological Science and Technology. **Results:** In the radiosynthesis of \[^11^C\]BMS and \[^11^C\]DMBMS, the decay-corrected radiochemical yield from ^11^CO~2~ at the end of radionuclide production was 19-28% (n = 6) and 22-26% (n = 4), respectively. In the biodistribution at 60 min after the injection of \[^11^C\]BMS and \[^11^C\]DMBMS, radioactivity level was relatively high in the kidney, small intestine and liver, and was low in the brain. By pretreatment with BMS (10 mg/kg), the radioactivity levels of kidney, lung and spleen at 30 min after the injection of \[^11^C\]BMS were significantly reduced, and the radioactivity levels of these organs added heart at 30 min after the injection of \[^11^C\]DMBMS were significantly reduced. **Conclusion:** \[^11^C\]DMS and \[^11^C\]DMBMS were successfully synthesized as an injection.\[^11^C\]DMBMS showed the specific binding of NPY Y~1~ receptors rich organs (heart, kidney, lung and spleen) in mice.
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**Background/Aims:** Currently, alpha particle emitting radionuclides have gained much attention in radionuclide therapy. Astatine-211 (^211^At) is one of promising alpha particle emitting radionuclides because it is a halogen element, which has similar chemical property to iodine, and has not too short half-life of 7.2 hours. However, ^211^At could not be introduced into a tyrosine residue in a peptide by the Chloramine-T method, which is commonly used for radioiodine labelling of proteins and peptides. In this study, to establish a novel ^211^At labelling method to peptides, RGD peptide was selected as a model peptide. ^211^At-labelled RGD peptide was prepared from a precursor with a tributylstannyl group on the phenylalanine residue in c(RGDfK) peptide, and evaluated. **Methods:** Cyclic\[Arg(Pbf)-Gly-Asp(OtBu)-D-Phe(4-I)-Lys(Boc)\] was prepared using a standard Fmoc-based solid-phase methodology using Fmoc-D-4-iodophenylalanine. After substitution of iodine for a tributylstannyl group, ^211^At-c(RGDfK) was obtained by ^211^At labelling and deprotection. Biodistribution experiments in U87MG tumour-bearing mice were performed by intravenous administration of a mixed solution of ^125^I-c(RGDfK) and ^211^At-c(RGDfK). Blocking study was performed by co-injection of ^211^At-c(RGDfK) with an excess of c(RGDfK). **Results:** ^211^At-c(RGDfK) was prepared with radiochemical yield of 63% and radiochemical purity of over 96%. As the results of biodistribution experiments, ^125^I-c(RGDfK) and ^211^At-c(RGDfK) showed high accumulation in the tumour at 1 hour post-injection \[4.6±1.3%ID/g for ^125^I-c(RGDfK) and 5.3±1.5%ID/g for ^211^At-c(RGDfK)\] and similar biodistribution. The uptakes of both radiotracers in stomach, as an index of dehalogenation, were not high \[0.5±0.2%ID for ^125^I-c(RGDfK) and 0.6±0.2%ID/g for ^211^At-c(RGDfK)\]. In the blocking studies, co-injection of an excess amount of c(RGDfK) significantly decreased tumour uptake at 1 h after injection of ^211^At-c(RGDfK) (0.9±0.2%ID/g). **Conclusion:** This study provides useful information for ^211^At labelling to peptides. Moreover, since this method could be applicable to other peptides directed to cancer, we will prepare and evaluation other ^211^At-labelled peptides to confirm it.
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**Background/Aims:** The aim of the study is to compare the outcomes of low activity radioiodine (1100 MBq) and high activity radioiodine (3700 MBq) and its association in successfully ablating post thyroidectomy differentiated thyroid cancer (DTC) remnants at 6-12 months. **Methods:** Post-thyroidectomy Filipino patients with a low risk thyroid carcinoma treated with low activity or high activity ^131^I for remnant ablation from 2010-2017 were assessed for successful ablation based on follow-up serum TSH-stimulated thyroglobulin(Tg), anti-thyroglobulin(Anti-Tg), and neck ultrasound at 6-12 months. Ablation was considered successful based on an undetectable serum Tg, normal Anti-Tg, and an empty thyroid bed without suspicious lymph nodes on neck ultrasound 6-12 months after radioiodine therapy. **Results:** 168 cases of low risk Filipino DTC with follow-up TSH-stimulated serum Tg, Anti-Tg and neck ultrasound at 6-12 months were grouped into high activity 103 (49%) and low activity 65 (31%) radioiodine. A detectable Tg, normal Anti-Tg, normal ultrasound, and incomplete ablation were more frequently observed in both groups. No significant difference in serum Tg (p=0.205) and Anti-Tg (p=0.2) among groups of radioiodine activities. No significant association was also observed between radioiodine activities and ultrasound results (p=0.530) nor ablation (p=0.378). **Conclusion:** Low activity radioiodine is comparable to high activity radioiodine based on serum Tg, anti-Tg, and neck ultrasound at 6-12 months follow-up. Successful ablation had no significant association with low or high activity radioiodine in patients with low risk differentiated thyroid cancers after total thyroidectomy.

P198: Prognostic Outcome of Papillary Thyroid Carcinoma with Coexistent Lymphocytic Thyroiditis: A Retrospective Analysis in a Single Center (Endocrinology)
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**Background/Aims:** Coexistence of lymphocytic thyroiditis (LT) with papillary thyroid carcinoma (PTC) is uncommon. The aim of this study was to identify the prognostic outcome in patient who had PTC with LT. **Methods:** Patients who underwent first dose ^131^I therapy (RAIT) following total thyroidectomy with histopathological (HP) diagnosis of PTC from January 2006 to December 2007 at the National Institute of Nuclear Medicine & Allied Sciences (NINMAS) were included in this study. These patients were retrospectively observed for association of HP feature of coexistent LT and clinico-pathological attributes of recurrence. **Results:** Out of 186 patients with PTC 163 (88%) had no coexisting LT (group A) and 23 (12%) had coexistent LT with PTC (group B). During the mean observation period of 6.9±3.4 years, while 30 (18.4%) patients in group A had to undergo repeated RAIT for two to five times due to metastasis and/or recurrence, no patients in group B underwent more than a single dose of RAIT (p\<0.001). Mean thyroglobulin level during pre-RAIT and last follow-up was 11.2±3.58 and 3.2±2.7 in group A and 6.47±3.0 and 2.2±1.6 in group B. **Conclusion:** Presence of coexistent LT was associated with absence of metastasis and/or recurrence in patients with PTC that required single dose of RAIT.

P199: Initial Experience with 1 year follow-up in 22 Patients Treated with Lu-177 I and T PSMA for Advanced Prostate Cancer-safety, Efficacy and Quality of Life (Oncology)
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**Background/Aims:** Since 2010 ^177^Lu-PSMA therapy has been used in advanced progressive metastatic castrate resistant prostate cancer (mCRPC) at several sites in Europe. Since 2015 our center has offered compassionate access ^177^Lu-PSMA as salvage therapy for such patients. Efficacy and toxicity of ^177^Lu-PSMA therapy is presented in this report of 22 consecutive patients in a real world clinical setting. **Methods:** ECOG performance status \<2, adequate baseline bone marrow function, eGFR \>45 ml/min. Exclusion criteria Tagawa *et al*.\[[@ref134]\] Lutetium-177-PSMA (^177^Lu-PSMA) was prepared and administered in compliance with the Australian Therapeutic Goods Administration Special Access Scheme regulations for compassionate patient usage. Prescribed activity was 3.5--7GBq/patient at 6-8-week intervals. Patients were monitored with 3 weekly blood counts and biochemistry. Toxicities graded according to NCI CTCAE v4.03. Risk factors assessed by contingency analysis Fishers exact test. Time to PSA progression calculated. Survival comparisons Kaplan-Meier methodology. Risk ratios and survival curves compared using Logrank test. Statistical analysis performed using IBM SPSS. Quality of life assessments prior to, during and at the end of therapy course. **Results:** Median age 71 years, median follow-up 17-months. All failed prior ADT. Median Gleason score 8, median PSA level 20.50ng/ml (range, 0.9-1800ng/ml). All completed one or more cycles of therapy, with median number of 4 cycles completed per patient. Improvement in QOL score in 17/22 patients following therapy. Side effects included nausea/GIT symptoms in 2/22, bone flare in 3/22 and xerostomia in 4/22 patients treated. 3 patients (15%) had baseline grade 1 cytopenia. 3 patients (15%) experienced grade 1/2 myelotoxicity. 4 patients (20%) experienced grade 3/4 myelotoxicity. All toxicities self-limiting. Grade 1 cytopenia at baseline was significantly associated with development of grade 3/4 myelotoxicity p-value 0.0035. At time of analysis, no instance of myelodysplastic syndrome or acute leukaemia. Disease response observed in 8 patients (40%). 7 (35%) experienced progression with 5 patients (20%) showing stability. Median time to PSA progression not reached. **Conclusion:** ^177^Lu-PSMA is well tolerated, safe and effective salvage therapy for mCRPC associated with improvements in QOL. Baseline cytopaenia may predict haematological toxicity of therapy.
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**Background/Aims:** To determine treatment efficacy, adverse effects, survival benefit and correlations between treatment doses and patient response to therapy in patients with hepatocellular carcinoma (HCC) treated with intra-arterial ^188^Re-Lipiodol therapy. **Methods:** The radioconjugate was prepared by using an HDD (4-hexadecyl 1.2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol) kit developed in Seoul National University Korea, and lipiodol. Over a period of 36 months, 92 patients with inoperable HCC or metastatic liver lesions received at least one treatment of radioconjugate. 27 patients were re-treated for residual active lesion or new lesions. The level of radioconjugate administered was calculated on the basis of tumour volume with a range of doses between 30 to 500 mCi. Patients were followed for at least 12 weeks after therapy, until recovery from all toxicity. The clinical parameters evaluated included toxicity, response as determined by contrast-enhanced computed tomography, palliation of symptoms, overall survival, performance status (Karnofsky) and hepatic function (Child's classification). Liver function tests, serum alfa-fetoprotein (AFP) levels and complete blood counts were done at each follow-up visit. **Results:** Of the 92 patients treated so far, 28 are still alive and do come for regular follow up. All of them report good quality of life. Progressive disease was noted in 16 patients, partial response in 45 patients, stable disease in 12 patients and complete response in 19 patients. Side-effects were minimal and usually presented as loss of appetite, right hypochondrial discomfort and low-grade fever, even at high levels of administered radioactivity. The symptoms resolved with simple supportive therapy within 3 days of onset. Liver function tests at 24 and 72 hours showed no significant changes and complete blood counts at 1 week, 4 weeks and 12 weeks showed no changes (no bone marrow suppression). Survival at 6 months was 74%. We could achieve biochemical or imaging stability of disease in more than 50% of patients and partial or complete regression in more than 2/3^rd^ of patients. **Conclusion:** The results of this study show that ^188^Re-lipiodol is a safe and cost-effective method to treat primary HCC or metastatic liver lesions via the transarterial route. In terms of efficacy, it is potentially a new therapeutic approach for further evaluation by treatment of larger numbers of patients.
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**Background/Aims:** To evaluate the diagnostic values of TgAb levels, the median time for disappearance and the change trend of TgAb after ^131^I radiotherapy in Tg-negative patients with differentiated thyroid carcinoma (DTC). **Methods:** 116 DTC patients who had undergone thyroidectomy in the case of Tg-negative and TgAb-positive from July 2012 to November 2016 were enrolled in this retrospective study. The patients were divided into two groups as M1(n=44) and M0(n=72), according to with or without metastasis/recurrence. Comparison of TgAb levels between the two groups by independent-sample *t* test, use survival analysis to assess the median time for disappearance of TgAb in the patients who were followed for 6 to 29 months and follow-up these patients' states and course of disease corresponding to the changing trend of TgAb levels dynamically after ^131^I radiotherapy. **Results:** Both the values of TgAb (t=0.221, p=0.825) and the median time for disappearance of TgAb (p=0.567) between M1 group and M0 group has no statistically significant difference. During the follow-up period, among patients whose TgAb were gradually decreased or became negative there were 96.8% (61/63) patients who were cured or improved, while those whose TgAb were gradually increased or remained persistently high there were 31% (9/29) patients who were ineffective or became worse. **Conclusion:** Value of TgAb and the median time for disappearance of TgAb can't diagnose recurrence or metastasis of DTC in the case of Tg-negative, but the changing pattern of TgAb levels is of vital importance to the treatment effect and prognosis of disease.

P202: Evaluating the Relationship between Ga68-PSMA-11 SUV and Lu-177-PSMA-617 Tumour Uptake in Patients with Metastatic Castrate-resistant Prostate Cancer (Oncology)
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**Background/Aims:** Prostate Specific Membrane Antigen (PSMA) targeted radio-ligand therapies, such as ^177^Lu-PSMA-617, have become increasingly popular as a new treatment option for prostate cancer.\[[@ref135][@ref136]\] Research and trials using ^177^Lu-PSMA-617 has indicated an increased satisfaction in quality of life,\[[@ref137]\] good response rates, and low short-term side-effects in patients with advanced metastatic castrate-resistant prostate cancer (mCRP).\[[@ref138]\] We aim to evaluate the relationship between the pre-therapeutic standard uptake value (SUV) of tumours in ^68^Ga-PSMA-11 PET/CT imaging and ^177^Lu-PSMA-617 tumour uptake in patients with mCRP. **Methods:** SUV's of 15 Patients were evaluated pre-therapy using ^68^Ga-PSMA-11 PET/CT imaging. Approximately 200MBq of ^68^Ga-PSMA-11 was administered with an uptake time between 45-60 minutes, 25ml of iodinated contrast was administered 10 minutes before the scan, and the acquisition time was 3 min/bed vertex to proximal thighs. ^68^Ga-PSMA-11 PET/CT images were assessed by Nuclear Medicine Physicians, who evaluated suitability for ^177^Lu-PSMA-617 therapy. Patients received doses ranging from 4-7GBq. Visual analysis of ^177^Lu-PSMA-617 tumour uptake was done 6 hours' post-infusion using a Siemens Symbia T16 SPECT/CT gamma camera for imaging. **Results:** Approximately 15 patients to date have undergone ^177^Lu-PSMA-617 therapy, in conjunction with ^68^Ga-PSMA-11 PET/CT imaging at the Wesley Hospital, Queensland. Pre-therapy imaging with ^68^Ga-PSMA-11 PET/CT has highlighted extensive and progressive tumour load, to which Nuclear medicine physician appoint SUVs. Tumours with an SUV~max~ above 25 have shown excellent uptake of ^177^Lu-PSMA-617, whereas tumours with values below 25 have shown remarkably decreased uptake. We have noted a correlation between the efficacy of ^177^Lu-PSMA-617 therapy and SUV~max~ score of targeted tumours. **Conclusion:** A positive correlation exists between pre-therapeutic SUV~max~ and ^177^Lu-PSMA-617 tumour uptake,\[[@ref137]\] emphasizing the need for PSMA-ligand PET imaging for patient selection criteria. Further research should be conducted in utilizing a patient's ^68^Ga-PSMA-11 SUV~max~ as a prerequisite for ^177^Lu-PSMA radio-ligand therapy.

Paediatrics: P204: Paediatric Chronic Myeloid Leukaemia Metastatic Calcification Assessed by Bone Scan and Fludeoxyglucose Positron Emission Tomography
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**Background/Aims:** Hypercalcemia in hematological diseases is an infrequent phenomenon, that confers a sinister prognosis with mean survival as low as two months.\[[@ref139][@ref140][@ref141][@ref142]\] **Methods:** We reviewed the case of a 5-year-old boy with severe hypercalcemia in the context of unexplained renal failure and generalized pain. He was investigated with bone scintigraphy, renal biopsy, FDG PET/CT and bone marrow biopsy. Pertinent MEDLINE literature was reviewed. **Results:** On bone scan, unexpected finding of metastatic calcification, with intense ^99m^Tc-MDP uptake in the stomach, kidneys and mild diffuse lung activity led to suspect long-term renal failure with chronic hypercalcemia. ^99m^Tc-MDP manifestations of metastatic calcification depend on tissue calcium phosphate, iron and magnesium.\[[@ref144][@ref145][@ref146]\] Metastatic calcification most often occurs at the gastric mucosa, basement membrane of alveolar cells in the lungs, renal tubules and myocardium.\[[@ref140][@ref145][@ref146][@ref148]\] Local alkalosis causes precipitation of calcium phosphate salts that circulate in high concentration in the blood in a soluble form when the calcium-phosphate product is high.\[[@ref140][@ref145][@ref146]\] Renal biopsy revealed acute tubular necrosis (ATN) secondary to hypercalcemia, but no chronic renal disease. FDG PET showed no solid malignancy but diffusely increased marrow uptake. Bone marrow biopsy found "Philadelphia chromosome" translocation \[t(9;22)\]. Final diagnosis was acute transformation of chronic myeloid leukemia (CML) presenting with hypercalcemia and metastatic calcification, a rare phenomenon, particularly among children. In chronic myeloid leukemia, hypercalcemia can result from: parathyroid hormone(PTH)-related protein (PTHrP) to trigger bone resorption or direct resorption by intense marrow activity, similar to what can be found in cases of osteolytic bone metastases from solid malignancies.\[[@ref140][@ref143]\] **Conclusion:** Our case illustrates the need to report metastatic calcification as a worrisome finding in the acute setting. FDG PET can be used to exclude a solid malignancy that could produce PTHrP and identify marrow changes.
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**Background/Aims:** Altered ^18^F-fluorodeoxyglucose (FDG) uptake patterns in paediatric lymphoblastic lymphoma during therapy have previously been reported in patients receiving induction chemotherapy that includes very high dose corticosteroids.\[[@ref149]\] The occurrence of altered FDG uptake on positron emission tomography/computed tomography (PET/CT) was evaluated in children with lymphoblastic lymphoma treated at our institution and the relationship to chemotherapy was assessed. **Methods:** Following Ethics Committee approval, a retrospective review of FDG PET/CT scans performed in children treated for lymphoblastic lymphoma at the Women's & Children's Hospital since 2000 was performed. Those who had FDG PET/CT scans immediately after induction chemotherapy were evaluated for chemotherapy protocol used and FDG uptake pattern. **Results:** Of 20 patients identified with lymphoblastic lymphoma, 6 had staging FDG PET/CT scans performed and of these, 2 had repeat scans immediately post-induction. A 4 year old patient was treated with 28 days 6mg/m^2^/day of dexamethasone and the scan on day 29 showed widespread prominent FDG uptake (SUV~max~ 1.8) in subcutaneous fat tissue of the face, neck, torso and proximal upper and lower limbs, decreased uptake in the liver (SUV~mean~ 0.4) and low uptake in a residual lymph node. The second 3 year old patient was treated with 14 days 10 mg/m^2^/day dexamethasone and the scan on day 29 showed extensive brown adipose tissue uptake but normal subcutaneous torso fat and liver uptake and no residual FDG-avid disease. **Conclusion:** Our cases support a previous report that FDG PET/CT scans performed in paediatric lymphoblastic lymphoma post-induction chemotherapy using high dose corticosteroids for 4 weeks can lead to an altered FDG uptake pattern diffusely involving subcutaneous fat and liver. This "Cushingoid" phenomenon should be recognised to avoid misinterpretation.\[[@ref149]\] The influence on uptake by residual lymphoma cannot be determined from this case review.

P206:

18

F-Fludeoxyglucose Positron Emission Tomography-Computed Tomography in Paediatric Langerhan's Cell Histiocytosis

McCallum

S

1

Crudgington

D

1

London\*

Kevin

1

2

Kellie

S

1

2

Howman-Giles

R

2

3

Department of Oncology, The Children's Hospital at Westmead, Australia

Discipline of Child and Adolescent Health, Sydney, Australia

Discipline of Imaging, University of Sydney Medical School, Sydney, Australia

**Background/Aims:** Langerhan's cell histiocytosis (LCH) in paediatric patients presents with single-system (commonly bone or skin) or multi-system disease. Accurate staging is essential for selecting the most appropriate therapy that may range from local surgery only, to multi-agent chemotherapy. **Methods:** A retrospective review was undertaken of reported FDG PET/CT scans performed in children with LCH from June 2006 to February 2017. FDG PET/CT findings were compared to a reference standard of biopsy or informed clinical follow-up. **Results:** 109 scans were performed in 33 patients (age seven weeks to 18 years). 19 patients had single-system, bone uni-focal disease; seven patients had single-system, bone multi-focal disease; four patients had single-system, skin uni-focal disease; two patients had multi-system disease; and one patient had single-system, lymph node disease. 26 scans were performed to stage biopsy proven LCH and 83 scans were performed during follow-up to assess treatment response or recurrence after completion of therapy. At staging, FDG PET/CT detected all sites of biopsy proven LCH (except where bone uni-focal disease had been resected) and there was one false positive thymic finding that resolved without therapy on follow-up. The per-patient false positive rate of FDG PET/CT at staging was 4% (1/26). During follow-up, five LCH recurrences (in four patients) and one case of progressive disease on therapy occurred and all were positive on FDG PET/CT (multiple bone lesions and one thymic recurrence). During follow-up two patients had FDG PET/CT scans with false positive findings (a T11 fracture and a clavicle fracture, respectively) and one patient with an MRI false positive finding (pineal gland). The per-scan false positive rate of FDG PET/CT during follow up was 2% (2/83). **Conclusion:** ^18^F-FDG PET/CT is highly sensitive for the staging and follow-up of paediatric patients with LCH, and has a very low false positive rate.
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**Background/Aims:** Demonstrate the usefulness of scintigraphy plus SPECT/CT with Thallium-201 (^201^Tl) in the evaluation of malignant musculoskeletal tumours with suspicion of recurrence or metastatic disease. **Methods:** Seventy-two scintigraphy and SPECT/CT studies were performed to assess regional recurrence and metastatic disease, at least 8 weeks after the last therapy in 42 patients with different types of malignant musculoskeletal tumours; such as osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma, retinoblastoma, synovial sarcoma, and Wilms' tumour of the Hospital Infantil de México. We calculated the positive predictive value (PPV), confidence interval (CI) of the scintigraphy and SPECT/CT when compared with the results of the histopathological analysis and the clinical and radiological follow-up for the identification of recurrence. **Results:** Scintigraphy was abnormal in 30 (71.4%) of the 42 patients. 33 lesions in 30 patients were detected by scintigraphy; and 25 lesions in 21 patients by chest x-ray and tomography of two regions. The SPECT/CT was performed on 30 patients, with a detection of 12 lesions in addition to the planar scintigraphy. Scintigraphy showed a positive predictive value (PPV) of 82%; while the SPECT/CT PPV was 100%. **Conclusion:** ^201^Tl scintigraphy can be considered as a feasible study, to identify the sites of tumour viability, with a high degree of diagnostic certainty combined with the SPECT/CT technique.
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**Background/Aims:** High-dose I-131 metaiodobenzylguanidine (MIBG) therapy has been applied as an effective treatment of patients with high-risk neuroblastoma. I-131 MIBG post-therapy scan is informative for evaluation of the disease extent, which is superior to I-123 MIBG pre-therapy scan in lesion detectability. F-18-fluorodeoxyglucose (FDG)-PET scan is also useful for detecting lesions. The objective of this study was to compare the evaluation of residual disease extent using a semiquantative scoring method (Curie scoring, CS) in MIBG images and FDG-PET images in patients with high-risk neuroblastoma. **Methods:** We retrospectively investigated 14 high-risk neuroblastoma patients (ages, 7±5 years) with high-dose I-131 MIBG therapy (15-18mCi/kg). FDG-PET scan was performed before the I-131 MIBG therapy. We analysed the I-131 MIBG SPECT/CT images and FDG-PET/CT images in 10 anatomic regions. Each region was scored on the scale of 0 to 3 based upon disease extent. Cumulative CS scores were generated and compared by T-test. A linear regression analysis was performed to examine the association of the CS scores between the images. **Results:** In 14 patients, the CS scores of I-131 MIBG post-therapy images were significantly higher than that of FDG-PET/CT images (mean CS score: 6.9±1.2 vs. 2.0±1.2, p\<0.05). FDG-PET/CT images showed 1 soft-tissue lesion, which could not be observed on I-131MIBG images. The association of the CS scores was not found between the images. **Conclusion:** I-131 MIBG post-therapy images provide higher CS scores in patients with high-risk neuroblastoma. Although FDG-PET/CT images can aid to detect non-MIBG-avid lesions, I-131 MIBG post-therapy images are essential for the accurate residual disease extent evaluation.
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**Background/Aims:** Molecular therapy is having an increasing role in child and adolescent health. Providing these therapies requires physical facilities and procedures that allows patient care which comply with occupational and community exposure to radiation. The practical aspects of undertaking and administering these therapies and radiation safety aspects in paediatric and adolescents are complex and require coordination between many medical disciplines. **Methods:** The Children's Hospital at Westmead has been undertaking therapies for thyroid carcinoma and neuroblastoma since 1995. The therapy isolation room is sited in the general oncology ward. The criteria for the therapy room are based on clinical criteria: oncology nursing and clinical support; clinical requirements and apparatus (sedation and general anaesthesia) and child life therapists interaction. Radiation safety aspects require an isolation room, dedicated bathroom (including shower) and toilet. Limitations are placed on personnel and family while in therapy room. Parents/carers are encouraged to assist in general daily care. An adjacent room is used as the parents/carers room and has video, skype and voice transmission facilities to the patient. Specific details of this will be presented. Clinical Indications: 1) Thyroid cancer: ^131^I ablation/adjuvant therapy in the majority of patients; 2) Neuroblastoma: ^131^I-MIBG therapy--palliative or 'intent to cure' or peptide receptor radiotherapy with ^177^Lu-DOTATATE; 3) Neuroendocrine tumours: ^131^I-MIBG therapy or peptide receptor radiotherapy with ^177^Lu-DOTATATE. **Results:** 1. Therapy room and set up for therapy; 2. Preparation of therapy dose and radiation safety issues; 3. Transport of therapy dose to patient; 4. Clinical aspects depends on age of child-requirement for sedation or general anaesthesia; 5. Delivery of dose to patient; 6. Monitoring during days of isolation; and 7. Instructions and radiation safety on discharge and following days. **Conclusion:** Molecular therapy plays a significant role in treatment of various childhood cancers. The practical aspects will be discussed.
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**Background/Aims:** The purpose of this study was to evaluate damage of the kidney with ^99m^Tc-DMSA scintigraphy in children with congenital hydronephrosis (CH) and the influence of postnatal associated diagnoses on abnormal ^99m^Tc-DMSA findings. **Methods:** ^99m^Tc-DMSA scintigraphy in 54 children (17 girls:37 boys), aged from 2 months to 5 years (median 11 months) with 66 congenital hydronephrotic renal units (RU) (42 unilateral hydronephrosis in 29 boys and 13 girls; 12 bilateral hydronephrosis in 8 boys and 4 girls) was performed. Male/female ratio was 2.2:1, unilateral/bilateral hydronephrosis ratio was 4:1. Hydronephrosis classified into three groups according to anteroposterior pelvic diameter APD: mild (APD 5-9.9mm) was present in 13/66 RU, moderate (APD 10-14.9mm) in 25/66 RU, and severe (APD ≥15mm) in 28/66 RU. Simple hydronephrosis was present in 15RU, and the postnatal associated clinical diagnosis were VUR in 21, PUJ obstruction in 7, pyelonephritis in duplex ureter in 11, megaureter in 11, and posterior urethra valves in 1RU, respectively. **Results:** ^99m^Tc-DMSA scintigraphy pathological findings were found in 40/66 RU with ANH, (60.6%). Relative accumulation in hydronephrotic kidney was \<40% in 17 RU, \<10% in 14 RU, and inhomogeneous radiopharmaceutical uptake with relative accumulation over 40% was detected in 9 RU. Normal DMSA scintigraphy finding were found in 26/66 RU (39.4%). Statistically significant correlation between the degree of the hydronephrosis (APD) and ^99m^Tc-DMSA scan findings (p\<0.001), and between the degree of the VUR and DMSA scan finding (p=0.002) was established. In our study, other associated diagnosis does not statistically correlate with pathological findings on ^99m^Tc-DMSA. **Conclusion:** On the basis of these results with 60% pathological findings, we recommend DMSA scintigraphy in the evaluation renal pathology in children with congenital hydronephrosis. Greater number of patients is needed for the estimation of the associated diagnosis (other than VUR) influence on the renal parenchymal damage in children with CH.
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**Background/Aims:** This study was planned to investigate the goiter prevalence with nail selenium level and urine iodine status among the primary school-age children of endemic and non-endemic area of Bangladesh. **Methods:** Two hundred and ninety six (296) primary school-going children; 90 from endemic area and 206 from non-endemic areas were investigated. Thyroid size was assessed by ultrasound, iodine content of the salt samples was determined by iodometric titration, urinary iodine concentration was measured by APDM (Ammonium Persulfate Digestion on Microplate) method and serum T3, T4, TSH were measured by radioimmunoassay (RIA) and nail selenium was assessed by Hydride Generation-Atomic Absorption Spectrometry (HGAAS). **Results:** This study revealed higher goiter rate in primary school children from endemic area (58%) as compared to non-endemic area (29%). Mean household salt iodine level was found to be statistically higher (1.5 times) in primary school children from non-endemic area (33.18 ppm) as compared to endemic area (23.74 ppm). Mean urinary iodine excretion level was also found to be statistically higher (1.4 times) in non-endemic area (242.36 µg/L) as compared to endemic area (175.79 µg/L). Mean Serum T3 and T4 level in children from non-endemic and endemic area didn't differ significantly but slightly raised TSH level was observed in endemic group. Mean Nail Selenium concentration was found to be statistically higher (1.8 times) in primary school children of non-endemic area (1.21 mg/kg) as compared to endemic area (0.69 mg/kg). **Conclusion:** This study revealed that lower selenium level and iodine deficiency is the contributory factors for the prevalence of goiter among the primary school-going children in the endemic region. Thus, it can be postulated that table salt iodization along with correction of selenium deficiency should be considered to prevent goiter in endemic area.

P212: Aligning with Global Standardisation: Results of the Australian and New Zealand Paediatric Nuclear Medicine Administered Activity Survey
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**Background/Aims:** Optimisation of administered activity is recognised as an important component of paediatric nuclear medicine imaging. This project used a survey to assess the guidelines used to calculate the administered paediatric activity by Nuclear Medicine departments throughout Australia and New Zealand. The last survey of this kind was performed in 2014 as part of the first Nuclear Medicine Global Initiative Project. This international collaboration involved 13 organisations representing 39 countries. The 2014 survey recommended progress toward global standardisation in the administration of radiopharmaceuticals for paediatrics. The results showed a wide variation in the paediatric administered activities for Australia and New Zealand departments. The current survey investigated whether this situation had changed and if a move towards standardisation had taken place. **Methods:** The survey was disseminated through the Australian and New Zealand Society of Nuclear Medicine by email to all financial members, asking that one survey be completed for each department. The questions asked how many paediatric scans are performed each year, method of calculating activities administered to paediatric patients, most commonly performed scans, and minimum and maximum activities for a list of procedures and CT parameters utilised in paediatric scans. Approval to perform this study was granted by the Hunter New England Human Research Ethics Committee of Hunter New England Local Health District. **Results:** The survey was run November-December 2017 to maximise participation. Early results from the first 19% of the predicted participants showed that 64% followed the European Association of Nuclear Medicine dosage card as the method of calculating the paediatric administered activity. An in-depth analysis of the results will be presented along with a comparison with the Australian and New Zealand results obtained in 2014. **Conclusion:** Preliminary results indicate that practices have changed their procedures to further minimise administered activities for paediatrics since the 2014 survey.
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**Background/Aims:** ^18^F-fluorodeoxyglucose PET/CT (FDG PET/CT) imaging is widely used for diagnosis and follow-up of cancers in both adults and children.\[[@ref150][@ref151][@ref152]\] In Vietnam, PET/CT has been using since 2009 but there were no studies of FDG PET/CT application in children. Therefore, this study was conducted to assess the role of this modern imaging technique in paediatric practice. **Methods:** Based on medical records and FDG PET/CT scan results of paediatric patients undergoing FDG PET/CT imaging at Cho Ray Hospital from June 2009 to May 2017. **Results:** Ninety-seven FDG PET/CT scans were performed in 73 paediatric patients. Among them, 59 patients underwent one PET scan, 8 patients underwent two PET scans, 3 patients underwent 3 PET scans, 2 patients underwent 4 PET scans and 1 patient had 5 PET scans. The number of FDG PET/CT scans in paediatric patients has increased over years, from 4 scans in 2009 to 24 scans in 2016. Among 73 paediatric patients, there were 33 cases (45.2%) of lymphoma, 13 cases (17.8%) of neuroblastoma, 7 cases (9.5%) of sarcoma and 20 cases (21.9%) of many other types of cancers. Among 97 FDG PET/CT scans: diagnosis in 4 scans (5.4%), staging in 21 scans (28.7%), evaluation of treatment response in 55 scans (75.3%) and follow-up in 17 scans (23.2%). Lymphoma was the most common indication: staging in 13/21 scans (61.9%), evaluation of treatment outcome in 30/55 scans (54.5%) and follow-up in 10/17 scans (58.8%). In diagnosis, malignant disease was indicated in 1 of 4 FDG PET/CT scan resutls. In staging, there were 5 upstaging results (23.8%). In evaluation of treatment outcome, 24 results had poor or no response or progressive disease (44%) and 31 results had good response (56%). In follow up, 12 results discovered relapses (71%). **Conclusion:** The role of FDG PET/CT has been increasing in paediatric practice in Vietnam. This modern whole body imaging technique supports oncologists in diagnosis, staging, evaluation of treatment outcome and identifying relapse of many childhood cancers, especially lymphoma. Therefore, FDG-PET/CT imaging has a big promising potential in paediatric application in future.
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**Background/Aims:** Brown adipose tissue (BAT) uptake is well-documented in ^18^F-FDG PET scans.\[[@ref150]\] The sympathetic nervous system innervates BAT.\[[@ref151]\] This can be activated in response to low body temperature and/or cold environment. General anaesthesia (GA) has the potential to cause a loss of thermoregulatory control resulting in activation of BAT to maintain temperature.\[[@ref152]\] Medications used during anaesthetic may increase the degree of BAT uptake. **Methods:** We present a case study of a 20-day old female with a cervical paraspinal mass. A whole-body ^18^F-FDG PET scan was requested to determine pathology, extent of the mass and presence of metabolic lesions. The patient arrived under general anaesthetic including muscle relaxation with Pancuronium. The patient was in a crib, warmed with a blanket. 16MBq of ^18^F-FDG was administered and imaging commenced after 77 minutes uptake. **Results:** A large soft tissue para-vertebral mass extending from the mid cervical to the upper thoracic levels was demonstrated with patchy mild FDG avidity. Intense extensive FDG avid BAT uptake was seen in the anterolateral chest walls and left cervical region. There are multiple factors that may have resulted in the increased BAT FDG uptake. In neonates, BAT can be extensive making up approximately 5% of body weight.\[[@ref153]\] This contributes to more significant BAT FDG uptake in neonates compared to adults. Anaesthesia may have conflicting effects on BAT uptake by reducing sympathetic drive but may cause issues with thermoregulation. Ensuring the patient kept warm in the hours prior to administration of FDG may have reduced BAT uptake.\[[@ref152]\] Pancuronium use during GA prior to FDG administration may have increased BAT uptake by sympathetic stimulation.\[[@ref154]\] **Conclusion:** Maintenance of temperature, avoidance of medications that promote BAT uptake and communication between the imaging and anaesthetic teams is likely to provide the best result for suppression of brown fat activity.
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**Background/Aims:** The diagnosis of pulmonary embolism (PE) is usually by means of Computed Tomography Pulmonary Angiography (CTPA) or Ventilation/Perfusion Scintigraphy (V/Q) scanning. In the PIOPED era, before the advent of SPECT imaging, VQ scanning was frequently associated with an indeterminate probability of PE in up to 40%,\[[@ref155]\] particularly in the setting of poor ventilation imaging quality. Recently, with improved technology, the "indeterminate" rate has decreased. We aimed to assess the rate of indeterminate studies in our institution, with the routine performance of SPECT, and the availability, as required of SPECT/CT. **Methods:** Retrospectively, the results of six months of VQ scans (172) from our private Nuclear Medicine Department at Cabrini Hospital were categorised into "Positive", "Negative" or "Indeterminate" studies. 24 VQ studies, for the purpose of assessing resolution of previously diagnosed PE (20 studies) and for quantification prior to surgery (4 studies) were completed in this period and excluded from our results. The reporting doctor was aware of the clinical history and had access to additional imaging (eg. CT) as required. **Results:** 34 patients had V/Q SPECT "Positive" for PE (23.0%) while 113 patients were found to have a "Negative" result (76.4%). One study was "Indeterminate" (0.6%). The indeterminate study was followed up with CTPA and found to be negative. Of our cohort, five had a SPECT/CT. The decision to anti-coagulate was at the clinician's discretion. Limitations of the study included absence of validation of the diagnosis. **Conclusion:** In the modern era, with routine use of V/Q-SPECT and the clinically-indicated addition of SPECT/CT, retrospective evaluation has confirmed an "indeterminate" rate of 0.6 % in our institution. V/Q SPECT should be strongly considered as a diagnostic modality in the correct clinical scenario as a reasonable alternative to CTPA.
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**Background/Aims:** Thrombosis and thromboembolism has been demonstrated to be a leading cause of maternal mortality. The absence of a reliable clinical score for pulmonary embolism (PE) necessitates the use of imaging such as V/Q lung scintigraphy or CT pulmonary angiography to rule out PE. The aim is to review the efficacy of perfusion only scan and compare the radiation dosage with other modalities in pregnant women with suspected PE, and to evaluate the diagnosis in comparison to the clinical guidelines. **Methods:** A retrospective clinical audit of the 64 pregnant patients with suspected PE from March 2014 to January 2017 was undertaken at Auckland City Hospital. Records for 64 patients were reviewed including the clinical history, investigations and imaging to exclude recurrent PE. Follow-up of patient progress over the next 6-12 months were done. **Results:** Results: Of the 64 patients, 3 (4.7%) were diagnosed with PE on perfusion scan only whereas the remainder of the patients showed normal findings with no evidence of PE. Of the 3 patients with perfusion only scan showing positive PE, only one patient went on to have ventilation scintigram the following day, which showed mismatched V/Q defects confirming the diagnosis of PE. CTPA was not performed on any of these patients. An average of 40.5MBq of ^99m^Tc-MAA was given which delivers significantly less radiation to the breast and fetus when compared to V/Q scan (0.015mGy and 0.14-0.25mGy vs 0.852mGy and 0.36mGy) and CTPA (10-70mGy and 0.24-0.47mGy) respectively. Of the 36 (55.4%) patients with D-dimer performed, 32 (88%) had raised D-dimer. None of these patients showed evidence of PE. The D-dimer was not measured in patients who showed positive result for PE. **Conclusion:** This audit has demonstrated the value of perfusion only scan as a suitable primary investigation/screening test for pregnant patients with suspected PE. The study emphasises the significantly lower dose of radiation to the breast and fetus versus V/Q scan and CTPA. As well, the nonclinical value of D-dimer in pregnancy is evident in this study.
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**Background/Aims:** It is not possible to confirm a diagnosis of pulmonary embolism (PE) based on clinical features alone. The diagnosis of PE must be confirmed or refuted on a conclusive imaging test. Previously, V/Q scans were reported according to the findings of segmental perfusion defects on planar imaging, however with the advent of Single Photon Emission Computed Tomography (SPECT), many centres have adopted this new approach. This study aims to compare the diagnostic ability of planar vs. SPECT V/Q Scintigraphy. **Methods:** All patients referred from November 2013 to June 2014 for V/Q scintigraphy for suspected PE had planar images followed by SPECT acquisition. PE was reported for planar imaging according to the modified PIOPED criteria and with the use of the EANM criteria for SPECT. **Results:** There were a total of 69 patients, age range of 21 to 82 years. Both planar and SPECT imaging showed the same number of segmental perfusion defects. However, SPECT showed more subsegmental defects (35% versus 21%). If two or more subsegmental defects were present on SPECT, the report was concluded as positive for PE. Only 9% of patients would have had positive PE on planar imaging versus 30% on SPECT imaging. There were 10% of patients that had a non-diagnostic scan on planar imaging versus none on SPECT. **Conclusion:** SPECT imaging showed more subsegmental defects than planar imaging and no patient had indeterminate scan results. The significance of clinically significant subsegmental PE is low, and the added value of SPECT is questionable. However, a clinical follow up of the patients in this cohort used as an end point would be crucial in assessing the accuracy of the two techniques. The value of SPECT over planar imaging would be in reducing or even eliminating the indeterminate findings on planar imaging.
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**Background/Aims:** D-dimer blood assay is touted to have an excellent negative predictive value (NPV) in patients with a low to intermediate pre-test probability for PE and is included in our institutions suspected pulmonary embolus (PE) clinical pathway. Pulmonary embolism (PE) is one of the more common causes of chest pain and left untreated has an estimated mortality of around 25%. We sought to assess the number of Ventilation/Perfusion (V/Q) scans referred from the Royal Adelaide Hospital Emergency Department that were D-dimer negative, yet PE positive. **Methods:** Ethics and governance approval obtained. The study period was from 25^th^ October 2015 to 25^th^ October 2016. All patients aged over 18 years referred from the Royal Adelaide Hospital ED for V/Q SPECT scan were included. V/Q scans were coded as positive or negative and alternative diagnoses were also recorded when present. The laboratory results for all patient's imaged with V/Q scans were interrogated to assess whether a recent D-dimer had been performed and whether it was positive (\>=0.5 mg/L) or negative (\<0.5 mg/L). **Results:** A total of 125 V/Q scans were performed with 25 (20%) overall positive for PE. 62 (49%) of V/Q scans had a D-dimer performed with 13 (21%) returning a negative result. Of these 13 D-dimer negative V/Q scans, 5 of these were reported positive for PE. **Conclusion:** The NPV of D-dimer is often overstated with the consequence that there is frequently a disproportionate focus on its value/role in clincial pathways. Although this study is small, it supports a common belief that D-dimer should have a limited place in the evaluation of PE in the acute setting. The value of a negative D-dimer could be considered "fake news".
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**Background/Aims:** Regional obstetric guidelines recommend that ventilation-perfusion (VQ) scan is the first line investigation for suspected pulmonary embolism (PE) during pregnancy. Our department protocol uses single photon emission computed tomography (SPECT) VQ imaging, in line with European Association of Nuclear Medicine (EANM) guidelines.\[[@ref159]\] The aim was to determine the diagnostic accuracy of VQ SPECT imaging in suspected PE during pregnancy. **Methods:** An audit of consecutive pregnant VQ SPECT studies was completed for the period August 2014 to June 2017. For each of the patients imaged, e-Health records were followed up to puerperium. In the absence of a gold standard for diagnosis of PE, VQ SPECT reports were compared with final clinical diagnosis made. **Results:** 331 VQ SPECT patients were investigated (age 17-46 years; gestation 3-40 weeks). The VQ SPECT reports were 81% negative (n=267), 7% positive (n=23) and 12% were unable to exclude PE (n=41). 264 of the negative patients were truly negative, 3 patients continued having symptoms and received treatment for PE throughout pregnancy and puerperium. Of the 23 positive patients, 3 patients subsequently underwent CTPA, and although reported as negative, these patients continued to receive treatment. The accuracy of reporting was estimated at 87%. The reports of the inconclusive studies were reviewed and re-categorised in line with the EANM reporting guidelines\[[@ref159][@ref160]\]-32 negative, 5 positive and 4 had inadequate image quality. Sensitivity, specificity and accuracy were calculated at 92%, 99% and 97% respectively. **Conclusion:** Due to the decreased maternal radiation dose burden,\[[@ref161]\] small foetal dose,\[[@ref161][@ref162]\] and higher sensitivity for observation of small PE, VQ SPECT imaging is the initial investigation of choice for PE diagnosis in this patient population. VQ SPECT is a useful and accurate tool for the exclusion of PE in the pregnant population. Accuracy can be improved when reported in line with the EANM reporting criteria guidelines.\[[@ref159][@ref160]\]

P221: 25-hydroxyvitamin-D Deficiency in Patients with Obstructive Sleep Apnoea Syndrome
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**Background/Aims:** Vitamin D (Vit D) insufficiency has been implicated in the pathophysiology of numerous diseases. Obstructive Sleep Apnoea Syndrome (OSAS), a disorder associated with increased cardiovascular and cerebrovascular morbidity, has been associated with lowered Vit D levels. To evaluate the association between serum 25-hydroxyvitamin-D (25-ΟΗ-D) levels, in OSAS patients and non-apnoeic controls in correlation with the OSAS severity. **Methods:** A total of 169 patients (135 men, 34 women) aged from 36 to 69 years (mean 54±10.6 years) were included. All patients came from the Pulmonary Clinic of the University Hospital of Evros. Consecutive subjects who had undergone polysomnography and pulmonary function testing were divided into controls (apnoea-hypopnea index, AHI \<5/h) and OSAS group (AHI ≥5/h). The vitamin D status was measured by radioimmunoassay (RIA) method with kits Diasorin at *in-vitro* laboratory of Nuclear Medicine Department. **Results:** OSAS patients (n=139) significantly differed from non-apnoeic controls in terms of age (53.9±12.8 vs. 44.9±12.8 years, p=0.002) and body mass index (BMI) (35.9±6.9 vs. 29.9±6.8 kg/m2, p\<0.001). Serum (25-ΟΗ-D) levels were lower (deficiency) in OSAS patients (17.8±7.8 vs. 23.9±12.4 ng/ml, p=0.019). In OSAS patients, levels of serum (25-ΟΗ-D) were negatively correlated with sleep stages transitions (r=-0.205, p=0.028), AHI (r=-0.187, p=0.045), oxygen desaturation index (r=-0.234, p=0.011) and percentage of time with oxyhaemoglobin saturation \<90% (r=-0.172, p=0.041). In contrast, they were positively correlated with average oxyhaemoglobin saturation during sleep (r=0.179, p=0.033), forced expiratory volume in 1 sec (r=0.207, p=0.037) and oxygen partial pressure (r=0.197, p=0.029). **Conclusion:** Vitamin D levels were lower (deficiency) in OSAS patients compared with non-apnoeic controls. Several indices of OSAS severity also correlated with Vitamin D levels.

P222: Does Obstruction in Small Airways Contribute to Lung Function Deterioration in Patients with Heart Congestion/Pulmonary Hypertension?
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**Background/Aims:** To study ventilation (V) and perfusion (P) in patients with heart congestion/pulmonary hypertension (HC/PH). V/P SPECT findings were then compared to spirometry. **Methods:** Forty-six patients with heart congestion/pulmonary hypertension (10 females, age 54.7±9.1 years) were examined with right heart catheterization, V/P SPECT (ventilation and perfusion single photon emission computed tomography), and spirometry (Global Lung Function Initiative 2012 reference values). Mean arterial pulmonary pressure (MPAP) ≥25 mmHg was used as threshold for PH. Pulmonary artery wedge pressure (PAWP) \>15 mmHg indicated HC in 36 patients. V/P SPECT images were assessed by expert reader. **Results:** V/P SPECT showed sign of heart congestion in 30 patients, and chronic PE in 12 patients. Among them different grade of obstructivity was observed as earlier described and graded by penetration of Technegas™ to the periphery and deposition of aerosol in small/larger airways (Vgrade). Total preserved lung function (TPLF%) was estimated by measuring matched ventilation and perfusion parts and calculated as a % of the total lung volume. Vgrade increased progressively with the reduced TPLF% (p\<0.05). Both VC and FEV1 were reduced (95% confidence interval (CI) for z from-5.1 to 0.1 and from-5.1 to-0.2, respectively), but FEV1/VC did not show any sign of obstruction (95% CI for z from-3.6 to 1.7). There was no significant relation of FEV1/VC to TPLF% or Vgrade, while both VC and FEV1 correlated significantly to TPLF% (p\<0.004). **Conclusion:** V/P SPECT showed reduced TPLF% in all HC/PH patients and Vgrade showed signs of different degree of obstruction. Spirometry showed reduced vital capacity (VC) and reduced ventilatory capacity (FEV1) but did not show signs of obstruction (FEV1/VC).
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**Background/Aims:** CA 19-9 is a serum tumour marker which can be elevated in gastrointestinal cancers; mainly pancreatic, biliary duct, and gastric.\[[@ref163]\] CA 19-9, however, only has a sensitivity of 79-81% and specificity of 82-90% for diagnosing pancreatic cancer (reference range \< 37).\[[@ref164]\] It may also be elevated in other non-gastrointestinal neoplastic processes and in multiple benign conditions.\[[@ref165][@ref166][@ref167]\] **Methods:** A PET/CT study was performed on a Philips Gemini TF scanner following the administration of ^18^F-fluorodeoxyglucose (^18^F-FDG). A low dose CT was also performed with dilute oral contrast for lesion localisation and attenuation correction as per departmental protocol. **Results:** A 64-year-old woman with a history of weight loss and an elevated serum carbohydrate antigen 19-9 (CA 19-9) level of 560 was referred for a ^18^F-FDG PET study to evaluate for occult malignancy. In addition to the weight loss, she had suffered from a chronic cough secondary to bronchiectasis for the last few years. She had recently undergone CT imaging, gastroscopy, and colonoscopy for investigation of a suspected gastrointestinal malignancy. Multiple foci of increased tracer avidity were noted throughout both lungs on ^18^F-FDG PET, corresponding to areas of bronchiectasis on CT. This supported an inflammatory process causing her elevated CA 19-9 rather than malignancy. **Conclusion:** Kodama *et al*. illustrated that 38.9% of patients with benign respiratory diseases such as bronchiectasis had elevated serum CA 19-9 levels.\[[@ref168]\] Previous case reports of patients with bronchiectasis have discussed CA 19-9 levels up to 1500.\[[@ref169][@ref170]\] Bronchiectasis has also been demonstrated to be an independent factor for increased CA 19-9 (Odds Ratio 2.48; 95%CI 1.22-5.02).\[[@ref166]\] This case illustrates the lack of specificity of CA 19-9 with bronchiectasis as a possible cause of elevated serum levels.

P224 Lobar Quantification by V/Q SPECT/Computed Tomography in Patients with Severe Emphysema Undergoing Endobronchial Lung Volume Reduction
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**Background/Aims:** Endoscopic Lung Volume Reduction (ELVR) with valves can reduce dyspnea and improve lung function in severe emphysema. We evaluated the regional effects of ELVR by ventilation/perfusion (V/Q) SPECT/CT analysis of changes of volume, V and Q. We also correlated the findings with those from planar lung scintigraphy and lung function tests. **Methods:** After approval from the scientific ethics committee, we included 24 consecutive subjects (60 years (46-74 years), 37.5% men)) with severe COPD and emphysema (average FEV1 26 % predicted). V/Q planar and SPECT/CT as well as lung function measurements were performed before and 6 months after ELVR. Intra-observer reproducibility of V/Q planar and SPECT/CT analysis were tested. **Results:** V/Q SPECT/CT analyses of volume of the targeted lobe showed a mean decrease of-395 mL and relative decrease of-24%, while V and Q decreased relatively-37% and-26%. There were significant increases in the same parameters of the ipsilateral non-targeted lobe(s). No such changes were found in the analysis of planar imaging. The total lung volume decreased in average-420 mL. Six months after ELVR, lung function (FEV1 and diffusion capacity (DLCO)) had increased 21%. Significant correlations were found between changes in DLCO and changes in the V and Q of the treated lobe (planar), and between FEV1 and changes in volume of the treated lobe (SPECT/CT). Intra-observer coefficient of variation was 1.3% (volume), 2.6% (V), and 2.7% (Q) of the treated lobe as assessed by SPECT/CT, while it was 0.7 % for both target V and target Q in planar analysis. **Conclusion:** V/Q SPECT/CT analysis can quantify volume, V and Q changes in pulmonary lobes and may be used in the assessment of patient eligibility for ELVR, identifying target lobes, and for evaluation of regional effects of treatment.

P226: Choosing Un-wisely: A Single Centre Retrospective Audit of V/Q and CTPA Positivity from ROYAL Adelaide Hospital Emergency Department
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**Background/Aims:** Chest pain is a common presentation to emergency departments (ED) around the world with many different causes. Pulmonary embolism (PE) is one of the more common causes of chest pain and left untreated has an estimated mortality of around 25%. Electronic ordering is used in the RAH ED which is bound by National Emergency Access Targets (NEAT's-4 hour rule) like many other hospitals in Australia. Consequently, imaging is often overused particularly in the setting of chest pain. Scans should detect PE in 15-37% of patients with alternate diagnosis found in up to 56% of scans. We sought to audit the RAH ED imaging test positivity to see if it matched the anticipated detection rate. **Methods:** Ethics and governance approval was obtained. The study period was from 25^th^ October 2015 to 25^th^ October 2016. All patients aged over 18 years referred from the Royal Adelaide Hospital ED for V/Q SPECT scan or CTPA were included. VQ scans were coded as positive or negative with CTPA having an indeterminate category. Alternative diagnoses were also recorded when present. The laboratory results for all patients were interrogated to assess whether a recent D-dimer had been performed and whether it was positive (\>=0.5mg/L) or negative (\<0.5mg/L). **Results:** A total of 125 V/Q scans and 939 CTPA scans were performed with 20% (25) of V/Q scans positive for PE and 12.8% (121) of CTPA's positive for PE. 49% (62) of the V/Q scans had a D-dimer performed with 13 returning a negative result. Only 24% (255) of CTPA's had a D-dimer performed with 26 returning negative. **Conclusion:** V/Q SPECT appears to be used appropriately, however CTPA appears over-utilised with only 12.8% of scans positive for PE (ideally \>15%) and 20% of CTPA's having an alternative diagnosis.
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**Background/Aims:** Due to gradual popularization of PET/MR, the frequency of scan is increasing worldwide. Because the soft tissue contrast is superior to other scanners, more anatomical and physiological information can be obtained using PET/MR imaging. Conventional PET/MR scanners were unable to scan simultaneously because PET and MR were separated, but integrated PET/MR scanner became popular due to technology development. The hardware and software technology of the scanner is evolving and the analytical data on the quality of the PET image acquired by the integrated PET/MR scanner is insufficient. Therefore, the aim of this study is to quantitatively analyse the quality of PET images using PET/MR scanners. **Methods:** To evaluate the PET images, PET/MR (Biograph mMR 3.0T, Siemens) was performed in 20 patients underwent ^18^F-FDG torso scan. The smallest spheres (10, 13, 17, and 22 mm) of the NEMA IEC body phantom were filled with ^18^F-FDG and maintained at a ratio of 8:1 to BKG. To obtain uniform attenuation correction map, the image was acquired by setting the initial voltage to 75 V. PET data were reconstructed with OSEM (Iteration: 3, subsets: 21) and OSEM + PSF (Iteration: 3, subsets: 21). Phantom images were evaluated for image quality with CR (Contrast recovery) and SNR (Signal to Noise Ratio) according to the two reconstruction methods by drawing the region of interest. Clinical patients were evaluated by SNR drawing the ROI to liver. **Results:** In the Phantom experiment, the image quality was improved when OSEM + PSF reconstruction method was applied with CR10mm 5.3% CR13mm 4.7% CR17mm 5.1% CR22mm 3.4% and SNR10mm 4.8% SNR13mm 5.2% SNR17mm 6.2% SNR22mm 5.1%. The OSEM + PSF reconstruction method showed the improvement of image quality. In clinical studies, the OSEM + PSF method improved the SNR ratio by 11.6%. **Conclusion:** The OSEM + PSF reconstruction method of PET images confirm the improvement of image quality. Integrated PET/MR scanner will be necessary for the quality evaluation data of PET images quantitatively using PET/MR in the future.
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**Background/Aims:** The aim of this study is to evaluate a quality assurance program of PET/CT studies in a hospital-based clinical PET service. **Methods:** Over a 12-week period, three nuclear medicine specialists evaluated for concordance prior studies in patients returning for PET/CT using a standardized scoring system during routine clinical reporting. **Results:** Of 202 PET/CT studies scored, 42 studies were excluded as the reviewer had reported the prior study, leaving 160 studies for analysis. The reports of 134/160 (84%) studies were concordant (score 1) and 26 (16%) discordant (score 2, 3 or 4). Of 14 studies scored 3 and 4, 7 (4.5%) cases were considered clinically significant, with missed bone lesions in 2, unreported lung nodules in 2, mis-registration in 1, ambiguity in 1 and misinterpretation in 1 accounting for the discrepancies. **Conclusion:** We have shown that a peer review quality assurance program for PET/CT is feasible with a low prevalence (\<5%) of clinically significant discrepancies in a hospital-based clinical PET service.
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**Background/Aims:** As part of an institutions ongoing commitment to providing high quality learning and teaching for its students, and to ensure graduates are market ready, programs typically undergo cyclic internal review. A five year review cycle is fairly typical, however, a number of triggers may see a shorter cycle (for example, external accreditation). While the program life cycle and review processes vary from institution to institution, and will accommodate nuances specific to different countries and regulatory procedures, traditionally the process has been fairly consistently insight driven. Here, an outcome driven approach is outlined as an alternative approach. **Methods:** The traditional approach to program development is somewhat counter-intuitive despite being well established. At CSU, program design has been re-imagined with the implementation of a new learning platform employed University wide for design, implementation and evaluation of programs. The MRS discipline team hybridised the learning platform philosophies and re-imagined application and implementation. The re-imagined approach to program review and design adopts a more intuitive approach; although less traditional. The program structure is not defined by intuition, experience and curricula. The starting point is simply the expected learning outcomes recognising they are a national standard and evidence based (against scope of practice). **Results:** These learning outcomes were scaffolded across the four years of the program with some learning outcomes not being evidenced until late in the program and others scaffolded over the four years. The capabilities themselves were not simply scaffolded against the traditional Blooms cognitive taxonomy but rather a hybridisation of both Blooms knowledge and cognitive domains provide a richer outcome for graduates. Establsihed learning outcomes then re-engineered the development of assessment tasks which drove development of curriculum and eventually structured units/subjects and the program itself. **Conclusion:** Program review need not be an onerous task with quality product, service and outcomes being enhanced by re-imagining program development and re-engineering program design; allowing learning outcomes to be the hero of the program.
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**Background/Aims:** Understanding glucose metabolism in the honeybee provides an insight into phenotypic physiological adaptations under varying stressful conditions. Bees require either stored honey or nectar to survive with limitation to access being fatal within 24hr. Various sugars can be used as a source in the absence of natural nutrition. The bee digests nutrients which are circulated in the haemolymph to be used as energy or stored in the fat bodies and varying levels of protein glycation occurs under different stress conditions. This study was to evaluate the potential for PET imaging of ^18^F-FDG to provide visual and quantitative mapping of post digestion glucose bio-distribution. Iodinated glucose has previously been used to image metabolic pathways in bees.\[[@ref171]\] **Methods:** Ten nurse bees were collected from the hive and deprived of food for 2 hours. The bees were then afforded a drop feeder containing concentrated ^18^F-FDG. After approximately 30 minutes of feeding time, bees were immobilised at-100C for 15 minutes. Individual bees were imaged for 10 minutes on a Sofie Biosciences Genesis 8 (G8) PET/CT system. CT was used to co-register ^18^F-FDG biodistribution. Insects are exempt from animal ethics requirements. **Results:** The G8 system allowed identification of ^18^F-FDG biodistribution in the haemolymph, proventriculus, ventriculus, fat bodies, flight muscles and brain. **Conclusion:** This study demonstrated the feasibility of using PET/CT to map oral accumulation and biodistribution of ^18^F-FDG as an analogue of natural energy sources. Further analysis in live bees, including post metformin intervention, is feasible using PET/CT.

P230: Positron Emission Tomography-Computed Tomography Imaging: Initial Clinical Experience From a Tertiary Care General Hospital in Kuwait
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**Background/Aims:** Bulk indications for PET/CT imaging are in the field of oncology. This initial experience from a tertiary-care hospital emphasises the utility of PET/CT imaging in the general-hospital setting highlighting the referral pattern especially its usefulness in non-oncological indications. **Methods:** From April 2014 to April 2017, 263 (147 ^18^F-FDG; 116 ^18^F-Sodium Fluoride (NaF) PET/CT studies were performed in the Nuclear Medicine Department, Al-Jahra Hospital Kuwait. Mean age of patients was 56.78 years (range 6-88). The weight-based tracer dosage was administered according to 0.08-0.1 mCi/kg body weight. Mean-dosage of ^18^F-FDG administered was 7.3 mCi (270.1 MBq) while that of NaF was 6.8 mCi (251.6 MBq). The mean-weight of patients undergoing ^18^F-FDG and NaF was 74.6kg and 76.3 kg respectively. Referral clinical indications for ^18^F-FDG studies were categorised into two major groups (oncological & non-oncological) with former having documented histopathology malignancy diagnoses prior to PET/CT study. Indications were further categorised into (baseline staging work-up, response evaluation, restaging/recurrence) for oncological group. Non-oncological group was further sub-categorized into characterization of pulmonary nodule(s), guiding biopsy site, localise focus of infection, finding primary malignancy, sarcoidosis work-up, malignant otitis externa evaluation and miscellaneous categories. Indication for NaF studies was evaluating metastatic osseous disease in histopathologically-proven or radiologically-suspicious malignancies. **Results:** 33.3% (49/147) ^18^F-FDG studies were performed in oncological category (baseline staging work-up 17%, response evaluation 6%, restaging/recurrence 10.2%). 66.6% (98/147) ^18^F-FDG studies were performed in non-oncological category (characterization of pulmonary nodule(s) 20.4%, guiding biopsy site 8.8%, localise focus of infection 16.3%, finding primary malignancy 6.8%, sarcoidosis work-up 5.4%, malignant otitis externa evaluation 4.8% and miscellaneous 9.5%. 92.2% (107/116) NaF studies done for histopathologically proven and 7.8% (9/116) for radiologically suspicious malignancies. **Conclusion:** Unlike routine understanding non-oncological indications for ^18^F-FDG PET/CT imaging forms bulk of studies in a general-hospital setting and appear highly varied. Further studies with larger number would validate these findings.
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**Background/Aims:** Security in nuclear medicine has always been second to safety. However, a (failed) attempt to steal radioactive material in a neighbouring institution in 2015, prompted us to assess the current security status in our nuclear medicine department as a starting point for improvement. We decided to elaborate the scope to all hazardous materials within our university. **Methods:** We assessed the security status in our institution via "mystery shopping". Incognito security personnel tried to gain access to the hazardous products in our laboratories, without using illegal means. Pictures were taken as proof of the situation. **Results:** As expected, the first round (December 2015--March 2016) showed that it was easy to gain access to our laboratories. Laboratories within the controlled zones were either open, or easy to unlock, or could be accessed without anyone checking the identity given by the mystery shoppers. In some cases, hazardous waste was even present in public areas, such as in hallways or near elevators. We then confronted the faculty deans and heads of department with their results and gave them instructions (both technical and organizational) for improvement. During the second round (Fall 2016), hazardous material could not be found anymore outside the controlled zones and most zones were effectively locked. However, the mystery shoppers could still access most laboratories without being checked. **Conclusion:** Technical measures will be extended. Controlled zones will be either accessed through a double barrier or equipped with double badge control and movement detection. Identity information and access codes will be on separate personnel badges. We will encourage university personnel to wear their identity badge visibly, so outsiders can be more clearly identified. Security will be kept on the agenda to increase the limited security awareness of the personnel. We will provide targeted information for each function.
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**Background/Aims:** Patients who receive Radioactive Iodine Therapy (RAI) for differentiated Thyroid Cancer at The Wollongong Hospital (TWH) are referred by several different treating specialists. The organisation of their treatment is complex involving multiple departments including: Surgery, Pathology, Nuclear Medicine and Oncology. TWH has no clearly defined pathway for these patients. Without a clearly defined pathway patient confusion and anxiety levels can increase which can impact on treatment outcomes. This is a quality improvement project to clarify the patient journey at TWH from the time of their diagnosis to the time of discharge following RAI. **Methods:** Every patient admitted through our department for RAI was invited to complete a patient survey. The survey assessed: information provided to the patient about their need for RAI by their treating clinician; the experience of the admissions process; the experience of the discharge process. In addition to seeking feedback from patients, treating Nuclear Medicine Physicians were also contacted and encouraged to give feedback about the admission and discharge process associated with RAI patients. **Results:** 71 patients admitted to TWH nuclear medicine from November 2014 to June 2017, 46 patients completed surveys (65% response-rate). The survey results highlighted that the journey is complex from the time of surgery, to post-surgical consultations, Recombinant-TSH injections, pathology requirements and admission for RAI. This process involved a multidisciplinary approach over many months. Survey results highlighted: 1) Anxiety over lack of information/inconsistent information as a key patient issue and; 2) timing of tests and treatment compliance as a key clinician issue. **Conclusion:** Our survey results suggest that a patient journey road map was required to ensure a safe and effective pathway for the thyroid cancer patient. A road map will be developed to allow a consistent, systematic process to follow for both the patient and clinicians. A patient feedback system will subsequently be implemented to assess the effectiveness of the road map in improving the patient's cancer journey.
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**Background/Aims:** PET/CT can be useful in diagnosis and management of many pathologies, other than those covered by the Australian Medicare system. The pathologies include rheumatological diseases, pyrexia of unknown origin, infection and oncological diseases not covered under the medicare system. The Illawarra PET Centre has been operating for the past 3.5 years with the majority of our scans being performed on outpatients for Medicare funded indications. Inpatient studies are also performed for both medicare and non-medicare indications. An audit of the PET/CTs performed at our centre over the past 3.5 years will be carried out in order to assess the number and indications studies have been performed on both out patients and inpatients. In particular the non-medicare indications of inpatients will be further analysed. This will give us a better understanding of the types of cases we are referred. **Methods:** A retrospective review of studies performed from 11/2/2014 to 11/8/2017 will be carried out and an assessment of the various indications determined. In particular the indications for inpatient PET/CTs will be further assessed. **Results:** An analysis of the PET/CTs performed over our first 3.5 years of operation will be performed. **Conclusion:** A conclusion will be drawn based on our research findings.

P234: Intravenous Contrast Administration Prior to PSMA Positron Emission Tomography Allows Discrimination of Disease from Excreted Tracer (Oncology)
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**Background/Aims:** Prostate specific membrane antigen positron emission tomography (PSMA PET) is a rapidly emerging tool in the management of prostate adenocarcinoma. Discrimination of disease from excreted tracer within the urinary tract may be difficult. Intravenous iodinated contrast administered prior to PET was adopted as part of a clinical imaging protocol. **Methods:** A clinical imaging protocol for PSMA PET which included prior administration of iodinated intravenous contrast was developed to allow discrimination of metastatic and recurrent disease from excreted urinary tract activity. Small volume lymph node metastases often lie closely adjacent to the course of the ureters and may be difficult to identify at PSMA PET. If the prostate is in situ following radiotherapy, recurrent or persistent disease may be difficult to distinguish from excreted tracer within the prostatic urethra, or a defect from previous transurethral resection of the prostate (TURP). Contrast administration prior to PET allows excretion into the urinary tract and helps distinguish these structures at reporting. **Results:** Administration of intravenous contrast as part of the imaging protocol for PSMA PET can be incorporated into imaging protocols for patients without renal impairment. Protocols for contrast administration are discussed. Clinical examples are demonstrated. **Conclusion:** Administration of intravenous contrast is easily incorporated into imaging protocols for PSMA PET. Confidence in reporting small volume nodal disease adjacent to the ureters and local recurrence at the prostate can be increased.
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**Background/Aims:** PSMA ligand such as N, N'-bis-\[2-hydroxy-5-(carboxyethyl)benzyl\]-ethylenediamine-N, N'-diacetic acid (HBED-CC) labelled with ^68^Gallium (^68^Ga) is increasingly used for the purpose of PET imaging in prostate cancer. We present a range of physiological and pathological causes for uptake of ^68^Ga-HBED-CC within the nervous system which may potentially mimic metastatic prostate cancer. **Methods:** Examples of physiological and pathological HBED-CC uptake in nervous systems were drawn from 826 cases of PSMA PET/CT and 443 cases of PET/MRI performed in the period between 01/08/2014 and 01/11/2017. All patients were undergoing clinically indicated PET scans to stage local and distant disease related to prostate cancer. **Results:** The following causes of ^68^Ga-HBED-CC uptake in the nervous system were identified as potential mimics for metastatic prostate cancer.

Physiological PSMA expression in the stellate and coeliac gangliaSciatic nerve plexiform neuromaAcoustic neuroma in the cerebellopontine angleSubacute cerebellar infarctCerebral metastases from other malignancies

**Conclusion:** PSMA expression is not only associated with prostatic epithelium but also a range of normal and pathological conditions within the nervous system that potentially mimic of metastatic prostate cancer on PSMA PET. Pathological uptake of ^68^Ga-HBED-CC within the nervous system is uncommon and therefore less likely to be anticipated as a potential false positive finding. Putative mechanisms for ^68^Ga-HBED-CC uptake within the nervous system include PSMA expression in nervous tissue, disruption of the blood-brain-barrier and PSMA expression related to neovascularisation.

POSTER PRESENTATIONS - MONDAY: Molecular Imaging: P001: Standardisation of FDG-PET/CT for Response Evaluation by RSNA-QIBA Profile: Preliminary Results of a Multicenter Study
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**Background/Aims:** International multicenter clinical trial of SP-02 (Darinaparsin) for peripheral T-cell lymphoma (PTCL) has been conducted. Therapeutic response is evaluated by FDG-PET/CT in each facility, and the imaging conditions should be standardised in advance. In this study, we show the results of standardisation by phantom tests based on RSNA-QIBA profile.\[[@ref172]\] **Methods:** We performed phantom test for each scanner in the participating facilities before patient enrolment. The institutional review board approved the clinical trial in each center. We used National Electrical Manufacturers Association (NEMA) International Electrotechnical Commission (IEC) Body Phantom and adjusted parameters of imaging equipment to meet the criteria for standardisation in compliance with RSNA-QIBA profile^1^ and Japanese guideline for the oncology FDG-PET/CT data acquisition protocol.\[[@ref173]\] The imaging parameters included acquisition time per bed position, time from ^18^F-FDG dosing until scan, and image reconstruction parameters. **Results:** Twenty-five facilities participated in this trial. Sixteen sites (64%) were required to change one or more parameters. Acquisition time per bed position had to be changed in 5 sites (20%). Time from ^18^F-FDG dosing until scan and image reconstruction parameters were altered in 3 sites (12%) and 16 sites (64%), respectively. After adjustment, we confirmed that the image quality met the criteria for standardisation. **Conclusion:** We performed the standardisation of imaging conditions, which was needed for evaluation by PET/CT image in a multicenter study.

P002: Utility of Molecular Breast Imaging as a Secondary Screening to Detect Breast Cancer Among Patients with Dense Breasts on Mammography: A Case Series
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**Background/Aims:** Breast density has been shown to be an independent risk factor for developing breast cancer.\[[@ref174]\] Molecular breast imaging (MBI) is a new nuclear medicine procedure that uses dual head cadmium zinc telluride (CZT) gamma camera to image functional uptake of radiotracer, ^99m^Tc-sestamibi.\[[@ref175]\] The aim is to demonstrate the use of molecular breast imaging (MBI) as a secondary screening to detect breast cancer among patients with dense breasts. **Methods:** A retrospective chart review of 3 patients with dense breasts who underwent molecular breast imaging, targeted breast ultrasound and biopsy was done. **Results:** Case1: 47 year old woman with dense breasts with cluster of microcalcifications on the right breast on mammogram. MBI showed an avid lesion at the upper outer quadrant of the right breast (with tumour to background ratio of 2.5). Biopsy revealed ductal carcinoma in situ. Case 2: 70 year old woman with palpable mass on the right breast. Mammogram showed dense breasts and microcalcifications. Ultrasound shows a right breast mass with microcalcifications. MBI showed avid lesion in the right sub-areolar area (with tumour to background ratio of 12.8). This corresponds to the palpable concern. Biopsy showed invasive ductal carcinoma. Case 3: 78 year old woman with dense breasts on mammogram. MBI showed mildly avid lesion in the upper outer quadrant of the left breast (tumour to background ratio of 2.3). Biopsy showed lobular carcinoma in situ. **Conclusion:** This case series shows that MBI can be used as a secondary screening to detect localized breast cancer among patients with dense breasts.

P003: Accurate Attenuation Correction for Simultaneous Positron Emission Tomography/MR Based on a Deep Learning Segmentation Method
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**Background/Aims:** The calculation of accurate attenuation correction maps (μ-maps) remains one of the major challenges for quantitative PET imaging with simultaneous PET/MRI scanners. Rapidly increasing computational capabilities enable usage of more complex models, such as deep learning, for tissue segmentation.\[[@ref176][@ref177]\] In this work, we present results of an application of a deep learning-based model\[[@ref178]\] for accurate tissue segmentation of MRI head images. **Methods:** Six subjects were scanned using a 3T PET/MRI scanner (Biograph mMR, Siemens, Erlangen, Germany). Dual ultra-short time echo (dUTE), T1w MPRAGE, and T2w sequences were acquired for m-map generation. Five subjects underwent PET scanning with 100MBq ^18^F-FDG tracer. Approval was granted by the institutional ethics committee. The neural network used for segmentation consists of a 49-layer deep residual encoder and a 10-layer deep convolutional decoder.\[[@ref178]\] The output of the network is a classification of each pixel as bone, tissue or air. The deep learning-based method (μ-map~DL~) was compared with μ-maps based on manually segmented images (μ-map~ref~), a vendor-provided technique (μ-map~UTE~), and state-of-the-art technique\[[@ref179]\] (μ-map~pCT~). In order to compare the PET reconstructed images, the μ-map~ref~-based PET (PET~ref~) image was taken as the reference. **Results:** We found significant improvements in bone segmentation using our technique. The greatest improvement was observed in the cervical vertebrae and skull base. The reconstructed PET images showed significant improvements in activity assessment in the whole brain using the proposed technique. Calculated mean relative error for the whole brain is smaller for PET~DL~ (-0.9%) compared to PET~pCT~ and PET~UTE~ (-3.6% and 1.7%, respectively). **Conclusion:** The proposed method shows significant improvements in segmentation in nasal cavities, vertebrae, and other extracranial regions, resulting in more accurate quantitative PET images throughout the whole head. The results provide proof-of-principle for deep learning-based segmentation as a method which could solve the attenuation correction issue for simultaneous PET/MR imaging.
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**Background/Aims:** Validation of a dose modelling approach\[[@ref180]\] to determine an optimum dose of the PET radiopharmaceutical ^124^I-Girentuximab\[[@ref181]\] for detection of clear cell renal carcinoma (ccRCC) in clinical trials. **Methods:** PET imaging data were acquired on a variety of PET/CT scanners and partitioned into subsets, which were sequentially added to provide images containing an increasing fraction of total events corresponding to different virtual dose levels (VDL). The SNR from ROIs placed over a number of tissues identified on CT scans was determined and compared with the conventional un-partitioned PET scan for each VDL. These results were used to determine potential dose levels that would provide adequate image quality. Images corresponding to 3 different VDLs were selected for a blinded read. The results from central pathology served as standard of truth for diagnostic classification. **Results:** A total of 60 subjects were analysed. Results from central pathological evaluation classified 43 as positive and 17 as negative for ccRCC. Curves presenting the examined SNR over VDL were used to derive graphically the SNR level in the renal mass where the partitioned data from abdominal scans in 3D reached a) the value from the whole body scan and b) a plateau. This predicts that a dose level of 0.3-0.4 full dose would not substantially diminish image quality and no significant loss in sensitivity or specificity would be expected in a blinded read. The following VDLs were selected for the blinded read: a) 20% minimum modelled VDL b) 40% average VDL yielding a similar SNR as full dose level images c) 100% full dose level. **Conclusion:** The presented approach was able to accurately predict the reduced dose level where image characterisation in terms of positive or negative for ccRCC would not be compromised. It allows faster determination of required dose levels without the need for dose escalation studies and repeated expert reading of images.

**Disclosure of interest:** M. Bronzel Conflict with: project funded by Wilex, K. Schmidt Conflict with: project funded by Wilex, N. Bitterlich Conflict with: project funded by Wilex, R. Bartz Conflict with: employee of Wilex, A. Kluge Conflict with: co-founder of Telix, Conflict with: project funded by Wilex.

P005: Using Molecular Imaging Techniques to Monitor Tumour Onset and Progression in a Murine Transgenic Osteosarcoma Model
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**Background/Aims:** Animal models to study human diseases need to be as reliable and reproducible as possible to allow evaluation of new therapeutic drugs. The aim of the study was to develop a method using molecular imaging techniques to monitor onset of disease and tumour progression in a genetic mouse model of osteosarcoma (OS) (*Osx*-Cre^+^ p53^fl/fl^ pRb^fl/fl^). **Methods:** *Osx*-Cre^+^ p53^fl/fl^ pRb^fl/fl^ mice were bred as described previously.\[[@ref182]\] All animal studies were approved by the Austin Hospital Animal Ethics Committee and were conducted in compliance with the Australian Code for the care and use of animals for scientific purposes. ^18^F-fluoride (^18^F-NaF)-positron emission computed tomography (PET)/magnetic resonance imaging (MRI) was used on a fortnightly basis starting at 12 weeks of age to determine onset of OS disease. Tumour volume was assessed using T1 MRI/T2 MRI and computed tomography (CT). Comparative imaging in mice showing focal ^18^F-NaF uptake in bone, was done with ^18^F-fluorodeoxyglucose (^18^F-FDG)-PET and ^99m^Tc-methyldiphosphonate (^99m^Tc-MDP). **Results:** ^18^F-NaF PET was more sensitive than ^18^F-FDG PET for early detection of OS lesions. ^18^F-NaF was localized in the bone whereas ^18^F-FDG localized in the soft tissue component of the tumour. ^18^F-NaF and ^99m^Tc-MDP showed uptake in the same lesions, but ^18^F-NaF showed more contrast with background. As determined by volume of interest (VOI) analysis, ^18^F-NaF tumour uptake increased over time with increasing tumour volume. The therapeutic window for jaw bone OS lesions was 2 to 3 weeks and for leg OS lesions 5 to 6 weeks. **Conclusion:** ^18^F-NaF PET in combination with ^18^F-FDG PET and MRI provides the ability to use murine transgenic osteosarcoma models for the evaluation of new cancer therapeutic drugs.

P006: Chemical Conjugation with Evans Blue Derivative: A Novel Strategy to Develop RGD-Based Theranostics through Albumin Binding
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**Background/Aims:** In this study, we proposed a novel platform for developing long-lasting theranostic RGD agent by conjugating a small molecular albumin binding moiety, truncated Evans blue (EB), to RGD peptide. We'd like to evaluate whether the radiolabelled EB conjugated RGD (EB-RGD) could be used for PET imaging and targeted radiotherapy in integrin α~v~β~3~ positive tumour. **Methods:** The EB-RGD conjugate was labelled with either ^64^Cu for *in vitro* cell study and *in vivo* PET imaging, or with ^90^Y for α~v~β~3~-targeted radiotherapy. *In vitro* cell uptake/internalization studies were performed on U87MG, MDA-MB-435 and HT-29 tumour cells, *in vitro* cell binding assay was performed on U87MG cells to determine the α~v~β~3~ receptor binding affinity of EB-RGD. *In vivo*, ^64^Cu-NOTA-EB-RGD PET was tested in U87MG, MDA-MB-435 and HT-29 tumour-bearing mice. The therapeutic anticancer effect of ^90^Y-DOTA-EB-RGD (200, 100 or 50μCi) applied as fractionated injections was investigated in different groups of mice by monitoring tumour size and body weight of treated mice. ^18^F-FDG and ^18^F-FLT PET were performed to evaluate the ^90^Y-DOTA-EB-RGD therapy response. The animal experimental study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Xiamen University. **Results:** *In vitro* cell binding assay revealed that EB-RGD has the similar α~v~β~3~ receptor binding affinity as compared to RGDfK. Cell uptake and internalization demonstrated that ^64^Cu-NOTA-EB-RGD has high uptake/internalization values in α~v~β~3~-positive tumour cells and was α~v~β~3~-specific. *In vivo* PET imaging studies showed that the tumour uptake of ^64^Cu-NOTA-EB-RGD increased with time and the highest uptake value reached 16.64±1.99 %ID/g (at 24 h after injection). Regarding targeted radiotherapy, ^90^Y-DOTA-EB-RGD revealed a great remission of tumours in the 200 μCi treated group. Both ^18^F-FDG and ^18^F-FLT PET imaging revealed a reduction of cell metabolic/proliferative activity in the 200μCi ^90^Y-DOTA-EB-RGD treated group. **Conclusion:** The chemical conjugation of a RGD peptide with an albumin binding entity EB resulted in a significant increase of the tumour uptake and tumour retention time of radiotracer, enabling the preclinical application of integrin α~v~β~3~-targeted radiotherapy in mice. This strategy as a general technology platform can be applied to other biologics for the development of long-acting theranostic drugs.
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**Background/Aims:** PET is a widespread functional imaging tool in the pre-surgical evaluation of patients suffering from epilepsy disorders. In PET, epileptogenic regions show a decreased glucose metabolism, however, precise detection of hypo-metabolic spots depends on SNR and image quality. Over or under iterations can create noise and artifacts. Pointing to the significance of optimal iteration cut off. In this study. We evaluate the influence of PET reconstruction parameters on quantitative results by means of variations in Z-score and SUVmax values. **Methods:** We apply 234 different combinations of iterations (i), subsets (s) and smoothing filter (G) with/without resolution recovery (HD/i-3D) on PET image data acquired by SIEMENS Biograph6 PET/CT scanner. Furthermore, PET images were attenuation corrected using low dose CT images (80-130 kV, 50-80 mAs). The reconstructed PET images were normalized to Talairach stereotactic atlas of human brain and variations in z-scores were reported as functional deficit cerebral zones, using Scenium software.\[[@ref183]\] As compared to FBP, iterative reconstruction methods provide images with better spatial resolution and improved SNR and image quality.\[[@ref184][@ref185][@ref186][@ref187]\] **Results:** The outcomes showed that reconstruction parameters can affect Z-scores and SUV~max~ up to 20% in comparison to reconstruction settings provided by software normal database. Also, it is defined that resolution recovery can influence the quantitative assessment. Variations up to 28% and 22% in SUV~max~ values in i-3D and HD reconstructions were seen respectively. Moreover, Variations up to 20% in z-score values in i-3D and HD reconstructions were seen resulting in many false positive epileptogenic sites. **Conclusion:** As quantitative and semi-quantitative information derived from ^18^F-FDG brain PET images can be strongly affected by noise, optimized reconstruction settings should be implemented. Various reconstruction settings can affect z-score and SUV~max~ differently. Thus, accurate use of reconstruction parameters has a vital role in diagnosis, characterisation and treatment response.

P010: Added Value of Combined Visual and Quantitative Analysis for Localizing Epileptic Regions with FDG Positron Emission Tomography Imaging
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**Background/Aims:** FDG Brain PET is a precious paraclinical tool for the evaluation of patients with epilepsy who are under assessment for surgical treatment. With the widespread availability of PET, identifying the functional deficit and preoperative evaluation of partial epilepsy has become a practical routine method. The aim of our study was to assess the efficacy of quantitative software-aided approach in localizing epileptic brain disorders using ^18^F-FDG brain PET scan in addition to the physician qualitative interpretation. **Methods:** The subject selection in our study was concentrated on patients who suffered from epilepsy disorders and referred for brain PET imaging. Thirteen patients (6 men; 5 women; 25±11 year old) underwent PET scan. Quantitative analysis was investigated using Scenium software, a statistical analysis tool providing z-score.\[[@ref188]\] The hypometabolic foci are defined as more than 2SD from the average of count/voxel for each region of the brain cortex using a standard database. The patients were categorized into normal cerebral gray matter (n=5) and local cerebral lesion (n=6) on the basis of MRI findings. Two physicians reported the qualitative findings of PET scans. Kappa concordance measure was used for statistical analysis. Ethics approval code:(IR. SSU. MEDICINE. REC.1395.293). **Results:** The Kappa index value for the localization agreement between MRI and PET/CT was 0.8 for both assessment methods. In the absence of MRI abnormality, the relative frequencies of localized spots were 60 and 100 for qualitative and quantitative diagnosis, respectively. Furthermore, these values were 83 and 100 while the MRI demonstrated abnormal foci. **Conclusion:** Destructive effects of epilepsy, declines the quality level of life, thus accurate diagnosis becomes very important.\[[@ref189]\] The foregoing study shows the added value of quantitative analysis on diagnosis of epileptogenic sites alongside visual analysis. In fact, it can be a potent supplementary to other modalities like MRI and EEG in surgical treatments of epilepsy disorders.\[[@ref190]\]

P011: Evaluation of Techniques for Data-driven Positron Emission Tomography-alone Motion Tracking
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**Background/Aims:** Patient motion during neurological positron emission tomography (PET) corrupts images, causing blurring and quantitation error due to misalignment with an attenuation correction image. Data-driven techniques for tracking motion in PET imaging allow for retrospective motion correction, where motion may not have been prospectively anticipated. **Methods:** A Hoffman phantom was filled with 65MBq of ^18^F-FDG. A three minute PET acquisition was acquired on a Biograph mCT Flow, during which the phantom was rocked, simulating periodic motion with varying frequency. Motion was tracked using the sensitivity method,\[[@ref191]\] the axial centre-of-mass (COM) method,\[[@ref192]\] a modified 3D COM method, and the principal component analysis (PCA) method.\[[@ref193][@ref194]\] A separate two minute acquisition was acquired with no motion as a gold standard. The tracking signal was discretised into a gating signal using k-means clustering. Motion was modelled and corrected using the reconstruct-transform-add (RTA) technique,\[[@ref195]\] leveraging the Advanced Normalisation Tools (ANTs)\[[@ref196]\] for rigid registration of non-attenuation-corrected 4D PET and the Software for Tomographic Image Reconstruction (STIR)\[[@ref197]\] for PET reconstructions. Evaluation was performed by segmenting white and grey matter from the attenuation correction CT, and analysing the separability of the distribution of activity in the two classes, measured by the t-statistic. **Results:** Resulting t-statistics were *t*=143.0 without correction, *t*=149.3 for sensitivity, *t*=175.7 for COM (axial), *t*=244.5 for COM (3D), *t*=348.5 for PCA and *t*=307.7 for the gold standard. These results are listed in order of subjective evaluation of image quality. The lower t-statistic for the gold standard compared with PCA in this experiment is attributed to a higher image variance, due to a shorter acquisition time. **Conclusion:** PCA is demonstrated to be most effective for tracking rigid periodic motion. The sensitivity and COM (axial) techniques are mostly sensitive to axial motion, and so were ineffective in this phantom experiment. COM (3D) demonstrates improved transaxial motion sensitivity, but not to the level of effectiveness of PCA. Future work could focus on comparing alternative components of the PET-alone motion correction process, such as the means of discretisation or registration.
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**Background/Aims:** CLR1404 is a cancer-selective alkyl phosphocholine (APC) analogue that can be radiolabelled with ^124^I for PET imaging and ^131^I for targeted radiotherapy and/or SPECT imaging. Studies have demonstrated avid CLR1404 uptake in a broad spectrum of preclinical tumour models.\[[@ref198]\] The purpose of this pilot trial was to demonstrate avidity of ^124^I-CLR1404 in human brain tumours. **Methods:** 12 patients (8 men and 4 women; mean age 43.9±15.1 years; range 23-66 years) with 13 tumours were enrolled. Eleven patients had suspected tumour recurrence and 1 patient had a new diagnosis of tumour. Patients were injected with 185 MBq ± 10% of ^124^I-CLR1404 followed by PET/CT imaging at 6, 24, and 48 hours. ^124^I-CLR1404 PET uptake was compared with MRI. SUV values and tumour to background ratios were calculated. **Results:** There was no significant uptake of ^124^I-CLR1404 in normal brain. In tumours, uptake was detected in 9 of 13 lesions: 5/5 high grade tumours, 1/2 low grade tumours, 1/1 meningioma, and 2/4 patients with treatment related changes. ^124^I-CLR1404 uptake was not detected in 1/2 low grade tumours, 2/4 lesions from treatment related changes, and 1/1 indeterminate lesion. For 6 malignant tumours, the average tumour to background ratios (TBR) were 9.32±4.33 (range 3.46-15.42) at 24 hours and 10.04±3.15 (range 5.17-13.17) at 48 hours. For 2 lesions from treatment related change, the average TBR were 5.05±0.4 (range 4.76-5.33) at 24 hours and 4.88±1.19 (range 4.04-5.72) at 48 hours. PET uptake had areas of both concordance and discordance compared with MRI. **Conclusion:** ^124^I-CLR1404 PET demonstrated avid tumour uptake in a variety of brain tumours with high tumour-to-background ratios. There were regions of concordance and discordance with MRI. Expansion of these studies is required to delineate the clinical significance of PET findings.

P013: Usefulness of Cu-64-labelled Cetuximab Positron Emission Tomography Screening to Predict Response to Cetuximab Treatment in Nonsmall Cell Lung Cancer
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**Background/Aims:** An anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, was considered to be a promising therapeutic option for the treatment of patients with EGFR-positive non-small cell cancer (NSCLC). However, cetuximab was not approved for the treatment of NSCLC partially because of the lack of the means to predict and select responder before treatment. It can be postulated that the tumour accumulation level and intra-tumour distribution of cetuximab would affect the therapeutic outcome of the treatment. Therefore, we investigated the association between the tumour accumulation of radiolabelled cetuximab and expression levels of EGFR. **Methods:** DOTA conjugated cetuximab was prepared and labelled with ^111^In or ^64^Cu. Six lung cancer cell lines with various EGFR expression levels and KRAS mutation status were used to prepare the respective tumour-bearing mice. Biodistribution studies or PET imaging were performed to compare the tumour uptake levels of ^111^In-or ^64^Cu-cetuximab in the xenograft tumours. The EGFR expression levels on the tumours were determined by ex vivo immunoblotting. **Results:** The highest uptake of ^111^In-cetuximab was found in the HCC827 tumour that has the highest expression levels of EGFR. PET imaging also demonstrated that the accumulation levels of ^64^Cu-cetuximab in the H827 tumour was higher than any other xenograft tumour. SUV~max~ of the HCC827 tumour and other cell lines were 9.4 and 4.7-6.8, respectively. Meanwhile, there was no correlation between tumour accumulation level and SUV~max~ of the xenograft tumours with EGFR expression level or KRAS mutation status. **Conclusion:** These findings suggest that ^64^Cu-cetuximab-PET has a potential to predict cetuximab accumulation level in NSCLC, which may enable proper patient screening.

P016: Development of Human Sodium/Iodide Symporter Transgenic Mouse as Resource of Stem Cells for In vivo Cell Tracking
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**Background/Aims:** A human sodium/iodide symporter (hNIS), a transmembrane glycoprotein of thyroid follicular cells, mediates uptake of iodine into the cells. Thus, hNIS gene has been used as a reporter gene combined with radioiodine or ^99m^TcO~4~^-^as its reporter probe; cell lines stably expressing hNIS gene can be tracked *in vivo* in mice. However, stable cell lines cannot be made with stem cells, because they differentiate during the procedure. In the current study, to obtain stem cells that innately uptake radioiodine and ^99m^TcO~4~^-^, we developed a transgenic mouse systemically expressing hNIS gene. **Methods:** hNIS genes driven by a CAG promotor were transferred into fertilized ova of C57BL/6N mice by the microinjection method. All animal experimental studies had prior Ethics Approval from institutional authorities. **Results:** Three founder lines were established from 5 founder mice. Biodistribution studies of ^99m^TcO~4~^-^in the transgenic mice showed increased uptake into various organs including bone marrows, and decreased uptake into thyroid glands and stomach compared with wild-type mice. Fluorescence in situ hybridization (FISH) and real-time polymerase chain reaction (PCR) confirmed physical mapping and copy numbers of the hNIS gene in each line of the transgenic mice. Small-animal SPECT imaging using ^99m^TcO~4~^-^and small-animal PET imaging using ^124^I could detect *in vivo*, the hNIS expressing stem cells (1x10^6^ and 1x10^5^ cells, respectively) derived from the transgenic mice and transplanted subcutaneously into nude mice. **Conclusion:** We developed a transgenic mouse systemically expressing a hNIS gene, which must contribute to regeneration medicine researches as a resource of stem cells innately enabling *in vivo* cell tracking in mice.

P017: Characteristics of a Small-Animal SPECT/Positron Emission Tomography Myocardial Imaging with a Clustered Multi-pinhole Collimator-Myocardial Phantom Study
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**Background/Aims:** A small-animal SPECT-PET/CT system with a clustered multi-pinhole collimator enables a high resolution PET imaging without coincidence counting as well as SPECT imaging. In nuclear cardiology, it is important to grasp differences and information among images obtained by some radionuclides. The aim of this study was to reveal each characteristic of myocardial images using four radioactive tracers. **Methods:** Data acquisition was performed using a small animal SPECT-PET/CT system equipped with a clustered multi-pinhole collimator. A myocardial phantom simulated a normal and a defective myocardium was used. The portion of defective myocardium set on an anterior wall, and the size of length and width and depth were 9, 3 and 1 mm, respectively. The phantom was filled with ^99m^Tc, ^123^I, ^201^Tl or ^18^F solution individually. Projection data was reconstructed by a pixel-based ordered-subsets expectation maximization algorithm with Gaussian filter. All images were not applied both scatter and attenuation corrections. For assessment, the percentage of uptake (%uptake) and the percent coefficient of variation (%CV) of 17 segments in a normal myocardium, and %uptake in a defective myocardium was calculated using a polar map, respectively. **Results:** Each %uptake of ^99m^Tc, ^123^I, ^201^Tl and ^18^F in the normal myocardium was from 89% to 98%, 82% to 95%, 75% to 96% and 86% to 95%, respectively. The minimum and maximum values of %CV were 2.8 and 5.6 which were calculated by ^99m^Tc and ^201^Tl, respectively. In addition, the average %uptake in defective segments was 29%, 38%, 36% and 31% for ^99m^Tc, ^123^I, ^201^Tl and ^18^F, respectively. **Conclusion:** It was indicated that there were unique characteristics of each image obtained by ^99m^Tc, ^123^I, ^201^Tl and ^18^F. Those findings may contribute to assess the myocardial imaging and the multi radionuclides acquisition in a small-animal SPECT-PET/CT system.

P018: Impact of Target-to-Background Ratio on Lesion Detectability Performance for Low-Dose
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Y Positron Emission Tomography-Computed Tomography Imaging: A Phantom Study
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**Background/Aims:** The aim of this study was to investigate the impact of target-to-background ratio (TBR) on lesion detectability performance and quantitative accuracy using PET/CT imaging of low-dose ^90^Y for the purpose of dosimetry. **Methods:** In this study a Jaszczak phantom containing five hot syringes (internal diameters 30.5, 22, 17.5, 13.65, and 9.15 mm), was imaged via a Siemens Biograph 6 True Point PET/CT scanner. To apply four target-to-background ratios (TBR1, 10:1; TBR2, 20:1; TBR3, 40:1; and TBR4, 80:1), the syringes were filled with various uniform concentrations of ^90^Y (activity concentration range, 2.07 MBq/mL to 14.03 MBq/mL). The phantom was imaged for 45 minutes and the raw data were reconstructed for 128 various parameters/algorithms. For the optimized reconstruction parameters, the quantitative accuracy and detectability performance were evaluated using contrast-to-noise-ratio (CNR) and recovery-coefficient (RC), taking partial volume effects (PVEs) into account. **Results:** In this study, the optimized reconstruction parameters regarding higher detectability and quantification performance are identified.\[[@ref199]\] Thus, the higher TBR led to higher detectability performance, regardless of the lesion size and activity concentration. For TBR3 and TBR4, all the syringes were detectable using the optimized reconstruction parameters. Syringes with diameter greater than 13.65 mm were detectable for all the TBRs. The recovered activities were underestimated generally with the highest underestimation for TBR1 decreasing to the lowest for TBR4. For TBR3 and TBR4 the amount of underestimation is less than 15%. The amount of underestimation for lesions with diameters greater than 17.5 mm and 13.65 mm were limited to −15% for TBR1 and TBR2 respectively. **Conclusion:** For depicting the distribution of ^90^Y, PET/CT imaging even with a low TBR is feasible above a given threshold for the lesion size and activity concentration. PET/CT imaging of lower TBRs could be fruitful by increasing the scan duration or activity concentrations using the optimized reconstruction parameters.

P019: Altering Blood-Brain Barrier Permeability to Enhance Brain Drug Delivery of Therapeutic Macromolecules
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**Background/Aims:** Glioblastoma multiforme (GBM) is the most common malignant primary brain tumour. Despite progress in current medical treatments, the mortality of GBM remains high. Herein, we describe the use of radiation therapy (RT), a mainstay of GBM treatment, as a blood-brain-barrier disruption (BBBD) strategy to enhance drug delivery of otherwise impermeable macromolecules to the brain. The goal is to identify the parameters for obtaining RT-induced BBBD, and enhanced size-dependent macromolecule drug delivery of antibody-based structures. **Methods:** All animal studies were conducted with approval from the Institutional Animal Care and Use Committee (IACUC) of Duke-NUS. BBBD was induced with 20 Gy RT beam focused on the right brain hemisphere of naïve nude mice using a Small Animal Radiation Research Platform (SARRP, University of Pennsylvania, USA) or a clinical irradiator (Clinac IX, Varian Medical System, National Cancer Centre Singapore). γH2Ax imaging of brain sections was used to validate hemi-brain irradiation using both approaches. Two antibody-based formats of different molecular weight, ^125^I-IgG (160 kDa) and ^125^I-scFv-Fc (120 kDa), were injected intravenously 24 hours prior to harvesting of whole brain between 1 and 16 days post-RT to quantify BBB permeability. SPECT-CT imaging, and autoradiography was used to identify pattern of brain uptake of radiotracers. **Results:** γH2Ax staining confirmed targeted irradiation on the right hemisphere of the brain 3 hours post-irradiation, with significant BBBD as early as 7 days post-RT. No size-dependent difference was observed between the two antibody formats. Tracer uptake in brain reverted back to baseline at 16 days post-RT. SPECT/CT imaging and DAR confirmed brain distribution of tracer aligned with irradiation field. **Conclusion:** RT temporarily permeabilises the BBB to allow enhanced brain delivery of different antibody formats. Preliminary results suggest that RT will induce focused disruption of the blood-brain tumour barrier to enhance tumour-specific uptake of targeted macromolecule therapeutics.

P020: Biological Evaluation and Micro-Positron Emission Tomography Imaging of
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Ga-DOTA-PA1 in a Mouse Model of Human Lung Cancer: A Novel Positron Emission Tomography Tracer Expand Somatostatin Receptor Imaging
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**Background/Aims:** Most of the radiolabelled somatostatin analogues (SSAs) are specific for subtype somatostatin receptors 2 (SSTR~2~). Lack of ligands targeting other subtypes of SSTRs, especially SSTR~1,~ SSTR~3~ and SSTR~5~, limited their applications in tumours of low SSTR~2~ expression, including lung tumour. In this study, we aimed to design and synthesize a positron emission tomography (PET) radiotracer targeting multi-subtypes of SSTRs for PET imaging. **Methods:** PA1 peptide and its conjugate with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator or fluorescein isothiocyanate (FITC) at the N-terminal of the lysine position were synthesized. ^68^Ga was chelated to DOTA-PA1 to obtain ^68^Ga-DOTA-PA1 radiotracer. The stability, lipophilicity, binding affinity, and binding specificity of ^68^Ga-DOTA-PA1 and FITC-PA1 were evaluated by various in-vitro experiments. Micro-PET imaging of ^68^Ga-DOTA-PA1 was performed in nude mice bearing A549 lung adenocarcinoma, as compared with ^68^Ga-DOTA-TATE. Histological analysis of SSTRs expression in A549 tumour tissues and human tumour tissues was conducted using immunofluorescence staining and immunohistochemical assay. All animal experiments were conducted in accordance with the guidelines approved by Peking University Cancer Hospital Animal Care and Use Committee. **Results:** ^68^Ga-DOTA-PA1 had high radiochemical yield and radiochemical purity of over 95% and 98%, respectively. The radiotracer was stable in vitro in different buffers over a 2-h incubation period. Cell uptake of ^68^Ga-DOTA-PA1 was 1.31-, 1.33-and 1.90-fold of that of ^68^Ga-DOTA-TATE after 2 h incubation in H520, PG and A549 lung cancer cell lines, respectively. Micro-PET images of ^68^Ga-DOTA-PA1 showed that PET imaging signal correlated with the total expression of SSTRs, instead of SSTR~2~ only, which was measured by western blotting and immunofluorescence analysis in mice bearing A549 tumours. **Conclusion:** A novel PET radiotracer, ^68^Ga-DOTA-PA1, targeting multi-subtypes of SSTRs was successfully synthesized and was confirmed to be useful for PET imaging. It may have potential as noninvasive PET radiotracer for imaging SSTRs-positive tumours.

P021: Intracellular Formation of AgI and its Effects on Retention of Radioactive Iodine in in Thyroid Cancer Cells
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**Background/Aims:** To increase the retention of radioiodine in cells through the formation of AgI in thyroid cancer cell. **Methods:** AgI nanoelustem were successfully prepared by using PEI dendrimers as templates in water system. Inorganic iodine ions were labelled at the end of the PEI molecule by linking the arginine molecular analog, 3-(4-hydroxy phenyl) propionic acid. Silver ions were introduced into PEI in situ by complexing methods to form PEI-organic iodine-AgCl nanoclusters (PEI-Ag nanoclusters). The characterisation, cytotoxicity and intracellular Ag ion concentration of PEI-Ag nanoparticles were detected by scanning electron microscopy, UV absorption spectra, MTT cytotoxicity test and ICP element assay. The thyroid papillary carcinoma cell line K1 was used as an iodine uptake cell to compare the changes in the retention of ^125^I after cell uptake of PEI-Ag nanoclusters. **Results:** Scanning electron microscopy showed that the size distribution of PEI-Ag nanoclusters was uniform, and the size was about 100 nm. UV absorption spectra show a visible absorption peak at 430 nm wavelength. In the cell experiments of PEI-Ag nanoclusters, no obvious cytotoxicity was observed, and the amount of silver ions entering the cells increased with time. After the addition of radioactive ^125^I, the amount of ^125^I retention in K1 cells increased significantly, and increased by 18%±5.4% in 10-120 minutes. **Conclusion:** PEI-Ag nanoclusters carrying silver ions into thyroid cancer cells can significantly increase the retention of radioactive ^125^I in cells.

P022: Independent Component Analysis of Functional Positron Emission Tomography Using a Continuous Infusion FDG Protocol
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**Background/Aims:** The recent development of constant infusion dynamic ^18^F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET), knowns as functional PET (fPET), can detect glucose utilisation change in the brain in semi-real time.\[[@ref200][@ref201]\] The General Linear Model (GLM) method was used to extract the task-specific glucose activation map.\[[@ref200][@ref201]\] However, GLM method relies on the temporal information, which is not available in many applications. To overcome this problem, we present a work using independent component analysis (ICA), a data-driven method,\[[@ref202]\] to obtain the task related activation map and its associate timecourse without the temporal knowledge. **Methods:** A group of 10 subjects were scanned on a 3T Siemens Biograph mMR. The study was approved by the institute ethics committee. Each participant was injected 100MBq ^18^F-FDG at a constant rate 36mL/hr over 90 minutes. All participants were asked to take part in three visual tasks (8Hz flickering checkerboard with 16/32 seconds of alternating off/on) during scan, one 10 minutes full board and two 5 minutes half checker board (left/right). The PET listmode data was binned into 1 minute frame, and reconstructed using ordered subset expectation maximisation (OSEM) with pseudo-CT attenuation correction and point-spread function correction. The 90 frames dynamic images were motion corrected.\[[@ref203]\] In the individual task analysis, 90 frames data were truncated into three segments corresponding to three tasks, respectively. **Results:** In the 90 frames full data analysis, the strong activation in visual cortex was identified in group analysis by using fastICA algorithm. The associate timecourse shows higher glucose utilisation change in visual cortex than the average change of overall gray matter during the task activated time. The strong visual cortex activation map can be obtained in 8 of 10 subjects in the single subject analysis. In individual task analysis, the strong activation map and expected timecourse were obtained in the full and the first half checkerboard tasks. The result of second half checkerboard tasks was weak. **Conclusion:** The task-specific fPET ICA analysis can succesfully extract both spatial and temporal information, which are consistent to the expectation of designated tasks. The ICA method can be potentially used to analyse the resting-state fPET.

P023: Radiolabelling of Extracellular Vesicles by Targeting Externalized Phosphatidyl-Ethanolamine
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**Background/Aims:** Cell-derived extracellular vesicles (EVs), including microvesicles and exosomes, contribute to the pathogenesis of various human diseases and have great potential as diagnostic or therapeutic targets. Externalization of phosphatidyl-ethanolamine (PE) and phosphatidylserine (PS) to the outer leaflet of the plasma membrane is a feature of EV formation. The objective of this study was to explore the feasibility of radiolabelling EVs using a PE specific molecular probe, ^99m^Tc-duramycin (^99m^Tc-DUR). **Methods:** EVs isolated from MCF-7 breast cancer (BC) cell culture media were characterized by flow cytometry (FCM) and transmission electron microscope analysis (TEM). EV sample (100 µg) in PBS was incubated with 185MBq ^99m^Tc-DUR generated from hydrazinonicotinamide-conjugated duramycin for 30-min followed by removal of free ^99m^Tc-DUR. Using SPECT imaging, distribution of intravenously injected ^99m^Tc-DUR-EVs was evaluated in healthy BALB/c mice (n=4) in comparison with ^99m^Tc-DUR (n=4). A direct charged-particle imager was applied to assess the distribution of topically administered ^99m^Tc-DUR-EVs in a mouse dorsal skin-fold window chamber (DSFWC) model implanted with MCF-7 BC cells. **Results:** FCM with PS-targeted fluorescent probes showed that isolated EVs appeared mostly (\>85%) positive for PS. TEM images demonstrated that the spherical vesicles with various sizes (40--600 nm). After purification, radiochemical purity of labelled EVs is greater than 95% and remained about 93% after 3-h incubation with serum at 37^o^C. SPECT images showed that ^99m^Tc-DUR-EVs mainly localized in the liver, spleen, and lungs of the healthy mice and 44, 31, and 2-fold higher than ^99m^Tc-DUR in those tissues. Images collected from DSFWC demonstrated that ^99m^Tc-DUR-EVs at 5-min post-administration was overlaid in the whole window area and predominantly retained over the MCF7 lesions at 120-min. **Conclusion:** PE targeting with ^99m^Tc-DUR may provide a feasible approach for radiolabelling and tracking of EVs to gain insights into the role of EVs in cancer and other disease development. Further studies are warranted to verify the capability of radiolabelled EVs to colonize in the tumour lesions.

P024: The Assessment of Low Dose Computed Tomography Protocols on Oral Contrast Artifacts in CTAC of Positron Emission Tomography Data: A Phantom Study
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**Background/Aims:** The aim of this is to study evaluate the effect of low dose CT protocol on oral contrast artifacts in CTAC of PET data. **Methods:** To assess the effect of low dose CT protocol on quantification of PET data, a house-made phantom with 9 cylindrical phantom was utilized. There were filled in the following way: three of them just have 20cc, 30cc and 40cc concentration of O. C. A.; the next three of them contained those O. C. A. concentrations and 10.6 MBq/ml of 18F-FDG solution; the rest of them filled up with those O. C. A. concentration and 5.3 MBq/ml of 18F-FDG solution similar to the concentration of background. It was scanned with Discovery 690 GE PET/CT scanner equipped with a 64-slice CT. Low dose CT protocol with tube voltage 120kVp, 100kVp, and 80kVp and tube current (10, 20, 30, 40, and 100 mA). **Results:** CT number of 20cc, 30cc, and 40cc of O. C. A. were 133 HU, 187 HU, and 233 HU, respectively. SUVmax at 20 cc, 30 cc, and 40 cc of O. C. A. were 2.1, 2.2, and 2.2 while voltage 80 kVp and 10 mA, respectively. At 30 cc, for all three voltage and 100mA SUV~max~ was 2.2±0.3 (p\>0.05). At 40cc and 40mA, for 80kVp, 100 kVp, and 120 kVp SUV~mean~ were 0.88±0.09, 0.87±0.09, and 0.86±0.08, respectively. At 100kVp, CV were 8.13%, 8.12%, 8.11%, 8.11%, and 8.11% for 10, 20, 30, 40, and 100mA, respectively (p\>0.05). **Conclusion:** Lowering tube current in each tube voltage and by decreasing tube potential lead SUV~max~ changed less than 1% in all three concentrations of O. C. A. In addition, CV decremented 1.5% where tube potential amplified from 80 kVp to 120 kVp at 10 mA. Therefore, the new CT protocol doesn't have significant effect on PET quantification.

P025: Reducing Radiation Burden to Patients Undergoing Positron Emission Tomography-Computed Tomography and SPECT/Computed Tomography by Optimising Noise Index and Computed Tomography Dose Modulation
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**Background/Aims:** Low dose CT (ldCT) is employed in current PET/CT and SPECT/CT scanners, but poses an additional radiation burden to patients. The aims of this study were to: 1) determine the appropriate Dose Right Index (DRI) on the Ingenuity TF128 PET/CT scanner for different Body Mass Indices (BMI) that will deliver an overall reduction in radiation dose to the patient, and 2) standardise the kV with regards to patient weight with a constant noise index whilst remaining under the Diagnostic Reference Level (DRL) on the GE Discovery 670 SPECT/CT scanner. **Methods:** PET/CT-the Dose Length Product (DLP) received with ldCT was used as a reference point for each patient. A region of interest was drawn within the abdominal aorta at the level of the kidneys, for all patients. The Hounsfield Unit values and Standard Deviation (SD) values were recorded. For different DRI, the SD was plotted against the BMI. For SPECT/CT (ldCT acquired for VQ lung scans) the noise index was kept constant at 30, whilst the kV varied between 100 kV for small patients, 120 kV for medium size patients and 140 kV for large patients. Images were qualitatively analysed by experienced nuclear medicine physicians. **Results:** Results show an increase in DLP as weight increases for both PET/CT and SPECT/CT. The appropriate DRI was obtained for varying BMI for PET/CT. BMI ranges of less than 22, 22.1 -- 25, 25.1 -- 30, 30.1 -- 40 and more than 40 had DRIs of 13, 12, 11, 10 and 9 respectively. A significant reduction in DLP was noted. The appropriate weight ranges were defined accordingly to the kV for SPECT/CT. Weight ranges of less than 70 kg, 70.1 kg -- 100 kg and more than 100 kg had kV of 100, 120 and 140 respectively. **Conclusion:** A 20% decrease in radiation dose to the patients (45% in some cases) for PET/CT was obtained with no impact on image quality. There was no degradation in image quality for ldCT for SPECT/CT when the appropriate kV was used according to the identified weight ranges.

P026: Preparation and Preclinical Evaluation of a Novel HER2-Targeted Combo Peptide for Diagnostic Imaging of HER2-Positive Breast Cancers
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**Background/Aims:** The human epidermal growth factor receptor-2 (HER2) is belong to the family of tyrosine kinase receptors and overexpressed in many cancers particularly in breast and ovarian. As HER2 is overexpressed at the cell surface tumour cells, the accessibility of the receptor makes it a good candidate for molecular imaging and therapy. In this study a 9-mer peptide derived from HER2 protein based on 369-377 (E75) sequence that overexpressed in many breast cancer patients is selected. Another peptide identified by phage display has shown potential for targeting HER2 expressing tumours is based on KCCYSL sequence. In an attempt to enhance targeting efficiency of HER2-targing vector we have combined the sequences of these two peptides to formulate a combo HER2-targeted peptide and investigated its potential as a tumour-targeting agent. **Methods:** The HER2-targeted combo peptide (GGC-E75+KCCYSL) was synthesised by solid-phase peptide synthesis and radiolabelled with ^99m^Tc via GGC chelating sequence. Tumour cell binding was conducted on HER2-positive SKBR3 and MCF7 breast cancer cell lines and in vivo tumour targeting was performed on nude mice with MCF7 tumour xenografts. Approval of the institutional animal care and use committee was obtained prior to the initiation of these animal studies. **Results:** The structure and purity of HER2 peptide was confirmed by mass spectrometry and HPLC. The hybrid HER2 peptide labelled efficiently with ^99m^Tc (\>90%) and exhibited a high binding affinity to HER2-positive SKBR3 and MCF7 cell lines (kd=\<50 nM). In nude mice with MCF7 xenografts, ^99m^Tc-HER2 peptide exhibited a rapid clearance from the blood and accumulation in most major organs was below 4% ID/g except the kidneys which hold a significant radioactivity (up to 14% ID/g). The uptake by the tumour was 2.10±0.67% ID/g with good tumour to blood and muscle ratios of 1.1 and 5.3. Tumour uptake was blocked by coinjection of excess HER2 peptide. Elimination of ^99m^Tc-HER2 peptide was observed both by renal and hepatobiliary pathways. **Conclusion:** The results demonstrate that novel combo HER2 targeting vector possess certain favorable preclinical characteristics that may make it a promising probe for diagnosis of HER2-positive cancers. Detailed biological evaluation is in progress to determine the full potential of this new and emerging class of tumour targeting peptides.

P027: Development of a Peptide-Based Apoptosis Imaging Agent with Improved Stability and Affinity
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**Background/Aims:** As an early marker of apoptosis, monitoring phosphatidylserin (PS) exposure on the external surface of the plasma membrane can offer information about efficacy of cancer treatment. A potential candidate as an apoptosis imaging agent is the use of a known PS-binding hexapeptide, LIKKPF, yet stability and affinity improvement are necessary. We hypothesized that bivalent, retro-inverso derivatives of LIKKPF could overcome these problems. Bivalent peptides show increased affinity due to the multivalent effect, whereas retro-inverso peptides, which has a reversed sequence with all D-amino acids, can improve stability without affecting the affinity of original L-form peptides. Therefore, we designed LIKKPF derivatives and evaluated its application as apoptosis imaging agents. **Methods:** The retro-inverso derivative of LIKKPF, fpkkil-NH~2~, was synthesised using Fmoc solid-phase synthesis. To enable radioiodine labelling, Tyr was attached to N-terminal of the monovalent peptide. To prepare a bivalent fpkkil-NH~2~ peptide blanched by glutamic acid, fpkkil-NH~2~ was reacted with Tyr-Glu at the molar ratio of 3 to 1. Each peptide was purified by RP-HPLC, and labelled with ^125^I or ^131^I. For the in vitro stability evaluation, ^131^I-fpkkil-NH~2~ was incubated in mouse serum for 6 hours at 37ºC, and the sample was analysed by RP-HPLC. The binding specificity and affinity of each ^125^I-labelled peptide was evaluated on the PS-coated 96-well plate. The radioactivity binding to well was measured by γ-counter. **Results:** We successfully prepared the bivalent fpkkil-NH~2~ peptide. In the stability study, more than 95% of ^131^I-fpkkil-NH~2~ remained intact in the serum for 6 hours. Both of ^125^I-labelled monovalent and bivalent fpkkil-NH~2~ showed specific binding to PS. The bivalent fpkkil-NH~2~ peptide showed significantly higher binding to PS than the monovalent one (24.7±1.8 and 16.8±1.5 %binding, respectively, *p*\<0.05). **Conclusion:** Our study demonstrated the potential usefulness of the bivalent fpkkil-NH~2~ peptide as an apoptosis imaging agent, which deserves further evaluation in vivo.

P028: Comparison of Interpolation Methods Used During Image Registration of Positron Emission Tomography-Computed Tomography Images

Kumar Pandey\*

Anil

1

Negi

A

1

Parida

G

1

Arora

S

1

Dhiman

V

1

Bisht

C S

1

Patel

C

1

Bal

C S

1

Kumar

R

1

Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India

**Background/Aims:** Spatial geometric transformations are performed to register PET and CT images so that the pixels representing the same structure achieve the space correspondence. In this process, image interpolation plays a significant role. It has been reported that the quality of interpolated images and hence accuracy of image registration improves at the expense of some increase in computational load. This study was conducted to compare the effect of interpolation methods on registration of PET/CT images. **Methods:** 30 transaxial slices of PET and their corresponding CT image of thirty patients were registered based on Normalized Mutual Information similarity metrics using MeVislab Registration toolkit (*MERIT*). The Registration toolkit uses nearest neighbour (N), linear (L) and cubic spline (C) interpolation method during registration when transforming the template image and also while producing output images. Each set of images were registered nine times, each time taking one from the set of nine combinations (NN, NL, NC, LN, LL, LC, CN, CL, CC; one interpolation algorithm used during the process of registration and one used to produce the result); this resulted in a set of total 270 registered images. Accuracy of image registration were visually assessed independently by two nuclear medicine physicians and a score (0-No Registration, 0.5-partial registration and 1-complete registration.) was assigned to each registered image. To find the significant difference between the scores assigned to the interpolation methods Wilcoxon rank sum test with continuity correction were applied. For statistical analysis, the free software R version 3.4.1 was used. **Results:** Highest score was assigned to NL and NC. The result of Wilcoxon rank sum test (W=452, p=0.9816) indicates that medians of these two distributions are similar at p=0.05. **Conclusion:** Both NL and NC produced similar results.

P030: The Use of Gallium-67 for Evaluating Dosimetry of a Novel Radiopharmaceutical in a Phase I Study of Prostate, Pancreatic and Bladder Cancer
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**Background/Aims:** Identifying molecular targets for cancer imaging and therapy using radionuclides is a major focus of ongoing research. Previously gamma-emitting radionuclides such as Indium-111 have been used to label monoclonal antibodies. However, the recent increase in interest in the use of the PET radionuclide Gallium-68 (^68^Ga), which due to its short physical half-life (68 mins) is not suitable for biodistribution studies over days, suggested to us that ^67^Ga (78 hr half-life) might be a suitable alternative as it is readily available and reasonably inexpensive. MIL-38 is an IgG1 murine monoclonal antibody directed against Glypican-1 (GPC-1). Pre-clinical models suggest chimeric MIL-38 (chMIL-38) is a good candidate for radioimmunotherapy. A phase 1 study of safety and tolerability of chMIL-38 conjugated with the chelator DOTA and labelled with ^67^Ga (chMIL-38-DOTA-^67^Ga = MILGa) was undertaken to assess biodistribution and dosimetry and assess safety and tolerability. **Methods:** Patients with known metastatic cancer were injected with a single dose of MILGa, +/-cold antibody 1hr prior to MILGa, and imaged with whole body gamma camera scans and SPECT/CT at multiple time points from 30 mins to 144 hours post infusion. The biodistribution of the labelled compound in the vital organs demonstrating significant uptake was determined. Blood samples for pharmacokinetics, dosimetry and biomarker studies were collected. This study has HREC approval from Macquarie University. **Results:** Nine patients with prostate, pancreatic or bladder cancer were recruited. At 30 minutes post-injection intense mediastinal uptake, corresponding to the cardiac blood pool, was demonstrated. Intense liver and spleen uptake was seen from \~30 minutes to 72 hours post-injection. There was diffuse tracer uptake in the large bowel from 48 hours onwards suggesting biliary excretion of the antibody. Cold antibody dosing led to a reduction in blood and liver uptake and showed complete washout of cardiac blood pool at 24 hours. **Conclusion:** This first-in-human study demonstrates that ^67^Ga can be used to determine biodistribution of monoclonal antibodies. Furthermore, it can be utilised in treatment planning to calculate organ dosimetry for monoclonal antibodies for subsequent ^177^Lu treatment and hence has great potential as a theranostic agent.

P031: Evaluation of Contraction Motion Compensation in Gated Myocardial Perfusion SPECT Using Intensity-and Land-Mark Based Registration Techniques
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**Background/Aims:** Cardiac contraction and respiratory motion have great impact on gated myocardial perfusion SPECT (MPS) image quality degradation, by inducing image blurring and quantification inaccuracies. Therefore, motion compensated temporal processing has a major impact on the quality of gated images. **Methods:** 50 patients without knowing heart condition underwent gated MPS. Image compensation was applied using B-spline algorithm along with affine transformation as the general transformation (FFD) and Motion Freezing application of Cedars-Sinai medical software (Cedars-Sinai, California, USA) to warp all image phases to fit the end-diastolic (ED) phase. Myocardial lateral wall thickness, myocardial to blood pool (M/BP) contrast and image CNR were measured in summed images before and after compensation with FFD and MF (BC and FFD-C and MF respectively). **Results:** Myocardial wall thickness before compensation was 5.40±3.65 mm and after compensation with FFD-C and MF were 5.39±4.38 mm (p\<0.0001) and 5.86±1.65 mm (p\<0.0001), respectively. M/BP contrast in compensated images are greater than the corresponding BC images 46% and 75% respectively (p\<0.05). CNR has increased 32% and 80% (p\<0.0001) in FFD-C and MF compared to corresponding BC images. **Conclusion:** FFD-C is a topology preserving method, transformation fields between frames are physically plausible and it doesn't need contour definition, while MF needs accurate definition of control points. FFD-C can model the non-linear motions in every pixel in myocardium; however, MF only considers motion orthogonal to endocardium and epicardium. Partial volume effect, is not displace by Thin Plate Spline (TPS) motion vectors, while FFD-C, doesn't eliminate partial volume effect, thus MF illustrates better improvement in CNR and contrast. Myocardial wall thickness significant decrease indicates, that motion blurring has been compensated in lateral wall to some extent. Both techniques improved M/BP contrast and CNR while preserving image SNR, which means signal cross contamination between myocardium and blood pool has been effectively reduced.
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**Background/Aims:** To evaluate the diagnostic utility of ^68^Ga-Pentixafor PET/CT in lung carcinoma and to correlate tumour uptake of the radiotracer with CXCR4 tumour expression/density as a function of the tumour subtype. **Methods:** Twenty-five patients (23M: 2F; mean age 60±10 years) with histopathologically proven lung carcinoma \[non-small cell lung carcinoma (NSCLC) = 19 (squamous cell in 15, adenocarcinoma in 3; NOS in 1)\], small cell lung carcinoma (SCLC) in 3 and primary lung neuroendocrine tumour (NET) in 3, underwent ^68^Ga-Pentixafor PET imaging. Biopsied lung tissue samples were subjected to fluorescence-activated cell sorting (FACS) analysis using CD184 antibody. Mean Fluorescence Index (MFI) was documented as measure of CXCR4receptor density. ^68^Ga PET/CT data was reconstructed and the estimated SUV~max~ values were correlated with FACS results for CXCR4 expression/density. **Results:** About 110-150MBq radioactivity of freshly prepared ^68^Ga-Pentixafor (synthesised by using Scintomics automated chemistry module procured under DST-FIST Project Funding) was administered intravenously. Whole body PET/CT data acquisition (3min/bed position; 7-8 positions) was started at 1-hour post injection. Data was reconstructed using iterative method (3 iterations, 28 sub-sets) and interpreted both visually and quantitatively. The mean ^68^Ga-Pentixafor SUV~max~ value in squamous cell and adenocarcinoma patients was 6.3±1.5 (n=15) and 8.5±1.5 (n=3), respectively. The corresponding MFI value assessed in these patients was 118±69 and 146±53, respectively. On the other hand, in SCLC patients (n=3), the mean SUV~max~ value was 10.4 ± 2.5 with MFI score of 151±59. In patients with primary lung NET disease (n=3), the mean SUV~max~ value was 5.1±0.03 with MFI score of 80±26. Our results demonstrated that among NSCLC patients, a significantly higher SUV~max~ was seen in adenocarcinoma variant than in squamous cell and the higher uptake correlated with higher CXCR4 expression. In SCLC, SUV~max~ value was significantly higher than in NSCLC and NET patients and was associated with the higher CXCR4expression/density in SCLC patients. **Conclusion:** ^68^Ga-Pentixafor uptake directly correlates with CXCR4 expression in lung carcinoma. SCLC demonstrates higher CXCR4 expression as compared to NSCLC.
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**Background/Aims:** To assess the value of incorporating an extra respiratory gating PET acquisition as routine protocol in assessment of lung nodules. **Methods:** 86 patients with lower zone lung nodules (ie. referral form indicates solitary pulmonary nodule or lung carcinoma) had FDG PET scan acquired using whole body flow technology in list mode with respiratory gating and reconstructed in non-gated and gated series using the Siemens mCT PET/CT scanner over a 6 month period. Images were de-identified, the gated and non-gated PET-CT acquisitions separated, and shown in random order to 3 experienced Nuclear Medicine specialists (\>5 years PET reporting experience) on a Syngo. via PET reporting station. Nodules/lesions were reviewed and classified with respect to their focal avidity according to a 3 point scale (1=no avidity, 2=equivocal, 3=avid). **Results:** There were 122 nodules in 86 patients; of size ranging from 3 mm to 65 mm. 5 subdiaphragmatic incidental liver lesions were also imaged, with concordant interpretation between observers. There was an improvement in confidence/change in point score classification in 3/122 nodules (3%), or 2/86 patients (2%). These cases involved small (\<7 mm nodules) in which there was movement misregistration between the PET and CT acquisitions. Interpretation of the incidental liver lesions was not altered by gated imaging. **Conclusion:** Respiratory gating has inherent utility as a problem solving tool in lesions prone to respiratory misregistration near the diaphragm. However, it may be more efficient to use this technique in a selected patient group in which the original PET acquisition flags an equivocal finding, rather than use it universally for all lung nodules.
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**Background/Aims:** ^18^F-FDG PET is a molecular imaging approach which comes to a critical role in cancer diagnosis, staging, therapy response assessments, and outcome predictions. Recently, in response assessments application, new metrics such as metabolic tumour volume (MTV) and total lesion glycolysis (TLG) have been investigated. The aim of this study was to develop the previously proposed PET image segmentation algorithm\[[@ref204][@ref205]\] for determination of quantification parameters in form of a software for application in response assessment. **Methods:** ^18^F-FDG PET imaging study of five patients were included and the proposed algorithm was utilized to delineate solid tumours. PET image derived parameters including SUV~max~, MTV, SUV~mean~ and TLG (mean SUV of tumour multiplied by MTV in milliliters) were determined in the segmented tumours. Moreover, tumour treatment responses were assessed according to TLG which was suggested in PERCIST1.0 as Recommended Exploratory Data. Obtained results were compared with the results derived from Osirix, which is an FDA-approved DICOM image processing software. 50%SUV~max~ thresholding segmentation approach was utilized for determination of abovementioned parameters in Osirix. **Results:** Results showed that SUV~max~ was determined accurately in all assessed tumours and obtained results for SUV~mean~, MTV and TLG illustrated mean differences of-6.5±2.0, 14.1±7.2 and 6.6±4.9, respectively. Moreover, according to PERCIST1.0 recommended criteria for response assessment by TLG (TLG increase ≥75% categorized as progressive metabolic disease and TLG decrease ≥45% categorized as partial metabolic response), obtained results of treatment response assessment utilizing TLG also demonstrated this criteria showed a good agreement with the Nuclear Medicine Specialist reports. Therefore, it was approved that TLG could play an effective role in evaluation of treatment response. **Conclusion:** In this study, an in-house software was developed to determine SUV~max~, SUV~mean~, MTV and TLG response metrics, to indicate the significant potential of this technique for translation to routine clinical applications.
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**Background/Aims:** Just after myocardial infarction, inflammatory response is triggered promptly. Thereafter, activation of the reparative change including angiogenesis proceeds and finally collagen based scar formation is accomplished. We aimed to explore the time course of the process of inflammatory response and angiogenesis using ^14^C-methionine as a marker of macrophage infiltration and ^125^I-RGD as a marker of angiogenesis in a rat model of myocardial severe ischaemia and reperfusion. **Methods:** The left coronary artery (LCA) was occluded for 30 minutes followed by reperfusion for 1, 3, 7, 14, 28 days. At the time of the study, 0.74MBq of ^14^C-methionine and 1.48 MBq of ^125^I-RGD were injected at 20 and 80 minutes before sacrifice, respectively. Just before sacrifice, LCA was reoccluded and ^99m^Tc-MIBI (150--180MBq) was injected to verify the area at risk. After sacrifice, dual tracer autoradiography of the left ventricular short axis slices was performed to obtain the images of the uptake of ^14^C-methionine, ^125^I-RGD, and area at risk demonstrated by ^99m^Tc-MIBI distribution. **Results:** At day 1, both tracer uptake was not observed in area at risk. At day 3, strong methionine uptake was observed (uptake ratio 2.03±0.33) in the area at risk and decreased slightly at day 7 (1.91±0.26) and further decreased at day 14 and 28 (1.47±0.15 and 1.26±0.08, respectively). However, at day 3, RGD uptake was mild (1.22±0.22) in the area at risk but peaked at day 7 (2.27±0.36) and persisted and slightly decreased at day 14 and 28 (2.04±0.17 and 1.91±0.26, respectively). **Conclusion:** In acute myocardial infarction, methionine and RGD imaging showed inflammatory process peaked at day 3 followed by rather rapid suppression but angiogenesis as a reparative process started subsequently and peaked at day 7 and persisted until at least 4 weeks.
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**Background/Aims:** ^123^I-FP-CIT SPECT scan quantitatively visualizes striatum dopamine transporter density by using specific binding ratio (SBR). Correction methods may affect the ^123^I-FP-CIT image quality and SBR result, however, currently there are no standard technique. The aim of our study was to dertemine the influence of attenuation correction (AC) and scatter correction (SC) on the quantitative analysis of ^123^I-FP-CIT SPECT. **Methods:** We imaged a striatal phantom to obtain images representing striatum-to-background ratios (from 10:1 to 1:1). Triple energy window SC and Chang AC method were used. DATview software calculated SBR semi-automatically. Correlation analysis and Bland-Altman plots were used to evaluate differences between SBR and the actual concentration ratio in four groups: NC (no correction), SC, AC, and CC (combined correction). The 49 clinical ^123^I-FP-CIT SPECT studies used the same imaging conditions, reconstruction protocol, and corrections to obtain SBR and asymmetric index value (AI). Receiver operating characteristic (ROC) analysis was used to obtain an AI diagnostic cut-off value. PD patients whose AI values were above this cut-off had their clinical symptoms compared to their ^123^I-FP-CIT SPECT findings. **Results:** *Phantom study*. ^123^I-FP-CIT SPECT images with AC or CC produced increased SBR that was very close to the standard ratios (AC: y = 1.19x -- 0.7; *R²* = 0.98; CC: y = 1.4x -- 1.2; *R^2^* = 0.98), while NC and SC underestimated SBR at low values (1 to 4). AC had the best agreement to the standard ratio (bias = 0.0). CC slightly overestimated SBR with bias of 0.39. SC and NC underestimated the SBR with bias of-1.44 and-1.76, respectively. *Clinical study*. SBR increased significantly when AC, SC and CC methods were applied (*p* \< 0.05). However, only SC affected AI values (*p* \< 0.05). The association between clinical symptoms and ^123^I-FP-CIT imaging results were maintained only when either NC (*n* = 12, *p* \< 0.05) or CC (*n* = 14, *p* \< 0.05) was applied. **Conclusion:** Both AC and SC influenced SBR value, and SC increased AI value more than other corrections. The association between clinical symptoms and SPECT results can be maintained when either NC or CC was applied.
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**Background/Aims:** The alpha~v~/beta~3~-integrin targeting tripeptide Arg-Gly-Asp (RGD) has become an increasingly recognized tool for nuclear imaging and clinical trials. ^18^F-and ^68^Ga-RGD derivatives are currently used testing their performance for imaging tumour angiogenesis.\[[@ref207]\] Recently, we developed a kit radiolabelling solution for 1,4,7-triaza-cyclononane-1,4,7-triacetic-acid-cyclo-Arg-Gly-Asp-d-Tyr-Lys (NOTA-RGD) followed by application in non-human primates.\[[@ref208]\] Herein, we investigate the kit performance towards good clinical practice including dose-dependent tracer administration, biodistribution, physiological ^68^Ga-NOTA-RGD uptake and excretion. This will allow for improved utilization of ^68^Ga-NOTA-RGD-PET/CT imaging in oncological or non-oncological disease. **Methods:** Seven male (23-62 y, 52-130 kg) and eight female (32-70 y, 49-100 kg) subjects received a total of twenty doses of ^68^Ga-NOTA-RGD followed by positron emission tomography/computed tomography (PET/CT) imaging at 60 post injections.\[[@ref208]\] Volume-of-interest analysis of organ/tissue tracer concentration (SUV~mean~) was performed on 3D-reconstructed image slides. Urinary radioactivity (kidneys/bladder) was expressed as percentage of the injected dose (%ID). **Results:** ^68^Ga-NOTA-RGD from kit radiolabelling met with all the requirements for radiopharmaceutical production and was safely administered to patients (4.7-7.2 mCi) as follows: the average activity doses, specific activities and injected tracer masses were 3.4±1.1 MBq/kg or 3.5±0.7 MBq/kg, 15±4 MBq/nmol or 14±5 MBq/nmol and 16±4 nmol or 18±5 nmol for males or females, respectively. Image analysis showed 17±6 %ID (n=18) in kidneys/bladder. The injected NOTA-RGD mass and activity dose for patients receiving two individual ^68^Ga-NOTA-RGD injections ranged 3-12 %; the difference in tracer uptake was low (1.2-11.1%; *p*≥0.111) for all organs/tissues, comparing the two ^68^Ga-NOTA-RGD-PET/CT images (n=4). Tracer concentration of 1.3-2.3g/ml (SUV~mean~) was observed for heart \< blood \< thyroid \< small intestines \< gonads \< salivary glands \< liver \< spleen. Favourably-low tracer concentrations were noted in brain, muscle, lung, bone marrow and bone. **Conclusion:** Our in-house ^68^Ga-NOTA-RGD kit met the quality requirements and release criteria for humans use and offers a convenient ready-to-use diagnostic tool for application in a wide spectrum of pathologies.
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**Background/Aims:** Peptide RRL can specifically bind to tumour angiogenesis. A ^99m^Tc labelled RRL was developed as a promising probe for detection tumours. In the previous study, we demonstrated that ^99m^Tc radiolabelled arginine-arginine-leucine (RRL) could be used to non-invasively image malignant tumours. To improve the detection of pulmonary metastases, experimental blood-borne pulmonary metastasis mouse models were established using three intravenously administered cell lines. In a previous study, we demonstrated that ^99m^Tc-radiolabelled RRL could be used to non-invasively image malignant tumours. **Methods:** The RRL peptide was designed and radiosynthesised with ^99m^Tc by a one-step method. The animal model was established. ^99m^Tc-RRL was prepared and injected intravenously in mice with pulmonary metastases that arose from the intravenous injection of HepG2, B16, and Hela cells. All animal experiments were approved by the authority of Peking University Animal Studies Committee in accordance with the Guidelines for the Care and Use of Research Animals (Approval ID: J201312). The biodistribution and imaging of ^99m^Tc-RRL were determined in different pulmonary metastases models and in normal mice. **Results:** ^99m^Tc RRL exhibited higher uptake values in the lungs of pulmonary metastatic mice compared with normal mice (P\<0.01; 3.92 ± 0.48 %ID/g 2 h post-injection and 3.89 ± 0.36 %ID/g 4 h post-injection in metastatic hepatic carcinoma \[HepG2\]-bearing lungs; 5.49 ± 0.84 %ID/g 2 h post-injection and 5.11 ± 0.75 %ID/g 4 h post-injection in metastatic melanoma \[B16\]-bearing lungs; 3.72 ± 0.52 %ID/g 2 2 h post-injection and 3.51 ± 0.35 %ID/g 4 h post-injection in metastatic cervical carcinoma \[Hela\]-bearing lungs; 2.38 ± 0.20 %ID/g 2 h post-injection and 2.11 ± 0.24 %ID/g 4 h post-injection in normal lungs). The pulmonary metastatic lesions were clearly visualized with ^99m^Tc RRL. **Conclusion:** ^99m^Tc-RRL exhibited favourable metastatic tumour targeting and imaging properties, thus highlighting its potential as an effective imaging probe for detection of pulmonary metastases.
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**Background/Aims:** Perfusion pressure is considered as a key factor in cerebral ischaemia, but little is known about oncology, especially its relation to hypoxia. The purpose of this study was to evaluate the intratumoural perfusion pressure (IPP) and its relation to hypoxia by comparing ^15^O-labelled gases and ^18^F-FMISO PET. **Methods:** Ten male Fischer rats with C6 glioma (body weight=220±15 g) were investigated with ^18^F-FMISO PET and steady state inhalation method of ^15^O-labelled gases PET. The TBF, tumoural metabolic rate of oxygen (TMRO~2~), oxygen extraction fraction (OEF), and tumoural blood volume (TBV) were measured under artificial ventilation with ^15^O-CO~2~, ^15^O-O~2~, and ^15^O-CO labelled gases. Multiple volumes of interest were placed on the co-registered ^18^F-FMISO (3 hrs post injection) and functional ^15^O-gases PET. IPP was calculated as the ratio of TBF to TBV and its correlation to ^18^F-FMISO uptake was evaluated by Spearman's correlation coefficient (r). The IPP, TBF, TMRO~2~, OEF, and TBV values were compared among the three groups classified by the ^18^F-FMISO uptake as follows: group Low, less than 1.0; group Moderate, between 1.0 and 2.0; and group High, more than 2.0 in the ^18^F-FMISO standardised uptake value (SUV). The experimental protocol was approved by the Animal Care and Use Committee of the Osaka University Graduate School of Medicine. **Results:** There were significant but weak correlations between IPP and ^18^F-FMISO SUV (r=-0.274, p\<0.01), IPP and OEF (r=-0.314, p\<0.01), and IPP and TMRO~2~ (r=0.365, p\<0.01). Quantitative values in the Low (L), Moderate (M), and High (H) groups were as follows: IPP, (L) 11.3±11.1, (M) 8.43±6.42, and (H) 8.15±4.11/min; TBF, (L) 54.7±30.3, (M) 31.8±16.5, and (H) 30.0±14.8 mL/100 mL/min; OEF, (L) 33.1±13.6, (M) 35.7±17.1 and (H) 40.8±16.2%; TMRO~2~, (L) 2.82±1.29, (M) 1.87±1.03 and (H) 2.07±1.13 mL/100 mL/min; and TBV, (L) 5.66±2.11, (M) 4.34±1.86, and (H) 3.90±1.24 mL/100 mL, respectively. In comparison between group Moderate and High, significant differences were observed only in OEF and TBV, but not in IPP. **Conclusion:** This study demonstrated IPP was decreased in the intratumoural hypoxia compared to non-hypoxic region, but failed to show the difference between moderate and severe hypoxia. Oxygen extraction and vascular density were considered as key factors to define the severity of intratumoural hypoxia.
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**Background/Aims:** Radioactive iodine--refractory (RAI-R) thyroid cancer is a special type of differentiated thyroid cancer (DTC) with high degree of malignancy and poor prognosis. The aim of this study was to assess the clinical diagnostic value of ^99m^Tc-3p-RGD2 SPECT/CT for the investigation of lung, lymph node and bone metastases in RAI-R DTC patients. **Methods:** Institutional review board approval and the requirement for informed consent was obtained for this study. Twenty-two patients (11 men and 11 women; mean age 54.1±17.4 years, age range, 22-82 years; 17 papillary and 5 follicular) who had total or near total thyroidectomy followed by radioiodine treatment underwent ^99m^Tc-3p-RGD2 SPECT/CT. For the suspicious lesions, three-dimensional regions of interest (3D--ROI) were manually drawn and the tumour/non-target (T/NT) values were collected. The results were verified by pathological examination, and the metastases were confirmed by other imaging examinations, such as post-ablative ^131^I whole body scan (WBS) with SPECT/CT, ultrasound, MRI, CT, bone scan and ^18^F-FDG PET/CT. Expression of the angiogenesis marker αvβ3 and CD31 in 10 lesions was analysed by immunohistochemistry. **Results:** ^99m^Tc-3p-RGD2 SPECT/CT detected metastases in 86.4% (19/22) patients. Lymph nodes, pulmonary and bone metastasis focuses were detected in 14, 7 and 4 patients, respectively. ^99m^Tc-3p-RGD2 SPECT/CT correctly identified 89.2% (66/74) and 81.8% (9/11) lesions located in lymph nodes and bones with an average T/NT value of 2.46±0.96 and 2.94±1.27, but only found positive focus in 2 patients with pulmonary metastases (average T/NT value = 1.58±0.94). In comparison, all the patients showed negative ^131^I whole body scan results. Furthermore, the immunohistochemical analysis showed specific and high expression of αvβ3 in RGD positive lesions. **Conclusion:** The present results indicates the ^99m^Tc-3p-RGD2 SPECT/CT can be a valuable tool for staging and prognosis of the patients with RAI-R DTC, and demonstrate the potential of integrins as targets for personalised tumour specific therapy.
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**Background/Aims:** Monoacylglycerol lipase (MGL) is a key enzyme for regulation of the endocannabinoid system, which relates to pain and multiple neurotransmissions in the central nervous system (CNS). Recently, ^11^C-SAR127303 was developed as a promising radioligand for MGL imaging.\[[@ref209]\] Herein, we aimed to quantify regional MGL activities using positron emission tomography (PET) with ^11^C-SAR127303. **Methods:** PET studies with artery blood sampling were conducted using seven Sprague Dawley rats (male, 8-10 wk). To estimate quantitative parameters (*k~3~*, *K~i~*, and lambda *k~3~*) for MGL activity, kinetic analyses were performed by the irreversible two tissue compartment model (2-TCMi, *k~4~* = 0) and Patlak plot. Subsequently, in vitro autoradiography using rat brain sections was carried out for determination of regional distribution of MAL with ^11^C-SAR127303. All animal experiments were approved by the Committee for the Care and Use of Laboratory Animals in National Institutes for Quantum and Radiological Science and Technology and performed according to the ARRIVE guidelines. **Results:** In PET study, quantitative parameters (*k~3~*, *K~i~*, and lambda *k~3~*) based on 2-TCMi were successfully obtained with high identifiability (\< 10%COV), with ranked order as follows: cingulate cortex \> striatum \> hippocampus \> thalamus \> cerebellum \> hypothalamus ≈ pons. In vitro autoradiograms using ^11^C-SAR127303 showed heterogeneous distribution of radioactivity as seen in PET images. The highest correlation with in vitro bindings was determined in the *K~i~* value. Additionally, the *K~i~* values based on Patlak plot showed high correlation with low underestimation compared to *K~i~* values based on 2-TCMi. Using *K~i~* value based on Patlak plot, we constructed parametric PET image, which succeeded in visualization of regional MGL activities in rat brain. **Conclusion:** We succeeded in in vivo mapping of MGL activity in rat brain regions for the first time by using PET with ^11^C-SAR127303.

P043: Algorithm for Amyloid Imaging to Preserve the Contrast between Gray and White Matter Using Simplified Reference Tissue Model
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**Background/Aims:** The contrast between gray and white matters is important for amyloid imaging, but it suffers from noise. The noise reduction algorithm based on a kinetics of amyloid traces was proposed,\[[@ref210]\] named CAKS, and its applicability combined with Logan Graphical Analysis (LGA) has been presented.\[[@ref211][@ref212]\] This study aims at investigating the performance with Simplified Reference Tissue Model (SRTM) that is a widely used algorithm for PET receptor study. However, SRTM is a nonlinear regression algorithm, and the computational time is thus problematic. CAKS can gather voxels that have similar clearance rate of amyloid traces in tissues, some hundreds of voxels, tissue time activity curves (tTAC) are averaged within this group, the noise level is reduced and the computational cost is decreased because SRTM is applied to the averaged tTAC. **Methods:** The algorithm is applied dynamic clinical data of PiB and *BP*~ND~ images are computed. This experimental procedure is validated by Ethical Committee of Kindai University. **Results:** The *BP*~ND~ image is computed within 15 seconds. The proposed method clearly visualized the accumulation of Aβ in positive cases. Especially in negative cases, the gray and white matters is more clearly distinguished than of conventional algorithm. **Conclusion:** If CAKS was combined with LGA, the contrast was 2.4 times developed.\[[@ref213]\] In conclusion, CAKS is applicable for amyloid imaging.
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**Background/Aims:** Octreotate (TATE) and cyclic arginine-glycine-aspartate (RGD) peptides have been suitably radiolabelled for lung cancer imaging. However, specific somatostatin receptor or integrin αvβ3 expressed in either small cell lung cancer or non-small cell lung cancer limited further applications of these monomeric-receptor-targeting imaging agents. We hypothesize that a peptide ligand recognizing both SSTR and integrin αvβ3 will be advantageous because of its dual-receptor-targeting ability. **Methods:** In this study, a TATE-RGD heterodimer was synthesized from TATE and RGD peptide and labelled with ^68^Ga. Receptor-binding characteristics and tumour-targeting efficacy were tested in vitro and in vivo using H69 (SSTR2 positive and integrin αvβ3 negative) and A549 (SSTR2 negative and integrin αvβ3 positive) lung cancer cell lines and xenograft models. All animal experiments were performed in adherence with the Peking Union Medical College Hospital (PUMCH) guidelines for the use of laboratory animals and were approved by PUMCH Clinical Center Animal Care and Use Committee. **Results:** ^68^Ga-TATE-RGD had a high binding affinity to both SSTR2 and integrin αvβ3 expressed in H69 and A549 cancer cells. In the blocking study, the tumour uptake of ^68^Ga-TATE-RGD was only partially inhibited in the presence of an excess amount of unlabelled TATE or RGD but was blocked completely in the presence of both TATE and RGD. **Conclusion:** The dual-receptor-targeting peptide tracer ^68^Ga-TATE-RGD with good tumour uptake and favourable pharmacokinetics warrants further investigation for potential clinical translation to image both of SSTR2 and integrin αvβ3.
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**Background/Aims:** Dual-modality contrast agents, such as radiolabelled nanoparticles, are promising candidates for a number of diagnostic applications, namely SPECT imaging with MR imaging. So, the aim of study was evaluate potential of Chitosan-coated magnetic nanoparticles (SPION) labelled with ^99m^Tc as new dual-modality probes for liver imaging. **Methods:** In this study chitosan particles were coated on SPION and radiolabelled with ^99m^Tc after purification. The quality control tests including determining particles size, labelling efficiency, stability and biodistribution study in the mice were performed. Finally, MRI and nuclear medicine imaging study in Balb/c mice in 1 and 4 hour after injection of complex were performed. **Results:** Results showed that the final complex have spherical shape and with average size 155 ± 30 nm. The labelling efficiency and stability of complex with ^99m^Tc were 89 ± 6%, 93 ± 6% respectively. Biodistribution study, MRI and nuclear medicine imaging showed high accumulation of Complex in liver. **Conclusion:** The results showed that the ^99m^Tc-Chitosan coated SPION may be considered as promising Dual-modality probes for liver Imaging.

P046: Multifunctional Polyethylenimine-Entrapped Gold Nanoparticles for Dual Mode Single Photon Emission Computed Tomography/Computed Tomography Imaging
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**Background/Aims:** We report the synthesis, characterization and utilization of ^99m^Tc-labelled polyethylenimine-entrapped gold nanoparticles (^99m^Tc-Au-PENPs) with different surface groups (acetyl or hydroxyl) for dual mode SPECT/CT imaging applications in different organs and sentinel lymph nodes. **Methods:** Polyethylenimines (PEIs) were selected as platforms to conjugate with DTPA and PEG to synthesize Au-PENPs, followed by acetylation or hydroxylation modification of the remaining PEI surface amine groups and radiolabelling of ^99m^Tc. The cytotoxicity of Au-PENPs was evaluated *via* cell viability assay and the biosafety in mice was confirmed by body weight measurement, behaviour observation and histological examination. The imaging performance of ^99m^Tc-Au-PENPs was assessed *via* SPECT/CT imaging of different organs in mice and sentinel lymph nodes in rabbits. The biodistribution of ^99m^Tc-Au-PENPs was measured in mice at 1 hour to 12 hours after intravenous injection. All animal experiments were approved by the ethical committee of Shanghai General Hospital. **Results:** The designed Au-PENPs were successfully prepared and showed enhanced X-ray attenuation property, excellently stability and biocompatibility. The ^99m^Tc-labelled Au-PENPs exhibited high radiochemical purity (\>95%), good stability (\>90% within 6 h) and efficient SPECT/CT imaging of the post-caval vein, heart, lung, liver, spleen, kidney, and bladder of mice, as well as sentinel lymph node SPECT/CT imaging in rabbits. ^99m^Tc-Au-DENPs with acetylation or hydroxylation modification had diverse biological behaviours and distributions *in vivo* due to their physicochemical differences in surface. **Conclusion:** The developed Au-PENPs with different surface groups enabled their diverse behaviours and distributions *in vivo*, allowing the versatile SPECT/CT imaging applications in different organs and sentinel lymph node. Taken consideration into the potential of PEIs for further functionalization with various targeting molecules and outstanding gene delivery ability, the designed nanoparticles in this study may be explored as a promising nanoplatform for targeted SPECT/CT imaging and therapy of cancer.
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**Background/Aims:** The aim of this study is to evaluate clinical role of ^18^F-DOPA PET/CT in the diagnosis of neuroendocrine tumours (NET) and compared with ^8^Ga-DOTA-NOC. **Methods:** Twenty six consecutive patients with diagnosed or suspected NET were enrolled in this study. All patients undertook ^18^F-DOPA and ^68^Ga-DOTA-NOC PET/CT in one week. Final diagnosis was confirmed by histopathology and follow-up. Diagnostic efficacy was analysed on per-patient and per-lesion basis respectively. **Results:** Seven patients with pNET, 6 patients with malignant pheochromocytoma (PHEO)/paraganglioma (PGL), 4 patients with MEN 2a, one ectopic ACTH tumour in the pancreas and 1 Merkel Cell Cancer, 1 patient with rectal NET were confirmed by histopathology, whereas 2 pancreas hyperplasia and 1 adrenal hyperplasia were confirmed by follow-up. ^18^F-DOPA showed favorable biodistribution with moderate uptake into the gallbladder and biliary tract and diffused uptake in the pancreas, whereas little uptake was accumulated in the liver and lung, mild uptake was in the adrenal glands. Patients with PHEO and MEN 2 presented with DOPA-avid lesions, except for patient with PGL in the pelvis was negative. whereas pNET showed great variability in the uptake of F-DOPA, the SUV~max~ in primary lesion was 10.57±10.97. However, the ^18^F-DOPA detected 25 lesions while the ^68^Ga-DOTA-NOC detected 23 lesions (23/25). SUV~max~ in tumour was 12.96±5.98 and 19.73±6.78 respectively. **Conclusion:** ^18^F-DOPA PET/CT is valuable for the diagnosis of malignant PHEO and PGL, as serve as an alternative modality for the diagnosis of NET, due to small scale study, large scale multi-centered study is needed.
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**Background/Aims:** The aim of this study to evaluate the value of ^18^F-FDG PET/CT guided percutaneous lung biopsy to improve precision of aspiration, and reduce adverse effects. **Methods:** A prospective study on ^18^F-FDG guided by PET/CT from September 2016 to September 2017 was undertaken our hospital. Twelve consecutive patients were included in this study. All patients had a ^18^F-FDG PET/CT and enhanced CT. The puncture target was selected on high focal uptake in PET images and significantly enhanced lesions in CT. Final diagnosis was confirmed by histopathology. **Results:** Out of twelve patients (6 patients with adenocarcinoma, 2 patients with squamous carcinoma, 1 with small cell carcinoma, 1 with tuberculoma, 1 with fungal infection, 1 with planned pneumonia). 58.3% (7/12) lesions were located at the edge or eccentricity of the high uptake area, and the target area of the biopsy was adjusted. No significant adverse effects were found except for pulmonary haemorrhage in 1 patient after biopsy. None of patients underwent repeated biopsy. **Conclusion:** ^18^F-FDG PET/CT serve as valuable tools for guidance of percutaneous lung biopsy, it improved the accuracy of biopsy and decrease the number of punctures, which lead to less adverse effects.
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**Background/Aims:** Glucagon-like peptide-1 receptor (GLP-1R) is a potential target for diagnosis and therapy of the tumour, which is especially high expression in insulinoma. Exendin-4, a protein with strong binding affinity for GLP-1R as an agonist, has developed many analogs, which are extensively used in receptor imaging studies. In this study, NOTA-MAL-Cys^39^-exendin-4 was designed and labelled with ^68^Ga as a new GLP-1R imaging agent, evaluated for insulinoma imaging. **Methods:** Cys^39^-exendin-4 was conjugated with MAL-NOTA, then the compound was labelled by ^68^GaCl~3~ to obtain ^68^Ga-NOTA-MAL-Cys^39^-exendin-4. The tumour-targeting characters of the tracer was assessed in Balb/c nude mice bearing positive expressing INS-1 insulinoma. **Results:** The yield of NOTA-MAL-Cys^39^-exendin-4 was in \~70% and confirmed by MS. NOTA-MAL-Cys^39^-exendin-4 was labelled by ^68^Ga in one-step method within 20 minutes with a yield about 85%. The radiochemical purity of the product was \>95%. Micro-PET/CT Imaging showed that INS-1 tumours were clearly visualized with good contrast to background. At 30, 60 and 120 minutes post-injection, the average tumour uptakes of ^68^Ga-NOTA-MAL-Cys^39^-exendin-4 in INS-1 tumours were 11.5±0.56%ID/g, 11.1±0.89%ID/g, and 10.67±1.1%ID/g respectively. On the contrast, tumour uptake significantly decreased to 0.42±0.05%ID/g in the blocking experiment at 60 minutes post-injection. It preliminarily proved the specificity of ^68^Ga-NOTA-MAL-Cys^39^-exendin-4 towards GLP-1R. ROI analysis showed that the kidneys uptake of ^68^Ga-NOTA-MAL-Cys^39^-exendin-4 were 51.7±2.8%ID/g, 51.1±3.2%ID/g and 48.5±3.7%ID/g respectively at 30, 60 and 120 minutes post-injection. This showed the excretion of ^68^Ga-NOTA-MAL-Cys^39^-exendin-4 mainly via the kidneys. The liver had lower uptakes of 2.3±0.38%ID/g at 60 minutes post-injection. It suggested that ^68^Ga-NOTA-MAL-Cys^39^-exendin-4 owned favourable pharmacokinetic, which may be benefit for tumour diagnosis. **Conclusion:** ^68^Ga-NOTA-MAL-Cys^39^-exendin-4 appears to be a promising candidate for insulinoma imaging with favourable preclinical results.
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**Background/Aims:** Although immune checkpoint blockade targeting programmed cell death protein 1/programmed cell death ligland 1 (PD-1/PD-L1) is a promising approach, not all patients respond. It is important to evaluate PD-L1 expression for selecting patients who will benefit from anti-PD-1/PD-L1 therapy as PD-L1 expression status is potentially predictive of prognosis and therapy responsiveness. **Methods:** This study was received prior ethics approval from our institutional authorities. In this study, we developed a novel immuno-PET technique to noninvasively determine PD-L1 expression *in vivo*, using KN035, a new anti-PD-L1 domain antibody which is in clinical trials. *In vivo* studies were performed to monitor PD-L1 levels in nude mice bearing LN229 xenografts and evaluate the whole-body biodistribution of anti-PD-L1 antibody in healthy non-human primates (NHPs). Tumour sections were analysed for PD-L1 expression using immunohistochemistry (IHC). **Results:** KN035 displayed high-affinity to PD-L1, which persisted even after KN035 conjugation with *p*-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS). ^89^Zr-Df-KN035 showed high radiochemical purity of \>98%, and good stability at 168 h. PET imaging in nude mice bearing LN229 xenografts was clearly visible from 6 h to 120 h. There was markedly reduced accumulation of ^89^Zr-Df-KN035 in the presence of excess KN035. *Ex vivo* biodistribution studies in mice demonstrated good tumour-to-muscle ratios. IHC analysis confirmed the positive expression for PD-L1 in LN229 xenografts. In the NHP model, the imaging demonstrated low background and the tracer moderately accumulated in the liver and kidneys tissues. The spleen, salivary glands and lymph nodes were mildly visualised. **Conclusion:** ^89^Zr-Df-KN035, a novel anti-PD-L1 domain antibody probe showed the feasibility of non-invasive *in vivo* evaluation of PD-L1 expression, importantly, allowing for same-day administration and imaging. This work further provides a template for immunotherapeutic agent-based imaging to evaluate human PD-L1 expression and augment the understanding of the biodistribution of the therapeutic agents *in vivo*, leading to better therapeutic strategies in the future.
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**Background/Aim:** As the Positron emission tomography (PET) has become a standard imaging in the management of patients with cancer, the Myanmar's first and only PET/CT together with 18 Mev cyclotron started at the Department of Nuclear Medicine, Yangon General Hospital on 7/92015. The purpose of this study is to review our clinical experiences of PET/CT in Myanmar. **Method:** All the ^18^F FDG PET/CT cases from January 2016 to December 2017 were compiled and analysed. **Results:** A total of 598 ^18^F-FDG PET/CT examinations were performed. The number of scans was 209 in 2016 and 389 in 2017. All the cases were referred for oncology practice with breast cancer (17.1%), head and neck cancer (12.9%), haematological malignancies (11.5%), lung cancer (9.7%), colorectal cancer (9.5%), gynaecological malignancies (9.4%), unknown primary (6.2%) and other malignancies (23.7%). Currently, there is no nationwide cancer registry. According to the data of Yangon General Hospital (2017), the most common malignancy is breast cancer. The referral indications for PET/CT were for diagnosis (11.5%), staging (12.9%), recurrence detection (55.5%) and response evaluation (20.1%). During the study period, there was a steep rise in the use of ^18^F FDG PET/CT because of an increased awareness and acceptance of the clinicians. We have noticed that PET/CT caused a change in diagnosis and/or staging and/or treatment plan in many cases but there has been a limitation in obtaining an adequate clinical outcome data of our patients. **Conclusion:** The first PET/CT service has been successfully established in our country with rising referrals together with an increased awareness and acceptance of the referring clinicians. We need a good follow-up system to prove that the use of PET/CT imaging help changed patient management in a significant number of cases. We also need to expand our service to non-oncology practice.
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**Background/Aims:** Vascular endothelial growth factor (VEGF) is a major angiogenic factor and its receptor has been shown to be over-expressed in human glioblastoma. In this study, we investigated the value of ^123^I-VEGF scintigraphy in patients with histologically verified brain tumours for the visualization of tumour angiogenesis. **Methods:** This study was approved by the ethical board of the Medical University of Vienna. 24 patients (9 females, 15 males, mean age 56±17 years) with histopathological verified glioblastoma (n = 16), astrocytoma (n = 2), anaplastic oligoastrocytoma (n = 3), haemangiopericytoma (n = 1), oligodendroglioma and malignant B-cell lymphoma (n = 1) were included in the study. Dynamic acquisition was initiated immediately after intravenous administration of ^123^I-VEGF (140±16MBq) and carried out until 30 minutes post injection. SPECT was performed at various time points post-injection (p.i.). Whole body images were acquired in anterior and posterior views at 1 hour p.i. **Results:** All glioblastoma lesions and anaplastic oligoastrocytoma as well as haemangiopericytoma were visible after intravenous injection of ^123^I-VEGF and were still shown clearly 18 hours p.i. Negative ^123^I-VEGF~165~ scan results were obtained in patients with astrocytoma, oligodendroglioma and malignant B-cell lymphoma. **Conclusion:** Our results suggest that ^123^I-VEGF scintigraphy may be useful for visualization of glioblastoma and the tumour angiogenesis.
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**Background/Aims:** Post-therapy changes in treated glioma patients can't be reliably differentiated from tumour recurrence. We evaluated the role of ^99m^Tc-Methionine SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) in diagnosis of recurrent glioma and compared the same with ^18^F-FDG PET/CT (Positron Emission Tomography) and contrast-enhanced Magnetic Resonance Imaging (CeMRI). **Methods:** 44 patients with histologically proven, previously treated glioma and clinical suspicion of recurrence were prospectively enrolled in the study. All patients underwent ^99m^Tc-Methionine SPECT/CT, ^18^F-FDG PET/CT and CeMRI of brain. Combination of repeat imaging, biopsy and/or clinical follow-up (6-36 months) was taken as reference standard. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and accuracy, with 95% CI, were calculated. Chi-square (χ2) test was used to compare diagnostic values among modalities. **Results:** Of 44 patients, 5 were lost to follow up, so the final analysis was done with data from 39 patients (28 male; 11 female, age 38.05±9.7 years). PPV and NPV for ^99m^Tc-Methionine SPECT/CT, ^18^F-FDG PET/CT and CeMRI were 95.6% & 56.2%, 92.3% & 61.5% and 79.4% & 42.9%, respectively. Sensitivity and specificity for the three modalities were 75.9% & 90%, 82.8% & 80% and 87.1% & 30%. Specificity of ^99m^Tc-Methionine SPECT/CT was significantly higher than CeMRI (p \< 0.0001) but not ^18^F-FDG PET/CT (p 0.36). No significant difference was seen between the modalities for sensitivity and accuracy. **Conclusion:** ^99m^Tc-Methionine is a promising tracer for evaluating recurrent glioma. Diagnostic values of ^99m^Tc-Methionine SPECT/CT and ^18^F-FDG PET/CT are similar, so it may be used as a cost-effective alternative. Also, ^99m^Tc-Methionine SPECT/CT is more specific than CeMRI.
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**Background/Aims:** In 2017, American Joint Committee on Cancer (AJCC) has released the eighth edition of AJCC cancer staging manual including significant modifications from 7th edition in oral cavity cancer (OCC) and oropharyngeal cancer (OPC). Highlights include incorporation of depth of invasion (DOI) and exclusion of extrinsic tongue muscle involvement in T-staging of OCC, separation of OPC staging by high-risk human papilloma virus status (p16 positivity), and inclusion of extranodal extension (ENE) in N-staging. **Methods:** The recent introduction of ^18^F-FDG PET/MR has demonstrated the advantages of simultaneous PET and MR imaging with higher soft-tissue contrast, multiplanar image acquisition and functional imaging capability. We illustrate the usefulness of ^18^F-FDG PET/MR imaging in the management of OCC/OPC patients based on the new AJCC cancer staging system. **Results:** In the 8th edition, T0 is deleted for OCC and OPC (p16-), and T-staging of OCC no longer depends solely upon tumour size in greatest dimension. DOI is a better predictive parameter than tumour thickness and is measured by using the basement membrane of normal adjacent tissue as reference. Incorporating the DOI by increments of 5mms helps to categorize patients by survival more effectively compared to the 7th edition staging system. ENE of the cervical lymph nodes has been added as a prognostic variable for N-staging of OCC and OPC (p16-). The presence of ENE is defined as the extension of malignancy through the capsule of an affected lymph node. N1-N2 criteria of OCC and OPC (p16-) in 8th edition are those in 7th edition without ENE. Prior N3 is divided into 2 subcategories, N3a and N3b. The new N3a criterion is prior N3 without ENE, and the new N3b is any lymph nodes with clinically overt ENE. For OPC (p16+), TX and Tis are deleted, and prior T4a and T4b are combined to single T4. In addition, unknown primary (T0) nodal positive disease should be staged using the definitions for OPC (p16+) if a node is p16+ and no primary site is identified. For N-staging of OPC (p16+), the presence or absence of ENE is not considered. Prior N1, N2a, N2b are combined to N1, and prior N2c is changed into N2 in 8th edition. **Conclusion:** ^18^F-FDG PET/MRI provides high-resolution/multiplanar MR images fused with ^18^F-FDG avidity and is useful for evaluating cancer stages in OCC and OPC based on the new AJCC cancer staging system.
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**Background/Aims:** HPV positive oropharyngeal carcinoma (HPV+OPC) are histologically and clinically distinct, and exhibit increased radiosensitivity with favourable prognosis. The use of imaging biomarkers may identify a lower risk group suitable for de-intensified treatment. There is limited published data on the predictive value of post-treatment FDG-PET for HPV+OPC, but not in mid-treatment setting. This study aims to evaluate whether FDG-PET-CT performed during the third week (iPET) of radiotherapy (RT) can predict treatment outcomes independent of the HPV status. **Methods:** This retrospective analysis included forty-three patients with newly diagnosed locally-advanced OPC and known HPV status treated with radical RT and concurrent systemic therapy who underwent pre-treatment PET and iPET. The mean follow-up was 42.6 months (range 9-91 months). HPV status was positive in 27 (63%) based on immunohistochemistry staining for P16 proteins. The maximum-standardised-uptake-value, metabolic-tumour-volume (MTV) and total-lesional-glycolysis (TLG) of the primary tumour and their % reductions in iPET were analysed, and results were correlated with 5-year-Kaplan-Meier disease-free-survival (DFS) and overall-survival (OS) and compared using log-rank test. Optimal-cutoffs (OC) were derived from Receiver-Operating-Characteristic curves. This study received institutional ethics approval. **Results:** The HPV+ve status is associated with better outcomes: DFS: 81.5% vs. 48.9%, p = 0.093 and OS: 88.4% vs. 37.3%, p = 0.002. Based on the assessment of response rate, more than 75% reduction in iPET tumour MTV provided the best predictor of DFS independent of HPV status. HPV-OPC: 80.0% vs. 35.4%, and HPV+OPC: 100% vs. 70.6%, p = 0.035. Based on the residual tumour metabolic burden, the iPET tumour TLG (OC≤6.25g) provided the best predictor of DFS. HPV-OPC: 75.0% vs. 37.0%, and HPV+OPC: 100% vs. 75%, p = 0.111. **Conclusion:** We have demonstrated that the treatment response rate and residual tumour metabolic burden derived from iPET can potentially predict for patients with HPV+OPC who have a very low risk of treatment failure, and can potentially benefit from de-intensified treatment.

P057: Analysis of Hilar and Mediastinal Nodal Parameters Predictive of Metastatic Involvement at Staging Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Non-Small Cell Lung Cancer. Audit of Local Experience Based on Comparison with Post-Operative Pathologic Stage, Assessment of Applicability of Two Semi-Quantitative Parameters to our Patient Population
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**Background/Aims:** At initial staging of non-small cell lung cancer, there is interest in increasing accuracy of FDG PET/CT determination of nodal status, recognising many potential confounders exist. We intend to audit local performance of PET against post operative staging and ascertain applicability of recently reported semi-quantitative parameter of node: primary tumour (PT) and of node: mediastinal blood pool (MBP) ratios to our population. Early experience is presented. **Methods:** Human Research and Ethics Committee approval was granted. Patients with regional nodal metastases on post operative staging were identified via our institution's CardioThoracic Surgical database. Parameters recorded were: Primary tumour histology, size and SUV~max~, histologically positive and negative node size, SUV~max~, node: MBP SUV~max~ ratio, and node: PT SUV~max~ ratio. Time interval between PET and surgery was also recorded. **Results:** The initial period audited captured 3 patients. One with a prospective imaging diagnosis of N1 disease with increased activity (SUV~max~ 8) in a mildly enlarged (12 mm) ipsilateral hilar node. Node: MBP ratio was 2.8 and N: PT ratio 0.36. Two patients had N1 disease on postoperative staging not prospectively demonstrated on imaging. Each had an intensely avid primary (SUV~max~ 14 and 15) but no suspicious nodal activity on visual or semi-quantitative retrospective analysis of the involved stations. There was however a 16-week period between PET and surgery for both patients. **Conclusion:** Initial data indicate period between imaging and surgery was a potential contributor to post-operative upstaging in 2 cases and may explain lack of positivity by visual or quantitative assessment. Where a prospective imaging diagnosis of N1 disease was made, node: PT and N: MBP ratios were elevated. As the audit progresses, validity of these ratios in our patient population and, potentially population specific thresholds, may be further elucidated.
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**Background/Aims:** A novel radiopharmaceutical, 4'-\[methyl-11C\]-thiothymidine (4DST), has been developed as an in vivo cell proliferation marker based on the DNA incorporation method. The purpose of this study was to evaluate 4DST uptake in patients with lung tumour and to correlate the results with proliferative activity and tumour grade. **Methods:** Investigations of 4DST and FDG PET/CT were performed retrospectively in 27 lesions of 27 patients with lung tumour (20 malignant tumours and 7 benign tumours (23 male and 4 female, mean age; 65.6 +/-9.9 years, median; 66 years). The maximum standardised uptake value (SUV~max~) for tumour was calculated. Histopathological diagnosis was proven by surgery when the clinical diagnosis was malignancy. Others were diagnosed as benign lung nodule by clinically follow-up. Proliferative activity as indicated by the Ki-67 index was estimated in tissue specimens. **Results:** Of 27 lung tumours examined, 20 lesions were malignant tumour (SqCC; 7, Adenoca.; 13), other 7 lesions were benign after surgery or clinical course observation. In 4DST PET/CT study, SUV~max~ were 2.92 for SqCC, 3.09 for Adenoca, and 1.82 for benign lesion, respectively (p \< 0.01). In FDG PET/CT study, SUV~max~ were 7.52 for SqCC, 6.63 for Adenoca, and 3.53 for benign lesion, respectively (p\>0.05). To distinguish from benign to malignant tumour, 4DST-PET was more suitable than FDG-PET. In analysis of T-stage and SUV~max~, increased uptake of 4DST was seen in larger sized tumour. Linear regression analysis between 4DST and FDG indicated a correlation for SUV~max~ (R^2^ = 0.53, p \< 0.001). Linear regression analysis indicated a significant correlation between FDG SUV~max~ and Ki-67 index (R^2^ = 0.52, p \< 0.001), and a significant correlation between 4DST SUV~max~ and Ki-67 index (R^2^ = 0.36, p \< 0.01) were found. Also, 4DST PET imaging may predict early response of treatment or clinical outcome after therapy. **Conclusion:** 4DST PET/CT is feasible for imaging of lung tumours, as well as FDG PET/CT.
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F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Image in Patients with Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy
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**Background/Aims:** Radiomics analysis is recently considered as a promising method for quantitative analysis of ^18^F-FDG PET/CT images. In this study, we analysed multiple radiomics parameters exhaustively to find useful parameters in predicting outcome in patients with stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT). **Methods:** Inclusion criteria was set as follows; (1) patients with stage I NSCLC treated with SBRT, (2) ^18^F-FDG PET/CT scan was obtained with a single PET/CT scanner within 90 days prior to the day when radiotherapy was started, and (3) recognizable accumulation of FDG in the primary tumour. Patients were followed up and the clinical outcome including local control (LC), progression free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier method. 35 radiomics features (6 histogram parameters, 7 co-occurrence parameters, 11 run-length parameters and 11 size-zone parameters) were calculated and analysed their effects on patients' outcome by log-rank test as univariate analysis. **Results:** 37 patients satisfied the criteria and included to this study. Median follow up period in survived patient was 49.3 months. 3-year LC rate was 78.4% (95% CI: 65.1-91.6%), 3-year PFS rate was 56.8% (95% CI: 38.4-75.1%) and 3-year OS rate was 59.7% (95% CI: 43.2-76.2%). In univariate analysis, 5 run-length parameters (long run emphasis, run percentage, high-intensity run emphasis, high-intensity short-run emphasis and low-intensity long-run emphasis) were significantly related with LC (p = 0.002-0.04). On the other hand, no radiomics parameters were related with PFS or OS with statistical significance. **Conclusion:** Among radiomics parameters of ^18^F-FDG PET/CT images, 5 run-length parameters might be useful to predict local control in patients with stage I NSCLC treated with SBRT.

P060: The Usefulness of Fractal Analysis in Diagnosing Therapeutic Effect of Non-Small Cell Lung Cancer
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**Background/Aims:** FDG uptake parameters such as SUV~peak~ and TLG are used to determine the therapeutic effect of non-small cell lung cancer (NSCLC), but reports on homogeneity of glucose metabolism are few. Although the fractal dimension (D value) is an index of self-similarity, it is expected to be useful as an indicator of the inhomogeneity of FDG uptake. Especially there is a possibility of subgrouping the therapeutic effect. We investigated the association of the change in FDG uptake before and after treatment in non-small cell lung cancer (NSCLC) and the change in uniformity using fractal analysis in the current study. **Methods:** Twenty-three NSCLC patients (17 Male, 6 Female) were included. All patients received 3-14 courses of chemotherapy. FDG PET/CT was done before and after chemotherapy. Therapeutic effect was evaluated by both PERCIST criteria and Fractal analysis by the box counting method. We divided all patients into 3 groups, namely PMR, SMD and PMD group according to the result of PERCIST. Both the value of fractal dimension (D) and the change of D value by the chemotherapy (ΔD) were compared among the three group. ΔD was calculated by the formula (D value at post-chemotherapy/D value at pre-chemotherapy). **Results:** Before the chemotherapy, the D value did not show any statistical significance among the three groups. In the PMR group, the D value decreased significantly after the chemotherapy compared with the PMD group. The ΔD value of PMR was significantly lower than that of PMD (0.69 vs. 1.32). **Conclusion:** After the chemotherapy, fractal dimension (D value) decreased in PMR group and it tended to increase in PMD group. Association between the changes of degree of glucose metabolism and the changes in homogeneity of glucose metabolism was suggested.
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**Background/Aims:** To evaluate the value of ^18^F-FDG PET/CT imaging combined with serum Lactate dehydrogenase (LDH) in predicting the prognosis of in newly diagnosed Small Cell Lung Cancer (SCLC). **Methods:** A total of 118 SCLC patients between June 2005 to December 2016 were retrospectively analysed. The general information, including LDH, Overall Survival (OS) and SUV~max~, were recorded. Life-table method and Kaplan-Meier analysis were used to estimate the median survival time (MST). The survival function curve was drawn. Log-rank test was used to analyse whether there existed statistical differences in survival period among different groups. **Results:** According to ROC curve, the optimal cutoff value of the SUV~max~ was 10.95. The AUC was 0.535 (95%CI: 0.407-0.663). The patients were devided into four groups according to the primary tumour SUV~max~ and serum LDH: A for SUV~max~\>10.95 and LDH\>245U/L, B for SUV~max~\>10.95 and LDH≤245U/L, C for SUV~max~≤10.95 and LDH\>245U/L, D for SUV~max~≤10.95 and LDH≤245U/L. In LD stage, there were 12, 19, 7 and 16 patients in group A, B, C, D and their MST were 28, 28, 27 and 72 months, respectively. There was no significant difference (p = 0.057). In ED stage, there were 22, 22, 9 and 11 patients in group A, B, C, D and their MST were 21, 14, 14 and 11 months, respectively. There was no significant difference (p = 0.742). In the whole group (LD+ED stage), there were 91 and 27 patients in group (A+B+C) and D and their MST was 20 and 36 months, respectively. The difference was statistically significant (p = 0.045). In LD SCLC, there were 38 patients in group (A+B+C) and its MST was 27 months. The difference was statistically significant (p = 0.012). **Conclusion:** The prognosis of SCLC patients with primary tumour low SUV~max~ and normal serum LDH is better than those of high SUV~max~ and/or elevated serum LDH.
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**Background/Aims:** To validate the value of ^18^F-FDG uptake on PET/CT and TTF-1 expression to predict the EGFR mutations in lung adenocarcinoma. **Methods:** A total of 137 lung adenocarcinoma patients (89 males, 48 females, age range 33-84 years) underwent EGFR mutations testing, ^18^F-FDG PET/CT scan and TTF-1 analysis before treatment were reviewed retrospectively. χ2 test was used to assess the differences of EGFR mutations in clinical parameters. Two-sample t test was used to compare the differences of SUVmax between EGFR mutations type and EGFR wild type, TTF-1 positive expression and negative expression. A multivariate logistic regression analysis was used to test the univariate models that yielded the best predictors of EGFR mutations. ROC curve analysis was performed to quantify the predictive value of these factors. **Results:** EGFR mutations were identified in 53 patients, including 2 cases in exon 18, 19 cases in exon 19, 3 cases in exon 20 and 29 cases in exon 21. The high risk factors of EGFR mutations were female (χ2 = 7.465, p = 0.006), non-smoking (χ2 = 7.193, p = 0.007) and positive expression of TTF-1 (χ2 = 9.104, p \< 0.05). The SUV~max~ of EGFR mutations type was siginificantly lower than that of EGFR wild type (8.76±4.59 and 11.20±5.09; t = 2.832, p = 0.005). Multivariate analysis showed the lower SUV~max~ (SUV~ma~\<8.65) and positive expression of TTF-1 were the independent risk factors for EGFR mutations (p = 0.018, p = 0.032). The combined use of SUV~max~ and TTF-1 yielded a higher area under the ROC curve (AUC = 0.697), suggesting a good discrimination. **Conclusion:** The combined evaluation of ^18^F-FDG uptake and expression of TTF-1 may be helpful in predicting EGFR mutation status in patients with lung adenocarcinoma, and can provide meaningful clues for clinical treatment.
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**Background/Aims:** To investigate the prognostic value of ^18^F-FDG PET/CT in extensive-stage small cell lung cancer (ES-SCLC). **Methods:** Fifty-five patients with ES-SCLC who underwent pretreatment ^18^F-FDG PET/CT were retrospectively included in this study. The student's t-test and Mann-Whitney U test were used to analysis the correlations between the SUV~max~ of primary lesion, MTV of primary lesion (MTVp), TLG of primary lesion (TLGp), the highest SUV~max~ of all lesions, the sum of metabolic volume (MTV~sum~), the sum of total lesions glycolysis (TLG~sum~) and clinical factors, respectively. The Kaplan-Meier method and Log-rank test were used to perform univariate survival analysis and Cox proportional hazards model for multivariate analysis. **Results:** SUV~max~, MTVp, and TLGp of the 55 patients were 11.34±7.02, 29.61 (1.76, 281.86) cm\[[@ref216]\], and 207.72 (5.73,2803.87), respectively. The highest SUV~max~, MTV~sum~, and TLG~sum~ were 13.61±7.10, 123.57 (9.61, 884.14) cm^3^, and 988.48 (53.39, 6628.37), respectively. SUV~max~ of the primary lesion, MTVp, and TLGp were associated with tumour type and maximum tumour length (p \< 0.05). MTVp and TLGp (p \< 0.05) were correlated with hydrothorax. MTV~sum~ and TLG~sum~ were associated with the number of lesions, hydrothorax, lactate dehydrogenase (LDH), haemoglobin, and Eastern Cooperative Oncology Group (ECOG) score (p \< 0.05). TLG~sum~ was also correlated with the maximum tumour length (p = 0.039). By contrast, the highest SUV~max~ was not correlated with clinical factors (p \> 0.05). Univariate analysis indicated that MTV~sum~, TLG~sum~, number of lesions, ECOG, liver metastasis, bone metastasis, chemotherapy cycles, and thoracic radiation therapy (P \< 0.05) were associated with PFS and OS (P \< 0.05). LDH and haemoglobin were associated with PFS (p \< 0.05). Multivariate analysis demonstrated that LDH, ECOG, liver metastasis, chemotherapy cycles, MTV~sum~, and TLG~sum~ were independent PFS predictors (p \< 0.05). ECOG and TLG~sum~ were independent OS predictors. ^18^F-FDG PET/CT yields a certain prognostic value in ES-SCLC patients. MTV~sum~ and TLG~sum~ are independent PFS predictors, whereas ECOG and TLG~sum~ are independent OS predictors. **Conclusion:** ^18^F-FDG PET/CT has certain prognostic value of patients with ES-SCLC. MTV~sum~ and TLG~sum~ are the independent predictors of PFS, and TLG~sum~ is also an independent predictor of OS.
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**Background/Aims:** To prospectively evaluate the role of volume based parameters obtained from ^18^F-FDG PET/CT in interim treatment response assessment in biopsy-proven NSCLC. **Methods:** Sixty patients (male/female: 47/13) with biopsy proven NSCLC and a mean age of 55.31±12.13 years (range: 31-80 years) were enrolled in the study. Each patient underwent whole-body ^18^F-FDG PET/CT scan after injecting 5.18-7.77 MBq/kg of ^18^F-FDG intravenously at baseline and after four cycles of chemotherapy. Four volume based parameters: metabolic tumour volume of primary tumour (MTV), total lesion glycolysis of primary tumour (TLG), whole body MTV (MTVwb), whole body TLG (TLGwb), and three SUV-based parameters (target-to-background ratio (TBR), maximum standardised uptake value (SUV~max~), average standardised uptake value (SUV~avg~)) were evaluated for both scans along with their percentage changes(Δ). Patients were divided into two response groups as per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria: responders and non-responders. All parameters were compared among the two response groups using student t-test or wilcoxon rank-sum test as suitable and best threshold of significant parameters related to response evaluation were determine using ROC analysis. P \< 0.05 was considered significant. **Results:** All post-therapy parameters were found to have a significant role in the prediction of two response groups. Post-MTVwb had the highest AUROC of 0.85 with a sensitivity and specificity of 81.6% and 77.3%, respectively, at a cutoff value of 70 cm^3^ whereas; post-SUV~max~ had AUROC of 0.76 with sensitivity and specificity of 71.1% and 72.7% at a cut off value of 10. Among the Δs, except ΔTBR all other parameters were found have role in prediction of response. Out of them ΔMTV, ΔMTVwb, ΔTLG, ΔTLGwb were most significant with AUROC of 0.90, 0.91, 0.88, 0.90 respectively and cut offs 55%, 55%, 70%, 72% respectively. In multivariate analysis, ΔMTVwb was found to be the independent variable for prediction of interim treatment response. **Conclusion:** Our study proves that a multitude of semiquantitative parameters of whole body ^18^F-FDG PET/CT as documented above differ significantly between two response groups in patients with NSCLC. However, the volume based parameters performed better than SUV based parameters in prediction of interim treatment response in NSCLC.

**Disclosure of Interest:** A Pandey Conflict with: All India Institute of Medical Sciences, C Patel Conflict with: All India Institute of Medical Sciences.
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**Background/Aims:** Staging of non-small-cell lung cancer (NSCLC) is a multidisciplinary process involving imaging. Mediastinal lymph node (MLN) staging is crucial for proper management of lung cancer. The aim of this retrospective study is to investigate the negative predictive value of ^18^F-FDG PET/CT in preoperative MLN staging of NSCLC, and to compare this integrated non-invasive modality with endobronchial ultrasound/transbronchial needle aspiration (EBUS/TBNA) as a minimally-invasive procedure. **Methods:** We identified all patients who were diagnosed with NSCLC at the King Hussein Cancer Center in Amman, Jordan, between June 2010 and June 2017. We collected relevant demographic and clinical data, pre-operative CT and PET/CT imaging results, EBUS/TBNA and mediastinoscopy findings, as well as histopathological diagnoses for proper staging correlation. Treatment and survival outcomes were also recorded. Staging by each individual modality was compared to the final TNM stage in reference to the tissue diagnosis. Sensitivity, specificity, positive and negative predictive values were calculated for each modality. This study was cleared by the institutional review board. **Results:** Comparison between PET/CT and EBUS/TBNA in 79 patients yielded 17 correlated true positive findings and 3 true negative findings. In seven patients, PET/CT detected metastatic MLNs that would have otherwise remained undiscovered by EBUS/TBNA alone. On the other hand, EBUS/TBNA conferred accurate staging in 3 patients, which were missed by PET/CT and would have otherwise been considered N0 stage. Both modalities had 1 false negative result. NPV of PET/CT was 66.7%, compared to 61.9% with EBUS/TBNA respectively, and 45.8% with CT scan, respectively. **Conclusion:** The NPV of PET/CT in mediastinal nodal staging in patients with NSCLC is more reliable compared to EBUS/TBNA and CT scan. PET/CT surpasses EBUS/TBNA in excluding mediastinal lymph node metastases in NSCLC. Positive PET/CT MLN, particularly if such a result would change treatment decisions and outcomes, should be verified histopathologically.

P066: Significance of Tumour Biological Parameters Assessed by Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography on Overall Survival in Patients with Non-Small Cell Lung Cancer
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**Background/Aims:** Lung cancer is the leading cause of death in both sexes. Several parameters of the biological activity of tumour in PET images have been introduced based on SUV and its derivatives as MTV and TLG. The aim of the study was to assess the significance of biological parameters of tumour using FDG-PET/CT scans in patients with NSCLC. **Methods:** 66 patients with histological confirmed and untreated NSCLC were enrolled to this study. PET scans were acquired 60min after IV injection of 18F-FDG with the mean activity 364±75MBq. PET parameters including SUVmax, MTV, TLG of both primary tumour and higher mediastinum lymph nodes (SUV-s, MTV-s and TLG-s) and heterogeneity (AUC-CSH) of primary tumour and lymph node were analysed. The relationship between these parameters and overall survival (OS) was evaluated. **Results:** Dependent on stage of the disease in stage IV SUV~max~, TLG, MTV, Total SUV and AUC-CSH (8.08 ± 3.05, 214.88 ± 390.46, 47.1 ± 84.6, 3356 ± 6101.8, 0.53 ± 0.1); for LN: (5.93 ± 2.49, 18.72 ± 20.94, 4.53 ± 3.86, 292.51 ± 327.24, 0.69 ± 0.1) respectively; in stage IIIB, TLG, MTV, Total SUV and AUC-CSH (12.74 ± 6.94; 575.68 ± 752.11; 69.11 ± 81.41; 8995.05 ± 11751.8; 0.55 ± 0.1), for LN: (8.22 ± 4.14, 24.71 ± 22.76, 4.21 ± 3.26, 386.07 ± 355.54; 0.67 ± 0.08) respectively, in stage IIIA, TLG, MTV, Total SUV and AUC-CSH (9.73 ± 4.56, 299.73 ± 370.18, 67.28 ± 84.63, 4683.07 ± 5784.25, 0.52 ± 0.1), for LN (6.22 ± 4.9, 12.68 ± 11.89, 3.91 ± 4.13, 198.08 ± 185.81; 0.69 ± 0.09) respectively, in stage IIA, TLG, MTV, Total SUV and AUC-CSH (8.98 ± 6.04; 35.86 ± 40.73; 6.11 ± 5.52, 560.36 ± 636.33, 0.64 ± 0.06), for LN: (4.43 ± 2.43, 25.72 ± 45.05, 6.07 ± 8.34, 401.89 ± 703.84; 0.74 ± 0.2). Mean OS: 13 ± 18mo, 19 ± 8, 19 ± 12, 20 ± 6 respectively for stage IV, IIIB, IIIA and IIA. Significant differences between primary tumour and lymph nodes were found in SUV~max~, TLG, VOL and heterogeneity in stage IIIA (p = 0.03, p = 0.003, p = 0.004, p = 0.0002), IIIB (p = 0.01, p = 0.003, p = 0.001, p = 0.0005) and IV (p = 0.002, p = 0.003, p = 0.004, p = 4.02E-08) respectively. **Conclusion:** Our preliminary results suggest that PET metabolic parameters in lymph nodes may be the prognostic factors for OS in advanced stages in patients with NSCLC.
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**Background/Aims:** Whole body metabolic tumour volume (MTV) and total lesions glycolysis (TLG) have been found to be reliable prognostic factors in predicting the biologic aggressiveness of non-small cell lung carcinoma (NSCLC), versus the maximum standard uptake value (SUV~max~). Whole body metabolic parameters in patients with extensive disease, however, can be lengthy and confounded by intense physiologic activity from other structures. The utility of intrathoracic PET MTV and TLG in relation to predicting clinical outcomes in patients with NSCLC remains to be clarified, however, and was looked into in this study. **Methods:** This retrospective cohort study was approved by the institutional review board. A total of 46 treatment-naive patients with NSCLC, who underwent PET/CT using ^18^F-FDG from 2012-2015 at a tertiary hospital in the Philippines were included. MTV and TLG of intrathoracic lesions on ^18^F-FDG PET CT were determined. Receiver operating characteristic curve was used to determine cut-off values for high and low MTV and TLG. The progression free survival (PFS) between groups, as determined by the cut-off levels, was assessed using the Kaplan-Meier method. **Results:** The median follow-up time was 9.8 months. The median PFS of patients with a high intrathoracic MTV of ≥135, was significantly lower than those with a low intrathoracic MTV of \<135 with 4.7 months and 14.8 months respectively (p = 0.00056). The median survival of patients with a high intrathoracic TLG of \>400 was also significantly lower at 6.6 months than those with a low intrathoracic TLG of \<400 of 14.8 months (p = 0.00044). The Kaplan-Meier curves also showed statistically significant differences in relation to PFS according to intrathoracic MTV and TLG. **Conclusion:** The role of using intrathoracic metabolic parameters such as MTV and TLG from baseline FDG PET/CT scans may provide clinicians with a more accurate prognosis for patients with NSCLC as both are significantly related to the length of PFS.
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**Background/Aims:** We investigated the correlation of semi-quantitative index of ^99m^Tc-4PRGD~3~ SPECT/CT and clinical histological characteristics such as lesion size, lymph node involvement, TNM stage, ER, PR, HER2, and Ki67 of patients with breast cancer. **Methods:** There were 45 patients (53.0±9.5 years old) with suspected breast malignant nodules or masses from October 2016 to June 2017. The patients were examined with SPECT/CT in position after injecting ^99m^Tc-4PRGD~3~. All cases had pathological results. ER, PR, HER2, and Ki67 were obtained by immunohistochemistry and fluorescence in situ hybridization (FISH). The Mann-Whitney U test was used to compare SPECT/CT parameters according to independent breast cancer subgroup. **Results:** 35 patients with invasive ductal carcinoma were confirmed by pathology. There were 7 patients in stage I, 11 patients in stage IIA and 17 patients in stage IIB according to the eighth edition of AJCC breast cancer guide. The cases of four breast cancer subtypes (luminal A subtype, luminal B subtype, HER2 subtype, triple negative subtype) were 6, 9, 9 and 11, respectively. The T/NT values were significantly higher in the HER2 subtype than in the triple negative subtype (5.03±1.77 vs 3.00±0.99, p = 0.02). And the T/NT values were significantly higher in the patients in stage IIB than in stage I and IIA (4.54 ± 1.46 vs 3.32 ± 1.72, p = 0.02). Besides, the T/NT values were significantly higher in the HER2-positive group than in the HER2-negative group (5.03 ± 1.77 vs 3.53 ± 1.52, p = 0.03). The T/NT values were significantly higher in the lymph nodes metastasis positive group than in the negative group (4.79 ± 1.38 vs 2.88 ± 1.45, p = 0.01). There was no statistical difference between ER-positive group and ER-negative group, PR positive group, and PR negative group, Ki67 positive group and Ki67 negative group (4.02 ± 1.86 vs 3.85 ± 1.63, 4.12 ± 1.66 vs 3.45 ± 1.76, 4.11 ± 1.84 vs 3.48 ± 1.28, p = 0.65, 0.28, 0.29, respectively). **Conclusion:** ^99m^Tc-4PRGD~3~ SPECT/CT semi-quantitative index has the correlation with the expression of HER2. It deserves further study to predict molecular phenotypes in breast cancer patients.

P069: Prognostic Value of Percentage Change in Metabolic Parameters as Measured by Dual Time Point
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F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Premenopausal Women With Invasive Ductal Breast Carcinoma
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**Background/Aims:** Young female patients with breast cancer have a poorer prognosis and higher recurrence probability compared to older women.\[[@ref214]\] The SUV~max~ using ^18^F-FDG PET/CT is preferred as a metabolic parameter. However, this parameter is limited because it reflects only a single pixel that does not represent the metabolism of the entire tumour. To overcome this limitation, the volumetric parameters as metabolic tumour volume (MTV) and total lesion glycolysis (TLG) were proposed for prognostic values.\[[@ref215]\] FDG accumulation in tumour cells continues to increase over time. It can improve the diagnostic performance and prognostic value in breast cancer.\[[@ref216]\] Therefore, the purpose of this study was to demonstrate the prognostic value of metabolic parameters using dual time point (DTP) ^18^F-FDG PET/CT compared with clinicopathological factors in premenopausal women with invasive ductal breast carcinoma (IDC). **Methods:** We reviewed clinical information from 66 premenopausal patients diagnosed with IDC. The SUV~max~, MTV and TLG were measured and percentage changes over time for early and delayed images were calculated. Clinicopathological characteristics including age, pathological tumour diameter (pTD), axillary lymph node status (ANS), nuclear grade, histological grade, and immunohistochemistry findings were analysed. For recurrence-free survival analysis, the Kaplan-Meier method was performed using a log-rank test. After that, multivariate analysis using Cox proportional hazards regression model was performed to evaluate independent prognostic factors. **Results:** Disease recurrence occurred in 22 patients. Premenopausal patients with a pathological tumour diameter greater than 2.8 cm (p = 0.001), metastatic ANS (p = 0.008), ER negativity (p = 0.013) and Triple negativity (p = 0.01) had poor RFS compared to those without. DTP parameters SUV~max~ (p = 0.013), MTV (p = 0.014), TLG (p \< 0.001), %ΔSUV~max~ (p = 0.007), and %ΔTLG (p = 0.046) were significant predictors of poor prognosis. After multivariate analysis, ER negativity (p \< 0.001), TLG (p \< 0.001), and %ΔSUV~max~ (p = 0.004) showed statistical significances. **Conclusion:** We demonstrated that percentage changes of SUV~max~ by DTP PET/CT and single time point of TLG were significant independent prognostic factors of disease recurrence align with ER negativity in premenopausal women with IDC.

This research was supported by grants from the National Research Foundation (2015R1C1A02037051, 2015R1C1A2A01054113).

P070: Prediction of Sentinel Lymph Node Status Using Single Photon Emission Computed Tomography/Computed Tomography Imaging of Breast Cancer: Comparison with Clinico-Pathological Factors
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**Background/Aims:** Single-photon emission computed tomography/computed tomography (SPECT/CT) improves the anatomical identification of sentinel lymph nodes (SNs). We aimed to evaluate the possibility of predicting the SN status and the additional value in breast cancer patients using SPECT/CT. **Methods:** SN mapping using a SPECT/CT system was performed in clinically node-negative, operable invasive 415 breast cancers of 411 patients, consequently. SNs are depicted as hot nodes on SPECT/CT. We assessed the number and the location of nodes detected on SPECT/CT, and compared and verified SN status and clinicopathological results. **Results:** The total number of hot nodes on SPECT/CT was 500 detected in 410 breast cancers. In 5 cases (1.2%), the SN could not be detected on SPECT/CT imaging. According to the final histological diagnosis, in 88 cases (21.2%), metastatic cancer was positively proven in the SN, and 327 (78.8%) were node negative. In 387 lesions (93.3%), the hot nodes were located within the Level I area, while 23 (5.5%) were located in other areas. The SN status was significantly correlated with the number of hot nodes in the Level I area (p \< 0.001) and total number of hot nodes (p = 0.021) detected on SPECT/CT. **Conclusion:** The SNs located outside of the Level I and the number of SNs detected using the SPECT/CT system may be the predictive risk factors for SN metastasis.

P071: Clinical impact of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Breast Cancer Restaging
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**Background/Aims:** Many clinical studies have demonstrated the value of position emission tomography/computed tomography (PET/CT) in breast cancer management. However, its use remains non-standardised as an unfunded indication and is subject to referral pattern, access and resources. This retrospective study aims to define the clinical impact of FDG-PET in our local health district. **Methods:** Patients with known breast cancer restaged with ^18^F-fluorodeoxyglucose (FDG) PET/CT for suspected recurrence, progression or to assess treatment response were eligible for review. PET/CT studies were compared with contemporaneous conventional imaging (CI) and whole-body bone scan (WBBS) as reference and all studies were independently reviewed. Data was referenced to either surgical histology or consensus clinical findings at follow-up and any change in management was recorded. Study was approved by the local ethics committee. **Results:** From January 2014 to August 2017, 114 patients with breast cancer had FDG-PET/CT for restaging. 60 patients (52.6%) had CI and 34 patients (30%) had WBBS as reference to non-osseous and osseous disease respectively within 60 days of the PET/CT. In the non-osseous group, there was a high level of concordance between the two imaging modalities but FDG-PET did reveal additional lesion in the same region/organ or new disease sites in 30% of the cases. In the osseous group, 65% had imaging concordance (77% negative and 23% same distribution). Overall, the management plan was altered based on the FDG-PET result in 22% of the subjects. **Conclusion:** In the setting of restaging breast cancer, FDG-PET altered management in 22% compared to current reference imaging in our local practice.
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F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Early Stage Breast Cancer with No Lymph Node Metastasis
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**Background/Aims:** To investigate the correlation between SUV~max~ of FDG-PET/CT and pathological findings including prognostic factors in early-stage T1-T2 breast cancer patients with no lymph node (LN) metastasis. **Methods:** This retrospective study investigated 75 patients (mean age 58.9 years; age range 30-82 years) with invasive breast cancer who underwent FDG PET/CT for preoperative staging. All patients underwent subsequent surgery without prior neoadjuvant chemotherapy or endocrine therapy, and those who were confirmed to have T1-or T2-stage by histopathology with no LN metastasis were included. Two patients who had no perceptible FDG accumulation on PET/CT scans were excluded. The correlations between the SUV~max~ of the tumour and the pathological and immunohistochemical data were evaluated. **Results:** The mean SUV~max~ for the total 73 tumours was 5.46±4.05. The mean SUV~max~ was 3.95±3.28 for the T1 stage group (n = 36) and 7.23±4.10 (p \< 0.001) for the T2 stage group (n = 37). A high SUV~max~ was significantly associated with high nuclear grade (p \< 0.001), negative hormone receptor status (p \< 0.001), positive HER2 status (p = 0.008), and high Ki-67 status (p \< 0.001), respectively. **Conclusion:** In T1-T2 breast cancer with no LN metastasis, the SUV~max~ of FDG-PET/CT had significant positive relationships with several prognostic parameters of pathological status. Even in early-stage breast cancer patients, pre-treatment FDG-PET/CT is useful for predicting malignant behaviour and prognosis.
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F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography with Conventional Imaging in the Detection of Tumour Recurrence and Metastasis in Breast Cancer
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**Background/Aims:** The aim of this study was to evaluate the impact of ^18^F-FDG PET/CT on clinical management in patients with recurrent breast cancer and to compare the FDG PET/CT results with the conventional imaging (CI) data. **Methods:** The aim of this study was to evaluate the impact of ^18^F-FDG PET/CT on clinical management in patients with recurrent breast cancer and to compare the FDG PET/CT results with the conventional imaging (CI) data. **Results:** Fifty patients were included. In 22 patients (44%) FDG PET/CT revealed locoregional tumour localisation. Distant metastases were detected in 10 patients (20%) on conventional imaging, and in 22 patients (44%) on ^18^F-FDG PET/CT images. In 22 patients, ^18^F-FDG PET/CT detected additional lesions not visible on conventional imaging. The sensitivity, specificity, accuracy, positive and negative predictive values of ^18^F-FDG PET/CT were 92%, 25%, 76%, 80%, and 50%, respectively. The sensitivity, specificity, accuracy, positive and negative predictive values of CI were 45%, 58%, 48%, 77%, and 25%, respectively. An upstaging could be observed in 18 patients by detecting more extensive locoregional or distant metastasis. Absence of recurrence was established in 12 patients. In 19 patients treatment option was changed. **Conclusion:** PET/CT demonstrates apparent advantages in the diagnosis of tumour recurrence or metastasis with breast cancer. compared with CI. In patients with clinical suspicion, PET/CT seems to be a reliable imaging tool for detection of tumour recurrence or metastasis.

P075: Evaluation of Mucinous Breast Carcinoma with Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Mammography
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**Background/Aims:** We evaluated the metabolic and anatomical characteristics of mucinous breast carcinoma using FDG PET/MR mammography. **Methods:** Fourteen pure and three mixed single mucinous carcinoma of the breast who underwent preoperative FDG PET/MR mammography (Biograph mMR, Siemens) were retrospectively studied. FDG uptake, apparent diffusion coefficient (ADC), signal intensities, and tumour enhancement patterns were analysed by PET/MR imaging. **Results:** FDG uptake was noted in 16 patients except one. The SUV~max~ was 2.7±1.6 (n = 16). The signal intensities on fat-saturated T2-weighted images of the regions with and without FDG uptake (n = 16 vs 6) were 747.9 ± 168.9 and 1021.8 ± 233.4, respectively (p \< 0.05). The ADC were 1678.5 ± 469.9 and 2405.61 ± 352.3 (p \< 0.05), respectively. The kinetic curve in 16 regions with FDG uptake showed 4 washout, 5 plateau and 2 gradually enhancing patterns. The six regions without FDG uptake showed one gradually enhancing pattern. **Conclusion:** Mucinous breast carcinoma showed FDG avidity in 94.1% and washout and plateau enhancing patterns in 56.3%. The areas with FDG uptake might be related with more cellularity and less mucin component.

P076: Unilateral Lactation Due to Contralateral Inflammatory Breast Cancer Demonstrated on FDG Positron Emission Tomography
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**Background/Aims:** During lactation, there is an increase in glandular vascularity and in the activity of the ductal muscles.\[[@ref217][@ref218]\] Additional glucose is thus utilised for mammary gland function. It has also been shown that suckling can increase the expression of insulin-independent glucose transporters, again increasing the uptake of glucose in the breast used for lactation.\[[@ref219]\] Overall this results in a diffuse symmetrical uptake of FDG in the lactating breasts, which may obscure the results of the PET investigation.\[[@ref217][@ref220][@ref221]\] Previous cases have demonstrated the phenomenon of increased avidity in lactating breasts with both ^123^I scintigraphy, Gallium, and ^18^F-FDG PET.\[[@ref220][@ref221][@ref222][@ref223][@ref224][@ref225][@ref226]\] **Methods:** A PET/CT study was performed on a Philips Gemini TF scanner following the administration of ^18^F-FDG. A low dose CT was also performed with dilute oral contrast for lesion localisation and attenuation correction as per departmental protocol. **Results:** A 35-year-old woman with a recent diagnosis of right sided inflammatory breast cancer presented for a staging ^18^F-FDG PET study. She was 11 weeks postpartum at the time. Intense tracer uptake was noted focally in the right breast, as well as superficially in the dermis of the right breast and in ipsilateral axillary lymph nodes. Diffuse intense FDG uptake was noted throughout the left breast without focality. The patient clarified that she was breastfeeding unilaterally with her left breast due to pain associated with the right breast carcinoma. She also had no abnormalities in the left breast on recent mammogram. **Conclusion:** This case due illustrates that pathology affecting one breast can alter behaviour resulting in normal physiological changes only present in the contralateral side, emphasizing the importance of the clinical history in interpreting FDG PET results.

P077: Utility of Molecular Breast Imaging as a Preoperative Imaging Modality to Localize the Sentinel lymph Node: A Case Series
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**Background/Aims:** Sentinel lymph node (SLN) localization and biopsy are now the "standard of care" for staging the axillary lymph nodes in breast cancer patients\[[@ref227]\]. The pre-operative procedure includes periareolar injection of ^99m^Tc-sulfur colloid, molecular breast imaging (MBI) and gamma probe localization. The intra-operative procedure includes administration of coloured dye, gamma probe localization and surgical removal of the detected SLNs.\[[@ref227]\] The objective is to demonstrate the utility molecular breast imaging in the pre-operative imaging of sentinel lymph node localization. **Methods:** Chart review of 2 patients who underwent sentinel node biopsy using molecular breast imaging (GE Discovery NB 750b) as the pre-operative imaging modality in the localization of sentinel lymph node was done. **Results:** First case is a 55 year old woman with infiltrating ductal carcinoma of the left breast. MBI showed successful localization of one SLN in the left axilla with 202 counts on the gamma probe. On surgical pathology report, the node was positive for metastasis. Second case is a 57 year old woman with invasive mammary carcinoma with lobular features. MBI showed successful localization of one SLN in the right axilla with 904 counts on the gamma probe. On surgical pathology report, the node was positive for metastasis. **Conclusion:** This case series show that MBI can be used as a pre-operative imaging modality to localize the sentinel lymph node.

P078: Metastatic Location on the Bones of Breast Cancer
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**Background/Aims:** Breast cancer is the most common cancer in women. The spread of this cancer most often to the bone, however, not many reported the frequency of occurrence of metastasis in each/bone group. The frequency is quite important to know in addition for treatment also for educating patients. Identification of bone metastasis can be easily performed by bone scan. The purpose of this study is to know the frequency and location of metastasis in each group or part of bone on breast cancer. **Methods:** This study method is descriptive retrospective based on medical record of breast cancer cases which carry out examination of bone scan in Hasan Sadikin Hospital from 2012-2016. Bone scan was performed statically using a gamma camera at 3 hours post-injection of ^99m^Tc-MDP. The presence or absence of metastases is determined by the conclusions of visual bone analysis results. The location of metastases corresponds to the location of the metastatic lesions listed in the description section of the bone scan report. **Results:** During 2012 to 2016, it has been noted that bone scan procedure has been performed on the indication of the presence/clinical information of metastasis in bone as much as 2084 cases (patients with breast cancer were 921 cases (44.1%), age range 23-84 years). The incidence of bone metastasis was found in 572 (62.1%) breast cancer cases. The five groups or bone segments that are commonly found in the presence of metastatic lesions are vertebrae in 395 (69%) cases, costae 257 (45.1%) cases, calvaria 186 (32.5%) cases, femur 171 (29.8%) cases, acetabulum 157 (27.4%) cases. **Conclusion:** Metastasis occurs in almost half of the breast cancer cases with the highest frequency of bone metastases occurring in the vertebrae.
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F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Posttreatment Monitoring of Female Patients with Invasive Ductal Breast Carcinoma: A Case Control Study
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**Background/Aims:** Breast cancer is the most common cancer and the leading cause of cancer death among women. ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is useful for staging advanced disease, monitoring response to therapy, restaging, and detecting recurrent disease. **Methods:** This is a pilot study of patients with invasive ductal breast carcinoma who had definitive surgical tumour removal, received standard treatment, and had at least one FDG-PET/CT scan post-treatment from January 2012 to September 2017. Participants were age-matched based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. **Results:** Twenty-one subjects were included. FDG-PET/CT increased tumour burden in six cases, reclassified one case to disease progression, and one case to complete response. FDG-PET/CT showed a higher incidence of disease progression in triple negative (TN) cases. TN cases had a 1.5 risk for disease progression compared to non-TN cases and had four times the risk for disease progression if the time interval to FDG-PET/CT scan from time of diagnosis is more than one year compared to non-TN cases. Diagnosis of TN in cases more than 50 years old had thrice the risk for disease progression. There was very good agreement between FDG-PET/CT and clinical diagnosis as shown by the Kappa value of 0.91. **Conclusion:** FDG-PET/CT can be best utilized clinically for invasive ductal breast carcinoma patients with a triple negative molecular subtype, diagnosed at aged 50 years and older, especially if with a clinical suspicion of disease progression or recurrence.

**Disclosure of Interest:** I Bandong Conflict with: St. Luke's Medical Center; F G Estrada Conflict with: St. Luke's Medical Center.

P080: Multimodal Radiomic Imaging: Comparison of Positron Emission Tomography, Magnetic Resonance Imaging-Postcontrast-Magnetic and Intravoxel-Incoherent-Motion Heterogeneity in Gastro-Oesophageal Cancer
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**Background/Aims:** This study investigated the value of pre-treatment ^18^F-FDG PET radiomics in comparison to T1-weighted-post-contrast-magnetic-resonance-imaging (MRI-pCM) and intravoxel-incoherent-motion-diffusion-weighted-magnetic-resonance-imaging (IVIM) radiomics in patients with gastro-oesophageal cancer. **Methods:** This prospective cohort study was approved by the review board of our institution. A total of 23 patients were prospectively analysed. 231 radiomic features of first, second, and higher order were extracted from the primary tumour. Dimensionality of features was reduced with a Principal Component Analysis. The relationship of selected features to clinical parameters was determined. Association of features between the different modalities was compared (Spearman "ρ"). **Results:** Selected radiomic features of PET showed only very weak correlation to staging (-0.2\<ρ\<0.15) and follow-up status (-0.1\<ρ\<0.2), and weak correlation to differentiation grading (-0.27\<ρ\<0.26). Heterogeneity features of MRI-pCM showed weak correlation to staging (-0.28\<ρ\<0.16), follow-up status (-0.26\<ρ\<0.34), and to differentiation grading (-0.15\<ρ\<0.33). In contrast, several heterogeneity features of IVIM showed strong correlation to staging (-0.6\<ρ\<0.62). Correlation to follow-up status (-0.4\<ρ\<0.4), and to differentiation grading (-0.15\<ρ\<0.36) was weak to moderate as well. Comparison between PET and MRI-pCM showed moderate to strong correlation for the comparison of the respective heterogeneity feature (0.47\<ρ\<0.77). Interestingly, comparison between PET and IVIM showed only very weak to moderate correlation (0.09\<ρ\<0.59). **Conclusion:** IVIM radiomic features provide useful and probably complementary information in addition to PET, which might help in prognostication and therapy prediction. PET and MRI-pCM heterogeneity parameters on the other hand showed stronger correlations. Radiomics in a multimodality approach might be a valuable tool for non-invasive pre-therapeutic characterization of gastro-oesophageal cancer.
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F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography as a Surveillance Tool in the Follow up of Gastrointestinal Stromal Tumours
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**Background/Aims:** The gastrointestinal stromal tumours (GIST) are generally effectively treated surgically however, depending on their variable risk, postoperative recurrence rate remains a concern. Surveillance post-surgery and chemotherapy assists in detecting recurrence early to allow timeous institution of relevant management. We evaluated the role of ^18^F-FDG PET/CT (PET/CT) in the surveillance of GIST patients post treatment. **Methods:** PET/CT scans were done according to departmental protocol following surgery or chemotherapeutic intervention. Disease recurrence, residual disease or progression was confirmed on histology, dedicated imaging or follow-up following initial management. **Results:** 46 patients aged 25 to 84 years (mean = 56.5±12.9) with histologically confirmed GIST tumours (27 stomach, 7 small bowel, 4 mesentery, 3 rectum, 2 gastro-oesophageal junction, 1 oesophagus, 1 bladder and 1 unknown) underwent a total of 161 PET/CT scans ranging from a period of 3 to 18 month intervals depending of the patients risk assessment. A total of 42 scans demonstrated FDG avid disease with 71% were due to recurrence or residual disease, 23% due to disease progression during the surveillance period. PET/CT had a sensitivity, specificity and accuracy of 90%, 98% and 96% respectively. Early detection of disease recurrence or progression with PET/CT during the surveillance period allowed for a change in management and/or institution of new management i.e. surgery/radiotherapy/chemotherapy in 45% of the cases and an overall change in 12.3% of all the cases monitored. Complete disease remission was acquired in 11 of the 46 patients monitored during the surveillance period. **Conclusion:** This study demonstrates the potential role of ^18^F-FDG PET/CT scan as a valid consideration in the surveillance of GIST tumours and may assist in early institution of management or augmentation of on going treatment in disease recurrence or monitoring disease response in this setting.
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**Background/Aims:** To investigate the prognostic value of SUV~max~, SUV~mean~, MTV and TLG calculated from ^18^F-FDG PET/CT results in patients with postoperative colorectal cancer. **Methods:** From March 2007 to October 2015, eighty patients with colorectal cancer who underwent preoperative ^18^F-FDG PET/CT were retrospectively enrolled. The optimal cutoff point of progression-free survival (PFS) of SUV~max~, SUV~mean~, MTV and TLG were investigated by using ROC curve analysis. The Kaplan-Meier method and Log-rank test were used to perform univariate survival analysis and Cox proportional hazards model for multivariate analysis. **Results:** The SUV~max~, SUV~mean~, MTV and TLG of 80 patients were 11.83 (4.26, 35.42), 7.0 (2.38, 20.92), 20.47 (1.29,161.50) cm^3^, 138.58 (14.17, 857.89), respectively. Univariate analysis showed that location, histopathological grade, N staging, M staging, clinical stage, MTV and TLG were all significantly associated with PFS and OS (all p \< 0.05), and postoperative chemotherapy was only significantly associated with PFS (p \< 0.05). In multivariate analysis, clinical staging and TLG were independent influencing factors for PFS (p = 0.007, HR = 9.879, 95% CI 1.854\~22.836); (p = 0.031, HR = 3.569, 95% CI 1.127\~11.306); and M staging, clinical staging and TLG were independent influencing factors for OS (p = 0.024, HR = 4.522, 95%CI 1.223\~6.717), (p = 0.014, HR = 9.315, 95%CI 1.338\~24.864); and (p = 0.002, HR = 10.120, 95%CI 2.385\~12.947). **Conclusion:** TLG in ^18^F-FDG PET/CT is an independent prognostic factor for predicting PFS and OS in patients with colorectal cancer after curative resection, suggesting that it can be used to guide individual treatment.

P083: Assessment of Tumour Response to Neoadjuvant Chemotherapy in Patients with Oesophageal Cancer with Computed Tomography and Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: RECIST 1.1 Versus PERCIST 1.0
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**Background/Aims:** To compare Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 with Positron Emission Tomography Response Criteria in Solid Tumours (PERCIST) 1.0 response classification and determine the best parameter for assessment of response to neoadjuvant chemotherapy in patients with oesophageal cancer. **Methods:** The institutional review board approved this study, waiving the requirement to obtain written informed consent. 62 patients with oesophageal cancer underwent fluorodeoxyglucose (FDG)-PET/CT and contrast-enhanced CT before and after neoadjuvant chemotherapy prior to planned surgical resection. Primary tumour's longest diameter, maximum standardised uptake value (SUV~max~), peak lean body mass SUV (SUL~peak~), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) were measured. Patients were divided into two pathological response groups: "responders" (grades 1b-3) or "non-responders" (grades 0-1a). **Results:** Concordance between RECIST 1.1 and PERCIST 1.0 response classifications was seen in 28 (45.2%) patients. Among 18 patients defined as "responders", the number of metabolic responders (partial metabolic response + complete metabolic response) by PERCIST 1.0 was 17 patients and the number of anatomic responder (partial response + complete response) by RECIST 1.1 was 13 patients. The areas under the receiver operating characteristics curves for distinguishing responders from non-responders were 0.724, 0.775, 0.781, 0.756, and 0.759 for the reduction rate of primary tumour's longest diameter, SUV~max~, SUL~peak~, MTV, and TLG, respectively. The optimal %decrease in longest diameter cut-off value of 39.2% was found to have 66.7% sensitivity and 70.5% specificity. The optimal %decrease in SUL~peak~ cut-off value of 55.8%, showed 77.8% sensitivity and 75.0% specificity. **Conclusion:** PERSIST 1.0 may be more suitable for evaluation of neoadjuvant therapeutic response to oesophageal cancer than RECIST 1.1.
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**Background/Aims:** To investigate the prognosis after surgical curative resection using fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (^18^F-FDG PET/CT) parameters in oesophageal cancer patients. **Methods:** This study was retrospective, and our patient population consisted of 205 patients (169 men and 36 women). The median age was 67 years (range, 34-82). The patients who underwent neoadjuvant chemotherapy were excluded. The maximum standardised uptake value (SUV~max~), volumetric parameters (metabolic tumour volume (MTV), total lesion glycolysis (TLG)), SUV~peak~ and maximum SUV corrected for lean body mass (SUL~max~) of primary lesions were calculated. Threshold of 40% of the maximum peak activity within the lesions and fix value (2.5) was used to delineate the MTV. Overall survival (OS) and disease-free survival (DFS) were evaluated by Kaplan-Meier method, and the difference in survival between subgroups was analysed by log-rank test. All continuous variables were dichotomized according to specific cut off values determined using ROC analysis. The prognostic significance of all PET parameters and clinicopathological variables was assessed by Cox proportional hazard regression analysis. **Results:** On the Kaplan-Meier survival curves, the patients with all high PET parameters showed significantly worse prognosis than those with low values for DFS and OS (p \< 0.001 for all). With adjustment for several clinicopathological variables, Cox regression analysis showed that all PET parameters were significantly related to DFS (p \< 0.005 for all), and that SUL~max~ remained statistically significant for OS (HR = 2.107; 95%CI 1.042-4.258; p = 0.038). However, volumetric parameters, SUV~max~ and SUV~peak~ were not significant prognostic factors for OS (SUV~max~: HR = 1.446; 95%CI 0.735-2.844; p = 0.285, MTV40: HR = 1.710; 95%CI 0.945-3.094; p = 0.076, TLG40: HR = 1.489; 95%CI 0.765-2.900; p = 0.241, SUV~peak~: HR = 1.943; 95%CI 0.963-3.923; p = 0.064, MTV2.5: HR = 1.278; 95%CI 0.673-2.474; p = 0.454, TLG2.5: HR = 1.307; 95%CI 0.675-2.529; p = 0.427). **Conclusion:** SUL~max~ is more useful prognostic factor for OS than SUV~max~, SUV~peak~ and volumetric parameters in surgically resected oesophageal cancer patients.
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**Background/Aims:** In Japan, FDG-PET has been covered by the national health insurance for oesophageal cancer since 2006. It is true that FDG-PET is useful for staging, especially for detection of distant metastases, but it is controversial whether FDG-PET can prolong survival of patients with locally advanced oesophageal cancer. The purpose of this study was therefore to determine whether FDG-PET can improve survival in patients with locally advanced oesophageal cancer. **Methods:** We retrospectively reviewed all patients with cT4 and without M1 oesophageal cancer who had been treated by definitive chemoradiotherapy in our institution between 2000 and 2014. The eligibility criteria included 1) cT4 oesophageal cancer without distant metastases or M1 lymph nodes (UICC 2002), 2) histologically proven squamous cell carcinoma, 3) 20 to 79 years of age, 4) having undergone at least 1 cycle of concomitant chemotherapy, 5) having been irradiated with 50 Gy or more, and 6) no other active malignant tumour during treatment. **Results:** Seventy-eight patients were enrolled in this study. The median observation period was 68 months. The 3-year and 5-year overall survival rates in all patients were 36.9% (95%CI 25.9-47.9%) and 30.8% (95%CI 20.2-41.4%), respectively. FDG-PET was not performed before treatment in 41 patients of the 78 patients and was performed in the other patients. There was no significant difference in overall survival (OS) or progression-free survival (PFS) between patients in whom FDG-PET was performed and those in whom FDG-PET was not performed (12 months vs. 11 months, p = 0.920, and 6 months vs. 6 months, p = 0.844, respectively). **Conclusion:** Compared with only CT, additional information from FDG-PET cannot prolong survival in patients with locally advanced oesophageal cancer.
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Huang\*

Yu-Ting

1

Lam

A K Y

2

3

Melville

P

3

Du

L

1

3

T Huang

Y T

1

3

Department of Medical Imaging, Australia

Pathology Queensland, Gold Coast University Hospital, Australia

School of Medicine, Griffith University, Southport, Australia

**Background/Aims:** Oesophageal cancer carries significant morbidity and mortality. Recent studies have demonstrated profound survival benefit with neoadjuvant chemoradiation therapy (CRT) prior to surgery. Positron emission tomography with computed tomography (PET/CT) using ^18^F-fluorodeoxyglucose (FDG) is useful for oesophageal carcinoma staging/restaging and is promising in defining CRT response with prognostic values. **Methods:** Single centre retrospective review of patients with oesophageal cancer treated with neoadjuvant therapy. All subjects had staging and restaging PET/CT under standard protocol. Multiple FDG-PET quantitative variables were assessed including standardised uptake value (SUV), metabolic tumour volume (MTV) and total lesion glycolysis (TLG). Pathologic tumour regression (TR) was assessed based on Mandard classification. Statistical correlation between metabolic and histologic parameters was performed in conjunction with disease-specific survival outcome from clinical records. Study was approved by the local ethics board. **Results:** 40 subjects, 82% male with mean age of 66 (range 41 to 86) were analysed. 85% had neoadjuvant CRT and others had chemotherapy or radiation alone. 71% were adenocarcinoma and 29% were squamous cell carcinoma. 47% had completion oesophagectomy and 5 additional patients had definitive CRT. At time of census, 11 subjects have deceased. There was a statistically significant correlation between a reduction in primary tumour SUV~max~ (ΔSUV~max~) and ΔTLG of \>35% with histologic TR (p \< 0.05) but stronger with ΔTLG. Primary tumour MTV and TLG at baseline showed a trend towards poor treatment response and death. ΔNodal parameters all statistically correlated with primary TR (p \< 0.05). **Conclusion:** In this study, primary tumour ΔSUV~max~, ΔTLG and all nodal parameters correlated with pathologic TR. TLG being the combination of metabolic activity and volumetric assessment of the tumour appears to be the most superior PET parameter.

P087: Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Ampullary Neoplasms: Diagnostic Utility and Correlation with Survival
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**Background/Aims:** Primary ampullary neoplasms account for one fifth of tumour-related bile obstruction despite its rare incidence.\[[@ref228]\] Whipple's procedure is indicated in ampullary cancer, whereas adenomas can be treated with local resection.\[[@ref228][@ref229]\] However, it is often difficult to distinguish malignant from benign neoplasms before surgery, especially in cases where adenocarcinoma arises from adenoma.\[[@ref229][@ref230]\] The aim of this study is to investigate whether ^18^F-FDG positron emission tomography/computed tomography (PET/CT) can aid in differentiating malignant and benign ampullary neoplasms. The association of PET imaging biomarkers with survival in patients with ampullary cancer will also be evaluated. **Methods:** This study was approved by the institutional review board and all participants signed informed consent. From June 2007 to July 2017, consecutive patients with known ampullary neoplasms referred from Endoscopic Center of National Taiwan University Hospital for PET/CT were enrolled. Lesions in PET/CT were analysed using 5-point visual scale and semiquantitatively by blood-pool corrected standardized uptake value (SUVR). All PET parameters were correlated with final histopathology using logistic regression. Cut-off values to differentiate malignant from benign lesions were obtained from the receiver-operating-characteristic curve analysis. The association between PET parameters and survival was further analysed by the Cox proportional hazards model. **Results:** Eighty-nine patients were enrolled: 32 ampullary adenomas (median size, 15.7±5.5mm) and 57 ampullary cancers (median size, 15.9±9.2mm). Using cut-off SUVR of 2.3 and 3.4 in early and delayed-phase scans, the sensitivity, specificity, and AUC of SUVR were 71.9%, 78.1%, 0.76, and 75.0%, 78.1%, 0.79, respectively. Patients with ampullary cancers showing SUVR\>2.5 had a lower progression-free survival at 3-year (39.2% *vs*. 74.6%, p \< 0.05). **Conclusion:** PET/CT shows fair sensitivity and specificity in differentiating malignant and benign ampullary neoplasms. Also, SUVR may predict progression-free survival in patients with ampullary cancers.
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**Background/Aims:** The aim of this study was to explore the predictive value of ^18^F-FDG PET/CT metabolic related parameters for KRAS mutation in colorectal cancer patients. **Methods:** Retrospective analysis was conducted in 150 patients (105 males, 45 females, median age 63 years) with CRC who underwent ^18^F-FDG PET/CT examination between November 2011 and August 2017. The patient numbers for KRAS-mutated and wild-type were 78 and 72, respectively. The primary tumour were removed by surgery and received genetic testing in one month after PET scans. None of the patients received prior chemotherapy or radiation therapy before surgery. ^18^F-FDG PET/CT metabolic related parameters were measured, including SUV~max~, MTV~2.5~, MTV~20%~, MTV~30%~, MTV~40%~, MTV~50%~, TLG~2.5~, TLG~20%~, TLG~30%~, TLG~40%~, TLG~50%~. Mann-Whitney U test and logistic regression analysis were carried out for this analysis; ROC curve was used to determine the optimal cut-off values of meaningful parameters. **Results:** Both SUV~max~ (P = 0.000) and MTV~2.5~ (P = 0.001) were significantly higher in the KRAS-mutated group compared with the wild-type group, multivariate analysis showed that SUV~max~ (OR 1.176; 95%CI,1.043-1.327, p = 0.008) and MTV~2.5~ (OR 1.125; 95%CI 1.002-1.263, p = 0.046) were the 2 predictors of KRAS mutation. The prediction accuracy of KRAS mutation were 67.33% and 65.33%, respectively, with SUV~max~ 15.5 and MTV~2.5~ 23.79cm^3^ as the cut-off value. The accuracy of SUV~max~ and MTV~2.5~ for predicting KRAS mutant were higher in rectal or sigmoid colon cancers. **Conclusion:** SUV~max~ and MTV~2.5~ can predict KRAS mutation in colorectal cancer, but the prediction efficiency is not enough to replace the clinical gene detection.

P089: Positron Emission Tomography/Computed Tomography Finding of Rectosigmoid Cancer with a Liver Metastasis in the Investigation of Fever of Unknown Origin: A Case Study
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**Background/Aims:** A 45 year old male presented with drenching night sweats, constipation, abdominal pain, 20kg weight loss in the last year and elevated C-Reactive Protein (CRP). He was diagnosed with Still's disease in childhood and was stable on prednisolone. The patient was referred for a Positron Emission Tomography/Computed Tomography (PET/CT) scan to exclude lymphoproliferative disorders, vasculitis or infection prior to escalating immunosuppression. **Methods:** Following a 6 hour fast, 275MBq of Fluorine-18 Fluorodeoxyglucose (^18^F-FDG) was injected intravenously and 60 minutes later PET/CT images were acquired from the skull vertex to the knees on a Siemens Biograph mCT Flow PET/CT scanner. **Results:** The PET/CT scan revealed prominent ^18^F-FDG uptake in a focal liver lesion with increased uptake at its periphery and reduced in its centre, and also patchy uptake in the rectosigmoid region. While the history of fevers, raised CRP and scan appearance of the liver were suggestive of a liver abscess, the colonic lesion suggested malignancy. The patient also had a CT of the chest and abdomen that reported a liver lesion and rectal thickening. Magnetic Resonance Imaging of the pelvis and liver, and biopsy of the rectal mass confirmed the diagnosis of rectosigmoid cancer with a liver metastasis. The patient responded to chemoradiotherapy and awaits surgery. **Conclusion:** As a result of performing the PET/CT this patient with FUO was diagnosed with rectosigmoid cancer and a liver metastasis. Still's disease that is an inflammatory disorder can result in many of the symptoms this patient experienced and care must be taken to rule out other causes of FUO, as in this case of malignancy. PET/CT has been found to be a useful tool for detecting infection, inflammation and malignancy, all of which can present as FUO.

P090: Importance of Delayed

18

F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in the Detection of Liver Metastasis

Yen\*

Yu-An

1

Huang

W S

2

Lee

C H

1

Department of Nuclear Medicine, Chi Mei Medical Center, Taiwan

Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

**Background/Aims:** The detection of liver metastasis in cancer patients is critical to patient management. We report the preliminary data of liver metastasis only identified on delayed fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging in a high cancer prevalence area, and evaluate the appropriate occasion for performing delayed imaging in terms of liver metastasis. **Methods:** A total of 194 subjects who underwent FDG PET cancer survey were recruited. In addition to routine whole-body imaging about 60 minutes after ^18^F-FDG injection, delayed local imaging including the liver at 90--120 minutes after ^18^F-FDG injection was performed. If liver lesions were visible, further imaging over 120 minutes after injection might be performed. The maximum standardised uptake value (SUV~max~) and the tumour-to-normal liver ratio (TNR) were further evaluated if liver lesions were visible only on delayed imaging. The study was approved by the institutional review board of Chi Mei Medical Center. **Results:** Among the 194 examinees, 4 (2%, 4/194) had liver lesions only visible on delayed imaging, and metastasis from primary malignancies were subsequently histopathologically confirmed in 3 (2 colon-rectal cancers and one head and neck cancer); no tissue proof was made in 1 examinee (oesophageal cancer). While the SUV~max~ values did no apparently increase with time, TNRs increased over time. Patient demographics and characteristics are presented in Tables. **Conclusion:** The findings in the four cases (2%) showing liver metastasis only on delayed ^18^F-FDG PET imaging, which critically changes disease management, indicated that delayed liver FDG PET/CT imaging might be needed especially for patients with primary malignancies that most commonly metastasise to the liver, cancer in late stages, previously proven or suspected liver metastatic history, elevated tumour marker levels (either above the reference value or having a rising trend), fatty liver, neoadjuvant chemotherapy, and insufficient time interval between chemotherapy and PET. Further analyses with more data are warranted to clarify the clinical significance.
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**Background/Aims:** MIBG labelled with ^123^I, and somatostatin receptor (SST) imaging, labelled with ^111^In-pentetreotide, respectively, are functional imaging modalities, which achieve moderate sensitivity in localizing extra-adrenal paragangliomas (PGL). However, both functional imaging modalities are limited in detecting (malignant) head and neck PGL due to limited resolution of planar scintigraphy and of single photon emission computed tomography (SPECT) compared to positron emission tomography (PET), respectively. We compared functional imaging modalities in the diagnosis and staging of head and neck PGL, using ^68^Ga-DOTATOC PET/CT (diagnostic CT), ^18^F-DOPA PET ("low-dose" CT) and ^123^I-MIBG scintigraphy, including SPECT/CT ("low-dose" CT). Functional and anatomical imaging (combined cross-sectional imaging) referred as reference standard. **Methods:** Three male and eight female patients (age range 26 to 73 years) with anatomical and/or histologically proven disease were included in this study. Comparative evaluation included morphological imaging with CT, functional imaging with ^68^Ga-DOTATOC PET, ^18^F-DOPA PET and ^123^I-MIBG imaging. Imaging results were analysed on a per lesion basis. **Results:** The overall detection rate of ^68^Ga-DOTATOC PET on a per lesion basis was 100% (McNemar p \< 0.5), of ^18^F-DOPA PET 67.9% (McNemar p \< 0.01), and that of ^123^I-MIBG imaging was only 8.0% (McNemar p \< 0.0001) and of SPECT/CT was 12.0 % (McNemar p \< 0.0001), respectively. Both, ^68^Ga-DOTATOC PET and anatomical imaging identified 28 lesions. ^18^F-DOPA detected 19 manifestations, ^123^I-MIBG imaging identified only 2 lesions and SPECT/CT 3 lesions. Two additional lesions were detected by ^68^Ga-DOTATOC PET, but negative in both, ^123^I-MIBG and CT imaging. **Conclusion:** ^68^Ga-DOTATOC PET/CT predicts exact tumour staging in head and neck paragangliomas, compared to ^18^F-DOPA PET and to ^123^I-MIBG imaging, including SPECT/CT, respectively.
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**Background/Aims:** Carcinoid is the most commonly diagnosed type of neuroendocrine tumour. ^111^In-Octreoscan has been the stalwart for the imaging and diagnosis of Carcinoid in Australia for many years, however with the introduction of ^68^Ga-DOTATATE PET/CT this is now rapidly becoming obsolete. PET/CT provides a higher spatial resolution, earlier imaging times and the ability to monitor treatment response with the use of standard uptake values. **Methods:** A patient was referred for a ^68^Ga-DOTATATE PET/CT study to investigate symptoms associated with carcinoid syndrome with possible recurrence of a previously treated carcinoid. **Results:** Imaging demonstrated widespread ^68^Ga-DOTATATE-avid malignancy involving the heart, mediastinum, liver, left supraclavicular fossa, retroperitoneal, abdominal and pelvic nodal chains. **Conclusion:** Cardiac metastases from carcinoid cancer are rare and have a reported incidence of about 4%. There are limited articles published about ^68^Ga-DOTATATE imaging demonstrating cardiac metastases. ^68^Ga-DOTATATE and other somatostatin analogue imaging are firmly establishing their place as an important tool for imaging neuroendocrine tumours. Patient diagnosis, treatment management and follow up can all be aided by using this modality.
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**Background/Aims:** Neuroendocrine tumours (NET) express somatostatin receptor on the tumour cell membrane. This has formed the basis of the use of radiolabelled somatostatin analogues for their imaging. We report on our experience on the use of ^68^Ga-DOTATATE PET/CT in the management of patients with neuroendocrine tumours. **Methods:** Patients with histologically confirmed well differentiated (Ki-67≤20%) NETs or suspected NET based on biochemical findings were evaluated with ^68^Ga-DOTATATE PET and ceCT. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of ^68^Ga-DOTATATE PET/CT was determined. The lesion detection rate of ^68^Ga-DOTATATE PET and ceCT were compared. It was determined if imaging led to a change in treatment option. Approval for the study was obtained from the institution's review board. **Results:** A total of 237 patients were included in this study (Male: Female = 114:123; mean age = 51.23±16.42). Midgut carcinoid was the commonest tumour type in 43 patients. In 31 patients, imaging was done based on biochemical findings consistent with neuroendocrine tumour while 22 had tumours of the sympathy-adrenal axis. Indications for imaging included: staging in 54, restaging in 72, evaluate suitability for ^177^Lu-DOTATATE therapy in 27, recurrence in 26, and localize primary tumour in 58. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of ^68^Ga-DOTATATE PET were 94%, 92%, 96%, 89% and 97%, respectively. In 32 patients, planned treatment option was altered based on imaging findings. ^68^Ga-DOTATATE PET detected more lesions than ceCT in 24 patients. In 11 patients, the additional lesions detected by PET imaging led to a change in treatment option. **Conclusion:** ^68^Ga-DOTATATE PET/CT is a useful modality in the management of patients with well differentiated neuroendocrine tumours. Its inclusion in patient management may lead to a change in therapeutic option. ^68^Ga-DOTATATE PET has superior sensitivity for lesion detection compared to ceCT.
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**Background/Aims:** Neuroendocrine tumours are a diverse group of tumours that often present late due to non-specific symptoms. The frequent expression of somatostatin receptors (SSTR) enables quantitative PET/CT imaging of these tumours with the added possibility of delivering targeted radionuclide therapy (PRRT) to such lesions. Here we report our initial results and experience with ^177^Lu-DOTATATE in a developing country, as one of the first groups to provide this therapy in South Africa. **Methods:** Eligible patients with confirmed inoperable neuroendocrine tumours were recruited prospectively and treated with ^177^Lu-DOTATATE. Baseline imaging was performed with either SPECT-or PET based SSR analogues, whereas follow-up was performed with ^68^Ga-DOTATATE PET/CT at six months post treatment completion. Interim treatment response evaluation was based on post-therapy imaging of ^177^Lu-DOTATATE. **Results:** A total of 48 patients with a mean age of 58 years were treated with PRRT, of whom 22 (46%) demonstrated stable disease, 20 (42%) demonstrated a partial response, and six (12%) demonstrated progressive disease. The median Progression Free Survival (PFS) was 20 months with an Interquartile range (IQR)~25-75%~ of 4.5-30 months. The median Freedom From Progression (FFP) duration was 32 months with an IQR~25-75%~ of 25-40 months and the median Overall Survival (OS) was 10 months at the time of our preliminary analysis. Our subgroup analysis demonstrated an inverse association between Metabolic Tumour Volume (MTV) with PFS, which requires further validation. **Conclusion:** Our preliminary results demonstrate a median Freedom From Progression (FFP) duration of 32 months, in the absence of significant side effects, which is comparable to that of other established centers.
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**Background/Aims:** Neuroendocrine tumours can be histologically classified into well-differentiated, intermediate, or poorly differentiated tumours. Distinction is clinically important, due to therapeutic and prognostic implications.\[[@ref231][@ref232][@ref233]\] ^68^Ga-DOTATATE has been described as 'superior' to ^18^F-FDG in typically histologically well-differentiated neuroendocrine tumours with regards to sensitivity, specificity, and accuracy.\[[@ref234]\] **Methods:** Two cases are presented which demonstrate discordance between molecular imaging and histological findings. **Conclusion:** Molecular imaging has been proposed as an alternative to histological grading for neuroendocrine tumours. Lococo et al have indicated that functional imaging can be considered a 'non-surgical biopsy', and that FDG positive, ^68^Ga-DOTATATE negative lesions represent atypical carcinoid tumours.\[[@ref235]\] This case has illustrated that SSTR expression in typical carcinoid tumours may not always manifest as avidity on neuroendocrine molecular imaging with ^68^Ga-DOTATATE.
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**Background/Aims:** The clinical presentation of the neuroendocrine tumours (NET) may vary depending on the site of tumour origin. About 72% of NETs arise in pancreas and gastrointestinal tract (GEP-NET). SPECT/CT with ^99m^Tc-Tektrotyd is a current imaging approach to GEP NET diagnostic, staging and follow-up. The aim of this study was to evaluate role of SPECT/CT scintigraphy with ^99m^Tc-Tektrotyd in the management of GEP-NET. **Methods:** 78 patients (38M; 40F) with various NET were studied. 172 examinations including whole body somatostatin scintigraphy followed by SPECT/CT studies of the neck and chest and/or abdomen were performed 2-4 hours post-intravenous injection of 740MBq (mean dosage) ^99m^Tc-HYNIC-TOC (Tektrotyd, Polatom). SPECT/CT gamma camera Symbia T2 (Siemens) was used. Patients were studied after 4 weeks withdrawal of Sandostatin LAR if applicable and emptying GIST before imaging procedure. **Results:** In 5 patients with unknown NET origin, and primary tumours were established as follows: mesenteric NET in 3 patients, and pancreatic NET in 2 patients, proven after biopsy and surgery. Exact N/M staging was performed in 73 patients-31 patients were with locoregional lymphadenopathy; 37 patients were with distant liver, bone and/or pulmonary metastatic lesions over expressing somatostatin receptors. ^99m^Tc-Tektrotyd SPECT/CT was very useful to assess SSTR expression in order to predict an individual response to therapy with somatostatin analogues and peptide receptor radionuclide therapy in individuals with non-operable NETs. In 35 patients, SPECT/CT studies were used to evaluate effect of complex therapy-1) Complete therapeutic response was obtained in 4 patients; 2) Partial response in 12 patients; 3) Stable disease in 10 patients; and 4) Progressive disease in 9 patients. **Conclusion:** Positive SPECT/CT studies with ^99m^Tc-Tektrotyd are very useful functional imaging modality in patients with GEP-NET in order to perform optimal personalised treatment with somatostatin analogues and/or peptide receptor radionuclide therapy.
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**Background/Aims:** Pulmonary neuroendocrine tumours (NET) and mediastinal NET tumours are rare neoplasms classified according to the grade of biological aggressiveness (G1-G3) and the extent of differentiation (well-differentiated, poorly-differentiated). The well-differentiated neoplasms comprise typical (G1) and atypical (G2) carcinoids. Large cell neuroendocrine carcinomas as well as small cell carcinomas (G3) are poorly differentiated. The aim of this study was to establish role of ^99m^Tc-Tektrotyd SPECT/CT studies in patients with pulmonary and mediastinal NET. **Methods:** 38 patients (33 with pulmonary, 5 with mediastinal tumours) with neuroendocrine differentiation (50%\>100% positive-staining tumour cells) were studied-5 with large cell neuroendocrine carcinomas; 6 with small cell lung carcinoma; 18 with lung carcinoids (typical and atypical); 5 with thymic NET; 4 were with metastatic lesions from tumour with unknown primary origin (UPO), expressed neuroendocrine markers, suspicious for lung neuroendocrine origin. SPECT/CT gamma camera Symbia T2 (Siemens) was used. 61 examinations including SPECT/CT studies of the chest and/or abdomen were performed 2-4 hours post intravenous injection of 740MBq ^99m^Tc-HYNIC-TOC (Tektrotyd, Polatom). **Results:** Primary lung NET were visualised in 4 patients with UPO, proven histologically. Primary bronchial and thymic NETs were imaged in all other 38 patients showing intensive tracer uptake. Correct pre-treatment N and M staging was performed in studied patients. Locoregional lymphadenopathy were imaged in 14/38 cases. Distant liver, pulmonary, bone and/or suprarenal positive metastatic lesions were visualized in 11/35 cases, showing a good correlation with increased level of secret serum marker -- CgA. False negative results were observed in 4 patients with liver metastases. 15 patients with locally advanced and extended disease were followed-up after the complex treatment. ^99m^Tc-Tektrotyd SPECT/CT was very useful to assess SSTR expression in order to predict an individual response to therapy with somatostatin analogues and thus could effectively influence the management of peptide receptor radionuclide therapy (PRRT) in individuals with non-operable thoracic NET respectively. **Conclusion:** In conclusion, SPECT/CT with ^99m^Tc-Tektrotyd is a promising diagnostic technique for staging and follow-up of patients with pulmonary and thymic NET.
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**Background/Aims:** 85% of phaeochromocytomas arise from the adrenal glands. Adrenal adenomas are a common finding on CT and can add to diagnostic uncertainty. Recent increasing availability of ^68^Ga-DOTATATE PET/CT has seen increasing use of this modality in the assessment of these patients and adrenal glands demonstrate high physiologic uptake. The aim was to assess whether SUV assessment allowed for discrimination between normal adrenal gland, phaeochromocytomas and adrenal adenomas. **Methods:** A retrospective analysis of all patients with phaeochromocytoma at Royal North Shore Hospital between 2012 and 2017 who had a preoperative ^68^Ga-DOTATATE PET/CT. 26 patients were identified. 12 patients with 13 incidental adrenal adenomas were identified on keyword search. 20 patients with near normal scans (screening post appendiceal NET) were assessed for adrenal uptake indices. The SUV~max~ of the phaeochromocytoma, adrenal adenomas, and contralateral gland were measured. **Results:** In the 26 patients with phaeochromocytoma, two patterns were observed. Most lesions below 4 cm (n = 15/16) demonstrated uniform high uptake with an average SUV~max~ of 32.9. Larger lesions were often diffusely necrotic. SUV in these lesions were variable ranging from 4.8 to 57. In the adrenal adenoma group, SUV~max~ of the adenoma ranged from 3.4 to 22.5 with a mean of 10.4. SUV~max~ of adjacent, normal gland was higher than the adenoma in 11/13. Average SUV~max~ of normal adrenal glands in the appendiceal group, phaeochromocytoma and adrenal groups was 17.9, 19.7 and 16.3 (NS). Overall range in the appendiceal group was 11.7 to 34.1. **Conclusion:** There is a wide range of uptake in normal adrenals. Non-necrotic primary phaeochromocytomas have higher than background uptake in 100%. The majority of smaller tumours demonstrate this pattern. Necrosis of the tumours is common when size \>4cm (70%). This was not a diagnostic issue. Adrenal adenomas are usually of lower intensity than the normal adrenal.
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**Background/Aims:** The aim of our study was to retrospectively compare the detection rate of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (^18^F-FDG PET/CT) to indium-111 Octreotide single photon emission computed tomography (^111^In-Octreotide SPECT) in patients with metastatic neuroendocrine tumours (NET). **Methods:** Four patients with metastatic NET who had undergone both ^18^F-FDG PET/CT and ^111^In-Octreotide SPECT within a maximum interval of 45 days (medium 15 days) between March 2016 and September 2017 were retrospectively evaluated. All 4 had also undergone contrast enhanced computed tomography (CT). Relationships were assessed among uptake on ^18^F-FDG-PET/CT and ^111^In-Octreotide SPECT, tumour grade and imaging features in MRI or contrast enhanced CT. **Results:** Four patients consisted of 3 gastrointestinal NET (2 Grade 3, 1 unknown) and 1 pancreatic NET (1 Grade 2. All 4 had multiple tumour lesions invading multiple organs. Although 2 of the 4 had negative lesions (lymph node, liver, and stomach) on both ^18^F-FDG PET/CT and ^111^In-Octreotide SPECT, the remaining tumours were positive on ^18^F-FDG PET/CT. A lower number of lesions were detected by ^111^In-Octreotide SPECT in comparison to ^18^F-FDG PET/CT. The uptake pattern in both modalities was varied for each lesion in the same patients. **Conclusion:** ^18^F-FDG PET/CT is superior to ^111^In-Octreotide SPECT for the detection of metastatic NET with multiple lesions in multiple organs; however, not all lesions can be detected by either ^18^F-FDG PET/CT or ^111^In-Octreotide SPECT. Uptake patterns by either modality was varied and did not depend on tumour grade. Metastatic NET tumour distribution should be evaluated by a combination of modalities, as well as ^18^F-FDG PET/CT and ^111^In-Octreotide SPECT.
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**Background/Aims:** Penile cancer (PC) has a low incidence, with a rate lower than 1 per 100,000 subjects. The risk factors are phimosis, chronic inflammatory diseases and smoking; having association with HPV between 45-80%. It occurs between the 6^th^ and 8^th^ decade and the most frequent location is the glans, followed by the foreskin and body. We present our experience with ^18^F-FDG PET/CT and histological correlation. **Methods:** Fourteen patients (range 31-80 years) were evaluated, with histological confirmation of PC; 13 squamous carcinomas and 1 epithelioid sarcoma. In 7 patients, there was no lymph node dissemination, 6 had multiple lymphatic involvement and 1 pulmonary metastasis. Histology and PET/CT result were recorded, considering primary lesion, nodal involvement and distance metastasis. Sensitivity and specificity were calculated, for both primary lesion and lymph node involvement, positive predictive value (PPV) and negative predictive value (NPV). **Results:** The PET/CT showed sensitivity of 90% for primary lesions with an average SUV~max~ of 8.7. For lymph node metastases, considering all lymphadenopathies, it showed sensitivity of 81.7%, detecting 9 of 11 involved lymph nodes with an average SUV~max~ of 11. The specificity was 11% in dissemination by lymph node group. There were 3 false positive patients (peri-vesical, peri-rectal and common iliac lymph nodes), as they were reactive to an associated inflammatory/infectious process. The PPV was 37.7%, while the NPV was 50%. **Conclusion:** Our study shows the value presented by PET/CT in the staging of CP. The false positives presented in lymphadenopathy are striking. Even so, its sensitivity in primary lesion and in lymph nodes continues to be very useful (90% and 81%). Our results resemble other studies, such as sensitivity (90% vs 91%), although the specificity is lower than that reported, which can be explained by associated local infections.
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**Background/Aims:** Low back pain is common among adults, but back pain secondary to a metastatic carcinoma is rare. We present a case of a 71-year-old male with low back pain who was referred for a ^18^F-fluorodeoxyglucose (FDG) PET/CT scan due to suspicious-looking lesions on MRI. **Methods:** On PET/CT, multiple foci of increased FDG uptake were noted in the axial and appendicular skeleton. When correlated with a CT stonogram done 2 months prior, an exophytic lesion in the right kidney did not show FDG uptake; rather, it was in the left kidney where an FDG-avid focus was seen. A concomitant bone scan revealed less bone lesions when compared with the PET/CT findings. Biopsy of the left renal mass and a vertebral lesion were consistent with metastatic renal cell carcinoma (RCC). **Results:** Carcinomas do not often present as low back pain. However, they are usually in an advanced stage already when they present as such. FDG PET/CT not only increased the certainty of metastasis in the patient in view of the MRI findings, but also determined the primary carcinoma present in the patient. There were less lesions noted on bone scan due to its poor sensitivity for lytic lesions, combined with the lytic nature of RCC. **Conclusion:** While not a first-line diagnostic in the management of low back pain, ^18^F-FDG PET/CT scan can be valuable in cases where metastasis is highly suspected without a known primary carcinoma site.
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**Background/Aims:** We present a case of a 59-year-old male, known to have renal cell carcinoma (RCC), who was referred for a bone scan. **Methods:** On bone scintigraphy, increased tracer uptake was noted in the maxillofacial region. However, on single-photon emission computed tomography (SPECT), focal tracer accumulation was seen in the paranasal sinuses. Biopsy of intranasal and maxillary masses revealed metastasis. **Results:** RCC metastasis to the paranasal sinuses is very rare, likewise their appearance as osteoblastic lesions on bone scintigraphy. However, such findings are possible in cases of RCC with concomitant metastatic bone disease. **Conclusion:** We therefore recommend performing SPECT, or SPECT/CT, in similar cases where head and neck metastasis is not completely ruled out on bone scan.
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**Background/Aims:** The study aims to perform a meta-analysis to compare the diagnostic performance of ^18^F-FDG PET/CT or PET and CT in diagnosis of metastatic lymph nodes in cervical cancer patients. **Methods:** Articles of ^18^F-FDG PET/CT or PET and CT in diagnosis of metastatic lymph nodes in cervical cancer published in English from January 1990 to September 2017 was searched in the PubMed, EMBASE, Cochrane Library, Web of Science, and EBSCO databases to identify eligible studies on PET/CT or PET and CT of cervical cancer. QUADAS was used to evaluate the methodological quality of the included studies. Pooled sensitivity, specificity, and diagnostic odds ratios (DOR) were calculated both on a per-patient basis and on a per-lesion basis. Summary receiver operating characteristic (SROC) curves were also drawn to obtain the area under curve (AUC) and Q\* value. **Results:** A total of 53 studies met the eligible criteria. On a per-patient basis, PET/CT or PET showed the highest pooled sensitivity (78%) and specificity (96%), while CT showed 52% and 90%, respectively. On a per-lesion basis, sensitivities of CT and PET/CT or PET were 50% and 56%, respectively, while specificities of PET/CT or PET (96%) were higher than that of CT (90%). **Conclusion:** PET/CT or PET are better than CT on both per-patient and per-lesion basis for diagnosis of metastatic lymph nodes in cervical cancer patients.
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**Background/Aims:** A major controversy in sentinel node biopsy of endometrial cancer is the injection site of the mapping material. There is still a major concern whether sentinel nodes identified by intracervical injection are true sentinel nodes. In the current study, we compared the lymphatic flow from the uterine cervix with that from the uterine body in the same patients by head to head comparison of intracervical radiotracer and fundal blue dye injection. **Methods:** All patients with pathologically proven endometrial cancer of any histology were included. Each patient received two intra-cervical injections of ^99m^Tc-phytate. At the time of laparotomy, the uterus was exposed, and each patient was injected with two aliquots of patent blue V (2mL each) in the sub-serosal fundal midline locations. The anatomical locations of all hot, blue or hot/blue sentinel nodes were recorded. **Results:** Overall 45 patients entered the study. At least one sentinel node could be identified in 75 out of 90 hemi-pelvises (83.3% overall detection rate, 82.2% for radiotracer (intra-cervical) alone, and 81.1% for blue dye (fundal) alone). In 71 hemipelvises, sentinel nodes were identified with both blue dye (fundal) and radiotracer (intra-cervical) injections. In 69 of these 71 hemipelvises at least one blue/hot sentinel node could be identified (97.18% concordance rate). In ten patients, para-aortic sentinel nodes were identified. All of these nodes were identified by fundal blue dye injection, and only two were hot. **Conclusion:** In conclusion, our study shows that lymphatic drainage to the pelvic area from the uterine corpus matches the lymphatic pathways from the cervix and both intra-cervical and fundal injections of sentinel node mapping materials go to same pelvic sentinel nodes.
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**Background/Aims:** HIV-positive women with cervical cancer have higher recurrence and death rates with shorter time to recurrence and death compared with HIV-negative subjects. Objective of this study was to compare recurrence patterns in HIV-positive women with invasive cervical cancer to their HIV-negative counterparts using ^18^F-FDG PET/CT. **Methods:** We evaluated 40 HIV-seropositive and 79 HIV-seronegative patients with recurrent cervical carcinoma using ^18^F-FDG PET/CT. The PET/CT datasets were interpreted by two independent readers blinded to the HIV status of the patients. Areas of disagreement were resolved by consensus. Cervical cancer recurrence was confirmed by biopsy and histological examination of tissue, correlation with conventional imaging (CT and MRI) and by follow-up ^18^F-FDG PET/CT. **Results:** HIV-positive patients were 9 years younger than the HIV-negative patients at the time of diagnosis; mean age 39 years versus 48 years respectively. Initial treatment was comparable in both groups. Time to recurrence was shorter in HIV-infected compared with HIV-uninfected women (11 vs. 24 months). Commonest sites of metastatic recurrence was in the lymph nodes. HIV-infected patients demonstrated significant higher recurrence in lymph nodes and lungs (p \< 0.05). No significant difference in recurrence rate in liver or bone (p \> 0.05) between both groups. HIV-infected patients showed unusual metastases to brain, spleen and skin. **Conclusion:** HIV-infected patients are diagnosed with cervical cancer at younger age compared to non-infected patients. Time to recurrence is shorter among HIV seropositive patients with the commonest site of metastatic recurrence being in the lymph nodes. Nodal and liver metastases are significantly higher in HIV seropositive patients compared with seronegative patients.
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**Background/Aims:** Quantitative parameters using ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) are increasing utilised as prognostic markers in oncology. The aim of this study was to evaluate the relationship between quantitative FDG-PET/CT variables and disease-specific outcome in patients with advanced ovarian carcinoma at diagnosis. We hypothesise higher tumour metabolic rate and larger burden of metabolically active tumour carries a poorer prognosis. **Methods:** 25 patients with clinically diagnosed advanced (stage IIIA to stage IV) ovarian carcinoma were retrospectively reviewed following local ethics approval. All patients had full assessment by the local multi-disciplinary panel and were examined under strict PET/CT protocol. Quantitative metabolic parameters including maximum and mean standardised uptake value (SUV~max~ and SUV~mean~), metabolic tumour volume (MTV) and total lesion glycolysis (TLG) defined with a threshold of 40% were calculated for the primary tumour and two largest sites of metastatic disease. Statistical correlation with disease-specific survival and outcome was performed based on review of the patients' medical records and subsequent imaging. **Results:** 20 stage III and five stage IV patients with mean age of 64 (range 40-77) years were analysed. All patients received chemotherapy and 19 (76%) had debulking surgery. At time of census, 17 patients (68%) had clinical progression or recurrence with a mean follow-up period of 22 months and 7 (28%) had died. Primary tumour PET metrics did not significantly correlate with progression-free survival (PFS) or overall survival (OS) but the sum-metrics of the primary and metastatic deposits showed a trend towards PFS and OS. Ratio-metrics between primary and metastatic deposits were also not prognostic of outcome. **Conclusion:** In this small series of advanced ovarian cancer, higher tumour metabolic rate and larger burden of metabolically active tumour did not correlate with poorer disease-specific outcome.
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**Background/Aims:** Vulva cancer is the fourth most common gynaecological malignancy and accounts for 5% of all malignancies of the female genital tract. Furthermore, HIV infected women are at increased risk of developing vulvar cancer. The aim of our study is to evaluate the effect of HIV infection on the PET/CT metabolic parameters and metastatic patterns in patients with vulva carcinoma. **Methods:** We evaluated 26 HIV-seropositive and 16 HIV-seronegative patients for initial staging and suspected recurrent vulva carcinoma using ^18^F-FDG PET/CT. The PET/CT datasets were interpreted by two independent readers blinded to the HIV status of the patients. Areas of disagreement were resolved by consensus. **Results:** HIV-positive patients were 24 years younger than the HIV-negative patients at the time of diagnosis; mean age 40 years versus 64 years respectively. There was no significant difference in the time to recurrence in HIV-infected compared with HIV-uninfected women (19 versus 21 months). The commonest sites of metastatic recurrence were in distal lymph nodes, liver and lungs in HIV-positive patients. SUV~max~ values in HIV-positive patients are higher (mean SUV~max~ 55.11) than in HIV-negative patients (mean SUV~max~ 8.11). **Conclusion:** HIV-positive patients are younger than HIV-negative patients at initial diagnosis, and have distant sites of metastasis at recurrence. In addition, SUV~max~ was significantly higher in HIV-positive patients when compared with HIV-negative patients.
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**Background/Aims:** Positron emission tomography/computed tomography (PET/CT) with ^18^F-fluorodeoxyglucose (FDG) and dedicated small field pelvic magnetic resonance imaging (MRI) are both established imaging tools in the staging of cervical carcinoma with specific strengths and limitations. This study reviewed the correlation between FDG-PET/CT and MRI at diagnosis of cervical carcinoma. **Methods:** Patients with histologically proven cervical adenocarcinoma staged with both FDG-PET/CT and pelvic MRI at diagnosis were included for retrospective analysis. All patients were reviewed and managed by the local multidisciplinary team. FIGO primary tumour staging and nodal status (both FDG-PET and MRI) were independently assessed by subspecialty radiologists blinded to correlative and clinically results. Data was referenced to either surgical histology or consensus clinical findings at follow-up. Study was approved by the local ethics committee. **Results:** 32 patients with mean age 61 (range 29 to 84) were studied. The average maximum standardised uptake value (SUV~max~) and metabolic tumour volume (MTV) of the primary was 14.2 and 30 respectively. FDG-PET was positive for nodal metastases in 10 patients (31.3%) and 3 patients (9.4%) had distant disease. MRI showed 22 patients (68.8%) with parametrial invasion. There was a statistically significant correlation with primary tumour MTV and MRI parametrial invasion (p \< 0.05). Based on either surgical histology and/or clinical follow-up, FDG-PET was more sensitive than MRI in detecting nodal disease. The FIGO staging was concordant between FDG-PET and MRI in 21 patients (66%). **Conclusion:** Higher MTV strongly correlated with parametrial invasion and may be used as a surrogate marker. FDG-PET is more sensitive than MRI in detecting nodal disease and occasionally can detect unsuspected distant disease. FIGO staging was concordant between the two modalities in 66%.

P111: Influence of Biological Parameters Assessed in Dual Tracer Fluorodeoxyglucose-FLT-Positron Emission Tomography/Computed Tomography Imaging in Patients with Cervical Cancer on Radiotherapy Planning
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**Background/Aims:** Cervical cancer is the second most common cancer in women. The assessment of metabolic activity and the extent of the primary tumour mass has an increasing importance for radiotherapy planning. The aim of the study was to evaluate the clinical value of metabolic and volumetric tumour parameters assessed in vivo by dual tracer ^18^FDG-FLT-PET/CT scans in patients with cervical cancer. **Methods:** 37 patients with histological confirmed cervical cancer underwent dual tracer PET/CT examinations performed for radiotherapy planning. PET scans were acquired on separate days (within one week) 60 minutes after injection of 300 MBq of ^18^F-FDG and 300 MBq of ^18^F-FLT. For both scans the same scan protocol and reconstruction algorithms were used. The reconstructed PET images were evaluated for metabolic tumour parameters as SUV~max~, MTV, TLG and heterogeneity for primary tumour. For verification of MTV calculations, a phantom study was performed. **Results:** Dependent of severity of the disease pts were divided into 3 groups. In 1^st^ group, there was statistically significant differences between SUV~max~ (p = 9.2E-10; p = 2.21E-0.8), TLG (p = 0.0004; p = 0.0002), VOL (p = 0.0002; p = 0.0002) with AUC-CSH respectively for FDG and FLT. In 2^nd^ group, SUV~max~ (p = 2.07E-0.8; p = 2.26E-0.8), TLG (p = 0.0004; p = 5.09E-0.6), VOL (p = 0.0002; p = 1.59E-0.6). In 3^rd^ group, SUV~max~ (p = 0.007) and VOL (p = 0.02) with AUC-CSH for FDG there were statistically significant differences. Correlation was shown only in 3^rd^ group between VOL and AUC-CSH (r = -0.6) in FDG and SUV~max~ and AUC-CSH (r = 0.63) in FLT, and in 2^nd^ week correlation between SUV~max~ and AUC-CSH (r = -0.54) in FDG was shown. Only 1^st^ showed statistically significant differences between AUC-CSH in FDG and FLT (p = 0.02). **Conclusion:** The preliminary results showed significant differences between metabolic and volumetric parameters in patients with disease limited only to cervix and disease limited to the cervix and iliac lymph nodes either using FDG or FLT and this may influence dedicated treatment and prognosis.
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**Background/Aims:** To evaluate the clinical impact of ^18^FDG-PET/CT in the staging of locally advanced cervical cancer (LACC) and treatment response assessment. **Methods:** This is an observational, prospective study. Between 2009 and 2013, 70 patients with LACC were staged by International Federation of Gynecology and Obstetrics (FIGO) recommendations and ^18^F-FDG PET/CT scans were added in the initial work up. Whenever technically feasible, histological confirmation was performed. Patients were treated with standard chemo-radiation therapy to the pelvic field plus brachytherapy. Locoregional response was evaluated clinically and with a second ^18^F-FDG PET/CT scan three months after treatment was completed. **Results:** In 51/70 (72,8%) of the patients, extrauterine hypermetabolic lesions were detected by ^18^F-FDG PET/CT, resulting in changes in FIGO's staging. 26 extrapelvic locations were found in 19/70 (27.1%) patients, and in all of them the initial proposed therapeutic approach was modified (extended lumbo-aortic, and/or inguinal radiation therapy field, and/or chemotherapy). A second ^18^F-FDG PET/CT after treatment was performed in 56/70 patients. Metabolic response in local cervical compromise was observed in 51/56 (91.07%) patients, with complete response in 36 patients (64.2%) and partial response in 15 patients (26.7%). In 5 (8.9%) patients there was no metabolic response or progression. In patients with pelvic lymph nodes compromise, the ^18^F-FDG-PET/CT complete response rate was 71.4%. ^18^F-FDG PET/CT sensitivity, specificity, PPV and NPV to evaluate locoregional complete response were 69%, 79%, 53% and 88% respectively. **Conclusion:** ^18^F-FDG PET/CT compensates the FIGO's classification limitations in LACC and its routine inclusion should be considered for initial staging. The low PPV of ^18^F-FDG PET/CT in locoregional response assessment, mainly due to the local inflammatory process after 3 months, makes it unsuitable to evaluate persistent disease so a later time point for the follow-up scan should be considered. Quantitative treatment response assessment could also be of value in addition to qualitative evaluation. Further validation is required with higher number of patients.
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**Background/Aims:** The key prognostic factor in cervical cancer is lymph node status. Sentinel lymph node procedures (SLN) have been purported to reduce pro and postoperative morbidity and operative time. **Methods:** One hundred twenty consecutive patients who had a histological verified cervical cancer and a lymphadenectomy indication based on FIGO stage (one or two) underwent lymphatic mapping on preoperative evaluation and were enrolled into the study. Detection of SLNs was accomplished through direct visualization of blue coloured lymphatics and detection of radioactivity, using handheld gamma probe, detected SLN were sent for frozen section evaluation, then pelvic and/or para-aortic (lB2, 2A1 and 2A2) lymphadenectomy regardless of surgical pathology diagnosis and Wertheim was performed. **Results:** Twenty four patients received neoadjuvant chemotherapy in stage 2B. Squamous cell carcinoma was the predominant histological type (75%). Twenty five patients (20.83%) had a history of conization. At least one sentinel node was identified unilaterally in 30 patients (25%) and bilaterally in 80 patients (66.66%). The total detection rate was 110/120 (91.66%). The detection rate for patients with a history of conization and neoadjuvant chemotherapy were shown in this study to be 23/25 (92%) and 18/24 (75%) respectively. Pelvic lymph node metastasis was described in 30 patients-in five of whom no sentinel node was detected. In the remaining 25 patients, the SLN predicted metastasis accurately in 22 patients. Using the sentinel node algorithm (considering each hemi-pelvis as the unit of measurements), 40 hemi-pelvises had lymph node involvement and sentinel nodes could be identified in all 40 hemi-pelvises correctly. Sensitivity in patients with a history of conization was (3/3) and in patients undergoing neoadjuvant chemotherapy was (7/7), both 100%. **Conclusion:** Sentinel node procedure is a reliable method to be used for determination of lymph node status in cervical cancers. This is an accurate method in patients with history of conization or neoadjuvant chemotherapy.
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**Background/Aims:** This study explored the reproducibility of ^18^F-fluorodihydrotestosterone (^18^F-FDHT) in men with metastatic castration resistant prostate cancer (mCRPC). **Methods:** We conducted a prospective multi-institutional study of mCRPC patients undergoing two (test/re-test) ^18^F-FDHT PET/CT scans on two consecutive days. Two independent readers evaluated standardized uptake values (SUV), metabolically active tumour volumes (MATV) and total lesion uptake (TLU) for the most avid lesion detected in each of 32 pre-defined anatomical regions. The relative absolute difference and the reproducibility coefficient (RC) of each metric were calculated between the test and retest scans. Linear regression analyses, intraclass correlation coefficient (ICC), and Bland-Altman plots were used to evaluate repeatability of ^18^F-FDHT metrics. **Results:** Twenty-seven patients with 140 ^18^F-FDHT avid regions were included. The best repeatability of ^18^F-FDHT uptake metrics was found for SUV metrics (SUV~max,~ SUV~mean~ and SUV~peak~), without significant differences in repeatability found between them. Correlations between the test and retest scans were strong for all SUV metrics (R^2^ ≥ 0.92; ICC ≥ 0.97). The RC's of the SUV metrics ranged from 21.3% for SUV~peak~ to 24.6% for SUV~max~. The test and retest MATV and TLU also showed a good correlation (R^2^ and ICC ≥ 0.97), although variability was significantly larger compared to SUV (RC's \> 46.4%). The PSA levels, Gleason score, weight and age did not affect repeatability nor did total injected dose, uptake time and differences in uptake time between both scans. Including the single most avid lesion per patient, the 5 most avid lesions per patient, only lesions ≥4.2 mL, only lesions with a SUV ≥4 g/mL, or normalizing of SUV to area under the parent plasma activity concentration curve did not significantly affect repeatability. **Conclusion:** ^18^F-FDHT is a highly reproducible means of imaging mCRPC, and SUV had best repeatability of the measures assessed. These performance characteristics lend themselves for further biomarker development and clinical qualification of ^18^F-FDHT.

This trial was supported by Movember.

P115: Association of Serum Prostate Specific Antigen, Gleason Score, and Age to Radionuclide Bone Scan Findings in Newly-Diagnosed Prostate Cancer Patients
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**Background/Aims:** Prostate cancer is the 3^rd^ most common male cancer in the world and 2^nd^ most commonly diagnosed cancer in the Philippines. Bone metastasis is regarded as one of the most important prognostic factors. Radionuclide bone scan is the most frequently used imaging modality to detect bone metastasis. The European Association of Urology and American Urological Association both recommend that bone scan may not be indicated for patients with \<PSA level of 20 ng/mL and Gleason score of \<7. The aim of this study was to estimate the probability of bone metastasis in prostate cancer patients. **Methods:** The medical records of all patients who underwent bone scan at the Section of Nuclear Medicine of our institution from 2011 to 2015 were reviewed. Among the 160 patients who were newly diagnosed with prostate cancer, ninety-eight patients has no prior treatment, with serum PSA and histopathology report, and were included in the study. Age, serum PSA, Gleason score, and radionuclide bone scan results were collected. Simple and multiple logistic regression analyses were used. Epi info 7 was used for statistical analysis. Subgroup analysis was performed using Chi square test. **Results:** Ninety-eight out of 160 patients were included in the study. The mean age of the patients was 69.17 years. The mean age of patients with bone metastasis was 71.7 years. Forty percent of patients with bone metastasis belonged to the 71-80 years age group. Sixty-five percent of patients with bone metastasis had serum PSA level of \>20 ng/mL. Gleason score of 8-10 was seen in 38 patients, 26 of which were positive for bone metastasis. Multiple logistic regression and Chi square analyses showed that serum PSA levels \>10.01 ng/mL was statistically significant in predicting bone metastasis. **Conclusion:** Initial radionuclide bone scan may be requested in patients presenting with serum PSA level \>10 ng/mL, concurrent with the guidelines published by the National Institute for Clinical Excellence (NICE). Gleason score and age were not strong predictors for bone metastasis.

P116: Intra-individual comparison of

99m

Tc-HYNIC Prostate-Specific Membrane Antigen Single Photon Emission Computed Tomography/Computed Tomography and

68

Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Carcinoma: A Prospective Study

Alexis Kaoma\*

Chimbabantu

1

Lawal

I

1

Ankrah

A

1

Mokgoro

N

1

Vorster

M

1

Maes

A

2

Sathekge

M

1

Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa

Department of Nuclear Medicine, AZ Groeninge, Kortrijk, Belgium

**Background/Aims:** Recent studies have shown the utility of ^68^Ga-PSMA in the management of prostate cancer. However, PET/CT machines are not readily available worldwide. Recently, ^99m^Tc-labelled PSMA has been used in single photon imaging of prostate cancer. We therefore evaluated the diagnostic sensitivity of ^68^Ga-PSMA PET/CT and ^99m^Tc-PSMA SPECT/CT in patients with prostate cancer. **Methods:** 14 patients with histologically confirmed prostate cancer were prospectively recruited to undergo ^68^Ga-PSMA PET/CT and ^99m^Tc-HYNIC PSMA SPECT/CT. The mean age was 67.21±8.15 years and the median PSA level was 45.18 ng/ml (range = 1.5-687 ng/mL). SUV~max~ of all lesions and the size of lymph nodes with PSMA avidity on ^68^Ga-PSMA PET/CT were determined. The lesions detected on ^99m^Tc-HYNIC PSMA SPECT/CT read independent of PET/CT findings were determined. **Results:** 46 lesions were seen on ^68^Ga-PSMA PET/CT localized to the prostate (n = 10), lymph nodes (n = 24) and bones (n = 12). Of these, ^99m^Tc-HYNIC PSMA SPECT/CT detected 36 lesions: prostate = 10/10 (100%), lymph nodes = 15/24 (62.5%) and bones = 11/12 (91.7%) with an overall sensitivity of 78.3%. Lesions detected on ^99m^Tc-HYNIC PSMA SPECT/CT were bigger in size (p \< 0.001) and had higher SUV~max~ (p \< 0.001) as measured on ^68^Ga-PSMA PET/CT compared to those lesions that were not detected. All lymph nodes \>10mm in size were detected while only 28% of nodes \<10 mm were detected by ^99m^Tc-HYNIC PSMA SPECT/CT. In a univariate analysis, lymph node size (p = 0.033) and the SUV~max~ of all lesions (p = 0.007) were significant predictors of lesion detection on ^99m^Tc-HYNIC PSMA SPECT/CT. **Conclusion:** ^99m^Tc-HYNIC PSMA showed lower sensitivity for lesion detection compared to ^68^Ga-PSMA PET/CT. Its use is recommended when ^68^Ga-PSMA is not readily available, in planning radioguided surgery or PRLT with ^177^Lu-or ^225^Ac-PSMA. It performed poorly in small lesions, hence its use in small volume disease is not recommended.

P117: Initial Risk Stratification and Staging in Prostate Cancer with Prostatic Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A First-Stop-Shop
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**Background/Aims:** Current imaging for prostate cancer (PCa) had limitations for risk stratification and staging. Magnetic resonance imaging frequently underestimated lymphnode metastasis while bone scintigraphy often had diagnostic dilemmas. Prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has been remarkable in PCa recurrence. **Methods:** 97 PSMA PET/CT were reanalysed for tumour node metastases (TNM) staging and risk stratification of lymphnode and distant metastases proportion. Histopathology of 23/97 patients was available as gold standard. Chi-square test was used for proportion comparison. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), over-estimation, under-estimation and correct-estimation of T and N stages were calculated. kappa coefficient (κ) was derived for inter-rater agreement. **Results:** Lymph node or distant metastases detection on PSMA PET/CT increased significantly with increase in risk category. PSMA PET/CT sensitivity, specificity, PPV and NPV for extraprostatic extension, seminal vesicle invasion and lymph node metastases were 63.16%, 100%, 100%, 36.36% & 55%, 100%, 100%, 25% and 65.62%, 99.31%, 87.50%, 97.53%, respectively. Kappa coefficient showed substantial agreement between PSMA PET/CT and histopathological lymph node metastases (κ 0.734) however, it was just in fair agreement (κ 0.277) with T stage. PSMA PET/CT over-estimated, under-estimated and correct-estimated T and N stages in 8.71%, 39.13%, 52.17% and 8.71%, 4.35%, 86.96% cases, respectively. **Conclusion:** PSMA PET/CT has potential for initial risk stratification with reasonable correct N stage estimation however underestimates T stage. Hence, we concluded, PSMA PET/CT should be used as 'First-stop-shop' for staging and initial risk stratification of PC with regional MRI in surgically resectable cases.

P118: A Prospective, Multinational Comparison of F-18 Fluoromethylcholine Positron Emission Tomography/Computed Tomography, Magnetic Resonance Imaging, and Ga-68 HBED-CC-Glu-NH-CO-NH-Lys(Ahx) Positron Emission Tomography/Computed Tomography (Prostate-Specific Membrane Antigen) in High Risk Men Being Considered for Salvage Radiation Treatment for Biochemical Failure Post Radical Prostatectomy for Prostate Cancer: Initial Results of the Movember PROPs trial
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**Background/Aims:** The aim of this study was to evaluate the predictive value of FCH and PSMA and MRI in identifying sites of recurrent disease in men with rising PSA following radical prostatectomy (RP) who were being considered for salvage prostate bed radiotherapy. **Methods:** Prospective, multisite, international trial in men post RP with high risk features (PSA \> 0.2ng/ml and \>GSC 7 or PSA DT \<10 months, or PSA \>1.0ng/ml) with a documented rising PSA being considered for standard salvage fossa radiotherapy. Ninety eligible enrolled men underwent FCH, and multiparametric pelvis MRI (mpMRI), with a subset (30/90) undergoing an additional PSMA scan. **Results:** Conventional imaging (bone scan and diagnostic CT) was negative or equivocal in all men. Median PSA at imaging 0.41±1.2/, mean Gleason score 8, mean PSA DT 5.0 months. Detection rates for any recurrent PCa were (24/89) 27%, (29/90) 32%, and (13/30) 43% for mpMRI, FCH and PSMA. In those men with positive scans, extra prostatic-bed disease was identified in (11/24) 41% (mpMRI), (17/29) 58% (FCH) and (9/13) 69% (PSMA); prostatic bed disease was identified in 15% (mpMRI), 13% (FCH) and 13% (PSMA). In the 30 men undergoing both PSMA and FCH imaging, PSMA identified 36 sites of disease (13/30 men) compared to 20 sites of disease (13/30 men) on FCH (p \< 0.005 per lesion, p = ns per individual). Positive findings were confirmed as true positive in 100% and 91% for PSMA and FCH respectively. Imaging findings changed management in 46% for FCH, and 24% for MRI. Incremental management impact of PSMA over FCH was identified in 8/30 (27%) patients. **Conclusion:** A high proportion incidence of extraprostatic bed disease was identified with FCH and PSMA PET/CT in high risk men with rising PSA post RP being considered for salvage radiotherapy, and these findings had a significant impact on patient management.

Trial was done under the auspices of Movember.
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**Background/Aims:** Prostate cancer is the sixth most common cancer in the world. The European Society of Medical Oncology Clinical Practice Guidelines includes the recommendation of using ^18^F-Fluorocholine (FCH) Positron Emission Tomography/Computed Tomography (PET/CT) scans in nodal staging and detection of metastases. In the absence of an existing Philippine guidelines, it is the aim of this study to evaluate FCH PET/CT for the detection of metastasis in relation to their current Prostate Specific Antigen (PSA) levels among prostate cancer patients in our local setting. **Methods:** The medical records of prostate cancer patients seen at the PET/CT center in our institution from March-September 2017 were reviewed. Analysis of the patient's demographics was described using the mean standard deviation, frequency and percentage distribution. FCH PET/CT detection rates were determined at various PSA thresholds and examined by ROC curve analysis. **Results:** Of the 14 patients in the pre-treatment population, the mean age was 71.57 years. 5 patients had bone metastases, 3 had lymph node metastases, 3 had metastases in other organs, and 4 had no metastases reported. Based on ROC, pretreatment serum PSA cut off of ≥6.1 ng/mL had sensitivity and specificity of 83% and 37.5% respectively. Of the 24 patients in the post-treatment population, the mean age was 70.58 years. 14 patients (58%) had bone metastases, 9 (37.5%) had lymph node metastases, 5 (20.8%) had metastases in other organs, and 6 (25%) had no metastases reported. Based on ROC, post-treatment serum PSA of ≥1.14 ng/mL, had sensitivity and specificity of 81% and 37.5% respectively. **Conclusion:** FCH PET/CT scans may be requested in patients presenting with serum PSA levels of \>6.1 ng/mL in newly diagnosed cases, and serum PSA levels of \>1.14 ng/mL in patients with biochemical failure with sensitivity of 83% and 81%, however, with low specificity of 37.5% for both.

P120: Comparison of Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography and Multi-Parametric Magnetic Resonance Imaging in the Local Staging of Prostate Cancer
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**Background/Aims:** Intermediate to high-risk primary prostate cancer is currently staged with multi-parametric magnetic resonance imaging (mpMRI) for local disease and ^68^Ga-Prostate-Specific Membrane Antigen-PET/CT (PSMA-PET/CT) for metastatic disease.\[[@ref236]\] Some authors have suggested that this combination can be further streamlined to PSMA-PET/CT alone. A retrospective study of 10 patients by Giesel showed good correlation between PSMA-PET/CT and mpMRI in patients with large tumours, while other studies comparing PSMA-PET/CT with post-prostatectomy histopathology also reported high sensitivities and specificities.\[[@ref237][@ref238][@ref239]\] While promising, these results involved small numbers of patients and large tumours, whereas the detection of small tumours, in particular the presence of extra-capsular extension, is crucial when planning treatment. **Methods:** We reviewed 9 cases of newly diagnosed prostate carcinoma for which both PSMA-PET/CT and mpMRI was performed. Local disease was classified as either early (defined as AJCC stage T2 and below), or advanced (AJCC stage T3 and above) disease. The results were analysed using McNemar's test, and equivalence testing performed using two one-sided t-tests (TOST). **Results:** All 9 cases showed presence of tumour on both PSMA-PET/CT and mpMRI. Of these, there was concordance between both modalities in 8 cases (88%), of which 4 had early and 4 had advanced disease. The discordant case was reported as early disease on PSMA-PET/CT, but advanced disease on mpMRI. Interestingly, the post-radical prostatectomy specimen confirmed the PET/CT diagnosis of prostate-confined disease. McNemar's test showed no significant difference between the two tests. However, TOST returned a p-value of 0.173, which was insufficient to demonstrate equivalence between the two modalities, likely due to the small sample size. **Conclusion:** PSMA-PET/CT was able to detect all cases of prostate cancers, including those classified as early local disease. There was 88% concordance with mpMRI in differentiating between early and advanced disease, although further work will be required to demonstrate statistical equivalence.
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**Background/Aims:** ^68^Ga-labelled prostate-specific membrane antigen (PSMA) has an increasing role in the management of prostate cancer and demonstrates high target tissue involvement in evaluating metastatic foci in prostate cancer. But so far, many false positive cases have been reported. However, there is relatively little information about PSMA expression in benign tumours and false positives in non-prostate malignancies. **Methods:** An 81-year-old man was referred to a ^68^Ga-PSMA PET/CT to evaluate chemoradiotherapy response. **Results:** There was heterogeneous ^68^Ga-PSMA involvement filling the right parieto-occipital area. The patient described the lesion since childhood. The lesion was evaluated as calvarial osseous cavernous haemangioma on MRI. **Conclusion:** Multiple factors clearly play a role in benign lesion localization of ^68^Ga-PSMA. This increased and heterogeneous ^68^Ga-PSMA uptake is probably related to (i) higher concentration of PSMA receptors; (ii) increased vascularity; and (iii) bone remodeling. In case of doubt, combined imaging, such as the MRI, will be a useful guide.
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**Background/Aims:** To evaluate whether there is a correlation between lymph node size and SUV~max~ values observed with PSMA expression on ^68^Ga-PSMA PET/CT images. **Methods:** A total of 178 patients with prostate cancer diagnosis and ^68^Ga-PSMA PET/CT performed at our center from 2015 to 2017 were assessed. 25 patients with lymph node metastasis and no bone metastasis were included in the study. Imaging was performed for staging in 10 patients (40%), for re-staging in 11 patients (44%) and to assess response to treatment in 4 patients (16%). Lymph nodes with ^68^Ga-PSMA involvement differentiated from the background activity in the literature were accepted as positive. As a result, all lymph nodes with PSMA expression differentiated from background activity had short axis diameters and SUV~max~ values measured on axial images. Lesion-based statistical analysis was completed with SPSS v22.0 (IBM, USA). **Results:** A total of 88 lymph nodes were identified as having PSMA expression. Of these 6 were lymph nodes located in cervical/thoracic region, 35 were abdominal and 47 were located in the pelvic region. The mean size of cervical/thoracic lymph nodes was 14.3±10.2 mm and mean SUV~max~ value was 6.9±8.5. For abdominal lymph nodes, mean size was 8.4±5.6 mm with mean SUV~max~ of 11.5±9.5. Pelvic lymph nodes had mean size of 9.2±6.8 mm with mean SUV~max~ of 7.3±7.1. When all lymph nodes are assessed together, lymph nodes with size 8 mm and smaller (range 2.7-8 mm) had mean SUV~max~ of 5.5±3.6, while those larger than 8 mm (range 8.1-31.4 mm) had mean SUV~max~ of 15.5±10.5. PSMA expression was identified even in the 2.7 mm lymph node (SUV~max~ 3.1). The correlation between lymph node size and SUV~max~ expression was at moderate levels and significant (correlation coefficient: 0.68, p \< 0.001). The SUV~max~ for lymph nodes of 8 mm and smaller size were significantly different to those from lymph nodes above 8 mm in size (p \< 0.05). **Conclusion:** To the best of our knowledge, there is no study in the literature researching the correlation between PSMA expression and lymph node size. Our findings show that the lower limit for detection of PSMA expression is below 8 mm. Additionally, as lymph node size increases, PSMA expression increases.
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**Background/Aims:** ^68^Ga-PSMA (prostate-specific membrane antigen) has been explored in staging and restaging of prostate cancer with excellent results in the past few years. This radiopharmaceutical has shown very good sensitivity and specificity in detection of primary, nodal and skeletal metastases. Recently PSMA labelled with ^18^F--DCFPyl has been made available for the use in prostate cancer. 2-(3-{1-carboxy-5-\[(6-\[^18^F\]fluoropyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid, or ^18^F-DCFPyL is a radiofluorinated, small molecule inhibitor of PSMA that allows PET imaging of this important cancer target. Initial human experience of this radiopharmaceutical has been reported in 9 patients.\[[@ref240]\] This study demonstrated its safety with no adverse events. In another study of 8 patients, more number of lesions were seen on ^18^F-DCFPyl PSMA as compared to CT and bone scan.\[[@ref241]\] The aim of the study was to see the lesion localization by ^18^F-DCFPyl as compared to ^68^Ga-PSMA. **Methods:** 13 patients (age range: 49-75 years), biopsy-proven cases of adenocarcinoma were included in this study. All 13 patients underwent ^18^F-DCFPyl PSMA imaging after IV injection of 5mCi of tracer. Imaging was done 60 minutes post injection. The Gleason score ranged between 7 and 10.4 patients were for staging, 2 were post radical radiotherapy and the rest were on chemotherapy. ^68^Ga-PSMA was done in 8 patients. **Results:** 2/13 did not show any abnormality i.e, the scans were normal in both ^18^F-PSMA and ^68^Ga-PSMA scans. Their PSA values were 0.01 and 0.05 ng/ml. 9 patients had PSMA avid pelvic adenopathy, 8 had distant nodal metastases, 8 were positive for skeletal metastases and 1 patient was positive for lung and subcapsular deposit. The PSA values in these patients ranged from 5-160 ng/ml. All lesions seen on ^68^Ga-PSMA were seen on ^18^F-PSMA. There was 100% concordance in lesion detection on ^18^F-PSMA as compared to ^68^Ga-PSMA. The tumour-to-background ratio was much better and sharper on ^18^F-PSMA as compared to ^68^Ga-PSMA. Few tiny lesions were better visualised on ^18^F-PSMA study. **Conclusion:** All lesions seen in ^68^Ga-PSMA PET were seen in ^18^F-DCFPyl PSMA PET. Due to better image quality, a larger amount of available activity; being cyclotron produced and excellent lesion detection, ^18^F-DCFPyl PSMA has the potential to replace ^68^Ga-PSMA and will lead imaging of prostate cancer in future.
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**Background/Aims:** ^68^Ga-PSMA PET/CT has established itself as an important imaging modality in carcinoma prostate. Several studies have shown its variable relationship with the serum PSA levels. However, no studies till today, have been done to find a relationship between the serial PET/CTs with serial serum PSA levels on patient to patient basis. We therefore tried to investigate the relationship between serial serum PSA levels and ^68^Ga-PSMA PET/CTs in patients with carcinoma prostate. **Methods:** A total of 53 consecutive patients (median age 67 years; range 30-81 years) who had undergone two serial ^68^Ga-PSMA PET/CTs, were included in this retrospective study after approval from the institutional ethical committee. The gap between the two serial PET/CTs ranged from 3 months to 15 months. Serum PSA was measured within 1 month of each PET-CT study and chronologically marked as PSA1 and PSA2. We compared the PET-CT response with the change in serum PSA. So, we calculated the PSA2/PSA1 for each patient and marked the PET-CT response as 1 for complete response, 2 for partial response, 3 for stable disease and 4 for progressive disease. **Results:** Out of these 53 patients with each patient having two PET/CTs, seven (13.3%) showed complete response, eleven (20.7%) showed partial response, twelve (22.6%) and twenty-three showed progressive disease. We tried to correlate these PET-CT responses with their respective change in serum PSA (i. e. PSA2/PSA1) for each patient. The Pearson's correlation coefficient r was found out to be 0.493 with a p value of 0.001, suggesting statistically significant moderately strong positive correlation between the change in PSA and PET/CT responses. **Conclusion:** ^68^Ga-PSMA PET/CT was found to be an effective tool for the response assessment in patients with prostate cancer and had a positive relationship with the change in serum PSA values.

P125:

68

Ga- Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings in Prostate Carcinoma Patients Presenting with a Low-Volume, Androgen Dependent Biochemical Recurrence: Ethnic Differences

Lengana\*

Thabo

1

Wiele

C Van de

2

3

Lawal

I

1

Maes

A

2

4

Ebenhan

T

1

Boshomane

T

1

Zeevaart

J R

1

Ankrah

A

1

5

Mokgoro

N

1

Vorster

M

1

Sathekge

M

1

Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa,

Department of Nuclear Medicine, AZ Groeninge, Kortrijk,

Department of Radiology and Nuclear Medicine, University Ghent,

Department of Morphology, University of Leuven, Leuven, Belgium,

Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, Netherlands

**Background/Aims:** To compare the diagnostic accuracy of ^68^Ga-PSMA-11 PET/CT imaging for the detection of androgen-dependent recurrent prostate carcinoma (ADPC) in black versus white patients with rising serum PSA values below or equal to 10 ng/ml. **Methods:** Sixty-seven ADPC patients were prospectively included in the study (mean age: 66.7 years), 40 white patients and 27 black patients. ^68^Ga-PSMA-11 PET/CT imaging results obtained were related to serum PSA levels and to ethnicity. Ethics approval was granted by the institutional review board. **Results:** Forty-five patients (67%) had a positive ^68^Ga-PSMA-11 scan result. ^68^Ga-PSMA-11 PET/CT positivity was significantly higher in patients with PSA values \>2 ng/ml \[35/41 patients (85%)\] when compared to patients with PSA values \<0.5 ng/ml \[6/11 patients (55%)\] or PSA values of 0.5-2 ng/ml \[5/15 patients (33%\]) (p = 0.0001). Mean PSA values proved not significantly different in patients presenting with extra-pelvic involvement when compared to those with intra-pelvic involvement, nor between patients that presented with bone involvement versus those that did not on ^68^Ga-PSMA-11 PET/CT (p\>0.147). Age, Gleason scores, median PSA values, frequency of a positive scan result, frequency of bone involvement and extra-pelvic involvement proved similar in white and black patients (p \> 0.417). **Conclusion:** No significant differences in imaging results were noted between the black and white patients suggesting that tumour burden and growth rate of androgen dependent prostate carcinoma is similar in both races. A recurrence in 67% of the study patients was identified on ^68^Ga-PSMA-11 PET/CT imaging. ^68^Ga-PSMA-11 PET/CT imaging positivity and detection rate was associated with higher PSA levels.
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**Background/Aims:** Prostate cancer is the 3^rd^ leading cause of death from cancer in Chile and the most frequent in people older than 70 in Europe. Clinical guidelines recommend digital rectal examination and prostate-specific antigen (PSA) in men over 50 years and over 45 years with family history of prostate cancer. The staging is performed with bone scan, computed tomography and magnetic resonance imaging. Currently, the role of ^68^Ga-PSMA PET/CT has been increasing, using a specific marker of the prostatic membrane. The bone scan is the gold standard to evaluate bone metastasis in patients with prostate cancer. The aim is to compare the diagnostic performance of ^68^Ga-PSMA PET/CT versus bone scan in detection of secondary bone lesions in prostate cancer. **Methods:** We studied 37 patients (average age 66 years, range 54-79, average PSA 7.3 ng/ml) diagnosed with prostatic adenocarcinoma with ^99m^Tc-MDP bone scan and ^68^Ga-PSMA PET/CT. Bone lesions were evaluated in PET/CT, registering SUV~max~ and location and the results of each bone scan were tabulated, specifying their location in case of suspected secondary lesions. **Results:** In our study, ^68^Ga-PSMA PET/CT detected 100% of the lesions detected in the bone scan as metastasis (27), also showed 18 secondary bone lesions not visualized in the bone scan. On the other hand, the bone scan showed 8 bone lesions suspected of metastasis, interpreted as non-neoplastic in PET/CT. **Conclusion:** ^68^Ga-PSMA PET/CT is able to identify more metastatic lesions than on the bone scan. Additionally, it allows more accurate characterization of lesions reported as suspicious of metastases in the bone scan, or the requirement of further evaluation with other anatomical images, which has an important cost/effectiveness implication. In addition, it provides information about nodal involvement and distance metastasis.
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**Background/Aims:** Approximately 27-53% of patients with prostate cancer have a biochemical recurrence after treatment with curative intent. Currently, clinical criteria and classical imaging techniques are poor to differentiate local biochemical recurrence versus distant involvement. ^68^Ga-PSMA PET/CT identifies suspicious areas of lymph node and/or distance compromise, which allows to plan lines of treatment in a better way. The aim of the study is to evaluate ^68^Ga-PSMA PET/CT as a re-capture study in patients with biochemical recurrence after treatment with curative intent. **Methods:** We studied 53 patients with prostate cancer (Gleason 7-9) and biochemical recurrence after treatment (average PSA 78.0 ng/mL, range 0.3-806 ng/mL) with curative intention by PET/CT with ^68^Ga-PSMA. **Results:** ^68^Ga-PSMA PET/CT was positive in 67% of the total patients, with 43% positive results with PSA values between 1.0 and 1.8 ng/ml. There was involvement of the prostate bed in 13/42 patients (32%) with an SUV~max~ average of 13.8. In 7 of these 13 patients, lymph node involvement with SUV~max~ averaged 16.9. In 5/13 patients, they also had bone involvement with average SUV~max~ of 14.6, and two cases with involvement of seminal vesicles with SUV~max~ of 24.8. In 20/42 (47%) patients with lymph node recurrence detected (average SUV~max~ 12.9) of which 6/20 had bone involvement (average SUV~max~ 25.3) and 8/20 had local involvement. In 9 cases, there was only bone involvement. In total, 77% sensitivity and 100% positive predictive value were calculated. **Conclusion:** ^68^Ga-PSMA PET/CT is a test that provides valuable additional information in patients with biochemical recurrence after treatment with curative intent and where the area of persistence or recurrence of the disease cannot usually be determined. Although we do not have histological follow-up at the moment, the sensitivity seems to be better compared to other study methods.
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**Background/Aims:** After primary treatment, approximately 30%-40% patients develop a recurrent or metastatic disease. Some of them the cause is unrecognised metastatic sites initially with conventional imaging modalities (CIM). These patients could not get appropriate treatment which may prevent recurrence. When biochemical recurrence (BCR) developed accurate restaging is also very important for therapy planning and management of patients. The aim of this study is to assess additional value of ^68^GA-PSMA to CIM for the restaging of biochemically recurrent patients and primary staging of high-risk patients. **Methods:** This is a retrospective study which includes 92 high-risk patients with Gleason Score\>7 for initial staging and 138 BCR patients with PSA \>0.5 ng/ml and/or recurrence suspected with other imaging modalities. ^68^Ga-PSMA PSMA-11 was used as an imaging agent. Images were taken by GE Discovery PET/CT. Results were evaluated with pathology reports and follow-up scans. **Results:** ^68^Ga-PSMA PET/CT detected distant metastases in 9 patients (10%), abdominal lymph node metastases in 7 patients (8%) and pelvic lymph node metastases in 10 (9%) of patients which were not identified before by CIM. Therapy planning was changed 25 of patients (27%) with additional Ga-68 PSMA scan findings. For recurrence detection, ^68^Ga-PSMA PET/CT detected recurrence sites in 115 of 138 (83%) and changed treatment strategies (salvage surgery/radiotherapy or systemic therapy) in 55 of 115 (48%) patients. **Conclusion:** It is concluded that ^68^Ga-PSMA PET/CT is superior to CIM for the detection of metastases in pelvic lymph nodes with normal size and abdominal lymph nodes and distant metastases which are usually outside of the scan area of CIM. ^68^Ga-PSMA PET/CT can be used solely for primary staging of intermediate/high-risk patients and detection of metastatic sites in BCR patients.
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**Background/Aims:** 68-Gallium (^68^Ga) prostate-specific membrane antigen (PSMA) PET-CT and prostate MRI are widely used for staging of prostate malignancy, and usually reported separately, with the MRI intended for the nodal staging and the ^68^Ga-PSMA PET-CT intended for whole body disease assessment. Fusion of the prostate MRI with the ^68^Ga-PSMA PET/CT can be performed manually but is time consuming. Fusion has been previously suggested to assist with biopsy planning in the case of negative biopsies and raised prostate specific antigen (PSA). This study was intended to assess whether routine fusion of the prostate MRI with the ^68^Ga-PSMA PET/CT would be beneficial to reduce discordance in detection of prostate lesions. **Methods:** A retrospective review was performed and 17 patients who previously had a prostate MRI and ^68^Ga-PSMA PET/CT scans at the same institution (Mercy Radiology, Epsom) within 3 months of each other, a time period we felt there was unlikely to be a significant change in imaging appearances. Data was collected including age, days between MRI and PSMA, Gleason score, PSA, PSMA and MRI stage, histology, location of and number of lesions on PSMA, MRI and fused images. **Results:** The median age of the 17 patients was 68 years (range 47-77) with a median Gleason Score of 8 (range 7-9) and median PSA level of 12.9 (range 0.8-30). The overall percentage concordance between the prostate MRI and the ^68^Ga-PSMA PET/CT was observed in 94% of patients. Number of lesions detected on the fused images mirrored the PSMA scan, with a caveat being non-PSMA secreting primaries. **Conclusion:** From our small sample size, we did find that the fused images confirmed the location of MRI lesions with overlay of the more sensitive PSMA study, but did not demonstrate any additional lesions over those already identified in the other 2 studies.
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**Background/Aims:** Radical prostatectomy (RP) is a widely used treatment for prostate cancer. However, 14-34% of men do not have an initial response to RP, and a multimodality approach is required. ^68^Ga-PSMA-HBED-CC PET/CT (PSMA PET) is emerging as a potential staging tool for prostate cancer. This study aims to evaluate the diagnostic and prognostic value of PSMA PET prior to RP. **Methods:** We analysed results of 142 men with staging PSMA PET prior to RP. Data collected included PSMA PET, bone scan (30/142), mpMRI (112/142), Gleason score, surgical margins, extracapsular extension (ECE), seminal vesicle involvement (SVI), pathological T stage (pT) stage and histopathology postoperatively. Prostate-specific antigen (PSA) was documented at staging scan, and following surgery (median 45 days (IQR 38-59). A PSA of \<0.03ng/ml was classified as biochemical response (BCR). Logistic regression was performed for association of clinical variables and BCR (excluding men on ADT). **Results:** 97.9% (139/142) of men had positive intraprostatic findings on PSMA PET. 14.1% (20/142) of men had further sites of extraprostatic disease identified on PSMA PET. In men with disease confined to the prostate, 83% (92/111) achieved a BCR, compared to 28.6% (4/14) in men with extraprostatic disease identified (p \< 0.0001). On logistic regression, PSMA PET was more independently predictive for BCR than ECE, surgical margin status, SVI or pT stage. MRI was less sensitive and more specific for SVI, and less sensitive for nodal involvement. **Conclusion:** PSMA PET scan positive extraprostatic disease is highly predictive of a poor biochemical response to RP, and should play an important staging role in men with intermediate or high-risk disease considering RP.
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**Background/Aims:** There is increasing interest in prostate cancer (PCa) surveillance, with evidence magnetic resonance imaging (mpMRI) has high sensitivity and negative predictive value for significant PCa. However, accuracy of the technique is insufficient to exclude need for biopsy. ^68^Gallium-prostate specific membrane antigen PET/CT (PSMA) has high specificity for PCa, and merits evaluation of its suitability for PCa surveillance. **Methods:** 56 consecutive patients with ISUP 2/3 PCa on radical prostatectomy histopathology (RP), with mpMRI and PSMA PET CT were enrolled. Accuracy of PSMA, mpMRI and in combination was analysed for identifying ISUP 1-3 within a 12 segment model. Accuracy of a combined predictive model (PSMA & mpMRI) was determined. An optimised quantitative cut-off for PSMA was assessed for maximum standardized uptake value (SUV~max~). **Results:** On per patient basis, identifying ISUP 2-3 PCa, sensitivity for PSMA and mpMRI were 100% and 97% respectively. Assessing ³ISUP 2 using a 12 segment analysis, PSMA PET demonstrated greater sensitivity, specificity, NPV and PPV of 88%, 93%, 95% and 85% than mpMRI (PIRADS 3-5) 68%, 91%, 87%, 75% respectively. Sensitivity for both modalities reduced when assessing ISUP 1, PSMA 18% and mpMRI 10%. When used in combination (PSMA & mpMRI PIRADS 4-5), sensitivity and NPV was 92% and 96% respectively. With hemi-gland analysis, a SUV~max~ value of 3.95 achieved a sensitivity and specificity of 94% and 100% for detecting ³ISUP 2. **Conclusion:** PSMA is accurate in detecting ISUP 2/3 intra-prostatic malignancies, compared with and complementary to mpMRI. The detection rate for ISUP 1 disease is low.
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**Background/Aims:** To assess the diagnostic performance of ^68^Ga-PSMA PET/CT in the detection of metastatic disease in patients undergoing staging of prostate cancer or investigation for biochemical relapse compared with conventional staging with computed tomography (CT) and bone scintigraphy (BS). **Methods:** We performed a retrospective, single institution analysis of all patients who had ^68^Ga-PSMA PET/CT for staging of prostate cancer and evaluation of biochemical relapse who also had concurrent BS and CT scans. The lesions that were detected in each modality were evaluated and compared. Further data evaluation included indication for imaging (staging or biochemical relapse), previous treatments, prostate specific antigen (PSA) levels and Gleason score (GS). **Results:** A total of 1309 patients had ^68^Ga-PSMA PET/CT with concurrent BS and CT scans between February 2015 and October 2017. There were 565 scans performed for initial staging of prostate cancer while 844 scans were performed for biochemical relapse. In the staging cohort, preliminary analysis identified 85 patients (15%) who had PSMA-avid foci which were not detected on BS or CT imaging including in regional/distant lymph nodes, bones and other sites. In patients referred for biochemical relapse, a total of 453 scans (53.7%) demonstrated PSMA-avid lesions that were occult on CT and BS imaging. The sites of PSMA uptake in these patients included the prostate gland itself, the prostatectomy surgical bed, regional lymph nodes and distant metastatic sites. 86/1309 patients also had suspicious bone lesions detected on BS and/or CT which did not demonstrate PSMA avidity. **Conclusion:** Preliminary data analysis supports the utility of ^68^Ga-PSMA PET/CT in the detection of potential sites of disease that are occult on BS and CT imaging. The full analysis of the data will be presented.
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**Background/Aims:** Multiparametric MRI and Ga-68 PSMA-HBED-CC imaging are rapidly growing investigations for patients with primary carcinoma of the prostate.\[[@ref242][@ref243]\] To assess the findings of multiparametric MRI and ^68^Ga-PSMA-HBED PET scan results of patients with primary carcinoma of the prostate in comparison to biopsy results of the prostate gland. **Methods:** We retrospectively analysed the data of 114 consecutive patients from a single urology clinic who underwent multiparametric MRI and ^68^Ga-PSMA-HBED-CC scans for primary staging and transperoneal biopsies of their prostate gland. Informed consent was obtained from every patient. Age of the patients was between 37 and 80.5 years with a median of 68.6 years. PSA levels were between 2.3 and 22 ug/L with a median of 7.2 ug/L. MRI images were analysed by PIRAD (version 2) criteria while ^68^Ga-PSMA-HBED-CC PET scans were analysed visually for focal lesions within the prostate gland with additional semi-quantitative assessment of the imaging findings with calculations of SUV~max~ values within focal lesions and also within the contralateral side of the glands. GG (Grade Group) values on biopsy were plotted against SUV~max~ values. EView was used for statistical analysis. **Results:** We have shown an increasing SUV~max~ value with increasing GG^3^ scores on biopsy. Pair wise comparisons confirmed our tentative conclusions based on the visual comparison of the 95% CI for the medians. Namely, there is a significant difference between the GG1 and GG2 groups, and between the GG2 and GG3 groups, but there is only some insignificant difference between the Normal and GG1 groups and also between the GG3 and GG4-5 groups. Using a cut-off SUV~max~ value of 4 on ^68^Ga-PSMA-HBED-CC images, PPV value was 94.87% with a specificity of 95.2% while sensitivity was 52% to diagnose GG2 or higher grade malignancy. Using a cut-off SUV~max~ value of 4, we have diagnosed 15 extra sites of malignancy on comparison to the results on multiparametric MRI. **Conclusion:** ^68^Ga-PSMA-HBED PET imaging demonstrates more primary prostate carcinoma than mpMRI when semiquantitative analysis of the data is applied in addition to visual analysis. Semi-quantitative analysis also shows that SUV~max~ values increase with severity of GG on biopsy results.
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**Background/Aims:** Prostate cancer (PC) cells typically show increased expression of prostate-specific membrane antigen (PSMA), which can be visualized by ^68^Ga-PSMA PET/CT. The aim of this study was to assess the intensity of ^68^Ga-PSMA PET/CT uptake in the metastases in patients with biopsy-proven PC after to radiotherapy, and to determine to diagnostic value of ^68^Ga-PSMA in determination of biochemical recurrence focus in the cases of prostate cancer that received radiation therapy as primer because they are not suitable for operation. **Methods:** Forty-five of 136 patients were evaluable for a retrospective analysis. The median and mean prostate-specific antigen (PSA) levels were 5.24 and 21 ng/mL (range, 0.1-148 ng/mL). All patients underwent PET/CT after injection of 3.5 ± 1.27 MBq of ^68^Ga-PSMA. The detection rates were correlated with PSA level and PSA kinetics. The influence of antihormonal treatment, primary Gleason score, and contribution of PET and morphologic imaging to the final diagnosis were assessed. **Results:** Forty-one (91%) patients showed pathologic findings in ^68^Ga-PSMA ligand PET/CT. The detection rates were 98% and 72.7% for PSA levels of ≥2 and 0, 1 to \<2 ng/mL, respectively. PET/CT with ^68^Ga-PSMA (compared with MR) 27 (60%) provided pathological findings in the patient. Additional sites were identified in 20 patients (44, 4%). Detection activity increased significantly at high Gleason scores (≤7 vs ≥8) and at high PSA level (\<2 ng/mL) (p = 0.01 and p = 0.01). There was no significant difference in detection efficacy for antiandrogen therapy (ns). **Conclusion:** ^68^Ga-PSMA PET/CT shows higher diagnostic accuracy than CT and MR imaging methods. More importantly, the clinically significant low PSA values (\<2 ng/mL) in the non-operated group of patients reveal a large number of positive findings. The ^68^Ga-PSMA PET/CT method is the first choice for investigating the biochemical recurrence rate in patients who received RT as primary therapy even if who were not operated.
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**Background/Aims:** PSMA targeting PET-tracers have become available for imaging due to the over expression of PSMA in prostate cancer (PC). ^68^Ga-PSMA-HBED-CC PET/CT represents a clinically relevant and commonly used technique for the evaluation of these patients. ^68^Ga labelled compounds are produced with generators providing limited activity per synthesis whereas ^18^F-labelled tracers, like Al^18^F-PSMA-HBED-CC, can be produced in large scales with a lower positron energy that potentially offers higher image quality. To test this hypothesis, we compared on a head-to-head basis the image quality and detection performance of both radiopharmaceuticals in a sample of PC patients. **Methods:** We analysed six patients (median age 67 years, range 52-78 years) who underwent both ^68^Ga-PSMA and Al^18^F-PSMA PET/CT scanning within a time window of 1-2 weeks, 60 minutes after the IV administration of 2.0 and 4.0 MBq/kg, respectively. Studies were performed with a 64-slice PET/CT scan with TOF correction. Five patients had high-risk biopsy proven PC prior therapy (Gleason \>7, PSA 10-38ng/mL). The remaining patient was imaged prior to ^177^Lu-PSMA therapy and had hormone-resistant metastatic disease (PSA 21ng/mL). The study was approved by the institutional Ethics Committee. We measured the SUV~max~ in all abnormal foci as well as the SUV~max~ ratio (SR) in all coincident lesions, defined as SUV~max~ lesion/SUV~max~ background. Gluteal musculature was selected as background. **Results:** Al^18^F-PSMA PET/CT demonstrated abnormal findings in all patients with images of high visual quality. Besides, 4/5 patients submitted for initial staging had evidence of metastatic disease. Abnormal foci (n = 41) were seen in the following sites: prostate gland (n = 7), lymph nodes (n = 4), bone (n = 29) and lung (n = 1). Seven bone lesions were positive only with this tracer (17%), whereas the remaining 34 (83%) were also abnormal for ^68^Ga-PSMA. For concordant lesions (n = 34), we found a significantly higher SR for Al^18^F-PSMA compared to ^68^Ga-PSMA: 10.7 (2.7-28.0) and 5.5 (1.7-19.0), median (range), for each tracer, respectively (P \< 0.0001). Furthermore, a significant correlation was found between the SUV~max~ of both radiopharmaceuticals (r = 0.35, p = 0.043). **Conclusion:** Al^18^F-PSMA PET/CT is a promising imaging technique for the evaluation of PC patients. Further studies are needed to confirm these preliminary results.
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**Background/Aims:** ^18^F-PSMA tracers are an attractive alternative to ^68^Ga-PSMA tracers due to the better spatial resolution, longer half-life and cyclotron production of ^18^F. ^18^F-PSMA-1007 has the added advantage of less urinary excretion and favourable tumour background ratios\[[@ref245]\]. The study aim was to assess the normal biodistribution of ^18^F-PSMA-1007 compared to ^68^Ga-PSMA-11. **Methods:** Ten ^18^F-PSMA-1007 PET/CTs (indications of staging, biochemical recurrence and metastatic disease) performed at the Royal Brisbane and Women's Hospital were assessed quantitatively (SUV~max~) at selected physiological and equivocal sites. Direct comparison made using t-tests to ten ^68^Ga-PSMA-11 studies performed for matched indications, including four patients imaged with both tracers. Local ethics approval was obtained. **Results:** ^18^F-PSMA-1007 studies demonstrated significantly lower bladder activity (mean 4.3 vs. 19.9, p = 0.002). Uptake was significantly higher within liver (14.9 vs. 6.7, p \< 0.001), gallbladder (23.9 vs. 1.5, p \< 0.001), parotid glands (25.2 vs. 17.6, p \< 0.001), axillary lymph nodes (2.2 vs. 1.3, p = 0.005), lumbar vertebrae (2.1 vs. 1.5, p = 0.02) and sympathetic ganglia (coeliac 6.5 vs. 2.5, p = 0.003 and stellate 4.2 vs. 2.3, p = 0.008). One ^18^F-PSMA-1007 case demonstrated moderate uptake within sacral ganglia (SUV~max~ 5.3). However, there was no significant difference in splenic (14.1 vs. 11, p = 0.34) and duodenal uptake (16.3 vs. 15.4, p = 0.68). Four patients received both tracers: ^18^F-PSMA-1007 identified a disease focus in the prostatic bed in one case (obscured by adjacent radiourine on ^68^Ga-PSMA); and three subsequent ^68^Ga-PSMA-11 PET/CT scans were performed to evaluate equivocal focal osseous uptake (and equivocal nodes in one case) demonstrated less uptake at these sites compared to ^18^F-PSMA-1007 (with one osseous lesion and nodes reclassified as probably benign on this basis). **Conclusion:** ^18^F-PSMA-1007 PET/CT has significant differences in physiological uptake compared to ^68^Ga-PSMA-11. Higher uptake within non-malignant lymph nodes, bone and sympathetic ganglia has implications for clinical interpretation. Less urinary excretion may improve identification of prostate bed recurrence.
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**Background/Aims:** ^68^Ga-prostate-specific membrane antigen (^68^Ga-PSMA) PET/CT has been witnessed as a paramount tool for detection of prostate cancer recurrence and currently for disease staging. Multi-parametric MRI (mp-MRI) of the prostate has aided in detecting intermediate to high grade lesions with high sensitivity values. Among these lesions, PIRAD-3 lesions are characterized as indeterminate, and consensus on whether to biopsy or not is left for the clinician's clinical judgment. Studies have shown the added effect of ^68^Ga-PSMA in detecting and locating tumour foci within prostate tissues, having a higher specificity and PPV due to low false-negative rates. We aimed to study detection rates of PIRAD-3 prostate lesions, on ^68^Ga-PSMA PET/CT, and correlate it with the final pathology on transrectal ultrasound (TRUS) guided biopsies. **Methods:** Reviewing our mp-MRI prostate database, a total of 170 patients having PIRAD-3 lesions were reported. Only 4 of those underwent ^68^Ga-PSMA PET/CT, anytime during their treatment course. Prostate size, PSA, and SUV~max~ values were mentioned. TRUS biopsy results were also noted. All studies were conducted after approval from the Institutional Review Board. **Results:** Mean patient age was 72.5 years (range 68-78). The mean triggering PSA was 17.7ng/mL(range 6.1-43.3), and the mean prostate size was 54 grams (range 37-76). In three patients, the ^68^Ga-PSMA PET/CT and the mp-MRI reports coincided in the prostate tumour location. No definitive evidence of gallium-avid disease was noted in the fourth patient. The SUV~max~ of index lesions ranged between 6.4 and 10.38. Targeted TRUS biopsies were performed on three patients; two of which came out benign and the third, Gleason 6, involving 1/3 cores. The patient with no avid lesion on PET/CT elected to withhold biopsy. **Conclusion:** The literature on PIRAD-3 lesions is scarce. Those indeterminate lesions offer controversy in treatment approach. The advent of ^68^Ga-PSMA PET/CT may add further proof that such lesions may carry a low potential for aggressiveness, thus supporting active surveillance protocols.
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**Background/Aims:** We designed a multi-centre national site validation process to test the veracity of PET imaging when using Ga-68 prior to commencing trial imaging with ^68^Ga-PSMA in patients with suspected prostate cancer (the ProPSMA trial, ACTRN12617000005358) based on the widely-accepted NEMA NU-2 (2012) PET Performance Evaluations procedures. **Methods:** A single IEC Body Phantom was transported to each site for evaluation. Sites followed specific instructions to fill the phantom with Ga-68 in solution (50 -- 200 MBq) to create an 8:1 sphere-to-background ratio. All spheres were filled with the radioactive solution (in the NEMA protocol the largest two spheres are filled with non-radioactive solution). PET/CT acquisition as performed after one hour replicating the clinical protocol (to incorporate radionuclide decay). Data about the dose calibrator and accuracy of PET imaging with F-18 were also obtained. The images were analysed by a core laboratory (PharmaScint, Sydney) using the NEMA NU-2 (2012) parameters of image quality for accuracy of attenuation and scatter correction derived from Contrast Recovery Coefficient (CRC%) and Background Variability (BV%) in the largest (37 mm diam) sphere as well as measuring the standardised uptake value (SUV) in the background compartment, which was designed to be equal to 1.0, and scatter fraction (SF%) in the non-radioactive void in the centre of the phantom. **Results:** Fifteen PET systems were evaluated at 9 PET facilities in Australia. Accuracy of image reconstruction was initially underestimated by 15% on average on 10 PET systems in 7 of the centres. The origin of the inaccuracy was traced to an incorrect dose calibrator setting on one manufacturer's device. After correction, all 15 PET systems passed and demonstrated an accuracy in SUV of 1.0±0.03, CRC of 68.2%±4.2%, BV of 3.9%±1.2% and SF of 18.6%±7.1%. **Conclusion:** The protocol that has been developed allows thorough evaluation of PET (or SPECT) systems including verification of accurate SUV and, as a surrogate, accuracy of dose calibrators. It initially uncovered a systematic error in a dose calibrator setting which was widespread and would have had implications for the clinical trial.
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**Background/Aims:** Prostate cancer (PCa) accounts for 15% of cancer diagnoses in men worldwide and 6.6% of total male mortality.\[[@ref246]\] It is estimated that 35% of patients treated for PCa relapse within 10 years.\[[@ref247]\] Biochemical relapse (BCR) may precede radiographic relapse by many years, with implications for management. Radiographic detection of relapse coincident with, or soon after, BCR can facilitate targeted and earlier initiation of therapy. The role of molecular imaging modalities, such as ^68^Ga-PSMA PET/CT in this context is becoming increasingly clear.\[[@ref248][@ref249][@ref250]\] This study aimed to compare rates of detection of recurrent PCa by ^68^Ga-PSMA-I&T with that by correlative diagnostic CT for patients stratified by serum prostate specific antigen (PSA) level. **Methods:** Patient data and images from 150 patients who had undergone ^68^Ga-PSMA-I&T PET/CT for a rising PSA (i.e., BCR) after definitive treatment for PCa were analysed retrospectively for rate of lesion detection. This detection rate compared to that yielded by CT imaging for the same patient. **Results:** Of the 150 patients who had a ^68^Ga-PSMA-I&T PET/CT for a rise in serum PSA following definitive treatment for PCa, PSMA-avid lesions were revealed in 102 (68%), while the overall detection rate in the same group by conventional CT imaging was 42%. The rate of PCa recurrence detection ^68^Ga-PSMA-I&T PET (vs. CT) for PSA stratified groups was: PSA \<0.5 ng/mL -25%(5%); PSA 0.5--1.5 ng/mL-67%(41%); PSA \>1.5 ng/mL -92%(63%). **Conclusion:** For patients with biochemically recurrent PCa, ^68^Ga-PSMA-I&T PET was superior to CT alone in detecting lesions, most notably for serum PSA levels \<0.5 ng/mL.
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**Background/Aims:** Prior to the utilisation of Gallium-labelled prostate specific membrane antigen (^68^Ga-PSMA) ligand PET/CT, biochemical recurrence as evidenced by elevated prostate specific antigen (PSA) was treated with empiric salvage radiation to the prostate bed with or without pelvic node irradiation at our institution. The purpose of this study was to describe the sites of PSMA-avid recurrent disease of studies performed at Mercy radiology between January to June 2017. **Methods:** This was a retrospective study of patients with biochemical recurrence; defined as PSA level of \>0.2 ng/mL following primary treatment with radical prostatectomy alone. Ethical approval was granted by the Southern Health and Disability Ethics Committee. **Results:** 65 patients (mean age 67±7 years) had a PSMA PET/CT for biochemical recurrence. Detection rate according to PSA levels at the time of recurrence was 33% for 0.2-0.5 ng/mL (8/24), 63% for \>0.5-1.0 ng/mL (7/11), 86% for \>1.0-2.0 ng/mL (6/7) and 91% for ≥2.0 ng/mL (21/23). 42 patients demonstrated PSMA-avid recurrent disease. 17% were limited to the prostate bed and 48% extended beyond the prostate bed involving the pelvic nodes, extra-pelvic nodes, bone or soft tissue. Amongst the group with recurrent disease, 7/42 patients had distant disease which also involved the prostate bed, whilst 24/42 patients had distant disease without involvement of the prostate bed. The most common site of recurrence were pelvic nodes (35%), followed by the prostate bed (28%), bone (17%), extra-pelvic nodes (12%) and soft tissue (6%). **Conclusion:** Recurrent disease beyond the prostate bed and pelvic nodes was detected in a significant proportion of patients following radical prostatectomy on PSMA PET/CT. Empiric radiation therapy without restaging would have undertreated more than one-third of patients with recurrent disease in our cohort.
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**Background/Aims:** We report the first documented case of floor of mouth mucoepidermoid carcinoma (MEC) found incidentally on PSMA PET/CT performed as part of surveillance of previously treated prostate cancer. We aim to determine the potential use of PSMA PET/CT in surveilling mucoepidermoid cancer of the head and neck. We report the first documented case of floor of mouth MEC found incidentally on PSMA PET/CT performed as part of surveillance of previously treated prostate cancer. We aim to determine the potential use of PSMA PET/CT in surveilling MEC of the head and neck. **Methods:** A literature review using PUBMED and MEDLINE with the search term "prostate specific membrane antigen (PSMA)", "salivary gland" and "positron emission tomography (PET)" was performed. **Results:** ^68^Ga-PSMA PET produces high target-to-background images of prostate cancer and its metastases due to the presence of PSMA in these cells and is used for the detection and restaging of prostate cancer. However, PSMA is not specific to the prostate with significant physiological uptake in normal tissues including the salivary glands, liver and kidney as well as in many benign neoplasms and malignancies. Non-prostatic malignancies include brain tumours, carcinoma of breast, lung, salivary glands, kidney, thyroid and liver. There are no documented cases of Ga-68-PSMA uptake in MEC. A recent retrospective review of 9 patients with adenoid cystic carcinoma of the head and neck demonstrated that PSMA PET/CT is able to detect and visualize local recurrent and distant metastatic disease and that PSMA-specific targeting is supported by PSMA expression on immunohistochemistry.\[[@ref251]\] Our patient underwent complete intra-oral excision and level I-IV neck dissection with no evidence of recurrence on repeat PSMA PET scan at 1 year. **Conclusion:** Further research is required to determine if PSMA PET can be reliably utilised for the surveillance of mucoepidermoid carcinoma of the head and neck. Furthermore, with the increasing use of PSMA PET in the management of prostate cancer, the appearance of PSMA uptake in salivary tumours is one with which reporting clinicians should be familiar.
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**Background/Aims:** Prostate cancer is the second most commonly diagnosed cancer in men worldwide having the highest incidence in Australia.\[[@ref252]\] In recent years, prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) radiotracers have been introduced with the clinical use of Gallium-68 (^68^Ga)-PSMA spreading rapidly around the world. Fluorine-18 (^18^F) labelled alternatives have started to emerge offering improved image quality and the benefits of a longer half-life and higher production capacity.\[[@ref253]\] This could increase the accessibility of PSMA imaging to small and remote PET departments. Our aim is to discuss our experiences with this radiotracer and provide insight into the implementation of new radiopharmaceuticals into clinical practice. **Methods:** 2-(3-{1-carboxy-5-\[(6-\[^18^F\] fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid (^18^F-DCFPyL) is an alternative to ^68^Ga-PSMA for prostate cancer imaging which recently became available to our department. We conducted research into the available delivery times, approval process, scanning parameters, and differences in comparison to ^68^Ga-PSMA prior to its implementation. Documentation providing clinical justification was sent to our local ethics committee to begin the approval process and subsequently sent to the therapeutic goods administration (TGA) to obtain authorised prescriber rights. Ethics was approved through the Princess Alexandra Hospital local ethics committee on behalf of Metro South Health. **Results:** A minimum scheduling of 3 patients was required for cost effectiveness. Other than the 200MBq injected activity and 2-hour uptake period, patients underwent the same preparation and scanning parameters as they would for a ^68^Ga-PSMA PET scan in our department. The scans showed overall improved image quality particularly regarding spatial resolution and were comparable to that of ^68^Ga-PSMA. **Conclusion:** In our clinical experience, ^18^F-DCFPyL is a viable option for departments that don't have access to ^68^Ga-PSMA. The higher production capacity and longer half-life of ^18^F-labelling enables more patients to be imaged and may increase the availability and accessibility of PSMA PET imaging.
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**Background/Aims:** To evaluate the utility of ^68^Gallium-prostate specific membrane antigen positron emission tomography/computed tomography (^68^Ga-PSMA PET/CT) in resolving specific clinical dilemmas in castration resistant prostate cancer (CRPC). **Methods:** Analysis of ^68^Ga-PSMA PET images performed between June 2016 and October 2017 in our department in patients with CRPC was done with a view to assess the detection efficiency of metastases in bones as well as soft tissues. Its superiority over CT was looked at with reference to the efficiency to determine the activity of disease. **Results:** Study group comprised of 21 men with CRPC. PET images demonstrated active disease in prostate in 17 patients. Among them, CT images could not differentiate active disease vs. disease in remission in 11 patients. In four of them CT images did not reveal the lesions. Six patients had active bone metastases in PET images, not demonstrated on CT and six patients had false positive lesions on CT images as these lesions were sclerotic. Active disease in metastatic nodes was seen on PET images in six patients, whereas nine showed false positive lymphadenopathy on CT images. **Conclusion:** In CRPC, ^68^Ga-PSMA PET/CT was beneficial in answering specific clinical questions like disease activity in metastases in bone and soft tissues and the primary site.
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**Background/Aims:** ^68^Ga-PSMA-11 PET/CT is recently used for diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the effect of different influence on PSMA uptake in 100 patients. **Methods:** Hundred patients who enrolled for ^68^Ga-PSMA-11 PET/CT were scanned and 1 hour or delayed imaging after 3 hours of injection was performed from July 2015 to August 2017 to detect the low level or recurrence of prostate cancer. The possible effects of different variables including PSA level, Gleason score, hormone therapy, radiotherapy and chemotherapy, patient age and radiopharmaceutical dose of injection were assessed. **Conclusion:** ^68^Ga-PSMA-11 PET/CT detects tumour lesions in a high percentage of patients with recurrent PCa. In fact, there was not any correlation between a positive ^68^Ga-PSMA PET/CT scan and patient age, amount of injected dose.
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**Background/Aims:** Response assessment at interim PET/CT scan can be done by using both qualitative and quantitative methods. A lot of work has been done in West and criteria have been designed for response assessment but in our setting ^18^F-FDG PET/CT is a newer technique and criteria for response assessment still requires further studies because of discrepancy among different centers in interpretation. **Methods:** Study comprised of 35 diagnosed, untreated lymphoma patients. All patients underwent ^18^F-FDG PET/CT as baseline scan before treatment. Interim scans were acquired after 2 cycles of chemotherapy in Hodgkin's lymphoma and in non-Hodgkin's lymphoma. Baseline and interim scans were reported using Deauville criteria and SUV~max~. Patients were categorized using Deauville Score/5-point score into complete metabolic response, partial metabolic response, stable disease and progressive disease, while patients were categorized into similar categories using PRECIST criteria on the basis of ΔSUV~max~. Baseline and interim scans were reviewed by 2 nuclear medicine experts using the 5-point score. **Results:** Out of the 35 patients, 12 (34%) had HL, while 23 (66%) had NHL. At interim scans, based on Deauville criteria complete metabolic response was achieved in 19 (54%) patients (Deauville score 1-3); 8 patients (23%) showed partial metabolic response (Deauville score 4-5); 3 patients (9%) were identified with stable disease; and 5 patients (14%) had disease progression. While on the basis of ΔSUV~max~, complete response was achieved in 16 patients (46%), 11 (31%) had partial metabolic response, 3 (9%) had stable disease, and 5 (14%) had disease progression. Value of Pearson's r was 0.941 (p\< 0.01) which indicated statistically significant correlation between Deauville criteria and ΔSUV~max~. Kappa test was statistically significant (kappa 0.826; p\<0.01) and indicated perfect agreement among reviewers. **Conclusion:** After analysing the data, it can be concluded that ΔSUV~max~ and Deauville criteria significantly correlate in response assessment at interim PET/CT scan in extranodal lymphomas. Deauville Score can predict the response very well in extranodal lymphomas in addition to Hodgkin's and non-Hodgkin's lymphoma, and can be used instead of standardised uptake value (SUV~max~), therefore should be used routinely.
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**Background/Aims:** Granulomatous lymphadenitis is a rare condition and is classified into two different groups; non-infectious and infectious types. Non-infectious type includes berylliosis, Hodgkin's lymphoma, non-Hodgkin's lymphoma, lymph node draining neoplasms (sarcoid-like granuloma) and sarcoidosis. Infectious type can be categorised into suppurative lymphadenitis and non-suppurative lymphadenitis.\[[@ref254][@ref255]\] Sarcoid-like granuloma can be found in many solid tumours and in their draining lymph nodes, such as those draining carcinomas of lung, stomach, uterus, ovaries and melanoma.\[[@ref256][@ref257][@ref258]\] It can occur in tumours that have been treated with chemotherapy and radiotherapy.\[[@ref259][@ref260]\] It can also be found in non-regional tissue including bone marrow and spleen.\[[@ref261]\] **Methods:** A PET/CT study was performed on a Philips Gemini TF scanner following the administration of ^18^F-FDG. A low dose CT was also performed with dilute oral contrast for lesion localisation and attenuation correction as per departmental protocol. **Results:** A 38-year-old woman was referred for staging PET/CT which demonstrated widespread intensely FDG-avid lymphadenopathy in multiple nodal stations above the diaphragm with focal uptake in the spleen and extranodal involvement in the lungs and vertebral bodies. She was treated with chemotherapy and radiotherapy. Progress PET/CT after 5 months demonstrated significant metabolic response. Repeat PET/CT one month later was highly suspicious of recurrent disseminated FDG avid lymphoma in multiple nodal stations above and below the diaphragm, spleen, multiple bones and lungs. Subsequent bone marrow biopsy demonstrated sarcoid-like granulomatous inflammation. The patient was clinically well and progress PET/CT two months later without treatment demonstrated complete spontaneous metabolic response. **Conclusion:** This case demonstrates the importance of confirming unexpected PET/CT findings with histopathology in avoiding unnecessary toxic treatment in non-neoplastic conditions.
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**Background/Aims:** Hodgkin's lymphoma (HL) accounts for approximately 10% of all lymphomas diagnosed in the developed world annually.\[[@ref262]\] The incidence has a bimodal age group distribution, with most patients diagnosed between 15 and 30 years of age and in adults over the age of 50. HL is usually confined to the lymph nodes.\[[@ref263]\] Extranodal involvement is less common in HL than in non-Hodgkin's lymphoma (NHL) and seen in only 10-15% of patients. The most frequent sites of extranodal involvement are bone, bone marrow, lung and liver.\[[@ref264]\] According to NCCN, ^18^F-Fluorodeoxyglucose (FDG) PET/CT is the corner stone for initial staging and evaluation of treatment response in HL. Response to treatment with chemotherapy or combined modality therapy is assessed by restaging with FDG-PET/CT at midcycle (interim PET/CT) or completion of treatment. Several studies have established the role of interim PET/CT in the prognosis of HL during chemotherapy.\[[@ref265]\] **Methods:** This is a prospective cohort study of HL patients who underwent interim FDG-PET/CT. This study was conducted in a tertiary hospital. Patients histologically diagnosed with HL who had undergone baseline FDG PET/CT in a tertiary hospital prior to chemotherapy and had at least one follow-up PET/CT in the same institution from January 2014 to October 2015 were included in the study. **Results:** The median age was 29-years-old with 31.2% aged in the 21--30 range. The study demonstrated that SUV~max~ in the lymph nodes was significantly associated with disease progression. In a study by Tseng *et al.*,\[[@ref266]\] SUV~max~ in the interim PET/CT scan was significantly associated with overall survival. In this study, MTV as a quantitative PET parametert is not significant. This may be due to the small size of our study. The results show a threefold risk of disease progression in females and 1.5 chance of disease progression in patients older than 40-years-old. **Conclusion:** In conclusion, mean difference of SUV~max~ in the lymph nodes after a treatment will likely be helpful in identifying patients at high risk of treatment failure at an early time when treatment modification could be considered.
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**Background/Aims:** The purpose of this study was to evaluate the bone marrow uptake pattern in posterior iliac crest of the 18-F-fluorodeoxyglucose (^18^F-FDG) positron emission tomography/computed tomography (PET/CT) in detecting bone marrow involvement in patients with lymphoma. **Methods:** 183 patients with newly diagnosed lymphoma who underwent ^18^F-FDG PET/CT and bone marrow biopsy (BMB) within 14 days in the EDa hospital were retrospectively reviewed. The SUV~max~ of right posterior iliac crest (SUVr) and left posterior iliac crest (SUVl) were compared to the result of BMB by Mann-Whitney U test. The area under curve (AUC) from the receiver-operating-characteristics (ROC) curve and the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated. **Results:** The subgroups of lymphoma included 103 diffuse large B-cell lymphoma (56.3%), 19 follicular lymphoma (10.4%), 13 Hodgkin's lymphoma (7.1%), 9 T-cell lymphoma (4.9%), 7 extranodal natural killer/T-Cell lymphoma (3.8%), and 32 other types lymphoma (17.5%). The mean of SUVr in positive and negative BMB result were 2.84±1.85 and 1.79±0.82 (p\<0.001). The mean of SUVl in positive and negative BMB result were 2.82±1.77 and 1.77±0.87 (p=0.002). The sensitivity, specificity, PPV and NPV for bone marrow invasion were 73.5%, 67.8%, 33.3% and 88.6% with SUVl \>1.815 (AUC=0.748). The sensitivity, specificity, PPV and NPV for bone marrow invasion were 67.6%, 72.5%, 35.9% and 90.8% with SUVr \>1.925 (AUC=0.745). **Conclusion:** Increased SUV~max~ of bilateral posterior iliac crests was associated with positive result of bone marrow biopsy and should be considered as a marker of bone marrow invasion in lymphoma.
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**Background/Aims:** Positron emission tomography (PET) with glucose analogue (FDG) has functional and morphological capacity to identify the extent and activity of multiple myeloma for diagnosis, staging and monitoring purpose. However, scintigraphy with ^99m^Tc-MIBI has also proven to be useful in diagnosis and staging of patients with multiple myeloma, showing high specificity and sensitivity. **Methods:** A 76 year old male with a history of diabetes mellitus and high blood pressure, underwent a myocardial revascularization twenty years ago, presents for a cardiologic follow up. The patient underwent myocardial perfusion scintigraphy after intravenous administration of ^99m^Tc-MIBI. **Results:** After the first image of the scintigraphy, accumulation of ^99m^Tc-MIBI was noticed in the sternum, thoracic spine and costal grid. The patient had no previous history of neoplasm, any complains of pain or skeletal events. Scintigraphy was interrupted and the patient was sent to the oncology team for further investigation. After four days, a chest computed tomography (CT) was done, and showed multiple osteolytic lesions spread in the thoracic spine, sternum and costal grid, with one insuflative lesion located in the 5^th^ left rib. On the same day, the patient was submitted to blood and urinary tests with the following results: Serum protein electrophoresis and immunofixation containing IgG heavy chain and kappa light chain; urinary monoclonal protein 476 mg/24hours; Beta-2-microglobulin 3009 ng/mL and creatinine clearance 35.6 mL/min/1.73m^2^. After that was done, a bone marrow biopsy for diagnostic confirmation of multiple myeloma, with the result still in analysis in the present date. **Conclusion:** ^99m^Tc-MIBI scintigraphy is rarely used for diagnosis of multiple myeloma, despite evidence on its usefulness. It has to be considered the low cost of the exam and the better accessibility if compared with FDG PET/CT, particularly in developing countries. Physicians should be inclined to consider the use of ^99m^Tc-MIBI scintigraphy as a diagnostic and monitoring procedure, especially when the access to PET/CT is limited.
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**Background/Aims:** To investigate the prognostic value of the maximum standardised uptake value (SUV~max~), metabolic tumour volume (MTV) and total lesion glycolysis (TLG) calculated from pre-treatment ^18^F-FDG PET/CT results in patients with diffuse large B-cell lymphoma of stage III-IV disease. **Methods:** The clinical data of 72 DLBCL patients with stage III-IV undergoing PET/CT scan at pre-treatment from June 2009 to May 2015 were analysed retrospectively. The Kaplan-Meier method and Log-rank test were used to perform univariate survival analysis, and Cox proportional hazards model for multivariate analysis. **Results:** The SUV~max~, MTV and TLG of 72 patients were 21.64 (5.97, 42.50), 139.48 (13.65, 2773.70) cm^3^ and 1413.77 (36.23, 21078.66), respectively. For DLBCL of stage III\~IV disease, univariate analysis showed that ECOG performance status, bulky disease, National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) and MTV were relative factors affecting PFS rate (all p\<0.05), and bulky disease, NCCN-IPI and MTV were also relative factors affecting overall survival (OS) rate; in multivariate analysis, only NCCN-IPI was the relative factor affecting PFS rate and OS rate (all p*\<*0.05). For DLBCL of stage III disease, SUV~max~ and TLG were not associated with PFS and OS rate (all p\>0.05). MTV was the relative factor affecting PFS rate and OS rate in univariate analysis (all p\<0.05), but wasn't the independent predictor of PFS and OS rate in multivariate analysis (RR=3.899, 95%CI 0.826-18.41, p=0.086; and RR=4.242, 95%CI 0.481-27.437, p=0.193). For DLBCL of stage IV disease, univariate analysis showed that SUV~max~, MTV, TLG weren't the relative factors affecting PFS and OS rate (all p\>0.05). **Conclusion:** For DLBCL of stage III-IV disease, the prognostic value of SUV~max~, MTV and TLG on pre-treatment PET/CT are indeterminate, and cannot be used to predict patient prognosis.
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**Background/Aims:** While ^18^F-FDG PET/CT quantitative parameters can better reflect the individual tumour burden status, more studies would focus on the role in the prognosis of lymphoma. The aim of this study is to investigate the prognostic significance of maximum standard uptake value (SUV~max~), whole body SUV~max~ (WBSUV~max~), whole body metabolic tumour volume (WBMTV) and whole body total lesion glycolysis (WBTLG) measured on pre-treatment ^18^F-PET/CT in patients with peripheral T-cell lymphoma (PTCL). **Methods:** Eighty PTCL patients who underwent pre-treatment ^18^F-PET/CT enrolled in this study. WBMTV and WBTLG were computed by using the margin thresholds as SUV \>3.0. WBSUV~max~ was obtained by summing of SUV~max~ of the whole-body SUV~max~ of 11 nodal and 10 extra-nodal lesions. **Results:** The receiver operating curve (ROC) analysis showed the optimal cut-off values with overall survival (OS) of WBSUV~max~, WBMTV and WBTLG were 22.2, 169.5 cm^3^ and 746.1, respectively. Patients with high WBMTV, WBTLG, and WBSUV~max~ had a worse prognosis. WBSUV~max~, WBMTV and WBTLG were associated with international prognostic index (IPI) and prognostic index for T-cell lymphoma (PIT). In multivariate analysis, WBTLG and PIT were independent predictors of both PFS and OS. **Conclusion:** Our study has shown that high WBTLG, WBMTV and WBSUV~max~ suggest a relatively poor prognosis, and a highly significant association with PIT and IPI. WBSUV~max~ seems easier to promote due to its operability. WBTLG appears as an independent predictor of PTCL outcome.

P156: Preliminary Results of the UK NCRI Multicentre Phase II Randomised CHEMO-T Trial Positron Emission Tomography/Computed Tomography Substudy: the role of

18

F FDG-Positron Emission Tomography/Computed Tomography in Peripheral T-Cell Lymphoma

Gleeson

M

1

Peckitt

C

2

Cunningham

D

1

To

Y

1

Edward

L

1

Chau

I

1

Johnson

P

3

Ardeshna

K M

4

Wotherspoon

A

5

Attygalle

A

5

Begum

R

6

Zerizer

I

7

Hawkes

E

8

Macheta

M

9

Collins

G

10

Radford

J

11

Forbes

A

12

Hart

A

13

Montoto

S

14

McKay

P

15

Benstead

K

16

Morley

N

17

Kalakonda

N

18

Hasan

Y

19

Turner

D

20

Chua\*

Sue

7

GI and Lymphoma Unit, London, United Kingdom

The Royal Marsden NHS Foundation Trust, London, United Kingdom

Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom

Department of Medical Oncology, University College Hospital, United Kingdom

Department of Histopathology, United Kingdom

Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, United Kingdom

Nuclear Medicine and PET/CT, The Royal Marsden NHS Foundation Trust, United Kingdom

Department of Oncology and Clinical Haematology, Austin Hospital and Eastern Health, Melbourne, Australia

Department of Medical Oncology, Blackpool Victoria Hospital, Blackpool, United Kingdom

Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom

Department of Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester, Truro, England

Department of Medical Oncology, Royal Cornwall Hospital, Truro, England

Department of Medical Oncology, New Victoria Hospital, United Kingdom

Department of Medical Oncology, St Bartholomew's Hospital, London, United Kingdom

Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Department of Medical Oncology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, England

Department of Medical Oncology, Royal Hallamshire Hospital, Sheffield, England

Department of Medical Oncology, Royal Liverpool University Hospital, Liverpool, England

Department of Medical Oncology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, England

Department of Medical Oncology, Torbay Hospital, Torquay, United Kingdom

**Background/Aims:** The UK multicenter phase II randomised CHEMO-T trial compared cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) with gemcitabine, cisplatin and methylprednisolone (GEM-P) in untreated adult patients with peripheral T-cell lymphoma (PTCL). A key secondary endpoint included response assessment by ^18^F-Fluoro-deoxyglucose positron emission tomography (^18^F-FDG PET/CT) and comparison of metabolic and contrast enhanced CT (CECT) determined response. **Methods:** All patients had baseline (BL) and end of treatment (EOT) PET/CTs which underwent blinded central review. The following parameters were assessed at BL and EOT: mean, max and peak standardised uptake values (SUV) and metabolic tumour volume (MTV). For patients with biopsy-proven bone marrow (BM) involvement, the BL PET/CT was reviewed to assess for FDG-uptake in BM/bone. PET/CT response was assessed according to the revised response criteria for lymphoma.\[[@ref268]\] EOT response and Deauville score (DS) were correlated with progression-free survival (PFS) and overall survival (OS). In an exploratory analysis, semi-quantitative PET/CT parameters at BL (SUV max/mean/peak and MTV) were compared with overall response rate (ORR) at EOT. **Results:** BL PET/CT data was available for n=75 and paired (BL and EOT) PET/CT data for n=59 of the intention-to-treat (ITT) population (n=84). All patients had FDG-avid disease at diagnosis. 6/19 (32%) of patients with biopsy-proven BM involvement of PTCL at diagnosis had corresponding uptake on PET/CT. For EOT response assessment, agreement between PET/CT and CECT was 69.8% overall, 87.3% for determination of CR/PR versus SD/PD and 77.8% for determination of CR versus PR/SD/PD. PFS and OS according to EOT PET response: p\<0.001 (PFS) p=0.001 (OS) for CR/PR versus PD/SD and p=0.005 (PFS) p=0.77 (OS) by Deauville score 1-3 versus 4-5. The exploratory analysis evaluating semi-quantitative PET/CT parameters at BL showed no assessment was associated with ORR on EOT PET/CT. **Conclusion:** All PTCL subtypes were FDG-avid at baseline. PET/CT does not appear a sensitive tool for determining BM infiltration in PTCL. CR/PR at EOT was associated with superior PFS (p\<0.001) and OS (p=0.001). A DS of 4-5 at EOT was associated with inferior PFS (p=0.005).
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F-FDG Positron Emission Tomography/Computed Tomography Imaging Characteristics of Extra-Nodal Marginal Zone Lymphoma of MALT Type (MALT lymphoma): A Pictorial Series
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**Background/Aims:** Extra-nodal MZL of MALT type, or MALT lymphoma, is the third commonest NHL subtype, accounting for \~8% of all B-cell lymphomas. It is a low grade subtype with a relatively indolent disease course. Despite conflicting reports on the clinical utility of ^18^F-FDG PET in MALT lymphoma, several publications and a recent meta-analysis have shown evidence of extra-gastric disease demonstrating sufficient FDG-avidity for PET/CT detection and staging. We present a pictorial series of four biopsy-proven non-transformed cases of extra-nodal MALT lymphoma, demonstrating relatively high FDG-avidity with unusual but characteristic appearances on ^18^F-FDG PET/CT, as well as highlighting the variable clinical manifestation of each patient. **Methods:** Four patients with biopsy-proven MALT lymphoma and pertinent imaging characteristics were selected based on metabolic intensity and the PET/CT appearance. Lesion SUV~max~ was evaluated in all target lesions, along with relevant clinical, radiological, and histopathological results. **Results:** The four cases of non-transformed extranodal MALT lymphoma demonstrated prominent lesion FDG-avidity, with SUV~max~ ranging between 7 and 13. Cases 1 and 2, depicting intensely FDG-avid discrete bilateral breast lesions and diffusely FDG-avid left upper lobe consolidation respectively, illustrates the incidental nature in which the diagnosis can come to light. Case 3 demonstrates an unusual PET appearance with multifocal plaque-like conformation in subcutaneous soft tissue, characteristic for fascial involvement. Case 4 illustrates a similar pattern of perinephric and peri-ureteric uptake, also typical for fascial infiltration. **Conclusion:** Our case series provides additional evidence regarding the potential clinical utility of ^18^F-FDG PET/CT in MALT lymphoma, as well as highlighting the widely variable PET appearances and clinical manifestations to which reporting PET specialists should be aware of.
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**Background/Aims:** The aim of this study was to determine whether maximum standardized uptake value (P-SUV~max~), whole body metabolic tumour volume (P-WBMTV), whole body total lesion glycolysis (P-WBTLG) at the pretreatment ^18^F-FDG PET/CT scans, the reduction in SUV~max~ (ΔSUV~max~), WBMTV (ΔMTV), and WBTLG (ΔTLG) at the interim ^18^F-FDG PET/CT can predict prognosis in patients newly diagnosed as extranodal natural killer/T cell lymphoma, nasal type (ENKTL). **Methods:** Ninety-one newly-diagnosed patients were enrolled in this retrospective study. P-WBMTV, P-WBTLG, ΔMTV and ΔTLG were calculated respectively automatically using the boundaries of voxels presenting SUV≥2.5. P-SUV~max~, P-WBMTV, P-WBTLG, ΔSUV~max~, ΔMTV, ΔTLG as well as Deauville five-point score (5-PS) were recorded for each patient. Survival curves were obtained using Kaplan--Meier analysis and compared using the log rank test, followed by multivariate analysis to assess the independent effects of PET parameters and clinical variables including sex, age, B symptoms, performance status, KPI score, lactate dehydrogenase (LDH) level and Ann Arbor stage on progression-free survival (PFS) and overall survival (OS). **Results:** Receiver operating characteristic (ROC) curve analysis demonstrated cut-off values for P-SUV~max~, P-WBMTV, P-WBTLG, ΔSUV~max~, ΔMTV and ΔTLG of 10.85, 129.70 cm 3, 511.04, 49.86%, 62.87% and 61.25%, respectively. During the follow-up period of range between 2--83 months (26.6±16.5 months), P-WBMTV, P-WBTLG, ΔSUV~max~, ΔMTV, ΔTLG, 5-PS, LDH level and KPI score were significant predictors of PFS and OS. P-SUV~max~ and Ann Arbor stage were only the significant predictors of PFS but not OS. Multivariate analysis revealed that P-WBMTV, ?TLG as well as KPI score were the independent predictors of OS and P-WBTLG, ?TLG, 5-PS, KPI score as well as Ann Arbor stage were independent predictors of PFS. **Conclusion:** P-WBMTV and P-WBTLG can predict the OS and PFS respectively in patients with ENKTL. ΔTLG can predict unfavourable outcomes following treatment.
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**Background/Aims:** To assess the role of maximum standardised uptake value (SUV~max~) in newly diagnosed multiple myeloma (MM) patients in positron emission tomography/computed tomography (PET/CT) in evaluation of response to therapy. **Methods:** A total of 27 newly diagnosed patients of MM (including 11 patients of extra-medullary plasmacytoma, EPM) were enrolled in the study. The SUV~max~ of bone marrow and the extramedullary lesion in PET/CT, laboratory data and International Staging System (ISS) score were collected. Treatment monitoring and prognosis were analysed and evaluated. **Results:** Six patients of sixteen patients of MM with normalization of FDG uptake before therapy had independent favourable prognostic variable, all eleven patents of EPM had relapse after therapy. After induction therapy, persistence of SUV~max~ was \>4.0 in bone marrow of three patients of MM had shorter progression-free survival (3/10 vs 7/10 in patients with SUV~max~ values \<4.0), while SUV~max~ \>2.7 in plasmacytoma of three patients of EPM had shorter progression-free survival (3/11 vs 8/11 in patients with SUV~max~ values \<2.7). **Conclusion:** The higher SUV~max~ value in lesions of MM was a poor prognostic factor.

P160: The Prognosis of Maximum Standard Uptake Value, Total Metabolic Tumour Volume and Total Lesion Glycolysis in Patients with Follicular Lymphoma
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**Background/Aims:** To investigate the prognosis of maximum standard uptake value (SUV~max~), total metabolic tumour volume (TMTV) and total lesion glycolysis (TLG) in patients with follicular lymphoma (FL) at baseline and interim with ^18^F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) scans. **Methods:** The study analysed data from 48 patients with FL who were treated in Jiangsu Province Hospital and reviewed their baseline PET/CT scans. At the same time, 22 interim PET/CT scans were researched. TMTV and TLG were computed by using the absolute value of 2.0, 2.5 and 3.0 thresholding method respectively. **Results:** The discrimination value of the three models (TMTV2.0/TLG2.0, TMTV2.5/TLG2.5, TMTV3.0/TLG3.0) was evaluated by using time-dependent receiver-operator characteristic (ROC) curves. The areas under the curve (AUC) of TMTV3.0 and TLG3.0 were largest. ROC curve analysis showed the optimal cut-off values for SUV~max~, TMTV3.0 and TLG3.0 were 8.0 (sensitivity 77.9%, specificity 55.9%, AUC 0.624; p=0.191), 600 cm^3^ (sensitivity 92.3%, specificity 50.0%, AUC 0.762; p=0.006) and 975g (sensitivity 76.9%, specificity 64.7%, AUC 0.756; p=0.007). The media overall survival (OS) of the patients with TMTV3.0\>600 cm^3^ and the patients with TMTV3.0\<600 cm^3^ was 57 months versus not reach (NR) (x^2^, 9.373; p=0.002). The media OS of the patients with TLG3.0\>975g and the patients with TLG3.0\<975g was 58 months versus NR (x^2^, 6.942; p=0.008). The media OS of the patients with the decline rate (DR) \<50% between baseline SUV~max~ and interim SUV~max~ and the patients with the DR \>50% were 20 months versus NR (x^2^, 15.5; p=0.00). The median progression-free survival (PFS) of the two groups were 9 months vs. NR (x^2^, 10.3; p=0.001). On multivariable analysis, TMTV3.0 (relative risk \[RR\], 1.01; p=0.002), TLG3.0 (RR, 1; p=0.006), FL international prognostic index 2 (FLIPI2) score (RR, 3.41; p=0.044) and bone marrow involvement (RR, 5.53; p=0.029) were independent predictors of OS. **Conclusion:** Baseline TMTV and TLG are strong predictors of OS in FL and baseline SUV~max~ is not. But the DR of interim SUV~max~ is an important prognostic factor of OS and PFS in FL.
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**Background/Aims:** To investigate the prognostic impact of baseline fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (^18^F-FDG-PET/CT) parameters, including maximum standardized uptake value (SUV~max~) and total metabolic tumour volume (TMTV), and their additive values to the international prognostic index (IPI) in identifying risk for patients with Diffuse Large B-Cell Lymphoma (DLBCL). **Methods:** A total of 64 patients with DLBCL who had undergone pre-chemotherapeutic ^18^F-FDG PET/CT were retrospectively enrolled. The highest SUV~max~, TMTV were calculated for all abnormal FDG-avid lesions. The 2-year progression free survival (2-year PFS) was the end point of survival evaluation. The relationships among prognostic factors and 2-year PFS were analysed with Kaplan-Meier curve, log-rank test and Cox-regression hazard ratio. **Results:** There were 27 patients (42.2%) developed events during the median follow-up period of 24 months (range: 4-72 months). The SUV~max~, TMTV and IPI stratified patients with DLBCL significantly to low and high risk (log-rank tests p=0.012, p=0.006 and p=0.003, respectively). We integrated significant metabolic parameters to IPI, developing a new prognostic score index, metabolic integrated-IPI (mIPI) composed of 7 points (5 points for IPI factors and one point for each high SUV~max~ and TMTV). The mIPI could stratify patients to 4 risk groups with 2-year PFS, low 88%, low intermediate 78%, high intermediate 52% and high risk 27% (p\<0.001) compared to IPI stratification of 91%, 78%, 40%, and 48%, respectively (p\<0.023). Moreover, the subgroups of high intermediate and high risk were more accurately identified by mIPI (p=0.006), which was not differentiated in IPI. **Conclusion:** A metabolic integrated-IPI could better predict prognosis and stratify the risk for patients with DLBCL than IPI. This new prognostic score can be useful in facilitating treatment selection and managements, especially for patients with DLBCL with the higher risks.
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**Background/Aims:** The paper of this study was to investigate the clinical value of ^18^F-FDG PET/CT in staging and assessing the glucose metabolic activity of multiple myeloma (MM). **Methods:** A total of 25 MM patients (13 males, 12 females, age: 39-67 years) newly diagnosed by Peking University First Hospital from May 2010 to April 2015 were enrolled in this retrospective study. The SUV~max~ of each patient reflecting the metabolic activity was recorded. D-S plus staging according to ^18^F-FDG PET/CT was compared with the traditional D-S staging. The SUV~max~ and the percentage of plasmacytes of bone marrow of phase 3 and non-phase 3 (phase 1 and 2) according to D-S plus staging were compared. One-way analysis of variance was used to analyse the data. **Results:** In 25 MM patients, the range of SUV~max~ of lesions was 1.8-12.0 and the mean value was 5.15±2.74. According to D-S staging, the number of phase 1, 2 and 3 were 7, 4 and 14, respectively. While the numbers were 3, 1 and 21, respectively on the results of ^18^F-FDG PET/CT according to D-S plus staging. Based on the D-S plus staging system, staging of 7 patients (28%, 7/25) was changed. According to the D-S plus staging system, the SUV~max~ between phase 3 and non-phase 3 patients was significantly different (5.75 ± 2.54 vs 3.00 ± 0.70, F=4.49, p\<0.05), while the percentage of plasmacytes of bone marrow between the two groups had no significant difference (27.66±28.76 vs 19.33±17.13, F=0.30, p\>0.05). **Conclusion:** ^18^F-FDG PET/CT is of great clinical importance for MM staging and metabolic activity assessment of MM.
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**Background/Aims:** In patients with documented malignant melanoma, the clinical significance of isolated ^18^F-FDG avid lymph nodes is frequently difficult to ascertain on the scans alone. The pattern of tracer uptake may improve the predictability of such findings. The aim of the study was to retrospectively compare the pattern of ^18^F-FDG uptake in lymph nodes in patients with/without documented nodal metastases; and to compare the radiological features of these nodes. **Methods:** 26 patients with documented malignant melanoma and oligo-metastases (n = 1-3) in any lymph node basin on ^18^F-FDG-PET scintigraphy were included. A total of 43 nodes were assessed. Radiological features, including size and shape of the lymph nodes, as well as scintigraphic parameters, such as location and tracer avidity, were evaluated. Follow-up ^18^F-FDG-PET scans were used to determine the likelihood of malignant involvement. **Results:** Malignant involvement was established in 17 patients (27 nodes). Such nodes tended to demonstrate higher SUV~max~ values, were more likely to be located in the draining lymph node basin of the primary lesion, and were larger and more round-shaped than benign lymph nodes. Lymph nodes in distant lymph node basins were more likely to be benign. Using an algorithm based on these observations, the benign nature of these lymph nodes was determined in a greater proportion of patients when combining the findings of the ^18^F-FDG-PET scan with the low dose concurrent CT scan, than when relying on either modality alone. **Conclusion:** Compared to each modality in isolation, the combined scan features on ^18^F-FDG-PET scan and on low dose concurrent CT scan improved the specificity of findings of isolated tracer-avid lymph nodes in patients with malignant melanoma. These findings will be tested in a larger cohort of patients and then assessed prospectively.
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**Background/Aims:** Sentinel lymph node (SLN) biopsy is useful tool for identification of primary tumour drainage site and regional lymph node involvement. Multiple lymphatic basins drainage (MLBD) is frequently observed in patients with truncal melanoma. We aimed to assess whether an association exists between MLDB and lymphatic metastasis in patients with truncal melanoma. **Methods:** Prospective collection of data on 413 cutaneous melanoma patients referred to our Institution between 2010 and 2017 for wide local excision and SLN biopsy was done. We identified 176 patients (119 males:57 females, mean age 53.8 years (range 9-89 years) with truncal melanoma. Dynamic, early and delayed lymphoscintigraphy were performed over the regional basins of drainage after intradermal injection of ^99m^Tc-nanocolloid dose activity 15MBq around the scar. Histopathology was done using H&E staining and S-100 as well as additional Melan-A and HMB-45 staining. Clinical and pathologic variables including patients' age, gender, Breslow thickness, number of mitoses, ulceration and regression and number of draining basins were analysed. Logistic regression analysis was performed using SLN metastasis (yes/no) as the binary outcome. **Results:** The SLN identification rate was 98.3 %. SLN metastases were found in 31/173 (17.9%) patients. Of these 31 patients, 24 had 1 basin of drainage, and 7 had 2 basins of drainage. Only three patients showed three drainage basins, all with negative SLNs. No significant correlation of sentinel node positivity and MLBD was found in our case series. On univariate analysis only increasing Breslow thickness was significant predictors for metastatic involvement of SLN (p=0.01) Breslow thickness of ≥4 mm enhanced the chances for SLN positivity by 3.4fold, compared with Breslow thickness of ≤1. **Conclusion:** Drainage to more than one regional lymph node basin did not significantly enhanced SLN metastatic involvement rate. Sentinel lymph node status did correlate with Breslow thickness.
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**Background/Aims:** The purpose of this study was to evaluate the usefulness of SPECT/CT in determining the individual anatomic localization of the sentinel lymph node (SLN) in patients with acral lentiginous melanoma. **Methods:** Observational and retrospective study where thirty patients with the diagnosis of acral lentiginous melanoma in clinical stage I-II were evaluated for the sentinel node detection prior to their surgery. In all cases, the results of clinical and instrumental (ultrasound) studies indicated no evidence of regional lymph nodes abnormalities. SPECT/CT imaging of SLN was performed 30-45 minutes after peritumoural injection of ^99m^Tc-rhenium sulphide nanocolloid, the acquisition was performed by a SPECT/CT of 64 images of 30 seconds with a matrix of 128 x 128 and the interpretation was done by two experienced nuclear medicine physicians. All SLN´s detected were removed and analysed by a transoperative pathology study; they were divided in 4 study groups: inguinal (group 1), popliteus (group 2), axillary (group 3) and non-standard localization (group 4). **Results:** Variability in the migration of the SLN's was demonstrated by the SPECT/CT. According to it, 14 patients were classified in the group 1 (46.7%); 4 patients in group 2 (13.3%); 9 in the group 3 (30%); and 3 in group 4 (10%), of whom two patients had migration to a cervical lymph node level IV and one patient to the internal mammary lymphatic chain. The pathologic result was positive for neoplastic cells in 27 of the 30 sentinel lymph nodes. **Conclusion:** The SPECT/CT mapping in the detection of the sentinel lymph node in acral lentiginous melanoma has shown to be a great ally in the diagnosis and treatment of patients who suffer from this disease, being able to identify a non-standard localization in at least 10% of them.
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**Background/Aims:** The detection of unexpected malignant lesions also has an important clinical effect in individuals considered to be healthy, not only in patients with known malignant diseases. We present a case of incidental breast lesion detection on SPECT/CT images of total body bone scintigraphy. **Methods:** A 60-year-old female patient was admitted to the lumbar vertebra with a collapse fracture. For further evaluation of the nature of the lesion, the patient was referred for ^99m^Tc-MDP scanning. **Results:** A SPECT/CT clearly showed the lesion in the vertebra. At the same time, 38 x 32 mm lesions and axillary lymph nodes were observed in the left breast on CT images. However, the breast lesion did not exhibit MDP accumulation; only distinguished on the CT image. Histopathology from breast lesion confirmed the diagnosis of an invasive ductal carcinoma. Subsequently, ^18^F-FDG PET/CT images were acquired for staging, and a lytic feature of the sternum metastasis was added to the bone scintigraphy findings. **Conclusion:** This case showed the yield of CT for the detection of unexpected additional lesion for known or suspected malignancies. It also demonstrates that lytic bone metastases can easily escape the eye in bone scintigraphy.
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**Background/Aims:** Oncology forms the cornerstone of Nuclear Medicine. Hybrid imaging with SPECT and computed tomography (SPECT/CT) is becoming more common, but remains expensive. The more accurate localization of tracer uptake on CT may impact on patient management, or provide prognostic information.**Methods:** We report selected patients who had SPECT/CT imaging. A 10-year-old girl with left femur osteosarcoma and suspected lung metastases had a ^99m^Tc-methylene diphosphonate (MDP) staging bone scan. An adult male with a previous pheochromocytoma and presenting with a renal and large cerebellum mass, suspected to be a cerebellar haemangioblastoma. He was referred for a restaging ^123^I-metaiodobenzylguanidine (MIBG) scan. The third patient is an elderly male with previous prostate carcinoma, now with rising PSA levels. Due to previous spinal metastases, as well as spinal degeneration, the CT and bone scan were inconclusive. He was referred for ^99m^Tc-HYNIC-iPSMA imaging. **Results:** The ^99m^Tc-MDP SPECT/CT identified several pulmonary nodules and multiple skeletal foci, as well as mediastinal, abdominal and pelvic lymph nodes. These findings conveyed a worse prognosis thus the parents could be counselled accordingly. The ^123^I-MIBG SPECT/CT localized uptake to multiple skeletal foci, in support of metastatic pheochromocytoma. Intense uptake was seen in the cerebellar mass, as well as the pituitary. This suggested a possible second, undiagnosed, haemangioblastoma. There was no uptake in the renal mass. These findings raised a clinical suspicion for Von Hippel Lindau syndrome with renal cell carcinoma, and the patient's management plan was adjusted accordingly. The ^99m^Tc-HYNIC-iPSMA SPECT/CT localized uptake to the iliac blade, acetabulum, and a single left internal iliac lymph node that confirmed disease progression. **Conclusion:** SPECT/CT is cost-effective in selected oncology cases and when used appropriately may be valuable for the clinical management decision making.
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**Background/Aims:** Breast cancer related lymphoedema (BCRL) affects 20% of women who have had auxiliary intervention. Advances in microsurgery have allowed the procedure of Vascularised Lymph Node Transfer (VLNT) to be a viable option for advanced stages of lymphoedema after all conservative measures have been exhausted. The procedure transfers lymph nodes from elsewhere in the body to the affected limb. The use of lymphoscintigraphy allows the surgeon to evaluate the degree of lymphatic drainage in the oedematous limb, while also analysing viable lymph nodes suitable for transfer. This is useful in avoiding the induction of secondary lymphoedema. **Methods:** A 49 year old female presented following a right sided mastectomy and axillary clearance in 2015. She had pitting oedema in her right arm and was referred for a ^99m^Tc-antimony trisulphide colloid (^99m^Tc-ATC) lymphoscintigraphy study. **Results:** The patient's leg lymphatic flow was assessed and a SPECT/CT was performed of the inguinal region to demonstrate non-tracer avid, and therefore hopefully non-essential lymph nodes suitable for resection. The patients arm lymphatic drainage was then assessed and demonstrated that the medial channel appeared intact, while the lateral channel showed dermal diffusion within the proximal forearm and upper arm. The patient went on to have a right deep inferior epigastric perforator artery flap breast reconstruction with vascularised lymph node flap transfer from her left leg and recovered well. **Conclusion:** At the patient's 6 month post-surgery physiotherapy review, she reported no symptoms of BCRL in her right arm or left leg. She has reduced the use of compression garments from 23 hours per day to 6 hours, with improved range of motion.

P171: Meningeal Masses and

68

Ga-Octreotate uptake Patterns

Thomas\*

Elizabeth

1

Pejovska

B

1

Angelides

S

1

Khan

S

1

Department of Nuclear Medicine, PET and Ultrasound, Westmead Hospital, NSW, Australia

**Background/Aims:** Meningeal masses are not an infrequent radiological finding. On ^68^Ga-Octreotate scans, they exhibit varying patterns of tracer uptake. We investigated the potential significance of these patterns. To retrospectively compare the pattern of ^68^Ga-Octreotate uptake in meningeal masses in patients referred with various clinical indications. **Methods:** 31 patients with documented ^68^Ga-Octreotate avid meningeal masses were included-3 patients had neurofibromatosis type II (NF), 3 had recurrent malignant meningioma, 4 had documented metastases to the meninges, 18 had documented neuroendocrine tumour (NET) and 3 patients had other tumours. Scintigraphic parameters, such as location and tracer avidity, as well as radiological features, including size and shape were evaluated. Follow-up clinical data was used to ascertain the underlying pathology. **Results:** The most avid tracer uptake was noted in the 3 patients with documented metastases to the meninges. The 3 recurrent meningiomata displayed greater tracer avidity than the lesions in patient with NF. Benign meningiomata exhibited the lowest tracer avidity. Amongst each subcohort, the SUV~max~ within the lesion correlated with its size. Other than the recurrent meningiomata, all the lesions demonstrated an oval or rounded shape. On the low dose concurrent CT scan, calcification was more likely to be detected in the benign meningiomata. At least one follow-up ^68^Ga-Octreotate was acquired in 9 patients with benign meningiomata, and the scan appearances remained unchanged in each lesion. There was increased tracer uptake noted in 3 patients on follow-up studies -- two cases of NF, and one case of a metastasis. **Conclusion:** Different meningeal pathologies tended to display different patterns of ^68^Ga-Octreotate uptake. Higher SUV~max~ levels were associated with higher grade malignancies.
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**Background/Aims:** Gestational trophoblastic neoplasia (GTN) is a rare pregnancy-related disorders. This disease has highest incidence in South East Asia, approximately 3-16 times higher than in developed countries. Metastases have been reported in 19% and imaging studies can be helpful in predicting resistance to monochemotherapy and for therapeutic decision. The role of ^18^F-FDG PET/CT in GTN is relatively limited. Apart from glucose, increased choline metabolism can also be found in trophoblastic tumour cell but the use of choline PET in GTN has not been reported. **Methods:** Imaging findings of ^18^F-FDG and ^18^F-FCH PET/CT in three patients with different stages of GTN and their correlations with the pathological findings and course of the disease were reviewed and discussed. **Results:** Both ^18^F-FDG and ^18^F-FCH PET/CT reveal positive results in all patients, with higher degree of ^18^F-FDG uptake in all detectable lesions. In one patient with ^18^F-FDG and ^18^F-FCH avidity only at the primary tumour showed good treatment response without recurrent disease. The other two patients whose primary tumours were already removed, both PET/CT studies suggested no active local disease. Both PET/CT studies had more advantage than CT in identifying suspicious active tiny subpleural nodules. For suspicious brain metastasis, both PET/CT studies showed no active intracranial lesion. One of these patients is still free from neurological symptom, so brain metastasis might possibly be ruled out. However, another patient developed clinical symptoms and imaging findings of suspicious haemorrhagic brain metastasis two months after negative PET/CT studies. None of our patients had evidence of hepatic metastasis. **Conclusion:** ^18^F-FDG and ^18^F-FCH PET/CT may play a role as a single whole body study used in correct staging/scoring for GTN, particularly in the indeterminate lesions such as tiny pulmonary nodules. However, rapid progression of brain metastasis may be undetected in the baseline PET/CT study, so close follow up in high risk patient is still recommended.
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**Background/Aims:** The SUV of background is often used as reference to assess tumour treatment response on ^18^F-FDG PET/CT. Previous studies focused on background SUV repeatability within variable time interval. But the changes of body habitus and tumour burden, and therapeutic regimes may have impact. Our objective was to assess the repeatability of different background SUV within several days, and the effect of some factors on SUVs. **Methods:** Patients who have had two ^18^F-FDG PET/CT scans within one week were selected. The mean SUV of ABP (ABP-SUV), liver (L-SUV) and muscle (M-SUV) were used for analyses. The relative difference in SUVs and factors were calculated between the first and the second scan. Bivariate correlations between background SUVs and each factor were analysed. The coefficient of variation (CV) of the relative magnitude of background SUV in the second scan compared with that of the first were calculated. **Results:** Fourteen patients were included. ABP-SUV, L-SUV and M-SUV of the first and the second scan were 1.60±0.17 and 1.67±0.24, 2.18±0.26 and 2.32±0.38, 0.89±0.21 and 0.92±0.21 respectively. There were strong positive correlations between differences of L-SUV and M-SUV and that of blood glucose level (BGL) (r=0.810, 0.750 respectively, p\<0.05 altogether). There was no correlation between differences of ABP-SUV and that of BGL, and between differences of background SUVs and that of tracer dose and ^18^F-FDG uptake period (p\>0.05 altogether). The relative magnitude of ABP-SUV in the second scan was 104.2%±9.6%, which resulted to a CV of 9.2%. It was lower than that of L-SUV and M-SUV, which had relative magnitudes of 106.3%±11.4% and 104.7%±15.3%, and CVs of 10.8% and 14.7% respectively. **Conclusion:** The repeatability of ABP-SUV is better than that of L-SUV and M-SUV. It should be the preferred reference for treatment response evaluation. L-SUV and M-SUV are more sensitive to BGL.
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**Background/Aims:** PET/CT with ^18^F-FDG is useful for detection of malignant lesion including metastatic lesion and it also widely spreads in cancer screening. Cancer incidence is 1.8-5.4% and cancer detection rate of PET/CT with ^18^F-FDG is 0.9-1.3% in cancer screening. Sometimes false positive and false negative become a problem. In our PET center, to increase accuracy rate in cancer screening, we use both PET/CT with ^18^F-FDG and whole body diffusion weighted image (WB-DWI) together. Aim of this study is to assess usefulness of both modalities. **Methods:** Twenty-five examiners were diagnosed by endoscopy or surgery finally. All of them undergo PET/CT with ^18^F-FDG, WB-DWI, ultrasonography, and blood test on the same day and they were diagnosed that a close examination was necessary. WB-MRI examinations were performed on a 1.5-T MRI and b value of WB-DWI was 0 and 800 or 1000 s/mm^2^. We made abnormal accumulation of PET/CT with ^18^F-FDG and abnormal intensity of WB-DWI a positive, and calculated diagnostic abilities from the result. **Results:** Fifteen out of 28 were malignant lesions, and 12 were benign lesions, or no abnormalities. A sensitivity and specificity of PET/CT with ^18^F-FDG only is 60% and 25%, respectively. A sensitivity and specificity of WB-DWI only is 53% and 100%, respectively. A sensitivity and specificity of PET/CT with ^18^F-FDG and WB-DWI are 80% and 100%, respectively. A number of false negative decreased from 6 to 4. A number of false positve decreased from 9 to 0. **Conclusion:** Our results suggest using both PET/CT with ^18^F-FDG and WB-DWI together are useful for decreasing false negative and false positive cases in cancer screening. However, sometimes it cannot detect malignant lesion even if both PET/CT with ^18^F-FDG and WB-DWI were used together, by combining tumour marker and ultrasonography we could reduce false negative.
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**Background/Aims:** A 29 year-old female (BMI 36.1) presented to her GP with a tender mass in the left iliac fossa. Ultrasound of lower abdomen/pelvis was reported as NAD. Contrast-enhanced CT showed a mass lesion in left iliac fossa of almost purely fat density, suggestive of intramuscular or retroperitoneal lipoma. Patient was referred to our centre for further investigation and management. **Methods:** ^18^F-FDG PET/CT scan was performed in August 2017. Despite provision of warm blankets during the uptake period, extensive brown fat activation was seen on the scan in the typical pattern. Diffuse heterogenous uptake was also seen in the highly fatty 11 x 8 cm mass in the left iliac fossa (SUV~max~ 9.4), considered unusual for a mass with high fat density. Following discussion with the patient and the referring clinician, a repeat ^18^F-FDG PET/CT scan was performed 5 days later, with the addition of beta-blockade (10mg oral propranolol administered 1 hour prior to ^18^F-FDG injection). In both instances the dose (360MBq), uptake time (60 minutes), scanner make (GE Discovery 710 PET/CT) and scan parameters were comparable. **Results:** Previously shown extensive brown fat activation disappeared with beta-blockade. SUV~max~ also decreased in the fatty mass by 50% (from 9.4 to 4.8). Although the ^18^F-FDG uptake on baseline scan was less than expected for a hibernoma, the reduction in uptake after beta-blockade is diagnostic that the mass is partially composed of brown fat. Subsequent core biopsy confirmed benign lipoma status. **Conclusion:** Hibernoma is a benign fatty tumour of vestigial brown fat. The appearance of hibernoma on ^18^F-FDG PET/CT scans has been discussed in the literature, however the use of beta-blockade to characterise the lesion is less common, with limited published data. This strategy may be helpful to provide characterisation and to differentiate hibernoma from malignant fat-containing tumours.

P176: Chemotherapy and Immunotherapy Induced Sarcoid-Like Reaction or Sarcoidosis: A Positron Emission Tomography/Computed Tomography Pitfall
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**Background/Aims:** FDG can accumulate in benign processes such as infection or granulomatous inflammation producing false positive results. Relatively symmetric FDG-avid bilateral hilar and mediastinal lymph nodes in a "lambda", "Christmas Tree" or "butterfly" distribution pattern, which we defined as "sarcoid-like" distribution pattern, are not uncommonly observed on FDG PET/CT but with different interpretation among different physicians, especially for the lymph nodes demonstrating high SUV (SUV \>2.5). This case presentation is to illustrate that FDG distribution pattern is more important than SUV~max~ in interpretation of PET/CT; and thoracic lymph nodes in a "sarcoid-like" distribution pattern on PET/CT are benign regardless of the SUV~max~ value. **Methods:** In addition to biopsy-proven sarcoidosis cases who have no history of cancer, we selected typical PET/CT studies performed in cancer patients with minimal 12 months clinical and imaging follow-up, and/or definitive pathology results shown sarcoidosis. Cancer patients with "sarcoid-like" chest lymph nodes distribution pattern on series FDG PET/CT were compared with non-cancer, sarcoidosis only patients' FDG PET/CT. **Results:** There is similar distribution pattern of FDG avid thoracic lymphadenopathy between non-cancer sarcoidosis patients and cancer patients who had chemotherapy and/or immunotherapy induced sarcoid-like reaction. Sarcoidosis and/or sarcoid-like reaction can involve multiorgans including lymph nodes, lung, cutaneous nodules, liver, spleen, and heart. The SUV~max~ of these lymph nodes varies from 2.4 to 17.7 in our cases. Sarcoid-like reaction in cancer patients persists up to 2+ years even in off-therapy observation course. Although FDG avidity of sarcoid-like reaction varies in series PET/CT in the same patient, the distribution pattern and sizes of thoracic lymphadenopathy are grossly stable. **Conclusion:** To avoid pitfalls in PET/CT interpretation, it is important to recognise the sarcoid-like pattern of FDG uptake, which regardless of SUV value is favoured to represent a benign rather than a malignant process.

P177: Low Reproducible Intratumoural 18F-FDG Accumulation in Pretreated Solid Malignancies during Short Interval in Patients: A Clue of Poor Outcome
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**Background/Aims:** We have previously observed in animal model of cancer that spatial intratumoural accumulation ^18^F-FDG changed with time. In the current study, we investigated whether solid malignancies of patients share same feature of low reproducible rate as we found in animal models of cancer. **Methods:** This study was preapproved by the IRBs of Inner Mongolian Medical University and Harbin Medical University, and in all patients the written content was obtained. Ten patients with pathologically confirmed and pre-treated solid malignancies (lung cancer 6, breast cancer 2, colon cancer 1 and ovary cancer 1) and metastases were included in this study. Two ^18^F-FDG PET/CT scans (60-min post-injection) was performed 2-4 days apart in the same pre-treated patient with cancer, spatial intratumoural ^18^F-FDG distribution were compared between two PET scans. These patients are followed-up for long term survive. **Results:** In all lesions (10 primary lesions and 8 metastases), spatial intratumoural distribution of ^18^F-FDG was heterogeneous, apparent changes in spatial intratumoural distribution of ^18^F-FDG was observed as short as 48 hours in untreated solid malignancies. The degree of change varied among lesions. **Conclusion:** Microenvironment in term of glucose metabolism changes in pre-treated solid malignancies, therefore, ^18^F-FDG PET used as a baseline to assess the efficacy of therapy should be carefully reconsidered. However, change ^18^F-FDG intratumoural distribution reflect the change in (unstable) tumour microenvironment, and may indicate poor outcome, this issue is under further investigation.
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**Background/Aims:** For Boron neutron capture therapy (BNCT), ^10^B-boronophenylalanine (BPA) has been used as a boron delivery agent, and ^18^F-fluoro-boronophenylalanine (FBPA)-PET has been carried out to evaluate BPA levels in the tumour. Before BNCT, the ^10^B concentration of the tumour tissue is estimated by measuring maximum standardized uptake value (SUV~max~), the tumour-to-normal tissue count ratio (TNR), or tumour-to-blood count ratio (TBR) using FBPA PET images. The purpose of this study is to determine whether the SUV~max~ of the targeted tumours depends on pathologic types of the tumours. **Methods:** Sixty-four patients including 21 squamous cell carcinomas, 10 rhabdomyosarcomas, 10 malignant gliomas, 9 malignant melanomas, 7 adenoid cystic carcinomas, 7 adenocarcinomas were set as the target, and had whole body PET/CT studies of FBPA at 1 hour post-injection. Region of interest were placed within tumour and SUV~max~ were calculated and compared with tumour pathologies. **Results:** The SUV of FBPA in squamous cell carcinomas ranged between 1.80 to 8.93 (average 4.47±2.08); rhabdomyosarcomas between 1.12 to 8.15 (average 3.66 ±2.20); malignant gliomas between 1.50 to 5.58 (average 3.12±1.40); malignant melanoma between 3.73 to 16.28 (average 8.69 ±4.07); adenoid cystic carcinoma between 2.56 to 3.90 (average, 3.23±0.50); and adenocarcinoma between 1.99 to 4.42 (average 3.20±0.98). Malignant melanomas showed significantly higher uptake than the others and the uptakes of all cases were enough high to be eligible for BNCT. On the other hand, there were no significant differences of tumour uptake among the other five tumour types. The uptakes of these tumours varied from low of not eligible to high enough for BNCT. **Conclusion:** Malignant melanoma showed high uptake and could be judged as an eligible for BNCT without FBPA-PET study. For the other type of tumours, FBPA-PET study would be essential and indispensable for BNCT.
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**Background/Aims:** It is known that hyperglycaemia can cause false negative findings in PET/CT using FDG. However, it is not easy to reschedule the study in clinical setting. The purpose of this study was to evaluate the diagnostic performance of FDG-PET/CT, performed under severe chronic hyperglycaemic status. **Methods:** The present study was approved by the Institutional Review Board, and was performed in accordance with pertinent ethical guidelines. There were 184 scans in 161 patients, who showed high plasma glucose level (\>200 mg/dl) at FDG injection despite at least 4 hour fasting. In the clinical follow-up, chronic hyperglycaemia was caused by uncontrolled diabetes (n=162) and untreated diabetes (n=22). Excluding 24 scans in 24 patients without sufficient follow-up, 160 scans in 137 patients were retrospectively analysed. Based on the final diagnosis obtained by histopathology or clinical follow-up for at least 6 months, the diagnostic performance of visual interpretation of PET/CT was evaluated. **Results:** At least one malignant lesion was finally confirmed in 80 scans in 72 patients, for which FDG-PET/CT demonstrated 65 true positive and 15 false negative results in patient-basis. It was considered that these false negative results were caused by low FDG-avid pathological characteristics, i.e. differentiated hepatocellular carcinoma, or small lesions. Overall, the sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy were 81%, 98%, 97%, 84% and 89%, respectively. **Conclusion:** Influence of severe hyperglycaemia for visual interpretation in FDG PET studies was considered minimum. FDG uptake of lesions was considered to be maintained a sufficiently high level for visual interpretations in most cases.
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**Background/Aims:** A 11 year old female with a known SDHB pathogenic mutation and a strong family history of metastatic phaeochromocytoma was found to have gradually rising plasma normetanephrine levels. Most phaeochromocytoma are sporadic, however recent research has demonstrated that many more phaeochromocytoma are familial (inherited or syndromic). Patients with inherited phaeochromocytoma syndromes possess unique characteristics because the mutation is present in every cell of the body. All chromaffin cells have a chance of growing into a phaeochromocytoma at some point in the person's life. Therefore, inherited phaeochromocytoma patients are much more likely to develop multiple tumours and tumours lying outside of the adrenal gland. Inherited phaeochromocytoma syndromes are variably penetrant, meaning that only a fraction of people who carry the gene will eventually develop one or more phaeochromocytoma. The approximate penetrance for SDHB is up to 80%. **Methods:** Phaeochromocytoma can be imaged using ^123^I-MIBG SPECT/CT, ^18^F-FDG PET/CT and ^68^Ga-DOTATATE. The diagnostic sensitivity for phaeochromocytoma in ^123^I-MIBG imaging was reported to be 88%.\[[@ref269]\] Another study concluded that for the staging and treatment monitoring of SDHB-related metastatic malignant paraganglioma, ^18^F-FDG PET is the preferred functioning imaging modality with a sensitivity approaching 100%.\[[@ref270]\] **Results:** An MRI failed to localise a phaeochromocytoma or paraganglioma. The patient was then referred for an ^123^I-MIBG SPECT/CT scan, which also showed no evidence of phaeochromocytoma or paraganglioma. Due to the high clinical suspicion of phaeochromocytoma and her predisposed SDHB gene mutation, the patient was then referred for a ^18^F-FDG PET/CT scan. The ^18^F-FDG PET/CT scan demonstrated a positive result with the localisation of the tumour to the abdominal para-aortic sympathetic chain. **Conclusion:** This case supports the literature finding that ^18^F-FDG PET imaging is more sensitive than ^123^I-MIBG for staging of SDHB-related phaeochromocytoma and paraganglioma.

P181: Positron Emission Tomography/Computed Tomography on a Pregnant Patient: Is It Worth the Risk?

Calabria\*

Frances

1

Mitchell

G

1

Horsfield

M

1

Wegner

E A

1

Department of Nuclear Medicine, Prince of Wales Hospital, Sydney, Australia

**Background/Aims:** Exposure to ionising radiation from medical investigations accounts for a substantial portion of total exposure to the public.\[[@ref271]\] Exposing pregnant females to ionising radiation results in potential adverse effects on the foetus.\[[@ref272][@ref273]\] While foetal radiation dose from a ^18^F-fluorodeoxyglucose-positron emission tomography (FDG-PET) scan is low, every effort should be made to minimize exposure. **Methods:** A 29 year old pregnant female (29/40 gestation) with a cough was found to have a mediastinal mass on MRI. In addition, several rib lesions were found. Following a biopsy, provisional diagnosis of Stage IV Hodgkin's Disease was made. A FDG PET scan was requested for staging. Following careful consideration of the radiation safety aspects and dose modification, the risks of radiation exposure to the foetus were outlined to the patient. 262MBq of ^18^F-FDG was administered and a low dose CT (50mAs and 120keV) was performed. **Results:** The scan demonstrated Stage II Hodgkin's Disease with nodal involvement above the diaphragm. Rib lesions were shown to be recent fractures, changing the stage of disease. Physiological uptake was seen in the foetal tissue. The patient received two cycles of ABVD chemotherapy. At 37 weeks of gestation a healthy baby was delivered. An interim follow-up FDG PET/CT scan performed 3 days post-partum demonstrated partial metabolic response (Deauville score 4), with a small area of residual FDG-avid disease. The patient received further treatment which resulted in a complete metabolic response. **Conclusion:** Foetal radiation exposure is to be avoided. However, in certain clinical circumstances the benefits of imaging with ionising radiation outweigh any potential detrimental effects on the foetus and performing studies should not be eschewed. This patient's initial FDG PET/CT scan changed the staging and subsequent treatment plan. Current literature provides support that the use of PET/CT is acceptable in pregnant patients when clinically indicated, as it may result in significant management change.\[[@ref274]\]

P182: The Merits of Adrenal Uptake on FDG Positron Emission Tomography/Computed Tomography Scans of Miscellaneous Cancer Patients: Metastasis or Not?
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**Background/Aims:** Adrenal metastases can be found approximately 25% to 75% in many different tumours. The aim of this study is to retrospectively review a rather large number of oncologic PET/CT studies to find out the frequency of adrenal hypermetabolism and to make differential diagnosis based on some PET/CT parameters along with other modalities. **Methods:** A total of 665 oncologic FDG PET/CT studies in 505 patients in about 5-year-period were included. PET/CT was performed 1 hour after IV injection of 6 MBq/kg FDG. The images were retrospectively reviewed by 2 experienced nuclear medicine physicians and correlated to histopathology, CT and/or MR findings. Both visual and quantitative analysis were used for interpretation. **Results:** Among all patients 40/505 (8%) showed adrenal hypermetabolism on FDG PET/CT, where 30/40 (75%) were found to be malignant and 10/40 (25%) benign. Adrenal metastates were unilateral in 26/30 (87%) while bilateral in 4 (13%) patients. Leading cause of adrenal metastates was lung cancer followed by lymphoma, colorectal, breast cancer and miscellenous. All metastatic sites were confirmed by other modalities (4 by histopathology and 26 by CT and/or MRI). Among benign adrenal hypermetabolism, 9/10 (90%) was due to adenoma where 1/10 (10%) was lipoma, confirmed by radiology. Adenomas were bilateral in just 2/9 (22%) patient. Mean SUV~max~ value of malignant adrenal hypermetabolism along with adrenal/liver SUV ratio was significantly higher than those of benign adrenal FDG uptake (p\<0,05 for both). Only 2/10 (20%) patients with benign uptake showed higher intensity than liver while all malignant FDG uptake values were higher compared to liver SUV~mean~. **Conclusion:** In oncological FDG PET/CT imaging, the intensity of adrenal FDG uptake compared to liver SUV~mean~, uni/bilateral pattern and primary diagnosis of the patient may be the key parameters which lead to correct differential diagnosis, based on confirmation by some other methods.

P183: Evaluation of 25-Hydroxyvitamin D Serum Levels in Cancer Patients of Northern Greece with Metastatic Bone Disease. Comparison with Bone Scintigraphy and Correlation with Disease's Severity
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**Background/Aims:** The evaluation of serum Vitamin D levels in cancer patients with metastatic bone disease to find a possible correlation with the disease's severity. **Methods:** 65 cancer patients participated in the study, 33 men and 32 women, aged 34-68 (median 59+/-7 years). 27 patients had prostate cancer, 28 had breast cancer, 7 had lung cancer and 3 had miscellaneous cancers. The patients undergone CT or MRI and bone scintigraphy with ^99^Tc-HDP in gamma camera at Nuclear Medicine department of the University General Hospital of Evros. The vitamin D status was measured by radioimmunoassay method with kits Diasorin at Nuclear Medicine department. **Results:** From the examined patients, 48 had metastasis. 16 had \<2 metastases (Group A), 20 had \<5 (Group B), and the rest had \>5 (Group C). The metastasis' activity and size were different in each group. In group A, 51% of the patients had deficiency of vitamin D levels (\<20ng/mL), 38% had insufficient levels (\<40ng/mL), and only 11% had sufficient vitamin D levels (\>40ng/mL). The respective percentages of group b and group c were 73%, 24%, 3% and 81%, 18%, 1%. Patients with multiple metastasis had very low levels of 25-hydroxy-vitamin D levels (p\<0.005). Patients without metastasis had higher 25-OH-D levels compared to those of patients with metastasis (p\<0.005). **Conclusion:** The determination of serum vitamin D levels in cancer patients with metastatic bone disease is useful. Patients with expanded metastatic bone disease had vitamin D deficiency. The (25-OH-D) very low levels are correlated with multiple metastasis. More studies are required for possible improvement in patients undergoing Vitamin D supplementation.

P184: First Reported FDG-Positron Emission Tomography Case of Primary Diffuse Leptomeningeal Histiocytic Sarcoma
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**Background/Aims:** Histiocytic sarcoma or malignant non-Langerhans histiocytosis is extremely rare and commonly presents with symptoms due to unifocal or multifocal extranodal tumours involving the intestine, skin, and soft tissues. The incidence of primary CNS Histiocytic sarcoma is even rarer with 28 cases reported in the literature; 26 reporting mass lesions and two reported cases with diffuse leptomeningeal involvement with no FDG PET performed. Therefore, to the best of our knowledge, this is the first FDG PET scan of primary diffuse leptomeningeal Histiocytic sarcoma. **Methods:** A 54 years old male presented with progressive headaches, visual disturbance, loss of weight, flu-like symptoms and gait disturbance requiring hospitalization. PET/CT scan (Siemens Biograph M-CT) was acquired 66 minutes after administration of 192 MBq ^18^F-FDG with blood glucose level 8.7 mmol/L. **Results:** Brain and spine MRI showed thickening of multiple bilateral cranial nerves and extensive leptomeningeal and nerve root thickening throughout the spine, most in the lumbar spine with complete effacement of the CSF spaces surrounding the conus medularis and cauda equina. FDG-PET study demonstrated intense hypermetabolism (SUV~max~12) throughout the lower spinal meningeal space from T10 to S2 level with lateral extension to the proximal nerve roots bilaterally. FDG uptake in cervical nerve roots extended from C4-C7 asymmetrically (SUV~max~14.8) with likely involvement of bilateral cranial nerves. No metabolically active nodal or extra nodal disease detected outside the CNS. The findings were in keeping with leptomeningeal malignancy such as lymphoma and carcinomatosis or infective/inflammatory process. The histopathology correlation confirmed diffuse Histiocytic sarcoma. **Conclusion:** Histiocytic sarcoma is extremely rare and primary CNS Histiocytic sarcoma is even rarer with only two cases in the literature being reported as diffuse leptomeningeal involvement with no FDG PET study performed. Therefore, we report the first FDG PET case of primary diffuse leptomeningeal histiocytic sarcoma.
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**Background/Aims:** Recently, ^18^F-fluoromisonidazole (^18^F-FMISO), a nitroimidazole derivative has been developed as a PET probe for hypoxia imaging and used in clinic. Our previous studies revealed that FMISO is reduced, metabolized to amino-FMISO conjugated with glutathione and trapped in hypoxic areas of tumour.\[[@ref275][@ref276]\] This finding speculates us that FMISO accumulation depends on glutathione level in a cell as well as hypoxic condition. In this study, we examined the influence of glutathione-suppressive condition on the correlation between FMISO distribution and hypoxic region in transplanted tumours. **Methods:** Buthionine sulfoximine (BSO) was used as a glutathione synthesis inhibitor. The mice bearing with human lung carcinoma NCI-H1975 were assigned to three groups (N=6), control, low-dose BSO treatment group (single i.p. dose at 1,000 mg/kg), and high-dose BSO treatment group (six repetitive doses at 500 mg/kg and 20 mM in drinking water for 3 days). ^18^F-FMISO was i.v. injected to mice 2 hr before sacrifice. Tumour tissues were subjected to a glutathione quantification test and ^18^F-FMISO distribution was analysed by autoradiography. Hypoxic region was visualized by the immunohistochemistry for a hypoxia marker, glucose transporter-1 (GLUT-1). **Results:** Intratumoural glutathione levels were reduced by BSO treatment (high-dose, 1.03±0.17 μmol/g tissue; low-dose, 3.01±0.28 μmol/g tissue vs. control 4.20±0.67 μmol/g tissue). The comparative analysis between ^18^F-FMISO accumulating region and GLUT-1-expressing region revealed a positive correlation in control tumours. Even high-dose BSO treatment did not exert any obvious influence on this correlation and no significant differences among the correlation coefficient values of three groups were observed (*r* = 0.54±0.09 for control, 0.58±0.13 for low-dose, 0.50±0.09 for high-dose). **Conclusion:** ^18^F-FMISO accumulation can reflect hypoxic region in the glutathione-suppressive condition generated by the BSO treatment. This suggested that ^18^F-FMISO can be used as a trusted hypoxia probe even during cancer therapy causing glutathione reduction to the extent tested in this study.
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**Background/Aims:** Capturing host anti-tumour responses to combinatorial immunotherapy remains a major challenge. From the standpoint of immunology, cancer immunotherapy is considered as a "double edged sword" in that it can trigger two opposite immunologic processes to limit potential toxicity associated with excessive response.\[[@ref277]\] So tracking its opposite immune regulatory-mechanisms has potential as surrogates for defining the complex anti-tumour scenarios. In this study, we developed a small-molecular positron emission tomography/computed tomography (PET/CT) method targeting the checkpoint protein, IDO1, in tumour-bearing hosts to address this challenge. **Methods:** Leveraging the very short-lived positron emitter carbon-11 (^11^C; half-life: 20.4 min) to label a small molecule IDO1 inhibitor, levorotary (L) form of 1-methyl-tryptophan (1MTrp), we developed a radioprobe 1-*N*-^11^C-methyl-l-tryptophan (^11^C-L-1MTrp).\[[@ref278]\] Using PET/CT with ^11^C-L-1MTrp, we specifically and serially monitored IDO1 changes to reveal the antitumour immune response in melanoma-bearing immunocompetent mice treated with immunotherapy combinatorial chemotherapy. Animal studies were approved by the Animal Ethics Committee of the National Institutes for Quantum and Radiological Science and Technology. **Results:** On combining the ^11^C-L-1MTrp and the imaging power of PET/CT, we observed that IDO1 exhibited dynamic alterations in mesenteric lymph nodes (MLN) and the caput of the epididymis, and observed a connection between active responses to combinatorial immunotherapy in immunocompetent mice. These imaging markers exhibited an empirical cut-off value of 7.023 %ID/g for radioactivity in MLN, which provided an early-on-treatment indicator with 97.92 % specificity. A cut-off value of 8.313 %ID/g in the epididymis offered a sensitivity of 100 % as an index of immune exhaustion. **Conclusion:** ^11^C-L-1MTrp-PET/CT provided a visual method to capture the dynamics of host responses to combinatorial immunotherapies, with near-term clinical application.

P188: GINS2 Interference Inhibits Cell Proliferation and Promotes Cell Apoptosis of Thyroid Cancer by Regulating CITED2 and LOXL2
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**Background/Aims:** To explore the mechanisms of GINS2 on cell proliferation and apoptosis in thyroid cancer (TC) cells. **Methods:** Expressions of GINS2 were inhibited in K1 and SW579 cells using gene interference technology. The abilities of proliferation and apoptosis and cell cycle were determined by MTT assay and flow cytometric assay. The downstream molecules of GINS2 were searched by microarray and bioinformatics and validated by qRT-PCR and western blotting. *In vivo* study, the tumour growth was compared and the whole-body fluorescent imaging was analysed. **Results:** After GINS2 was interfered, cell proliferation was significantly inhibited (p\<0.01) and apoptosis rate increased (p\<0.01) in both K1 and SW579 cells. Cell cycle changed significantly in K1 cells, but not in SW579 cells. With bioinformatics upstream analysis, TGF-β1 was found as the most significantly upstream regulator. Expressions of TGF-β1 and its downstream target molecules CITED2 and LOXL2 were validated and found down-regulated significantly in mRNA and protein levels (p\<0.05). The results of the nude mouse xenograft assay suggested that the volume and weight of tumour in ones infected with shGINS2 were statistically smaller than controls (p\<0.05). **Conclusion:** GINS2 plays an important role in cell proliferation and apoptosis of thyroid cancer by regulating the expressions of CITED2 and LOXL2, which may be a potential biomarker for diagnosis or prognosis and a drug target for therapy.
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**Background/Aims:** More than 90% of ovarian and endometrial cancers express a high-affinity folate receptor, involved in cellular folate accumulation by receptor-mediated endocytosis, that is absent from most normal tissues. We prepare ^68^Ga-DOTA-K-PEG~2~-(K-FA) ~2~ (^68^Ga-DOTA-FA~2~) and investigate its value for folate receptor targeted imaging of ovary cancer and peritoneal metastases. **Methods:** All animal experimental studies were approved by the Ethics Committee from Nanjing First Hospital and Nanjing Medical University. Characteristics of ^68^Ga-DOTA-lys-FA~2~ was investigated after its preparation. Ovary cancer xenografts (SKOV3) bearing nude mice was established to investigate the distribution of ^68^Ga-DOTA-lys-FA~2~ in vivo. MicroPET-CT imaging was performed at 1h, 2h after tail vein injection. Mice with Pre-administration of overdose folic acid was served as blocking group while mice bearing lung cancer (A549: folate receptor negative) were served as control group. **Results:** ^68^Ga-DOTA-FA~2~ was stable in vitro after its preparation with radiopurity of (96.3±1.28%). Folate receptor affinity (IC~50~) was 17.1nM. Octanol-water partition coefficients (log P) was -1.89. Radiotracer uptake (%ID/g) of SKOV3 bearing nude mice reached peak at 120 minutes. ^68^Ga-DOTA-FA~2~ was rapidly cleared from blood while its excretion in kidney could be effectively accelerated by co-injection of the pemetrexed. Based on microPET-CT imaging, ovary cancer uptake of ^68^Ga-DOTA-FA~2~ (SUV=5.59±1.14) was significantly higher than blocking group (SUV=1.57±0.32) and LNCap lung cancer (A549: folate receptor negative) group (SUV=1.21±0.07). Regional aggregation of ^68^Ga-DOTA-FA~2~ was demonstrated in peritoneal metastasis and confirmed by fluorescence imaging. **Conclusion:** ^68^Ga-DOTA-FA~2~ is a prospective folate receptor targeted imaging agent for ovary cancer and peritoneal metastasis.

**Disclosure of interest:** G Shao Conflict with: This study is supported by National Natural Science Foundation of China (NSFC) projects (81301247), the Nanjing Outstanding Youth Fund (JQX14009). Jiangsu Provincial Medical Youth Talent (QNRC2016075).
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**Background/Aims:** We have developed *meta*-\[^211^At\] astato-benzylguanidine (MABG) for targeted alpha-radionuclide therapy of malignant pheochromocytoma and shown its high anti-tumour effects in tumour-bearing mice. However, body weight loss, an indicator of toxicity, was transiently observed at therapeutic dose. In this study, we investigated for alleviation of toxicity whether non-specific uptake of MABG could be reduced by inhibiting organic cation transporter (OCT). **Methods:** The uptake of MABG was examined using the following cell lines, PC-12, rat pheochromocytoma, HT-29, human colorectal adenocarcinoma, ACHN, human renal cell adenocarcinoma, BxPC-3, human pancreatic adenocarcinoma. To inhibit OCT, cells were treated with phenoxybenzamine (POB), an inhibitor of OCT1-3, ranitidine (RAN), an inhibitor of OCT1, or hydrocortisone (HDC), an inhibitor of OCT3. **Results:** POB (3 μM), RAN (100 μM) and HDC (10 μM) significantly reduced the uptake of MABG in HT-29, ACHN and BxPC-3. While, the uptake of MABG in PC-12 was slightly inhibited by treatment with POB, but not RAN and HDC. These results indicate that OCT1 and OCT3 were involved in the uptake of MABG in HT-29, ACHN and BxPC-3, but not in PC-12. Therefore, RAN or HDC possibly inhibit the non-specific uptake of MABG in colon, kidney and pancreas. Dose-response study showed that the inhibitory effect of RAN and HDC in HT-29, ACHN and BxPC-3 was enhanced dose-dependently. However, high-dose of RAN (1000 μM), but not HDC (100 μM), reduced the uptake of MABG in PC-12. These results suggest that HDC can inhibit the non-specific uptake of MABG more selectively. **Conclusion:** Our results showed that the non-specific uptake of MABG is possibly reduced by inhibiting OCT1 and OCT3. Furthermore, HDC is a clinically approved drug, and can be a selective inhibitor for reducing non-specific uptake of MABG. At present, we are investigating the usefulness of HDC in tumour-bearing mice.
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**Background/Aims:** Although glucose transporter-1 (GLUT-1) and hexokinase-2 (HK2) have been considered to be associated with ^18^F-FDG (FDG) uptake in cancer cells, the molecular mechanisms that determine FDG uptake are more to be revealed. Since HK2 preferentially use ATP derived from mitochondria by binding to VDAC, we investigated the correlation between FDG uptake and adenine nucleotide translocase 2 (ANT2) in mitochondria, which provides ATP/ADP to the cytosol and involve in tumour malignancy. **Methods:** Human thyroid cell lines and thyroid cancer tissue-array cores were used. Protein expressions were measured by western blot and immunostaining. ANT2 siRNAs and pcDNA3.1-ANT2 vectors were used to modify ANT2 expression. To visualize HK2-VDAC-ANT2 complex by BiFC based FRET (fluorescence resonance energy transfer), we established fluorescence vectors with each of proteins, and transfected each vector into 293FT cells. ^18^F-FDG PET scans for thyroid cancer patients were performed with a Siemens PET scanner. **Results:** In various thyroid cancer cells, ANT2 expression was very well correlated with FDG uptake. ANT2 siRNA decreased FDG uptake by 0.55-fold, and pcDNA3.1-ANT2 increased FDG uptake by 1.7-fold. 293FT cells treated with HK2-VDAC-ANT2 were shown the highest FDG uptake. At the same time, HK2-VDAC-ANT2 complex was visualized by generating FRET signal, indicating their bindings. In thyroid tissues, ANT2 were highly expressed in poorly differentiated cancer (mean = 48.0, SD = 25.6). In FDG-PET scans of patients, high maximum standardized uptake value (SUV~max~) was related to ANT2 expression. **Conclusion:** ANT2 expression are closely related with FDG uptake in the thyroid cancer. ANT2 plays a crucial role in phosphorylation of HK2 by forming ternary complexes with VDAC. Higher level of ANT2 expression was observed in dedifferentiated cancer, indicating that ANT2 can be used as an additional marker for FDG-PET positive cancer.
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**Background/Aims:** The aim of this study is to investigate changes in the accumulation of ^18^F-FDG and ^18^F-FLT in cancer cells treated with charged particle irradiation under hypoxic condition for prediction of the therapeutic effect. **Methods:** Colorectal cancer cell line Colon 26 cells were used. Cells were cultured under 1% oxygen concentration for 24 hr, and then were respectively treated with proton and carbon ion irradiation. Irradiation doses were 0.1, 0.5, 1, 5 and 10 Gy. From day 1 to day 4 after irradiation treatment, the cell number was measured. The ^18^F-FDG and ^18^F-FLT cell uptake experiment was assessed at 26 and 50 hr after irradiation. Cells were also treated with X-ray irradiation as a control. **Results:** In proton treated cells, compared with control group, a significant difference in the cell number was observed in the group at 1, 5 and 10 Gy at day 4 after irradiation. In carbon ion treated cells, there were significant differences from 0.5 Gy irradiated group. In X-ray treated cells, there were significant differences in 5 and 10 Gy irradiated groups. In cell uptake study at 26 hr after irradiation, changes in the accumulation of both ^18^F-FDG and ^18^F-FLTdid not reflect changes in cell numbers. In cell uptake study at 50 hr after irradiation, changes in the accumulation of ^18^F-FLT reflected changes in cell numbers, although changes in the accumulation of ^18^F-FDG did not. **Conclusion:** ^18^F-FLT is a promising tracer for monitoring early responses of cancer to charged particle irradiation under hypoxic condition.

This study was partially supported by a research fund of the Wakasa Wan Energy Research Center and JSPS KAKENHI Grant Number 24249065.
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**Background/Aims:** Ectopically expressed metabotropic glutamate receptor 1 (mGluR1) independently induces melanocyte carcinogenesis,\[[@ref279]\] and it is therefore becoming an important target for personalised diagnosis and treatment strategies for melanomas.\[[@ref280][@ref281]\] Recently, we developed ^18^F-FITM and its other radiohalogen-substituted probes for PET imaging of mGluR1 in melanoma.\[[@ref281][@ref282]\] In this study, we synthesized 4-\[^131^I\] iodo (\[^131^I\] 1)-or 4-\[^211^At\] astato (\[^211^At\] 1)-*N*-\[4-(6-(isopropylamino) pyrimidin-4-yl)-1,3-thiazol-2-yl\]-*N*-methylbenzamide as two target-radionuclide-therapy probes and evaluated their anti-tumour effects on mice bearing B16F10 melanoma. **Methods:** Unlabelled 1 and its tin precursor for radiosynthesis were prepared according to the method reported by our laboratory.\[[@ref280][@ref281]\] Radiosynthesis of \[^131^I\] 1 was performed by reaction of tin precursor with \[^131^I\] NaI in the presence of 30% H~2~O~2~ at room temperature for 2 hours. ^211^At for radiolabelling was produced using a remotely controlled versatile system developed in house. 5 The anti-tumour effect of two radioprobes was evaluated in the mice bearing B16F10 melanoma with rich mGluR1 expression. Animal studies were approved by the Animal Ethics Committee of the National Institutes for Quantum and Radiological Science and Technology. **Results:** After purification and formulation, \[^131^I\] 1 was obtained in 45±20% radiochemical yield (n\>3, based on the total \[^131^I\] NaI). The molar radioactivity and radiochemical purity of \[^131^I\] 1 were 40±4 GBq/μmol and \>99%. \[^211^At\] 1 was successfully synthesized by the reaction of tin precursor with ^211^At in the presence of *N*-chlorosuccinimide at room temperature for 1 hour. The radiochemical conversion of \[^211^At\] 1 exceeded 40%. Treatment the B16F10-bearing mice with \[^131^I\] 1 at 18 MBq and 9 MBq in 2 doses/mouse reduced the tumour volumes (P \< 0.05), compared to the untreated group. Further, the administration of \[^211^At\] 1 at 1.1 MBq in single doses/mouse significantly inhibited B16F10-melanoma growth, resulted in tumour regression and a durable anti-tumour response. **Conclusion:** \[^131^I\] 1 and \[^211^At\] 1 are useful radioprobes for targeted radiotherapy of melanoma with overexpressed mGluR1.

P196: Oncogenic Exosomes Derived from Thyroid Cancer Cells Accelerate the Aggressive Neoplastic Progression
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**Background/Aims:** Thyroid cancer is the most prevalent endocrine-related cancer. In recent years, an increasing number of studies have attempted to understand the biology of its progression. However, the potential roles of thyroid cancer cell-derived exosomes in the progression of human anaplastic (ATC)/papillary (PTC) thyroid cancer have not been investigated. In this study, we have delineated the neoplastic effects of exosomes derived from ATC/PTC cell on thyroid cancer cells and elucidated the activation of the underlying oncogenic signalling. **Methods:** ATC: CAL-62 and 8505c; PTC: BCPAP and TPC1 cells were used in this study. All cell's culture media was harvested, and exosomes were isolated by ultracentrifugation. exosomes were characterized by western blot, electron microscopy and nanoparticle tracking analysis. Exosomes from all cells were co-cultured with their corresponding cells, exosome uptake and cell proliferations (CCK8 assay) and trans-well migration were analysed. Furthermore, the oncogenic pathways were analysed by western blot. *In vivo* tumour progression on subcutaneous tumour. **Results:** The size of the exosomes ranged between 120-150 nm and ATC secreted more exosomes than PTC. In response to exosome administration, the cellular proliferation of all four thyroid cancer cell lines increased significantly. In addition, ATC exosomes induced higher levels of proliferation than PTC exosomes. Furthermore, the protein expression of proliferating cell nuclear antigen (PCNA) and NF-kB directly correlated with the proliferation rate of thyroid cancer upon exosome treatment. Moreover, the migration rate of thyroid cancer cells also increased significantly following exosome administration, and ATC exosomes led to an increase in migration compared to PTC exosomes. Exosome administration increased the expression of phosphorylated ERK and AKT, which was correlated with the proliferation and migration. *In vivo* experiment confirms that thyroid cancer progression following exosome treatment. **Conclusion:** Thyroid cancer cell-derived exosomes induce neoplastic progression through the proliferation and migration of thyroid cancer cells, by regulating oncogenic signalling pathways.
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**Background/Aims:** ^177^Lu-PSMA is emerging as an effective therapy in men with castrate resistant metastatic prostate cancer, with high PSA response rates in men undergoing treatment. However, not all men have prolonged treatment responses. This prospective pilot study analyses imaging predictors of treatment response to ^177^Lu-PSMA DKFZ 617. **Methods:** Men with mCRPC, who had failed androgen deprivation therapy (ADT), abiraterone or enzalutamide, and had failed, refused or not been eligible for chemotherapy, with symptomatic disease progression, Hb\>90 and platelets\>75, were enrolled for screening. Screening included both ^18^F-FDG and ^68^Ga-PSMA PET/CT. Men meeting enrolment criteria had PSMA+ve disease at an intensity above liver, and no FDG PET/CT (FDG+/PSMA-) result demonstrating sites of major discordant disease. All men enrolled underwent up to 4 cycles of ^177^Lu-PSMA-DKFZ-617 therapy (6-8GBq/dose) at 6 weekly intervals. **Results:** 18 men were screened and 14 underwent ^177^Lu-PSMA therapy. 2/18 did not undergo therapy due to inadequate intensity of PSMA on screening scans, 2/18 failed screening due to progressive marrow failure prior to therapy. ^177^Lu-PSMA was administered 6 weekly for up to 4 cycles. 14/14 (100%) completed 2 cycles, 7/14 had 3 cycles and 3/14 had 4 cycles. 1/14 received 2 cycles only due to marked treatment response. 3/14 had progressive disease. A PSA response to treatment was seen in 10/14 (71%) men (mean 59% reduction in PSA). A \>50% reduction in PSA occurred in 5/14 (36%) (4/5 \>70% PSA reduction), and \> 25% PSA reduction in 9/14 (64%). PSMA SUV~mean~ and SUV~max~ at baseline were predictive of \>25% reduction in PSA (SUV~mean~ 4.5 non-responders vs. 7.6 responders (p \< 0.007) PSMA SUV~max~ 18 non-responders vs. 58 responders (p \< 0.01). No screening imaging parameter was predictive for \>50% reduction in PSA. **Conclusion:** Both the heterogeneity and intensity of PSMA activity on screening imaging is predictive of \>25% PSA response to ^177^Lu-PSMA-DKFZ 617 therapy, but are not predictive of exceptional responses.
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**Background/Aims:** To establish the utility of baseline ^18^F-Fluorocholine PET/CT and bone scintigraphy (BS) in the outcome prediction of patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with ^223^Ra. **Methods:** Prospective, multicenter and non-randomized study (ChoPET-Rad study). ^18^F-Fluorocholine PET/CT and BS were performed before the initiation of ^223^Ra (basal PET/CT and BS). Bone disease was classified attending the number of lesions in baseline BS and PET/CT. PET/CT was semiquantitatively evaluated to obtain the SUV~max~ in the 5 bone lesions with the highest metabolism and the average SUV~max~. Gleason score, baseline levels of prostate specific antigen (PSA), alkaline phosphatase (AP) and lactate dehydrogenase (LDH), time of evolution of prostate cancer, time of evolution of BM and ^223^Ra line were registered. Each patient was clinically and biochemically monitored. Progression free survival (PFS) and overall survival (OS) since the onset of ^223^Ra treatment were calculated. Therapeutic failure was considered when patient did not finish the ^223^Ra treatment. Relations between clinical and imaging variables with PFS and OS were evaluated by Pearson, Mann-Whitney tests and Kapplan-Meier analysis. Univariate and multivariate Cox regression analysis was performed. **Results:** Forty patients were enrolled. The mean±SD of PFS and OS were 4.6±2.3 and 11.2±8.1 months respectively. 33 patients progressed and 13 dead during the follow-up. The extension of the bone disease by PET/CT (p=0.011, χ^2^= 10.63), BS (p=0.044, χ^2^=8.04), SUV~max~ (p=0.012) and average SUV~max~ (p=0.014) were related to OS. No significant association was found for the PFS. ROC analysis revealed significant association of SUV~max~, average SUV~max~ and basal PSA with OS. Only therapeutic failure was associated with OS In the multivariate analysis (HR=3.6, p=0.04). **Conclusion:** ^18^F-Fluorocholine PET/CT had prognostic aim in the prediction of OS. None clinical or imaging variable was able to predict the PFS, probably due to the high rate of progressive disease.

P199: Initial Experience with 1 Year Follow-up in 22 Patients Treated with Lu-177 I&T PSMA for Advanced Prostate Cancer-Safety, Efficacy and Quality of Life
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**Background/Aims:** Since 2010 ^177^Lu-PSMA therapy has been used in advanced progressive metastatic castrate resistant prostate cancer (mCRPC) at several sites in Europe. Since 2015 our center has offered compassionate access ^177^Lu-PSMA as salvage therapy for such patients. Efficacy and toxicity of ^177^Lu-PSMA therapy is presented in this report of 22 consecutive patients in a real world clinical setting. **Methods:** ECOG performance status \<2, adequate baseline bone marrow function, eGFR \>45 ml/min. Exclusion criteria Tagawa *et al*.\[[@ref284]\] Lutetium-177-PSMA (^177^Lu-PSMA) was prepared and administered in compliance with the Australian Therapeutic Goods Administration Special Access Scheme regulations for compassionate patient usage. Prescribed activity was 3.5--7GBq/patient at 6-8-week intervals. Patients were monitored with 3 weekly blood counts and biochemistry. Toxicities graded according to NCI CTCAE v4.03. Risk factors assessed by contingency analysis Fishers exact test. Time to PSA progression calculated. Survival comparisons Kaplan-Meier methodology. Risk ratios and survival curves compared using Logrank test. Statistical analysis performed using IBM SPSS. Quality of life assessments prior to, during and at the end of therapy course. **Results:** Median age 71 years, median follow-up 17-months. All failed prior ADT. Median Gleason score 8, median PSA level 20.50ng/ml (range, 0.9-1800ng/ml). All completed one or more cycles of therapy, with median number of 4 cycles completed per patient. Improvement in QOL score in 17/22 patients following therapy. Side effects included nausea/GIT symptoms in 2/22, bone flare in 3/22 and xerostomia in 4/22 patients treated. 3 patients (15%) had baseline grade 1 cytopenia. 3 patients (15%) experienced grade 1/2 myelotoxicity. 4 patients (20%) experienced grade 3/4 myelotoxicity. All toxicities self-limiting. Grade 1 cytopenia at baseline was significantly associated with development of grade 3/4 myelotoxicity p-value 0.0035. At time of analysis, no instance of myelodysplastic syndrome or acute leukemia. Disease response observed in 8 patients (40%). 7 (35%) experienced progression with 5 patients (20%) showing stability. Median time to PSA progression not reached. **Conclusion:** ^177^Lu-PSMA is well tolerated, safe and effective salvage therapy for mCRPC associated with improvements in QOL. Baseline cytopaenia may predict haematological toxicity of therapy.
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**Background/Aims:** Ra-223 therapy is recommended for CRPC patients with bone metastases 5-6 cycles with 4 weeks intervals to gain survival benefit. But some clinical cases may change the look at standard recommendations. **Methods:** Chemo-naïve CRPC patient after two years of androgen-deprivation therapy had widespread bone metastases, PSA-4186 ng/ml, ALP-2982 U/l, вone marrow involvement with anemia and thrombocytopenia. ^223^RaCl~2~ therapy was started in August 2014. **Results:** After the first two cycles of ^223^RaCl~2~, PSA dropped to 70ng/ml, alkaline phosphatase (ALP) to 877U/l. The third cycle was delayed for 5.5 months due to technical reasons. Unexpectedly, during Ra-therapy interruption the positive changes were still going. PSA level decreased more to 0.28ng/l, ALP to 254U/l. Haemoglobin level increased from 101 to 125g/l, platelets from 101 to 180x10^9^/l. Later, he received 4 planned cycles. In the follow-up period, he demonstrated minimal disease signs-normal ALP, PSA 0.11ng/ml, pathologic uptake only in the shoulder joints on bone scan. From 6/2015 to 8/2016, the patient had clinical remission, so ^223^RaCl~2~ gave him about two years of active life. For two other patients, the ^223^Ra was also unexpectedly interrupted for 5.5 months. One patient had stabilization after initial treatment cycles, and after restart of ^223^Ra, he remained stable and started to progress two months after the end of the treatment. The second patient had progression after the first two cycles, he was switched to Abiraterone. **Conclusion:** Ra-223 therapy can give a pronounced antitumour effect, as can be seen from the significant decrease in the PSA level. Ra-223 positively affects bone tissue condition, which is evident by a significant decrease in the ALP level. Breaks in Ra-223 therapy are not dramatic, and can be continued. This fact can be taken into account when planning therapy and after completing 6 cycles.
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**Background/Aims:** Docrates Cancer Center has offered multiple targeted radiotherapies for metastatic prostate cancer. Recently, we have introduced ^177^Lutetium-PSMA, so far we have been given more than 100 ^177^Lutetium therapy cycles. The therapy is effective and many symptoms may be related to treatment effects. To separate side effects from treatment effects we started to monitor carefully our patient's symptoms. A web-monitoring tool was taken into our weekly routine. **Methods:** We administer the ^177^Lu-activity in a slow 30-minute infusion 2-7 times over the course of 4-6 weeks. Normal physiologic uptake is seen in salivary glands, and parotid glands are protected with cooling compressions in order to minimize side effects. The patients fill out a web-based EORTC-30-QLQ questionnaire for the follow-up of their symptoms and possible side effects after receiving the treatment. There are 10 questions addressing common symptoms such as general well being, fatigue, xerostomia etc. We have developed these questions to evaluate severity of symptoms as well. The web-based follow-up tool also gives symptom related self-care instructions to patients. **Results:** The program sends an automatic email notifications weekly. To fill the questionnaire takes less than three minutes. Despite it being quick and easy for the patients, the obtained information is valuable, and can also be used for planning of the future treatments. **Conclusion:** It has been reported that digital patient monitoring helps patients live longer and is cost-effective (Denis *et al*. *JNCI* 2017;109(9):djx029). It gives important information to medical staff and helps us react quickly to alarming symptoms. Since the ^177^Lu treatment is still very new and experimental, this program will help us learn more about it and separate treatment effects from side effects. This enables better patient support.

**Disclosure of Interest:** H Virtanen Conflict with: Kaiku Health; T Joensuu Conflict with: Docrates Cancer Center.

P203: Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA-Radio-Ligand-Therapy: An Empiric Proof of a Promising Concept
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**Background/Aims:** The dose-limiting salivary gland toxicity using ^225^Ac-labelled PSMA for treatment of metastatic, castration-resistant prostate cancer (mCRPC) remains unresolved. Experience in external beam radiotherapy (EBRT) of the head and neck region demonstrates that xerostomia is a life-quality-limiting factor. Suppressing the gland metabolism appears to be a promising method to achieve a lower uptake. Because of its safety injection of botulinum toxin into the salivary glands is used to treat severe sialorrhoea even in children and has already been investigated as a potential radioprotective agent in EBRT. **Methods:** A 63-year-old patient with mCRPC received ultrasound-guided injections of botulinum toxin A, total 80 units, into his right parotid gland after a detailed informed consent. A dynamic salivary gland scintigraphy (SGS) using ^99m^Tc-pertechnetate was performed before and after 70 hours. At 45 days post-injection, SGS as well as ^68^Ga-PSMA PET/CT were obtained. Standardized uptake values (SUV) of the right and left parotid glands were compared to the baseline PET/CT study. The patient underwent regular clinical follow up. **Results:** ^68^Ga-PSMA PET/CT performed 45 days after the botulinum toxin injection showed a heterogeneous, but significant reduction of the radioligand uptake by up to 60% (SUV~mean~) in the injected right-sided parotid gland as compared to the left one. There was a drop of the SUV~mean~ in the right parotid gland by up to 64 %, whereas no significant change in uptake of the left parotid gland was noted, when compared to the baseline PET/CT. The SGS also revealed a distinct decline in the peak uptake of ^99m^Tc-pertechnetate in the injected parotid gland. No adverse effects of the injections have been observed throughout the follow-up period. **Conclusion:** Intra-parenchymal botulinum toxin injection impressively decreases the uptake of PSMA radioligands in the salivary glands. Therefore, this approach could be a significant breakthrough for salivary gland protection under PSMA radioligand therapy.

P204: Variation in the Absorbed Radiation dose and PSA Response after Serial Lu-177 PSMA Radioligand Therapy
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**Background/Aims:** The aim of our study was to determine the inter-cycle dosimetry variation in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing at least 2 cycles of Lu-177 PSMA radioligand therapy (PRLT), in correlation with the change in serum PSA after PRLT. **Methods:** Dosimetry was performed during each PRLT cycle in 10 patients with mCRPC. PSMA expression was verified before therapy using Ga-68 PSMA PET/CT. The patients received at least 2 cycles of PRLT using 3.4-7.5GBq Lu-177 PSMA. The time-dependent biodistribution was determined based on whole-body scintigraphies and SPECT/CT. Dosimetric calculations were performed using OLINDA/EXM. For intra-patient comparison, the following dosimetric parameters were determined for kidneys and metastases: uptake at 20h p.i. and mean absorbed dose. Variations between first and following therapy cycles were also analysed as mean with respect to the first cycle (=100%). Serum PSA was determined before and every 4 weeks after the first PRLT cycle. **Results:** In 9 patients, all dosimetric parameters pertaining to metastases demonstrated variations between the first and second therapy cycles: the mean uptake declined by 57% and the average dose by 64%. In contrast, the mean renal uptake increased by 62% and the average renal dose was therefore higher in the following cycles (34%), except for a lower renal dose at the second cycle in 1 patient (-17%). One of the patients showed inverse results, an increase in the tumour uptake (+84%) and dose (+154%) and a decrease in the renal uptake (-9%). However, the renal dose exhibited a mild increment (+19%). Patients with a fall in the absorbed tumour dose also demonstrated a biochemical response (decrease of serum PSA by 41%). The patient exhibiting an increasing PSA after the first cycle revealed a higher absorbed tumour dose during the second PRLT cycle. **Conclusion:** There is a significant inter-cycle variation of the absorbed tumour and kidney doses, which correlates with the change in PSA after PRLT. A decrease in serum PSA, indicating a therapy response, is therefore associated with a decrease in the absorbed tumour dose during subsequent PRLT cycle and vice versa. Administration of a higher amount of radioactivity in the first cycle seems to be reasonable, since the tumour doses tend to decrease in the subsequent cycles due to therapy response.

P205: Peptide Receptor Radionuclide Therapy of Neuroendocrine Neoplasms: An Intention to Treat Analysis in over 1000 Patients
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**Background/Aims:** Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin receptor (SSR) expressing gastroenteropancreatic neuroendcrine neoplasms (NEN) has shown promising results in a recently published clinical trial.\[[@ref285]\] In this study, we performed an intention to treat analysis in over 1000 patients with NEN (pancreas, mid-gut, lung and others) treated at our center. **Methods:** From 2004, 1048 patients received at least one cycle of Yttrium-90 or Lutetium-177 based PRRT, and were included in an intention to treat analysis. Ga-68 SSR PET/CT was used for restaging and response to therapy assessment (EORTC criteria). Accordingly, overall survival (OS) and progression free survival (PFS) were calculated. Adverse events (hematotoxicity and nephrotoxicity) were determined by CTCAE (v4.03). **Results:** Overall survival (95% CI) was 51 months (47.0-54.9) and differed according to tumour grade, location of primary tumour, functionality, previous therapies, and the radioisotope used for PRRT. PFS was 19 months (16.9-21.0), which was influenced by tumour grade, location of primary tumour, and the radioisotope used for PRRT. PFS after initial progression and first and second resumption of PRRT, following therapy-free intervals of \>6 months, was 11 months (9.4-12.5) and 8 months (6.4-9.5), respectively. Myelodysplastic syndrome or leukemia developed in 2.1% patients. No grade 4 nephrotoxicity was observed with Lu-177. Few patients with severe renal dysfunction before PRRT, progressed to end-stage renal disease. No patient with normal renal function before PRRT developed G3 (or higher) nephrotoxicity. **Conclusion:** PRRT is effective as it favorably prolongs the OS and PFS in patients with metastatic neuroendocrine neoplasms. However, this depends on the tumour grade, location of primary tumour, and the radionuclide used for therapy. Low rate of severe hematotoxicity were observed. There was no therapy associated severe nephrotoxicity in patients with normal renal function prior to commencement of PRRT.

P206: Relationship between Blood Test Results, Administered Activity and Effective Half-Life in Lu-177-Octreotate Treatment
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**Background/Aims:** The administered activity of Lutetium-177-octreotate should be personalized in the light of radiation-induced toxicity. In this preliminary study, we investigated the relation between clinical laboratory blood test results and Lu-177 activity levels in the blood circulation after the first circle of Lu-177-octreotate. **Methods:** 15 patients (5 females, 10 males, mean age 66±27 years, range 51-78 y) were given Lu-177-octerotate (mean activity 6.6±4.8 GBq; range 3.3-8.1 GBq) to treat metastatic neuroendocrine tumours (NET). Clinical blood samples (hemoglobin, leucocytes, thrombocytes, creatinine, AFOS and ALAT) were taken in three different time points; before treatment (range 1-8 days), about a week after treatment (range 5-16 days) and 1.5 months after treatment (range 41-63 days). We compared the blood test results with the injected treatment Lu-177 activity. In addition, whole-body (WB) planar scans were acquired from the subgroup of ten patients after the treatment. The total activity from WB scans (excluding bladder and lower extremities) were determined from images and the effective half-life (Teff) of Lu-177 was estimated using mono-exponential fit. **Results:** We observed that administered activity of Lu-177 correlated with elevation of creatinine values measured after one week (mean 71±16µmol/l, range 49-98µmol/l) and after 1.5 months (mean 71 ±15µmol/l, range 58-110µmol/l) from the treatment (p=0.028). The mean Teff measured from WB images was 70 hours (range 53-87 hours). In addition, we recognized another correlation between Teff and baseline creatinine value (p=0.022). Between other measured blood sample values or their changes measured between the time points and administrated activity or Teff there was no statistical correlation. **Conclusion:** Kidney function seems to be the main factor to determine the residence time for unbound-Lu-177 in the blood circulation. Our findings help to predict that if baseline creatinine value is low, the activity will be excreted through the kidneys faster and thus Lu-177-octreotate-treatment is less likely to cause hematological toxicities.

P207: Effect of Peptide Receptor Radionuclide Therapy on Absolute Glomerular Filtration Rate in Patients with Neuroendocrine Tumours
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**Background/Aims:** ^177^Lutetium-DOTATATE (Lutate) is a form of PRRT, which binds to somatostatin-receptor positive tumours and is effective at treating advanced NET. It is typically given in 4 cycles every 8 weeks. The kidneys are known to be radiosensitive from external beam radiotherapy studies. The effect of PRRT on renal function is less well understood, although the kidneys are considered as the dose limiting organ. Much of the early discussion about renal toxicity was using Y-90 whereas today Lu-177 is the more common radiotherapeutic. The aim of this study was to determine the effects of PRRT on renal function measured with ^99m^Tc-DTPA GFR. **Methods:** Patients undergoing 4 cycles of Lutate had ^99m^Tc-DTPA GFR, serum creatinine and eGFR prior to commencing Lutate at baseline (B), \~6 weeks after cycle 2 (mid-treatment (M)) and 10-12 weeks after cycle 4 (follow-up (F)). Amino acid infusions are given concurrently with each Lutate cycle for kidney protection. DTPA clearance was calculated using the 2 sample method, calculating absolute clearance in ml/min and normalised for body surface area in ml/min/1.73 m^2^. To compensate for potential confounders between Lutate cycles including weight and hydration status, we analysed absolute GFR and classified change as a difference of greater or less than 5 ml/min. **Results:** 65 patients who completed 4 Lutate cycles were included, 65 had baseline, 63 had mid-treatment and 56 had follow-up GFRs respectively. Mean time to M GFR was 4.5 months (range 2.6-8.8) and to F GFR was 9.2 months (range 7.2-14.1). From B to M, GFR increased in 26.5%, decreased in 26.5% and was unchanged in 47%. From B to F, GFR increased in 22%, decreased in 36% and remained unchanged in 42% of patients. The median decline in GFR was 11 ml/min. Changes seen at the M GFR measurement were generally not predictive of the change seen at the F point. No differences were observed in change in GFR, from B to F, between patients with baseline GFR of \<60 ml/min versus patients with baseline GFR ≥ 60 ml/min. **Conclusion:** Our results suggest there is little clinically significant renal impairment from 4 cycles of Lutate, however, a longer follow-up period would be beneficial to assess this, as radiation nephropathy may develop as a later effect. Our results also suggest there is no need for mid-treatment GFR measurement, as this is not predictive of follow-up GFR.
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**Background/Aims:** Management of head and neck paragangliomas (HNPGL) is challenging and often associated with serious morbidity due to high vascularity and critical location. Similar to other neuroendocrine tumours, HNPGL overexpress somatostatin receptors (SSTR) allowing peptide receptor radionuclide therapy (PRRNT). We explored the treatment outcome in patients with unresectable HNPGL following PRRNT. **Methods:** We retrospectively reviewed 33 patients with inoperable HNPGL treated with PRRNT and followed for 11.2-69.3 months. Patients received 1-6 cycles of ^177^Lu-DOTATATE (median cumulative activity 17.02GBq) following SSTR expression confirmation on ^68^Ga-DOTANOC PET/CT. Molecular and morphological responses were determined based on PERCIST 1.0 and RECIST 1.1 criteria, respectively. Clinical benefit (symptomatic improvement related to HNPGL) and treatment tolerability were assessed. We also investigated factors associated with PRRNT response (p=0.05). The study was approved by Institutional Ethics Committee. **Results:** Molecular partial responses were obtained in 15 (45.5%) cases and associated with clinical benefit, attained in 12 of 23 previously symptomatic patients (p=0.003). Morphological response was limited (2 patients had partial and 3 had minor responses) and did not relate to clinical benefit (p=0.590), with the majority (84.8%) of patients remaining stable according to RECIST criteria. During follow-up 3 (9.1%) patients progressed according to both morphological and molecular criteria. Transient subacute grade 1/2 haematological toxicity (anaemia, leucopaenia, thrombocytopaenia) occurred in 17 (51.5%) patients. No grade 3/4 haematological toxicity or serum creatinine increase was observed. Multivariable analysis identified increasing lesional SUV~peak~ normalized to lean body mass on baseline ^68^Ga-DOTANOC PET/CT to associate with higher chance of molecular (OR 1.11; p=0.007) and clinical (OR 1.39; p=0.047) responses. **Conclusion:** PRRNT showed favourable and sustained results in patients with HNPGL exhibiting high SSTR expression, while maintaining minimal toxicity. Molecular imaging based criteria related to clinical benefit and is possibly more sensitive than morphologic criteria for evaluating PRRNT response, offering additional value in predicting treatment outcome through baseline quantification.

P209: Reproducibility of Radiation dose to Kidneys for Multiple

177

Lu-DOTATATE Treatment Cycles

Hidayati

N R

1

Poon

A

2

Willowson

K

3

Eslick

E

4

Ryu

H

3

L Bailey\*

Dale

4

Center for Technology of Radiation Safety and Metrology, Batan, Jakarta, Indonesia

Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia

University of Sydney, Australia

Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia

**Background/Aims:** Radiation dose to the kidneys in ^177^Lu-DOTATATE PRRT (Lutate) is considered to be the main potential side-effect from treatment. Prospective assessment of kidney dose can be made with SPECT, however, this requires an intensive imaging regime over a number of days. For this reason, a retrospective investigation of the reproducibility of kidney uptake using quantitative SPECT was performed. The aim of the study was to compare the estimated radiation dose to kidneys for each cycle, to test whether full imaging over multiple days for the initial cycle can be used to estimate kidney dose for subsequent cycles. **Methods:** Seventeen patients treated with Lutate for metastatic neuroendocrine tumours had full imaging for each of their treatment cycles on a Siemens Intevo SPECT/CT gamma camera. One course of treatment consisted of 3 or 4 cycles approximately 8 weeks apart spanning 6 months. SPECT/CT scans of the abdomen were acquired at 3 time points (4, 24 and 96-120 hours) after administration of \~7.8 GBq of Lutate. Nine patients received three cycles in total and eight patients had four cycles. Volumes of interest (VOIs) were defined on a CT scan co-registered with the SPECT images and repeated over all time points, to give the radioactivity in the kidney. Whole organ dosimetry was estimated using OLINDA/EXM using an exponential clearance model. This gives an estimate of radiation absorbed dose to kidney (Gy/GBq) for each treatment cycle. The mean of the 3 or 4 cycles and variation can then be determined. **Results:** The mean amount of Lutate administered per cycle for all 17 subjects was 7.76±0.36 GBq. From this, the average kidney dose was 0.23 Gy/GBq (range: 0.06 -- 0.42) and average variation between cycles for all subjects expressed as a percentage was (12.5±7.8)% (median:11.4%, range:1.8%--29.4%). **Conclusion:** Estimated radiation dose to the kidneys for Lutate PRRT shows good reproducibility (typically \<20% variation) within an individual across all cycles within one course of treatment (up to 4 cycles). The errors introduced by assuming that the dosimetry estimate per unit GBq administered from the initial cycle could be used for subsequent cycles within a course are unlikely to contribute significantly to the overall estimate of radiation burden and are likely to be safe.
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**Background/Aims:** Metastatic myoepithelial carcinoma (MMC) is a rare malignancy which lacks evidence-based treatment guidelines and requires an individualised treatment approach. We present a 65-year-old woman with histopathologically confirmed MMC who demonstrates strong somatostatin receptor (SSR) avidity on ^68^Gallium-DOTATATE positron emission tomography (PET). The patient was considered suitable for peptide receptor radionuclide therapy (PRRT) using ^177^Lutetium-Octreotate. We have selected this unusual case to review the use of PRRT for non-neuroendocrine malignancies. **Methods:** The patient's initial ^68^Gallium-DOTATATE imaging demonstrated widespread liver and skeletal metastases, with repeat scans showing mild disease progression. Two additional areas of disease in segment 6/7 of the liver and the lumbar spine were also identified on ^18^Fluroine-Flurodeoxyglucose (^18^F-FDG) PET. The ^18^F-FDG avid liver metastases were surgically resected. External beam radiotherapy (EBRT) was directed toward the lumbar spine, with good response in keeping with the radiosensitive nature of this disease. The patient also responded well to monthly octreotide injections. Given the widespread SSR targets, and positive response to octreotide and EBRT, the patient was considered a suitable candidate for ^177^Lutetium-Octreotate PRRT. The patient received four cycles of PRRT. Whole-body planar images were acquired at four hours post-infusion for each cycle, and 24-hours post-infusion after the second and third cycles. Twenty-four hour post-infusion whole-body single-photon emission computed tomography/computed tomography images from the vertex to mid-thighs were also acquired following the first and fourth cycles. **Results:** Good avidity of ^177^Lutetium-Octreotate was demonstrated after each cycle, with a similar distribution to the baseline ^68^Gallium-DOTATATE imaging. The patient's overall quality of life (QOL) remained very good throughout the course of therapy. **Conclusion:** PRRT can be added to the treatment algorithm for non-neuroendocrine tumours, regardless of histology if strong SSR-avidity is identified. In cases where treatment guidelines do not exist, a compassionate and common sense approach may provide prolonged improvement in QOL and a slowing of disease progression.
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**Background/Aims:** The kidney is among the more radiosensitive late-responding organs. It is considered an organ-at-risk in peptide receptor radiation therapy, where patient-specific absorbed kidney doses are difficult to predict by clinical factors.\[[@ref286][@ref287][@ref288]\] We investigated kidney doses and renal function over time in Lu-177-octreotate treated patients. **Methods:** 20 patients (10 males, 10 females; mean age 60±9 y, range 30-73 y) with metastatic grade 1-2 neuroendocrine tumours received Lu-177-octreotate in 3-6 cycles a total activity of 26.8±6.4 (range 11.7-37.6) GBq with an 8h infusion of amino acid solution to decrease renal uptake. The absorbed kidney doses were determined using a SPECT/CT-based dosimetry protocol.\[[@ref289]\] Creatinine levels were measured and estimated glomerular filtration rates (eGFR) were calculated using the CKD-EPI creatinine equation. The mean follow-up time was 3.7±1.1 y (range 2.4-6.2 y). **Results:** Baseline mean eGFR was 89±11 (range 54-105) ml/min/1.73 m^2^. One month, one year and two years after the last cycle, mean eGFR was 88±10 (range 61-103) ml/min/1.73 m^2^, 87±16 (range 52-113) ml/min/1.73 m^2^, and 86±14 (range 51-114) ml/min/1.73 m^2^, respectively. The mean yearly decrease in eGFR was 1.4±2.6 (range-6.7-4.3) ml/min/1.73 m^2^. The age-associated decline in GFR is approximately 1 ml/min/1.73 m^2^ per year, and there was no statistically significant temporal change in eGFR in the patient cohort. The mean cumulative kidney dose was 11.5±4.6 (range 4.1-20.2) Gy. There was no correlation between the absorbed kidney dose and the yearly decrease in eGFR. Unexpectedly, we did not observe correlation between the baseline eGFR and the absorbed kidney dose per activity (mean 0.43±0.17 Gy/GBq, range 0.22-0.88 Gy/GBq). **Conclusion:** In this patient cohort, we neither observed any change in kidney function after Lu-177-octreotate treatment, nor any correlation between absorbed kidney dose and eGFR. The result showing no obvious dose response is expected as the mean doses were well below the expected tolerance limit of kidneys.
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**Background/Aims:** This is first experience on PRRT in China, thirty patients consecutively were enrolled in this study, patients with Krenning Score (3-4) were included. At 3 days post-therapy, ^177^Lu-DOTA-TOC SPECT/CT and whole body scans were performed. This primary study showed PRRT had mild and transient adverse effects, and presented with significantly symptom releasing and tumour marker reduction. To our experience, PRRT had better outcomes in phaeochromocytoma/paraganglioma (PHEO/PGL). Treatment with lutetium-labelled peptide receptors radionuclide therapy (PRRT) is a promising treatment strategy for patients with inoperable or metastatic neuroendocrine tumours (NET). The aim of this study is to evaluate the outcome of PRRT and main adverse effects. **Methods:** Twenty five patients with advanced unresectable progressive differentiated NET and five patients with PHEO/PGL were consecutively enrolled in this prospective study from August 2016 to September 2017. All patients showed multiple ^68^Ga-DOTA-NOC avid lesions, and received 80-190mCi (143±25mCi) ^177^Lu-DOTA-TOC at 12 weeks interval, amino acid protection protocols were routinely performed before and after administration. Totally, 52 cycles were performed in 30 patients, tumour response were evaluated with RECIST or PERCIST criteria. ^177^Lu-DOTA-TOC SPECT/CT and wholebody scan was performed 3 days post-therapy. **Results:** No significant adverse effects such as nephrotoxicity and acute bone marrow depression were observed in this study. However, transient mild hematological toxicity and acratia appeared in some patients, abdominal pains which associated with heavy tumour burden were also observed. Out of 30 patients, 11 patients had partial response, 13 patients had stable disease, 5 patients progressed. Three patients were dead, 1 died of intestinal obstruction and acute kidney failure, 1 with massive hemorrhage of gastrointestinal tract, the third with cachexia and multiple organ failure. PRRT showed better outcomes in PHEO/PGL, catecholamine and serum CGA was significantly decreased, symptoms were gradually released. **Conclusion:** This Chinese study on PRRT resulted in SD or PR in GEP-NET, which showed significant symptom relief and tumour marker reduction, however, transient and mild adverse effects were observed but tolerable. Due to small patient population, large scale multi-center studies are needed in the future.
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**Background/Aims:** Merkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine tumour (NET) with propensity for locoregional & distant spread. Metatastatic disease shows poor outcomes.\[[@ref286]\] Due to its NET nature, upregulation of somatostatin receptors is often found.\[[@ref287]\] Somatostatin receptor PET imaging using ^68^Ga-analogues has been described in this tumour.\[[@ref288]\] We present 2 cases of metastatic MCC imaged with ^68^Ga-octreotate (Ga-Oc) & treated with peptide receptor radionuclide therapy (PRRT) on compassionate grounds with ^177^Lu-octreotate (Lu-Oc). **Methods:** Ga-Oc PET imaging was performed pre-& post-PRRT. Lu-Oc was prepared to GLP standards in Scintomics production unit. Dose administered following TLC and HPLC quality control. Clinical parameters-bloods, ECOG status and quality of life collected and analysed. **Results:** 1) A 89 year old woman, MCC diagnosed 7/2015. 2 months later metastatic axillary adenopathy. Patient developed osseous pain. Ga-Oc scan-widespread octreotate-avid metastases. 5GBq dose of Lu-Oc given with decrease in pain and improvement in quality of life. 4 months later-recurrent symptoms-dose of 2.9 GBq Lu-Oc resulted in further palliation. Eventually succumbed to disease 8 months after first dose. 2) A 72 year old MCC diagnosed 6/2016. Sentinel lymph node biopsy 7/2016-microscopic MCC. Adjuvant radiotherapy then 6 cycles of adjuvant pembrolizumab. Mass developed in right axilla-confirmed recurrence. FDG PET-axillary and sternal metastases. Ga-Oc scan-intense octreotate uptake. Treated with 3 cycles Lu-Oc at 6 weekly intervals (cumulative dose 18 GBq). Follow up imaging-no evidence of Ga-Oc avid disease. **Conclusion:** MCC is more common in the elderly and incidence is rising. Risk factors include age, UV light exposure & polyoma virus.\[[@ref289]\] ^177^Lu-DOTATATE in metastatic MCC has been described with response to treatment noted.\[[@ref290]\] Tumour appears responsive to ionizing radiation with locoregional control described with external beam radiotherapy.\[[@ref291]\] These 2 cases illustrate the ^68^Ga/^177^Lu-octreotate theranostics principle. In one case, treatment induced significant palliation of symptoms and possible improvement in survival. In the other case, a complete response to therapy in small volume metastatic disease was noted. The systemic nature of targeted PRRT and the radiosensitivity of this tumour may explain possible improved efficacy of this treatment modality in this disease. These results warrant further work in this area.
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**Background/Aims:** In July 2016, Peter MacCallum Cancer Centre opened a new purpose-built hospital focused on providing better treatments and care for patients with cancer. As part of the expanding radionuclide therapy program providing outpatient therapies to patients with metastatic neuroendocrine tumours and more recently prostate cancer, a dedicated area has been set up for therapy administrations. **Methods:** We describe the set-up of an integrated radionuclide therapy treatment area, with the aims to improve access between patients and the nuclear medicine team, with closer proximity to imaging areas for early phase dosimetry scanning, whilst providing adequate radiation safety protection to staff. Patients were previously treated in a day therapy or general ward situated a distance from Molecular Imaging department, where portable shielding and other equipment were required to be mobilized for each therapy session. **Results:** The new therapy area is strategically located within the molecular imaging department, within short distances from radiopharmacy, imaging and reporting areas. The dedicated wing consists of a shielded bay for 3 patients, plus 3 areas for single patient administration, allowing for treatment up to 6 patients in each session. A centrally placed staff work area is glass-shielded, with clear views of all patients and treatment bays. This whole area is light and airy with spectacular views through large windows. It includes a dedicated disabled toilet and has easy access to the general waiting area for accompanying persons. Area monitoring has shown minimal radiation reaching the staff work area, and radiation readings taken immediately after ^177^Lu-DOTA-Octreotate or ^177^Lu-PSMA therapy administrations of approximately 3.5 uSv/hr at the edge of patient shielded area. **Conclusion:** The inclusion of a dedicated radionuclide treatment area as part of Molecular Imaging has enabled more efficient delivery of radionuclide therapy in a pleasant and safe environment for both patients and staff.

P215: Imaging and Radiation Safety Considerations of Phosphorus-32 Radionuclide Therapy in Inoperable Pancreatic Primary Cancer
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**Background/Aims:** OncoSil Medical Ltd (Sydney, Australia) have a novel therapeutic approach for treating inoperable primary pancreatic tumours utilising siliconized phosphorus-32 Microparticles (called 'OncoSil™').\[[@ref292]\] Typical amounts of OncoSil administered are of the order of tens of MBqs. The emission of high energy Bremsstrahlung photons create challenges such as the potential for (1) radiation exposure to caregivers; and (2) poor post-treatment image quality.\[[@ref293]\] The purpose of this work was to estimate the radiation exposure to operators and caregivers during an OncoSil treatment and to assess the post-treatment image quality. **Methods:** A water-filled IEC body phantom containing an internal spherical component located off the central axis was filled with a representative therapeutic activity of 85MBq of OncoSil suspension to simulate the body situation. A Radeye B20-ER survey meter (Thermo Fisher Scientific Messtechnik GMbH) was used for radiation exposure assessments at a number of locations. A Siemens Intevo.6 SPECT/CT gamma camera (Siemens Healthineers, Hoffman Estates, USA) with medium energy collimators was used for imaging. Image were reconstructed using an ordered subset ML-EM (OSEM) reconstruction algorithm. Energy spectra were acquired after removing the collimator from the detector. **Results:** The pulse height analyser (PHA) spectrum acquired on the gamma camera showed that the majority of photons were below 150keV, however there was an appreciable tail extending beyond 200keV. An imaging window of 50-100keV can provide successful imaging. The highest exposure rate to an operator or caregiver, directly adjacent to the source in the phantom, was approx. 0.16 µSv. hr^-1^. MBq^-1^ so that exposure from a typical OncoSil treatment of 20 MBq is 3 µSv. hr^-1^. **Conclusion:** The estimated exposure of exposed individuals during and after a treatment is very small. It would require over 300 hours of standing directly beside a patient to approach the annual limit of exposure for a member of the public Caregivers are further allowed five times this limit. Acceptable image quality has been demonstrated on an unmodified, conventional gamma camera using medium energy collimation.

**Disclosure of interest:** D Bailey Conflict with: consultant for OncoSil Medical Ltd, M Bradney Conflict with: Financial support for study.
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**Background/Aims:** The most common location of the local nodular form of PVS is the knee joint, followed by the finger joints. Occurrence in the ankle joint is realy rare but should be considered if clinical findings are present. Treatment consists of isolated surgical resection of the neoplastic synovium. Radiosynoviorthesis (RS) is recommended as a post-operative treatment to increase the probability of a total removal of persisting PVS cells. **Methods:** We present our experience of 5 (3 women) young (19-31 years) athletes with PVS of the ankle joint. All patients were treated in 2 stages: surgical synovectomy (SS) with arthroplasty of the ankle joint followed by adjuvant treatment with intra-articular injection of 2mCi Re-186 performed within 2-3 months after SS. Treatment efficacy was evaluated 2, 6 and 12 months after the initial RS by a questionnaire reporting the relief of limiting the daily activities pain as a percentage of the pretherapeutic joint discomfort using a visual analog scale (VAS). Relative uptake of ^99m^Tc-diphosphonate in the knee joint involved on the blood pool was also taken into consideration. **Results:** In the 1 out of the 5 cases a repeated Re-186 injection was needed for better outcome. The overall response rate for all knee treatments was 80%. Results in double treated joints were significantly worse than in single treated ones. A significant improvement in blood pool bone scintigraphic signs of inflammation was noticed. On the other hand, there was no influence on late diphosphonate uptake. **Conclusion:** A combination of debulking surgery with adjuvant intra-articular injection of Re-186 for the rare cases of PVS of the ankle joints seems to be a reliable treatment method, with encouraging results

P217: Biodistribution of Implanted Phosphorus-32 into Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination with Gemcitabine+Nab-Paclitaxel Chemotherapy: A Single Centre Experience
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**Background/Aims:** Pancreatic cancer (PaC) is the 12^th^ most common form of cancer in both genders globally,\[[@ref294]\] but is ranked 7^th^ as a cause of cancer death.\[[@ref295]\] Surgical resection is the only potentially curative treatment option, however \<20% of tumours are deemed resectable at the time of diagnosis.\[[@ref296]\] Locally advanced pancreatic cancer (LAPaC) has a prognosis almost as poor as metastatic PaC, as current standard of care chemotherapy (SOCC) management outcomes remain poor. Up to 30% of PaC patients die from consequences of locally invasive disease.\[[@ref297]\] Therefore, improving local control and development of more effective therapies in LAPaC is important. There is evidence to suggest that brachytherapy, including Phosphorus-32 (P-32) microparticles, may have the potential to reduce tumour size and provide palliative benefit for LAPaC patients. **Methods:** The patient-specific P-32 dose was calculated based on the patient's tumour volume. P-32 microparticles were injected directly into the target pancreatic tumour via endoscopic ultrasound (EUS) guidance. Bremsstrahlung delayed whole body planar and SPECT/CT imaging of the abdomen and pelvis was performed within 4 hours and 7 days post-implantation. Biodistribution of the implanted P-32 was analysed and was reliably depicted via Bremsstrahlung SPECT/CT hybrid imaging, and hence enabled improved modification of injection approach on subsequent cases, where appropriate. **Results:** Consecutive implanted case series will be discussed focusing on patient and procedure related factors (i.e. tumour size, location, ease of EUS access, implant needle placement, the degree of resistance experienced whilst injecting and absence or presence of biliary/tumoural/duodenal stents in situ), that may alter the biodistribution of the implanted P-32, and possible ways of reducing extra-tumoural losses. **Conclusion:** EUS guided implantation of P-32 into LAPaC, given in combination with SOCC (gemcitabine+nab-paclitaxel) is a safe procedure with no immediate adverse effects reported in all cases implanted thus far. However, the individual biodistribution of the implanted P-32 may vary.

**Disclosure of interest:** I Jong Conflict with: Study sponsored by OncoSil Medical Ltd, consulted for OncoSil Medical Ltd for matter of experimental design; D Croagh Conflict with: Study sponsored by OncoSil, Conflict with: received honoraria from OncoSil Medical Ltd, M Harris Conflict with: Study sponsored by OncoSil Medical Ltd, Conflict with: received honoraria from OncoSil Medical Ltd; M Bradney Conflict with: Currently a full time employee and shareholder of OncoSil Medical Ltd.

Chemotherapy was supported by Specialised Therapeutics Australia Pty Ltd
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**Background/Aims:** Survivorship in carcinoid patients treated with high dose ^131^I-MIBG has been limited by small cohorts and short follow up. We report response and progression-free survival in a cohort of 211 carcinoid tumour patients treated with ^131^I-MIBG between 1991 and 2014, mean follow up of 39 months, total of 685 patients. **Methods:** A registry review of patients receiving median dose (500 mCi) ^131^I-MIBG at an academic tertiary center was performed. Imaging response was assessed via (RECIST) version 1.1. Symptomatic response was assessed via review of clinical encounters. Lab response was assessed by a 20% change in 2 consecutive values from baseline in either 5HIAA or chromogranin A. 19% of patients received additional rounds of ^131^I-MIBG. **Results:** At follow up, 71% of patients reported improvement in pre-treatment symptoms, primarily reduction in GI symptoms (80%), fatigue (40%), flushing (32%), and pain (28%). 33% experienced no symptomatic progression (SP). Median time to SP was 1.4y ± SE 0.3. Initial follow up imaging demonstrated 2% complete response, 18% partial response, 60% stability and 20% progression. 43% of patients showed no post MIBG imaging progression with median time to progression of 1.7±0.2 years. 34% of patients demonstrated lab response and 48% were stable. 43% of patients remained without lab progression with median time to laboratory progression 2.5±0.5 years. Overall median survival was 6.3±0.5 years, with 5, 10 and 20-year survival of 59, 31 and 10%. Median survival post diagnosis of metastatic disease was 5±0.5 years. Survival post treatment was 2.4±0.2 years. Improved survival was predicted by: a) multiple MIBG treatments vs. one treatment (4.0±0.5 vs. 2.0±0.3 years, p\<0.05); b) stable/response vs. progression at first imaging follow up (4.0y±0.4 vs. 1.3±0.3 years, p\<0.001); c) symptomatic response vs. non-response (4.2±0.4 vs. 1.7±0.6 years, p\<0.001); d) response/stability vs. progression in labs (6.2±1.5 vs. 2.9±1.6 years, p\<0.05). **Conclusion:** Initial imaging, symptomatic and laboratory response to high dose ^131^I-MIBG predict long term outcomes in stage IV carcinoid tumour. Stratification by these factors may provide post therapy clinical decision making. Multiple rounds of MIBG therapy was also associated with prolonged survival and valuable to inform the management of stage IV carcinoid.
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**Background/Aims:** Iodine-131-labeled metaiodobenzylguanidine (^131^I-MIBG) is used worldwide for the therapy of high-risk neuroblastoma. Kanazawa University Hospital is the only institution which can perform high-dose ^131^I-MIBG therapy for neuroblastoma in Japan. We investigated the outcomes and the prognostic values of high-dose ^131^I-MIBG therapy in patients with high-risk neuroblastoma. **Methods:** This study included 18 patients with high-risk neuroblastoma who underwent the first high-dose ^131^I-MIBG therapy between September 2008 to August 2013 at Kanazawa University Hospital, Japan. Eight were males and 10 were females. The mean age at the ^131^I-MIBG therapy was 8.0 years old. All doses of ^131^I-MIBG were more than 444MBq (12mCi)/kg. The mean dose of ^131^I-MIBG was 586MBq (15.8mCi)/kg. We investigated the outcomes and prognostic values of high-dose MIBG therapy. This study was approved by the Institutional Review Board of Kanazawa University Hospital. **Results:** Following MIBG therapy, 17 of 18 patients were performed chemotherapy and/or stem-cell transplantation. The initial response rate (complete response and partial response) was 56%. Event-free survival (EFS) rate at 1 year and 2 years after ^131^I-MIBG therapy were 50% and 28%. Overall survival (OS) rate at 1 year and 2 years after ^131^I-MIBG therapy were 67% and 56%. The OS times were significantly longer for patients with complete or partial initial responses (p\<0.05), for patients without pain at the MIBG therapy (p\<0.01) and for patients without elevated urine vanillylmandelic acid (VMA) or homovanillic acid (HVA) at the MIBG therapy (p\<0.01). **Conclusion:** High-dose ^131^I-MIBG therapy combined with other therapies may provide good response for patients with high-risk neuroblastoma. The initial good response to the ^131^I-MIBG therapy, symptoms and urine VMA/HVA elevation at the ^131^I-MIBG therapy may be prognostic factors of high-dose MIBG therapy in patients with high-risk neuroblastoma.
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**Background/Aims:** Haemophilic arthopathy is a chronic debiliating condition in Haemophilia patients. There is a viscous cycle of chronic synovitis and resulting irreversible fibroses of the joints.\[[@ref298]\] Besides the conventional clotting factor replacement and symptomatic treatment of haemarthrosis, radiation synovecomty may offer a potential role in better management of such conditions.\[[@ref299]\] **Methods:** We have performed prospective evaluation of patients with radiation synovecomty performed at the Nuclear Medicine Unit, Queen Elizabeth Hospital, a tertiary referral centre in Hong Kong. Study parameters include number of haemarthrosis attacks and related hospital admissions, clotting factor consumption and patient's evaluation by means of pain assessment score and questionaire. **Results:** A total of 22 cases of radiation synovectomy were performed over the study period with no incidence of major side-effects or complication. Joints treated include knees, elbows and ankles joints. Statistically significant (p\<0.05) comparing 1 year before and 1 year after radiation synovectomy shown reduction in hospital admission, number of haemarthrosis attacks and subsequently, reduction in clotting factor consumption. There is also significant improvement in patient's satisfaction and joint mobility (reduced pain and improved motion). **Conclusion:** Radiation synovectomy is an effective treatment in patients suffering from haemophilic arthopathy. It can reduce episodes of hemarthrosis attacks, improve patient's activity and quality of life. There may in turn be reduction in the related health-care cost in Haemophilia cases.

P221: The Role of Positron Emission Tomography/Computed Tomography and Single-Photon Emission Computed Tomography/Computed Tomography for Imaging the Biodistribution of SIRspheres in Inoperable Liver Tumours
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**Background/Aims:** SIRspheres (Yttrium-90 microspheres) are used in Selective Internal Radiation Therapy for inoperable liver tumours. Imaging of the biodistribution of SIRspheres post treatment can be performed using SPECT/CT Bremsstrahlung or PET/CT Pair Production imaging, and can assist in ensuring proper delivery, to estimate dose to tumour, and in predicting complications. A comparison study done in 2015 at the Austin Hospital concluded that ^90^Y-PET/CT demonstrated superior detection of biodistribution of the SIR-spheres to ^90^Y-SPECT/CT. The aim of this study is to perform a qualitative comparison between pair production PET/CT and Bremsstrahlung SPECT/CT imaging of the biodistribution of SIRspheres using the Philips Ingenuity TF 128 and a new GE Discovery 670 Pro to expand on the previous study. **Methods:** Bremsstrahlung SPECT and Pair Production PET imaging was performed on patients post SIRspheres therapy. SPECT/CT imaging was performed on a GE Discovery 670Pro, at 30sec/view, 60 views, 128 matrix size and zoom of 1. Images were reconstructed using OSEM, and resolution recovery was also performed. PET/CT imaging was performed on a Philips Ingenuity TF128, 15 mins/bed over the liver in 2 bed positions. Different levels of smoothing and point spread function as post processing were applied. The PET/CT and SPECT/CT images were qualitatively reviewed by two experienced Nuclear Medicine Physicians. **Results:** Image quality was optimised with PET/CT imaging when reconstruction with the Smooth B filter and PSF 1 iteration. Tumour delineation and biodistribution of the SIRspheres was better visualised on PET/CT compared to SPECT/CT. Image quality of SPECT/CT has improved due to advances in gamma camera technology including improved detector technology, larger field of view and advanced reconstruction protocols compared to two years ago, with the added bonus of faster acquisition times than PET/CT. **Conclusion:** Pair production PET/CT reflects clearer tumour delineation and biodistribution than traditional Bremsstrahlung SPECT/CT due to the superior spatial resolution. However, advancements in SPECT/CT technology is improving the Bremsstrahlung image quality.
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**Background/Aims:** Intravenous injection (IV) of radiotherapeutic agents often leads to severe complications and abandonment of therapy due to systemic toxicity. To overcome this problem it is important to explore alternative modes of delivery for anticancer drugs to decrease systemic toxicity and improve the therapeutic potential. It has been shown that intratumoural (IT) delivery of cytotoxic drugs by direct injection into the solid tumour mass can provide extremely high doses of anticancer agent throughout the tumour with minimal systemic toxicity. Direct IT injection of cancer drugs therefore represents a new treatment paradigm that may be particularly valuable for treating solid tumours, especially in early stage. The aim of this study is to compare tumour targeting behavior after IT vs. IV administration of ^177^Lu-labelled tumour targeting peptide in breast tumour bearing mice. **Methods:** DOTA-GGC-BN(7-14) was synthesised by standard solid-phase peptide synthesis. Labelling with ^177^Lu was accomplished using 0.1M NH~4~OAc buffer (pH 4-5). In vitro tumour cell-binding was conducted on MCF7, T47D breast and PC3 prostate cancer cell lines. For tumour targeting, ^177^Lu-labelled BN peptide was administered by IT or IV injection into nude mice with MCF7 tumours xenografts. Approval of the institutional animal care and use committee was obtained prior to the initiation of these studies. **Results:** ^177^Lu-DOTA-BN displayed high binding affinity (Kd \<20 nM) towards breast and prostate cancer cell lines and significant internalization (\~20%) into these cell lines. Following IT injection into nude mice, \~36% of the ID/g was found in the breast tumour over 2 h whereas uptake in other major organs including kidneys was below 1% ID/g. Tumour to blood, muscle and kidney ratios were 252, 360 and 36. When IV route of administration was used a completely different and variable pattern of tissue uptake was observed in terms of accumulation in the nontarget tissues (up to 7% ID/g). The uptake in the tumours was found to be below 2% ID/g. **Conclusion:** IT injection significantly enhanced the uptake of radiopeptide in breast tumour when compared with IV injected animals. Direct IT administration may thus offer less systemic exposure than IV delivery and serve as a successful local method to deliver high radiation dose into tumours. Further studies should explore the more effectiveness of this emerging approach.
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**Background/Aims:** Anti-CD20 monoclonal antibodies (mAbs) radiolabelled with ^131^I and ^90^Y have demonstrated effectiveness in treating patients B-cell non-Hodgkin's lymphoma (NHL) where conventional therapies have failed.\[[@ref300]\] ^177^Lu-Rituximab is a new candidate radioimmunoconjugate for the treatment of refractive and relapsed NHL. Rituximab is an anti-CD20 mAb routinely used in the treament regime of CD20+ NHL, and ^177^Lu has suitable properties for dosimetric imaging and radionuclide therapy, with reduced radiation safety concerns allowing patients to be treated as outpatients.\[[@ref301]\] In this study, various bifunctional chelates and immunoconjugation techniques were investigated to preclinically assess the feasibility of ^177^Lu-Rituximab radioimmunoconjugates for the treatment of NHL. **Methods:** Rituximab was immunoconjugated with the bifunctional chelates p-SCN-Bn-DOTA, CHX-A" DTPA and DOTA-NHS-ester under different conditions and compared. p-SCN-Bn-DOTA was also immunoconjugated to Rituximab prepared with tris (2-carboxyethyl) phospine (TCEP) to potentially improve site selection of the immunoconjugation and subsequent *in vivo* stability.\[[@ref302][@ref303]\] Immunoconjugates were radiolabelled with ^177^Lu and yield, stability and biological stability were assessed. *In vitro* cell binding and inhibition studies were performed on NHL cells expressing the CD20 antigen. Preclinical SPECT/CT imaging was performed at 24, 72 and 144 for the *in vivo* assessment of tumour uptake and biodistribution of ^177^Lu-Rituximab in mice with CD20+ xenografts. Animal ethics approval was obtained from the Animal Ethics Committees of RMIT and Monash Universities. **Results:** Immunoconjugation with CHX-A" DTPA and p-SCN-Bn-DOTA could be achieved in 2 hours, while DOTA-NHS required 24 hours incubation. All immunoconjugates radiolabelled with ^177^Lu achieved \>99% label and were stable in plasma. The TCEP manipulation of Rituximab prior to immunoconjugation with p-SCN-Bn-DOTA did not affect radiolabelling yield, although the immunoreactivity was considerably reduced. At the time of writing this abstract, the preclinical SPECT/CT imaging investigation was in progress but incomplete. **Conclusion:** Radioimmunoconjugation of Rituximab with ^177^Lu can be performed using the bifunctional chelates DOTA-NHS, CHX-A" DTPA and p-SCN-Bn-DOTA. The products are stable in plasma and the antibody retains its immunoreactivity.
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**Background/Aims:** The treatment of patients with rheumatoid arthritis (RA) has been spectaculary changed since the 1950's. During biological therapy, sometimes 1 or 2 joints could be affected by inflammation. In this cases, always the question is how to solve the problem-change of the biological or basic therapy, or use surgical synovectomy or radiosynovectomy (RSO)? **Methods:** In our reumatological department 2100 patients with RA and PA were treated with biological therapy between 2002 and 2015. In 100 patients we applied RSO because of the inflammation of the knee joint during biological therapy. We had long term follow-up in 72 patients. All participants provided written informed consent. 62 participants inflammatory knee joint disease was diagnosed on the basis of the American College of Rheumatology. 55 of 62 patients with rheumatoid arthritis were seropositive, 7 seronegative. Steinbrocker functional stadium II was observed in 52, stadium III in 10. 10 patients were psoriatic arthritis. Mean age of 13 male and 61 female patients was 51.4 years (range 24-79) years. In 38 patients the right knee, in 34 the left knee was treated by radiosynovectomy. Mean duration of disease was 7.3 years (range 0.5-25), of synovitis (6.3 month (range 3-8)). Mean number of punctions of the treated joint prior to radiosynovectomy was 4.2 per patient and of steroid administrations prior to radiosynovectomy 3.0. In 12 patients, systemic steroid therapy has been performed. **Results:** During the study period, inflammation decreased. In the first two years excellent and good results were recorded in 82.2%. Two years after radiosynoviorthesis 83.3% of patients did not need another punction. Before the knee inflammation patients were in complete remission which status has been achieved after RSO as well. DAS: 2,4+-0,4. **Conclusion:** 1. RSO is an effective method to treat the inflammation of the knes. 2. The RSO performed during biological tehrapy is as effective as in the case of patients without biological therapy. 3. In case of a succesful RSO there is no need for biological or basic therapy neither for surgical synovectomy. 4. However an intraarticular injection has a low risk for infection it is recomended to avoid the biological therapy during the RSO.
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**Background/Aims:** 90Y-microsphere treatment is a palliative regional therapy of primary or secondary liver tumours. Two types of microspheres that are commercially available are resin and glass microspheres. The aim of this study is to compare the baseline characteristics of the patients, results and adverse events of both type of ^90^Y-microsphere treatments performed in a university hospital between 2008-2017 retrospectively. **Methods:** A total of 375 patients (mean age: 57.6 years; M: F = 244 (65.1%):131 (34.9%)) received 477 ^90^Y-microsphere traetments (Resin: Glass = 239 (50.1%):238 (49.9%)). All the patients had planning angiography, hepatic artery perfusion scintigraphy (HAPS), pre-and post-treatment computerized tomography (CT) or magnetic resonance imaging (MRI). The patients' whole blood count, serum markers of liver and kidney functions at baseline were noted. FDG PET-CT images were also evaluated if available. Therapy response was assessed with CT/MRI/FDG PET/CT and clinical follow-up. **Results:** The diagnoses of these patients were hepatocellular carcinoma (HCC) (n=108, 29.1%), cholangiocarcinoma (n=24,6.5%), and unresectable metastatic colorectal carcinoma (n=111, 29.9%), neuroendocrine tumours (n=31, 8.4%), metastatic breast carcinoma (n=37,10%), and other metastatic disease (n=64, 16.1%). The patient baseline characteristics were similar in both therapy groups. There was no significant difference between whole blood count, serum markers of liver and kidney functions at baseline, 15 days and 4-8 weeks after treatment. The mean survival was 13.9 months (95%CI 7.9-19.8) for resin and 11.3 months (95%CI 8.5-14.0) and not statistically different (p=0.327) in HCC patients. The mean survival was 12.7 months (95%CI 9.0-16.4) for resin and 15.7 months (95%CI 9.9-21.4), and not statistically different (p=0.94) in metastatic colorectal cancer patients. However, a significant difference was noted for glass microspheres in metastatic neuroendocrine tumour patients. The mean survival was 21.4 months (95%CI 5.2-37.6) for resin and 31.4 months (95%CI 19.6-43.1) (p=0.03). **Conclusion:** The survival difference of resin and glass microspheres in neuroendocrine tumour patients is prone to discussion.
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**Background/Aims:** The effects of absorbed radiation dose to healthy liver parenchyma as a result of radioembolisation with ^90^Y-microspheres are poorly understood. This has implications for treatment planning due to the lack of an evidence-based organ toxicity threshold in combination with individual patient characteristics, such as prior chemotherapy history and pre-treatment liver function. The aim of this study was to use ^99m^Tc-mebrofenin to assess changes in liver function as a result of radioembolisation, and to correlate with changes in standard liver function blood tests. **Methods:** Patients underwent a dynamic mebrofenin assessment immediately prior to and \~8 weeks post-radioembolisation with \[Y-90\]-SIR-Spheres (Sirtex Medical, Sydney). The change in liver uptake rate was compared to the absorbed dose measured in healthy liver parenchyma at the time of radioembolisation derived from ^90^Y PET imaging. Liver function blood results (bilirubin, albumin, ALT, AST, ALP and GGT) were also examined for changes from baseline. **Results:** Baseline liver uptake rates ranged from 6.3-18.6%/min. 30% of patients demonstrated an increase in liver uptake rate post-treatment, whilst 70% experienced a decrease. The largest change in liver uptake rate was a drop of 44% corresponding to an average healthy liver dose of 32Gy. A correlation was found between the minimum dose to 70% of healthy liver volume (D70) and changes in liver uptake rate. Average healthy liver dose and volume receiving 50Gy did not demonstrate a correlation. Baseline liver uptake rate correlated negatively with the subsequent change in uptake rate. D70 also correlated with changes in albumin, ALP and GGT following treatment. **Conclusion:** Mebrofenin assessment of liver function may play a role in individualised treatment planning of radioembolisation. D70 may be more predictive of potential radiation induced liver disease than average dose.
